[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjC60CdjsImxNPEcawblt792-BuXccmnS8RrTiqP33sg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Memorial Sloan Kettering Cancer Center",[4],1930,false,701,72,328835,421,816,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",209,{"name":18,"count":19},"Prostate Cancer",127,{"name":21,"count":22},"Lung Cancer",96,{"name":24,"count":25},"Lymphoma",91,{"name":27,"count":28},"Leukemia",85,{"name":30,"count":31},"Ovarian Cancer",75,{"name":33,"count":34},"Sarcoma",55,{"name":36,"count":34},"Colorectal Cancer",[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02673333","Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma","2019-01-11","Pembrolizumab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02422498","Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent\u002FMetastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy","2022-12-19","cisplatin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03215095","RAI Plus Immunotherapy for Recurrent\u002FMetastatic Thyroid Cancers","2023-02-06","Durvalumab",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04459416","Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma","2024-07-02","opioid",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03414229","A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and\u002For Locally Advanced Sarcoma","2024-09-09","Epacadostat",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03808077","The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer","2024-10-11","Rocuronium 0.3mg\u002Fkg\u002Fhr",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03290950","A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma","2025-05-21","daratumumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05203445","A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer","2025-05-29","Olaparib",{"nctId":79,"briefTitle":80,"date":81,"intervention":42},"NCT03728972","Study of Pembrolizumab in Patients With Early-Stage NK\u002FT-cell Lymphoma, Nasal Type","2025-06-15",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04262154","Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","2025-07-07","Atezolizumab",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,124,142,177,201,922,1231,1446,1555,1728,1776,1820,1933,1980,2014,2049,2067,2091,2109,2132,2153,2171,2195,2213,2231,2249,2272,2600,2887,3343,3579,3794,3866,4035,4093,4166,4318,4410,4523,4679,4838,4914,4960,5025,5133,5329,5394,5446,5487,5624,5723,5773,5854,5911,5956,6019,6075,6141,6179,6213,6243,6303,6379,6441,6502,6562,6606,6640,6700,6746,6783,6809,6843,6869,6961,7003,7070,7108,7161,7206,7232,7324,7436,7534,7607,7693,7742,7801,7855,7893,7925,7954,7987,8022,8054,8084,8114,8141,8165,8202,8227,8253,8275,8297,8319,8345,8367,8389,8411,8433,8458,8495,8517,8544,8649,8756,8852,8890,8930,9033,9086,9117,9155,9211,9263,9301,9352,9401,9438,9482,9518,9548,9581,9611,9640,9667,9701,9723,9755,9782,9804,9841,9863,9885,9912,9946,9974,9996,10029,10051,10077,10101,10119,10149,10167,10185,10211,10236,10260,10278,10302,10320,10338,10360,10385,10403,10421,10439,10457,10483,10501,10522,10546,10573,10591,10617,10641,10665,10688,10709,10731,10749,10767,10785,10803,10821,10839,10864,10882,10900,10918,10936,10954,10977,10995,11017,11041,11068,11086,11110,11128,11151,11173,11191,11213,11238,11256,11279,11302,11320,11338,11361,11386,11404,11422,11440,11458,11476,11494,11512,11530,11554,11578,11596,11622,11640,11658,11676,11697,11715,11742,11765,11788,11806,11830,11854,11872,11895,11913,11931,11953,11976,12000,12018,12036,12054,12077,12099,12117,12142,12160,12178,12200,12222,12244,12267,12289,12307,12325,12343,12361,12385,12411,12429,12447,12471,12489,12513,12537,12555,12579,12597,12621,12644,12662,12680,12698,12721,12739,12769,12792,12813,12831,12849,12867,12893,12911,12929,12947,12965,12990,13015,13033,13051,13274,13381,13463,13541,13581,13615,13642,13674,13704,13726,13748,13772,13814,13868,13890,13917,13947,13974,14000,14018,14042,14066,14084,14102,14124,14142,14160,14181,14203,14226,14249,14267,14289,14313,14331,14359,14384,14402,14424,14447,14465,14487,14513,14531,14549,14567,14590,14612,14635,14661,14686,14704,14729,14754,14777,14795,14819,14848,14866,14884,14907,14925,14943,14966,14984,15002,15020,15038,15056,15081,15099,15117,15135,15153,15179,15197,15215,15242,15263,15281,15299,15317,15335,15353,15376,15398,15421,15439,15457,15481,15499,15525,15565,15587,15610,15633,15655,15673,15696,15714,15738,15756,15778,15805,15827,15851,15869,15887,15920,15938,15962,15980,16004,16026,16049,16067,16090,16114,16137,16161,16179,16201,16223,16241,16262,16284,16308,16331,16355,16373,16400,16418,16436,16461,16479,16509,16535,16561,16587,16623,16645,16663,16687,16712,16730,16755,16773,16791,16809,16834,16852,16875,16897,16920,16944,16967,16992,17010,17028,17052,17070,17088,17106,17124,17142,17211,17282,17342,17406,17454,17488,17537,17567,17597,17630,17660,17696,17726,17756,17807,17837,17870,17903,17934,17960,17994,18027,18059,18089,18115,18141,18171,18197,18226,18263,18291,18317,18341,18363,18385,18409,18435,18467,18494,18521,18548,18570,18601,18631,18653,18675,18697,18727,18749,18771,18798,18820,18850,18872,18899,18921,18954,18981,19009,19037,19055,19073,19096,19114,19136,19157,19178,19196,19219,19237,19263,19281,19305,19326,19344,19362,19380,19402,19424,19446,19470,19494,19512,19530,19551,19574,19597,19621,19643,19661,19679,19697,19720,19738,19759,19781,19799,19821,19844,19862,19880,19898,19919,19943,19961,19979,20004,20022,20040,20064,20082,20106,20124,20147,20169,20190,20213,20234,20252,20274,20297,20315,20333,20351,20369,20391,20409,20431,20453,20471,20489,20510,20533,20556,20579,20604,20622,20643,20665,20687,20709,20727,20745,20763,20786,20804,20822,20840,20858,20881,20902,20928,20950,20973,20994,21016,21034,21055,21073,21091,21109,21127,21148,21169,21187,21209,21227,21250,21272,21290,21311,21333,21354,21376,21394,21412,21441,21459,21477,21495,21513,21531,21552,21573,21596,21618,21641,21668,21689,21714,21735,21759,21777,21798,21819,21837,21858,21883,21905,21923,21945,21963,21988,22006,22024,22046,22064,22089,22107,22130,22148,22170,22191,22209,22237,22255,22273,22294,22318,22336,22357,22375,22393,22415,22433,22456,22481,22499,22517,22535,22556,22577,22600,22618,22641,22664,22682,22700,22722,22745,22763,22781,22804,22825,22843,22865,22883,22901,22922,22940,22961,22982,23000,23023,23041,23063,23084,23106,23124,23149,23173,23194,23220,23254,23278,23306,23328,23350,23372,23398,23422,23449,23476,23499,23517,23540,23558,23576,23594,23612,23630,23651,23672,23693,23711,23732,23753,23771,23792,23813,23839,23857,23875,23893,23915,23938,23959,23982,24005,24023,24046,24067,24085,24103,24124,24148,24166,24189,24211,24229,24247,24268,24289,24311,24335,24353,24374,24394,24412,24430,24448,24472,24490,24508,24531,24552,24570,24588,24611,24629,24650,24668,24686,24707,24725,24748,24771,24789,24810,24828,24846,24868,24889,24911,24929,24947,24971,24995,25013,25031,25049,25070,25091,25112,25134,25163,25181,25199,25217,25235,25253,25271,25289,25311,25332,25350,25373,25394,25415,25438,25456,25479,25503,25521,25542,25564,25587,25609,25630,25651,25669,25695,25713,25731,25752,25770,25788,25813,25836,25857,25877,25898,25916,25937,25960,25983,26001,26019,26042,26064,26086,26104,26125,26143,26166,26188,26210,26234,26252,26274,26292,26315,26340,26366,26384,26402,26470,26516,26558,26608,26642,26668,26704,26736,26758,26780,26813,26837,26859,26881,26907,26932,26950,26974,26992,27010,27033,27054,27076,27094,27116,27139,27161,27187,27210,27233,27255,27276,27297,27318,27342,27360,27383,27406,27424,27447,27470,27492,27510,27532,27554,27575,27596,27622,27640,27662,27680,27702,27724,27748,27771,27793,27815,27836,27861,27882,27904,27927,27949,27970,27991,28015,28038,28059,28077,28095,28119],{"intervention":96,"totalTrials":97,"cells":98},"Nicotine Replacement Therapy",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":122},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT03315910","Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites","ACTIVE_NOT_RECRUITING",[92],"2026-10","2017-10-10",807,[119],"Smoking Cessation",[96,121],"Nicotine Lozenge",{"trials":123,"activeCount":101},[],{"intervention":121,"totalTrials":97,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":101},[],{"trials":129,"activeCount":101},[],{"trials":131,"activeCount":101},[],{"trials":133,"activeCount":101},[],{"trials":135,"activeCount":97,"soonestReadout":115},[136],{"nctId":111,"briefTitle":112,"status":113,"phases":137,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":138,"interventions":139},[92],[119],[96,121],{"trials":141,"activeCount":101},[],{"intervention":143,"totalTrials":97,"cells":144},"Revaree Plus",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":175},{"trials":146,"activeCount":101},[],{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":97,"soonestReadout":160},[155],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":174},"NCT07042581","A Study of Revaree Plus in People With Breast Cancer","RECRUITING",[92],"2029-06-20","2025-06-20",60,[15,164,165,166,167,168,169,170,171,172,173],"Stage 0 Breast Cancer","Stage I Breast Cancer","Stage II Breast Cancer","Stage III Breast Cancer","Stage 0 Breast Carcinoma","Stage II Breast Carcinoma","Stage III Breast Carcinoma","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast",[143],{"trials":176,"activeCount":101},[],{"intervention":178,"totalTrials":97,"cells":179},"Vancomycin and Gentamicin",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":199},{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":101},[],{"trials":185,"activeCount":101},[],{"trials":187,"activeCount":101},[],{"trials":189,"activeCount":97,"soonestReadout":194},[190],{"nctId":191,"briefTitle":192,"status":158,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT07220967","A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement",[92],"2027-10","2025-10-21",392,[15],[178],{"trials":200,"activeCount":101},[],{"intervention":202,"totalTrials":203,"cells":204},"cyclophosphamide",63,{"EARLY_PHASE1":205,"PHASE1":226,"PHASE2":333,"PHASE3":839,"PHASE4":882,"NA":884},{"trials":206,"activeCount":97,"soonestReadout":211},[207],{"nctId":208,"briefTitle":209,"status":113,"phases":210,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":217},"NCT04947501","A Study of N9 Chemotherapy in Children With Neuroblastoma",[88],"2026-06-22","2021-06-22",26,[215,216],"Neuroblastoma","Pediatric Cancer",[218,219,220,221,222,223,224,225],"Cyclophosphamide","Topotecan","Vincristine","Doxorubicin","Ifosfamide","Etoposide","Carboplatin","Mesna",{"trials":227,"activeCount":332,"soonestReadout":232},[228,241,254,266,277,290,300,312,320],{"nctId":229,"briefTitle":230,"status":113,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT03531736","T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia",[89],"2026-05","2018-05-09",17,[236],"Myeloid Diseases",[238,239,202,240],"Antithymocyte globulin","fludarabine","Rituxan",{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":28,"conditions":248,"interventions":250},"NCT02650648","Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","COMPLETED",[89],"2025-07-28","2016-01-05",[215,249],"High-Risk",[202,251,252,253],"NK cells","hu3F8","rIL-2",{"nctId":255,"briefTitle":256,"status":113,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT02792114","T-Cell Therapy for Advanced Breast Cancer",[89],"2026-06","2016-06",186,[15,262],"Metastatic HER2-negative Breast",[218,264,265],"Mesothelin-targeted T cells","AP1903",{"nctId":267,"briefTitle":268,"status":113,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT04577326","Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma",[89],"2026-09-30","2020-09-30",14,[274],"Malignant Pleural Mesothelioma (MPM)",[202,276],"CAR T cells",{"nctId":278,"briefTitle":279,"status":244,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":287},"NCT00562640","Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12\u002F01\u002F2009)",[89],"2021-08-03","2007-10-16",12,[285,30,286],"Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer",[288,289,202],"filgrastim","therapeutic autologous lymphocytes",{"nctId":291,"briefTitle":292,"status":244,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT01416974","Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab",[89],"2019-01-07","2011-08-22",13,[27],[202,299],"modified T cells",{"nctId":301,"briefTitle":302,"status":113,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT03070327","BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma",[89],"2027-02","2017-02-27",20,[308],"Multiple Myeloma",[310,218,311],"EGFRt\u002FBCMA-41BBz CAR T cell","Lenalidomide.",{"nctId":313,"briefTitle":314,"status":113,"phases":315,"primaryCompletion":258,"completion":258,"start":316,"enrollment":296,"conditions":317,"interventions":318},"NCT01140373","Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)",[89],"2010-06",[18],[319,202],"engineered autologous T cells",{"nctId":321,"briefTitle":322,"status":113,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},"NCT02498912","Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors",[89],"2026-08","2015-08",18,[328],"Solid Tumors",[218,330,331],"Infusion of 4H11-28z\u002FfIL-12\u002FEGFRt+ Genetically-modified T cells","Fludarabine",6,{"trials":334,"activeCount":296,"soonestReadout":789},[335,350,364,380,392,406,422,432,448,466,480,494,502,517,527,540,550,559,568,583,595,608,617,626,633,644,653,663,676,684,691,700,712,723,732,742,751,759,770,777,785,799,808,821,831],{"nctId":336,"briefTitle":337,"status":244,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT00002634","Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma",[90],"2004-09","1995-02",45,[215],[288,344,47,202,345,346,347,348,349],"monoclonal antibody 3F8","doxorubicin hydrochloride","etoposide","mesna","perfosfamide","vincristine sulfate",{"nctId":351,"briefTitle":352,"status":244,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT00002598","Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",[90],"2004-06","1994-06",30,[27],[359,360,202,361,346,362,363],"recombinant interferon alfa","sargramostim","cytarabine","methotrexate","mitoxantrone hydrochloride",{"nctId":365,"briefTitle":366,"status":244,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT00546377","Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",[89,90],"2014-05","2005-07",50,[27,24],[288,373,374,360,202,363,375,376,377,378,379],"pegfilgrastim","rituximab","pentostatin","fluorescence in situ hybridization","gene rearrangement analysis","polymerase chain reaction","protein expression analysis",{"nctId":381,"briefTitle":382,"status":244,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"conditions":386,"interventions":388},"NCT00002489","Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors",[90],"2002-06","1991-10",[387,30],"Extragonadal Germ Cell Tumor",[389,288,390,202,345,346,391,362,349],"dactinomycin","carboplatin","leucovorin calcium",{"nctId":393,"briefTitle":394,"status":244,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":400},"NCT00425802","Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[90],"2016-10-28","2006-11-28",61,[27,24],[401,288,402,374,202,403,404,405],"anti-thymocyte globulin","graft-versus-tumor induction therapy","cyclosporine","fludarabine phosphate","mycophenolate mofetil",{"nctId":407,"briefTitle":408,"status":244,"phases":409,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":417},"NCT01119066","HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies",[90],"2021-03-30","2010-05-03",422,[414,415,416,308],"Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Myelodysplastic Syndrome",[418,218,419,420,331,421],"Thiotepa","Busulfan","Melphalan","Clofarabine",{"nctId":423,"briefTitle":424,"status":244,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"conditions":428,"interventions":429},"NCT00003667","Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma",[90],"2000-08","1998-09",[33],[202,430,431,345,349],"dexrazoxane hydrochloride","disaccharide tripeptide glycerol dipalmitoyl",{"nctId":433,"briefTitle":434,"status":244,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":440},"NCT00574496","Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma",[90],"2022-08-02","2007-11-13",25,[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],"gemcitabine hydrochloride","ifosfamide","mechlorethamine hydrochloride","melphalan","prednisone","procarbazine hydrochloride","vinorelbine tartrate",{"nctId":449,"briefTitle":450,"status":158,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":459},"NCT05736419","A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)",[90],"2027-02-09","2023-02-09",24,[456,457,458],"Sickle Cell Disease","Thalassemia, Beta","Thalassemia",[331,218,460,461,462,463,464,465],"Tacrolimus","Mycophenolate Mofetil","Rabbit ATG","Dexamethasone","Bortezomib","Rituximab",{"nctId":467,"briefTitle":468,"status":244,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":477},"NCT00002718","T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia",[90],"2004-01","2008-10","1995-11",31,[27,24,475,476],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[401,288,202,361,478,479],"methylprednisolone","thiotepa",{"nctId":481,"briefTitle":482,"status":158,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":490},"NCT06765317","A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",[90],"2028-01","2025-01-16",42,[488,489],"Diffuse Large B Cell Lymphoma (DLBCL)","High Grade B Cell Lymphoma",[491,492,465,218,221,493],"Glofitamab","Polatuzumab","Obinutuzumab:",{"nctId":495,"briefTitle":496,"status":113,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":370,"conditions":500,"interventions":501},"NCT00466531","Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",[89,90],"2026-12","2007-03-21",[27],[289,202],{"nctId":503,"briefTitle":504,"status":505,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":514},"NCT03600909","A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","TERMINATED",[90],"2021-04-09","2018-05-15",3,[511,512,513],"Fanconi Anemia","Myelodysplastic Syndrome (MDS)","Acute Myelogenous Leukemia (AML)",[419,331,218,515,516],"Anti-Thymocyte Globulin","G-CSF",{"nctId":518,"briefTitle":519,"status":244,"phases":520,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":525},"NCT00058422","Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",[90],"2019-11-14","2003-02-10",65,[24],[526,288,374,202,345,445,349],"darbepoetin alfa",{"nctId":528,"briefTitle":529,"status":113,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":538},"NCT04872595","A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant",[90],"2027-04","2021-04-30",59,[535,536,537],"Acute Myeloid Leukemia (AML)","Acute Lymphoid Leukemia (ALL)","Myelodysplastic Syndromes (MDS)",[418,218,539,419,420,331],"GCSF",{"nctId":541,"briefTitle":542,"status":244,"phases":543,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":547,"interventions":548},"NCT00003631","Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma",[90],"2010-04","1998-08",118,[24],[288,390,549,202,361,346,442,444],"carmustine",{"nctId":551,"briefTitle":552,"status":244,"phases":553,"primaryCompletion":554,"completion":554,"start":427,"conditions":555,"interventions":557},"NCT00003754","Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers",[90],"2001-07",[556],"Unspecified Childhood Solid Tumor, Protocol Specific",[202,558],"thalidomide",{"nctId":560,"briefTitle":561,"status":244,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT00541034","Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia",[90],"2016-01","2005-05",49,[27,24],[374,202,375],{"nctId":569,"briefTitle":570,"status":113,"phases":571,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":574,"interventions":575},"NCT01920737","A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia",[90],"2013-08-07",39,[27],[576,220,577,578,579,580,218,581,582,463],"Daunorubicin","Prednisone","PEG-Asparaginase","Methotrexate","6-MP","Cytarabine","Leucovorin",{"nctId":584,"briefTitle":585,"status":244,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT00004061","Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer",[90],"2003-05","2009-12","1999-05",111,[27,24,592],"Oral Complications",[288,594,202,346,442],"palifermin",{"nctId":596,"briefTitle":597,"status":505,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":607},"NCT03615105","Donor Stem Cell Transplantation Using α\u002Fβ+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",[90],"2024-03-06","2018-07-25",9,[536,535,603,604,605,606],"Chronic Myeloid Leukemia (CML)","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[418,218,419,331,420,421,465],{"nctId":609,"briefTitle":610,"status":158,"phases":611,"primaryCompletion":115,"completion":115,"start":612,"enrollment":306,"conditions":613,"interventions":615},"NCT06083922","A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)",[90],"2023-10-16",[308,614],"Monoclonal Gammopathy of Renal Significance",[218,464,463,616],"Daratumumab",{"nctId":618,"briefTitle":619,"status":158,"phases":620,"primaryCompletion":621,"completion":621,"start":622,"enrollment":213,"conditions":623,"interventions":624},"NCT07454382","A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma",[90],"2029-08-27","2026-02-27",[308],[625,218],"Elranatamab-bcmm",{"nctId":627,"briefTitle":628,"status":244,"phases":629,"primaryCompletion":630,"completion":630,"start":427,"enrollment":573,"conditions":631,"interventions":632},"NCT00003659","Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia",[90],"2009-05",[27],[288,374,202,404],{"nctId":634,"briefTitle":635,"status":244,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"conditions":639,"interventions":640},"NCT00002691","Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma",[90],"2000-06","1995-08",[24],[288,641,202,361,642,643,346,391,347,362,349],"asparaginase","daunorubicin hydrochloride","dexamethasone",{"nctId":645,"briefTitle":646,"status":244,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":650,"interventions":652},"NCT00002675","Chemotherapy in Treating Patients With Retinoblastoma",[90],"2001-01","1995-05",[651],"Retinoblastoma",[288,390,47,202,346,347,349],{"nctId":654,"briefTitle":655,"status":244,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":661},"NCT00295932","Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",[89,90],"2018-03-11","2005-12-13",79,[27,24],[374,662,202,445],"bortezomib",{"nctId":664,"briefTitle":665,"status":158,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":673},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[90],"2030-04-28","2026-04-28",71,[415,414,475,671,604,27,24,672],"Non-hodgkin Lymphoma","Graft-versus-host Disease",[674,218,331,421,419,418,460,461,675],"Cord Blood Units","Cyclosporine",{"nctId":677,"briefTitle":678,"status":113,"phases":679,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":681,"interventions":682},"NCT00077285","Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma",[90],"2003-10",[33],[288,390,202,430,345,346,442,683,349],"irinotecan hydrochloride",{"nctId":685,"briefTitle":686,"status":244,"phases":687,"primaryCompletion":688,"completion":688,"start":427,"enrollment":162,"conditions":689,"interventions":690},"NCT00003658","Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers",[90],"2005-10",[27,24],[288,374,202,375],{"nctId":692,"briefTitle":693,"status":244,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"conditions":697,"interventions":698},"NCT00002471","Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",[90],"2003-01","1990-02",[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],"therapeutic hydrocortisone",{"nctId":701,"briefTitle":702,"status":113,"phases":703,"primaryCompletion":498,"completion":498,"start":704,"enrollment":705,"conditions":706,"interventions":708},"NCT01746849","Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation",[90],"2012-12",82,[27,308,416,707],"Non-Hodgkin's Lymphoma",[709,710,418,218,711],"Palifermin","Lupron","Degarelix",{"nctId":713,"briefTitle":714,"status":158,"phases":715,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT07359859","A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant",[90],"2029-01","2026-01-20",40,[720],"Hematologic Malignancies",[218,218,461,722,460,460],"Ruxolitinib",{"nctId":724,"briefTitle":725,"status":244,"phases":726,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":729,"interventions":730},"NCT00003541","Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma",[89,90],"2006-07","1998-06",[24],[288,731,390,202,345,346,442,445,349],"CHOP regimen",{"nctId":733,"briefTitle":734,"status":244,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"conditions":738,"interventions":739},"NCT00072319","Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer",[90],"2006-11","2003-08",[15],[288,202,740,741],"epirubicin hydrochloride","paclitaxel",{"nctId":743,"briefTitle":744,"status":244,"phases":745,"primaryCompletion":746,"completion":746,"start":637,"conditions":747,"interventions":748},"NCT00040872","Multiple Therapies in Treating Patients With Advanced Neuroblastoma",[90],"2007-01",[215],[288,344,360,390,47,202,345,346,749,479,750,349],"isotretinoin","topotecan hydrochloride",{"nctId":752,"briefTitle":753,"status":244,"phases":754,"primaryCompletion":727,"completion":755,"start":756,"enrollment":438,"conditions":757,"interventions":758},"NCT00028730","Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer",[90],"2008-06","2001-08",[27,24,475,476],[401,288,202,404,479],{"nctId":760,"briefTitle":761,"status":244,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT00482391","Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2\u002FNeu-Overexpressed Breast Cancer",[90],"2011-07","2007-03",95,[15],[768,202,345,769,741],"trastuzumab","lapatinib ditosylate",{"nctId":771,"briefTitle":772,"status":244,"phases":773,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":775,"interventions":776},"NCT00387959","Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",[90],"2014-04",[27,24],[288,374,202,403,404,405],{"nctId":778,"briefTitle":779,"status":244,"phases":780,"primaryCompletion":564,"completion":564,"start":781,"conditions":782,"interventions":784},"NCT00002466","Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer",[90],"1990-05",[783,33],"Kidney Cancer",[202,345,346,442,349],{"nctId":786,"briefTitle":787,"status":113,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":796},"NCT02414269","Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin",[89,90],"2026-04-30","2015-05",113,[793,794,795,21,15],"Malignant Pleural Disease","Mesothelioma","Metastases",[797,202,798],"iCasp9M28z T cell infusions","pembrolizumab",{"nctId":800,"briefTitle":801,"status":244,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":283,"conditions":805,"interventions":806},"NCT00526292","Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant",[90],"2015-07","2007-08",[27,475],[807,202,239],"natural killer cell therapy",{"nctId":809,"briefTitle":810,"status":113,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":817},"NCT01864109","Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma",[90],"2027-05","2013-05",83,[816],"Newly Diagnosed Ewing Sarcoma",[218,220,222,223,818,819,225,820,516],"Temozolomide","Irinotecan","Dexrazoxane",{"nctId":822,"briefTitle":823,"status":244,"phases":824,"primaryCompletion":825,"completion":825,"start":826,"conditions":827,"interventions":829},"NCT00002502","Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome",[90],"2000-05","1992-07",[27,24,828,475],"Multiple Myeloma and Plasma Cell Neoplasm",[830,202,361],"busulfan",{"nctId":832,"briefTitle":833,"status":244,"phases":834,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":837,"interventions":838},"NCT00039195","Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma",[90],"2010-01",98,[24],[288,374,390,202,345,346,442,445,349],{"trials":840,"activeCount":97,"soonestReadout":845},[841,852,860,871],{"nctId":842,"briefTitle":843,"status":158,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT07223021","A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia",[91],"2028-10","2025-10-20",130,[849],"B-cell Acute Lymphoblastic Leukemia",[331,218,331,851],"CAR-T",{"nctId":853,"briefTitle":854,"status":244,"phases":855,"primaryCompletion":856,"completion":856,"start":857,"conditions":858,"interventions":859},"NCT00002534","Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission",[91],"2003-04","1993-05",[27],[401,202,361,478,479],{"nctId":861,"briefTitle":862,"status":244,"phases":863,"completion":727,"start":864,"enrollment":865,"conditions":866,"interventions":869},"NCT00002596","Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors",[91],"1994-09",270,[867,387,868],"Childhood Germ Cell Tumor","Testicular Germ Cell Tumor",[870,288,390,47,202,346],"bleomycin sulfate",{"nctId":872,"briefTitle":873,"status":244,"phases":874,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT00002766","Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma",[91],"2011-09","1996-03",170,[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],"mercaptopurine","pegaspargase",{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[886,894,902,913],{"nctId":887,"briefTitle":888,"status":505,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":509,"conditions":892,"interventions":893},"NCT02360111","GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8\u002F8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant",[93],"2017-09","2015-02",[27,416,707],[218],{"nctId":895,"briefTitle":896,"status":244,"phases":897,"primaryCompletion":813,"completion":813,"start":898,"enrollment":899,"conditions":900,"interventions":901},"NCT00595127","Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine",[93],"2001-06",21,[511],[218,331],{"nctId":903,"briefTitle":904,"status":244,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":911},"NCT02880293","Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor",[93],"2023-11-20","2016-08-23",44,[910],"Hematologic Malignancy",[444,239,479,218,225,461,912,460],"Filgrastim",{"nctId":914,"briefTitle":915,"status":916,"phases":917,"start":727,"enrollment":31,"conditions":918,"interventions":919},"NCT00436709","Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer","UNKNOWN",[93],[15],[920,373,202,345,921],"bevacizumab","paclitaxel albumin-stabilized nanoparticle formulation",{"intervention":923,"totalTrials":213,"cells":924},"Gemcitabine",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":962,"PHASE3":1193,"PHASE4":1215,"NA":1217},{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":97,"soonestReadout":933},[929,946],{"nctId":930,"briefTitle":931,"status":158,"phases":932,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":935,"interventions":939},"NCT07532902","A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",[89],"2029-04","2026-04-07",[936,937,938],"Diffuse Pleural Mesothelioma","Gastroesophageal Carcinoma","Urothelial Carcinoma",[940,941,942,943,582,944,923,945],"BMS-986504","Ipilimumab","Nivolumab","5-FU","Oxaliplatin","Platinum",{"nctId":947,"briefTitle":948,"status":244,"phases":949,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":958},"NCT01938729","Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma",[89],"2020-09-10","2013-09-05",8,[954,955,956,957],"Intrahepatic Cholangiocarcinoma","Peripheral Cholangiocarcinoma","Cholangiolar Carcinoma","Cholangiocellular Carcinoma) (ICC)",[959,960,961],"FLOXURIDINE","DEXAMETHASONE","GEMCITABINE",{"trials":963,"activeCount":601,"soonestReadout":324},[964,975,986,997,1008,1024,1037,1046,1058,1067,1078,1088,1098,1109,1118,1126,1136,1146,1158,1169,1182],{"nctId":965,"briefTitle":966,"status":113,"phases":967,"primaryCompletion":498,"completion":498,"start":968,"enrollment":969,"conditions":970,"interventions":973},"NCT02989584","A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer",[89,90],"2016-12-20",54,[971,972,938],"Bladder Cancer","Metastatic Bladder Cancer",[86,923,974],"Cisplatin",{"nctId":976,"briefTitle":977,"status":244,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":341,"conditions":981,"interventions":983},"NCT02252887","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab\u002FPertuzumab, or Pertuzumab Based Therapy",[90],"2025-07-24","2015-01-12",[982],"Metastatic HER2-Positive Breast Cancer",[923,984,985],"Trastuzumab","Pertuzumab",{"nctId":987,"briefTitle":988,"status":113,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":996},"NCT03093922","A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer",[90],"2027-03","2017-03-22",32,[938,994,995],"Locally Advanced","Unresectable",[86,923,974],{"nctId":998,"briefTitle":999,"status":158,"phases":1000,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":1002,"interventions":1003},"NCT06377566","A Study of BV-AVD in People With Bulky Hodgkin Lymphoma",[90],"2024-04-17",[604],[1004,221,1005,1006,42,923,1007],"Brentuximab vedotin","Vinblastine","Dacarbazine","Vinorelbine",{"nctId":1009,"briefTitle":1010,"status":244,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1021},"NCT00887809","Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes",[90],"2014-10","2014-11","2009-04",47,[33,1017,1018,1019,1020],"Leiomyosarcoma","Malignant Fibrous","Histiocytoma","Angiosarcoma",[1022,1023,920],"gemcitabine","docetaxel",{"nctId":1025,"briefTitle":1026,"status":113,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":272,"conditions":1030,"interventions":1036},"NCT04960618","Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome",[90],"2027-07","2021-10-01",[1031,1032,1033,1034,1035],"Mycosis Fungoides","Mycosis Fungoides\u002FSezary Syndrome","Sezary Syndrome","Sézary","Advanced Mycosis Fungoides",[923,42],{"nctId":1038,"briefTitle":1039,"status":158,"phases":1040,"primaryCompletion":812,"completion":812,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1044},"NCT04891289","Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery",[90],"2021-05-07",164,[954],[923,944,463,1045],"Floxuridine",{"nctId":1047,"briefTitle":1048,"status":244,"phases":1049,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1055},"NCT03693807","A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma",[90],"2024-06-27","2018-10-18",35,[36,1054],"Cholangiocarcinoma",[1045,923,944,819,1056,1057],"Fluorouracil","Anti-EGFR",{"nctId":1059,"briefTitle":1060,"status":244,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":325,"enrollment":718,"conditions":1063,"interventions":1065},"NCT02525653","Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers",[90],"2019-05",[21,1064],"Untreated Stage IV or Recurrent Squamous Cell Lung Cancers",[1066,1022],"albumin-bound paclitaxel",{"nctId":1068,"briefTitle":1069,"status":158,"phases":1070,"primaryCompletion":324,"completion":324,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1075},"NCT03618550","Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma",[90],"2018-08-01",257,[604,1074],"Relapsed or Refractory Hodgkin Lymphoma",[798,1022,1076,1077],"vinorelbine","liposomal doxorubicin",{"nctId":1079,"briefTitle":1080,"status":244,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":326,"conditions":1084,"interventions":1086},"NCT00847015","Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",[90],"2012-11","2009-02",[971,1085],"Urinary Bladder",[1087,923,47],"Sunitinib",{"nctId":1089,"briefTitle":1090,"status":505,"phases":1091,"primaryCompletion":1092,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1096},"NCT01622660","Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced\u002FMetastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy",[90],"2016-02","2012-06",2,[971],[923,1097],"Pazopanib",{"nctId":1099,"briefTitle":1100,"status":158,"phases":1101,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":1103,"interventions":1106},"NCT04991025","Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery",[90],"2022-10-19",[21,1104,1105],"Lung Cancer Stage II","Lung Cancer Stage III",[974,1107,923,224,1108,942],"Pemetrexed","Certolizumab",{"nctId":1110,"briefTitle":1111,"status":505,"phases":1112,"primaryCompletion":803,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT01916109","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",[90],"2013-08",4,[971],[923,224,1117],"Panitumumab",{"nctId":1119,"briefTitle":1120,"status":244,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":813,"enrollment":34,"conditions":1123,"interventions":1125},"NCT01862315","Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)",[90],"2025-03-18",[954,955,956,1124],"Cholangiocellular Carcinoma",[1045,643,923,944],{"nctId":1127,"briefTitle":1128,"status":113,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":969,"conditions":1132,"interventions":1134},"NCT04179162","Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment",[89,90],"2026-11","2019-11-22",[1133],"Non-Muscle Invasive Bladder Cancer (NMIBC)",[1135,923],"Bacillus Calmette-Guérin",{"nctId":1137,"briefTitle":1138,"status":244,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":486,"conditions":1142,"interventions":1144},"NCT01828034","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",[89,90],"2019-05-30","2013-04",[1143],"Advanced Biliary Tract Carcinoma",[923,974,1145],"MEK162",{"nctId":1147,"briefTitle":1148,"status":244,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1156},"NCT00588666","Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced\u002FMetastatic Urothelial Carcinoma",[90],"2011-12","2006-05",51,[1154,938,1155],"Myeloproliferative Disorder","Cancer",[1157,224,923],"Bevacizumab",{"nctId":1159,"briefTitle":1160,"status":244,"phases":1161,"primaryCompletion":1162,"completion":1162,"start":1163,"enrollment":272,"conditions":1164,"interventions":1167},"NCT05275426","A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor",[90],"2025-08-11","2022-03-02",[1165,1166],"Ewing Sarcoma","Ewing-Like Sarcoma",[1168,923],"LY2880070",{"nctId":1170,"briefTitle":1171,"status":158,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":836,"conditions":1175,"interventions":1179},"NCT04577014","Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma",[89,90],"2026-09-29","2020-09-29",[1176,1177,33,1178],"Soft Tissue Sarcoma","Sarcoma,Soft Tissue","Soft Tissue Sarcoma Adult",[1180,923,1181],"Retifanlimab","Docetaxel",{"nctId":1183,"briefTitle":1184,"status":244,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":573,"conditions":1188,"interventions":1191},"NCT00919061","Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy",[90],"2014-03","2009-08",[1189,1190],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[923,974,1192],"Sorafenib",{"trials":1194,"activeCount":97,"soonestReadout":1208},[1195,1204],{"nctId":1196,"briefTitle":1197,"status":244,"phases":1198,"completion":1199,"start":695,"enrollment":1200,"conditions":1201,"interventions":1203},"NCT00142571","Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma",[91],"2007-09",120,[1202],"Sarcoma, Soft Tissue",[923,1181],{"nctId":1205,"briefTitle":1206,"status":158,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1213},"NCT06929286","A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)",[91],"2028-04","2025-04-11",125,[1212],"Non-Muscle Invasive Bladder Cancer",[1214,923,1181],"Nadofaragene Firadenovec",{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":97,"soonestReadout":115},[1219],{"nctId":1220,"briefTitle":1221,"status":113,"phases":1222,"primaryCompletion":115,"completion":115,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1228},"NCT02921022","Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma",[93],"2016-10",110,[1226,1227],"Pancreatic Cancer","Advanced Pancreatic Ductal Adenocarcinoma",[923,1229,1230],"Nab-paclitaxel","PEGPH20",{"intervention":374,"totalTrials":1232,"cells":1233},28,{"EARLY_PHASE1":1234,"PHASE1":1248,"PHASE2":1280,"PHASE3":1404,"PHASE4":1415,"NA":1417},{"trials":1235,"activeCount":97,"soonestReadout":1240},[1236],{"nctId":1237,"briefTitle":1238,"status":113,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT03684980","LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma",[88],"2027-11","2018-11-14",58,[1244],"Central Nervous System Lymphoma",[579,465,1246,1247],"leucovorin","Glucarpidase",{"trials":1249,"activeCount":97,"soonestReadout":1130},[1250,1262,1272],{"nctId":1251,"briefTitle":1252,"status":244,"phases":1253,"primaryCompletion":1254,"completion":1254,"start":1255,"enrollment":438,"conditions":1256,"interventions":1259},"NCT03703167","Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent\u002FRefractory Primary or Secondary Central Nervous System Lymphoma (PCNSL\u002FSCNSL)",[89],"2026-01-26","2019-01-22",[1257,1258],"Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)",[1260,1261,465],"Ibrutinib","Lenalidomide",{"nctId":1263,"briefTitle":1264,"status":505,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":509,"conditions":1268,"interventions":1270},"NCT00087009","Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation",[89],"2008-08","2004-05",[27,24,1269],"Lymphoproliferative Disorder",[1271,374],"beta-glucan",{"nctId":1273,"briefTitle":1274,"status":113,"phases":1275,"primaryCompletion":1130,"completion":1130,"start":1276,"enrollment":1232,"conditions":1277,"interventions":1278},"NCT03352765","A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed\u002FRefractory B-cell Lymphoma in Elderly Patients",[89],"2017-11-20",[24],[374,1279,444],"bendamustine",{"trials":1281,"activeCount":332,"soonestReadout":258},[1282,1286,1298,1302,1306,1316,1328,1332,1339,1343,1352,1360,1364,1372,1376,1380,1384,1388,1392,1400],{"nctId":365,"briefTitle":366,"status":244,"phases":1283,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":1284,"interventions":1285},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":1287,"briefTitle":1288,"status":158,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":61,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT06561360","A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)",[90],"2027-09-09",86,[1293],"Hairy Cell Leukemia",[1295,1296,1297,465],"Vemurafenib","Obinutuzumab","Cladribine",{"nctId":393,"briefTitle":394,"status":244,"phases":1299,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":1300,"interventions":1301},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":449,"briefTitle":450,"status":158,"phases":1303,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":1304,"interventions":1305},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":1307,"briefTitle":1308,"status":158,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":438,"conditions":1312,"interventions":1314},"NCT06756308","A Study of Enasidenib in People With T-Cell Lymphoma",[90],"2027-12","2024-12-24",[1313],"T-cell Lymphoma",[1315,465],"Enasidenib",{"nctId":1317,"briefTitle":1318,"status":158,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":718,"conditions":1322,"interventions":1325},"NCT07231952","A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)\u002FLymphoplasmacytic Lymphoma (LPL)",[90],"2028-04-11","2025-11-11",[1323,1324],"Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[1326,1327,465],"Pirtobrutinib","Venetoclax",{"nctId":481,"briefTitle":482,"status":158,"phases":1329,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":1330,"interventions":1331},[90],[488,489],[491,492,465,218,221,493],{"nctId":1333,"briefTitle":1334,"status":244,"phases":1335,"completion":354,"start":695,"conditions":1336,"interventions":1337},"NCT00059904","Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma",[90],[24],[1338,374],"aldesleukin",{"nctId":518,"briefTitle":519,"status":244,"phases":1340,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":1341,"interventions":1342},[90],[24],[526,288,374,202,345,445,349],{"nctId":1344,"briefTitle":1345,"status":505,"phases":1346,"primaryCompletion":1083,"completion":1083,"start":1347,"enrollment":509,"conditions":1348,"interventions":1349},"NCT00567229","Lenalidomide and Rituximab in Treating Patients With Recurrent and\u002For Refractory Multiple Myeloma",[90],"2007-11",[828],[374,1350,1351],"lenalidomide","microarray analysis",{"nctId":1353,"briefTitle":1354,"status":244,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"conditions":1358,"interventions":1359},"NCT00005631","Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma",[90],"2002-11","1999-11",[24],[288,374,390,346,442],{"nctId":560,"briefTitle":561,"status":244,"phases":1361,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":1362,"interventions":1363},[90],[27,24],[374,202,375],{"nctId":1365,"briefTitle":1366,"status":113,"phases":1367,"primaryCompletion":258,"completion":258,"start":1368,"enrollment":332,"conditions":1369,"interventions":1371},"NCT04416451","A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma",[90],"2021-05-04",[1370],"Marginal Zone Lymphoma",[465,1327],{"nctId":596,"briefTitle":597,"status":505,"phases":1373,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":1374,"interventions":1375},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":627,"briefTitle":628,"status":244,"phases":1377,"primaryCompletion":630,"completion":630,"start":427,"enrollment":573,"conditions":1378,"interventions":1379},[90],[27],[288,374,202,404],{"nctId":654,"briefTitle":655,"status":244,"phases":1381,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":1382,"interventions":1383},[89,90],[27,24],[374,662,202,445],{"nctId":685,"briefTitle":686,"status":244,"phases":1385,"primaryCompletion":688,"completion":688,"start":427,"enrollment":162,"conditions":1386,"interventions":1387},[90],[27,24],[288,374,202,375],{"nctId":771,"briefTitle":772,"status":244,"phases":1389,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":1390,"interventions":1391},[90],[27,24],[288,374,202,403,404,405],{"nctId":1393,"briefTitle":1394,"status":244,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":1398,"interventions":1399},"NCT00521014","GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma",[90],"2013-07","2007-10",[24],[288,374,360,549,361,346,444],{"nctId":832,"briefTitle":833,"status":244,"phases":1401,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":1402,"interventions":1403},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":1405,"activeCount":97,"soonestReadout":1410},[1406],{"nctId":1407,"briefTitle":1408,"status":113,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT04212013","A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma",[91],"2027-03-18","2019-12-23",23,[1370],[1260,465],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":97,"soonestReadout":531},[1419,1428,1437],{"nctId":1420,"briefTitle":1421,"status":244,"phases":1422,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":213,"conditions":1425,"interventions":1427},"NCT00648037","Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT",[93],"2008-12","2008-03",[1426,27,416,707],"Hodgkin's Disease",[465],{"nctId":1429,"briefTitle":1430,"status":244,"phases":1431,"primaryCompletion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1436},"NCT00082836","Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma",[93],"2007-05","2004-12",10,[24],[374],{"nctId":1438,"briefTitle":1439,"status":113,"phases":1440,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":1441,"conditions":1442,"interventions":1445},"NCT01829958","Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy",[93],201,[1443,1444],"Non Hodgkin Lymphoma (NHL)","Diffuse Large B-cell Lymphoma (DLBCL)",[374,445],{"intervention":331,"totalTrials":1447,"cells":1448},16,{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1479,"PHASE3":1537,"PHASE4":1543,"NA":1545},{"trials":1450,"activeCount":101},[],{"trials":1452,"activeCount":509,"soonestReadout":232},[1453,1457,1465,1475],{"nctId":229,"briefTitle":230,"status":113,"phases":1454,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":1455,"interventions":1456},[89],[236],[238,239,202,240],{"nctId":1458,"briefTitle":1459,"status":244,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":704,"enrollment":1462,"conditions":1463,"interventions":1464},"NCT01758328","Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed\u002FRefractory Multiple Myeloma",[89],"2025-03-17",29,[308],[830,444,239,401],{"nctId":1466,"briefTitle":1467,"status":113,"phases":1468,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":573,"conditions":1471,"interventions":1472},"NCT04098393","Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation",[89],"2026-09","2019-09-18",[720],[1473,331,420,238,1474],"Busulfan 3.2 mg\u002Fkg\u002Fday","Busulfan 0.8 mg\u002Fkg",{"nctId":321,"briefTitle":322,"status":113,"phases":1476,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":1477,"interventions":1478},[89],[328],[218,330,331],{"trials":1480,"activeCount":1114,"soonestReadout":1518},[1481,1490,1494,1498,1502,1506,1510,1514,1533],{"nctId":1482,"briefTitle":1483,"status":505,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":97,"conditions":1487,"interventions":1489},"NCT03615144","TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors",[90],"2020-11-13","2018-07-23",[1488],"Non-Malignant Hematologic Disorders",[420,418,421,331,515],{"nctId":407,"briefTitle":408,"status":244,"phases":1491,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":1492,"interventions":1493},[90],[414,415,416,308],[418,218,419,420,331,421],{"nctId":449,"briefTitle":450,"status":158,"phases":1495,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":1496,"interventions":1497},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":503,"briefTitle":504,"status":505,"phases":1499,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":1500,"interventions":1501},[90],[511,512,513],[419,331,218,515,516],{"nctId":528,"briefTitle":529,"status":113,"phases":1503,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":1504,"interventions":1505},[90],[535,536,537],[418,218,539,419,420,331],{"nctId":596,"briefTitle":597,"status":505,"phases":1507,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":1508,"interventions":1509},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":664,"briefTitle":665,"status":158,"phases":1511,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":1512,"interventions":1513},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":1515,"briefTitle":1516,"status":158,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":1520,"interventions":1530},"NCT04644016","Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders",[90],"2026-12-20","2020-11-20",[1521,1522,1523,1524,1525,1526,1527,1528,1529],"AML","ALL","MDS","MPD Withou Myelofibrosis","NHL or HL","Inherited Metabolic Disorders","Hemoglobinopathies","Bone Marrow Failure","HLH",[421,331,419,1531,461,1532],"Cyclosporine-A","Cord Blood Graft",{"nctId":800,"briefTitle":801,"status":244,"phases":1534,"primaryCompletion":803,"completion":803,"start":804,"enrollment":283,"conditions":1535,"interventions":1536},[90],[27,475],[807,202,239],{"trials":1538,"activeCount":97,"soonestReadout":845},[1539],{"nctId":842,"briefTitle":843,"status":158,"phases":1540,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":1541,"interventions":1542},[91],[849],[331,218,331,851],{"trials":1544,"activeCount":101},[],{"trials":1546,"activeCount":101},[1547,1551],{"nctId":895,"briefTitle":896,"status":244,"phases":1548,"primaryCompletion":813,"completion":813,"start":898,"enrollment":899,"conditions":1549,"interventions":1550},[93],[511],[218,331],{"nctId":903,"briefTitle":904,"status":244,"phases":1552,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":1553,"interventions":1554},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":1023,"totalTrials":326,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1604,"PHASE3":1714,"PHASE4":1724,"NA":1726},{"trials":1558,"activeCount":101},[],{"trials":1560,"activeCount":97,"soonestReadout":1583},[1561,1571,1579,1596],{"nctId":1562,"briefTitle":1563,"status":244,"phases":1564,"primaryCompletion":1565,"completion":588,"start":1566,"conditions":1567,"interventions":1569},"NCT00045448","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors",[89],"2006-01","2002-04",[1568],"Unspecified Adult Solid Tumor, Protocol Specific",[1570,1023],"alvocidib",{"nctId":1572,"briefTitle":1573,"status":244,"phases":1574,"primaryCompletion":727,"start":1575,"conditions":1576,"interventions":1577},"NCT00084786","Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors",[89],"2004-03",[1568],[1023,1578],"gefitinib",{"nctId":1580,"briefTitle":1581,"status":158,"phases":1582,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":1585,"interventions":1592},"NCT04722523","A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer",[89],"2026-06-20","2021-01-20",[1586,1587,1588,1589,1590,1591],"Head and Neck Cancer","Head Cancer","Head Cancer Neck","Neck Cancer","Head and Neck Squamous Cell Carcinoma","HNSCC",[974,224,1181,1593,1594,1595],"Cetuximab","Cemiplimab","Paclitaxel",{"nctId":1597,"briefTitle":1598,"status":244,"phases":1599,"primaryCompletion":588,"completion":588,"start":856,"enrollment":1600,"conditions":1601,"interventions":1603},"NCT00601692","Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer",[89],27,[1602],"Esophageal Cancer",[47,1023,683],{"trials":1605,"activeCount":1094,"soonestReadout":1173},[1606,1617,1625,1633,1637,1648,1659,1669,1681,1689,1698,1710],{"nctId":1607,"briefTitle":1608,"status":244,"phases":1609,"primaryCompletion":1610,"completion":1610,"start":1611,"conditions":1612,"interventions":1614},"NCT00006038","Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer",[90],"2003-02","2000-02",[1602,1613],"Gastric Cancer",[47,1023,1615,1616,391],"floxuridine","fluorouracil",{"nctId":1618,"briefTitle":1619,"status":244,"phases":1620,"primaryCompletion":1621,"start":1622,"conditions":1623,"interventions":1624},"NCT00059943","Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer",[90],"2005-09","2002-09",[15,21,18],[1023],{"nctId":1626,"briefTitle":1627,"status":244,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"conditions":1631,"interventions":1632},"NCT00003037","Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",[89,90],"2002-03","1997-04",[21],[47,1023,441],{"nctId":1009,"briefTitle":1010,"status":244,"phases":1634,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1635,"interventions":1636},[90],[33,1017,1018,1019,1020],[1022,1023,920],{"nctId":1638,"briefTitle":1639,"status":244,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":1643,"interventions":1644},"NCT01443078","Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)",[90],"2015-04","2011-10",[21],[1645,47,224,1646,1647,1181],"pemetrexed","Gemcitabine Hydrochloride","Vinorelbine Tartrate",{"nctId":1649,"briefTitle":1650,"status":244,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1656},"NCT00587431","Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer",[90],"2008-02","2003-07",102,[18],[1657,1658,1181],"GnRh","Testosterone Gel",{"nctId":1660,"briefTitle":1661,"status":244,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1665,"conditions":1666,"interventions":1667},"NCT00003103","Chemotherapy in Treating Patients With Solid Tumors",[89,90],"2002-08","1997-08",57,[971,15,36,1602,1586,783,21,30,18,1568],[1668,1023],"oblimersen sodium",{"nctId":1670,"briefTitle":1671,"status":158,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":1675,"interventions":1678},"NCT06123338","A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer",[90],"2027-11-30","2024-02-01",[1602,1676,1677],"Gastric Adenocarcinoma","HER2 Gene Mutation",[42,984,944,1679,1680,1181],"Capecitabine","5-Fluorouracil",{"nctId":1682,"briefTitle":1683,"status":244,"phases":1684,"primaryCompletion":680,"completion":680,"start":1685,"enrollment":705,"conditions":1686,"interventions":1688},"NCT00004066","Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma",[90],"1999-06",[30,33,1687],"Small Intestine Cancer",[288,1023,441],{"nctId":1690,"briefTitle":1691,"status":244,"phases":1692,"completion":746,"start":1693,"enrollment":306,"conditions":1694,"interventions":1696},"NCT00260026","Safety and Pharmacokinetics of Jin Fu Kang in Comb w\u002FDocetaxel for Patients w\u002FNon-Small Cell Lung Cancer",[90],"2004-11",[1695],"Non-Small Cell Lung Cancer",[1181,1697],"Jin Fu Kang",{"nctId":1699,"briefTitle":1700,"status":244,"phases":1701,"primaryCompletion":1702,"start":1703,"conditions":1704,"interventions":1706},"NCT00014352","Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer",[90],"2003-03","2000-09",[18,1705],"Thromboembolism",[1023,345,1707,1708,1709],"estramustine phosphate sodium","ketoconazole","warfarin",{"nctId":1170,"briefTitle":1171,"status":158,"phases":1711,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":836,"conditions":1712,"interventions":1713},[89,90],[1176,1177,33,1178],[1180,923,1181],{"trials":1715,"activeCount":97,"soonestReadout":1208},[1716,1720],{"nctId":1196,"briefTitle":1197,"status":244,"phases":1717,"completion":1199,"start":695,"enrollment":1200,"conditions":1718,"interventions":1719},[91],[1202],[923,1181],{"nctId":1205,"briefTitle":1206,"status":158,"phases":1721,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1722,"interventions":1723},[91],[1212],[1214,923,1181],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[],{"intervention":1729,"totalTrials":509,"cells":1730},"Chemoradiation",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1760,"PHASE4":1772,"NA":1774},{"trials":1732,"activeCount":101},[],{"trials":1734,"activeCount":101},[],{"trials":1736,"activeCount":1094,"soonestReadout":1751},[1737,1747],{"nctId":1738,"briefTitle":1739,"status":158,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT06984861","A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer",[90],"2028-05","2025-05-13",74,[1745],"Oropharyngeal Carcinoma",[1729],{"nctId":1748,"briefTitle":1749,"status":158,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":356,"conditions":1753,"interventions":1759},"NCT05307939","A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)",[90],"2027-03-24","2022-03-24",[1754,1755,1756,1757,1758],"HPV","Oropharynx Cancer","HPV-Related Carcinoma","HPV-Related Malignancy","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[1729],{"trials":1761,"activeCount":97,"soonestReadout":1766},[1762],{"nctId":1763,"briefTitle":1764,"status":158,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1771},"NCT06563479","A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer",[91],"2027-08","2024-08-19",291,[1770],"HPV-Related Squamous Cell Carcinoma",[1729,1729],{"trials":1773,"activeCount":101},[],{"trials":1775,"activeCount":101},[],{"intervention":1777,"totalTrials":509,"cells":1778},"N-Acetylcysteine",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1791,"PHASE3":1803,"PHASE4":1816,"NA":1818},{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":97,"soonestReadout":1787},[1783],{"nctId":1784,"briefTitle":1785,"status":113,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":601,"conditions":1789,"interventions":1790},"NCT05081479","A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma",[89],"2026-10-21","2021-12-08",[24],[1777],{"trials":1792,"activeCount":97,"soonestReadout":812},[1793],{"nctId":1794,"briefTitle":1795,"status":113,"phases":1796,"primaryCompletion":812,"completion":812,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1801},"NCT04374461","A Study of N-acetylcysteine in Patients With COVID-19 Infection",[90],"2020-05-01",48,[1800],"Covid-19",[1802],"N-acetylcysteine",{"trials":1804,"activeCount":97,"soonestReadout":531},[1805],{"nctId":1806,"briefTitle":1807,"status":113,"phases":1808,"primaryCompletion":531,"completion":531,"start":1809,"enrollment":1810,"conditions":1811,"interventions":1814},"NCT02750319","Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery",[91],"2016-04",184,[1812,1813],"Thoracic Surgery","Atrial Fibrillation in High Risk Patients",[1815,1777],"Amiodarone",{"trials":1817,"activeCount":101},[],{"trials":1819,"activeCount":101},[],{"intervention":1260,"totalTrials":1434,"cells":1821},{"EARLY_PHASE1":1822,"PHASE1":1836,"PHASE2":1888,"PHASE3":1923,"PHASE4":1929,"NA":1931},{"trials":1823,"activeCount":101},[1824],{"nctId":1825,"briefTitle":1826,"status":505,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1094,"conditions":1830,"interventions":1835},"NCT02966730","Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy",[88],"2019-06-20","2016-11",[1831,1832,1833,1834],"Follicular Lymphoma","Follicular Lymphoma, Grade 1","Follicular Lymphoma, Grade 2","Follicular Lymphoma Grade IIIa",[1260],{"trials":1837,"activeCount":97,"soonestReadout":1851},[1838,1847,1861,1865,1877],{"nctId":1839,"briefTitle":1840,"status":244,"phases":1841,"primaryCompletion":1842,"completion":1842,"start":1843,"enrollment":272,"conditions":1844,"interventions":1846},"NCT02309580","Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma",[89],"2023-05-08","2015-01",[1313,1845],"Relapsed and Refractory T-cell Lymphoma",[1260],{"nctId":1848,"briefTitle":1849,"status":158,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":213,"conditions":1853,"interventions":1858},"NCT07082868","A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)",[89],"2028-08","2025-08-13",[1257,1854,1855,1856,1244,1857,1258],"Primary Central Nervous System Lymphoma","Relapsed Primary Central Nervous System Lymphoma","Refractory Primary Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma",[1859,1860],"ibrutinib","Epcoritamab",{"nctId":1251,"briefTitle":1252,"status":244,"phases":1862,"primaryCompletion":1254,"completion":1254,"start":1255,"enrollment":438,"conditions":1863,"interventions":1864},[89],[1257,1258],[1260,1261,465],{"nctId":1866,"briefTitle":1867,"status":244,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1875},"NCT03939182","Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",[89],"2025-04-22","2019-05-29",15,[1873,1874],"Diffuse Large B-cell Lymphoma","Mantle Cell Lymphoma",[1876,1260],"Abexinostat",{"nctId":1878,"briefTitle":1879,"status":244,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1883,"conditions":1884,"interventions":1886},"NCT02756247","A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",[89],"2022-10-06","2016-05-09",37,[24,1874,1831,1885],"Diffuse Large B Cell Lymphoma",[1887,1260],"Buparlisib",{"trials":1889,"activeCount":101},[1890,1900,1914],{"nctId":1891,"briefTitle":1892,"status":244,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":952,"conditions":1896,"interventions":1898},"NCT03877055","A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma",[89,90],"2022-10-07","2019-03-13",[1897],"Mantle Cell Lymphoma (MCL)",[1899,1260],"Copanlisib",{"nctId":1901,"briefTitle":1902,"status":244,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1910},"NCT02315326","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory\u002FRecurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory\u002FRecurrent Secondary Central Nervous System Lymphoma (SCNSL)",[89,90],"2026-01-28","2014-12-08",93,[1908,1909],"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)","Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)",[1260,1911,1912,1913],"HD- Methotrexate","Rituximab + HD- Methotrexate","procarbazine",{"nctId":1915,"briefTitle":1916,"status":244,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":326,"conditions":1920,"interventions":1922},"NCT03581942","Copanlisib With Ibrutinib for Patients With Recurrent\u002F Refractory Primary Central Nervous System Lymphoma (PCNSL)",[89,90],"2026-02-05","2018-08-23",[1921],"Refractory\u002FRecurrent Primary Central Nervous System Lymphoma (PCNSL)",[1260,1899],{"trials":1924,"activeCount":97,"soonestReadout":1410},[1925],{"nctId":1407,"briefTitle":1408,"status":113,"phases":1926,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1927,"interventions":1928},[91],[1370],[1260,465],{"trials":1930,"activeCount":101},[],{"trials":1932,"activeCount":101},[],{"intervention":478,"totalTrials":1934,"cells":1935},5,{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1950,"PHASE4":1976,"NA":1978},{"trials":1937,"activeCount":101},[],{"trials":1939,"activeCount":101},[],{"trials":1941,"activeCount":101},[1942,1946],{"nctId":467,"briefTitle":468,"status":244,"phases":1943,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":1944,"interventions":1945},[90],[27,24,475,476],[401,288,202,361,478,479],{"nctId":692,"briefTitle":693,"status":244,"phases":1947,"primaryCompletion":695,"completion":695,"start":696,"conditions":1948,"interventions":1949},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"trials":1951,"activeCount":97,"soonestReadout":1960},[1952,1956,1967],{"nctId":853,"briefTitle":854,"status":244,"phases":1953,"primaryCompletion":856,"completion":856,"start":857,"conditions":1954,"interventions":1955},[91],[27],[401,202,361,478,479],{"nctId":1957,"briefTitle":1958,"status":158,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":1962,"conditions":1963,"interventions":1965},"NCT07507643","A Study of Methylprednisolone in People Having Liver Surgery",[91],"2029-03-27","2026-03-27",750,[1964],"Hepatectomy",[1966],"Methylprednisolone",{"nctId":1968,"briefTitle":1969,"status":244,"phases":1970,"completion":1971,"start":1566,"conditions":1972,"interventions":1974},"NCT00043147","Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease",[91],"2005-01",[1973],"Graft Versus Host Disease",[1975,478,445],"beclomethasone dipropionate",{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"intervention":1981,"totalTrials":1094,"cells":1982},"Methadone",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1999,"PHASE4":2010,"NA":2012},{"trials":1984,"activeCount":101},[],{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[1989],{"nctId":1990,"briefTitle":1991,"status":244,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":370,"conditions":1995,"interventions":1997},"NCT00142519","Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain",[90],"2018-07","2005-03",[1996],"Pain",[1981,1998],"methadone and morphine",{"trials":2000,"activeCount":97,"soonestReadout":2005},[2001],{"nctId":2002,"briefTitle":2003,"status":113,"phases":2004,"primaryCompletion":2005,"completion":2005,"start":2006,"enrollment":234,"conditions":2007,"interventions":2009},"NCT05417100","Understanding How Methadone Treatment During Surgery Affects Pain Levels and the Need for Pain Medications After Surgery",[91],"2027-06","2022-06-06",[2008],"Spinal Surgery",[1981],{"trials":2011,"activeCount":101},[],{"trials":2013,"activeCount":101},[],{"intervention":2015,"totalTrials":1094,"cells":2016},"Radium-223",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2032,"PHASE4":2045,"NA":2047},{"trials":2018,"activeCount":101},[],{"trials":2020,"activeCount":101},[],{"trials":2022,"activeCount":101},[2023],{"nctId":2024,"briefTitle":2025,"status":244,"phases":2026,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":1462,"conditions":2029,"interventions":2031},"NCT02278055","Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer",[90],"2022-02-02","2014-10-08",[2030,1996],"Metastatic Prostate Cancer",[2015],{"trials":2033,"activeCount":97,"soonestReadout":2038},[2034],{"nctId":2035,"briefTitle":2036,"status":113,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2042},"NCT03574571","A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer",[91],"2027-04-01","2018-06-19",732,[18],[2043,2044,2015],"Docetaxel 75 mg\u002Fm2","Docetaxel 60 mg\u002Fm2",{"trials":2046,"activeCount":101},[],{"trials":2048,"activeCount":101},[],{"intervention":851,"totalTrials":97,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"trials":2058,"activeCount":97,"soonestReadout":845},[2059],{"nctId":842,"briefTitle":843,"status":158,"phases":2060,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":2061,"interventions":2062},[91],[849],[331,218,331,851],{"trials":2064,"activeCount":101},[],{"trials":2066,"activeCount":101},[],{"intervention":2068,"totalTrials":97,"cells":2069},"antibiotic prophylaxis",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2087,"NA":2089},{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":101},[],{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":97,"soonestReadout":2082},[2078],{"nctId":2079,"briefTitle":2080,"status":113,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":763,"enrollment":2083,"conditions":2084,"interventions":2085},"NCT01407263","Trial of Modifications to Radical Prostatectomy",[91],"2026-07",3204,[18],[2068,2086],"Hemostatic Agent",{"trials":2088,"activeCount":101},[],{"trials":2090,"activeCount":101},[],{"intervention":2086,"totalTrials":97,"cells":2092},{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2105,"NA":2107},{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":101},[],{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":97,"soonestReadout":2082},[2101],{"nctId":2079,"briefTitle":2080,"status":113,"phases":2102,"primaryCompletion":2082,"completion":2082,"start":763,"enrollment":2083,"conditions":2103,"interventions":2104},[91],[18],[2068,2086],{"trials":2106,"activeCount":101},[],{"trials":2108,"activeCount":101},[],{"intervention":2110,"totalTrials":97,"cells":2111},"Bupivacaine",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2128,"NA":2130},{"trials":2113,"activeCount":101},[],{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":97,"soonestReadout":1130},[2120],{"nctId":2121,"briefTitle":2122,"status":158,"phases":2123,"primaryCompletion":1130,"completion":1130,"start":2124,"enrollment":2125,"conditions":2126,"interventions":2127},"NCT03351348","Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control",[91],"2017-11-16",165,[15],[2110],{"trials":2129,"activeCount":101},[],{"trials":2131,"activeCount":101},[],{"intervention":57,"totalTrials":97,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2149,"NA":2151},{"trials":2135,"activeCount":101},[],{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":101},[],{"trials":2141,"activeCount":97,"soonestReadout":56},[2142],{"nctId":54,"briefTitle":55,"status":113,"phases":2143,"primaryCompletion":56,"completion":258,"start":2144,"enrollment":2145,"conditions":2146,"interventions":2148},[91],"2020-06-30",299,[308,2147,605],"Hodgkin Disease",[57],{"trials":2150,"activeCount":101},[],{"trials":2152,"activeCount":101},[],{"intervention":1214,"totalTrials":97,"cells":2154},{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2167,"NA":2169},{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":97,"soonestReadout":1208},[2163],{"nctId":1205,"briefTitle":1206,"status":158,"phases":2164,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":2165,"interventions":2166},[91],[1212],[1214,923,1181],{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[],{"intervention":2172,"totalTrials":97,"cells":2173},"Alvimopan",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2191,"NA":2193},{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[],{"trials":2181,"activeCount":97,"soonestReadout":2186},[2182],{"nctId":2183,"briefTitle":2184,"status":158,"phases":2185,"primaryCompletion":2186,"completion":2186,"start":2187,"enrollment":2188,"conditions":2189,"interventions":2190},"NCT06703476","A Study of Surgical Techniques During Cystectomy",[91],"2028-11","2024-11-21",530,[971],[2172],{"trials":2192,"activeCount":101},[],{"trials":2194,"activeCount":101},[],{"intervention":1815,"totalTrials":97,"cells":2196},{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2209,"NA":2211},{"trials":2198,"activeCount":101},[],{"trials":2200,"activeCount":101},[],{"trials":2202,"activeCount":101},[],{"trials":2204,"activeCount":97,"soonestReadout":531},[2205],{"nctId":1806,"briefTitle":1807,"status":113,"phases":2206,"primaryCompletion":531,"completion":531,"start":1809,"enrollment":1810,"conditions":2207,"interventions":2208},[91],[1812,1813],[1815,1777],{"trials":2210,"activeCount":101},[],{"trials":2212,"activeCount":101},[],{"intervention":2043,"totalTrials":97,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":101},[],{"trials":2218,"activeCount":101},[],{"trials":2220,"activeCount":101},[],{"trials":2222,"activeCount":97,"soonestReadout":2038},[2223],{"nctId":2035,"briefTitle":2036,"status":113,"phases":2224,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":2040,"conditions":2225,"interventions":2226},[91],[18],[2043,2044,2015],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"intervention":2044,"totalTrials":97,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":101},[],{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":97,"soonestReadout":2038},[2241],{"nctId":2035,"briefTitle":2036,"status":113,"phases":2242,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":2040,"conditions":2243,"interventions":2244},[91],[18],[2043,2044,2015],{"trials":2246,"activeCount":101},[],{"trials":2248,"activeCount":101},[],{"intervention":2250,"totalTrials":97,"cells":2251},"Local anesthesia",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2268,"NA":2270},{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":101},[],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":97,"soonestReadout":1741},[2260],{"nctId":2261,"briefTitle":2262,"status":158,"phases":2263,"primaryCompletion":1741,"completion":1741,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2267},"NCT06986083","A Study of Changes to Prostate Procedures",[91],"2025-05-19",800,[18],[2250],{"trials":2269,"activeCount":101},[],{"trials":2271,"activeCount":101},[],{"intervention":42,"totalTrials":1052,"cells":2273},{"EARLY_PHASE1":2274,"PHASE1":2284,"PHASE2":2354,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2275,"activeCount":97,"soonestReadout":304},[2276],{"nctId":2277,"briefTitle":2278,"status":113,"phases":2279,"primaryCompletion":304,"completion":304,"start":2280,"enrollment":234,"conditions":2281,"interventions":2283},"NCT03832569","Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors",[88],"2019-02-20",[328,2282],"Identified by NGS, PCR or IHC",[42],{"trials":2285,"activeCount":1114,"soonestReadout":2082},[2286,2295,2304,2319,2328],{"nctId":2287,"briefTitle":2288,"status":113,"phases":2289,"primaryCompletion":324,"completion":324,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2294},"NCT04897022","A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma",[89],"2021-08-10",7,[2293],"Malignant Pleural Mesothelioma",[42],{"nctId":2296,"briefTitle":2297,"status":113,"phases":2298,"primaryCompletion":2082,"completion":2082,"start":2299,"enrollment":1232,"conditions":2300,"interventions":2301},"NCT03220477","Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.",[89],"2017-08-04",[21],[42,2302,2303],"Guadecitabine","Mocetinostat",{"nctId":2305,"briefTitle":2306,"status":158,"phases":2307,"primaryCompletion":2308,"completion":2308,"start":2309,"enrollment":356,"conditions":2310,"interventions":2318},"NCT06246968","A Study of Pembrolizumab and Cryoablation in People With Breast Cancer",[89],"2027-01-29","2024-01-29",[2311,15,2312,2313,2314,2315,2316,2317],"Metastatic Breast Cancer","Breast Cancer Stage IV","Triple Negative Breast Cancer","Triple Negative Breast Neoplasms","Metastatic Triple-Negative Breast Carcinoma","Locally Advanced Breast Cancer","Locally Advanced Triple-Negative Breast Carcinoma",[42],{"nctId":2320,"briefTitle":2321,"status":244,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":1094,"conditions":2325,"interventions":2327},"NCT05071014","A Study of Pembrolizumab and Cryoablation in People With Mesothelioma",[89],"2023-12-18","2021-09-24",[21,2326],"Unresectable Mesothelioma",[42],{"nctId":2329,"briefTitle":2330,"status":158,"phases":2331,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2352},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[89],"2028-05-04","2023-05-04",56,[2336,2337,2338,2339,2340,2341,2342,2343,2344,2345,1590,1591,2346,1020,2347,2348,2349,2350,2351],"Cutaneous Squamous Cell Carcinoma","SCC - Squamous Cell Carcinoma","Basal Cell Carcinoma","BCC","BCC - Basal Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Sebaceous Carcinoma","Extramammary Paget Disease","Kaposi Sarcoma","Adnexal Carcinoma","Cutaneous Neoplasm","Advanced Cancer","Metastatic Cancer","Refractory Cancer","Solid Tumor",[2353,42],"MQ719",{"trials":2355,"activeCount":1412,"soonestReadout":41},[2356,2365,2376,2386,2402,2413,2421,2430,2434,2443,2451,2455,2468,2478,2486,2494,2498,2507,2512,2517,2525,2535,2540,2548,2558,2562,2566,2576],{"nctId":2357,"briefTitle":2358,"status":244,"phases":2359,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":213,"conditions":2362,"interventions":2364},"NCT05156268","A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma",[90],"2026-04-24","2022-01-27",[2363],"Endometrial Carcinosarcoma",[42,77],{"nctId":2366,"briefTitle":2367,"status":158,"phases":2368,"primaryCompletion":2038,"completion":2038,"start":2369,"enrollment":356,"conditions":2370,"interventions":2374},"NCT04332874","A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg",[90],"2020-04-01",[33,2371,2372,2373],"Myxofibrosarcoma","Undifferentiated Pleomorphic Sarcoma","Alveolar Soft Part Sarcoma",[42,2375],"infusion of melphalan and dactinomycin",{"nctId":2377,"briefTitle":2378,"status":244,"phases":2379,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":234,"conditions":2383,"interventions":2385},"NCT02730130","Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients",[90],"2017-09-26","2022-10-12","2016-06-03",[15,2384],"Metastatic Triple Negative",[42],{"nctId":2387,"briefTitle":2388,"status":505,"phases":2389,"primaryCompletion":2390,"completion":2390,"start":2391,"enrollment":97,"conditions":2392,"interventions":2401},"NCT04510285","A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection",[90],"2022-12-30","2020-08-10",[2393,1613,2394,1602,2395,2396,2397,2398,2399,2400],"Esophagogastric Tumors","Gastric Tumor","Esophageal Neoplasms","Esophageal Tumor","GastroEsophageal Cancer","Gastroesophageal Junction Adenocarcinoma","Gastroesophageal Junction Tumor","Gastroesophageal Junction Cancer",[984,42],{"nctId":2403,"briefTitle":2404,"status":113,"phases":2405,"primaryCompletion":498,"completion":498,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2411},"NCT04209660","Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers",[90],"2020-06-02",64,[2409,2410],"Adenoid Cystic Carcinoma","Salivary Gland Cancer",[2412,42],"Lenvatinib",{"nctId":2414,"briefTitle":2415,"status":158,"phases":2416,"primaryCompletion":2005,"completion":2005,"start":2417,"enrollment":1412,"conditions":2418,"interventions":2419},"NCT05239624","Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer",[90],"2022-06-02",[938],[2420,42],"Enfortumab vedotin",{"nctId":2422,"briefTitle":2423,"status":113,"phases":2424,"primaryCompletion":990,"completion":990,"start":2425,"enrollment":2426,"conditions":2427,"interventions":2429},"NCT04784247","Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma",[90],"2021-03-18",52,[2428],"Advanced Sarcoma",[2412,42],{"nctId":998,"briefTitle":999,"status":158,"phases":2431,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":2432,"interventions":2433},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":2435,"briefTitle":2436,"status":244,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":1641,"enrollment":2439,"conditions":2440,"interventions":2442},"NCT02437071","Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients",[90],"2024-09-20",34,[2441],"Metastatic Colorectal Cancer",[42],{"nctId":79,"briefTitle":80,"status":113,"phases":2444,"primaryCompletion":81,"completion":1130,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2450},[90],"2018-11-09",19,[2448,2449],"NK\u002FT-Cell Lymphoma of Nasal Cavity (Diagnosis)","NK\u002FT-Cell Lymphoma of Nasopharynx (Diagnosis)",[42],{"nctId":1025,"briefTitle":1026,"status":113,"phases":2452,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":272,"conditions":2453,"interventions":2454},[90],[1031,1032,1033,1034,1035],[923,42],{"nctId":2456,"briefTitle":2457,"status":113,"phases":2458,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":2462,"conditions":2463,"interventions":2466},"NCT03069378","A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and\u002For Locally Advanced Sarcoma",[90],"2025-07-22","2026-03","2017-03-03",41,[33,2464,2465],"Epithelioid Sarcoma","Cutaneous Angiosarcoma",[2467,42],"Talimogene Laherparepvec",{"nctId":2469,"briefTitle":2470,"status":113,"phases":2471,"primaryCompletion":2472,"completion":2472,"start":2473,"enrollment":203,"conditions":2474,"interventions":2477},"NCT04666740","A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy",[90],"2027-01","2020-12-18",[2475,2476],"Metastatic Pancreatic Ductal Adenocarcinoma","Homologous Recombination Deficiency (HRD)",[42,77],{"nctId":2479,"briefTitle":2480,"status":113,"phases":2481,"primaryCompletion":2005,"completion":2005,"start":2482,"enrollment":2483,"conditions":2484,"interventions":2485},"NCT03179917","Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma",[90],"2017-06-08",22,[604],[42],{"nctId":2487,"briefTitle":2488,"status":113,"phases":2489,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":341,"conditions":2492,"interventions":2493},"NCT03504163","Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]",[90],"2026-04","2018-06-27",[971],[42,1135],{"nctId":1068,"briefTitle":1069,"status":158,"phases":2495,"primaryCompletion":324,"completion":324,"start":1071,"enrollment":1072,"conditions":2496,"interventions":2497},[90],[604,1074],[798,1022,1076,1077],{"nctId":2499,"briefTitle":2500,"status":158,"phases":2501,"primaryCompletion":2472,"completion":2472,"start":2502,"enrollment":1665,"conditions":2503,"interventions":2505},"NCT05188508","Pembrolizumab, Olaparib, and Temozolomide for People With Glioma",[90],"2022-01-14",[2504],"Glioma",[42,2506],"Olaparib and Temozolomide",{"nctId":59,"briefTitle":60,"status":113,"phases":2508,"primaryCompletion":61,"completion":2472,"start":2509,"enrollment":356,"conditions":2510,"interventions":2511},[90],"2018-01-23",[33],[62,42],{"nctId":74,"briefTitle":75,"status":113,"phases":2513,"primaryCompletion":76,"completion":2472,"start":2514,"enrollment":332,"conditions":2515,"interventions":2516},[90],"2022-01-31",[15],[77,42],{"nctId":2518,"briefTitle":2519,"status":158,"phases":2520,"primaryCompletion":2472,"completion":2472,"start":2521,"enrollment":2439,"conditions":2522,"interventions":2524},"NCT04683679","A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive\u002FHer2 Negative Breast Cancer",[90],"2021-04-21",[2313,2523,15,2311],"TNBC - Triple-Negative Breast Cancer",[42,77],{"nctId":2526,"briefTitle":2527,"status":113,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":718,"conditions":2531,"interventions":2534},"NCT05147558","A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma",[90],"2026-12-23","2021-12-23",[2532,2533],"Uterine Carcinosarcoma","Advanced Uterine Carcinosarcoma",[42,2412],{"nctId":39,"briefTitle":40,"status":113,"phases":2536,"primaryCompletion":41,"completion":304,"start":1092,"enrollment":573,"conditions":2537,"interventions":2539},[90],[2538],"Adrenocortical Carcinoma",[42],{"nctId":2541,"briefTitle":2542,"status":158,"phases":2543,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":992,"conditions":2546,"interventions":2547},"NCT07089992","A Study of Pembrolizumab in People With Ultra-Rare Sarcomas",[90],"2028-12","2025-12-04",[33],[42],{"nctId":2549,"briefTitle":2550,"status":244,"phases":2551,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":2555,"interventions":2556},"NCT02954536","Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer",[90],"2022-06-01","2023-03-14","2016-11-03",[1602,1613],[798,768,2557,47,944,1680],"capecitabine",{"nctId":1670,"briefTitle":1671,"status":158,"phases":2559,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":2560,"interventions":2561},[90],[1602,1676,1677],[42,984,944,1679,1680,1181],{"nctId":786,"briefTitle":787,"status":113,"phases":2563,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":2564,"interventions":2565},[89,90],[793,794,795,21,15],[797,202,798],{"nctId":2567,"briefTitle":2568,"status":158,"phases":2569,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":283,"conditions":2572,"interventions":2575},"NCT06066333","Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma",[90],"2026-09-27","2023-09-27",[2538,2573,2574],"ACC","Metastatic Adrenocortical Carcinoma",[42],{"nctId":2577,"briefTitle":2578,"status":113,"phases":2579,"primaryCompletion":258,"completion":258,"start":2580,"enrollment":1015,"conditions":2581,"interventions":2584},"NCT03179930","Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas",[90],"2017-06-07",[24,2582,2583],"Relapsed","Refractory",[2585,42],"Entinostat",{"trials":2587,"activeCount":101},[],{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":97,"soonestReadout":2472},[2592],{"nctId":2593,"briefTitle":2594,"status":113,"phases":2595,"primaryCompletion":2472,"completion":2472,"start":2596,"enrollment":1600,"conditions":2597,"interventions":2599},"NCT02658279","Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype",[93],"2016-01-22",[2504,2598],"Recurrent Malignant Glioma",[42],{"intervention":942,"totalTrials":1462,"cells":2601},{"EARLY_PHASE1":2602,"PHASE1":2613,"PHASE2":2670,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2603,"activeCount":97,"soonestReadout":531},[2604],{"nctId":2605,"briefTitle":2606,"status":113,"phases":2607,"primaryCompletion":531,"completion":531,"start":2608,"enrollment":306,"conditions":2609,"interventions":2611},"NCT03143270","A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer",[88],"2017-04-28",[2610],"Liver Cancer",[2612,942],"Drug Eluting Bead Transarterial Chemoembolization",{"trials":2614,"activeCount":1094,"soonestReadout":1130},[2615,2625,2638,2650,2658,2662],{"nctId":2616,"briefTitle":2617,"status":244,"phases":2618,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":601,"conditions":2621,"interventions":2623},"NCT03922880","Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",[89],"2023-01-20","2019-04-16",[2622],"Uveal Melanoma",[2624,942,941],"ADI PEG20",{"nctId":2626,"briefTitle":2627,"status":244,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":1809,"enrollment":2630,"conditions":2631,"interventions":2635},"NCT02737787","A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer",[89],"2023-04-06",11,[30,2632,2633,2634],"Fallopian Tube","Primary Peritoneal Cancer","Recurrent Ovarian Cancer",[2636,942,2637],"WT1 Vaccine","NY-ESO-1 Vaccine",{"nctId":2639,"briefTitle":2640,"status":244,"phases":2641,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":1434,"conditions":2644,"interventions":2647},"NCT04040231","Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma",[89],"2024-11-14","2019-07-24",[794,2645,2646],"Pleural Mesothelioma","Wilms Tumor",[2648,942,2649],"Galinpepimut-S","Sargramostim",{"nctId":2651,"briefTitle":2652,"status":113,"phases":2653,"primaryCompletion":1130,"completion":1130,"start":2654,"enrollment":2483,"conditions":2655,"interventions":2656},"NCT04162015","A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma",[89],"2019-11-12",[2293],[942,1107,2657],"Cisplatin or Carboplatin",{"nctId":930,"briefTitle":931,"status":158,"phases":2659,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":2660,"interventions":2661},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"nctId":2663,"briefTitle":2664,"status":244,"phases":2665,"primaryCompletion":2545,"completion":2545,"start":2299,"enrollment":1600,"conditions":2666,"interventions":2668},"NCT03245892","A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer",[89],[2667,2632,2633],"High Grade Serous Ovarian",[2669,942,941],"Carboplatin and Paclitaxel",{"trials":2671,"activeCount":296,"soonestReadout":2082},[2672,2684,2694,2706,2721,2729,2737,2746,2756,2770,2780,2784,2792,2799,2810,2820,2829,2838,2846,2856,2865],{"nctId":2673,"briefTitle":2674,"status":113,"phases":2675,"primaryCompletion":304,"completion":304,"start":2676,"enrollment":573,"conditions":2677,"interventions":2680},"NCT04757363","A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer",[90],"2021-02-11",[2678,2679],"Esophagogastric Cancer","HER2-Negative",[2681,2682,2683],"regorafenib","nivolumab","FOLFOX chemotherapy with oxaliplatin",{"nctId":2685,"briefTitle":2686,"status":244,"phases":2687,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":2690,"conditions":2691,"interventions":2692},"NCT02553642","Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)",[90],"2024-04-29","2015-09-14",81,[971,2341],[942,2693],"Nivolumab plus Ipilimumab",{"nctId":2695,"briefTitle":2696,"status":244,"phases":2697,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":1434,"conditions":2700,"interventions":2705},"NCT04042753","Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors",[90],"2026-06-01","2019-07-31",[2701,2702,2703,2704],"Pituitary","Pituitary Tumor","Pituitary Carcinoma","Pituitary Cancer",[941,942,942],{"nctId":2707,"briefTitle":2708,"status":113,"phases":2709,"primaryCompletion":324,"completion":324,"start":2710,"enrollment":162,"conditions":2711,"interventions":2719},"NCT03635892","A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma",[90],"2018-08-13",[2712,2713,2714,2715,2716,2717,2718],"Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma","Unclassified Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Fumarate Hydratase Deficient Renal Cell Carcinoma","Succinate Dehydrogenase Deficient Renal Cell Carcinoma","Collecting Duct Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma",[2720,2682],"cabozantinib",{"nctId":2722,"briefTitle":2723,"status":244,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":272,"conditions":2727,"interventions":2728},"NCT04401774","Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy",[90],"2026-01-22","2020-05-22",[1257],[942],{"nctId":2730,"briefTitle":2731,"status":244,"phases":2732,"primaryCompletion":2733,"completion":2733,"start":2734,"enrollment":2407,"conditions":2735,"interventions":2736},"NCT03172624","Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer",[90],"2024-12-18","2017-05-26",[2410],[942,941],{"nctId":2738,"briefTitle":2739,"status":113,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":306,"conditions":2743,"interventions":2744},"NCT04624178","A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma",[90],"2026-11-16","2020-11-05",[1017],[2745,942],"Rucaparib",{"nctId":2747,"briefTitle":2748,"status":113,"phases":2749,"primaryCompletion":531,"completion":531,"start":2750,"enrollment":2751,"conditions":2752,"interventions":2754},"NCT03122522","A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",[90],"2017-04-17",70,[2753],"Metastatic Melanoma",[2755,2682],"ipilimumab",{"nctId":2757,"briefTitle":2758,"status":244,"phases":2759,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":1052,"conditions":2762,"interventions":2769},"NCT03241745","A Study of Nivolumab in Selected Uterine Cancer Patients",[90],"2024-04-01","2017-08-03",[2763,2764,2765,1017,2766,2767,2768],"Uterine Cancer","Endometrial Carcinoma","Carcinosarcoma","Undifferentiated Sarcoma","High Grade Endometrial Stromal Sarcoma","Clear Cell Carcinoma",[942],{"nctId":2771,"briefTitle":2772,"status":113,"phases":2773,"primaryCompletion":990,"completion":990,"start":2774,"enrollment":601,"conditions":2775,"interventions":2778},"NCT05239533","Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer",[90],"2022-02-16",[2776,783,2777],"Clear Cell Renal Cell Carcinoma","Advanced Renal Cell Carcinoma",[2779,942],"177Lu-labeled-girentuximab",{"nctId":1099,"briefTitle":1100,"status":158,"phases":2781,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":2782,"interventions":2783},[90],[21,1104,1105],[974,1107,923,224,1108,942],{"nctId":2785,"briefTitle":2786,"status":113,"phases":2787,"primaryCompletion":1130,"completion":1130,"start":2788,"enrollment":573,"conditions":2789,"interventions":2791},"NCT03743662","Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma",[90],"2018-11-12",[2790],"Glioblastoma",[1157,942],{"nctId":2793,"briefTitle":2794,"status":113,"phases":2795,"primaryCompletion":2472,"completion":2472,"start":2796,"enrollment":2426,"conditions":2797,"interventions":2798},"NCT03520491","A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy",[90],"2018-04-25",[971],[942,941],{"nctId":2800,"briefTitle":2801,"status":113,"phases":2802,"primaryCompletion":2472,"completion":2472,"start":2803,"enrollment":705,"conditions":2804,"interventions":2805},"NCT03033914","A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)",[89,90],"2017-01-25",[604],[2806,2807,2808,2809,942],"doxorubicin","Bleomycin","vinblastine","dacarbazine",{"nctId":2811,"briefTitle":2812,"status":113,"phases":2813,"primaryCompletion":1469,"completion":1469,"start":2814,"enrollment":2815,"conditions":2816,"interventions":2818},"NCT03282344","A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and\u002For Locally Advanced Sarcoma",[90],"2017-09-12",88,[2817],"SARCOMA",[2819,942],"NKTR-214",{"nctId":2821,"briefTitle":2822,"status":113,"phases":2823,"primaryCompletion":1469,"completion":1469,"start":2824,"enrollment":454,"conditions":2825,"interventions":2827},"NCT04106414","Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment",[90],"2019-09-24",[2826,2363],"Endometrial Adenocarcinoma",[942,2828],"BMS- 986205",{"nctId":2830,"briefTitle":2831,"status":2832,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":1895,"enrollment":101,"conditions":2835,"interventions":2836},"NCT03879811","Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer","WITHDRAWN",[90],"2021-03",[36],[2837,942],"TMZ",{"nctId":2839,"briefTitle":2840,"status":113,"phases":2841,"primaryCompletion":2082,"completion":2082,"start":2842,"enrollment":326,"conditions":2843,"interventions":2845},"NCT04457284","Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer",[90],"2020-11-18",[2844],"Colorectal Adenocarcinoma",[818,974,942],{"nctId":2847,"briefTitle":2848,"status":244,"phases":2849,"primaryCompletion":2850,"completion":2850,"start":2851,"enrollment":1462,"conditions":2852,"interventions":2854},"NCT02350764","Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs",[90],"2023-09-25","2015-01-20",[2853],"Advanced Stage Non-small Cell Lung Cancer",[2682,2855],"pilimumab",{"nctId":2857,"briefTitle":2858,"status":113,"phases":2859,"primaryCompletion":2860,"completion":2860,"start":2861,"enrollment":1232,"conditions":2862,"interventions":2864},"NCT05289193","CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma",[90],"2027-03-11","2022-03-11",[2341,2863],"Melanoma Stage III",[942,941],{"nctId":2866,"briefTitle":2867,"status":244,"phases":2868,"primaryCompletion":2869,"completion":2869,"start":2870,"enrollment":523,"conditions":2871,"interventions":2873},"NCT02684253","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",[90],"2021-01-22","2016-02-11",[2872],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[942],{"trials":2875,"activeCount":101},[],{"trials":2877,"activeCount":101},[],{"trials":2879,"activeCount":101},[2880],{"nctId":2881,"briefTitle":2882,"status":244,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":259,"enrollment":1934,"conditions":2885,"interventions":2886},"NCT02833233","A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer",[93],"2024-06-07",[15],[941,942],{"intervention":47,"totalTrials":2888,"cells":2889},62,{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":3021,"PHASE3":3317,"PHASE4":3331,"NA":3333},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":97,"soonestReadout":1583},[2894,2902,2910,2918,2927,2936,2943,2951,2957,2965,2969,2978,2986,2994,2998,3006,3013],{"nctId":2895,"briefTitle":2896,"status":244,"phases":2897,"primaryCompletion":2898,"completion":588,"start":737,"conditions":2899,"interventions":2900},"NCT00072332","Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors",[89],"2005-12",[1602,1613,1568],[47,2901],"edotecarin",{"nctId":2903,"briefTitle":2904,"status":244,"phases":2905,"primaryCompletion":648,"start":2906,"enrollment":454,"conditions":2907,"interventions":2908},"NCT00003358","Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[89],"1998-01",[285,30,286],[2909,47,441],"chemotherapy",{"nctId":2911,"briefTitle":2912,"status":244,"phases":2913,"primaryCompletion":2914,"completion":2914,"start":2915,"conditions":2916,"interventions":2917},"NCT00005638","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer",[89],"2004-04","1999-10",[1602,1613],[47,683],{"nctId":2919,"briefTitle":2920,"status":244,"phases":2921,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":234,"conditions":2924,"interventions":2925},"NCT02121990","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV\u002FIP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",[89],"2020-08-19","2014-04-21",[30,2633,285],[2926,1157,974,77],"Paclitaxel,",{"nctId":2928,"briefTitle":2929,"status":244,"phases":2930,"primaryCompletion":2931,"completion":2931,"start":2932,"conditions":2933,"interventions":2934},"NCT00003242","Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors",[89],"2001-10","1998-02",[1568],[2935,47,741],"bryostatin 1",{"nctId":2937,"briefTitle":2938,"status":244,"phases":2939,"primaryCompletion":2940,"completion":588,"start":2915,"conditions":2941,"interventions":2942},"NCT00005791","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2002-07",[1568],[47,1616,683],{"nctId":2944,"briefTitle":2945,"status":2832,"phases":2946,"primaryCompletion":1641,"completion":1641,"start":1141,"enrollment":101,"conditions":2947,"interventions":2949},"NCT01836341","Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation",[89],[2948],"Non-small Cell Lung Cancer",[2950,974,224,1107],"Afatinib",{"nctId":2952,"briefTitle":2938,"status":244,"phases":2953,"primaryCompletion":756,"completion":756,"start":2954,"conditions":2955,"interventions":2956},"NCT00003742",[89],"1998-10",[1568],[47,683,741],{"nctId":2958,"briefTitle":2959,"status":244,"phases":2960,"primaryCompletion":875,"completion":875,"start":736,"enrollment":356,"conditions":2961,"interventions":2962},"NCT00423865","Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors",[89],[1568],[47,2963,2964],"everolimus","gene expression analysis",{"nctId":1580,"briefTitle":1581,"status":158,"phases":2966,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":2967,"interventions":2968},[89],[1586,1587,1588,1589,1590,1591],[974,224,1181,1593,1594,1595],{"nctId":2970,"briefTitle":2971,"status":244,"phases":2972,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":356,"conditions":2975,"interventions":2977},"NCT02120807","Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas",[89],"2023-01-24","2014-04-15",[2976],"Stage IV Lung Adenocarcinoma",[1108,47,1645],{"nctId":2979,"briefTitle":2980,"status":244,"phases":2981,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":454,"conditions":2984,"interventions":2985},"NCT00002711","Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus",[89],"2000-10","1995-10",[1602],[2909,47,741],{"nctId":2987,"briefTitle":2988,"status":244,"phases":2989,"primaryCompletion":695,"completion":695,"start":2990,"enrollment":356,"conditions":2991,"interventions":2993},"NCT00003133","Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer",[89],"1997-09",[971,2992],"Transitional Cell Cancer of the Renal Pelvis and Ureter",[288,47,345,441,741],{"nctId":1597,"briefTitle":1598,"status":244,"phases":2995,"primaryCompletion":588,"completion":588,"start":856,"enrollment":1600,"conditions":2996,"interventions":2997},[89],[1602],[47,1023,683],{"nctId":2999,"briefTitle":3000,"status":244,"phases":3001,"primaryCompletion":2931,"completion":2931,"start":3002,"enrollment":3003,"conditions":3004,"interventions":3005},"NCT00003004","Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors",[89],"1997-07",73,[1568],[1570,47,741],{"nctId":3007,"briefTitle":3008,"status":244,"phases":3009,"start":2940,"conditions":3010,"interventions":3011},"NCT00045604","Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[89],[21],[47,3012,683],"imatinib mesylate",{"nctId":3014,"briefTitle":3015,"status":244,"phases":3016,"primaryCompletion":1083,"completion":1083,"start":1575,"enrollment":3017,"conditions":3018,"interventions":3019},"NCT00084812","Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],43,[1568],[47,3020],"safingol",{"trials":3022,"activeCount":2630,"soonestReadout":46},[3023,3027,3036,3040,3047,3055,3059,3068,3082,3089,3097,3105,3109,3117,3126,3130,3137,3144,3153,3165,3169,3176,3182,3189,3193,3197,3204,3216,3223,3227,3234,3238,3247,3254,3262,3266,3270,3277,3284,3288,3301,3305],{"nctId":336,"briefTitle":337,"status":244,"phases":3024,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":3025,"interventions":3026},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":3028,"briefTitle":3029,"status":244,"phases":3030,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":1447,"conditions":3033,"interventions":3034},"NCT00397904","Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin",[90],"2010-09","2006-10",[1602,1613],[3035,47,683],"cetuximab",{"nctId":1607,"briefTitle":1608,"status":244,"phases":3037,"primaryCompletion":1610,"completion":1610,"start":1611,"conditions":3038,"interventions":3039},[90],[1602,1613],[47,1023,1615,1616,391],{"nctId":3041,"briefTitle":3042,"status":244,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":3045,"interventions":3046},"NCT00003105","Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer",[89,90],"2004-08",[971,2992],[288,47,345,441,442,741],{"nctId":3048,"briefTitle":3049,"status":244,"phases":3050,"primaryCompletion":695,"completion":695,"start":3051,"enrollment":356,"conditions":3052,"interventions":3053},"NCT00002919","Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer",[90],"1996-11",[971],[288,47,345,362,3054],"vinblastine sulfate",{"nctId":965,"briefTitle":966,"status":113,"phases":3056,"primaryCompletion":498,"completion":498,"start":968,"enrollment":969,"conditions":3057,"interventions":3058},[89,90],[971,972,938],[86,923,974],{"nctId":3060,"briefTitle":3061,"status":113,"phases":3062,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":3065,"interventions":3067},"NCT01873326","Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors",[90],"2013-06",92,[3066],"Germ Cell Tumors",[1595,222,974,225,2807,223],{"nctId":3069,"briefTitle":3070,"status":158,"phases":3071,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":3075,"interventions":3078},"NCT07477457","A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma",[90],"2028-03","2028-03-11","2026-03-11",[3076,3077],"Osteosarcoma","Metastasis",[579,221,974,3079,3080,3081,1087,222],"Gefitinib","Trametinib","Disulfiram",{"nctId":3083,"briefTitle":3084,"status":244,"phases":3085,"primaryCompletion":588,"completion":588,"start":1356,"enrollment":398,"conditions":3086,"interventions":3088},"NCT00590031","Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.",[90],[3087],"Esophageal Carcinoma",[974,819],{"nctId":3090,"briefTitle":3091,"status":244,"phases":3092,"primaryCompletion":1150,"completion":1150,"start":1347,"enrollment":601,"conditions":3093,"interventions":3095},"NCT00577707","Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)",[90],[3094,21],"Non Small Cell Lung Cancer",[3096,1107,974],"erlotinib",{"nctId":3098,"briefTitle":3099,"status":244,"phases":3100,"primaryCompletion":3101,"completion":3101,"start":3102,"conditions":3103,"interventions":3104},"NCT00003055","Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer",[90],"2001-04","1997-06",[1602,1613],[47,683],{"nctId":987,"briefTitle":988,"status":113,"phases":3106,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":3107,"interventions":3108},[90],[938,994,995],[86,923,974],{"nctId":3110,"briefTitle":3111,"status":113,"phases":3112,"primaryCompletion":1130,"completion":1130,"start":3113,"enrollment":1114,"conditions":3114,"interventions":3115},"NCT06145412","A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer",[90],"2023-11-16",[1586],[3116,974],"Xevinapan",{"nctId":3118,"briefTitle":3119,"status":244,"phases":3120,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":3123,"interventions":3124},"NCT00003776","Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma",[90],"2000-03","1998-12",[33],[288,47,345,442,391,362,3125],"trimetrexate glucuronate",{"nctId":1626,"briefTitle":1627,"status":244,"phases":3127,"primaryCompletion":1629,"completion":1629,"start":1630,"conditions":3128,"interventions":3129},[89,90],[21],[47,1023,441],{"nctId":44,"briefTitle":45,"status":113,"phases":3131,"primaryCompletion":46,"completion":3132,"start":3133,"enrollment":565,"conditions":3134,"interventions":3136},[90],"2028-04-14","2015-04-14",[3135],"Locally Recurrent\u002FMetastatic Triple Negative Breast Cancer",[47],{"nctId":3138,"briefTitle":3139,"status":244,"phases":3140,"primaryCompletion":695,"completion":695,"start":3141,"enrollment":3017,"conditions":3142,"interventions":3143},"NCT00002559","Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin",[89,90],"1994-01",[30,868],[288,47,442,741],{"nctId":3145,"briefTitle":3146,"status":244,"phases":3147,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":2439,"conditions":3150,"interventions":3151},"NCT00354679","Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer",[90],"2015-06","2006-04",[1602],[920,47,683,3152],"proteomic profiling",{"nctId":3154,"briefTitle":3155,"status":158,"phases":3156,"primaryCompletion":3157,"completion":3157,"start":3158,"enrollment":2407,"conditions":3159,"interventions":3164},"NCT06057935","A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma",[90],"2028-09-21","2023-09-21",[3160,3161,794,3162,3163],"Malignant Peritoneal Mesothelioma","Peritoneal Mesothelioma","Mesothelioma, Malignant","Malignant Mesothelioma",[1107,974,224],{"nctId":1638,"briefTitle":1639,"status":244,"phases":3166,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":3167,"interventions":3168},[90],[21],[1645,47,224,1646,1647,1181],{"nctId":3170,"briefTitle":3171,"status":244,"phases":3172,"primaryCompletion":2931,"completion":2931,"start":3173,"enrollment":1052,"conditions":3174,"interventions":3175},"NCT00003345","Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer",[90],"1997-10",[285,30,286],[47,683],{"nctId":3177,"briefTitle":3178,"status":244,"phases":3179,"primaryCompletion":1083,"completion":1083,"start":1653,"enrollment":718,"conditions":3180,"interventions":3181},"NCT00586846","Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma",[90],[3076],[974,221,579],{"nctId":3183,"briefTitle":3184,"status":244,"phases":3185,"primaryCompletion":648,"completion":648,"start":3186,"enrollment":370,"conditions":3187,"interventions":3188},"NCT00002783","Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer",[90],"1996-05",[1613],[47,1615,1616,391],{"nctId":1079,"briefTitle":1080,"status":244,"phases":3190,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":326,"conditions":3191,"interventions":3192},[90],[971,1085],[1087,923,47],{"nctId":1099,"briefTitle":1100,"status":158,"phases":3194,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":3195,"interventions":3196},[90],[21,1104,1105],[974,1107,923,224,1108,942],{"nctId":3198,"briefTitle":3199,"status":244,"phases":3200,"primaryCompletion":1397,"completion":1397,"start":649,"enrollment":718,"conditions":3201,"interventions":3203},"NCT00002684","Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer",[90],[971,3202],"Urethral Cancer",[47,442,741],{"nctId":3205,"briefTitle":3206,"status":113,"phases":3207,"primaryCompletion":3208,"completion":3208,"start":3209,"enrollment":3210,"conditions":3211,"interventions":3214},"NCT03323463","Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma",[90],"2026-10-31","2017-10-16",316,[3212,3213],"HPV-Associated Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Neck",[974,224,3215],"5Fluorouracil",{"nctId":3217,"briefTitle":3218,"status":244,"phases":3219,"primaryCompletion":3220,"completion":3220,"start":2931,"conditions":3221,"interventions":3222},"NCT00030862","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus",[90],"2003-12",[1602],[47,683],{"nctId":645,"briefTitle":646,"status":244,"phases":3224,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":3225,"interventions":3226},[90],[651],[288,390,47,202,346,347,349],{"nctId":3228,"briefTitle":3229,"status":244,"phases":3230,"primaryCompletion":3231,"completion":3231,"start":3032,"enrollment":908,"conditions":3232,"interventions":3233},"NCT00423930","Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[90],"2016-07",[1586],[920,47],{"nctId":2549,"briefTitle":2550,"status":244,"phases":3235,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":3236,"interventions":3237},[90],[1602,1613],[798,768,2557,47,944,1680],{"nctId":3239,"briefTitle":3240,"status":505,"phases":3241,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":2291,"conditions":3244,"interventions":3245},"NCT02726399","Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer",[90],"2019-02-26","2016-03-18",[1613,2400],[3246,984,1679,974],"Ramucirumab",{"nctId":3248,"briefTitle":3249,"status":244,"phases":3250,"primaryCompletion":688,"completion":688,"start":3251,"conditions":3252,"interventions":3253},"NCT00005814","Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer",[90],"1999-12",[1586],[3035,47],{"nctId":3255,"briefTitle":3256,"status":244,"phases":3257,"primaryCompletion":259,"completion":259,"start":764,"enrollment":162,"conditions":3258,"interventions":3261},"NCT00470366","Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors",[90],[3259,387,30,3260,868],"Brain and Central Nervous System Tumors","Teratoma",[373,47,442,741],{"nctId":743,"briefTitle":744,"status":244,"phases":3263,"primaryCompletion":746,"completion":746,"start":637,"conditions":3264,"interventions":3265},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":1137,"briefTitle":1138,"status":244,"phases":3267,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":486,"conditions":3268,"interventions":3269},[89,90],[1143],[923,974,1145],{"nctId":3271,"briefTitle":3272,"status":244,"phases":3273,"primaryCompletion":3274,"completion":3274,"start":1664,"enrollment":438,"conditions":3275,"interventions":3276},"NCT00003087","Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus",[90],"2005-02",[1602],[47,741],{"nctId":3278,"briefTitle":3279,"status":244,"phases":3280,"primaryCompletion":3281,"completion":3281,"start":1622,"enrollment":438,"conditions":3282,"interventions":3283},"NCT00052429","High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer",[89,90],"2010-11",[1586],[47,1616],{"nctId":2839,"briefTitle":2840,"status":113,"phases":3285,"primaryCompletion":2082,"completion":2082,"start":2842,"enrollment":326,"conditions":3286,"interventions":3287},[90],[2844],[818,974,942],{"nctId":3289,"briefTitle":3290,"status":158,"phases":3291,"primaryCompletion":3292,"completion":3292,"start":3293,"enrollment":3294,"conditions":3295,"interventions":3299},"NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer",[90],"2027-08-04","2022-08-04",121,[1754,3296,1745,3297,3298],"Throat Cancer","Oropharyngeal Cancer","Human Papilloma Virus",[974,224,3300],"5-fluorouracil",{"nctId":1183,"briefTitle":1184,"status":244,"phases":3302,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":573,"conditions":3303,"interventions":3304},[90],[1189,1190],[923,974,1192],{"nctId":3306,"briefTitle":3307,"status":244,"phases":3308,"primaryCompletion":3309,"completion":3309,"start":3310,"enrollment":509,"conditions":3311,"interventions":3315},"NCT03274414","A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages",[90],"2023-01-13","2017-09-01",[3312,3313,3314],"Paranasal Sinus Cancer","Nasal Cavity Tumor","Nasal Cavity Adenocarcinoma",[974,3316],"cisplatin and etoposide",{"trials":3318,"activeCount":101},[3319,3327],{"nctId":3320,"briefTitle":3321,"status":244,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":1357,"conditions":3324,"interventions":3325},"NCT00005636","Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery",[91],"2000-11",[3163],[47,3326],"pemetrexed disodium",{"nctId":861,"briefTitle":862,"status":244,"phases":3328,"completion":727,"start":864,"enrollment":865,"conditions":3329,"interventions":3330},[91],[867,387,868],[870,288,390,47,202,346],{"trials":3332,"activeCount":101},[],{"trials":3334,"activeCount":101},[3335],{"nctId":3336,"briefTitle":3337,"status":244,"phases":3338,"primaryCompletion":3339,"completion":3339,"start":1610,"enrollment":332,"conditions":3340,"interventions":3341},"NCT00058370","Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma",[93],"2019-06",[3259],[47,3342,349],"lomustine",{"intervention":390,"totalTrials":3344,"cells":3345},36,{"EARLY_PHASE1":3346,"PHASE1":3364,"PHASE2":3405,"PHASE3":3569,"PHASE4":3575,"NA":3577},{"trials":3347,"activeCount":1094,"soonestReadout":211},[3348,3352],{"nctId":208,"briefTitle":209,"status":113,"phases":3349,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":3350,"interventions":3351},[88],[215,216],[218,219,220,221,222,223,224,225],{"nctId":3353,"briefTitle":3354,"status":158,"phases":3355,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":1232,"conditions":3358,"interventions":3363},"NCT05691010","A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer",[88],"2027-01-10","2023-01-10",[3359,3360,3361,2764,3362],"Endometrial Cancer","Stage III Endometrial Cancer","Stage III Endometrial Carcinoma","Endometrial Carcinoma Stage III",[224,1595],{"trials":3365,"activeCount":97,"soonestReadout":1583},[3366,3374,3378,3385,3389,3398],{"nctId":3367,"briefTitle":3368,"status":244,"phases":3369,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":356,"conditions":3372,"interventions":3373},"NCT00003342","Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer",[89],"2007-07","1997-12",[971,2992],[288,390,345,441,741],{"nctId":2944,"briefTitle":2945,"status":2832,"phases":3375,"primaryCompletion":1641,"completion":1641,"start":1141,"enrollment":101,"conditions":3376,"interventions":3377},[89],[2948],[2950,974,224,1107],{"nctId":3379,"briefTitle":3380,"status":244,"phases":3381,"primaryCompletion":1629,"completion":1629,"start":3382,"conditions":3383,"interventions":3384},"NCT00005806","Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer",[89],"1999-09",[21],[390,1578,741],{"nctId":1580,"briefTitle":1581,"status":158,"phases":3386,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":3387,"interventions":3388},[89],[1586,1587,1588,1589,1590,1591],[974,224,1181,1593,1594,1595],{"nctId":3390,"briefTitle":3391,"status":244,"phases":3392,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":1412,"conditions":3395,"interventions":3396},"NCT02269293","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",[89],"2021-04-20","2014-10-13",[30,3359],[1595,224,3397],"Selinexor",{"nctId":3399,"briefTitle":3400,"status":244,"phases":3401,"start":3402,"conditions":3403,"interventions":3404},"NCT00028912","Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",[89],"2001-11",[285,30,286],[662,390],{"trials":3406,"activeCount":952,"soonestReadout":232},[3407,3414,3418,3430,3439,3447,3457,3461,3465,3469,3473,3481,3485,3489,3493,3500,3510,3514,3518,3526,3530,3534,3538,3544,3551,3555,3565],{"nctId":3408,"briefTitle":3409,"status":244,"phases":3410,"primaryCompletion":1014,"completion":1014,"start":3141,"enrollment":3411,"conditions":3412,"interventions":3413},"NCT00002558","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors",[89,90],108,[387,30,868],[288,390,346,442,741],{"nctId":381,"briefTitle":382,"status":244,"phases":3415,"primaryCompletion":384,"completion":384,"start":385,"conditions":3416,"interventions":3417},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":3419,"briefTitle":3420,"status":158,"phases":3421,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":3424,"interventions":3427},"NCT06528496","N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma",[90],"2029-07-22","2024-07-22",[3425,215,3426],"High-risk Neuroblastoma","Childhood Neuroblastoma",[3428,2649,3429,219,220,221,222,223,224,819,818],"DANYELZA","Cytoxan",{"nctId":3431,"briefTitle":3432,"status":244,"phases":3433,"primaryCompletion":3434,"completion":3434,"start":3281,"enrollment":3435,"conditions":3436,"interventions":3438},"NCT01248962","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",[90],"2018-08",146,[30,285,3437],"Peritoneal Cancer",[390,390],{"nctId":3440,"briefTitle":3441,"status":244,"phases":3442,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":213,"conditions":3445,"interventions":3446},"NCT00423852","Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin",[89,90],"2013-02","2006-08",[3259,387,30,3260,868],[288,390,442,741],{"nctId":3448,"briefTitle":3449,"status":244,"phases":3450,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":3452,"interventions":3453},"NCT00003394","Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer",[89,90],"1998-04",[18],[390,3454,1707,3455,3456,741],"endocrine-modulating drug therapy","goserelin acetate","leuprolide acetate",{"nctId":541,"briefTitle":542,"status":244,"phases":3458,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":3459,"interventions":3460},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":1353,"briefTitle":1354,"status":244,"phases":3462,"primaryCompletion":1356,"completion":1356,"start":1357,"conditions":3463,"interventions":3464},[90],[24],[288,374,390,346,442],{"nctId":3154,"briefTitle":3155,"status":158,"phases":3466,"primaryCompletion":3157,"completion":3157,"start":3158,"enrollment":2407,"conditions":3467,"interventions":3468},[90],[3160,3161,794,3162,3163],[1107,974,224],{"nctId":1638,"briefTitle":1639,"status":244,"phases":3470,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":3471,"interventions":3472},[90],[21],[1645,47,224,1646,1647,1181],{"nctId":3474,"briefTitle":3475,"status":244,"phases":3476,"primaryCompletion":3477,"completion":3477,"start":3478,"conditions":3479,"interventions":3480},"NCT00002697","Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma",[90],"2003-06","1995-09",[24],[288,360,390,346,442],{"nctId":1099,"briefTitle":1100,"status":158,"phases":3482,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":3483,"interventions":3484},[90],[21,1104,1105],[974,1107,923,224,1108,942],{"nctId":1110,"briefTitle":1111,"status":505,"phases":3486,"primaryCompletion":803,"start":1113,"enrollment":1114,"conditions":3487,"interventions":3488},[90],[971],[923,224,1117],{"nctId":3205,"briefTitle":3206,"status":113,"phases":3490,"primaryCompletion":3208,"completion":3208,"start":3209,"enrollment":3210,"conditions":3491,"interventions":3492},[90],[3212,3213],[974,224,3215],{"nctId":3494,"briefTitle":3495,"status":244,"phases":3496,"primaryCompletion":688,"completion":688,"start":3497,"conditions":3498,"interventions":3499},"NCT00002982","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma",[90],"1997-01",[24],[288,390,549,361,346,442,444],{"nctId":3501,"briefTitle":3502,"status":158,"phases":3503,"primaryCompletion":232,"completion":232,"start":3504,"enrollment":3505,"conditions":3506,"interventions":3508},"NCT04410796","Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers",[90],"2020-05-28",571,[3507],"Metastatic Non-small Cell Lung Cancer",[3509,224,1107],"Osimertinib",{"nctId":645,"briefTitle":646,"status":244,"phases":3511,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":3512,"interventions":3513},[90],[651],[288,390,47,202,346,347,349],{"nctId":677,"briefTitle":678,"status":113,"phases":3515,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":3516,"interventions":3517},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":3519,"briefTitle":3520,"status":244,"phases":3521,"primaryCompletion":3522,"completion":3522,"start":3523,"conditions":3524,"interventions":3525},"NCT00002515","Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer",[90],"2005-04","1992-10",[867,387,1586,783,2610,24,215,30,651,33,868],[288,390,479,750],{"nctId":724,"briefTitle":725,"status":244,"phases":3527,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":3528,"interventions":3529},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":743,"briefTitle":744,"status":244,"phases":3531,"primaryCompletion":746,"completion":746,"start":637,"conditions":3532,"interventions":3533},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":1147,"briefTitle":1148,"status":244,"phases":3535,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":3536,"interventions":3537},[90],[1154,938,1155],[1157,224,923],{"nctId":3539,"briefTitle":3540,"status":244,"phases":3541,"primaryCompletion":695,"completion":695,"start":637,"conditions":3542,"interventions":3543},"NCT00006377","Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer",[90],[3359],[390,345,741],{"nctId":3545,"briefTitle":3546,"status":244,"phases":3547,"primaryCompletion":3548,"completion":3548,"start":2914,"enrollment":836,"conditions":3549,"interventions":3550},"NCT00255723","Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma",[90],"2012-07",[24],[390,346,442],{"nctId":3289,"briefTitle":3290,"status":158,"phases":3552,"primaryCompletion":3292,"completion":3292,"start":3293,"enrollment":3294,"conditions":3553,"interventions":3554},[90],[1754,3296,1745,3297,3298],[974,224,3300],{"nctId":3556,"briefTitle":3557,"status":158,"phases":3558,"primaryCompletion":3559,"completion":3559,"start":3560,"enrollment":283,"conditions":3561,"interventions":3564},"NCT05544136","A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer",[90],"2027-03-12","2022-09-12",[1586,3562,3563,1590],"Head and Neck Carcinoma","Head and Neck Neoplasms",[224],{"nctId":832,"briefTitle":833,"status":244,"phases":3566,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":3567,"interventions":3568},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":3570,"activeCount":101},[3571],{"nctId":861,"briefTitle":862,"status":244,"phases":3572,"completion":727,"start":864,"enrollment":865,"conditions":3573,"interventions":3574},[91],[867,387,868],[870,288,390,47,202,346],{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"intervention":643,"totalTrials":1462,"cells":3580},{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3639,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3582,"activeCount":101},[],{"trials":3584,"activeCount":97,"soonestReadout":258},[3585,3594,3604,3610,3618,3627,3635],{"nctId":3586,"briefTitle":3587,"status":244,"phases":3588,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":3591,"interventions":3592},"NCT00462787","Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia",[89],"2013-11","2007-04",[27],[288,3593,643,479,750,447],"clofarabine",{"nctId":3595,"briefTitle":3596,"status":244,"phases":3597,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":3600,"interventions":3601},"NCT00059930","Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer",[89],"2025-03-24",38,[36,2349],[3602,643,1615,1616,391,3603],"FOLFOX regimen","oxaliplatin",{"nctId":3605,"briefTitle":3606,"status":244,"phases":3607,"primaryCompletion":1151,"start":426,"conditions":3608,"interventions":3609},"NCT00008294","Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer",[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":3611,"briefTitle":3612,"status":113,"phases":3613,"primaryCompletion":258,"completion":258,"start":3614,"enrollment":283,"conditions":3615,"interventions":3616},"NCT02494882","Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older",[89],"2015-06-29",[414],[722,3617,463],"Dasatinib",{"nctId":3619,"briefTitle":3620,"status":244,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3231,"enrollment":326,"conditions":3623,"interventions":3625},"NCT02831686","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",[89],"2020-11-19",[308,3624],"Relapsed and\u002For Refractory Multiple Myeloma",[3397,3626,463],"Ixazomib",{"nctId":3628,"briefTitle":3629,"status":244,"phases":3630,"primaryCompletion":3631,"completion":3631,"start":1092,"enrollment":272,"conditions":3632,"interventions":3634},"NCT02697383","Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study",[89],"2024-05-08",[308,3633],"High Risk Smoldering Multiple Myeloma",[3626,463],{"nctId":947,"briefTitle":948,"status":244,"phases":3636,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":3637,"interventions":3638},[89],[954,955,956,957],[959,960,961],{"trials":3640,"activeCount":601,"soonestReadout":71},[3641,3651,3659,3665,3669,3677,3685,3689,3700,3704,3710,3714,3721,3725,3729,3738,3745,3749,3757,3766,3772,3780],{"nctId":3642,"briefTitle":3643,"status":113,"phases":3644,"primaryCompletion":990,"completion":990,"start":3645,"enrollment":234,"conditions":3646,"interventions":3648},"NCT04329325","Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[90],"2020-03-30",[414,3647],"Philadelphia Chromosome-Positive",[3649,3650,643,362],"Blinatumomab","dasatinib",{"nctId":3652,"briefTitle":3653,"status":244,"phases":3654,"primaryCompletion":3655,"completion":3655,"start":736,"enrollment":341,"conditions":3656,"interventions":3657},"NCT00458705","Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma",[90],"2011-04",[828],[662,643,3658,558],"pegylated liposomal doxorubicin hydrochloride",{"nctId":3660,"briefTitle":3661,"status":244,"phases":3662,"primaryCompletion":1565,"completion":1565,"start":426,"conditions":3663,"interventions":3664},"NCT00008242","Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma",[90],[828],[643,345,558],{"nctId":449,"briefTitle":450,"status":158,"phases":3666,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":3667,"interventions":3668},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":3670,"briefTitle":3671,"status":244,"phases":3672,"primaryCompletion":3673,"completion":3673,"start":1223,"enrollment":1462,"conditions":3674,"interventions":3675},"NCT02937571","High Dose Carfilzomib for Newly Diagnosed Myeloma",[89,90],"2024-10-08",[308],[3676,1261,463],"Carfilzomib",{"nctId":3678,"briefTitle":3679,"status":244,"phases":3680,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":2483,"conditions":3683,"interventions":3684},"NCT00410956","Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery",[90],"2024-05-07","2007-05-09",[2610],[920,643,1615,379],{"nctId":1038,"briefTitle":1039,"status":158,"phases":3686,"primaryCompletion":812,"completion":812,"start":1041,"enrollment":1042,"conditions":3687,"interventions":3688},[90],[954],[923,944,463,1045],{"nctId":3690,"briefTitle":3691,"status":2832,"phases":3692,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":3695,"interventions":3697},"NCT03069950","Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver",[90],"2019-05-16","2017-02-28",[3696],"Colorectal Adenocarcinoma Metastatic to the Liver",[1045,819,3698,3699,960,582],"FLUOROURACIL","PANITUMUMAB",{"nctId":569,"briefTitle":570,"status":113,"phases":3701,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":3702,"interventions":3703},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":3705,"briefTitle":3706,"status":244,"phases":3707,"primaryCompletion":2914,"completion":2914,"start":427,"conditions":3708,"interventions":3709},"NCT00003753","Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer",[90],[36,2349],[643,1615,683],{"nctId":609,"briefTitle":610,"status":158,"phases":3711,"primaryCompletion":115,"completion":115,"start":612,"enrollment":306,"conditions":3712,"interventions":3713},[90],[308,614],[218,464,463,616],{"nctId":69,"briefTitle":70,"status":113,"phases":3715,"primaryCompletion":71,"completion":1469,"start":3716,"enrollment":3717,"conditions":3718,"interventions":3719},[90],"2017-09-25",69,[308],[72,3720,1350,643,643],"carfilzomib",{"nctId":1119,"briefTitle":1120,"status":244,"phases":3722,"primaryCompletion":1122,"completion":1122,"start":813,"enrollment":34,"conditions":3723,"interventions":3724},[90],[954,955,956,1124],[1045,643,923,944],{"nctId":634,"briefTitle":635,"status":244,"phases":3726,"primaryCompletion":637,"completion":637,"start":638,"conditions":3727,"interventions":3728},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":3730,"briefTitle":3731,"status":244,"phases":3732,"primaryCompletion":3733,"completion":3733,"start":704,"enrollment":1412,"conditions":3734,"interventions":3735},"NCT01745588","Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin\u002F Pomalidomide \u002F Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma",[90],"2025-09-03",[308],[3736,463,3737],"Pomalidomide","Clarithromycin",{"nctId":3739,"briefTitle":3740,"status":113,"phases":3741,"primaryCompletion":1028,"completion":1028,"start":3742,"enrollment":2462,"conditions":3743,"interventions":3744},"NCT03556332","A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed\u002FRefractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation",[90],"2018-07-02",[308],[3676,1261,463,616],{"nctId":692,"briefTitle":693,"status":244,"phases":3746,"primaryCompletion":695,"completion":695,"start":696,"conditions":3747,"interventions":3748},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":3750,"briefTitle":3751,"status":244,"phases":3752,"primaryCompletion":3753,"completion":3753,"start":3754,"enrollment":718,"conditions":3755,"interventions":3756},"NCT00458822","Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis",[90],"2015-03","2007-02",[828],[662,643],{"nctId":3758,"briefTitle":3759,"status":244,"phases":3760,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":356,"conditions":3763,"interventions":3765},"NCT01919086","Response Adapted Therapy With Bortezomib\u002FDexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma",[90],"2024-05-16","2013-08-06",[3764],"Multiple Myeloma (MM)",[464,463,1261],{"nctId":3767,"briefTitle":3768,"status":113,"phases":3769,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":3770,"interventions":3771},"NCT00492999","Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver",[90],[36,2349],[643,1615,1616,683,391,3603],{"nctId":3773,"briefTitle":3774,"status":244,"phases":3775,"primaryCompletion":3776,"start":3777,"conditions":3778,"interventions":3779},"NCT00089167","Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis",[90],"2007-12","2002-05",[828],[288,643,444,558],{"nctId":3781,"briefTitle":3782,"status":113,"phases":3783,"primaryCompletion":324,"completion":324,"start":3784,"enrollment":234,"conditions":3785,"interventions":3787},"NCT03618537","Ixazomib Maintenance Study in Patients With AL Amyloidosis",[90],"2018-08-02",[3786],"AL Amyloidosis",[3626,463],{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":101},[],{"trials":3793,"activeCount":101},[],{"intervention":1327,"totalTrials":952,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3805,"PHASE2":3807,"PHASE3":3860,"PHASE4":3862,"NA":3864},{"trials":3797,"activeCount":97,"soonestReadout":232},[3798],{"nctId":3799,"briefTitle":3800,"status":113,"phases":3801,"primaryCompletion":232,"completion":232,"start":3802,"enrollment":283,"conditions":3803,"interventions":3804},"NCT05386576","A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",[88],"2022-06-16",[414],[1327],{"trials":3806,"activeCount":101},[],{"trials":3808,"activeCount":2291,"soonestReadout":258},[3809,3819,3826,3834,3838,3842,3850],{"nctId":3810,"briefTitle":3811,"status":158,"phases":3812,"primaryCompletion":2005,"completion":2005,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3817},"NCT06903702","A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia",[90],"2025-06-04",100,[3816],"Acute Myeloid Leukemia",[3818,1327],"Azacitidine",{"nctId":3820,"briefTitle":3821,"status":158,"phases":3822,"primaryCompletion":2472,"completion":2472,"start":3823,"enrollment":356,"conditions":3824,"interventions":3825},"NCT06773208","A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)",[90],"2025-01-07",[535],[3818,1327],{"nctId":3827,"briefTitle":3828,"status":158,"phases":3829,"primaryCompletion":484,"completion":484,"start":3830,"enrollment":341,"conditions":3831,"interventions":3832},"NCT07392242","A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia",[90],"2026-01-27",[3816],[3833,3818,1327],"Ivosidenib",{"nctId":1317,"briefTitle":1318,"status":158,"phases":3835,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":718,"conditions":3836,"interventions":3837},[90],[1323,1324],[1326,1327,465],{"nctId":1365,"briefTitle":1366,"status":113,"phases":3839,"primaryCompletion":258,"completion":258,"start":1368,"enrollment":332,"conditions":3840,"interventions":3841},[90],[1370],[465,1327],{"nctId":3843,"briefTitle":3844,"status":113,"phases":3845,"primaryCompletion":2082,"completion":2082,"start":3846,"enrollment":3814,"conditions":3847,"interventions":3849},"NCT04447768","The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)",[90],"2020-12-03",[3848],"Chronic Lymphocytic Leukemia (CLL)",[1296,1327],{"nctId":3851,"briefTitle":3852,"status":158,"phases":3853,"primaryCompletion":304,"completion":304,"start":3854,"enrollment":3855,"conditions":3856,"interventions":3858},"NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",[90],"2019-02-22",230,[3848,3857],"Small Lymphocytic Leukemia (SLL)",[3859,1296,1327],"Zanubrutinib",{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"trials":3865,"activeCount":101},[],{"intervention":346,"totalTrials":992,"cells":3867},{"EARLY_PHASE1":3868,"PHASE1":3874,"PHASE2":3900,"PHASE3":4021,"PHASE4":4031,"NA":4033},{"trials":3869,"activeCount":97,"soonestReadout":211},[3870],{"nctId":208,"briefTitle":209,"status":113,"phases":3871,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":3872,"interventions":3873},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":3875,"activeCount":1094,"soonestReadout":258},[3876,3884,3891],{"nctId":3877,"briefTitle":3878,"status":244,"phases":3879,"primaryCompletion":3880,"completion":3880,"start":3881,"conditions":3882,"interventions":3883},"NCT00006040","Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia",[89],"2003-11","2000-04",[27,475,476],[288,346],{"nctId":3885,"briefTitle":3886,"status":113,"phases":3887,"primaryCompletion":258,"completion":258,"start":3888,"enrollment":2630,"conditions":3889,"interventions":3890},"NCT03567642","A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers",[89],"2018-06-12",[21],[3509,945,223],{"nctId":3892,"briefTitle":3893,"status":113,"phases":3894,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":3895,"interventions":3896},"NCT01840566","High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma",[89],[707],[3897,223,581,420,3898,3899],"Carmustine","Pegfilgrastim","19-28z T CELLS",{"trials":3901,"activeCount":1114,"soonestReadout":258},[3902,3906,3910,3914,3918,3922,3926,3933,3943,3947,3951,3955,3959,3963,3967,3973,3977,3981,3985,3989,3993,3997,4001,4005,4013,4017],{"nctId":336,"briefTitle":337,"status":244,"phases":3903,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":3904,"interventions":3905},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":3408,"briefTitle":3409,"status":244,"phases":3907,"primaryCompletion":1014,"completion":1014,"start":3141,"enrollment":3411,"conditions":3908,"interventions":3909},[89,90],[387,30,868],[288,390,346,442,741],{"nctId":351,"briefTitle":352,"status":244,"phases":3911,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":3912,"interventions":3913},[90],[27],[359,360,202,361,346,362,363],{"nctId":381,"briefTitle":382,"status":244,"phases":3915,"primaryCompletion":384,"completion":384,"start":385,"conditions":3916,"interventions":3917},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":3060,"briefTitle":3061,"status":113,"phases":3919,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":3920,"interventions":3921},[90],[3066],[1595,222,974,225,2807,223],{"nctId":3419,"briefTitle":3420,"status":158,"phases":3923,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":3924,"interventions":3925},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":3927,"briefTitle":3928,"status":244,"phases":3929,"primaryCompletion":339,"start":3930,"conditions":3931,"interventions":3932},"NCT00004110","Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma",[90],"1999-08",[215],[344,346,749],{"nctId":3934,"briefTitle":3935,"status":244,"phases":3936,"primaryCompletion":1702,"completion":1702,"start":3937,"enrollment":162,"conditions":3938,"interventions":3940},"NCT00002800","Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome",[90],"1996-07",[27,475,3939],"Neutropenia",[288,3941,361,346,3942],"lintuzumab","idarubicin",{"nctId":541,"briefTitle":542,"status":244,"phases":3944,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":3945,"interventions":3946},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":1353,"briefTitle":1354,"status":244,"phases":3948,"primaryCompletion":1356,"completion":1356,"start":1357,"conditions":3949,"interventions":3950},[90],[24],[288,374,390,346,442],{"nctId":3474,"briefTitle":3475,"status":244,"phases":3952,"primaryCompletion":3477,"completion":3477,"start":3478,"conditions":3953,"interventions":3954},[90],[24],[288,360,390,346,442],{"nctId":584,"briefTitle":585,"status":244,"phases":3956,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":3957,"interventions":3958},[90],[27,24,592],[288,594,202,346,442],{"nctId":3494,"briefTitle":3495,"status":244,"phases":3960,"primaryCompletion":688,"completion":688,"start":3497,"conditions":3961,"interventions":3962},[90],[24],[288,390,549,361,346,442,444],{"nctId":634,"briefTitle":635,"status":244,"phases":3964,"primaryCompletion":637,"completion":637,"start":638,"conditions":3965,"interventions":3966},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":3968,"briefTitle":3969,"status":244,"phases":3970,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":3971,"interventions":3972},"NCT00003632","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma",[90],[24],[288,549,361,346,444,362],{"nctId":645,"briefTitle":646,"status":244,"phases":3974,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":3975,"interventions":3976},[90],[651],[288,390,47,202,346,347,349],{"nctId":677,"briefTitle":678,"status":113,"phases":3978,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":3979,"interventions":3980},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":692,"briefTitle":693,"status":244,"phases":3982,"primaryCompletion":695,"completion":695,"start":696,"conditions":3983,"interventions":3984},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":724,"briefTitle":725,"status":244,"phases":3986,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":3987,"interventions":3988},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":743,"briefTitle":744,"status":244,"phases":3990,"primaryCompletion":746,"completion":746,"start":637,"conditions":3991,"interventions":3992},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":778,"briefTitle":779,"status":244,"phases":3994,"primaryCompletion":564,"completion":564,"start":781,"conditions":3995,"interventions":3996},[90],[783,33],[202,345,346,442,349],{"nctId":3545,"briefTitle":3546,"status":244,"phases":3998,"primaryCompletion":3548,"completion":3548,"start":2914,"enrollment":836,"conditions":3999,"interventions":4000},[90],[24],[390,346,442],{"nctId":1393,"briefTitle":1394,"status":244,"phases":4002,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":4003,"interventions":4004},[90],[24],[288,374,360,549,361,346,444],{"nctId":4006,"briefTitle":4007,"status":244,"phases":4008,"primaryCompletion":3323,"completion":3323,"start":4009,"enrollment":341,"conditions":4010,"interventions":4012},"NCT00002567","High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission",[90],"1994-03",[4011,27],"Bone Marrow Ablation",[288,346],{"nctId":809,"briefTitle":810,"status":113,"phases":4014,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":4015,"interventions":4016},[90],[816],[218,220,222,223,818,819,225,820,516],{"nctId":832,"briefTitle":833,"status":244,"phases":4018,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":4019,"interventions":4020},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":4022,"activeCount":101},[4023,4027],{"nctId":861,"briefTitle":862,"status":244,"phases":4024,"completion":727,"start":864,"enrollment":865,"conditions":4025,"interventions":4026},[91],[867,387,868],[870,288,390,47,202,346],{"nctId":872,"briefTitle":873,"status":244,"phases":4028,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":4029,"interventions":4030},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":4032,"activeCount":101},[],{"trials":4034,"activeCount":101},[],{"intervention":221,"totalTrials":601,"cells":4036},{"EARLY_PHASE1":4037,"PHASE1":4043,"PHASE2":4045,"PHASE3":4087,"PHASE4":4089,"NA":4091},{"trials":4038,"activeCount":97,"soonestReadout":211},[4039],{"nctId":208,"briefTitle":209,"status":113,"phases":4040,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":4041,"interventions":4042},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":4044,"activeCount":101},[],{"trials":4046,"activeCount":332,"soonestReadout":2472},[4047,4056,4060,4064,4068,4072,4076,4083],{"nctId":4048,"briefTitle":4049,"status":244,"phases":4050,"primaryCompletion":4051,"completion":4051,"start":4052,"enrollment":1600,"conditions":4053,"interventions":4055},"NCT01882816","Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer",[90],"2021-11-04","2013-06-13",[4054],"Thyroid Cancer",[221],{"nctId":3069,"briefTitle":3070,"status":158,"phases":4057,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":4058,"interventions":4059},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":481,"briefTitle":482,"status":158,"phases":4061,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":4062,"interventions":4063},[90],[488,489],[491,492,465,218,221,493],{"nctId":3419,"briefTitle":3420,"status":158,"phases":4065,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":4066,"interventions":4067},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":998,"briefTitle":999,"status":158,"phases":4069,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":4070,"interventions":4071},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":3177,"briefTitle":3178,"status":244,"phases":4073,"primaryCompletion":1083,"completion":1083,"start":1653,"enrollment":718,"conditions":4074,"interventions":4075},[90],[3076],[974,221,579],{"nctId":4077,"briefTitle":4078,"status":113,"phases":4079,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":356,"conditions":4080,"interventions":4082},"NCT01840592","Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib",[90],[4081],"Hepatocellular Carcinoma",[1192,221],{"nctId":2800,"briefTitle":2801,"status":113,"phases":4084,"primaryCompletion":2472,"completion":2472,"start":2803,"enrollment":705,"conditions":4085,"interventions":4086},[89,90],[604],[2806,2807,2808,2809,942],{"trials":4088,"activeCount":101},[],{"trials":4090,"activeCount":101},[],{"trials":4092,"activeCount":101},[],{"intervention":722,"totalTrials":952,"cells":4094},{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4124,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":509,"soonestReadout":258},[4099,4108,4120],{"nctId":4100,"briefTitle":4101,"status":158,"phases":4102,"primaryCompletion":2472,"completion":2472,"start":4103,"enrollment":326,"conditions":4104,"interventions":4106},"NCT05714072","A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis",[89],"2023-01-25",[4105],"Myelofibrosis Due to and Following Polycythemia Vera",[722,4107],"Abemaciclib",{"nctId":4109,"briefTitle":4110,"status":158,"phases":4111,"primaryCompletion":1766,"completion":1766,"start":4112,"enrollment":2751,"conditions":4113,"interventions":4118},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[89],"2021-08-12",[4114,4115,4116,4117],"T-cell Lymphomas","NK-Cell Lymphomas","T-cell Prolymphocytic Leukemia","T-cell Large Granular Lymphocyte Leukemia",[722,4119],"Duvelisib",{"nctId":3611,"briefTitle":3612,"status":113,"phases":4121,"primaryCompletion":258,"completion":258,"start":3614,"enrollment":283,"conditions":4122,"interventions":4123},[89],[414],[722,3617,463],{"trials":4125,"activeCount":1114,"soonestReadout":304},[4126,4135,4143,4150,4156],{"nctId":4127,"briefTitle":4128,"status":244,"phases":4129,"primaryCompletion":4130,"completion":4130,"start":4131,"enrollment":2483,"conditions":4132,"interventions":4133},"NCT02155465","Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib",[89,90],"2017-10","2014-06",[21],[722,4134],"Erlotinib",{"nctId":4136,"briefTitle":4137,"status":158,"phases":4138,"primaryCompletion":484,"completion":484,"start":3823,"enrollment":1883,"conditions":4139,"interventions":4141},"NCT06773195","A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis",[89,90],[4140],"Myelofibrosis",[4142,722],"Ulixertinib",{"nctId":4144,"briefTitle":4145,"status":113,"phases":4146,"primaryCompletion":304,"completion":304,"start":305,"enrollment":356,"conditions":4147,"interventions":4148},"NCT03069326","A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis",[90],[4140],[722,4149],"Thalidomide",{"nctId":4151,"briefTitle":4152,"status":158,"phases":4153,"primaryCompletion":1240,"completion":1240,"start":1829,"enrollment":814,"conditions":4154,"interventions":4155},"NCT02974647","Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma",[90],[24],[722],{"nctId":713,"briefTitle":714,"status":158,"phases":4157,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":4158,"interventions":4159},[90],[720],[218,218,461,722,460,460],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[],{"trials":4165,"activeCount":101},[],{"intervention":52,"totalTrials":1871,"cells":4167},{"EARLY_PHASE1":4168,"PHASE1":4175,"PHASE2":4197,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4169,"activeCount":97,"soonestReadout":51},[4170],{"nctId":49,"briefTitle":50,"status":113,"phases":4171,"primaryCompletion":51,"completion":2082,"start":4172,"enrollment":2630,"conditions":4173,"interventions":4174},[88],"2017-07-10",[4054],[52],{"trials":4176,"activeCount":101},[4177,4188],{"nctId":4178,"briefTitle":4179,"status":244,"phases":4180,"primaryCompletion":4181,"completion":4181,"start":4182,"enrollment":296,"conditions":4183,"interventions":4185},"NCT03122496","Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer",[89],"2022-06-03","2017-04-25",[4184],"Metastatic Anaplastic Thyroid Cancer",[4186,4187],"durvalumab","tremelimumab",{"nctId":4189,"briefTitle":4190,"status":2832,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":4193,"enrollment":101,"conditions":4194,"interventions":4196},"NCT03196401","A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma",[89],"2020-06","2017-07-27",[4195],"Solitary Bone Plasmacytoma",[52],{"trials":4198,"activeCount":332,"soonestReadout":232},[4199,4213,4222,4230,4238,4251,4259,4267,4275,4285,4293],{"nctId":4200,"briefTitle":4201,"status":113,"phases":4202,"primaryCompletion":1130,"completion":1130,"start":4203,"enrollment":356,"conditions":4204,"interventions":4211},"NCT03158064","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed\u002FRefractory Germ Cell Tumors",[90],"2017-05-15",[4205,4206,4207,4208,4209,4210],"Germ Cell Tumor","Nonseminomatous Germ Cell Tumor","Seminoma","Germinomatous Germ Cell Tumor","Dysgerminoma","Pineal Germ Cell Tumor",[52,4212],"Tremelimumab",{"nctId":4214,"briefTitle":4215,"status":113,"phases":4216,"primaryCompletion":232,"completion":232,"start":4217,"enrollment":2462,"conditions":4218,"interventions":4219},"NCT04905316","A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer",[90],"2021-05-21",[2948],[4220,52,4221],"Canakinumab","Chemotherapy",{"nctId":4223,"briefTitle":4224,"status":505,"phases":4225,"primaryCompletion":4226,"completion":4226,"start":4227,"enrollment":1934,"conditions":4228,"interventions":4229},"NCT03810105","A Study of Olaparib and Durvalumab in Prostate Cancer",[90],"2023-07-06","2019-03-07",[18],[77,52],{"nctId":4231,"briefTitle":4232,"status":113,"phases":4233,"primaryCompletion":1469,"completion":1469,"start":4234,"enrollment":326,"conditions":4235,"interventions":4237},"NCT03245541","Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer",[89,90],"2020-08-14",[4236],"Pancreatic Adenocarcinoma",[52],{"nctId":4239,"briefTitle":4240,"status":113,"phases":4241,"primaryCompletion":304,"completion":304,"start":4242,"enrollment":296,"conditions":4243,"interventions":4250},"NCT04716946","Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy",[90],"2021-01-27",[4244,2948,21,4245,4246,4247,4248,4249],"NSCLC","Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage III","Non-small Cell Lung Cancer Stage IIIA","PD-L1 Gene Mutation",[52],{"nctId":4252,"briefTitle":4253,"status":244,"phases":4254,"primaryCompletion":4255,"completion":4255,"start":4256,"enrollment":438,"conditions":4257,"interventions":4258},"NCT03122509","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",[90],"2021-04-28","2017-04-24",[2441],[4186,4187],{"nctId":4260,"briefTitle":4261,"status":244,"phases":4262,"primaryCompletion":1584,"completion":1584,"start":4263,"enrollment":1462,"conditions":4264,"interventions":4265},"NCT02764333","TPIV200\u002FhuFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer",[90],"2016-05-06",[30],[4266,52],"TPIV200",{"nctId":4268,"briefTitle":4269,"status":244,"phases":4270,"primaryCompletion":3830,"completion":3830,"start":4271,"enrollment":1434,"conditions":4272,"interventions":4273},"NCT06333678","A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)",[90],"2024-03-20",[1695],[52,4274],"Sotorasib",{"nctId":4276,"briefTitle":4277,"status":113,"phases":4278,"primaryCompletion":2082,"completion":2082,"start":4279,"enrollment":398,"conditions":4280,"interventions":4284},"NCT03999710","Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer",[90],"2019-07-19",[3094,21,4281,4282,4283],"Nsclc","NSCLC Stage II","NSCLC, Stage III",[52],{"nctId":4286,"briefTitle":4287,"status":113,"phases":4288,"primaryCompletion":1130,"completion":1130,"start":1829,"enrollment":2407,"conditions":4289,"interventions":4291},"NCT02962063","Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",[89,90],[4290,2398],"Esophageal Adenocarcinoma",[4186,4292,4212],"carboplatin AUC 2\u002Fpaclitaxel",{"nctId":4294,"briefTitle":4295,"status":244,"phases":4296,"primaryCompletion":2390,"completion":2390,"start":4297,"enrollment":4298,"conditions":4299,"interventions":4302},"NCT03015129","A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer",[90],"2017-01",80,[3359,2363,2764,4300,4301],"Endometrial Cancer Recurrent","Endometrial Carcinoma, Recurrent",[52,4212],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[4309],{"nctId":4310,"briefTitle":4311,"status":244,"phases":4312,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1232,"conditions":4315,"interventions":4316},"NCT02563925","Brain Irradiation and Tremelimumab in Metastatic Breast Cancer",[93],"2021-07-14","2015-09-18",[2311],[4212,4317,52],"HER2 directed therapy",{"intervention":941,"totalTrials":272,"cells":4319},{"EARLY_PHASE1":4320,"PHASE1":4322,"PHASE2":4344,"PHASE3":4400,"PHASE4":4402,"NA":4404},{"trials":4321,"activeCount":101},[],{"trials":4323,"activeCount":97,"soonestReadout":933},[4324,4328,4332,4336],{"nctId":2616,"briefTitle":2617,"status":244,"phases":4325,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":601,"conditions":4326,"interventions":4327},[89],[2622],[2624,942,941],{"nctId":930,"briefTitle":931,"status":158,"phases":4329,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":4330,"interventions":4331},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"nctId":2663,"briefTitle":2664,"status":244,"phases":4333,"primaryCompletion":2545,"completion":2545,"start":2299,"enrollment":1600,"conditions":4334,"interventions":4335},[89],[2667,2632,2633],[2669,942,941],{"nctId":4337,"briefTitle":4338,"status":244,"phases":4339,"primaryCompletion":4340,"completion":4340,"start":1150,"enrollment":2446,"conditions":4341,"interventions":4343},"NCT01502592","Pre-Operative, Single-Dose Ipilimumab and\u002For Cryoablation in Early Stage\u002FResectable Breast Cancer",[89],"2014-12",[15,4342],"Invasive Adenocarcinoma of the Breast",[941],{"trials":4345,"activeCount":332,"soonestReadout":1469},[4346,4355,4359,4366,4370,4374,4384,4388,4396],{"nctId":4347,"briefTitle":4348,"status":505,"phases":4349,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":509,"conditions":4352,"interventions":4354},"NCT04635735","Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed\u002FRefractory Multiple Myeloma",[89,90],"2023-02-02","2020-01-12",[4353],"Relapsed\u002FRefractory Multiple Myeloma",[941],{"nctId":2695,"briefTitle":2696,"status":244,"phases":4356,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":1434,"conditions":4357,"interventions":4358},[90],[2701,2702,2703,2704],[941,942,942],{"nctId":4360,"briefTitle":4361,"status":113,"phases":4362,"primaryCompletion":1469,"completion":1469,"start":4363,"enrollment":969,"conditions":4364,"interventions":4365},"NCT01688492","Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer",[89,90],"2012-09",[18],[941],{"nctId":2730,"briefTitle":2731,"status":244,"phases":4367,"primaryCompletion":2733,"completion":2733,"start":2734,"enrollment":2407,"conditions":4368,"interventions":4369},[90],[2410],[942,941],{"nctId":2747,"briefTitle":2748,"status":113,"phases":4371,"primaryCompletion":531,"completion":531,"start":2750,"enrollment":2751,"conditions":4372,"interventions":4373},[90],[2753],[2755,2682],{"nctId":4375,"briefTitle":4376,"status":158,"phases":4377,"primaryCompletion":4378,"completion":4378,"start":4379,"enrollment":2815,"conditions":4380,"interventions":4382},"NCT06594991","A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",[90],"2027-09","2024-09-10",[4381],"Advanced Melanoma",[4383,1594,941],"Fianlimab",{"nctId":2793,"briefTitle":2794,"status":113,"phases":4385,"primaryCompletion":2472,"completion":2472,"start":2796,"enrollment":2426,"conditions":4386,"interventions":4387},[90],[971],[942,941],{"nctId":4389,"briefTitle":4390,"status":113,"phases":4391,"primaryCompletion":498,"completion":498,"start":4392,"enrollment":1447,"conditions":4393,"interventions":4395},"NCT02020070","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",[90],"2013-12-18",[4394],"Metastatic Castration Sensitive Prostate Cancer",[711,941],{"nctId":2857,"briefTitle":2858,"status":113,"phases":4397,"primaryCompletion":2860,"completion":2860,"start":2861,"enrollment":1232,"conditions":4398,"interventions":4399},[90],[2341,2863],[942,941],{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[4406],{"nctId":2881,"briefTitle":2882,"status":244,"phases":4407,"primaryCompletion":2884,"completion":2884,"start":259,"enrollment":1934,"conditions":4408,"interventions":4409},[93],[15],[941,942],{"intervention":442,"totalTrials":454,"cells":4411},{"EARLY_PHASE1":4412,"PHASE1":4418,"PHASE2":4427,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4413,"activeCount":97,"soonestReadout":211},[4414],{"nctId":208,"briefTitle":209,"status":113,"phases":4415,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":4416,"interventions":4417},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":4419,"activeCount":101},[4420],{"nctId":4421,"briefTitle":4422,"status":244,"phases":4423,"primaryCompletion":825,"completion":825,"start":4424,"conditions":4425,"interventions":4426},"NCT00003198","Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors",[89],"1997-11",[1568],[442,750],{"trials":4428,"activeCount":1934,"soonestReadout":258},[4429,4433,4437,4441,4445,4449,4453,4457,4461,4465,4469,4473,4477,4481,4485,4489,4493,4497,4501,4505,4509,4513],{"nctId":3041,"briefTitle":3042,"status":244,"phases":4430,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":4431,"interventions":4432},[89,90],[971,2992],[288,47,345,441,442,741],{"nctId":3408,"briefTitle":3409,"status":244,"phases":4434,"primaryCompletion":1014,"completion":1014,"start":3141,"enrollment":3411,"conditions":4435,"interventions":4436},[89,90],[387,30,868],[288,390,346,442,741],{"nctId":433,"briefTitle":434,"status":244,"phases":4438,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":4439,"interventions":4440},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":3060,"briefTitle":3061,"status":113,"phases":4442,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":4443,"interventions":4444},[90],[3066],[1595,222,974,225,2807,223],{"nctId":3069,"briefTitle":3070,"status":158,"phases":4446,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":4447,"interventions":4448},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":3419,"briefTitle":3420,"status":158,"phases":4450,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":4451,"interventions":4452},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":3118,"briefTitle":3119,"status":244,"phases":4454,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":4455,"interventions":4456},[90],[33],[288,47,345,442,391,362,3125],{"nctId":3138,"briefTitle":3139,"status":244,"phases":4458,"primaryCompletion":695,"completion":695,"start":3141,"enrollment":3017,"conditions":4459,"interventions":4460},[89,90],[30,868],[288,47,442,741],{"nctId":3440,"briefTitle":3441,"status":244,"phases":4462,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":213,"conditions":4463,"interventions":4464},[89,90],[3259,387,30,3260,868],[288,390,442,741],{"nctId":541,"briefTitle":542,"status":244,"phases":4466,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":4467,"interventions":4468},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":1353,"briefTitle":1354,"status":244,"phases":4470,"primaryCompletion":1356,"completion":1356,"start":1357,"conditions":4471,"interventions":4472},[90],[24],[288,374,390,346,442],{"nctId":3474,"briefTitle":3475,"status":244,"phases":4474,"primaryCompletion":3477,"completion":3477,"start":3478,"conditions":4475,"interventions":4476},[90],[24],[288,360,390,346,442],{"nctId":584,"briefTitle":585,"status":244,"phases":4478,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":4479,"interventions":4480},[90],[27,24,592],[288,594,202,346,442],{"nctId":3198,"briefTitle":3199,"status":244,"phases":4482,"primaryCompletion":1397,"completion":1397,"start":649,"enrollment":718,"conditions":4483,"interventions":4484},[90],[971,3202],[47,442,741],{"nctId":3494,"briefTitle":3495,"status":244,"phases":4486,"primaryCompletion":688,"completion":688,"start":3497,"conditions":4487,"interventions":4488},[90],[24],[288,390,549,361,346,442,444],{"nctId":677,"briefTitle":678,"status":113,"phases":4490,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":4491,"interventions":4492},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":724,"briefTitle":725,"status":244,"phases":4494,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":4495,"interventions":4496},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":3255,"briefTitle":3256,"status":244,"phases":4498,"primaryCompletion":259,"completion":259,"start":764,"enrollment":162,"conditions":4499,"interventions":4500},[90],[3259,387,30,3260,868],[373,47,442,741],{"nctId":778,"briefTitle":779,"status":244,"phases":4502,"primaryCompletion":564,"completion":564,"start":781,"conditions":4503,"interventions":4504},[90],[783,33],[202,345,346,442,349],{"nctId":3545,"briefTitle":3546,"status":244,"phases":4506,"primaryCompletion":3548,"completion":3548,"start":2914,"enrollment":836,"conditions":4507,"interventions":4508},[90],[24],[390,346,442],{"nctId":809,"briefTitle":810,"status":113,"phases":4510,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":4511,"interventions":4512},[90],[816],[218,220,222,223,818,819,225,820,516],{"nctId":832,"briefTitle":833,"status":244,"phases":4514,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":4515,"interventions":4516},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":101},[],{"intervention":1261,"totalTrials":306,"cells":4524},{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4542,"PHASE3":4673,"PHASE4":4675,"NA":4677},{"trials":4526,"activeCount":101},[],{"trials":4528,"activeCount":97,"soonestReadout":4533},[4529,4538],{"nctId":4530,"briefTitle":4531,"status":113,"phases":4532,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":573,"conditions":4535,"interventions":4537},"NCT06192888","A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma",[89],"2028-01-08","2024-01-08",[1874,4536],"MCL",[491,1296,1261],{"nctId":1251,"briefTitle":1252,"status":244,"phases":4539,"primaryCompletion":1254,"completion":1254,"start":1255,"enrollment":438,"conditions":4540,"interventions":4541},[89],[1257,1258],[1260,1261,465],{"trials":4543,"activeCount":1934,"soonestReadout":71},[4544,4548,4559,4570,4574,4582,4590,4598,4602,4612,4619,4626,4630,4638,4642,4650,4657,4665],{"nctId":3670,"briefTitle":3671,"status":244,"phases":4545,"primaryCompletion":3673,"completion":3673,"start":1223,"enrollment":1462,"conditions":4546,"interventions":4547},[89,90],[308],[3676,1261,463],{"nctId":4549,"briefTitle":4550,"status":113,"phases":4551,"primaryCompletion":4552,"completion":4552,"start":4553,"enrollment":899,"conditions":4554,"interventions":4557},"NCT04174196","A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma",[90],"2026-11-19","2019-11-19",[4555,4556,308],"Plasmacytoma","Plasmacytoma of Bone",[4558,1261],"CC-486",{"nctId":4560,"briefTitle":4561,"status":244,"phases":4562,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":565,"conditions":4565,"interventions":4567},"NCT02633137","Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma",[90],"2023-11-07","2015-12-14",[1874,4566],"Untreated",[1261,4568,4569],"R-CHOP","high-dose cytarabine",{"nctId":1344,"briefTitle":1345,"status":505,"phases":4571,"primaryCompletion":1083,"completion":1083,"start":1347,"enrollment":509,"conditions":4572,"interventions":4573},[90],[828],[374,1350,1351],{"nctId":4575,"briefTitle":4576,"status":113,"phases":4577,"primaryCompletion":324,"completion":324,"start":4578,"enrollment":3411,"conditions":4579,"interventions":4581},"NCT02538198","Lenalidomide Maintenance in Plasma Cell Myeloma",[90],"2015-08-31",[4580],"Plasma Cell Myeloma",[1261],{"nctId":4583,"briefTitle":4584,"status":505,"phases":4585,"primaryCompletion":4586,"completion":4586,"start":2553,"enrollment":1114,"conditions":4587,"interventions":4588},"NCT05788289","A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma",[90],"2024-08-01",[1874,4536],[4589,1261],"Tafasitamab",{"nctId":4591,"briefTitle":4592,"status":244,"phases":4593,"primaryCompletion":4594,"completion":4594,"start":4595,"enrollment":2630,"conditions":4596,"interventions":4597},"NCT01463670","Lenalidomide Intensification in Patients With Serologic\u002FAsymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance",[90],"2021-03-19","2011-10-28",[308],[1350],{"nctId":69,"briefTitle":70,"status":113,"phases":4599,"primaryCompletion":71,"completion":1469,"start":3716,"enrollment":3717,"conditions":4600,"interventions":4601},[90],[308],[72,3720,1350,643,643],{"nctId":4603,"briefTitle":4604,"status":244,"phases":4605,"primaryCompletion":4606,"completion":4606,"start":4607,"enrollment":1600,"conditions":4608,"interventions":4610},"NCT02341014","Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas",[89,90],"2023-01-11","2015-01-02",[4114,4609],"Relapsed or Refractory",[3676,4611,1261],"Romidepsin",{"nctId":4613,"briefTitle":4614,"status":244,"phases":4615,"primaryCompletion":4616,"completion":4616,"start":704,"enrollment":565,"conditions":4617,"interventions":4618},"NCT01755975","Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma",[89,90],"2023-10",[308,707],[4611,1261],{"nctId":4620,"briefTitle":4621,"status":2832,"phases":4622,"primaryCompletion":4623,"completion":4623,"start":1852,"enrollment":101,"conditions":4624,"interventions":4625},"NCT07030699","A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma",[90],"2026-03-31",[24],[1860,1261,4589],{"nctId":3739,"briefTitle":3740,"status":113,"phases":4627,"primaryCompletion":1028,"completion":1028,"start":3742,"enrollment":2462,"conditions":4628,"interventions":4629},[90],[308],[3676,1261,463,616],{"nctId":4631,"briefTitle":4632,"status":2832,"phases":4633,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":101,"conditions":4636,"interventions":4637},"NCT01180569","Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma",[89,90],"2011-05","2010-08",[24,1831],[1350],{"nctId":3758,"briefTitle":3759,"status":244,"phases":4639,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":356,"conditions":4640,"interventions":4641},[90],[3764],[464,463,1261],{"nctId":4643,"briefTitle":4644,"status":244,"phases":4645,"primaryCompletion":4646,"completion":4646,"start":4647,"enrollment":1434,"conditions":4648,"interventions":4649},"NCT03490344","Short Course Daratumumab in Patients With Multiple Myeloma",[90],"2023-03-23","2018-05-03",[308],[616,1261],{"nctId":4651,"briefTitle":4652,"status":113,"phases":4653,"primaryCompletion":324,"completion":324,"start":4654,"enrollment":765,"conditions":4655,"interventions":4656},"NCT04497961","A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide",[90],"2020-08-28",[308],[1261,616],{"nctId":4658,"briefTitle":4659,"status":244,"phases":4660,"primaryCompletion":4661,"start":4662,"conditions":4663,"interventions":4664},"NCT00096525","Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer",[90],"2005-08","2004-07",[783],[1350],{"nctId":4666,"briefTitle":4667,"status":244,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":213,"conditions":4671,"interventions":4672},"NCT01011894","Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age",[90],"2016-02-23","2009-11-06",[606,27],[1350],{"trials":4674,"activeCount":101},[],{"trials":4676,"activeCount":101},[],{"trials":4678,"activeCount":101},[],{"intervention":818,"totalTrials":2446,"cells":4680},{"EARLY_PHASE1":4681,"PHASE1":4694,"PHASE2":4726,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4682,"activeCount":97,"soonestReadout":258},[4683],{"nctId":4684,"briefTitle":4685,"status":113,"phases":4686,"primaryCompletion":258,"completion":258,"start":4687,"enrollment":1798,"conditions":4688,"interventions":4690},"NCT03189706","Study of Chemoimmunotherapy for High-Risk Neuroblastoma",[88],"2017-06-12",[4689],"Neuroblastoma (NB)",[819,4691,4692,4693],"temozolomide","Hu3F8","GM-CSF",{"trials":4695,"activeCount":1094,"soonestReadout":194},[4696,4702,4713],{"nctId":4697,"briefTitle":4698,"status":244,"phases":4699,"primaryCompletion":3477,"completion":588,"start":3251,"conditions":4700,"interventions":4701},"NCT00005637","Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma",[89],[3259],[549,4691],{"nctId":4703,"briefTitle":4704,"status":158,"phases":4705,"primaryCompletion":1208,"completion":1208,"start":4706,"enrollment":162,"conditions":4707,"interventions":4709},"NCT06934889","Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma",[89],"2025-04-07",[2790,4708],"Gliosarcoma",[4710,4711,4712,818],"ERAS-801","ABBV-637","ABBV-155",{"nctId":4714,"briefTitle":4715,"status":158,"phases":4716,"primaryCompletion":194,"completion":194,"start":4717,"enrollment":306,"conditions":4718,"interventions":4724},"NCT07223034","A Study of 177Lu-PSMA-617 in People With Gliomas",[89],"2025-10-27",[2504,4719,4720,4721,4722,4723],"Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)","Glioblastoma, IDH-wildtype","Diffuse Midline Glioma, H3 K27-Altered","Diffuse Hemispheric Glioma, H3 G34-mutant","Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype",[818,4725],"177Lu-PSMA-617",{"trials":4727,"activeCount":509,"soonestReadout":2082},[4728,4736,4742,4746,4755,4767,4776,4785,4791,4797,4803,4811,4815,4822,4826],{"nctId":4729,"briefTitle":4730,"status":244,"phases":4731,"primaryCompletion":3044,"start":1653,"conditions":4732,"interventions":4735},"NCT00072345","Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",[90],[4733,4734],"Intraocular Melanoma","Melanoma (Skin)",[3342,4691,558],{"nctId":4737,"briefTitle":4738,"status":244,"phases":4739,"primaryCompletion":3044,"completion":3044,"start":3251,"conditions":4740,"interventions":4741},"NCT00005815","Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma",[89,90],[4733,4734],[4691,558],{"nctId":3419,"briefTitle":3420,"status":158,"phases":4743,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":4744,"interventions":4745},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":4747,"briefTitle":4748,"status":244,"phases":4749,"primaryCompletion":4750,"completion":4750,"start":4751,"conditions":4752,"interventions":4753},"NCT00027742","Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma",[90],"2005-06","2001-05",[4733,4734],[4754,4691],"pegylated interferon alfa",{"nctId":4756,"briefTitle":4757,"status":244,"phases":4758,"primaryCompletion":2545,"completion":2545,"start":4759,"enrollment":1447,"conditions":4760,"interventions":4765},"NCT04019327","A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer",[89,90],"2019-07-11",[18,4761,4762,4763,4764],"Prostate Adenocarcinoma","Prostate Neoplasm","Prostate Cancer Metastatic","Castration-resistant Prostate Cancer",[4766,818],"Talazoparib",{"nctId":4768,"briefTitle":4769,"status":244,"phases":4770,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":1015,"conditions":4773,"interventions":4774},"NCT00498927","Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma",[90],"2013-12","2007-06",[3259],[4691,379,4775],"reverse transcriptase-polymerase chain reaction",{"nctId":4777,"briefTitle":4778,"status":244,"phases":4779,"primaryCompletion":4780,"completion":4780,"start":4781,"enrollment":19,"conditions":4782,"interventions":4784},"NCT00200161","Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w\u002FGlioblastoma",[90],"2017-05-04","2005-08-09",[2790,4783],"Gliomas",[818,818],{"nctId":4786,"briefTitle":4787,"status":244,"phases":4788,"primaryCompletion":3402,"completion":3402,"start":1611,"conditions":4789,"interventions":4790},"NCT00006043","Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin",[90],[30,868],[4691],{"nctId":4792,"briefTitle":4793,"status":244,"phases":4794,"primaryCompletion":755,"completion":755,"start":1971,"enrollment":1152,"conditions":4795,"interventions":4796},"NCT00591370","Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma",[90],[2341],[818],{"nctId":4798,"briefTitle":4799,"status":244,"phases":4800,"primaryCompletion":2931,"completion":2931,"start":1685,"conditions":4801,"interventions":4802},"NCT00004113","Temozolomide in Treating Patients With Recurrent Malignant Glioma",[90],[3259],[4691],{"nctId":4804,"briefTitle":4805,"status":244,"phases":4806,"primaryCompletion":4807,"completion":4807,"start":1621,"enrollment":454,"conditions":4808,"interventions":4810},"NCT00588341","Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection",[90],"2009-03",[2341,4809,1155],"Skin Cancer",[818],{"nctId":2839,"briefTitle":2840,"status":113,"phases":4812,"primaryCompletion":2082,"completion":2082,"start":2842,"enrollment":326,"conditions":4813,"interventions":4814},[90],[2844],[818,974,942],{"nctId":4816,"briefTitle":4817,"status":244,"phases":4818,"primaryCompletion":4819,"completion":4819,"start":554,"enrollment":565,"conditions":4820,"interventions":4821},"NCT00026494","Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases",[89,90],"2008-04",[2349],[4691,447],{"nctId":809,"briefTitle":810,"status":113,"phases":4823,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":4824,"interventions":4825},[90],[816],[218,220,222,223,818,819,225,820,516],{"nctId":4827,"briefTitle":4828,"status":244,"phases":4829,"primaryCompletion":3443,"completion":3443,"start":1266,"enrollment":3064,"conditions":4830,"interventions":4831},"NCT00740636","Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer",[90],[21],[818,818],{"trials":4833,"activeCount":101},[],{"trials":4835,"activeCount":101},[],{"trials":4837,"activeCount":101},[],{"intervention":4107,"totalTrials":2291,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4860,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4841,"activeCount":101},[],{"trials":4843,"activeCount":1094,"soonestReadout":2472},[4844,4848],{"nctId":4100,"briefTitle":4101,"status":158,"phases":4845,"primaryCompletion":2472,"completion":2472,"start":4103,"enrollment":326,"conditions":4846,"interventions":4847},[89],[4105],[722,4107],{"nctId":4849,"briefTitle":4850,"status":158,"phases":4851,"primaryCompletion":4852,"completion":4852,"start":4853,"enrollment":1232,"conditions":4854,"interventions":4859},"NCT06678269","A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer",[89],"2028-11-30","2024-11-15",[2311,4855,15,2312,4856,4857,4858,171],"Stage IV Breast Cancer","Breast Cancer Metastatic","HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma",[4107],{"trials":4861,"activeCount":1114,"soonestReadout":2082},[4862,4870,4880,4890,4899],{"nctId":4863,"briefTitle":4864,"status":113,"phases":4865,"primaryCompletion":2082,"completion":2082,"start":3231,"enrollment":4866,"conditions":4867,"interventions":4869},"NCT02846987","Study of Abemaciclib in Dedifferentiated Liposarcoma",[90],33,[33,4868],"Dedifferentiated Liposarcoma",[4107],{"nctId":4871,"briefTitle":4872,"status":158,"phases":4873,"primaryCompletion":304,"completion":304,"start":4874,"enrollment":3017,"conditions":4875,"interventions":4878},"NCT06835972","A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)",[89,90],"2025-02-14",[4876,4877],"Metastatic Renal Cell Carcinoma","Translocation Renal Cell Carcinoma",[4107,4879],"Cabozantinib",{"nctId":4881,"briefTitle":4882,"status":244,"phases":4883,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":1232,"conditions":4886,"interventions":4888},"NCT03643510","Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer",[90],"2026-03-12","2018-08-21",[4887],"Adenocarcinoma of Endometrium",[4889,4107],"Fulvestrant",{"nctId":4891,"briefTitle":4892,"status":158,"phases":4893,"primaryCompletion":4894,"completion":4894,"start":4895,"enrollment":31,"conditions":4896,"interventions":4897},"NCT07209449","A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer",[90],"2028-10-01","2025-10-01",[3359],[4107,4898],"Elacestrant",{"nctId":4900,"briefTitle":4901,"status":113,"phases":4902,"primaryCompletion":2082,"completion":2082,"start":4903,"enrollment":2407,"conditions":4904,"interventions":4906},"NCT03220646","Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors",[90],"2017-07-13",[4905],"Brain Tumor",[4907,4907],"abemaciclib",{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"intervention":1296,"totalTrials":332,"cells":4915},{"EARLY_PHASE1":4916,"PHASE1":4918,"PHASE2":4924,"PHASE3":4954,"PHASE4":4956,"NA":4958},{"trials":4917,"activeCount":101},[],{"trials":4919,"activeCount":97,"soonestReadout":4533},[4920],{"nctId":4530,"briefTitle":4531,"status":113,"phases":4921,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":573,"conditions":4922,"interventions":4923},[89],[1874,4536],[491,1296,1261],{"trials":4925,"activeCount":1934,"soonestReadout":2082},[4926,4930,4938,4942,4946],{"nctId":1287,"briefTitle":1288,"status":158,"phases":4927,"primaryCompletion":1290,"completion":1290,"start":61,"enrollment":1291,"conditions":4928,"interventions":4929},[90],[1293],[1295,1296,1297,465],{"nctId":4931,"briefTitle":4932,"status":113,"phases":4933,"primaryCompletion":2472,"completion":2472,"start":4934,"enrollment":356,"conditions":4935,"interventions":4937},"NCT03410875","A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia",[90],"2018-02-09",[1293,27,4936],"Leukemia, Hairy Cell",[1295,1296],{"nctId":3843,"briefTitle":3844,"status":113,"phases":4939,"primaryCompletion":2082,"completion":2082,"start":3846,"enrollment":3814,"conditions":4940,"interventions":4941},[90],[3848],[1296,1327],{"nctId":3851,"briefTitle":3852,"status":158,"phases":4943,"primaryCompletion":304,"completion":304,"start":3854,"enrollment":3855,"conditions":4944,"interventions":4945},[90],[3848,3857],[3859,1296,1327],{"nctId":4947,"briefTitle":4948,"status":113,"phases":4949,"primaryCompletion":304,"completion":304,"start":4217,"enrollment":34,"conditions":4950,"interventions":4952},"NCT04722172","A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL",[90],[606,4951],"Small Lymphocytic Lymphoma",[4953,1296],"Acalabrutinib",{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[],{"trials":4959,"activeCount":101},[],{"intervention":4961,"totalTrials":332,"cells":4962},"Ivonescimab",{"EARLY_PHASE1":4963,"PHASE1":4965,"PHASE2":4976,"PHASE3":5019,"PHASE4":5021,"NA":5023},{"trials":4964,"activeCount":101},[],{"trials":4966,"activeCount":97,"soonestReadout":4971},[4967],{"nctId":4968,"briefTitle":4969,"status":158,"phases":4970,"primaryCompletion":4971,"completion":4971,"start":4972,"enrollment":1447,"conditions":4973,"interventions":4974},"NCT07619339","A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer",[89],"2029-05","2026-05-27",[1695],[4975,4961],"Tepotinib",{"trials":4977,"activeCount":1934,"soonestReadout":531},[4978,4987,4995,5002,5010],{"nctId":4979,"briefTitle":4980,"status":158,"phases":4981,"primaryCompletion":1208,"completion":1208,"start":4982,"enrollment":4983,"conditions":4984,"interventions":4985},"NCT07535437","A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer",[89,90],"2026-04-09",66,[1695],[4961,4986,3509],"Dato-DXd",{"nctId":4988,"briefTitle":4989,"status":158,"phases":4990,"primaryCompletion":1208,"completion":1208,"start":4991,"enrollment":4992,"conditions":4993,"interventions":4994},"NCT07535463","A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer",[89,90],"2026-04-10",53,[1695],[4961],{"nctId":4996,"briefTitle":4997,"status":158,"phases":4998,"primaryCompletion":933,"completion":933,"start":4999,"enrollment":306,"conditions":5000,"interventions":5001},"NCT07516925","A Study of Ivonescimab in People With Leiomyosarcoma",[90],"2026-04-01",[1017],[4961],{"nctId":5003,"briefTitle":5004,"status":158,"phases":5005,"primaryCompletion":5006,"completion":5006,"start":5007,"enrollment":3344,"conditions":5008,"interventions":5009},"NCT07594522","A Study of Ivonescimab in People With Non-Small Cell Lung Cancer",[89,90],"2028-05-12","2026-05-12",[1695],[4961],{"nctId":5011,"briefTitle":5012,"status":158,"phases":5013,"primaryCompletion":531,"completion":5014,"start":5015,"enrollment":370,"conditions":5016,"interventions":5018},"NCT06925724","A Study of Ivonescimab in People With Endometrial and Cervical Cancers",[90],"2027-04-04","2025-04-04",[3359,5017],"Cervical Cancer",[4961],{"trials":5020,"activeCount":101},[],{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":101},[],{"intervention":3603,"totalTrials":234,"cells":5026},{"EARLY_PHASE1":5027,"PHASE1":5029,"PHASE2":5057,"PHASE3":5120,"PHASE4":5122,"NA":5124},{"trials":5028,"activeCount":101},[],{"trials":5030,"activeCount":97,"soonestReadout":933},[5031,5035,5039,5043,5049],{"nctId":3595,"briefTitle":3596,"status":244,"phases":5032,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":5033,"interventions":5034},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":3605,"briefTitle":3606,"status":244,"phases":5036,"primaryCompletion":1151,"start":426,"conditions":5037,"interventions":5038},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":930,"briefTitle":931,"status":158,"phases":5040,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":5041,"interventions":5042},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"nctId":5044,"briefTitle":5045,"status":244,"phases":5046,"start":3881,"conditions":5047,"interventions":5048},"NCT00005860","Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum",[89],[1155],[1615,391,3603],{"nctId":5050,"briefTitle":5051,"status":244,"phases":5052,"primaryCompletion":1566,"completion":1566,"start":3451,"enrollment":3344,"conditions":5053,"interventions":5056},"NCT00003427","Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer",[89],[5054,36,1602,1189,1190,1613,5055,2610,1226,1687],"Anal Cancer","Gastrointestinal Carcinoid Tumor",[683,3603],{"trials":5058,"activeCount":1934,"soonestReadout":232},[5059,5066,5070,5074,5082,5086,5090,5094,5101,5108,5116],{"nctId":5060,"briefTitle":5061,"status":244,"phases":5062,"completion":3044,"start":1663,"conditions":5063,"interventions":5064},"NCT00049101","Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",[89,90],[36],[5065,1616,391,3603],"erlotinib hydrochloride",{"nctId":1038,"briefTitle":1039,"status":158,"phases":5067,"primaryCompletion":812,"completion":812,"start":1041,"enrollment":1042,"conditions":5068,"interventions":5069},[90],[954],[923,944,463,1045],{"nctId":1047,"briefTitle":1048,"status":244,"phases":5071,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":5072,"interventions":5073},[90],[36,1054],[1045,923,944,819,1056,1057],{"nctId":5075,"briefTitle":5076,"status":113,"phases":5077,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":5078,"conditions":5079,"interventions":5081},"NCT02008656","Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management",[90],358,[5080],"Rectal Cancer",[944,1680,582,1679],{"nctId":1119,"briefTitle":1120,"status":244,"phases":5083,"primaryCompletion":1122,"completion":1122,"start":813,"enrollment":34,"conditions":5084,"interventions":5085},[90],[954,955,956,1124],[1045,643,923,944],{"nctId":2549,"briefTitle":2550,"status":244,"phases":5087,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":5088,"interventions":5089},[90],[1602,1613],[798,768,2557,47,944,1680],{"nctId":1670,"briefTitle":1671,"status":158,"phases":5091,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":5092,"interventions":5093},[90],[1602,1676,1677],[42,984,944,1679,1680,1181],{"nctId":5095,"briefTitle":5096,"status":244,"phases":5097,"primaryCompletion":4363,"completion":5098,"start":1397,"enrollment":573,"conditions":5099,"interventions":5100},"NCT00536874","Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery",[90],"2017-02",[1226],[441,3603,379,3152],{"nctId":5102,"briefTitle":5103,"status":244,"phases":5104,"primaryCompletion":3339,"completion":3339,"start":1396,"enrollment":573,"conditions":5105,"interventions":5106},"NCT01913639","FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer",[90],[1602,1613],[5107,1680,582,944],"Regorafenib",{"nctId":5109,"briefTitle":5110,"status":113,"phases":5111,"primaryCompletion":498,"completion":498,"start":1266,"enrollment":5112,"conditions":5113,"interventions":5114},"NCT00335816","Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer",[90],248,[36],[1616,391,3603,5115,378],"DNA analysis",{"nctId":3767,"briefTitle":3768,"status":113,"phases":5117,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":5118,"interventions":5119},[90],[36,2349],[643,1615,1616,683,391,3603],{"trials":5121,"activeCount":101},[],{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[5126],{"nctId":5127,"briefTitle":5128,"status":244,"phases":5129,"primaryCompletion":5130,"completion":5130,"start":764,"enrollment":1052,"conditions":5131,"interventions":5132},"NCT00462501","Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer",[93],"2014-02",[36],[920,1616,391,3603],{"intervention":741,"totalTrials":992,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5149,"PHASE2":5210,"PHASE3":5323,"PHASE4":5325,"NA":5327},{"trials":5136,"activeCount":1094,"soonestReadout":1469},[5137,5141],{"nctId":3353,"briefTitle":3354,"status":158,"phases":5138,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":1232,"conditions":5139,"interventions":5140},[88],[3359,3360,3361,2764,3362],[224,1595],{"nctId":5142,"briefTitle":5143,"status":113,"phases":5144,"primaryCompletion":1469,"completion":1469,"start":5145,"enrollment":296,"conditions":5146,"interventions":5148},"NCT03085056","Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer",[88],"2017-03-15",[5147],"Anaplastic Thyroid Cancer",[3080,1595],{"trials":5150,"activeCount":97,"soonestReadout":1583},[5151,5155,5170,5174,5178,5182,5186,5190,5194,5198,5202],{"nctId":3367,"briefTitle":3368,"status":244,"phases":5152,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":356,"conditions":5153,"interventions":5154},[89],[971,2992],[288,390,345,441,741],{"nctId":5156,"briefTitle":5157,"status":244,"phases":5158,"primaryCompletion":5159,"completion":5159,"start":774,"enrollment":601,"conditions":5160,"interventions":5167},"NCT02060253","Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer",[89],"2018-06",[5161,5162,5163,5164,5165,5166,4855],"HER2-positive Breast Cancer","Male Breast Cancer","Recurrent Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[5168,741,768,5169],"ganetespib","pertuzumab",{"nctId":2928,"briefTitle":2929,"status":244,"phases":5171,"primaryCompletion":2931,"completion":2931,"start":2932,"conditions":5172,"interventions":5173},[89],[1568],[2935,47,741],{"nctId":3379,"briefTitle":3380,"status":244,"phases":5175,"primaryCompletion":1629,"completion":1629,"start":3382,"conditions":5176,"interventions":5177},[89],[21],[390,1578,741],{"nctId":2952,"briefTitle":2938,"status":244,"phases":5179,"primaryCompletion":756,"completion":756,"start":2954,"conditions":5180,"interventions":5181},[89],[1568],[47,683,741],{"nctId":1580,"briefTitle":1581,"status":158,"phases":5183,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":5184,"interventions":5185},[89],[1586,1587,1588,1589,1590,1591],[974,224,1181,1593,1594,1595],{"nctId":3390,"briefTitle":3391,"status":244,"phases":5187,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":1412,"conditions":5188,"interventions":5189},[89],[30,3359],[1595,224,3397],{"nctId":2979,"briefTitle":2980,"status":244,"phases":5191,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":454,"conditions":5192,"interventions":5193},[89],[1602],[2909,47,741],{"nctId":2987,"briefTitle":2988,"status":244,"phases":5195,"primaryCompletion":695,"completion":695,"start":2990,"enrollment":356,"conditions":5196,"interventions":5197},[89],[971,2992],[288,47,345,441,741],{"nctId":2999,"briefTitle":3000,"status":244,"phases":5199,"primaryCompletion":2931,"completion":2931,"start":3002,"enrollment":3003,"conditions":5200,"interventions":5201},[89],[1568],[1570,47,741],{"nctId":5203,"briefTitle":5204,"status":244,"phases":5205,"primaryCompletion":5206,"completion":5206,"start":3122,"enrollment":718,"conditions":5207,"interventions":5208},"NCT00004057","Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas",[89],"2000-12",[24,1568],[5209,741],"L-778,123",{"trials":5211,"activeCount":1094,"soonestReadout":258},[5212,5216,5220,5227,5231,5235,5239,5243,5266,5270,5279,5285,5289,5293,5299,5303,5309,5313,5317],{"nctId":3041,"briefTitle":3042,"status":244,"phases":5213,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":5214,"interventions":5215},[89,90],[971,2992],[288,47,345,441,442,741],{"nctId":3408,"briefTitle":3409,"status":244,"phases":5217,"primaryCompletion":1014,"completion":1014,"start":3141,"enrollment":3411,"conditions":5218,"interventions":5219},[89,90],[387,30,868],[288,390,346,442,741],{"nctId":5221,"briefTitle":5222,"status":244,"phases":5223,"completion":804,"start":5224,"conditions":5225,"interventions":5226},"NCT00006245","Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel",[90],"2000-07",[1602],[1570,741],{"nctId":3060,"briefTitle":3061,"status":113,"phases":5228,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":5229,"interventions":5230},[90],[3066],[1595,222,974,225,2807,223],{"nctId":3138,"briefTitle":3139,"status":244,"phases":5232,"primaryCompletion":695,"completion":695,"start":3141,"enrollment":3017,"conditions":5233,"interventions":5234},[89,90],[30,868],[288,47,442,741],{"nctId":3440,"briefTitle":3441,"status":244,"phases":5236,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":213,"conditions":5237,"interventions":5238},[89,90],[3259,387,30,3260,868],[288,390,442,741],{"nctId":3448,"briefTitle":3449,"status":244,"phases":5240,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":5241,"interventions":5242},[89,90],[18],[390,3454,1707,3455,3456,741],{"nctId":5244,"briefTitle":5245,"status":113,"phases":5246,"primaryCompletion":5247,"completion":5247,"start":1674,"enrollment":306,"conditions":5248,"interventions":5262},"NCT06251973","A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer",[90],"2027-08-01",[5249,5250,5251,5252,5253,5254,5255,5256,5257,5258,5259,5260,5261],"Metastatic Esophageal Carcinoma","Advanced Unresectable Gastric Adenocarcinoma","Metastatic Gastric Cancer","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Esophageal Cancer","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastric Carcinoma","Unresectable Esophageal Cancer","Unresectable Esophageal Adenocarcinoma","Unresectable Gastric Carcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma",[5263,5264,5265,3246,1595],"AgenT-797","Botensilimab","Balstilimab",{"nctId":3198,"briefTitle":3199,"status":244,"phases":5267,"primaryCompletion":1397,"completion":1397,"start":649,"enrollment":718,"conditions":5268,"interventions":5269},[90],[971,3202],[47,442,741],{"nctId":5271,"briefTitle":5272,"status":244,"phases":5273,"primaryCompletion":5274,"completion":5274,"start":1141,"enrollment":306,"conditions":5275,"interventions":5277},"NCT01827163","Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer",[90],"2019-01",[5276],"HER2-Positive Early Stage Breast Cancer",[1595,984,5278,3898],"Lapatinib",{"nctId":5280,"briefTitle":5281,"status":244,"phases":5282,"primaryCompletion":774,"completion":774,"start":1423,"enrollment":908,"conditions":5283,"interventions":5284},"NCT00807573","Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment",[90],[21],[1595,1107,1157],{"nctId":3255,"briefTitle":3256,"status":244,"phases":5286,"primaryCompletion":259,"completion":259,"start":764,"enrollment":162,"conditions":5287,"interventions":5288},[90],[3259,387,30,3260,868],[373,47,442,741],{"nctId":733,"briefTitle":734,"status":244,"phases":5290,"primaryCompletion":736,"completion":736,"start":737,"conditions":5291,"interventions":5292},[90],[15],[288,202,740,741],{"nctId":5294,"briefTitle":5295,"status":244,"phases":5296,"completion":3044,"start":1611,"conditions":5297,"interventions":5298},"NCT00005599","Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer",[90],[1602,1613],[2935,741],{"nctId":3271,"briefTitle":3272,"status":244,"phases":5300,"primaryCompletion":3274,"completion":3274,"start":1664,"enrollment":438,"conditions":5301,"interventions":5302},[90],[1602],[47,741],{"nctId":5304,"briefTitle":5305,"status":244,"phases":5306,"primaryCompletion":756,"completion":756,"start":3497,"conditions":5307,"interventions":5308},"NCT00002928","Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer",[90],[30],[741],{"nctId":3539,"briefTitle":3540,"status":244,"phases":5310,"primaryCompletion":695,"completion":695,"start":637,"conditions":5311,"interventions":5312},[90],[3359],[390,345,741],{"nctId":760,"briefTitle":761,"status":244,"phases":5314,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":5315,"interventions":5316},[90],[15],[768,202,345,769,741],{"nctId":5318,"briefTitle":5319,"status":244,"phases":5320,"primaryCompletion":1610,"completion":1610,"start":3451,"enrollment":370,"conditions":5321,"interventions":5322},"NCT00003539","Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer",[90],[15],[768,741],{"trials":5324,"activeCount":101},[],{"trials":5326,"activeCount":101},[],{"trials":5328,"activeCount":101},[],{"intervention":86,"totalTrials":2291,"cells":5330},{"EARLY_PHASE1":5331,"PHASE1":5333,"PHASE2":5354,"PHASE3":5388,"PHASE4":5390,"NA":5392},{"trials":5332,"activeCount":101},[],{"trials":5334,"activeCount":1094,"soonestReadout":5348},[5335,5344],{"nctId":5336,"briefTitle":5337,"status":158,"phases":5338,"primaryCompletion":2472,"completion":2472,"start":5339,"enrollment":454,"conditions":5340,"interventions":5342},"NCT06807632","A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer",[89],"2025-01-29",[5341],"Extensive-stage Small-cell Lung Cancer",[5343,86],"Valemetostat",{"nctId":5345,"briefTitle":5346,"status":113,"phases":5347,"primaryCompletion":5348,"completion":5348,"start":5349,"enrollment":1462,"conditions":5350,"interventions":5351},"NCT04161755","Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery",[89],"2026-11-11","2019-12-13",[1226],[86,5352,5353],"RO7198457","mFOLFIRINOX",{"trials":5355,"activeCount":509,"soonestReadout":85},[5356,5360,5368,5372,5379],{"nctId":965,"briefTitle":966,"status":113,"phases":5357,"primaryCompletion":498,"completion":498,"start":968,"enrollment":969,"conditions":5358,"interventions":5359},[89,90],[971,972,938],[86,923,974],{"nctId":83,"briefTitle":84,"status":113,"phases":5361,"primaryCompletion":85,"completion":1469,"start":5362,"enrollment":1232,"conditions":5363,"interventions":5364},[90],"2020-03-03",[2030],[86,5365,577,5366,5367],"Abiraterone","GnRH analog","Enzalutamide",{"nctId":987,"briefTitle":988,"status":113,"phases":5369,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":5370,"interventions":5371},[90],[938,994,995],[86,923,974],{"nctId":5373,"briefTitle":5374,"status":505,"phases":5375,"primaryCompletion":2788,"completion":2788,"start":5376,"enrollment":509,"conditions":5377,"interventions":5378},"NCT03120676","Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma",[90],"2017-04-14",[604],[86],{"nctId":5380,"briefTitle":5381,"status":505,"phases":5382,"primaryCompletion":5383,"completion":5383,"start":5384,"enrollment":1094,"conditions":5385,"interventions":5386},"NCT03465891","Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma",[90],"2019-12-17","2018-03-09",[24],[5387],"atezolizumab",{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"intervention":1594,"totalTrials":1934,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5404,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5397,"activeCount":101},[],{"trials":5399,"activeCount":97,"soonestReadout":1583},[5400],{"nctId":1580,"briefTitle":1581,"status":158,"phases":5401,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":5402,"interventions":5403},[89],[1586,1587,1588,1589,1590,1591],[974,224,1181,1593,1594,1595],{"trials":5405,"activeCount":1114,"soonestReadout":5432},[5406,5415,5424,5428],{"nctId":5407,"briefTitle":5408,"status":5409,"phases":5410,"primaryCompletion":3072,"completion":3072,"start":232,"enrollment":908,"conditions":5411,"interventions":5413},"NCT07414992","A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer","NOT_YET_RECRUITING",[90],[5412],"Bladder Urothelial Carcinoma",[1594,5414],"Cemiplimab and Fianlimab",{"nctId":5416,"briefTitle":5417,"status":158,"phases":5418,"primaryCompletion":5419,"completion":5419,"start":5420,"enrollment":1434,"conditions":5421,"interventions":5423},"NCT06699602","A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma",[90],"2028-02","2025-02-11",[5422],"Renal Cell Carcinoma",[1594,4383],{"nctId":4375,"briefTitle":4376,"status":158,"phases":5425,"primaryCompletion":4378,"completion":4378,"start":4379,"enrollment":2815,"conditions":5426,"interventions":5427},[90],[4381],[4383,1594,941],{"nctId":5429,"briefTitle":5430,"status":113,"phases":5431,"primaryCompletion":5432,"completion":5432,"start":1881,"enrollment":2439,"conditions":5433,"interventions":5439},"NCT05574101","A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer",[90],"2026-10-06",[2336,4809,5434,5435,5436,5437,5438],"Squamous Cell Carcinoma","Locally Advanced Squamous Cell Carcinoma","Locally Advanced Squamous Cell Carcinoma of the Skin","Locally Advanced Cutaneous Squamous Cell Carcinoma","Locally Advanced Skin Squamous Cell Carcinoma",[1594],{"trials":5441,"activeCount":101},[],{"trials":5443,"activeCount":101},[],{"trials":5445,"activeCount":101},[],{"intervention":2412,"totalTrials":1934,"cells":5447},{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5481,"PHASE4":5483,"NA":5485},{"trials":5449,"activeCount":101},[],{"trials":5451,"activeCount":101},[],{"trials":5453,"activeCount":1934,"soonestReadout":232},[5454,5458,5462,5469,5473],{"nctId":2403,"briefTitle":2404,"status":113,"phases":5455,"primaryCompletion":498,"completion":498,"start":2406,"enrollment":2407,"conditions":5456,"interventions":5457},[90],[2409,2410],[2412,42],{"nctId":2422,"briefTitle":2423,"status":113,"phases":5459,"primaryCompletion":990,"completion":990,"start":2425,"enrollment":2426,"conditions":5460,"interventions":5461},[90],[2428],[2412,42],{"nctId":5463,"briefTitle":5464,"status":113,"phases":5465,"primaryCompletion":232,"completion":232,"start":5466,"enrollment":4866,"conditions":5467,"interventions":5468},"NCT02780310","Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma",[90],"2016-05-19",[2409],[2412],{"nctId":2526,"briefTitle":2527,"status":113,"phases":5470,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":718,"conditions":5471,"interventions":5472},[90],[2532,2533],[42,2412],{"nctId":5474,"briefTitle":5475,"status":158,"phases":5476,"primaryCompletion":1240,"completion":1240,"start":5477,"enrollment":969,"conditions":5478,"interventions":5479},"NCT06110793","A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer",[89,90],"2023-12-29",[2311],[2412,5480,4889],"Pembrolizuma",{"trials":5482,"activeCount":101},[],{"trials":5484,"activeCount":101},[],{"trials":5486,"activeCount":101},[],{"intervention":444,"totalTrials":1412,"cells":5488},{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5509,"PHASE3":5603,"PHASE4":5605,"NA":5607},{"trials":5490,"activeCount":101},[],{"trials":5492,"activeCount":509,"soonestReadout":1469},[5493,5497,5501,5505],{"nctId":1458,"briefTitle":1459,"status":244,"phases":5494,"primaryCompletion":1461,"completion":1461,"start":704,"enrollment":1462,"conditions":5495,"interventions":5496},[89],[308],[830,444,239,401],{"nctId":1466,"briefTitle":1467,"status":113,"phases":5498,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":573,"conditions":5499,"interventions":5500},[89],[720],[1473,331,420,238,1474],{"nctId":1273,"briefTitle":1274,"status":113,"phases":5502,"primaryCompletion":1130,"completion":1130,"start":1276,"enrollment":1232,"conditions":5503,"interventions":5504},[89],[24],[374,1279,444],{"nctId":3892,"briefTitle":3893,"status":113,"phases":5506,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":5507,"interventions":5508},[89],[707],[3897,223,581,420,3898,3899],{"trials":5510,"activeCount":1094,"soonestReadout":531},[5511,5515,5521,5525,5529,5536,5545,5549,5553,5561,5565,5574,5578,5584,5588,5595,5599],{"nctId":1482,"briefTitle":1483,"status":505,"phases":5512,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":97,"conditions":5513,"interventions":5514},[90],[1488],[420,418,421,331,515],{"nctId":5516,"briefTitle":5517,"status":244,"phases":5518,"primaryCompletion":3477,"completion":3477,"start":426,"conditions":5519,"interventions":5520},"NCT00008268","Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma",[90],[828],[288,444],{"nctId":407,"briefTitle":408,"status":244,"phases":5522,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":5523,"interventions":5524},[90],[414,415,416,308],[418,218,419,420,331,421],{"nctId":433,"briefTitle":434,"status":244,"phases":5526,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":5527,"interventions":5528},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":5530,"briefTitle":5531,"status":244,"phases":5532,"primaryCompletion":4772,"start":3930,"enrollment":1052,"conditions":5533,"interventions":5534},"NCT00004250","Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery",[90],[4734,33],[389,5535,444],"isolated limb perfusion",{"nctId":5537,"briefTitle":5538,"status":158,"phases":5539,"primaryCompletion":1240,"completion":1240,"start":5540,"enrollment":5541,"conditions":5542,"interventions":5543},"NCT06679829","A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant",[90],"2024-11-06",215,[308],[5544,420],"Siltuximab",{"nctId":528,"briefTitle":529,"status":113,"phases":5546,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":5547,"interventions":5548},[90],[535,536,537],[418,218,539,419,420,331],{"nctId":541,"briefTitle":542,"status":244,"phases":5550,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":5551,"interventions":5552},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":5554,"briefTitle":5555,"status":244,"phases":5556,"primaryCompletion":5557,"completion":5557,"start":4750,"enrollment":1434,"conditions":5558,"interventions":5559},"NCT00357396","Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors",[90],"2009-10",[33],[5560,830,444,479],"graft versus host disease prophylaxis\u002Ftherapy",{"nctId":596,"briefTitle":597,"status":505,"phases":5562,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":5563,"interventions":5564},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":5566,"briefTitle":5567,"status":244,"phases":5568,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":5571,"interventions":5572},"NCT00423514","Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and\u002For Advanced Hematologic Cancer or Other Disease",[89,90],"2021-06-18","2006-11-20",[1973,27,475],[288,3593,444,405,5573,479],"tacrolimus",{"nctId":3494,"briefTitle":3495,"status":244,"phases":5575,"primaryCompletion":688,"completion":688,"start":3497,"conditions":5576,"interventions":5577},[90],[24],[288,390,549,361,346,442,444],{"nctId":5579,"briefTitle":5580,"status":244,"phases":5581,"primaryCompletion":1432,"completion":1432,"start":5206,"conditions":5582,"interventions":5583},"NCT00014469","Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer",[90],[1973,27,475,476],[830,444,362,5573],{"nctId":3968,"briefTitle":3969,"status":244,"phases":5585,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":5586,"interventions":5587},[90],[24],[288,549,361,346,444,362],{"nctId":5589,"briefTitle":5590,"status":244,"phases":5591,"primaryCompletion":1014,"completion":1014,"start":554,"enrollment":1152,"conditions":5592,"interventions":5593},"NCT00027560","Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",[90],[27,24,828,475,476],[5594,403,404,444],"alemtuzumab",{"nctId":1393,"briefTitle":1394,"status":244,"phases":5596,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":5597,"interventions":5598},[90],[24],[288,374,360,549,361,346,444],{"nctId":3773,"briefTitle":3774,"status":244,"phases":5600,"primaryCompletion":3776,"start":3777,"conditions":5601,"interventions":5602},[90],[828],[288,643,444,558],{"trials":5604,"activeCount":101},[],{"trials":5606,"activeCount":101},[],{"trials":5608,"activeCount":101},[5609,5620],{"nctId":5610,"briefTitle":5611,"status":505,"phases":5612,"primaryCompletion":3209,"completion":3209,"start":5613,"enrollment":509,"conditions":5614,"interventions":5618},"NCT01598025","Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor",[93],"2012-05-02",[5615,5616,416,5617],"Acute Leukemia","Chronic Leukemia","Non-Hodgkins Lymphoma",[479,404,444,401,5619],"peripheral blood stem cell transplantation",{"nctId":903,"briefTitle":904,"status":244,"phases":5621,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":5622,"interventions":5623},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":362,"totalTrials":326,"cells":5625},{"EARLY_PHASE1":5626,"PHASE1":5632,"PHASE2":5640,"PHASE3":5713,"PHASE4":5719,"NA":5721},{"trials":5627,"activeCount":97,"soonestReadout":1240},[5628],{"nctId":1237,"briefTitle":1238,"status":113,"phases":5629,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":5630,"interventions":5631},[88],[1244],[579,465,1246,1247],{"trials":5633,"activeCount":101},[5634],{"nctId":5635,"briefTitle":5636,"status":244,"phases":5637,"primaryCompletion":3590,"start":3522,"enrollment":326,"conditions":5638,"interventions":5639},"NCT00119301","Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma",[89],[33],[391,362,3125],{"trials":5641,"activeCount":509,"soonestReadout":324},[5642,5646,5655,5659,5663,5667,5671,5675,5679,5683,5687,5691,5701,5705,5709],{"nctId":351,"briefTitle":352,"status":244,"phases":5643,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":5644,"interventions":5645},[90],[27],[359,360,202,361,346,362,363],{"nctId":5647,"briefTitle":5648,"status":244,"phases":5649,"primaryCompletion":3220,"completion":5650,"start":4009,"enrollment":326,"conditions":5651,"interventions":5652},"NCT00587873","Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)",[90],"2009-06",[1426],[579,5653,5654],"Leucovorin calcium","6-Thioguanine",{"nctId":381,"briefTitle":382,"status":244,"phases":5656,"primaryCompletion":384,"completion":384,"start":385,"conditions":5657,"interventions":5658},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":3642,"briefTitle":3643,"status":113,"phases":5660,"primaryCompletion":990,"completion":990,"start":3645,"enrollment":234,"conditions":5661,"interventions":5662},[90],[414,3647],[3649,3650,643,362],{"nctId":3048,"briefTitle":3049,"status":244,"phases":5664,"primaryCompletion":695,"completion":695,"start":3051,"enrollment":356,"conditions":5665,"interventions":5666},[90],[971],[288,47,345,362,3054],{"nctId":433,"briefTitle":434,"status":244,"phases":5668,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":5669,"interventions":5670},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":3069,"briefTitle":3070,"status":158,"phases":5672,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":5673,"interventions":5674},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":3118,"briefTitle":3119,"status":244,"phases":5676,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":5677,"interventions":5678},[90],[33],[288,47,345,442,391,362,3125],{"nctId":569,"briefTitle":570,"status":113,"phases":5680,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":5681,"interventions":5682},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":3177,"briefTitle":3178,"status":244,"phases":5684,"primaryCompletion":1083,"completion":1083,"start":1653,"enrollment":718,"conditions":5685,"interventions":5686},[90],[3076],[974,221,579],{"nctId":5579,"briefTitle":5580,"status":244,"phases":5688,"primaryCompletion":1432,"completion":1432,"start":5206,"conditions":5689,"interventions":5690},[90],[1973,27,475,476],[830,444,362,5573],{"nctId":5692,"briefTitle":5693,"status":244,"phases":5694,"primaryCompletion":5695,"completion":5650,"start":5696,"enrollment":1934,"conditions":5697,"interventions":5699},"NCT00588536","Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH",[90],"2008-07","1995-01",[5698],"Langerhans Cell Histiocytosis",[579,5654,5700],"Leucovorin Calcium",{"nctId":634,"briefTitle":635,"status":244,"phases":5702,"primaryCompletion":637,"completion":637,"start":638,"conditions":5703,"interventions":5704},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":3968,"briefTitle":3969,"status":244,"phases":5706,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":5707,"interventions":5708},[90],[24],[288,549,361,346,444,362],{"nctId":692,"briefTitle":693,"status":244,"phases":5710,"primaryCompletion":695,"completion":695,"start":696,"conditions":5711,"interventions":5712},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"trials":5714,"activeCount":101},[5715],{"nctId":872,"briefTitle":873,"status":244,"phases":5716,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":5717,"interventions":5718},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":5720,"activeCount":101},[],{"trials":5722,"activeCount":101},[],{"intervention":1107,"totalTrials":601,"cells":5724},{"EARLY_PHASE1":5725,"PHASE1":5727,"PHASE2":5741,"PHASE3":5767,"PHASE4":5769,"NA":5771},{"trials":5726,"activeCount":101},[],{"trials":5728,"activeCount":97,"soonestReadout":1130},[5729,5733,5737],{"nctId":2944,"briefTitle":2945,"status":2832,"phases":5730,"primaryCompletion":1641,"completion":1641,"start":1141,"enrollment":101,"conditions":5731,"interventions":5732},[89],[2948],[2950,974,224,1107],{"nctId":2651,"briefTitle":2652,"status":113,"phases":5734,"primaryCompletion":1130,"completion":1130,"start":2654,"enrollment":2483,"conditions":5735,"interventions":5736},[89],[2293],[942,1107,2657],{"nctId":2970,"briefTitle":2971,"status":244,"phases":5738,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":356,"conditions":5739,"interventions":5740},[89],[2976],[1108,47,1645],{"trials":5742,"activeCount":509,"soonestReadout":232},[5743,5747,5751,5755,5759,5763],{"nctId":3090,"briefTitle":3091,"status":244,"phases":5744,"primaryCompletion":1150,"completion":1150,"start":1347,"enrollment":601,"conditions":5745,"interventions":5746},[90],[3094,21],[3096,1107,974],{"nctId":3154,"briefTitle":3155,"status":158,"phases":5748,"primaryCompletion":3157,"completion":3157,"start":3158,"enrollment":2407,"conditions":5749,"interventions":5750},[90],[3160,3161,794,3162,3163],[1107,974,224],{"nctId":1638,"briefTitle":1639,"status":244,"phases":5752,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":5753,"interventions":5754},[90],[21],[1645,47,224,1646,1647,1181],{"nctId":1099,"briefTitle":1100,"status":158,"phases":5756,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":5757,"interventions":5758},[90],[21,1104,1105],[974,1107,923,224,1108,942],{"nctId":3501,"briefTitle":3502,"status":158,"phases":5760,"primaryCompletion":232,"completion":232,"start":3504,"enrollment":3505,"conditions":5761,"interventions":5762},[90],[3507],[3509,224,1107],{"nctId":5280,"briefTitle":5281,"status":244,"phases":5764,"primaryCompletion":774,"completion":774,"start":1423,"enrollment":908,"conditions":5765,"interventions":5766},[90],[21],[1595,1107,1157],{"trials":5768,"activeCount":101},[],{"trials":5770,"activeCount":101},[],{"trials":5772,"activeCount":101},[],{"intervention":5367,"totalTrials":952,"cells":5774},{"EARLY_PHASE1":5775,"PHASE1":5777,"PHASE2":5806,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5776,"activeCount":101},[],{"trials":5778,"activeCount":101},[5779,5789,5798],{"nctId":5780,"briefTitle":5781,"status":244,"phases":5782,"primaryCompletion":5783,"completion":5783,"start":5784,"enrollment":283,"conditions":5785,"interventions":5787},"NCT03310541","AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations",[89],"2023-05-03","2017-10-11",[15,18,5786],"Advanced Solid Tumors",[5788,5367,4889],"AZD5363",{"nctId":5790,"briefTitle":5791,"status":244,"phases":5792,"primaryCompletion":5793,"completion":5793,"start":5794,"enrollment":1232,"conditions":5795,"interventions":5796},"NCT02642913","Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients",[89],"2021-03-01","2015-12",[4081],[5367,5797],"Enzalutamide with Sorafenib",{"nctId":5799,"briefTitle":5800,"status":244,"phases":5801,"primaryCompletion":3309,"completion":3309,"start":3231,"enrollment":718,"conditions":5802,"interventions":5804},"NCT02833883","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",[89],[18,5803],"Castration Resistant Prostate Cancer",[5367,5805],"CC-115",{"trials":5807,"activeCount":1114,"soonestReadout":85},[5808,5812,5823,5832,5839],{"nctId":83,"briefTitle":84,"status":113,"phases":5809,"primaryCompletion":85,"completion":1469,"start":5362,"enrollment":1232,"conditions":5810,"interventions":5811},[90],[2030],[86,5365,577,5366,5367],{"nctId":5813,"briefTitle":5814,"status":244,"phases":5815,"primaryCompletion":5816,"completion":5816,"start":5817,"enrollment":533,"conditions":5818,"interventions":5822},"NCT01974765","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",[90],"2022-02-28","2013-11-05",[5819,5820,2632,5821],"Advanced Epithelial Ovarian","Recurrent Epithelial Ovarian","Primary Peritoneal Carcinoma",[5367],{"nctId":5824,"briefTitle":5825,"status":158,"phases":5826,"primaryCompletion":2005,"completion":2005,"start":5827,"enrollment":370,"conditions":5828,"interventions":5829},"NCT06457919","A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer",[89,90],"2024-06-04",[18],[5830,5831,5367],"Tinengotinib","abiraterone acetate with prednisone",{"nctId":5833,"briefTitle":5834,"status":113,"phases":5835,"primaryCompletion":232,"completion":232,"start":5466,"enrollment":370,"conditions":5836,"interventions":5838},"NCT02750358","Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer",[90],[15,5837,2313],"Early Stage",[5367],{"nctId":5840,"briefTitle":5841,"status":158,"phases":5842,"primaryCompletion":194,"completion":194,"start":5843,"enrollment":1441,"conditions":5844,"interventions":5845},"NCT06099769","A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer",[90],"2023-10-18",[2311],[5367,5846,5847],"Mifepristone","TPC",{"trials":5849,"activeCount":101},[],{"trials":5851,"activeCount":101},[],{"trials":5853,"activeCount":101},[],{"intervention":1679,"totalTrials":952,"cells":5855},{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5905,"PHASE4":5907,"NA":5909},{"trials":5857,"activeCount":101},[],{"trials":5859,"activeCount":101},[],{"trials":5861,"activeCount":1114,"soonestReadout":1130},[5862,5868,5872,5876,5880,5884,5891,5899],{"nctId":5863,"briefTitle":5864,"status":244,"phases":5865,"primaryCompletion":3655,"completion":3655,"start":4750,"enrollment":2888,"conditions":5866,"interventions":5867},"NCT00468585","Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model",[89,90],[15],[1679,1157],{"nctId":5075,"briefTitle":5076,"status":113,"phases":5869,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":5078,"conditions":5870,"interventions":5871},[90],[5080],[944,1680,582,1679],{"nctId":2549,"briefTitle":2550,"status":244,"phases":5873,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":5874,"interventions":5875},[90],[1602,1613],[798,768,2557,47,944,1680],{"nctId":3239,"briefTitle":3240,"status":505,"phases":5877,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":2291,"conditions":5878,"interventions":5879},[90],[1613,2400],[3246,984,1679,974],{"nctId":1670,"briefTitle":1671,"status":158,"phases":5881,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":5882,"interventions":5883},[90],[1602,1676,1677],[42,984,944,1679,1680,1181],{"nctId":5885,"briefTitle":5886,"status":113,"phases":5887,"primaryCompletion":531,"completion":531,"start":5888,"enrollment":1015,"conditions":5889,"interventions":5890},"NCT03523312","Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer",[90],"2018-04-30",[1226],[2557],{"nctId":5892,"briefTitle":5893,"status":113,"phases":5894,"primaryCompletion":498,"completion":498,"start":5895,"enrollment":2439,"conditions":5896,"interventions":5897},"NCT03377387","Capecitabine 7\u002F7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer",[89,90],"2017-12-13",[15],[1679,5898],"Neratinib",{"nctId":5900,"briefTitle":5901,"status":244,"phases":5902,"primaryCompletion":5206,"completion":5206,"start":3122,"conditions":5903,"interventions":5904},"NCT00004012","Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],[285,30,286],[2557],{"trials":5906,"activeCount":101},[],{"trials":5908,"activeCount":101},[],{"trials":5910,"activeCount":101},[],{"intervention":77,"totalTrials":2291,"cells":5912},{"EARLY_PHASE1":5913,"PHASE1":5915,"PHASE2":5921,"PHASE3":5950,"PHASE4":5952,"NA":5954},{"trials":5914,"activeCount":101},[],{"trials":5916,"activeCount":101},[5917],{"nctId":2919,"briefTitle":2920,"status":244,"phases":5918,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":234,"conditions":5919,"interventions":5920},[89],[30,2633,285],[2926,1157,974,77],{"trials":5922,"activeCount":1114,"soonestReadout":76},[5923,5927,5931,5935,5939,5943],{"nctId":2357,"briefTitle":2358,"status":244,"phases":5924,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":213,"conditions":5925,"interventions":5926},[90],[2363],[42,77],{"nctId":4223,"briefTitle":4224,"status":505,"phases":5928,"primaryCompletion":4226,"completion":4226,"start":4227,"enrollment":1934,"conditions":5929,"interventions":5930},[90],[18],[77,52],{"nctId":2469,"briefTitle":2470,"status":113,"phases":5932,"primaryCompletion":2472,"completion":2472,"start":2473,"enrollment":203,"conditions":5933,"interventions":5934},[90],[2475,2476],[42,77],{"nctId":74,"briefTitle":75,"status":113,"phases":5936,"primaryCompletion":76,"completion":2472,"start":2514,"enrollment":332,"conditions":5937,"interventions":5938},[90],[15],[77,42],{"nctId":2518,"briefTitle":2519,"status":158,"phases":5940,"primaryCompletion":2472,"completion":2472,"start":2521,"enrollment":2439,"conditions":5941,"interventions":5942},[90],[2313,2523,15,2311],[42,77],{"nctId":5944,"briefTitle":5945,"status":113,"phases":5946,"primaryCompletion":2082,"completion":2082,"start":5145,"enrollment":1412,"conditions":5947,"interventions":5949},"NCT03085147","A Dye for the Detection of Cancer of the Tongue and Mouth",[89,90],[5948],"Oral Squamous Cell Carcinoma (OSCC)",[77],{"trials":5951,"activeCount":101},[],{"trials":5953,"activeCount":101},[],{"trials":5955,"activeCount":101},[],{"intervention":3509,"totalTrials":2291,"cells":5957},{"EARLY_PHASE1":5958,"PHASE1":5971,"PHASE2":5985,"PHASE3":6013,"PHASE4":6015,"NA":6017},{"trials":5959,"activeCount":101},[5960],{"nctId":5961,"briefTitle":5962,"status":244,"phases":5963,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":234,"conditions":5966,"interventions":5969},"NCT03755102","A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.",[88],"2023-07-07","2018-11-21",[5967,21,5968],"EGFR Gene Mutation","Lung Cancer Metastatic",[5970,3509],"Dacomitinib",{"trials":5972,"activeCount":97,"soonestReadout":258},[5973,5981],{"nctId":5974,"briefTitle":5975,"status":244,"phases":5976,"primaryCompletion":5977,"completion":5977,"start":5978,"enrollment":2483,"conditions":5979,"interventions":5980},"NCT03810807","Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer",[89],"2025-12-15","2019-01-17",[3507],[5970,3509],{"nctId":3885,"briefTitle":3886,"status":113,"phases":5982,"primaryCompletion":258,"completion":258,"start":3888,"enrollment":2630,"conditions":5983,"interventions":5984},[89],[21],[3509,945,223],{"trials":5986,"activeCount":509,"soonestReadout":232},[5987,5991,6001,6009],{"nctId":4979,"briefTitle":4980,"status":158,"phases":5988,"primaryCompletion":1208,"completion":1208,"start":4982,"enrollment":4983,"conditions":5989,"interventions":5990},[89,90],[1695],[4961,4986,3509],{"nctId":5992,"briefTitle":5993,"status":244,"phases":5994,"primaryCompletion":5995,"completion":5995,"start":5996,"enrollment":565,"conditions":5997,"interventions":5999},"NCT02803203","Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers",[89,90],"2022-03-01","2016-06-29",[2948,5998],"EGFR-mutant Lung Cancers",[6000,1157],"osimertinib",{"nctId":6002,"briefTitle":6003,"status":158,"phases":6004,"primaryCompletion":1310,"completion":1310,"start":6005,"enrollment":2334,"conditions":6006,"interventions":6008},"NCT06741085","A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain",[90],"2024-12-13",[6007],"Non Small Cell Lung Cancer Metastatic",[6000],{"nctId":3501,"briefTitle":3502,"status":158,"phases":6010,"primaryCompletion":232,"completion":232,"start":3504,"enrollment":3505,"conditions":6011,"interventions":6012},[90],[3507],[3509,224,1107],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"trials":6018,"activeCount":101},[],{"intervention":4879,"totalTrials":332,"cells":6020},{"EARLY_PHASE1":6021,"PHASE1":6023,"PHASE2":6044,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6022,"activeCount":101},[],{"trials":6024,"activeCount":97,"soonestReadout":1240},[6025,6033],{"nctId":6026,"briefTitle":6027,"status":113,"phases":6028,"primaryCompletion":1240,"completion":1240,"start":6029,"enrollment":1094,"conditions":6030,"interventions":6032},"NCT06132945","A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain",[89],"2023-11-10",[4876,6031],"Brain Metastases",[4879],{"nctId":6034,"briefTitle":6035,"status":244,"phases":6036,"primaryCompletion":6037,"completion":6037,"start":6038,"enrollment":306,"conditions":6039,"interventions":6043},"NCT03667482","Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer",[89],"2024-07-17","2018-09-07",[6040,6041,6042],"Head and Neck Squamous Cell Cancer","Recurrent Head and Neck Squamous Cell Cancer","Metastatic Head and Neck Squamous Cell Cancer",[4879,1593],{"trials":6045,"activeCount":509,"soonestReadout":2082},[6046,6050,6056,6060],{"nctId":4871,"briefTitle":4872,"status":158,"phases":6047,"primaryCompletion":304,"completion":304,"start":4874,"enrollment":3017,"conditions":6048,"interventions":6049},[89,90],[4876,4877],[4107,4879],{"nctId":6051,"briefTitle":6052,"status":158,"phases":6053,"primaryCompletion":2082,"completion":2082,"start":3548,"enrollment":1291,"conditions":6054,"interventions":6055},"NCT01639508","Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity",[90],[1695],[4879],{"nctId":2707,"briefTitle":2708,"status":113,"phases":6057,"primaryCompletion":324,"completion":324,"start":2710,"enrollment":162,"conditions":6058,"interventions":6059},[90],[2712,2713,2714,2715,2716,2717,2718],[2720,2682],{"nctId":6061,"briefTitle":6062,"status":244,"phases":6063,"primaryCompletion":6064,"completion":6064,"start":6065,"enrollment":2630,"conditions":6066,"interventions":6068},"NCT01866293","Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma",[89,90],"2016-08-18","2013-05-28",[6067],"Relapsed or Refractory Multiple Myeloma",[4879],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[],{"intervention":3080,"totalTrials":332,"cells":6076},{"EARLY_PHASE1":6077,"PHASE1":6083,"PHASE2":6094,"PHASE3":6135,"PHASE4":6137,"NA":6139},{"trials":6078,"activeCount":97,"soonestReadout":1469},[6079],{"nctId":5142,"briefTitle":5143,"status":113,"phases":6080,"primaryCompletion":1469,"completion":1469,"start":5145,"enrollment":296,"conditions":6081,"interventions":6082},[88],[5147],[3080,1595],{"trials":6084,"activeCount":101},[6085],{"nctId":6086,"briefTitle":6087,"status":244,"phases":6088,"primaryCompletion":6089,"completion":6089,"start":4297,"enrollment":326,"conditions":6090,"interventions":6091},"NCT03026517","Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma",[89],"2025-01-21",[2341],[6092,3080,6093],"Dabrafenib","Phenformin",{"trials":6095,"activeCount":509,"soonestReadout":1583},[6096,6100,6109,6124],{"nctId":3069,"briefTitle":3070,"status":158,"phases":6097,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":6098,"interventions":6099},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":6101,"briefTitle":6102,"status":113,"phases":6103,"primaryCompletion":1583,"completion":1583,"start":6104,"enrollment":1447,"conditions":6105,"interventions":6108},"NCT04238624","Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer",[90],"2020-01-20",[5147,4054,6106,6107],"BRAF Gene Mutation","BRAF Mutation-Related Tumors",[6092,3080],{"nctId":6110,"briefTitle":6111,"status":113,"phases":6112,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":2446,"conditions":6115,"interventions":6122},"NCT04544111","PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer",[90],"2026-09-02","2020-09-02",[4054,6116,6117,6118,6119,6120,6121],"Thyroid Cancer, Follicular","Papillary Thyroid Cancer","Follicular Thyroid Cancer","Hurthle Cell Tumor","Poorly Differentiated Thyroid Gland Carcinoma","Hurthle Cell Thyroid Neoplasia",[3080,6092,6123],"PDR001",{"nctId":6125,"briefTitle":6126,"status":244,"phases":6127,"primaryCompletion":2473,"completion":2473,"start":6128,"enrollment":454,"conditions":6129,"interventions":6134},"NCT03076164","A Phase 1\u002F2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib",[89,90],"2017-03-01",[6130,21,5968,6131,6132,6133],"Lung Adenocarcinoma","Lung Cancer Stage IV","Recurrent Lung Adenocarcinoma","Recurrent Lung Cancer",[3080,4134],{"trials":6136,"activeCount":101},[],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[],{"intervention":582,"totalTrials":332,"cells":6142},{"EARLY_PHASE1":6143,"PHASE1":6149,"PHASE2":6155,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6144,"activeCount":97,"soonestReadout":1240},[6145],{"nctId":1237,"briefTitle":1238,"status":113,"phases":6146,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":6147,"interventions":6148},[88],[1244],[579,465,1246,1247],{"trials":6150,"activeCount":97,"soonestReadout":933},[6151],{"nctId":930,"briefTitle":931,"status":158,"phases":6152,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":6153,"interventions":6154},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"trials":6156,"activeCount":1094,"soonestReadout":324},[6157,6161,6165,6169],{"nctId":3690,"briefTitle":3691,"status":2832,"phases":6158,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":6159,"interventions":6160},[90],[3696],[1045,819,3698,3699,960,582],{"nctId":569,"briefTitle":570,"status":113,"phases":6162,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":6163,"interventions":6164},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":5075,"briefTitle":5076,"status":113,"phases":6166,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":5078,"conditions":6167,"interventions":6168},[90],[5080],[944,1680,582,1679],{"nctId":5102,"briefTitle":5103,"status":244,"phases":6170,"primaryCompletion":3339,"completion":3339,"start":1396,"enrollment":573,"conditions":6171,"interventions":6172},[90],[1602,1613],[5107,1680,582,944],{"trials":6174,"activeCount":101},[],{"trials":6176,"activeCount":101},[],{"trials":6178,"activeCount":101},[],{"intervention":616,"totalTrials":1934,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6182,"activeCount":101},[],{"trials":6184,"activeCount":101},[],{"trials":6186,"activeCount":1114,"soonestReadout":71},[6187,6191,6195,6199,6203],{"nctId":609,"briefTitle":610,"status":158,"phases":6188,"primaryCompletion":115,"completion":115,"start":612,"enrollment":306,"conditions":6189,"interventions":6190},[90],[308,614],[218,464,463,616],{"nctId":69,"briefTitle":70,"status":113,"phases":6192,"primaryCompletion":71,"completion":1469,"start":3716,"enrollment":3717,"conditions":6193,"interventions":6194},[90],[308],[72,3720,1350,643,643],{"nctId":3739,"briefTitle":3740,"status":113,"phases":6196,"primaryCompletion":1028,"completion":1028,"start":3742,"enrollment":2462,"conditions":6197,"interventions":6198},[90],[308],[3676,1261,463,616],{"nctId":4643,"briefTitle":4644,"status":244,"phases":6200,"primaryCompletion":4646,"completion":4646,"start":4647,"enrollment":1434,"conditions":6201,"interventions":6202},[90],[308],[616,1261],{"nctId":4651,"briefTitle":4652,"status":113,"phases":6204,"primaryCompletion":324,"completion":324,"start":4654,"enrollment":765,"conditions":6205,"interventions":6206},[90],[308],[1261,616],{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"intervention":220,"totalTrials":1114,"cells":6214},{"EARLY_PHASE1":6215,"PHASE1":6221,"PHASE2":6223,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6216,"activeCount":97,"soonestReadout":211},[6217],{"nctId":208,"briefTitle":209,"status":113,"phases":6218,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":6219,"interventions":6220},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":6222,"activeCount":101},[],{"trials":6224,"activeCount":509,"soonestReadout":324},[6225,6229,6233],{"nctId":3419,"briefTitle":3420,"status":158,"phases":6226,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":6227,"interventions":6228},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":569,"briefTitle":570,"status":113,"phases":6230,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":6231,"interventions":6232},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":809,"briefTitle":810,"status":113,"phases":6234,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":6235,"interventions":6236},[90],[816],[218,220,222,223,818,819,225,820,516],{"trials":6238,"activeCount":101},[],{"trials":6240,"activeCount":101},[],{"trials":6242,"activeCount":101},[],{"intervention":6244,"totalTrials":1114,"cells":6245},"Avutometinib",{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6270,"PHASE3":6297,"PHASE4":6299,"NA":6301},{"trials":6247,"activeCount":101},[],{"trials":6249,"activeCount":97,"soonestReadout":6254},[6250],{"nctId":6251,"briefTitle":6252,"status":158,"phases":6253,"primaryCompletion":6254,"completion":6254,"start":6255,"enrollment":1412,"conditions":6256,"interventions":6269},"NCT06104488","A Study of Avutometinib for People With Solid Tumor Cancers",[89],"2029-10-20","2023-10-20",[2350,6257,6258,6259,6260,6261,6262,6263,6264,215,6265,2351,6266,6267,6268],"CNS Tumors","CNS Tumor, Adult","CNS Tumor, Childhood","MAP Kinase Family Gene Mutation","NF1","Plexiform Neurofibroma","Low-grade Glioma","Optic Pathway Gliomas","Primary Brain Tumor","Solid Tumor, Adult","Solid Carcinoma","Central Nervous System Tumor",[6244],{"trials":6271,"activeCount":509,"soonestReadout":990},[6272,6281,6289],{"nctId":6273,"briefTitle":6274,"status":158,"phases":6275,"primaryCompletion":531,"completion":531,"start":2688,"enrollment":306,"conditions":6276,"interventions":6278},"NCT06394804","A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer",[90],[6277],"Low-Grade Serous Ovarian Cancer",[6244,6279,6280],"Defactinib","Letrozole",{"nctId":6282,"briefTitle":6283,"status":158,"phases":6284,"primaryCompletion":6285,"completion":6285,"start":6286,"enrollment":356,"conditions":6287,"interventions":6288},"NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer",[90],"2027-08-16","2023-08-16",[4054],[6244,6279],{"nctId":6290,"briefTitle":6291,"status":158,"phases":6292,"primaryCompletion":990,"completion":990,"start":6293,"enrollment":718,"conditions":6294,"interventions":6296},"NCT05787561","A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer",[90],"2023-03-15",[6295],"Mesonephric Gynecologic Cancer",[6244,6279],{"trials":6298,"activeCount":101},[],{"trials":6300,"activeCount":101},[],{"trials":6302,"activeCount":101},[],{"intervention":445,"totalTrials":283,"cells":6304},{"EARLY_PHASE1":6305,"PHASE1":6307,"PHASE2":6309,"PHASE3":6361,"PHASE4":6371,"NA":6373},{"trials":6306,"activeCount":101},[],{"trials":6308,"activeCount":101},[],{"trials":6310,"activeCount":509,"soonestReadout":85},[6311,6321,6325,6329,6333,6337,6341,6345,6357],{"nctId":6312,"briefTitle":6313,"status":244,"phases":6314,"primaryCompletion":6315,"completion":6315,"start":6316,"enrollment":2439,"conditions":6317,"interventions":6319},"NCT02496585","Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis",[90],"2024-04-12","2015-07-08",[21,6318],"Lung Metastases",[6320,577],"Nintedanib",{"nctId":433,"briefTitle":434,"status":244,"phases":6322,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":6323,"interventions":6324},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":83,"briefTitle":84,"status":113,"phases":6326,"primaryCompletion":85,"completion":1469,"start":5362,"enrollment":1232,"conditions":6327,"interventions":6328},[90],[2030],[86,5365,577,5366,5367],{"nctId":518,"briefTitle":519,"status":244,"phases":6330,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":6331,"interventions":6332},[90],[24],[526,288,374,202,345,445,349],{"nctId":569,"briefTitle":570,"status":113,"phases":6334,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":6335,"interventions":6336},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":654,"briefTitle":655,"status":244,"phases":6338,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":6339,"interventions":6340},[89,90],[27,24],[374,662,202,445],{"nctId":724,"briefTitle":725,"status":244,"phases":6342,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":6343,"interventions":6344},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":6346,"briefTitle":6347,"status":113,"phases":6348,"primaryCompletion":6349,"completion":6350,"start":6351,"enrollment":1654,"conditions":6352,"interventions":6353},"NCT03436654","Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma",[90],"2026-03-16","2027-02-14","2018-06-21",[18],[6354,6355,577,6356],"Apalutamide","Abiraterone Acetate","GnRH agonist\u002Fantagonist",{"nctId":832,"briefTitle":833,"status":244,"phases":6358,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":6359,"interventions":6360},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":6362,"activeCount":101},[6363,6367],{"nctId":1968,"briefTitle":1969,"status":244,"phases":6364,"completion":1971,"start":1566,"conditions":6365,"interventions":6366},[91],[1973],[1975,478,445],{"nctId":872,"briefTitle":873,"status":244,"phases":6368,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":6369,"interventions":6370},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":6372,"activeCount":101},[],{"trials":6374,"activeCount":97,"soonestReadout":531},[6375],{"nctId":1438,"briefTitle":1439,"status":113,"phases":6376,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":1441,"conditions":6377,"interventions":6378},[93],[1443,1444],[374,445],{"intervention":461,"totalTrials":1434,"cells":6380},{"EARLY_PHASE1":6381,"PHASE1":6383,"PHASE2":6385,"PHASE3":6431,"PHASE4":6433,"NA":6435},{"trials":6382,"activeCount":101},[],{"trials":6384,"activeCount":101},[],{"trials":6386,"activeCount":1114,"soonestReadout":1518},[6387,6391,6403,6407,6411,6415,6419,6423,6427],{"nctId":393,"briefTitle":394,"status":244,"phases":6388,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":6389,"interventions":6390},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":6392,"briefTitle":6393,"status":244,"phases":6394,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":6397,"conditions":6398,"interventions":6401},"NCT03434730","Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation",[90],"2025-04-18","2018-02-07",46,[3816,414,5615,475,6399,1154,6400,604,27],"Myelodysplastic-Myeloproliferative Diseases","Non Hodgkin Lymphoma",[675,461,6402,912],"Tocilizumab",{"nctId":433,"briefTitle":434,"status":244,"phases":6404,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":6405,"interventions":6406},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":449,"briefTitle":450,"status":158,"phases":6408,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":6409,"interventions":6410},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":5566,"briefTitle":5567,"status":244,"phases":6412,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":6413,"interventions":6414},[89,90],[1973,27,475],[288,3593,444,405,5573,479],{"nctId":664,"briefTitle":665,"status":158,"phases":6416,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":6417,"interventions":6418},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":1515,"briefTitle":1516,"status":158,"phases":6420,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":6421,"interventions":6422},[90],[1521,1522,1523,1524,1525,1526,1527,1528,1529],[421,331,419,1531,461,1532],{"nctId":713,"briefTitle":714,"status":158,"phases":6424,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":6425,"interventions":6426},[90],[720],[218,218,461,722,460,460],{"nctId":771,"briefTitle":772,"status":244,"phases":6428,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":6429,"interventions":6430},[90],[27,24],[288,374,202,403,404,405],{"trials":6432,"activeCount":101},[],{"trials":6434,"activeCount":101},[],{"trials":6436,"activeCount":101},[6437],{"nctId":903,"briefTitle":904,"status":244,"phases":6438,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":6439,"interventions":6440},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":419,"totalTrials":2630,"cells":6442},{"EARLY_PHASE1":6443,"PHASE1":6445,"PHASE2":6451,"PHASE3":6496,"PHASE4":6498,"NA":6500},{"trials":6444,"activeCount":101},[],{"trials":6446,"activeCount":101},[6447],{"nctId":1458,"briefTitle":1459,"status":244,"phases":6448,"primaryCompletion":1461,"completion":1461,"start":704,"enrollment":1462,"conditions":6449,"interventions":6450},[89],[308],[830,444,239,401],{"trials":6452,"activeCount":509,"soonestReadout":1518},[6453,6457,6461,6465,6469,6473,6477,6481,6485,6489],{"nctId":407,"briefTitle":408,"status":244,"phases":6454,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":6455,"interventions":6456},[90],[414,415,416,308],[418,218,419,420,331,421],{"nctId":503,"briefTitle":504,"status":505,"phases":6458,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":6459,"interventions":6460},[90],[511,512,513],[419,331,218,515,516],{"nctId":528,"briefTitle":529,"status":113,"phases":6462,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":6463,"interventions":6464},[90],[535,536,537],[418,218,539,419,420,331],{"nctId":5554,"briefTitle":5555,"status":244,"phases":6466,"primaryCompletion":5557,"completion":5557,"start":4750,"enrollment":1434,"conditions":6467,"interventions":6468},[90],[33],[5560,830,444,479],{"nctId":596,"briefTitle":597,"status":505,"phases":6470,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":6471,"interventions":6472},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":5579,"briefTitle":5580,"status":244,"phases":6474,"primaryCompletion":1432,"completion":1432,"start":5206,"conditions":6475,"interventions":6476},[90],[1973,27,475,476],[830,444,362,5573],{"nctId":664,"briefTitle":665,"status":158,"phases":6478,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":6479,"interventions":6480},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":1515,"briefTitle":1516,"status":158,"phases":6482,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":6483,"interventions":6484},[90],[1521,1522,1523,1524,1525,1526,1527,1528,1529],[421,331,419,1531,461,1532],{"nctId":822,"briefTitle":823,"status":244,"phases":6486,"primaryCompletion":825,"completion":825,"start":826,"conditions":6487,"interventions":6488},[90],[27,24,828,475],[830,202,361],{"nctId":6490,"briefTitle":6491,"status":244,"phases":6492,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":6494,"interventions":6495},"NCT00003101","Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma",[90],"2002-01",[3259],[288,830,3342,446,479,349],{"trials":6497,"activeCount":101},[],{"trials":6499,"activeCount":101},[],{"trials":6501,"activeCount":101},[],{"intervention":819,"totalTrials":952,"cells":6503},{"EARLY_PHASE1":6504,"PHASE1":6510,"PHASE2":6512,"PHASE3":6556,"PHASE4":6558,"NA":6560},{"trials":6505,"activeCount":97,"soonestReadout":258},[6506],{"nctId":4684,"briefTitle":4685,"status":113,"phases":6507,"primaryCompletion":258,"completion":258,"start":4687,"enrollment":1798,"conditions":6508,"interventions":6509},[88],[4689],[819,4691,4692,4693],{"trials":6511,"activeCount":101},[],{"trials":6513,"activeCount":1094,"soonestReadout":812},[6514,6518,6522,6533,6537,6541,6552],{"nctId":3083,"briefTitle":3084,"status":244,"phases":6515,"primaryCompletion":588,"completion":588,"start":1356,"enrollment":398,"conditions":6516,"interventions":6517},[90],[3087],[974,819],{"nctId":3419,"briefTitle":3420,"status":158,"phases":6519,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":6520,"interventions":6521},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":6523,"briefTitle":6524,"status":244,"phases":6525,"primaryCompletion":6526,"completion":6526,"start":6527,"enrollment":899,"conditions":6528,"interventions":6531},"NCT04095221","A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma",[89,90],"2025-02-18","2019-09-17",[6529,6530],"Desmoplastic Small Round Cell Tumor","Rhabdomyosarcoma",[6532,819],"Prexasertib",{"nctId":3690,"briefTitle":3691,"status":2832,"phases":6534,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":6535,"interventions":6536},[90],[3696],[1045,819,3698,3699,960,582],{"nctId":1047,"briefTitle":1048,"status":244,"phases":6538,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":6539,"interventions":6540},[90],[36,1054],[1045,923,944,819,1056,1057],{"nctId":6542,"briefTitle":6543,"status":505,"phases":6544,"primaryCompletion":6545,"completion":6545,"start":6546,"enrollment":2483,"conditions":6547,"interventions":6549},"NCT03879798","DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer",[89,90],"2023-05-02","2019-03-15",[6548],"Small Cell Lung Cancer",[6550,6551],"DS-3201b","irinotecan",{"nctId":809,"briefTitle":810,"status":113,"phases":6553,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":6554,"interventions":6555},[90],[816],[218,220,222,223,818,819,225,820,516],{"trials":6557,"activeCount":101},[],{"trials":6559,"activeCount":101},[],{"trials":6561,"activeCount":101},[],{"intervention":3818,"totalTrials":1934,"cells":6563},{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6568,"PHASE3":6600,"PHASE4":6602,"NA":6604},{"trials":6565,"activeCount":101},[],{"trials":6567,"activeCount":101},[],{"trials":6569,"activeCount":509,"soonestReadout":2472},[6570,6574,6578,6582,6592],{"nctId":3810,"briefTitle":3811,"status":158,"phases":6571,"primaryCompletion":2005,"completion":2005,"start":3813,"enrollment":3814,"conditions":6572,"interventions":6573},[90],[3816],[3818,1327],{"nctId":3820,"briefTitle":3821,"status":158,"phases":6575,"primaryCompletion":2472,"completion":2472,"start":3823,"enrollment":356,"conditions":6576,"interventions":6577},[90],[535],[3818,1327],{"nctId":3827,"briefTitle":3828,"status":158,"phases":6579,"primaryCompletion":484,"completion":484,"start":3830,"enrollment":341,"conditions":6580,"interventions":6581},[90],[3816],[3833,3818,1327],{"nctId":6583,"briefTitle":6584,"status":2832,"phases":6585,"primaryCompletion":6586,"completion":6586,"start":6587,"enrollment":101,"conditions":6588,"interventions":6590},"NCT03699384","Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)",[89,90],"2019-02-18","2018-10-03",[535,6589],"Minimal Residual Disease",[3818,6591],"Avelumab",{"nctId":6593,"briefTitle":6594,"status":244,"phases":6595,"completion":737,"start":825,"conditions":6596,"interventions":6597},"NCT00006019","Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer",[90],[27,21,24,828,475,18],[6598,6599],"azacitidine","sodium phenylbutyrate",{"trials":6601,"activeCount":101},[],{"trials":6603,"activeCount":101},[],{"trials":6605,"activeCount":101},[],{"intervention":1680,"totalTrials":1934,"cells":6607},{"EARLY_PHASE1":6608,"PHASE1":6610,"PHASE2":6612,"PHASE3":6634,"PHASE4":6636,"NA":6638},{"trials":6609,"activeCount":101},[],{"trials":6611,"activeCount":101},[],{"trials":6613,"activeCount":509,"soonestReadout":1130},[6614,6618,6622,6626,6630],{"nctId":5075,"briefTitle":5076,"status":113,"phases":6615,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":5078,"conditions":6616,"interventions":6617},[90],[5080],[944,1680,582,1679],{"nctId":2549,"briefTitle":2550,"status":244,"phases":6619,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":6620,"interventions":6621},[90],[1602,1613],[798,768,2557,47,944,1680],{"nctId":1670,"briefTitle":1671,"status":158,"phases":6623,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":6624,"interventions":6625},[90],[1602,1676,1677],[42,984,944,1679,1680,1181],{"nctId":5102,"briefTitle":5103,"status":244,"phases":6627,"primaryCompletion":3339,"completion":3339,"start":1396,"enrollment":573,"conditions":6628,"interventions":6629},[90],[1602,1613],[5107,1680,582,944],{"nctId":3289,"briefTitle":3290,"status":158,"phases":6631,"primaryCompletion":3292,"completion":3292,"start":3293,"enrollment":3294,"conditions":6632,"interventions":6633},[90],[1754,3296,1745,3297,3298],[974,224,3300],{"trials":6635,"activeCount":101},[],{"trials":6637,"activeCount":101},[],{"trials":6639,"activeCount":101},[],{"intervention":6641,"totalTrials":1114,"cells":6642},"Palbociclib",{"EARLY_PHASE1":6643,"PHASE1":6645,"PHASE2":6657,"PHASE3":6694,"PHASE4":6696,"NA":6698},{"trials":6644,"activeCount":101},[],{"trials":6646,"activeCount":101},[6647],{"nctId":6648,"briefTitle":6649,"status":2832,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":101,"conditions":6653,"interventions":6655},"NCT04872608","A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer",[89],"2023-04-25","2021-09-09",[2311,6654],"Unresectable Breast Cancer",[6280,6641,6656],"Onapristone ER",{"trials":6658,"activeCount":509,"soonestReadout":258},[6659,6668,6685],{"nctId":6660,"briefTitle":6661,"status":113,"phases":6662,"primaryCompletion":1130,"completion":1130,"start":6663,"enrollment":6397,"conditions":6664,"interventions":6666},"NCT02605486","Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)",[89,90],"2015-11-11",[6665],"Metastatic Breast Cancer (MBC)",[6641,6667],"Bicalutamide",{"nctId":6669,"briefTitle":6670,"status":158,"phases":6671,"primaryCompletion":6672,"completion":6672,"start":6673,"enrollment":969,"conditions":6674,"interventions":6683},"NCT06843967","A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma",[89,90],"2028-08-19","2025-02-19",[6675,4868,6676,6677,6678,6679,6680,6681,6682],"Well Differentiated Liposarcoma","Liposarcoma","Myxoid Liposarcoma","Round Cell Liposarcoma","Myxoid Pleomorphic Liposarcoma","Pleomorphic Liposarcoma","Unresectable Liposarcoma","Unresectable Dedifferentiated Liposarcoma",[6684,6641],"Mirdametinib",{"nctId":6686,"briefTitle":6687,"status":113,"phases":6688,"primaryCompletion":258,"completion":258,"start":6689,"enrollment":486,"conditions":6690,"interventions":6692},"NCT04438824","Palbociclib and INCMGA00012 in People With Advanced Liposarcoma",[90],"2020-06-17",[6691],"Well-differentiated\u002FDedifferentiated Liposarcoma",[6693,6641],"INCMGA00012",{"trials":6695,"activeCount":101},[],{"trials":6697,"activeCount":101},[],{"trials":6699,"activeCount":101},[],{"intervention":6701,"totalTrials":509,"cells":6702},"Conditioning chemotherapy",{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6726,"PHASE3":6740,"PHASE4":6742,"NA":6744},{"trials":6704,"activeCount":101},[],{"trials":6706,"activeCount":1094,"soonestReadout":115},[6707,6716],{"nctId":6708,"briefTitle":6709,"status":158,"phases":6710,"primaryCompletion":6711,"completion":6711,"start":6712,"enrollment":718,"conditions":6713,"interventions":6714},"NCT05748197","A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia",[89],"2028-04-18","2024-04-18",[3816],[6715,6701],"ADCLEC.syn1 CAR T cells",{"nctId":6717,"briefTitle":6718,"status":113,"phases":6719,"primaryCompletion":115,"completion":115,"start":6720,"enrollment":306,"conditions":6721,"interventions":6724},"NCT05574114","A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma",[89],"2022-10-05",[605,6722,6723],"Non-Hodgkin's Lymphoma, Relapsed","Non-Hodgkin's Lymphoma Refractory",[6701,6725],"CAR T-cell product",{"trials":6727,"activeCount":97,"soonestReadout":6732},[6728],{"nctId":6729,"briefTitle":6730,"status":158,"phases":6731,"primaryCompletion":6732,"completion":6732,"start":6733,"enrollment":969,"conditions":6734,"interventions":6737},"NCT05884333","Cord Blood Transplant in Adults With Blood Cancers",[90],"2028-05-22","2023-05-22",[513,6735,6736,537,1154,707],"Acute Lymphoblastic Leukemia (ALL)","Chronic Myelogenous Leukemia (CML)",[6738,6739],"Conditioning Chemotherapy","Cord blood graft",{"trials":6741,"activeCount":101},[],{"trials":6743,"activeCount":101},[],{"trials":6745,"activeCount":101},[],{"intervention":5265,"totalTrials":509,"cells":6747},{"EARLY_PHASE1":6748,"PHASE1":6750,"PHASE2":6752,"PHASE3":6777,"PHASE4":6779,"NA":6781},{"trials":6749,"activeCount":101},[],{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":509,"soonestReadout":5247},[6754,6764,6768],{"nctId":6755,"briefTitle":6756,"status":158,"phases":6757,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":718,"conditions":6760,"interventions":6763},"NCT06843434","A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma",[90],"2028-02-20","2025-02-20",[6761,6762],"Microsatellite Stable Rectal Carcinoma","Locally Advanced Rectal Adenocarcinoma",[5265,5264],{"nctId":5244,"briefTitle":5245,"status":113,"phases":6765,"primaryCompletion":5247,"completion":5247,"start":1674,"enrollment":306,"conditions":6766,"interventions":6767},[90],[5249,5250,5251,5252,5253,5254,5255,5256,5257,5258,5259,5260,5261],[5263,5264,5265,3246,1595],{"nctId":6769,"briefTitle":6770,"status":158,"phases":6771,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":6774,"conditions":6775,"interventions":6776},"NCT07227636","A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy",[90],"2030-11","2025-11-07",284,[36,5080],[5264,5265],{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[],{"trials":6782,"activeCount":101},[],{"intervention":5264,"totalTrials":509,"cells":6784},{"EARLY_PHASE1":6785,"PHASE1":6787,"PHASE2":6789,"PHASE3":6803,"PHASE4":6805,"NA":6807},{"trials":6786,"activeCount":101},[],{"trials":6788,"activeCount":101},[],{"trials":6790,"activeCount":509,"soonestReadout":5247},[6791,6795,6799],{"nctId":6755,"briefTitle":6756,"status":158,"phases":6792,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":718,"conditions":6793,"interventions":6794},[90],[6761,6762],[5265,5264],{"nctId":5244,"briefTitle":5245,"status":113,"phases":6796,"primaryCompletion":5247,"completion":5247,"start":1674,"enrollment":306,"conditions":6797,"interventions":6798},[90],[5249,5250,5251,5252,5253,5254,5255,5256,5257,5258,5259,5260,5261],[5263,5264,5265,3246,1595],{"nctId":6769,"briefTitle":6770,"status":158,"phases":6800,"primaryCompletion":6772,"completion":6772,"start":6773,"enrollment":6774,"conditions":6801,"interventions":6802},[90],[36,5080],[5264,5265],{"trials":6804,"activeCount":101},[],{"trials":6806,"activeCount":101},[],{"trials":6808,"activeCount":101},[],{"intervention":6810,"totalTrials":509,"cells":6811},"Enfortumab Vedotin",{"EARLY_PHASE1":6812,"PHASE1":6814,"PHASE2":6816,"PHASE3":6837,"PHASE4":6839,"NA":6841},{"trials":6813,"activeCount":101},[],{"trials":6815,"activeCount":101},[],{"trials":6817,"activeCount":509,"soonestReadout":990},[6818,6825,6829],{"nctId":6819,"briefTitle":6820,"status":158,"phases":6821,"primaryCompletion":990,"completion":990,"start":6822,"enrollment":2439,"conditions":6823,"interventions":6824},"NCT06891560","A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma",[90],"2025-03-31",[2409],[6810],{"nctId":2414,"briefTitle":2415,"status":158,"phases":6826,"primaryCompletion":2005,"completion":2005,"start":2417,"enrollment":1412,"conditions":6827,"interventions":6828},[90],[938],[2420,42],{"nctId":6830,"briefTitle":6831,"status":158,"phases":6832,"primaryCompletion":6833,"completion":6833,"start":6834,"enrollment":454,"conditions":6835,"interventions":6836},"NCT05868265","A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract",[90],"2027-06-02","2023-06-02",[938],[6810],{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"intervention":6279,"totalTrials":509,"cells":6844},{"EARLY_PHASE1":6845,"PHASE1":6847,"PHASE2":6849,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6846,"activeCount":101},[],{"trials":6848,"activeCount":101},[],{"trials":6850,"activeCount":509,"soonestReadout":990},[6851,6855,6859],{"nctId":6273,"briefTitle":6274,"status":158,"phases":6852,"primaryCompletion":531,"completion":531,"start":2688,"enrollment":306,"conditions":6853,"interventions":6854},[90],[6277],[6244,6279,6280],{"nctId":6282,"briefTitle":6283,"status":158,"phases":6856,"primaryCompletion":6285,"completion":6285,"start":6286,"enrollment":356,"conditions":6857,"interventions":6858},[90],[4054],[6244,6279],{"nctId":6290,"briefTitle":6291,"status":158,"phases":6860,"primaryCompletion":990,"completion":990,"start":6293,"enrollment":718,"conditions":6861,"interventions":6862},[90],[6295],[6244,6279],{"trials":6864,"activeCount":101},[],{"trials":6866,"activeCount":101},[],{"trials":6868,"activeCount":101},[],{"intervention":479,"totalTrials":2446,"cells":6870},{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6879,"PHASE3":6943,"PHASE4":6949,"NA":6951},{"trials":6872,"activeCount":101},[],{"trials":6874,"activeCount":101},[6875],{"nctId":3586,"briefTitle":3587,"status":244,"phases":6876,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":6877,"interventions":6878},[89],[27],[288,3593,643,479,750,447],{"trials":6880,"activeCount":509,"soonestReadout":498},[6881,6885,6889,6893,6897,6901,6905,6911,6915,6919,6923,6927,6931,6935,6939],{"nctId":1482,"briefTitle":1483,"status":505,"phases":6882,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":97,"conditions":6883,"interventions":6884},[90],[1488],[420,418,421,331,515],{"nctId":407,"briefTitle":408,"status":244,"phases":6886,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":6887,"interventions":6888},[90],[414,415,416,308],[418,218,419,420,331,421],{"nctId":467,"briefTitle":468,"status":244,"phases":6890,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":6891,"interventions":6892},[90],[27,24,475,476],[401,288,202,361,478,479],{"nctId":528,"briefTitle":529,"status":113,"phases":6894,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":6895,"interventions":6896},[90],[535,536,537],[418,218,539,419,420,331],{"nctId":5554,"briefTitle":5555,"status":244,"phases":6898,"primaryCompletion":5557,"completion":5557,"start":4750,"enrollment":1434,"conditions":6899,"interventions":6900},[90],[33],[5560,830,444,479],{"nctId":596,"briefTitle":597,"status":505,"phases":6902,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":6903,"interventions":6904},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":6906,"briefTitle":6907,"status":244,"phases":6908,"primaryCompletion":587,"completion":587,"start":2990,"enrollment":3344,"conditions":6909,"interventions":6910},"NCT00003173","High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors",[90],[3259,867,387,30,651,868,1568,556],[288,479],{"nctId":5566,"briefTitle":5567,"status":244,"phases":6912,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":6913,"interventions":6914},[89,90],[1973,27,475],[288,3593,444,405,5573,479],{"nctId":664,"briefTitle":665,"status":158,"phases":6916,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":6917,"interventions":6918},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":3519,"briefTitle":3520,"status":244,"phases":6920,"primaryCompletion":3522,"completion":3522,"start":3523,"conditions":6921,"interventions":6922},[90],[867,387,1586,783,2610,24,215,30,651,33,868],[288,390,479,750],{"nctId":692,"briefTitle":693,"status":244,"phases":6924,"primaryCompletion":695,"completion":695,"start":696,"conditions":6925,"interventions":6926},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":701,"briefTitle":702,"status":113,"phases":6928,"primaryCompletion":498,"completion":498,"start":704,"enrollment":705,"conditions":6929,"interventions":6930},[90],[27,308,416,707],[709,710,418,218,711],{"nctId":743,"briefTitle":744,"status":244,"phases":6932,"primaryCompletion":746,"completion":746,"start":637,"conditions":6933,"interventions":6934},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":752,"briefTitle":753,"status":244,"phases":6936,"primaryCompletion":727,"completion":755,"start":756,"enrollment":438,"conditions":6937,"interventions":6938},[90],[27,24,475,476],[401,288,202,404,479],{"nctId":6490,"briefTitle":6491,"status":244,"phases":6940,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":6941,"interventions":6942},[90],[3259],[288,830,3342,446,479,349],{"trials":6944,"activeCount":101},[6945],{"nctId":853,"briefTitle":854,"status":244,"phases":6946,"primaryCompletion":856,"completion":856,"start":857,"conditions":6947,"interventions":6948},[91],[27],[401,202,361,478,479],{"trials":6950,"activeCount":101},[],{"trials":6952,"activeCount":101},[6953,6957],{"nctId":5610,"briefTitle":5611,"status":505,"phases":6954,"primaryCompletion":3209,"completion":3209,"start":5613,"enrollment":509,"conditions":6955,"interventions":6956},[93],[5615,5616,416,5617],[479,404,444,401,5619],{"nctId":903,"briefTitle":904,"status":244,"phases":6958,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":6959,"interventions":6960},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":225,"totalTrials":2291,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6969,"PHASE2":6971,"PHASE3":6993,"PHASE4":6995,"NA":6997},{"trials":6964,"activeCount":97,"soonestReadout":211},[6965],{"nctId":208,"briefTitle":209,"status":113,"phases":6966,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":6967,"interventions":6968},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":6970,"activeCount":101},[],{"trials":6972,"activeCount":1094,"soonestReadout":258},[6973,6977,6981,6985,6989],{"nctId":336,"briefTitle":337,"status":244,"phases":6974,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":6975,"interventions":6976},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":3060,"briefTitle":3061,"status":113,"phases":6978,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":6979,"interventions":6980},[90],[3066],[1595,222,974,225,2807,223],{"nctId":634,"briefTitle":635,"status":244,"phases":6982,"primaryCompletion":637,"completion":637,"start":638,"conditions":6983,"interventions":6984},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":645,"briefTitle":646,"status":244,"phases":6986,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":6987,"interventions":6988},[90],[651],[288,390,47,202,346,347,349],{"nctId":809,"briefTitle":810,"status":113,"phases":6990,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":6991,"interventions":6992},[90],[816],[218,220,222,223,818,819,225,820,516],{"trials":6994,"activeCount":101},[],{"trials":6996,"activeCount":101},[],{"trials":6998,"activeCount":101},[6999],{"nctId":903,"briefTitle":904,"status":244,"phases":7000,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":7001,"interventions":7002},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":711,"totalTrials":2291,"cells":7004},{"EARLY_PHASE1":7005,"PHASE1":7007,"PHASE2":7009,"PHASE3":7046,"PHASE4":7055,"NA":7057},{"trials":7006,"activeCount":101},[],{"trials":7008,"activeCount":101},[],{"trials":7010,"activeCount":509,"soonestReadout":498},[7011,7020,7031,7038,7042],{"nctId":7012,"briefTitle":7013,"status":158,"phases":7014,"primaryCompletion":7015,"completion":7015,"start":7016,"enrollment":356,"conditions":7017,"interventions":7018},"NCT07335796","A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer",[90],"2030-01-09","2026-01-09",[18],[7019,711],"BMS-986165",{"nctId":7021,"briefTitle":7022,"status":244,"phases":7023,"primaryCompletion":7024,"completion":7024,"start":7025,"enrollment":7026,"conditions":7027,"interventions":7028},"NCT01751451","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",[90],"2020-09-28","2012-12-18",124,[18],[7029,7030,711],"Abiraterone acetate","Abiraterone acetate plus degarelix",{"nctId":7032,"briefTitle":7033,"status":2832,"phases":7034,"primaryCompletion":2472,"completion":2472,"start":7035,"enrollment":101,"conditions":7036,"interventions":7037},"NCT06218667","A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer",[89,90],"2024-01-11",[18],[1899,711],{"nctId":701,"briefTitle":702,"status":113,"phases":7039,"primaryCompletion":498,"completion":498,"start":704,"enrollment":705,"conditions":7040,"interventions":7041},[90],[27,308,416,707],[709,710,418,218,711],{"nctId":4389,"briefTitle":4390,"status":113,"phases":7043,"primaryCompletion":498,"completion":498,"start":4392,"enrollment":1447,"conditions":7044,"interventions":7045},[90],[4394],[711,941],{"trials":7047,"activeCount":101},[7048],{"nctId":7049,"briefTitle":7050,"status":505,"phases":7051,"primaryCompletion":6286,"completion":6286,"start":7052,"enrollment":2334,"conditions":7053,"interventions":7054},"NCT03056638","Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer",[91],"2017-03-28",[18],[711],{"trials":7056,"activeCount":101},[],{"trials":7058,"activeCount":101},[7059],{"nctId":7060,"briefTitle":7061,"status":244,"phases":7062,"primaryCompletion":7063,"completion":7063,"start":7064,"enrollment":2462,"conditions":7065,"interventions":7067},"NCT01542021","Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer",[93],"2024-09-30","2012-02-24",[18,7066],"Prostatic Adenocarcinoma",[7068,7068,7069],"degarelix","androgen deprivation therapy",{"intervention":460,"totalTrials":332,"cells":7071},{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7076,"PHASE3":7098,"PHASE4":7100,"NA":7102},{"trials":7073,"activeCount":101},[],{"trials":7075,"activeCount":101},[],{"trials":7077,"activeCount":509,"soonestReadout":452},[7078,7082,7086,7090,7094],{"nctId":449,"briefTitle":450,"status":158,"phases":7079,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":7080,"interventions":7081},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":5566,"briefTitle":5567,"status":244,"phases":7083,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":7084,"interventions":7085},[89,90],[1973,27,475],[288,3593,444,405,5573,479],{"nctId":5579,"briefTitle":5580,"status":244,"phases":7087,"primaryCompletion":1432,"completion":1432,"start":5206,"conditions":7088,"interventions":7089},[90],[1973,27,475,476],[830,444,362,5573],{"nctId":664,"briefTitle":665,"status":158,"phases":7091,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":7092,"interventions":7093},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":713,"briefTitle":714,"status":158,"phases":7095,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":7096,"interventions":7097},[90],[720],[218,218,461,722,460,460],{"trials":7099,"activeCount":101},[],{"trials":7101,"activeCount":101},[],{"trials":7103,"activeCount":101},[7104],{"nctId":903,"briefTitle":904,"status":244,"phases":7105,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":7106,"interventions":7107},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":4693,"totalTrials":1934,"cells":7109},{"EARLY_PHASE1":7110,"PHASE1":7116,"PHASE2":7118,"PHASE3":7147,"PHASE4":7149,"NA":7151},{"trials":7111,"activeCount":97,"soonestReadout":258},[7112],{"nctId":4684,"briefTitle":4685,"status":113,"phases":7113,"primaryCompletion":258,"completion":258,"start":4687,"enrollment":1798,"conditions":7114,"interventions":7115},[88],[4689],[819,4691,4692,4693],{"trials":7117,"activeCount":101},[],{"trials":7119,"activeCount":1094,"soonestReadout":7132},[7120,7128,7138],{"nctId":7121,"briefTitle":7122,"status":113,"phases":7123,"primaryCompletion":2082,"completion":2082,"start":803,"enrollment":6397,"conditions":7124,"interventions":7126},"NCT02502786","Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma",[90],[7125],"Recurrent Osteosarcoma",[7127,4693],"humanized anti-GD2 antibody",{"nctId":7129,"briefTitle":7130,"status":158,"phases":7131,"primaryCompletion":7132,"completion":7132,"start":7133,"enrollment":7134,"conditions":7135,"interventions":7136},"NCT04936529","A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma",[90],"2026-06-15","2021-08-02",286,[215],[4693,7137],"OPT-821",{"nctId":7139,"briefTitle":7140,"status":244,"phases":7141,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":533,"conditions":7144,"interventions":7145},"NCT03033303","A Study of the Effect of Hu3F8\u002FGM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma",[90],"2025-09-29","2017-01-23",[215],[4692,4693,7146],"Isotretinoin",{"trials":7148,"activeCount":101},[],{"trials":7150,"activeCount":101},[],{"trials":7152,"activeCount":101},[7153],{"nctId":7154,"briefTitle":7155,"status":244,"phases":7156,"primaryCompletion":4227,"completion":4227,"start":1186,"enrollment":3717,"conditions":7157,"interventions":7158},"NCT02100930","Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma",[93],[215],[7159,4693,7160],"Anti-GD2 3F8 Monoclonal Antibody","oral isotretinoin",{"intervention":1004,"totalTrials":1114,"cells":7162},{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7167,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7164,"activeCount":101},[],{"trials":7166,"activeCount":101},[],{"trials":7168,"activeCount":1094,"soonestReadout":531},[7169,7180,7184],{"nctId":7170,"briefTitle":7171,"status":244,"phases":7172,"primaryCompletion":7173,"completion":7173,"start":7174,"enrollment":4983,"conditions":7175,"interventions":7177},"NCT01508312","Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma",[90],"2024-03-14","2012-01-05",[7176],"Hodgkin's Lymphoma",[7178,7179],"brentuximab vedotin","Brentuximab Vedotin",{"nctId":998,"briefTitle":999,"status":158,"phases":7181,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":7182,"interventions":7183},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":7185,"briefTitle":7186,"status":158,"phases":7187,"primaryCompletion":1028,"completion":1028,"start":7188,"enrollment":1242,"conditions":7189,"interventions":7191},"NCT03587844","Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients",[90],"2018-07-03",[1031,7190,1033],"Lymphomatoid Papulosis",[7178,7178,7178],{"trials":7193,"activeCount":101},[],{"trials":7195,"activeCount":101},[],{"trials":7197,"activeCount":97,"soonestReadout":232},[7198],{"nctId":7199,"briefTitle":7200,"status":113,"phases":7201,"primaryCompletion":232,"completion":232,"start":813,"enrollment":546,"conditions":7202,"interventions":7203},"NCT01868451","Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma",[93],[604],[1004,7204,7205,1006],"Doxorubicin HCL","Vinblastine Sulfate",{"intervention":1006,"totalTrials":509,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7222,"PHASE4":7224,"NA":7226},{"trials":7209,"activeCount":101},[],{"trials":7211,"activeCount":101},[],{"trials":7213,"activeCount":1094,"soonestReadout":2472},[7214,7218],{"nctId":998,"briefTitle":999,"status":158,"phases":7215,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":7216,"interventions":7217},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":2800,"briefTitle":2801,"status":113,"phases":7219,"primaryCompletion":2472,"completion":2472,"start":2803,"enrollment":705,"conditions":7220,"interventions":7221},[89,90],[604],[2806,2807,2808,2809,942],{"trials":7223,"activeCount":101},[],{"trials":7225,"activeCount":101},[],{"trials":7227,"activeCount":97,"soonestReadout":232},[7228],{"nctId":7199,"briefTitle":7200,"status":113,"phases":7229,"primaryCompletion":232,"completion":232,"start":813,"enrollment":546,"conditions":7230,"interventions":7231},[93],[604],[1004,7204,7205,1006],{"intervention":361,"totalTrials":234,"cells":7233},{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7242,"PHASE3":7310,"PHASE4":7320,"NA":7322},{"trials":7235,"activeCount":101},[],{"trials":7237,"activeCount":97,"soonestReadout":531},[7238],{"nctId":3892,"briefTitle":3893,"status":113,"phases":7239,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":7240,"interventions":7241},[89],[707],[3897,223,581,420,3898,3899],{"trials":7243,"activeCount":97,"soonestReadout":324},[7244,7248,7252,7261,7265,7269,7273,7280,7286,7290,7294,7298,7302,7306],{"nctId":351,"briefTitle":352,"status":244,"phases":7245,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":7246,"interventions":7247},[90],[27],[359,360,202,361,346,362,363],{"nctId":467,"briefTitle":468,"status":244,"phases":7249,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":7250,"interventions":7251},[90],[27,24,475,476],[401,288,202,361,478,479],{"nctId":7253,"briefTitle":7254,"status":244,"phases":7255,"primaryCompletion":426,"completion":426,"start":3930,"conditions":7256,"interventions":7259},"NCT00004215","Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia",[90],[7257,27,3939,7258],"Anemia","Thrombocytopenia",[288,7260,361,642],"leridistim",{"nctId":3934,"briefTitle":3935,"status":244,"phases":7262,"primaryCompletion":1702,"completion":1702,"start":3937,"enrollment":162,"conditions":7263,"interventions":7264},[90],[27,475,3939],[288,3941,361,346,3942],{"nctId":541,"briefTitle":542,"status":244,"phases":7266,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":7267,"interventions":7268},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":569,"briefTitle":570,"status":113,"phases":7270,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":7271,"interventions":7272},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"nctId":7274,"briefTitle":7275,"status":244,"phases":7276,"primaryCompletion":1610,"completion":1610,"start":7277,"enrollment":718,"conditions":7278,"interventions":7279},"NCT00002609","Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission",[90],"1994-08",[27],[3941,361,3942],{"nctId":7281,"briefTitle":7282,"status":244,"phases":7283,"primaryCompletion":588,"completion":588,"start":3323,"enrollment":992,"conditions":7284,"interventions":7285},"NCT00014495","Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer",[89,90],[27,475,476],[288,361],{"nctId":3494,"briefTitle":3495,"status":244,"phases":7287,"primaryCompletion":688,"completion":688,"start":3497,"conditions":7288,"interventions":7289},[90],[24],[288,390,549,361,346,442,444],{"nctId":634,"briefTitle":635,"status":244,"phases":7291,"primaryCompletion":637,"completion":637,"start":638,"conditions":7292,"interventions":7293},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":3968,"briefTitle":3969,"status":244,"phases":7295,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":7296,"interventions":7297},[90],[24],[288,549,361,346,444,362],{"nctId":692,"briefTitle":693,"status":244,"phases":7299,"primaryCompletion":695,"completion":695,"start":696,"conditions":7300,"interventions":7301},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":1393,"briefTitle":1394,"status":244,"phases":7303,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":7304,"interventions":7305},[90],[24],[288,374,360,549,361,346,444],{"nctId":822,"briefTitle":823,"status":244,"phases":7307,"primaryCompletion":825,"completion":825,"start":826,"conditions":7308,"interventions":7309},[90],[27,24,828,475],[830,202,361],{"trials":7311,"activeCount":101},[7312,7316],{"nctId":853,"briefTitle":854,"status":244,"phases":7313,"primaryCompletion":856,"completion":856,"start":857,"conditions":7314,"interventions":7315},[91],[27],[401,202,361,478,479],{"nctId":872,"briefTitle":873,"status":244,"phases":7317,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":7318,"interventions":7319},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[],{"intervention":683,"totalTrials":306,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7366,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[7330,7334,7340,7344,7348,7352,7356,7360],{"nctId":2911,"briefTitle":2912,"status":244,"phases":7331,"primaryCompletion":2914,"completion":2914,"start":2915,"conditions":7332,"interventions":7333},[89],[1602,1613],[47,683],{"nctId":7335,"briefTitle":7336,"status":244,"phases":7337,"primaryCompletion":3220,"start":1703,"conditions":7338,"interventions":7339},"NCT00006485","Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors",[89],[1568],[1570,683],{"nctId":2937,"briefTitle":2938,"status":244,"phases":7341,"primaryCompletion":2940,"completion":588,"start":2915,"conditions":7342,"interventions":7343},[89],[1568],[47,1616,683],{"nctId":2952,"briefTitle":2938,"status":244,"phases":7345,"primaryCompletion":756,"completion":756,"start":2954,"conditions":7346,"interventions":7347},[89],[1568],[47,683,741],{"nctId":5050,"briefTitle":5051,"status":244,"phases":7349,"primaryCompletion":1566,"completion":1566,"start":3451,"enrollment":3344,"conditions":7350,"interventions":7351},[89],[5054,36,1602,1189,1190,1613,5055,2610,1226,1687],[683,3603],{"nctId":1597,"briefTitle":1598,"status":244,"phases":7353,"primaryCompletion":588,"completion":588,"start":856,"enrollment":1600,"conditions":7354,"interventions":7355},[89],[1602],[47,1023,683],{"nctId":3007,"briefTitle":3008,"status":244,"phases":7357,"start":2940,"conditions":7358,"interventions":7359},[89],[21],[47,3012,683],{"nctId":7361,"briefTitle":7362,"status":244,"phases":7363,"primaryCompletion":554,"completion":588,"start":545,"enrollment":718,"conditions":7364,"interventions":7365},"NCT00004051","Irinotecan in Treating Patients With Advanced Solid Tumors",[89],[1568],[683],{"trials":7367,"activeCount":1094,"soonestReadout":232},[7368,7372,7376,7380,7384,7388,7394,7403,7411,7418,7422,7426],{"nctId":3028,"briefTitle":3029,"status":244,"phases":7369,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":1447,"conditions":7370,"interventions":7371},[90],[1602,1613],[3035,47,683],{"nctId":3098,"briefTitle":3099,"status":244,"phases":7373,"primaryCompletion":3101,"completion":3101,"start":3102,"conditions":7374,"interventions":7375},[90],[1602,1613],[47,683],{"nctId":3145,"briefTitle":3146,"status":244,"phases":7377,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":2439,"conditions":7378,"interventions":7379},[90],[1602],[920,47,683,3152],{"nctId":3170,"briefTitle":3171,"status":244,"phases":7381,"primaryCompletion":2931,"completion":2931,"start":3173,"enrollment":1052,"conditions":7382,"interventions":7383},[90],[285,30,286],[47,683],{"nctId":3705,"briefTitle":3706,"status":244,"phases":7385,"primaryCompletion":2914,"completion":2914,"start":427,"conditions":7386,"interventions":7387},[90],[36,2349],[643,1615,683],{"nctId":7389,"briefTitle":7390,"status":244,"phases":7391,"completion":727,"start":354,"conditions":7392,"interventions":7393},"NCT00087282","Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer",[90],[2610],[1570,683],{"nctId":7395,"briefTitle":7396,"status":244,"phases":7397,"primaryCompletion":384,"completion":384,"start":1685,"conditions":7398,"interventions":7402},"NCT00004922","Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors",[90],[7399,7400,7401],"Carcinoma of Unknown Primary","Neuroendocrine Carcinoma","Neuroendocrine Carcinoma of the Skin",[683],{"nctId":7404,"briefTitle":7405,"status":244,"phases":7406,"primaryCompletion":7407,"completion":7407,"start":7408,"conditions":7409,"interventions":7410},"NCT00020917","Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer",[90],"2004-02","2001-02",[36],[3035,1616,683,391],{"nctId":7412,"briefTitle":7413,"status":244,"phases":7414,"primaryCompletion":7415,"completion":7415,"start":728,"conditions":7416,"interventions":7417},"NCT00003544","Irinotecan in Treating Patients With Metastatic Colorectal Cancer",[90],"2001-03",[36],[683],{"nctId":3217,"briefTitle":3218,"status":244,"phases":7419,"primaryCompletion":3220,"completion":3220,"start":2931,"conditions":7420,"interventions":7421},[90],[1602],[47,683],{"nctId":677,"briefTitle":678,"status":113,"phases":7423,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":7424,"interventions":7425},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":3767,"briefTitle":3768,"status":113,"phases":7427,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":7428,"interventions":7429},[90],[36,2349],[643,1615,1616,683,391,3603],{"trials":7431,"activeCount":101},[],{"trials":7433,"activeCount":101},[],{"trials":7435,"activeCount":101},[],{"intervention":768,"totalTrials":1871,"cells":7437},{"EARLY_PHASE1":7438,"PHASE1":7440,"PHASE2":7457,"PHASE3":7528,"PHASE4":7530,"NA":7532},{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[7442,7446],{"nctId":5156,"briefTitle":5157,"status":244,"phases":7443,"primaryCompletion":5159,"completion":5159,"start":774,"enrollment":601,"conditions":7444,"interventions":7445},[89],[5161,5162,5163,5164,5165,5166,4855],[5168,741,768,5169],{"nctId":7447,"briefTitle":7448,"status":244,"phases":7449,"primaryCompletion":7450,"completion":7450,"start":7451,"enrollment":1412,"conditions":7452,"interventions":7453},"NCT02167854","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",[89],"2021-07-07","2014-06-16",[15],[7454,7455,7456],"BYL719","LJM716","TRASTUZUMAB",{"trials":7458,"activeCount":1094,"soonestReadout":7479},[7459,7465,7469,7475,7487,7491,7497,7501,7505,7509,7513,7520,7524],{"nctId":7460,"briefTitle":7461,"status":244,"phases":7462,"primaryCompletion":737,"completion":737,"start":3930,"conditions":7463,"interventions":7464},"NCT00004925","Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer",[89,90],[15],[768,3658],{"nctId":2387,"briefTitle":2388,"status":505,"phases":7466,"primaryCompletion":2390,"completion":2390,"start":2391,"enrollment":97,"conditions":7467,"interventions":7468},[90],[2393,1613,2394,1602,2395,2396,2397,2398,2399,2400],[984,42],{"nctId":7470,"briefTitle":7471,"status":244,"phases":7472,"primaryCompletion":1622,"completion":1622,"start":2954,"conditions":7473,"interventions":7474},"NCT00003740","Trastuzumab in Treating Patients With Prostate Cancer",[90],[18],[768],{"nctId":7476,"briefTitle":7477,"status":158,"phases":7478,"primaryCompletion":7479,"completion":7480,"start":2390,"enrollment":1883,"conditions":7481,"interventions":7485},"NCT05672524","A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",[90],"2027-07-30","2030-07-31",[7482,6762,7483,7484,5080],"Adenocarcinoma of the Rectum","Rectal Adenocarcinoma","HER2 Positive Rectal Adenocarcinoma",[984,7486],"Tucatinib",{"nctId":976,"briefTitle":977,"status":244,"phases":7488,"primaryCompletion":979,"completion":979,"start":980,"enrollment":341,"conditions":7489,"interventions":7490},[90],[982],[923,984,985],{"nctId":7492,"briefTitle":7493,"status":244,"phases":7494,"completion":3044,"start":3251,"conditions":7495,"interventions":7496},"NCT00005033","Trastuzumab in Treating Patients With Recurrent Osteosarcoma",[90],[33],[768],{"nctId":2549,"briefTitle":2550,"status":244,"phases":7498,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":1883,"conditions":7499,"interventions":7500},[90],[1602,1613],[798,768,2557,47,944,1680],{"nctId":5271,"briefTitle":5272,"status":244,"phases":7502,"primaryCompletion":5274,"completion":5274,"start":1141,"enrollment":306,"conditions":7503,"interventions":7504},[90],[5276],[1595,984,5278,3898],{"nctId":3239,"briefTitle":3240,"status":505,"phases":7506,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":2291,"conditions":7507,"interventions":7508},[90],[1613,2400],[3246,984,1679,974],{"nctId":1670,"briefTitle":1671,"status":158,"phases":7510,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":565,"conditions":7511,"interventions":7512},[90],[1602,1676,1677],[42,984,944,1679,1680,1181],{"nctId":7514,"briefTitle":7515,"status":244,"phases":7516,"completion":7407,"start":637,"conditions":7517,"interventions":7518},"NCT00006381","Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer",[90],[15],[768,7519],"celecoxib",{"nctId":760,"briefTitle":761,"status":244,"phases":7521,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":7522,"interventions":7523},[90],[15],[768,202,345,769,741],{"nctId":5318,"briefTitle":5319,"status":244,"phases":7525,"primaryCompletion":1610,"completion":1610,"start":3451,"enrollment":370,"conditions":7526,"interventions":7527},[90],[15],[768,741],{"trials":7529,"activeCount":101},[],{"trials":7531,"activeCount":101},[],{"trials":7533,"activeCount":101},[],{"intervention":1615,"totalTrials":272,"cells":7535},{"EARLY_PHASE1":7536,"PHASE1":7538,"PHASE2":7556,"PHASE3":7601,"PHASE4":7603,"NA":7605},{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[7540,7544,7548,7552],{"nctId":3595,"briefTitle":3596,"status":244,"phases":7541,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":7542,"interventions":7543},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":3605,"briefTitle":3606,"status":244,"phases":7545,"primaryCompletion":1151,"start":426,"conditions":7546,"interventions":7547},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":5044,"briefTitle":5045,"status":244,"phases":7549,"start":3881,"conditions":7550,"interventions":7551},[89],[1155],[1615,391,3603],{"nctId":947,"briefTitle":948,"status":244,"phases":7553,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":7554,"interventions":7555},[89],[954,955,956,957],[959,960,961],{"trials":7557,"activeCount":1094,"soonestReadout":232},[7558,7562,7569,7573,7577,7581,7585,7589,7593,7597],{"nctId":1607,"briefTitle":1608,"status":244,"phases":7559,"primaryCompletion":1610,"completion":1610,"start":1611,"conditions":7560,"interventions":7561},[90],[1602,1613],[47,1023,1615,1616,391],{"nctId":7563,"briefTitle":7564,"status":244,"phases":7565,"primaryCompletion":5466,"completion":5466,"start":3477,"enrollment":2439,"conditions":7566,"interventions":7568},"NCT00587067","A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy",[90],[7567],"Hepatic Cancer",[959],{"nctId":3678,"briefTitle":3679,"status":244,"phases":7570,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":2483,"conditions":7571,"interventions":7572},[90],[2610],[920,643,1615,379],{"nctId":1038,"briefTitle":1039,"status":158,"phases":7574,"primaryCompletion":812,"completion":812,"start":1041,"enrollment":1042,"conditions":7575,"interventions":7576},[90],[954],[923,944,463,1045],{"nctId":3690,"briefTitle":3691,"status":2832,"phases":7578,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":7579,"interventions":7580},[90],[3696],[1045,819,3698,3699,960,582],{"nctId":1047,"briefTitle":1048,"status":244,"phases":7582,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":7583,"interventions":7584},[90],[36,1054],[1045,923,944,819,1056,1057],{"nctId":3705,"briefTitle":3706,"status":244,"phases":7586,"primaryCompletion":2914,"completion":2914,"start":427,"conditions":7587,"interventions":7588},[90],[36,2349],[643,1615,683],{"nctId":3183,"briefTitle":3184,"status":244,"phases":7590,"primaryCompletion":648,"completion":648,"start":3186,"enrollment":370,"conditions":7591,"interventions":7592},[90],[1613],[47,1615,1616,391],{"nctId":1119,"briefTitle":1120,"status":244,"phases":7594,"primaryCompletion":1122,"completion":1122,"start":813,"enrollment":34,"conditions":7595,"interventions":7596},[90],[954,955,956,1124],[1045,643,923,944],{"nctId":3767,"briefTitle":3768,"status":113,"phases":7598,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":7599,"interventions":7600},[90],[36,2349],[643,1615,1616,683,391,3603],{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[],{"trials":7606,"activeCount":101},[],{"intervention":662,"totalTrials":296,"cells":7608},{"EARLY_PHASE1":7609,"PHASE1":7611,"PHASE2":7634,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7610,"activeCount":101},[],{"trials":7612,"activeCount":101},[7613,7624,7630],{"nctId":7614,"briefTitle":7615,"status":244,"phases":7616,"primaryCompletion":7617,"completion":7617,"start":7618,"enrollment":7619,"conditions":7620,"interventions":7622},"NCT02783625","Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed\u002FRefractory T-cell Lymphomas",[89],"2026-04-21","2016-05-23",114,[24,7621],"Relapsed\u002FRefractory T-cell Lymphomas",[4611,464,7623],"duvelisib",{"nctId":7625,"briefTitle":7626,"status":244,"phases":7627,"primaryCompletion":2931,"completion":2931,"start":3881,"conditions":7628,"interventions":7629},"NCT00006098","PS-341 in Treating Patients With Hematologic Cancer",[89],[27,24,828,475],[662],{"nctId":3399,"briefTitle":3400,"status":244,"phases":7631,"start":3402,"conditions":7632,"interventions":7633},[89],[285,30,286],[662,390],{"trials":7635,"activeCount":1094,"soonestReadout":115},[7636,7640,7644,7650,7659,7663,7667,7673,7677,7681],{"nctId":3652,"briefTitle":3653,"status":244,"phases":7637,"primaryCompletion":3655,"completion":3655,"start":736,"enrollment":341,"conditions":7638,"interventions":7639},[90],[828],[662,643,3658,558],{"nctId":449,"briefTitle":450,"status":158,"phases":7641,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":7642,"interventions":7643},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"nctId":7645,"briefTitle":7646,"status":244,"phases":7647,"primaryCompletion":2914,"start":3101,"conditions":7648,"interventions":7649},"NCT00017329","PS-341 in Treating Patients With Metastatic Kidney Cancer",[90],[783],[662],{"nctId":7651,"briefTitle":7652,"status":244,"phases":7653,"primaryCompletion":7654,"completion":7654,"start":7655,"enrollment":234,"conditions":7656,"interventions":7657},"NCT01833143","Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D",[90],"2019-08-28","2013-04-11",[1695],[464,7658],"Acyclovir",{"nctId":609,"briefTitle":610,"status":158,"phases":7660,"primaryCompletion":115,"completion":115,"start":612,"enrollment":306,"conditions":7661,"interventions":7662},[90],[308,614],[218,464,463,616],{"nctId":654,"briefTitle":655,"status":244,"phases":7664,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":7665,"interventions":7666},[89,90],[27,24],[374,662,202,445],{"nctId":7668,"briefTitle":7669,"status":244,"phases":7670,"primaryCompletion":1267,"completion":1267,"start":2931,"conditions":7671,"interventions":7672},"NCT00027716","Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma",[90],[33],[662],{"nctId":3750,"briefTitle":3751,"status":244,"phases":7674,"primaryCompletion":3753,"completion":3753,"start":3754,"enrollment":718,"conditions":7675,"interventions":7676},[90],[828],[662,643],{"nctId":3758,"briefTitle":3759,"status":244,"phases":7678,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":356,"conditions":7679,"interventions":7680},[90],[3764],[464,463,1261],{"nctId":7682,"briefTitle":7683,"status":244,"phases":7684,"primaryCompletion":3522,"start":680,"conditions":7685,"interventions":7686},"NCT00074009","Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[90],[1613],[662],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[],{"trials":7692,"activeCount":101},[],{"intervention":421,"totalTrials":952,"cells":7694},{"EARLY_PHASE1":7695,"PHASE1":7697,"PHASE2":7703,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7696,"activeCount":101},[],{"trials":7698,"activeCount":101},[7699],{"nctId":3586,"briefTitle":3587,"status":244,"phases":7700,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":7701,"interventions":7702},[89],[27],[288,3593,643,479,750,447],{"trials":7704,"activeCount":1094,"soonestReadout":1518},[7705,7709,7713,7720,7724,7728,7732],{"nctId":1482,"briefTitle":1483,"status":505,"phases":7706,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":97,"conditions":7707,"interventions":7708},[90],[1488],[420,418,421,331,515],{"nctId":407,"briefTitle":408,"status":244,"phases":7710,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":7711,"interventions":7712},[90],[414,415,416,308],[418,218,419,420,331,421],{"nctId":7714,"briefTitle":7715,"status":244,"phases":7716,"primaryCompletion":5793,"completion":5793,"start":7717,"enrollment":1462,"conditions":7718,"interventions":7719},"NCT00416351","Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",[89,90],"2006-06-27",[27,24,1687],[3593],{"nctId":596,"briefTitle":597,"status":505,"phases":7721,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":7722,"interventions":7723},[90],[536,535,603,604,605,606],[418,218,419,331,420,421,465],{"nctId":5566,"briefTitle":5567,"status":244,"phases":7725,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":7726,"interventions":7727},[89,90],[1973,27,475],[288,3593,444,405,5573,479],{"nctId":664,"briefTitle":665,"status":158,"phases":7729,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":7730,"interventions":7731},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":1515,"briefTitle":1516,"status":158,"phases":7733,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":7734,"interventions":7735},[90],[1521,1522,1523,1524,1525,1526,1527,1528,1529],[421,331,419,1531,461,1532],{"trials":7737,"activeCount":101},[],{"trials":7739,"activeCount":101},[],{"trials":7741,"activeCount":101},[],{"intervention":1295,"totalTrials":332,"cells":7743},{"EARLY_PHASE1":7744,"PHASE1":7755,"PHASE2":7768,"PHASE3":7795,"PHASE4":7797,"NA":7799},{"trials":7745,"activeCount":101},[7746],{"nctId":7747,"briefTitle":7748,"status":244,"phases":7749,"primaryCompletion":2187,"completion":2187,"start":7750,"enrollment":283,"conditions":7751,"interventions":7753},"NCT02145143","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",[88],"2014-05-20",[7752],"Thyroid Carcinoma",[1295,7754],"thyrotropin alpha",{"trials":7756,"activeCount":101},[7757],{"nctId":7758,"briefTitle":7759,"status":244,"phases":7760,"primaryCompletion":7761,"completion":7761,"start":7762,"enrollment":952,"conditions":7763,"interventions":7767},"NCT04462471","Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers",[89],"2023-09-29","2020-06-26",[7752,4054,6116,7764,7765,7766],"Thyroid Cancer (Follicular Cell)","Thyroid Cancer, Papillary","BRAF V600E Mutation Positive",[1295,1899],{"trials":7769,"activeCount":1094,"soonestReadout":2472},[7770,7774,7783,7791],{"nctId":1287,"briefTitle":1288,"status":158,"phases":7771,"primaryCompletion":1290,"completion":1290,"start":61,"enrollment":1291,"conditions":7772,"interventions":7773},[90],[1293],[1295,1296,1297,465],{"nctId":7775,"briefTitle":7776,"status":505,"phases":7777,"primaryCompletion":7778,"completion":7778,"start":7779,"enrollment":1094,"conditions":7780,"interventions":7781},"NCT01474551","Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E\u002FK Mutation",[90],"2013-03","2011-11",[2341],[7782],"vemurafenib",{"nctId":7784,"briefTitle":7785,"status":244,"phases":7786,"primaryCompletion":7787,"completion":7787,"start":7788,"enrollment":3344,"conditions":7789,"interventions":7790},"NCT01711632","BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",[90],"2024-08-16","2012-10",[1293],[1295],{"nctId":4931,"briefTitle":4932,"status":113,"phases":7792,"primaryCompletion":2472,"completion":2472,"start":4934,"enrollment":356,"conditions":7793,"interventions":7794},[90],[1293,27,4936],[1295,1296],{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[],{"trials":7800,"activeCount":101},[],{"intervention":4889,"totalTrials":332,"cells":7802},{"EARLY_PHASE1":7803,"PHASE1":7805,"PHASE2":7811,"PHASE3":7849,"PHASE4":7851,"NA":7853},{"trials":7804,"activeCount":101},[],{"trials":7806,"activeCount":101},[7807],{"nctId":5780,"briefTitle":5781,"status":244,"phases":7808,"primaryCompletion":5783,"completion":5783,"start":5784,"enrollment":283,"conditions":7809,"interventions":7810},[89],[15,18,5786],[5788,5367,4889],{"trials":7812,"activeCount":1094,"soonestReadout":7843},[7813,7817,7821,7831,7839],{"nctId":4881,"briefTitle":4882,"status":244,"phases":7814,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":1232,"conditions":7815,"interventions":7816},[90],[4887],[4889,4107],{"nctId":5474,"briefTitle":5475,"status":158,"phases":7818,"primaryCompletion":1240,"completion":1240,"start":5477,"enrollment":969,"conditions":7819,"interventions":7820},[89,90],[2311],[2412,5480,4889],{"nctId":7822,"briefTitle":7823,"status":244,"phases":7824,"primaryCompletion":7825,"completion":7825,"start":7826,"enrollment":332,"conditions":7827,"interventions":7830},"NCT05054374","A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer",[89,90],"2023-10-26","2021-09-14",[15,2312,4857,6267,7828,7829,2311],"MEK1 Gene Mutation","MEK2 Gene Mutation",[6684,4889],{"nctId":7832,"briefTitle":7833,"status":244,"phases":7834,"primaryCompletion":4112,"completion":4112,"start":7835,"enrollment":1434,"conditions":7836,"interventions":7837},"NCT03344536","A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer",[89,90],"2017-11-10",[15],[4889,7838],"Debio 1347",{"nctId":7840,"briefTitle":7841,"status":113,"phases":7842,"primaryCompletion":7843,"completion":7843,"start":7844,"enrollment":1871,"conditions":7845,"interventions":7846},"NCT05090358","Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer",[90],"2026-10-08","2021-10-08",[15,2312,2311],[7847,4889,7848],"Alpelisib","Canagliflozin",{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"trials":7854,"activeCount":101},[],{"intervention":3676,"totalTrials":1934,"cells":7856},{"EARLY_PHASE1":7857,"PHASE1":7859,"PHASE2":7861,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[],{"trials":7862,"activeCount":1094,"soonestReadout":71},[7863,7867,7875,7879,7883],{"nctId":3670,"briefTitle":3671,"status":244,"phases":7864,"primaryCompletion":3673,"completion":3673,"start":1223,"enrollment":1462,"conditions":7865,"interventions":7866},[89,90],[308],[3676,1261,463],{"nctId":7868,"briefTitle":7869,"status":244,"phases":7870,"primaryCompletion":7871,"completion":7871,"start":7872,"enrollment":908,"conditions":7873,"interventions":7874},"NCT01351623","Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma",[90],"2016-01-26","2011-05-09",[308],[3676],{"nctId":69,"briefTitle":70,"status":113,"phases":7876,"primaryCompletion":71,"completion":1469,"start":3716,"enrollment":3717,"conditions":7877,"interventions":7878},[90],[308],[72,3720,1350,643,643],{"nctId":4603,"briefTitle":4604,"status":244,"phases":7880,"primaryCompletion":4606,"completion":4606,"start":4607,"enrollment":1600,"conditions":7881,"interventions":7882},[89,90],[4114,4609],[3676,4611,1261],{"nctId":3739,"briefTitle":3740,"status":113,"phases":7884,"primaryCompletion":1028,"completion":1028,"start":3742,"enrollment":2462,"conditions":7885,"interventions":7886},[90],[308],[3676,1261,463,616],{"trials":7888,"activeCount":101},[],{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"intervention":6092,"totalTrials":1114,"cells":7894},{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7903,"PHASE3":7919,"PHASE4":7921,"NA":7923},{"trials":7896,"activeCount":101},[],{"trials":7898,"activeCount":101},[7899],{"nctId":6086,"briefTitle":6087,"status":244,"phases":7900,"primaryCompletion":6089,"completion":6089,"start":4297,"enrollment":326,"conditions":7901,"interventions":7902},[89],[2341],[6092,3080,6093],{"trials":7904,"activeCount":1094,"soonestReadout":1583},[7905,7909,7915],{"nctId":6101,"briefTitle":6102,"status":113,"phases":7906,"primaryCompletion":1583,"completion":1583,"start":6104,"enrollment":1447,"conditions":7907,"interventions":7908},[90],[5147,4054,6106,6107],[6092,3080],{"nctId":7910,"briefTitle":7911,"status":244,"phases":7912,"primaryCompletion":1062,"completion":1062,"start":4363,"enrollment":1412,"conditions":7913,"interventions":7914},"NCT01682213","Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E\u002FK Mutation",[90],[2341],[6092],{"nctId":6110,"briefTitle":6111,"status":113,"phases":7916,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":2446,"conditions":7917,"interventions":7918},[90],[4054,6116,6117,6118,6119,6120,6121],[3080,6092,6123],{"trials":7920,"activeCount":101},[],{"trials":7922,"activeCount":101},[],{"trials":7924,"activeCount":101},[],{"intervention":3650,"totalTrials":509,"cells":7926},{"EARLY_PHASE1":7927,"PHASE1":7929,"PHASE2":7935,"PHASE3":7948,"PHASE4":7950,"NA":7952},{"trials":7928,"activeCount":101},[],{"trials":7930,"activeCount":97,"soonestReadout":258},[7931],{"nctId":3611,"briefTitle":3612,"status":113,"phases":7932,"primaryCompletion":258,"completion":258,"start":3614,"enrollment":283,"conditions":7933,"interventions":7934},[89],[414],[722,3617,463],{"trials":7936,"activeCount":97,"soonestReadout":990},[7937,7941],{"nctId":3642,"briefTitle":3643,"status":113,"phases":7938,"primaryCompletion":990,"completion":990,"start":3645,"enrollment":234,"conditions":7939,"interventions":7940},[90],[414,3647],[3649,3650,643,362],{"nctId":7942,"briefTitle":7943,"status":244,"phases":7944,"primaryCompletion":875,"completion":875,"start":7945,"enrollment":2483,"conditions":7946,"interventions":7947},"NCT00570401","Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib",[90],"2006-06",[21],[3650],{"trials":7949,"activeCount":101},[],{"trials":7951,"activeCount":101},[],{"trials":7953,"activeCount":101},[],{"intervention":3246,"totalTrials":509,"cells":7955},{"EARLY_PHASE1":7956,"PHASE1":7958,"PHASE2":7960,"PHASE3":7981,"PHASE4":7983,"NA":7985},{"trials":7957,"activeCount":101},[],{"trials":7959,"activeCount":101},[],{"trials":7961,"activeCount":1094,"soonestReadout":5247},[7962,7973,7977],{"nctId":7963,"briefTitle":7964,"status":158,"phases":7965,"primaryCompletion":7966,"completion":7966,"start":7967,"enrollment":2334,"conditions":7968,"interventions":7971},"NCT06007937","A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer",[89,90],"2028-08-17","2023-08-17",[3094,7969,7970],"Metastatic","Recurrent",[7972,3246],"Lorlatinib",{"nctId":5244,"briefTitle":5245,"status":113,"phases":7974,"primaryCompletion":5247,"completion":5247,"start":1674,"enrollment":306,"conditions":7975,"interventions":7976},[90],[5249,5250,5251,5252,5253,5254,5255,5256,5257,5258,5259,5260,5261],[5263,5264,5265,3246,1595],{"nctId":3239,"briefTitle":3240,"status":505,"phases":7978,"primaryCompletion":3242,"completion":3242,"start":3243,"enrollment":2291,"conditions":7979,"interventions":7980},[90],[1613,2400],[3246,984,1679,974],{"trials":7982,"activeCount":101},[],{"trials":7984,"activeCount":101},[],{"trials":7986,"activeCount":101},[],{"intervention":1315,"totalTrials":509,"cells":7988},{"EARLY_PHASE1":7989,"PHASE1":7991,"PHASE2":8010,"PHASE3":8016,"PHASE4":8018,"NA":8020},{"trials":7990,"activeCount":101},[],{"trials":7992,"activeCount":97,"soonestReadout":304},[7993,8001],{"nctId":7994,"briefTitle":7995,"status":158,"phases":7996,"primaryCompletion":304,"completion":304,"start":7997,"enrollment":326,"conditions":7998,"interventions":7999},"NCT05756777","A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)",[89],"2023-06-26",[535],[8000,3833,1315],"Gilteritinib",{"nctId":8002,"briefTitle":8003,"status":244,"phases":8004,"primaryCompletion":1254,"completion":1254,"start":8005,"enrollment":1114,"conditions":8006,"interventions":8009},"NCT05102370","A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance",[89],"2021-10-06",[8007,8008],"Clonal Cytopenia of Undetermined Significance","CCUS Clonal Cytopenia of Undetermined Significance",[1315],{"trials":8011,"activeCount":97,"soonestReadout":1310},[8012],{"nctId":1307,"briefTitle":1308,"status":158,"phases":8013,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":438,"conditions":8014,"interventions":8015},[90],[1313],[1315,465],{"trials":8017,"activeCount":101},[],{"trials":8019,"activeCount":101},[],{"trials":8021,"activeCount":101},[],{"intervention":4274,"totalTrials":509,"cells":8023},{"EARLY_PHASE1":8024,"PHASE1":8026,"PHASE2":8034,"PHASE3":8048,"PHASE4":8050,"NA":8052},{"trials":8025,"activeCount":101},[],{"trials":8027,"activeCount":97,"soonestReadout":484},[8028],{"nctId":8029,"briefTitle":8030,"status":158,"phases":8031,"primaryCompletion":484,"completion":484,"start":5339,"enrollment":1447,"conditions":8032,"interventions":8033},"NCT06807619","A Study of Sotorasib in People With Brain Tumors",[89],[4905],[4274],{"trials":8035,"activeCount":97,"soonestReadout":324},[8036,8044],{"nctId":8037,"briefTitle":8038,"status":158,"phases":8039,"primaryCompletion":324,"completion":324,"start":8040,"enrollment":573,"conditions":8041,"interventions":8043},"NCT06582771","A Study of Sotorasib in People With Non-Small Cell Lung Cancer",[90],"2024-08-30",[8042],"Non Small Lung Cancer",[4274],{"nctId":4268,"briefTitle":4269,"status":244,"phases":8045,"primaryCompletion":3830,"completion":3830,"start":4271,"enrollment":1434,"conditions":8046,"interventions":8047},[90],[1695],[52,4274],{"trials":8049,"activeCount":101},[],{"trials":8051,"activeCount":101},[],{"trials":8053,"activeCount":101},[],{"intervention":1135,"totalTrials":509,"cells":8055},{"EARLY_PHASE1":8056,"PHASE1":8058,"PHASE2":8060,"PHASE3":8078,"PHASE4":8080,"NA":8082},{"trials":8057,"activeCount":101},[],{"trials":8059,"activeCount":101},[],{"trials":8061,"activeCount":1094,"soonestReadout":2490},[8062,8066,8070],{"nctId":2487,"briefTitle":2488,"status":113,"phases":8063,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":341,"conditions":8064,"interventions":8065},[90],[971],[42,1135],{"nctId":1127,"briefTitle":1128,"status":113,"phases":8067,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":969,"conditions":8068,"interventions":8069},[89,90],[1133],[1135,923],{"nctId":8071,"briefTitle":8072,"status":244,"phases":8073,"primaryCompletion":8074,"completion":8074,"start":1012,"enrollment":4298,"conditions":8075,"interventions":8077},"NCT02281383","Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer",[90],"2022-02-24",[971,8076],"High Risk Superficial",[1135],{"trials":8079,"activeCount":101},[],{"trials":8081,"activeCount":101},[],{"trials":8083,"activeCount":101},[],{"intervention":6684,"totalTrials":509,"cells":8085},{"EARLY_PHASE1":8086,"PHASE1":8088,"PHASE2":8090,"PHASE3":8108,"PHASE4":8110,"NA":8112},{"trials":8087,"activeCount":101},[],{"trials":8089,"activeCount":101},[],{"trials":8091,"activeCount":1094,"soonestReadout":6672},[8092,8096,8100],{"nctId":6669,"briefTitle":6670,"status":158,"phases":8093,"primaryCompletion":6672,"completion":6672,"start":6673,"enrollment":969,"conditions":8094,"interventions":8095},[89,90],[6675,4868,6676,6677,6678,6679,6680,6681,6682],[6684,6641],{"nctId":7822,"briefTitle":7823,"status":244,"phases":8097,"primaryCompletion":7825,"completion":7825,"start":7826,"enrollment":332,"conditions":8098,"interventions":8099},[89,90],[15,2312,4857,6267,7828,7829,2311],[6684,4889],{"nctId":8101,"briefTitle":8102,"status":158,"phases":8103,"primaryCompletion":8104,"completion":8104,"start":4991,"enrollment":213,"conditions":8105,"interventions":8107},"NCT07539441","A Study of Mirdametinib in People With Central Nervous System Tumors",[89,90],"2029-10-10",[8106,2504],"Central Nervous System Tumors",[6684],{"trials":8109,"activeCount":101},[],{"trials":8111,"activeCount":101},[],{"trials":8113,"activeCount":101},[],{"intervention":7137,"totalTrials":1094,"cells":8115},{"EARLY_PHASE1":8116,"PHASE1":8118,"PHASE2":8120,"PHASE3":8135,"PHASE4":8137,"NA":8139},{"trials":8117,"activeCount":101},[],{"trials":8119,"activeCount":101},[],{"trials":8121,"activeCount":1094,"soonestReadout":7132},[8122,8131],{"nctId":8123,"briefTitle":8124,"status":158,"phases":8125,"primaryCompletion":8126,"completion":8126,"start":3158,"enrollment":8127,"conditions":8128,"interventions":8130},"NCT06057948","A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma",[90],"2027-03-21",94,[215,3425,8129],"Metastatic Neuroblastoma",[7137],{"nctId":7129,"briefTitle":7130,"status":158,"phases":8132,"primaryCompletion":7132,"completion":7132,"start":7133,"enrollment":7134,"conditions":8133,"interventions":8134},[90],[215],[4693,7137],{"trials":8136,"activeCount":101},[],{"trials":8138,"activeCount":101},[],{"trials":8140,"activeCount":101},[],{"intervention":5898,"totalTrials":1094,"cells":8142},{"EARLY_PHASE1":8143,"PHASE1":8145,"PHASE2":8147,"PHASE3":8159,"PHASE4":8161,"NA":8163},{"trials":8144,"activeCount":101},[],{"trials":8146,"activeCount":101},[],{"trials":8148,"activeCount":1094,"soonestReadout":115},[8149,8155],{"nctId":8150,"briefTitle":8151,"status":113,"phases":8152,"primaryCompletion":115,"completion":115,"start":1223,"enrollment":272,"conditions":8153,"interventions":8154},"NCT02932280","Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment",[89,90],[2351,6268,24,27],[5898],{"nctId":5892,"briefTitle":5893,"status":113,"phases":8156,"primaryCompletion":498,"completion":498,"start":5895,"enrollment":2439,"conditions":8157,"interventions":8158},[89,90],[15],[1679,5898],{"trials":8160,"activeCount":101},[],{"trials":8162,"activeCount":101},[],{"trials":8164,"activeCount":101},[],{"intervention":8166,"totalTrials":1094,"cells":8167},"Trastuzumab Deruxtecan",{"EARLY_PHASE1":8168,"PHASE1":8170,"PHASE2":8172,"PHASE3":8196,"PHASE4":8198,"NA":8200},{"trials":8169,"activeCount":101},[],{"trials":8171,"activeCount":101},[],{"trials":8173,"activeCount":1094,"soonestReadout":8178},[8174,8184],{"nctId":8175,"briefTitle":8176,"status":158,"phases":8177,"primaryCompletion":8178,"completion":8178,"start":8179,"enrollment":272,"conditions":8180,"interventions":8183},"NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer",[90],"2027-02-13","2026-02-13",[1695,4246,8181,8182],"Non-Small Cell Lung Cancer Stage IIIA","Non-Small Cell Lung Cancer Stage IIIB",[8166],{"nctId":8185,"briefTitle":8186,"status":158,"phases":8187,"primaryCompletion":8188,"completion":8188,"start":8189,"enrollment":356,"conditions":8190,"interventions":8194},"NCT06058988","Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer",[90],"2027-09-22","2023-09-22",[8191,2790,2349,8192,8193],"Brain Cancer","Leptomeningeal Metastasis","Recurrent Glioblastoma",[8195],"Trastuzumab deruxtecan",{"trials":8197,"activeCount":101},[],{"trials":8199,"activeCount":101},[],{"trials":8201,"activeCount":101},[],{"intervention":4142,"totalTrials":1094,"cells":8203},{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8221,"PHASE4":8223,"NA":8225},{"trials":8205,"activeCount":101},[],{"trials":8207,"activeCount":101},[],{"trials":8209,"activeCount":1094,"soonestReadout":812},[8210,8217],{"nctId":8211,"briefTitle":8212,"status":158,"phases":8213,"primaryCompletion":812,"completion":812,"start":3681,"enrollment":3599,"conditions":8214,"interventions":8216},"NCT06411821","Ulixertinib in People With Histiocytic Neoplasms",[90],[8215],"Histiocytic Neoplasms",[4142],{"nctId":4136,"briefTitle":4137,"status":158,"phases":8218,"primaryCompletion":484,"completion":484,"start":3823,"enrollment":1883,"conditions":8219,"interventions":8220},[89,90],[4140],[4142,722],{"trials":8222,"activeCount":101},[],{"trials":8224,"activeCount":101},[],{"trials":8226,"activeCount":101},[],{"intervention":3649,"totalTrials":1094,"cells":8228},{"EARLY_PHASE1":8229,"PHASE1":8231,"PHASE2":8233,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8230,"activeCount":101},[],{"trials":8232,"activeCount":101},[],{"trials":8234,"activeCount":1094,"soonestReadout":990},[8235,8239],{"nctId":3642,"briefTitle":3643,"status":113,"phases":8236,"primaryCompletion":990,"completion":990,"start":3645,"enrollment":234,"conditions":8237,"interventions":8238},[90],[414,3647],[3649,3650,643,362],{"nctId":8240,"briefTitle":8241,"status":5409,"phases":8242,"primaryCompletion":716,"completion":716,"start":258,"enrollment":213,"conditions":8243,"interventions":8246},"NCT07313852","A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",[89,90],[849,8244,8245],"B-Cell Acute Lymphoblastic Leukemia, Adult","B-ALL",[3649],{"trials":8248,"activeCount":101},[],{"trials":8250,"activeCount":101},[],{"trials":8252,"activeCount":101},[],{"intervention":219,"totalTrials":1094,"cells":8254},{"EARLY_PHASE1":8255,"PHASE1":8261,"PHASE2":8263,"PHASE3":8269,"PHASE4":8271,"NA":8273},{"trials":8256,"activeCount":97,"soonestReadout":211},[8257],{"nctId":208,"briefTitle":209,"status":113,"phases":8258,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":8259,"interventions":8260},[88],[215,216],[218,219,220,221,222,223,224,225],{"trials":8262,"activeCount":101},[],{"trials":8264,"activeCount":97,"soonestReadout":3422},[8265],{"nctId":3419,"briefTitle":3420,"status":158,"phases":8266,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":8267,"interventions":8268},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"trials":8270,"activeCount":101},[],{"trials":8272,"activeCount":101},[],{"trials":8274,"activeCount":101},[],{"intervention":3833,"totalTrials":1094,"cells":8276},{"EARLY_PHASE1":8277,"PHASE1":8279,"PHASE2":8285,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8278,"activeCount":101},[],{"trials":8280,"activeCount":97,"soonestReadout":304},[8281],{"nctId":7994,"briefTitle":7995,"status":158,"phases":8282,"primaryCompletion":304,"completion":304,"start":7997,"enrollment":326,"conditions":8283,"interventions":8284},[89],[535],[8000,3833,1315],{"trials":8286,"activeCount":97,"soonestReadout":484},[8287],{"nctId":3827,"briefTitle":3828,"status":158,"phases":8288,"primaryCompletion":484,"completion":484,"start":3830,"enrollment":341,"conditions":8289,"interventions":8290},[90],[3816],[3833,3818,1327],{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[],{"intervention":2807,"totalTrials":1094,"cells":8298},{"EARLY_PHASE1":8299,"PHASE1":8301,"PHASE2":8303,"PHASE3":8313,"PHASE4":8315,"NA":8317},{"trials":8300,"activeCount":101},[],{"trials":8302,"activeCount":101},[],{"trials":8304,"activeCount":1094,"soonestReadout":258},[8305,8309],{"nctId":3060,"briefTitle":3061,"status":113,"phases":8306,"primaryCompletion":258,"completion":258,"start":3063,"enrollment":3064,"conditions":8307,"interventions":8308},[90],[3066],[1595,222,974,225,2807,223],{"nctId":2800,"briefTitle":2801,"status":113,"phases":8310,"primaryCompletion":2472,"completion":2472,"start":2803,"enrollment":705,"conditions":8311,"interventions":8312},[89,90],[604],[2806,2807,2808,2809,942],{"trials":8314,"activeCount":101},[],{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[],{"intervention":7486,"totalTrials":1094,"cells":8320},{"EARLY_PHASE1":8321,"PHASE1":8323,"PHASE2":8325,"PHASE3":8339,"PHASE4":8341,"NA":8343},{"trials":8322,"activeCount":101},[],{"trials":8324,"activeCount":101},[],{"trials":8326,"activeCount":1094,"soonestReadout":7479},[8327,8331],{"nctId":7476,"briefTitle":7477,"status":158,"phases":8328,"primaryCompletion":7479,"completion":7480,"start":2390,"enrollment":1883,"conditions":8329,"interventions":8330},[90],[7482,6762,7483,7484,5080],[984,7486],{"nctId":8332,"briefTitle":8333,"status":113,"phases":8334,"primaryCompletion":8335,"completion":8335,"start":8336,"enrollment":601,"conditions":8337,"interventions":8338},"NCT05892068","A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain",[90],"2028-05-09","2023-05-09",[2311],[7486],{"trials":8340,"activeCount":101},[],{"trials":8342,"activeCount":101},[],{"trials":8344,"activeCount":101},[],{"intervention":4383,"totalTrials":1094,"cells":8346},{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8351,"PHASE3":8361,"PHASE4":8363,"NA":8365},{"trials":8348,"activeCount":101},[],{"trials":8350,"activeCount":101},[],{"trials":8352,"activeCount":1094,"soonestReadout":4378},[8353,8357],{"nctId":5416,"briefTitle":5417,"status":158,"phases":8354,"primaryCompletion":5419,"completion":5419,"start":5420,"enrollment":1434,"conditions":8355,"interventions":8356},[90],[5422],[1594,4383],{"nctId":4375,"briefTitle":4376,"status":158,"phases":8358,"primaryCompletion":4378,"completion":4378,"start":4379,"enrollment":2815,"conditions":8359,"interventions":8360},[90],[4381],[4383,1594,941],{"trials":8362,"activeCount":101},[],{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[],{"intervention":491,"totalTrials":1094,"cells":8368},{"EARLY_PHASE1":8369,"PHASE1":8371,"PHASE2":8377,"PHASE3":8383,"PHASE4":8385,"NA":8387},{"trials":8370,"activeCount":101},[],{"trials":8372,"activeCount":97,"soonestReadout":4533},[8373],{"nctId":4530,"briefTitle":4531,"status":113,"phases":8374,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":573,"conditions":8375,"interventions":8376},[89],[1874,4536],[491,1296,1261],{"trials":8378,"activeCount":97,"soonestReadout":484},[8379],{"nctId":481,"briefTitle":482,"status":158,"phases":8380,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":8381,"interventions":8382},[90],[488,489],[491,492,465,218,221,493],{"trials":8384,"activeCount":101},[],{"trials":8386,"activeCount":101},[],{"trials":8388,"activeCount":101},[],{"intervention":1005,"totalTrials":1094,"cells":8390},{"EARLY_PHASE1":8391,"PHASE1":8393,"PHASE2":8395,"PHASE3":8405,"PHASE4":8407,"NA":8409},{"trials":8392,"activeCount":101},[],{"trials":8394,"activeCount":101},[],{"trials":8396,"activeCount":1094,"soonestReadout":2472},[8397,8401],{"nctId":998,"briefTitle":999,"status":158,"phases":8398,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":8399,"interventions":8400},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":2800,"briefTitle":2801,"status":113,"phases":8402,"primaryCompletion":2472,"completion":2472,"start":2803,"enrollment":705,"conditions":8403,"interventions":8404},[89,90],[604],[2806,2807,2808,2809,942],{"trials":8406,"activeCount":101},[],{"trials":8408,"activeCount":101},[],{"trials":8410,"activeCount":101},[],{"intervention":1007,"totalTrials":1094,"cells":8412},{"EARLY_PHASE1":8413,"PHASE1":8415,"PHASE2":8417,"PHASE3":8427,"PHASE4":8429,"NA":8431},{"trials":8414,"activeCount":101},[],{"trials":8416,"activeCount":101},[],{"trials":8418,"activeCount":1094,"soonestReadout":324},[8419,8423],{"nctId":998,"briefTitle":999,"status":158,"phases":8420,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":669,"conditions":8421,"interventions":8422},[90],[604],[1004,221,1005,1006,42,923,1007],{"nctId":1068,"briefTitle":1069,"status":158,"phases":8424,"primaryCompletion":324,"completion":324,"start":1071,"enrollment":1072,"conditions":8425,"interventions":8426},[90],[604,1074],[798,1022,1076,1077],{"trials":8428,"activeCount":101},[],{"trials":8430,"activeCount":101},[],{"trials":8432,"activeCount":101},[],{"intervention":5544,"totalTrials":1094,"cells":8434},{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8452,"PHASE4":8454,"NA":8456},{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[],{"trials":8440,"activeCount":1094,"soonestReadout":115},[8441,8445],{"nctId":5537,"briefTitle":5538,"status":158,"phases":8442,"primaryCompletion":1240,"completion":1240,"start":5540,"enrollment":5541,"conditions":8443,"interventions":8444},[90],[308],[5544,420],{"nctId":8446,"briefTitle":8447,"status":113,"phases":8448,"primaryCompletion":115,"completion":115,"start":8449,"enrollment":356,"conditions":8450,"interventions":8451},"NCT03315026","Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis",[90],"2017-12-14",[308,3786],[5544],{"trials":8453,"activeCount":101},[],{"trials":8455,"activeCount":101},[],{"trials":8457,"activeCount":101},[],{"intervention":8459,"totalTrials":1094,"cells":8460},"Mezigdomide",{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8474,"PHASE3":8489,"PHASE4":8491,"NA":8493},{"trials":8462,"activeCount":101},[],{"trials":8464,"activeCount":97,"soonestReadout":8469},[8465],{"nctId":8466,"briefTitle":8467,"status":158,"phases":8468,"primaryCompletion":8469,"completion":8469,"start":8470,"enrollment":326,"conditions":8471,"interventions":8472},"NCT07105059","A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma",[89],"2028-08-08","2025-08-08",[308],[8473,8459],"Teclistamab",{"trials":8475,"activeCount":97,"soonestReadout":8480},[8476],{"nctId":8477,"briefTitle":8478,"status":158,"phases":8479,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":2426,"conditions":8482,"interventions":8487},"NCT07356154","A Study of Revumenib and Mezigdomide in People With Leukemia",[89,90],"2029-01-16","2026-01-16",[27,5615,8483,8484,8485,3816,414,8486],"Relapse Leukemia","Refractory Leukemia","Refractory Acute Leukemia","Mixed Phenotype Acute Leukemia",[8488,8459],"Revumenib",{"trials":8490,"activeCount":101},[],{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":101},[],{"intervention":1532,"totalTrials":1094,"cells":8496},{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8498,"activeCount":101},[],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":1094,"soonestReadout":1518},[8503,8507],{"nctId":1515,"briefTitle":1516,"status":158,"phases":8504,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":8505,"interventions":8506},[90],[1521,1522,1523,1524,1525,1526,1527,1528,1529],[421,331,419,1531,461,1532],{"nctId":6729,"briefTitle":6730,"status":158,"phases":8508,"primaryCompletion":6732,"completion":6732,"start":6733,"enrollment":969,"conditions":8509,"interventions":8510},[90],[513,6735,6736,537,1154,707],[6738,6739],{"trials":8512,"activeCount":101},[],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"intervention":3859,"totalTrials":1094,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8523,"PHASE3":8538,"PHASE4":8540,"NA":8542},{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[],{"trials":8524,"activeCount":1094,"soonestReadout":498},[8525,8529],{"nctId":3851,"briefTitle":3852,"status":158,"phases":8526,"primaryCompletion":304,"completion":304,"start":3854,"enrollment":3855,"conditions":8527,"interventions":8528},[90],[3848,3857],[3859,1296,1327],{"nctId":8530,"briefTitle":8531,"status":158,"phases":8532,"primaryCompletion":498,"completion":498,"start":8533,"enrollment":8534,"conditions":8535,"interventions":8536},"NCT05389293","A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma",[90],"2022-05-27",152,[1831,24],[8537,3859],"Mosunetuzumab",{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[],{"trials":8543,"activeCount":101},[],{"intervention":391,"totalTrials":306,"cells":8545},{"EARLY_PHASE1":8546,"PHASE1":8548,"PHASE2":8582,"PHASE3":8639,"PHASE4":8641,"NA":8643},{"trials":8547,"activeCount":101},[],{"trials":8549,"activeCount":101},[8550,8558,8562,8570,8574,8578],{"nctId":8551,"briefTitle":8552,"status":244,"phases":8553,"primaryCompletion":648,"completion":588,"start":8554,"enrollment":438,"conditions":8555,"interventions":8556},"NCT00003956","Combination Chemotherapy in Treating Patients With Advanced Cancer",[89],"1999-04",[24,1568],[1616,391,8557],"lonafarnib",{"nctId":3595,"briefTitle":3596,"status":244,"phases":8559,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":8560,"interventions":8561},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":8563,"briefTitle":8564,"status":244,"phases":8565,"primaryCompletion":3220,"completion":588,"start":8566,"enrollment":356,"conditions":8567,"interventions":8568},"NCT00002801","Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer",[89],"1996-04",[36],[391,8569],"tegafur-uracil",{"nctId":3605,"briefTitle":3606,"status":244,"phases":8571,"primaryCompletion":1151,"start":426,"conditions":8572,"interventions":8573},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":5044,"briefTitle":5045,"status":244,"phases":8575,"start":3881,"conditions":8576,"interventions":8577},[89],[1155],[1615,391,3603],{"nctId":5635,"briefTitle":5636,"status":244,"phases":8579,"primaryCompletion":3590,"start":3522,"enrollment":326,"conditions":8580,"interventions":8581},[89],[33],[391,362,3125],{"trials":8583,"activeCount":1094,"soonestReadout":232},[8584,8588,8592,8596,8600,8604,8608,8612,8616,8620,8624,8631,8635],{"nctId":1607,"briefTitle":1608,"status":244,"phases":8585,"primaryCompletion":1610,"completion":1610,"start":1611,"conditions":8586,"interventions":8587},[90],[1602,1613],[47,1023,1615,1616,391],{"nctId":5647,"briefTitle":5648,"status":244,"phases":8589,"primaryCompletion":3220,"completion":5650,"start":4009,"enrollment":326,"conditions":8590,"interventions":8591},[90],[1426],[579,5653,5654],{"nctId":381,"briefTitle":382,"status":244,"phases":8593,"primaryCompletion":384,"completion":384,"start":385,"conditions":8594,"interventions":8595},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":5060,"briefTitle":5061,"status":244,"phases":8597,"completion":3044,"start":1663,"conditions":8598,"interventions":8599},[89,90],[36],[5065,1616,391,3603],{"nctId":3118,"briefTitle":3119,"status":244,"phases":8601,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":8602,"interventions":8603},[90],[33],[288,47,345,442,391,362,3125],{"nctId":3183,"briefTitle":3184,"status":244,"phases":8605,"primaryCompletion":648,"completion":648,"start":3186,"enrollment":370,"conditions":8606,"interventions":8607},[90],[1613],[47,1615,1616,391],{"nctId":7404,"briefTitle":7405,"status":244,"phases":8609,"primaryCompletion":7407,"completion":7407,"start":7408,"conditions":8610,"interventions":8611},[90],[36],[3035,1616,683,391],{"nctId":5692,"briefTitle":5693,"status":244,"phases":8613,"primaryCompletion":5695,"completion":5650,"start":5696,"enrollment":1934,"conditions":8614,"interventions":8615},[90],[5698],[579,5654,5700],{"nctId":634,"briefTitle":635,"status":244,"phases":8617,"primaryCompletion":637,"completion":637,"start":638,"conditions":8618,"interventions":8619},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":692,"briefTitle":693,"status":244,"phases":8621,"primaryCompletion":695,"completion":695,"start":696,"conditions":8622,"interventions":8623},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":8625,"briefTitle":8626,"status":244,"phases":8627,"primaryCompletion":7945,"completion":7945,"start":8628,"enrollment":438,"conditions":8629,"interventions":8630},"NCT00002738","Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma",[90],"1996-01",[27,24,33],[391,3125],{"nctId":5109,"briefTitle":5110,"status":113,"phases":8632,"primaryCompletion":498,"completion":498,"start":1266,"enrollment":5112,"conditions":8633,"interventions":8634},[90],[36],[1616,391,3603,5115,378],{"nctId":3767,"briefTitle":3768,"status":113,"phases":8636,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":8637,"interventions":8638},[90],[36,2349],[643,1615,1616,683,391,3603],{"trials":8640,"activeCount":101},[],{"trials":8642,"activeCount":101},[],{"trials":8644,"activeCount":101},[8645],{"nctId":5127,"briefTitle":5128,"status":244,"phases":8646,"primaryCompletion":5130,"completion":5130,"start":764,"enrollment":1052,"conditions":8647,"interventions":8648},[93],[36],[920,1616,391,3603],{"intervention":1616,"totalTrials":2446,"cells":8650},{"EARLY_PHASE1":8651,"PHASE1":8653,"PHASE2":8695,"PHASE3":8739,"PHASE4":8741,"NA":8743},{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[8655,8663,8667,8671,8679,8683,8687],{"nctId":8656,"briefTitle":8657,"status":244,"phases":8658,"primaryCompletion":3402,"completion":3402,"start":8659,"conditions":8660,"interventions":8661},"NCT00002828","Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer",[89],"1995-04",[36],[1616,8662],"raltitrexed",{"nctId":8551,"briefTitle":8552,"status":244,"phases":8664,"primaryCompletion":648,"completion":588,"start":8554,"enrollment":438,"conditions":8665,"interventions":8666},[89],[24,1568],[1616,391,8557],{"nctId":3595,"briefTitle":3596,"status":244,"phases":8668,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":8669,"interventions":8670},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":8672,"briefTitle":8673,"status":244,"phases":8674,"primaryCompletion":1622,"completion":1622,"start":8675,"conditions":8676,"interventions":8677},"NCT00004059","Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors",[89],"1999-07",[1568],[8678,1616],"7-hydroxystaurosporine",{"nctId":3605,"briefTitle":3606,"status":244,"phases":8680,"primaryCompletion":1151,"start":426,"conditions":8681,"interventions":8682},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":2937,"briefTitle":2938,"status":244,"phases":8684,"primaryCompletion":2940,"completion":588,"start":2915,"conditions":8685,"interventions":8686},[89],[1568],[47,1616,683],{"nctId":8688,"briefTitle":8689,"status":244,"phases":8690,"primaryCompletion":1663,"completion":1663,"start":728,"enrollment":326,"conditions":8691,"interventions":8692},"NCT00003543","Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer",[89],[36],[8693,549,1616,8694,349],"monoclonal antibody A33","streptozocin",{"trials":8696,"activeCount":1094,"soonestReadout":232},[8697,8701,8705,8711,8715,8719,8723,8727,8731,8735],{"nctId":1607,"briefTitle":1608,"status":244,"phases":8698,"primaryCompletion":1610,"completion":1610,"start":1611,"conditions":8699,"interventions":8700},[90],[1602,1613],[47,1023,1615,1616,391],{"nctId":5060,"briefTitle":5061,"status":244,"phases":8702,"completion":3044,"start":1663,"conditions":8703,"interventions":8704},[89,90],[36],[5065,1616,391,3603],{"nctId":8706,"briefTitle":8707,"status":244,"phases":8708,"completion":339,"start":2940,"conditions":8709,"interventions":8710},"NCT00045747","UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer",[90],[1226],[8678,1616],{"nctId":3690,"briefTitle":3691,"status":2832,"phases":8712,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":8713,"interventions":8714},[90],[3696],[1045,819,3698,3699,960,582],{"nctId":1047,"briefTitle":1048,"status":244,"phases":8716,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":8717,"interventions":8718},[90],[36,1054],[1045,923,944,819,1056,1057],{"nctId":3183,"briefTitle":3184,"status":244,"phases":8720,"primaryCompletion":648,"completion":648,"start":3186,"enrollment":370,"conditions":8721,"interventions":8722},[90],[1613],[47,1615,1616,391],{"nctId":7404,"briefTitle":7405,"status":244,"phases":8724,"primaryCompletion":7407,"completion":7407,"start":7408,"conditions":8725,"interventions":8726},[90],[36],[3035,1616,683,391],{"nctId":3278,"briefTitle":3279,"status":244,"phases":8728,"primaryCompletion":3281,"completion":3281,"start":1622,"enrollment":438,"conditions":8729,"interventions":8730},[89,90],[1586],[47,1616],{"nctId":5109,"briefTitle":5110,"status":113,"phases":8732,"primaryCompletion":498,"completion":498,"start":1266,"enrollment":5112,"conditions":8733,"interventions":8734},[90],[36],[1616,391,3603,5115,378],{"nctId":3767,"briefTitle":3768,"status":113,"phases":8736,"primaryCompletion":232,"completion":232,"start":1432,"enrollment":2407,"conditions":8737,"interventions":8738},[90],[36,2349],[643,1615,1616,683,391,3603],{"trials":8740,"activeCount":101},[],{"trials":8742,"activeCount":101},[],{"trials":8744,"activeCount":101},[8745,8752],{"nctId":8746,"briefTitle":8747,"status":244,"phases":8748,"primaryCompletion":746,"completion":8749,"start":1575,"enrollment":1232,"conditions":8750,"interventions":8751},"NCT00084773","Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer",[93],"2010-03",[36],[3035,1616],{"nctId":5127,"briefTitle":5128,"status":244,"phases":8753,"primaryCompletion":5130,"completion":5130,"start":764,"enrollment":1052,"conditions":8754,"interventions":8755},[93],[36],[920,1616,391,3603],{"intervention":3035,"totalTrials":283,"cells":8757},{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8786,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8759,"activeCount":101},[],{"trials":8761,"activeCount":97,"soonestReadout":1583},[8762,8770,8778,8782],{"nctId":8763,"briefTitle":8764,"status":244,"phases":8765,"primaryCompletion":8766,"completion":8766,"start":8767,"enrollment":1447,"conditions":8768,"interventions":8769},"NCT02282371","Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III\u002FIVB Head and Neck Squamous Cell Cancer (HNSCC)",[89],"2021-10-22","2014-10-30",[6040],[1593,7454],{"nctId":8771,"briefTitle":8772,"status":244,"phases":8773,"primaryCompletion":8774,"completion":8774,"start":5888,"enrollment":454,"conditions":8775,"interventions":8776},"NCT03524326","Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma",[89],"2022-10-13",[1590,2336,1586,3562],[8777,8777,8777,1593,8777,8777],"Lenvatinib Pill",{"nctId":1580,"briefTitle":1581,"status":158,"phases":8779,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":718,"conditions":8780,"interventions":8781},[89],[1586,1587,1588,1589,1590,1591],[974,224,1181,1593,1594,1595],{"nctId":6034,"briefTitle":6035,"status":244,"phases":8783,"primaryCompletion":6037,"completion":6037,"start":6038,"enrollment":306,"conditions":8784,"interventions":8785},[89],[6040,6041,6042],[4879,1593],{"trials":8787,"activeCount":97,"soonestReadout":8819},[8788,8792,8798,8802,8806,8815],{"nctId":3028,"briefTitle":3029,"status":244,"phases":8789,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":1447,"conditions":8790,"interventions":8791},[90],[1602,1613],[3035,47,683],{"nctId":8793,"briefTitle":8794,"status":244,"phases":8795,"primaryCompletion":1663,"start":7415,"conditions":8796,"interventions":8797},"NCT00020930","Cetuximab in Treating Patients With Stage IV Colorectal Cancer",[90],[36],[3035],{"nctId":7404,"briefTitle":7405,"status":244,"phases":8799,"primaryCompletion":7407,"completion":7407,"start":7408,"conditions":8800,"interventions":8801},[90],[36],[3035,1616,683,391],{"nctId":3248,"briefTitle":3249,"status":244,"phases":8803,"primaryCompletion":688,"completion":688,"start":3251,"conditions":8804,"interventions":8805},[90],[1586],[3035,47],{"nctId":8807,"briefTitle":8808,"status":244,"phases":8809,"primaryCompletion":8810,"completion":8810,"start":1347,"enrollment":398,"conditions":8811,"interventions":8814},"NCT00661427","Cetuximab at Either 500 or 750 mg\u002Fm2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer",[90],"2012-08",[8812,8813],"Head and Neck","Squamous Cell Cancer",[3035,3035],{"nctId":8816,"briefTitle":8817,"status":158,"phases":8818,"primaryCompletion":8819,"completion":8819,"start":8820,"enrollment":718,"conditions":8821,"interventions":8832},"NCT07063212","A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)",[90],"2028-01-02","2025-07-02",[8822,8823,8824,8825,1755,8826,8827,8828,8829,8830,8831,1758],"Squamous Cell Carcinoma of Head and Neck","Sinus Cancer","Nasal Cavity Cancer","Oral Cavity Cancer","Hypopharynx Cancer","Larynx Cancer","Oral Squamous Cell Carcinoma","Oropharynx Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma",[8833,1593],"Sacituzumab Govitecan",{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[],{"trials":8839,"activeCount":101},[8840,8844],{"nctId":8746,"briefTitle":8747,"status":244,"phases":8841,"primaryCompletion":746,"completion":8749,"start":1575,"enrollment":1232,"conditions":8842,"interventions":8843},[93],[36],[3035,1616],{"nctId":8845,"briefTitle":8846,"status":244,"phases":8847,"primaryCompletion":8848,"completion":8848,"start":8849,"enrollment":1094,"conditions":8850,"interventions":8851},"NCT02241187","Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection",[93],"2016-09-13","2014-09-12",[1226],[1230,1593],{"intervention":4212,"totalTrials":332,"cells":8853},{"EARLY_PHASE1":8854,"PHASE1":8856,"PHASE2":8862,"PHASE3":8880,"PHASE4":8882,"NA":8884},{"trials":8855,"activeCount":101},[],{"trials":8857,"activeCount":101},[8858],{"nctId":4178,"briefTitle":4179,"status":244,"phases":8859,"primaryCompletion":4181,"completion":4181,"start":4182,"enrollment":296,"conditions":8860,"interventions":8861},[89],[4184],[4186,4187],{"trials":8863,"activeCount":1094,"soonestReadout":1130},[8864,8868,8872,8876],{"nctId":4200,"briefTitle":4201,"status":113,"phases":8865,"primaryCompletion":1130,"completion":1130,"start":4203,"enrollment":356,"conditions":8866,"interventions":8867},[90],[4205,4206,4207,4208,4209,4210],[52,4212],{"nctId":4252,"briefTitle":4253,"status":244,"phases":8869,"primaryCompletion":4255,"completion":4255,"start":4256,"enrollment":438,"conditions":8870,"interventions":8871},[90],[2441],[4186,4187],{"nctId":4286,"briefTitle":4287,"status":113,"phases":8873,"primaryCompletion":1130,"completion":1130,"start":1829,"enrollment":2407,"conditions":8874,"interventions":8875},[89,90],[4290,2398],[4186,4292,4212],{"nctId":4294,"briefTitle":4295,"status":244,"phases":8877,"primaryCompletion":2390,"completion":2390,"start":4297,"enrollment":4298,"conditions":8878,"interventions":8879},[90],[3359,2363,2764,4300,4301],[52,4212],{"trials":8881,"activeCount":101},[],{"trials":8883,"activeCount":101},[],{"trials":8885,"activeCount":101},[8886],{"nctId":4310,"briefTitle":4311,"status":244,"phases":8887,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1232,"conditions":8888,"interventions":8889},[93],[2311],[4212,4317,52],{"intervention":8891,"totalTrials":509,"cells":8892},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":8893,"PHASE1":8895,"PHASE2":8905,"PHASE3":8915,"PHASE4":8917,"NA":8919},{"trials":8894,"activeCount":101},[],{"trials":8896,"activeCount":97,"soonestReadout":232},[8897],{"nctId":8898,"briefTitle":8899,"status":113,"phases":8900,"primaryCompletion":232,"completion":232,"start":8901,"enrollment":1114,"conditions":8902,"interventions":8904},"NCT04883762","Stool Transplant to Control Treatment-related Diarrhea",[89],"2021-05-10",[8903],"Fecal Microbiota Transplantation (FMT)",[8891],{"trials":8906,"activeCount":97,"soonestReadout":115},[8907],{"nctId":8908,"briefTitle":8909,"status":113,"phases":8910,"primaryCompletion":115,"completion":115,"start":1012,"enrollment":533,"conditions":8911,"interventions":8913},"NCT02269150","Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation",[90],[8912],"Allogeneic Hematopoietic Stem Cell",[8914],"fecal microbiota transplantation",{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[8921],{"nctId":8922,"briefTitle":8923,"status":244,"phases":8924,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":1434,"conditions":8927,"interventions":8929},"NCT02770326","Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection",[93],"2024-02-16","2016-05-10",[8928,1155],"C. Difficile Infection",[8891],{"intervention":360,"totalTrials":1447,"cells":8931},{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8968,"PHASE3":9023,"PHASE4":9029,"NA":9031},{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[8936,8943,8949,8957,8964],{"nctId":8937,"briefTitle":8938,"status":244,"phases":8939,"primaryCompletion":3777,"completion":3777,"start":8675,"conditions":8940,"interventions":8941},"NCT00005630","Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer",[89],[21],[8942,360],"ras peptide cancer vaccine",{"nctId":8944,"briefTitle":8945,"status":244,"phases":8946,"primaryCompletion":1141,"completion":1141,"start":4750,"enrollment":992,"conditions":8947,"interventions":8948},"NCT00450307","Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma",[89],[215],[344,360],{"nctId":8950,"briefTitle":8951,"status":244,"phases":8952,"primaryCompletion":5650,"completion":5650,"start":3032,"enrollment":2483,"conditions":8953,"interventions":8954},"NCT00398138","Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma",[89],[27,21,3163,475,286],[8955,8956,360,378],"WT-1 analog peptide vaccine","incomplete Freund's adjuvant",{"nctId":8958,"briefTitle":8959,"status":244,"phases":8960,"primaryCompletion":8961,"start":1685,"enrollment":97,"conditions":8962,"interventions":8963},"NCT00003959","Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome",[89],"2001-12",[27,475],[8942,360],{"nctId":2639,"briefTitle":2640,"status":244,"phases":8965,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":1434,"conditions":8966,"interventions":8967},[89],[794,2645,2646],[2648,942,2649],{"trials":8969,"activeCount":97,"soonestReadout":3422},[8970,8974,8978,8982,8989,8995,9001,9005,9015,9019],{"nctId":351,"briefTitle":352,"status":244,"phases":8971,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":8972,"interventions":8973},[90],[27],[359,360,202,361,346,362,363],{"nctId":365,"briefTitle":366,"status":244,"phases":8975,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":8976,"interventions":8977},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":3419,"briefTitle":3420,"status":158,"phases":8979,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":8980,"interventions":8981},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"nctId":8983,"briefTitle":8984,"status":244,"phases":8985,"primaryCompletion":3522,"completion":3522,"start":8986,"enrollment":718,"conditions":8987,"interventions":8988},"NCT00002560","Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma",[90],"1994-02",[215],[344,360],{"nctId":8990,"briefTitle":8991,"status":2832,"phases":8992,"primaryCompletion":1994,"completion":1994,"start":1575,"enrollment":101,"conditions":8993,"interventions":8994},"NCT00085579","Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma",[90],[4734],[1338,360],{"nctId":8996,"briefTitle":8997,"status":244,"phases":8998,"primaryCompletion":736,"start":4662,"enrollment":1743,"conditions":8999,"interventions":9000},"NCT00089258","Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment",[90],[215],[1271,344,360,749],{"nctId":3474,"briefTitle":3475,"status":244,"phases":9002,"primaryCompletion":3477,"completion":3477,"start":3478,"conditions":9003,"interventions":9004},[90],[24],[288,360,390,346,442],{"nctId":9006,"briefTitle":9007,"status":244,"phases":9008,"primaryCompletion":7408,"completion":7408,"start":9009,"conditions":9010,"interventions":9011},"NCT00003362","Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma",[90],"1998-05",[4734],[9012,9013,8956,360,9014],"QS21","gp100 antigen","tyrosinase peptide",{"nctId":743,"briefTitle":744,"status":244,"phases":9016,"primaryCompletion":746,"completion":746,"start":637,"conditions":9017,"interventions":9018},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":1393,"briefTitle":1394,"status":244,"phases":9020,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":9021,"interventions":9022},[90],[24],[288,374,360,549,361,346,444],{"trials":9024,"activeCount":101},[9025],{"nctId":872,"briefTitle":873,"status":244,"phases":9026,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":9027,"interventions":9028},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":9030,"activeCount":101},[],{"trials":9032,"activeCount":101},[],{"intervention":9034,"totalTrials":1934,"cells":9035},"bicalutamide",{"EARLY_PHASE1":9036,"PHASE1":9038,"PHASE2":9040,"PHASE3":9072,"PHASE4":9082,"NA":9084},{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":97,"soonestReadout":1130},[9042,9046,9058,9066],{"nctId":6660,"briefTitle":6661,"status":113,"phases":9043,"primaryCompletion":1130,"completion":1130,"start":6663,"enrollment":6397,"conditions":9044,"interventions":9045},[89,90],[6665],[6641,6667],{"nctId":9047,"briefTitle":9048,"status":244,"phases":9049,"primaryCompletion":4807,"completion":4807,"start":554,"enrollment":3344,"conditions":9050,"interventions":9053},"NCT00586898","Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle",[90],[9051,1155,9052],"Prostate","Hormonal Cycling",[9054,9055,6667,9056,9057],"GnRH","Ketoconazole","Testosterone transdermal gel","Estrogen transdermal patch",{"nctId":9059,"briefTitle":9060,"status":244,"phases":9061,"primaryCompletion":9062,"completion":9062,"start":9063,"enrollment":1232,"conditions":9064,"interventions":9065},"NCT00468715","Bicalutamide in Treating Patients With Metastatic Breast Cancer",[90],"2021-06-24","2007-03-23",[15],[9034],{"nctId":9067,"briefTitle":9068,"status":244,"phases":9069,"primaryCompletion":2914,"completion":2914,"start":1703,"conditions":9070,"interventions":9071},"NCT00012090","Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum",[90],[285,30,286],[9034,3455],{"trials":9073,"activeCount":101},[9074],{"nctId":9075,"briefTitle":9076,"status":244,"phases":9077,"primaryCompletion":9078,"completion":9079,"start":587,"enrollment":509,"conditions":9080,"interventions":9081},"NCT00067015","Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer",[91],"2004-10","2008-09",[18],[9034,3455],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[],{"intervention":9087,"totalTrials":1094,"cells":9088},"Pasireotide",{"EARLY_PHASE1":9089,"PHASE1":9091,"PHASE2":9093,"PHASE3":9103,"PHASE4":9113,"NA":9115},{"trials":9090,"activeCount":101},[],{"trials":9092,"activeCount":101},[],{"trials":9094,"activeCount":97,"soonestReadout":304},[9095],{"nctId":9096,"briefTitle":9097,"status":158,"phases":9098,"primaryCompletion":304,"completion":304,"start":9099,"enrollment":1434,"conditions":9100,"interventions":9102},"NCT06295952","A Study of Pasireotide in People With Prolactinoma",[90],"2024-02-27",[9101],"Prolactin-Producing Pituitary Tumor",[9087],{"trials":9104,"activeCount":101},[9105],{"nctId":9106,"briefTitle":9107,"status":244,"phases":9108,"primaryCompletion":9109,"completion":9109,"start":5557,"enrollment":9110,"conditions":9111,"interventions":9112},"NCT00994110","Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",[91],"2014-09",439,[1226],[9087],{"trials":9114,"activeCount":101},[],{"trials":9116,"activeCount":101},[],{"intervention":9118,"totalTrials":1094,"cells":9119},"Piperacillin-tazobactam",{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9137,"PHASE4":9151,"NA":9153},{"trials":9121,"activeCount":101},[],{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":97,"soonestReadout":304},[9126],{"nctId":9127,"briefTitle":9128,"status":113,"phases":9129,"primaryCompletion":304,"completion":304,"start":9130,"enrollment":9131,"conditions":9132,"interventions":9135},"NCT03078010","Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant",[90],"2017-02-10",347,[9133,9134],"Intestinal Microbiome","Febrile Neutropenia",[9118,9136],"cefepime",{"trials":9138,"activeCount":101},[9139],{"nctId":9140,"briefTitle":9141,"status":244,"phases":9142,"primaryCompletion":9143,"completion":9143,"start":9144,"enrollment":9145,"conditions":9146,"interventions":9149},"NCT03269994","Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?",[91],"2025-01-28","2017-11-21",967,[1226,9147,9148],"Pancreas Cancer","Pancreatic Diseases",[9150,9118],"Cefoxitin",{"trials":9152,"activeCount":101},[],{"trials":9154,"activeCount":101},[],{"intervention":558,"totalTrials":601,"cells":9156},{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9161,"PHASE3":9205,"PHASE4":9207,"NA":9209},{"trials":9158,"activeCount":101},[],{"trials":9160,"activeCount":101},[],{"trials":9162,"activeCount":97,"soonestReadout":304},[9163,9167,9171,9175,9179,9185,9189,9193,9201],{"nctId":4729,"briefTitle":4730,"status":244,"phases":9164,"primaryCompletion":3044,"start":1653,"conditions":9165,"interventions":9166},[90],[4733,4734],[3342,4691,558],{"nctId":3652,"briefTitle":3653,"status":244,"phases":9168,"primaryCompletion":3655,"completion":3655,"start":736,"enrollment":341,"conditions":9169,"interventions":9170},[90],[828],[662,643,3658,558],{"nctId":3660,"briefTitle":3661,"status":244,"phases":9172,"primaryCompletion":1565,"completion":1565,"start":426,"conditions":9173,"interventions":9174},[90],[828],[643,345,558],{"nctId":4737,"briefTitle":4738,"status":244,"phases":9176,"primaryCompletion":3044,"completion":3044,"start":3251,"conditions":9177,"interventions":9178},[89,90],[4733,4734],[4691,558],{"nctId":9180,"briefTitle":9181,"status":244,"phases":9182,"primaryCompletion":1575,"completion":1575,"start":648,"conditions":9183,"interventions":9184},"NCT00016224","Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer",[90],[30],[558],{"nctId":4144,"briefTitle":4145,"status":113,"phases":9186,"primaryCompletion":304,"completion":304,"start":305,"enrollment":356,"conditions":9187,"interventions":9188},[90],[4140],[722,4149],{"nctId":551,"briefTitle":552,"status":244,"phases":9190,"primaryCompletion":554,"completion":554,"start":427,"conditions":9191,"interventions":9192},[90],[556],[202,558],{"nctId":9194,"briefTitle":9195,"status":244,"phases":9196,"primaryCompletion":3220,"completion":3220,"start":7415,"conditions":9197,"interventions":9200},"NCT00027638","Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors",[90],[5055,9198,21,9199],"Islet Cell Tumor","Neoplastic Syndrome",[558],{"nctId":3773,"briefTitle":3774,"status":244,"phases":9202,"primaryCompletion":3776,"start":3777,"conditions":9203,"interventions":9204},[90],[828],[288,643,444,558],{"trials":9206,"activeCount":101},[],{"trials":9208,"activeCount":101},[],{"trials":9210,"activeCount":101},[],{"intervention":1578,"totalTrials":2291,"cells":9212},{"EARLY_PHASE1":9213,"PHASE1":9215,"PHASE2":9225,"PHASE3":9257,"PHASE4":9259,"NA":9261},{"trials":9214,"activeCount":101},[],{"trials":9216,"activeCount":101},[9217,9221],{"nctId":1572,"briefTitle":1573,"status":244,"phases":9218,"primaryCompletion":727,"start":1575,"conditions":9219,"interventions":9220},[89],[1568],[1023,1578],{"nctId":3379,"briefTitle":3380,"status":244,"phases":9222,"primaryCompletion":1629,"completion":1629,"start":3382,"conditions":9223,"interventions":9224},[89],[21],[390,1578,741],{"trials":9226,"activeCount":97,"soonestReadout":3072},[9227,9231,9237,9244,9250],{"nctId":3069,"briefTitle":3070,"status":158,"phases":9228,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":9229,"interventions":9230},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":9232,"briefTitle":9233,"status":244,"phases":9234,"completion":1575,"start":648,"conditions":9235,"interventions":9236},"NCT00012337","ZD 1839 in Treating Patients With Metastatic Kidney Cancer",[90],[783],[1578],{"nctId":9238,"briefTitle":9239,"status":244,"phases":9240,"primaryCompletion":9241,"completion":9241,"start":1267,"enrollment":1743,"conditions":9242,"interventions":9243},"NCT00096486","Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer",[89,90],"2010-07",[21],[2963,1578],{"nctId":9245,"briefTitle":9246,"status":244,"phases":9247,"primaryCompletion":1652,"completion":1652,"start":1575,"enrollment":398,"conditions":9248,"interventions":9249},"NCT00085566","Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer",[89,90],[3259,18],[2963,1578],{"nctId":9251,"briefTitle":9252,"status":244,"phases":9253,"primaryCompletion":3031,"completion":3031,"start":354,"enrollment":523,"conditions":9254,"interventions":9256},"NCT00588445","Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene",[90],[21,2948,9255],"Bronchioloalveolar Cancer",[3079],{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[],{"intervention":403,"totalTrials":332,"cells":9264},{"EARLY_PHASE1":9265,"PHASE1":9267,"PHASE2":9269,"PHASE3":9295,"PHASE4":9297,"NA":9299},{"trials":9266,"activeCount":101},[],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":97,"soonestReadout":667},[9271,9275,9279,9283,9287,9291],{"nctId":393,"briefTitle":394,"status":244,"phases":9272,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":9273,"interventions":9274},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":6392,"briefTitle":6393,"status":244,"phases":9276,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":6397,"conditions":9277,"interventions":9278},[90],[3816,414,5615,475,6399,1154,6400,604,27],[675,461,6402,912],{"nctId":433,"briefTitle":434,"status":244,"phases":9280,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":9281,"interventions":9282},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":664,"briefTitle":665,"status":158,"phases":9284,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":9285,"interventions":9286},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"nctId":5589,"briefTitle":5590,"status":244,"phases":9288,"primaryCompletion":1014,"completion":1014,"start":554,"enrollment":1152,"conditions":9289,"interventions":9290},[90],[27,24,828,475,476],[5594,403,404,444],{"nctId":771,"briefTitle":772,"status":244,"phases":9292,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":9293,"interventions":9294},[90],[27,24],[288,374,202,403,404,405],{"trials":9296,"activeCount":101},[],{"trials":9298,"activeCount":101},[],{"trials":9300,"activeCount":101},[],{"intervention":6591,"totalTrials":1934,"cells":9302},{"EARLY_PHASE1":9303,"PHASE1":9305,"PHASE2":9317,"PHASE3":9346,"PHASE4":9348,"NA":9350},{"trials":9304,"activeCount":101},[],{"trials":9306,"activeCount":101},[9307],{"nctId":9308,"briefTitle":9309,"status":244,"phases":9310,"primaryCompletion":9311,"completion":9311,"start":9312,"enrollment":992,"conditions":9313,"interventions":9315},"NCT04242238","Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas",[89],"2025-08-26","2020-01-22",[33,2428,9314,1017,2372,2371,4868],"High Grade Sarcoma",[9316,6591],"DCC-3014",{"trials":9318,"activeCount":97,"soonestReadout":990},[9319,9327,9334,9338],{"nctId":9320,"briefTitle":9321,"status":244,"phases":9322,"primaryCompletion":2619,"completion":2619,"start":9323,"enrollment":1871,"conditions":9324,"interventions":9326},"NCT03399552","Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma",[89,90],"2017-12-20",[9325],"Malignant Mesothelioma (MPM)",[6591],{"nctId":9328,"briefTitle":9329,"status":113,"phases":9330,"primaryCompletion":990,"completion":990,"start":9331,"enrollment":326,"conditions":9332,"interventions":9333},"NCT04792073","Study of Avelumab and\u002For Radiation Therapy in People With Advanced Merkel Cell Carcinoma",[90],"2021-03-08",[2342],[6591],{"nctId":6583,"briefTitle":6584,"status":2832,"phases":9335,"primaryCompletion":6586,"completion":6586,"start":6587,"enrollment":101,"conditions":9336,"interventions":9337},[89,90],[535,6589],[3818,6591],{"nctId":9339,"briefTitle":9340,"status":244,"phases":9341,"primaryCompletion":9342,"completion":9342,"start":9343,"enrollment":326,"conditions":9344,"interventions":9345},"NCT04068831","Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma",[90],"2023-12-06","2019-08-22",[4876,2715,2716],[4766,6591],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"trials":9351,"activeCount":101},[],{"intervention":3012,"totalTrials":1934,"cells":9353},{"EARLY_PHASE1":9354,"PHASE1":9356,"PHASE2":9362,"PHASE3":9395,"PHASE4":9397,"NA":9399},{"trials":9355,"activeCount":101},[],{"trials":9357,"activeCount":101},[9358],{"nctId":3007,"briefTitle":3008,"status":244,"phases":9359,"start":2940,"conditions":9360,"interventions":9361},[89],[21],[47,3012,683],{"trials":9363,"activeCount":97,"soonestReadout":1130},[9364,9375,9382,9388],{"nctId":9365,"briefTitle":9366,"status":244,"phases":9367,"primaryCompletion":9368,"completion":9368,"start":9369,"enrollment":1447,"conditions":9370,"interventions":9372},"NCT02257541","BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)",[89,90],"2019-03-25","2014-10-02",[9371],"Advanced Gastrointestinal Stromal Tumor (GIST)",[9373,9374],"BGJ398","Imatinib Mesylate",{"nctId":9376,"briefTitle":9377,"status":113,"phases":9378,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":31,"conditions":9379,"interventions":9381},"NCT01991379","MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)",[89,90],[9380],"Gastrointestinal Stromal Tumor (GIST)",[1145,9374],{"nctId":9383,"briefTitle":9384,"status":244,"phases":9385,"primaryCompletion":680,"completion":680,"start":1566,"conditions":9386,"interventions":9387},"NCT00045422","Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",[90],[27],[359,3012],{"nctId":9389,"briefTitle":9390,"status":244,"phases":9391,"primaryCompletion":3274,"completion":3274,"start":3220,"conditions":9392,"interventions":9393},"NCT00081133","Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[89,90],[27],[9394,3012],"arsenic trioxide",{"trials":9396,"activeCount":101},[],{"trials":9398,"activeCount":101},[],{"trials":9400,"activeCount":101},[],{"intervention":5107,"totalTrials":1114,"cells":9402},{"EARLY_PHASE1":9403,"PHASE1":9405,"PHASE2":9407,"PHASE3":9432,"PHASE4":9434,"NA":9436},{"trials":9404,"activeCount":101},[],{"trials":9406,"activeCount":101},[],{"trials":9408,"activeCount":97,"soonestReadout":304},[9409,9413,9420,9428],{"nctId":2673,"briefTitle":2674,"status":113,"phases":9410,"primaryCompletion":304,"completion":304,"start":2676,"enrollment":573,"conditions":9411,"interventions":9412},[90],[2678,2679],[2681,2682,2683],{"nctId":9414,"briefTitle":9415,"status":244,"phases":9416,"primaryCompletion":9417,"completion":9417,"start":1186,"enrollment":3599,"conditions":9418,"interventions":9419},"NCT02098538","Regorafenib in Patients With Progressive, Recurrent\u002FMetastatic Adenoid Cystic Carcinoma",[90],"2024-11-07",[2409],[5107],{"nctId":9421,"briefTitle":9422,"status":244,"phases":9423,"primaryCompletion":9311,"completion":9311,"start":9424,"enrollment":2630,"conditions":9425,"interventions":9427},"NCT02023333","Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma",[90],"2013-12-10",[9426],"Metastatic Colorectal Adenocarcinoma",[5107],{"nctId":5102,"briefTitle":5103,"status":244,"phases":9429,"primaryCompletion":3339,"completion":3339,"start":1396,"enrollment":573,"conditions":9430,"interventions":9431},[90],[1602,1613],[5107,1680,582,944],{"trials":9433,"activeCount":101},[],{"trials":9435,"activeCount":101},[],{"trials":9437,"activeCount":101},[],{"intervention":3397,"totalTrials":1114,"cells":9439},{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9452,"PHASE3":9476,"PHASE4":9478,"NA":9480},{"trials":9441,"activeCount":101},[],{"trials":9443,"activeCount":101},[9444,9448],{"nctId":3619,"briefTitle":3620,"status":244,"phases":9445,"primaryCompletion":3622,"completion":3622,"start":3231,"enrollment":326,"conditions":9446,"interventions":9447},[89],[308,3624],[3397,3626,463],{"nctId":3390,"briefTitle":3391,"status":244,"phases":9449,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":1412,"conditions":9450,"interventions":9451},[89],[30,3359],[1595,224,3397],{"trials":9453,"activeCount":97,"soonestReadout":9458},[9454,9467],{"nctId":9455,"briefTitle":9456,"status":158,"phases":9457,"primaryCompletion":9458,"completion":9458,"start":9459,"enrollment":341,"conditions":9460,"interventions":9466},"NCT05985161","A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors",[90],"2029-08-01","2023-08-01",[2646,9461,9462,9463,9464,9465,2351],"Rhabdoid Tumor","Malignant Peripheral Nerve Sheath Tumors","MPNST","Nephroblastoma","XPO1 Gene Mutation",[3397],{"nctId":9468,"briefTitle":9469,"status":244,"phases":9470,"primaryCompletion":9471,"completion":9471,"start":9472,"enrollment":438,"conditions":9473,"interventions":9474},"NCT02228525","Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes",[90],"2021-04-06","2014-08-27",[475],[9475],"selinexor",{"trials":9477,"activeCount":101},[],{"trials":9479,"activeCount":101},[],{"trials":9481,"activeCount":101},[],{"intervention":3626,"totalTrials":1114,"cells":9483},{"EARLY_PHASE1":9484,"PHASE1":9486,"PHASE2":9496,"PHASE3":9512,"PHASE4":9514,"NA":9516},{"trials":9485,"activeCount":101},[],{"trials":9487,"activeCount":101},[9488,9492],{"nctId":3619,"briefTitle":3620,"status":244,"phases":9489,"primaryCompletion":3622,"completion":3622,"start":3231,"enrollment":326,"conditions":9490,"interventions":9491},[89],[308,3624],[3397,3626,463],{"nctId":3628,"briefTitle":3629,"status":244,"phases":9493,"primaryCompletion":3631,"completion":3631,"start":1092,"enrollment":272,"conditions":9494,"interventions":9495},[89],[308,3633],[3626,463],{"trials":9497,"activeCount":97,"soonestReadout":324},[9498,9508],{"nctId":9499,"briefTitle":9500,"status":244,"phases":9501,"primaryCompletion":9502,"completion":9502,"start":9503,"enrollment":306,"conditions":9504,"interventions":9507},"NCT03082677","Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies",[90],"2021-09-02","2017-03-10",[9505,9506],"Myeloid Hematologic Malignancy","Lymphoid Hematologic Malignancy",[3626],{"nctId":3781,"briefTitle":3782,"status":113,"phases":9509,"primaryCompletion":324,"completion":324,"start":3784,"enrollment":234,"conditions":9510,"interventions":9511},[90],[3786],[3626,463],{"trials":9513,"activeCount":101},[],{"trials":9515,"activeCount":101},[],{"trials":9517,"activeCount":101},[],{"intervention":1145,"totalTrials":509,"cells":9519},{"EARLY_PHASE1":9520,"PHASE1":9522,"PHASE2":9532,"PHASE3":9542,"PHASE4":9544,"NA":9546},{"trials":9521,"activeCount":101},[],{"trials":9523,"activeCount":101},[9524],{"nctId":9525,"briefTitle":9526,"status":244,"phases":9527,"primaryCompletion":4255,"completion":4255,"start":9528,"enrollment":509,"conditions":9529,"interventions":9530},"NCT03158103","A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)",[89],"2017-04-15",[9380],[1145,9531],"Pexidartinib",{"trials":9533,"activeCount":97,"soonestReadout":1130},[9534,9538],{"nctId":9376,"briefTitle":9377,"status":113,"phases":9535,"primaryCompletion":1130,"completion":1130,"start":3589,"enrollment":31,"conditions":9536,"interventions":9537},[89,90],[9380],[1145,9374],{"nctId":1137,"briefTitle":1138,"status":244,"phases":9539,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":486,"conditions":9540,"interventions":9541},[89,90],[1143],[923,974,1145],{"trials":9543,"activeCount":101},[],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[],{"intervention":1087,"totalTrials":509,"cells":9549},{"EARLY_PHASE1":9550,"PHASE1":9552,"PHASE2":9554,"PHASE3":9575,"PHASE4":9577,"NA":9579},{"trials":9551,"activeCount":101},[],{"trials":9553,"activeCount":101},[],{"trials":9555,"activeCount":97,"soonestReadout":3072},[9556,9560,9571],{"nctId":3069,"briefTitle":3070,"status":158,"phases":9557,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":9558,"interventions":9559},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"nctId":9561,"briefTitle":9562,"status":244,"phases":9563,"primaryCompletion":1012,"completion":1012,"start":1397,"enrollment":370,"conditions":9564,"interventions":9570},"NCT00589784","Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma",[90],[9565,9566,9567,9568,9569],"CNS Cancer","Meningioma","Intracranial Hemangiopericytoma","Hemangioblastoma","Neurofibromatosis",[1087],{"nctId":1079,"briefTitle":1080,"status":244,"phases":9572,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":326,"conditions":9573,"interventions":9574},[90],[971,1085],[1087,923,47],{"trials":9576,"activeCount":101},[],{"trials":9578,"activeCount":101},[],{"trials":9580,"activeCount":101},[],{"intervention":6280,"totalTrials":509,"cells":9582},{"EARLY_PHASE1":9583,"PHASE1":9585,"PHASE2":9599,"PHASE3":9605,"PHASE4":9607,"NA":9609},{"trials":9584,"activeCount":101},[],{"trials":9586,"activeCount":101},[9587,9595],{"nctId":9588,"briefTitle":9589,"status":244,"phases":9590,"primaryCompletion":5816,"completion":5816,"start":813,"enrollment":2426,"conditions":9591,"interventions":9593},"NCT01870505","BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer",[89],[9592],"Metastatic or Locally-advanced Unresectable Breast Cancer",[7454,6280,9594],"Exemestane",{"nctId":6648,"briefTitle":6649,"status":2832,"phases":9596,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":101,"conditions":9597,"interventions":9598},[89],[2311,6654],[6280,6641,6656],{"trials":9600,"activeCount":97,"soonestReadout":531},[9601],{"nctId":6273,"briefTitle":6274,"status":158,"phases":9602,"primaryCompletion":531,"completion":531,"start":2688,"enrollment":306,"conditions":9603,"interventions":9604},[90],[6277],[6244,6279,6280],{"trials":9606,"activeCount":101},[],{"trials":9608,"activeCount":101},[],{"trials":9610,"activeCount":101},[],{"intervention":1192,"totalTrials":509,"cells":9612},{"EARLY_PHASE1":9613,"PHASE1":9615,"PHASE2":9624,"PHASE3":9634,"PHASE4":9636,"NA":9638},{"trials":9614,"activeCount":101},[],{"trials":9616,"activeCount":101},[9617],{"nctId":9618,"briefTitle":9619,"status":244,"phases":9620,"primaryCompletion":5995,"completion":5995,"start":9621,"enrollment":899,"conditions":9622,"interventions":9623},"NCT01724606","Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)",[89],"2012-11-05",[15,6031],[1192],{"trials":9625,"activeCount":97,"soonestReadout":531},[9626,9630],{"nctId":4077,"briefTitle":4078,"status":113,"phases":9627,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":356,"conditions":9628,"interventions":9629},[90],[4081],[1192,221],{"nctId":1183,"briefTitle":1184,"status":244,"phases":9631,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":573,"conditions":9632,"interventions":9633},[90],[1189,1190],[923,974,1192],{"trials":9635,"activeCount":101},[],{"trials":9637,"activeCount":101},[],{"trials":9639,"activeCount":101},[],{"intervention":5365,"totalTrials":1094,"cells":9641},{"EARLY_PHASE1":9642,"PHASE1":9644,"PHASE2":9646,"PHASE3":9661,"PHASE4":9663,"NA":9665},{"trials":9643,"activeCount":101},[],{"trials":9645,"activeCount":101},[],{"trials":9647,"activeCount":97,"soonestReadout":85},[9648,9657],{"nctId":9649,"briefTitle":9650,"status":244,"phases":9651,"primaryCompletion":2725,"completion":2725,"start":9652,"enrollment":2407,"conditions":9653,"interventions":9654},"NCT02772588","AASUR in High Risk Prostate Cancer",[90],"2016-05-12",[18],[9655,5365,9656],"ARN-509","Leuprolide",{"nctId":83,"briefTitle":84,"status":113,"phases":9658,"primaryCompletion":85,"completion":1469,"start":5362,"enrollment":1232,"conditions":9659,"interventions":9660},[90],[2030],[86,5365,577,5366,5367],{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[],{"trials":9666,"activeCount":101},[],{"intervention":9668,"totalTrials":1094,"cells":9669},"Mogamulizumab",{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9674,"PHASE3":9695,"PHASE4":9697,"NA":9699},{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[],{"trials":9675,"activeCount":97,"soonestReadout":9688},[9676,9684],{"nctId":9677,"briefTitle":9678,"status":244,"phases":9679,"primaryCompletion":9680,"completion":9680,"start":1012,"enrollment":234,"conditions":9681,"interventions":9683},"NCT02281409","Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and\u002For Metastatic Solid Tumors",[89,90],"2020-02",[5786,9682],"Metastatic Solid Tumors",[9668],{"nctId":9685,"briefTitle":9686,"status":158,"phases":9687,"primaryCompletion":9688,"completion":9688,"start":4853,"enrollment":9689,"conditions":9690,"interventions":9694},"NCT06698003","A Study of Mogamulizumab to Prevent Adult T-cell Leukemia\u002FLymphoma in People With HTLV-1",[90],"2029-11-15",134,[9691,9692,9693,24],"T-Cell Leukemia\u002FLymphoma, Adult","T-cell Leukemia\u002FLymphoma","T-cell Leukemia",[9668],{"trials":9696,"activeCount":101},[],{"trials":9698,"activeCount":101},[],{"trials":9700,"activeCount":101},[],{"intervention":7029,"totalTrials":1094,"cells":9702},{"EARLY_PHASE1":9703,"PHASE1":9705,"PHASE2":9707,"PHASE3":9717,"PHASE4":9719,"NA":9721},{"trials":9704,"activeCount":101},[],{"trials":9706,"activeCount":101},[],{"trials":9708,"activeCount":97,"soonestReadout":6349},[9709,9713],{"nctId":7021,"briefTitle":7022,"status":244,"phases":9710,"primaryCompletion":7024,"completion":7024,"start":7025,"enrollment":7026,"conditions":9711,"interventions":9712},[90],[18],[7029,7030,711],{"nctId":6346,"briefTitle":6347,"status":113,"phases":9714,"primaryCompletion":6349,"completion":6350,"start":6351,"enrollment":1654,"conditions":9715,"interventions":9716},[90],[18],[6354,6355,577,6356],{"trials":9718,"activeCount":101},[],{"trials":9720,"activeCount":101},[],{"trials":9722,"activeCount":101},[],{"intervention":9724,"totalTrials":1094,"cells":9725},"Amivantamab",{"EARLY_PHASE1":9726,"PHASE1":9728,"PHASE2":9730,"PHASE3":9749,"PHASE4":9751,"NA":9753},{"trials":9727,"activeCount":101},[],{"trials":9729,"activeCount":101},[],{"trials":9731,"activeCount":97,"soonestReadout":1130},[9732,9739],{"nctId":9733,"briefTitle":9734,"status":113,"phases":9735,"primaryCompletion":1130,"completion":1130,"start":9736,"enrollment":438,"conditions":9737,"interventions":9738},"NCT05117931","A Study of Amivantamab in People With Esophagogastric Cancer",[90],"2021-12-02",[2678],[9724],{"nctId":9740,"briefTitle":9741,"status":244,"phases":9742,"primaryCompletion":5977,"completion":5977,"start":9743,"enrollment":3017,"conditions":9744,"interventions":9747},"NCT04965090","A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)",[90],"2021-09-30",[9745,9746],"Metastatic Non Small Cell Lung Cancer","Recurrent Non Small Cell Lung Cancer",[9724,9748],"Lazertinib",{"trials":9750,"activeCount":101},[],{"trials":9752,"activeCount":101},[],{"trials":9754,"activeCount":101},[],{"intervention":9756,"totalTrials":1094,"cells":9757},"apalutamide",{"EARLY_PHASE1":9758,"PHASE1":9760,"PHASE2":9770,"PHASE3":9776,"PHASE4":9778,"NA":9780},{"trials":9759,"activeCount":101},[],{"trials":9761,"activeCount":101},[9762],{"nctId":9763,"briefTitle":9764,"status":244,"phases":9765,"primaryCompletion":9766,"completion":9766,"start":774,"enrollment":601,"conditions":9767,"interventions":9768},"NCT02106507","ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate",[89],"2021-06-28",[18],[9756,9769],"Everolimus",{"trials":9771,"activeCount":97,"soonestReadout":6349},[9772],{"nctId":6346,"briefTitle":6347,"status":113,"phases":9773,"primaryCompletion":6349,"completion":6350,"start":6351,"enrollment":1654,"conditions":9774,"interventions":9775},[90],[18],[6354,6355,577,6356],{"trials":9777,"activeCount":101},[],{"trials":9779,"activeCount":101},[],{"trials":9781,"activeCount":101},[],{"intervention":430,"totalTrials":1094,"cells":9783},{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9788,"PHASE3":9798,"PHASE4":9800,"NA":9802},{"trials":9785,"activeCount":101},[],{"trials":9787,"activeCount":101},[],{"trials":9789,"activeCount":97,"soonestReadout":194},[9790,9794],{"nctId":423,"briefTitle":424,"status":244,"phases":9791,"primaryCompletion":426,"completion":426,"start":427,"conditions":9792,"interventions":9793},[90],[33],[202,430,431,345,349],{"nctId":677,"briefTitle":678,"status":113,"phases":9795,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":9796,"interventions":9797},[90],[33],[288,390,202,430,345,346,442,683,349],{"trials":9799,"activeCount":101},[],{"trials":9801,"activeCount":101},[],{"trials":9803,"activeCount":101},[],{"intervention":9805,"totalTrials":1094,"cells":9806},"Triamcinolone Acetonide",{"EARLY_PHASE1":9807,"PHASE1":9809,"PHASE2":9811,"PHASE3":9835,"PHASE4":9837,"NA":9839},{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[],{"trials":9812,"activeCount":97,"soonestReadout":2082},[9813,9826],{"nctId":9814,"briefTitle":9815,"status":244,"phases":9816,"primaryCompletion":9817,"completion":9817,"start":9818,"enrollment":326,"conditions":9819,"interventions":9824},"NCT05190770","A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer",[90],"2024-08-27","2021-12-15",[15,9820,9821,9822,9823,2312],"Breast Cancer Stage","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[9805,9825],"Oleogel-S10",{"nctId":9827,"briefTitle":9828,"status":113,"phases":9829,"primaryCompletion":2082,"completion":2082,"start":9830,"enrollment":1798,"conditions":9831,"interventions":9833},"NCT04469075","Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields",[90],"2020-07-09",[2790,8193,9832],"Skin Toxicity",[9834,9805],"Clindamycin Phosphate",{"trials":9836,"activeCount":101},[],{"trials":9838,"activeCount":101},[],{"trials":9840,"activeCount":101},[],{"intervention":289,"totalTrials":1094,"cells":9842},{"EARLY_PHASE1":9843,"PHASE1":9845,"PHASE2":9851,"PHASE3":9857,"PHASE4":9859,"NA":9861},{"trials":9844,"activeCount":101},[],{"trials":9846,"activeCount":101},[9847],{"nctId":278,"briefTitle":279,"status":244,"phases":9848,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":9849,"interventions":9850},[89],[285,30,286],[288,289,202],{"trials":9852,"activeCount":97,"soonestReadout":498},[9853],{"nctId":495,"briefTitle":496,"status":113,"phases":9854,"primaryCompletion":498,"completion":498,"start":499,"enrollment":370,"conditions":9855,"interventions":9856},[89,90],[27],[289,202],{"trials":9858,"activeCount":101},[],{"trials":9860,"activeCount":101},[],{"trials":9862,"activeCount":101},[],{"intervention":516,"totalTrials":1094,"cells":9864},{"EARLY_PHASE1":9865,"PHASE1":9867,"PHASE2":9869,"PHASE3":9879,"PHASE4":9881,"NA":9883},{"trials":9866,"activeCount":101},[],{"trials":9868,"activeCount":101},[],{"trials":9870,"activeCount":97,"soonestReadout":812},[9871,9875],{"nctId":503,"briefTitle":504,"status":505,"phases":9872,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":9873,"interventions":9874},[90],[511,512,513],[419,331,218,515,516],{"nctId":809,"briefTitle":810,"status":113,"phases":9876,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":9877,"interventions":9878},[90],[816],[218,220,222,223,818,819,225,820,516],{"trials":9880,"activeCount":101},[],{"trials":9882,"activeCount":101},[],{"trials":9884,"activeCount":101},[],{"intervention":2745,"totalTrials":1094,"cells":9886},{"EARLY_PHASE1":9887,"PHASE1":9889,"PHASE2":9900,"PHASE3":9906,"PHASE4":9908,"NA":9910},{"trials":9888,"activeCount":101},[],{"trials":9890,"activeCount":101},[9891],{"nctId":9892,"briefTitle":9893,"status":244,"phases":9894,"primaryCompletion":9895,"completion":9896,"start":9897,"enrollment":473,"conditions":9898,"interventions":9899},"NCT03542175","A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy",[89],"2024-07-25","2025-09-10","2018-05-23",[15],[2745],{"trials":9901,"activeCount":97,"soonestReadout":2741},[9902],{"nctId":2738,"briefTitle":2739,"status":113,"phases":9903,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":306,"conditions":9904,"interventions":9905},[90],[1017],[2745,942],{"trials":9907,"activeCount":101},[],{"trials":9909,"activeCount":101},[],{"trials":9911,"activeCount":101},[],{"intervention":9913,"totalTrials":1094,"cells":9914},"axitinib",{"EARLY_PHASE1":9915,"PHASE1":9917,"PHASE2":9919,"PHASE3":9940,"PHASE4":9942,"NA":9944},{"trials":9916,"activeCount":101},[],{"trials":9918,"activeCount":101},[],{"trials":9920,"activeCount":97,"soonestReadout":812},[9921,9930],{"nctId":9922,"briefTitle":9923,"status":158,"phases":9924,"primaryCompletion":812,"completion":812,"start":9925,"enrollment":306,"conditions":9926,"interventions":9928},"NCT05384496","Axitinib and Nivolumab for the Treatment of Mucosal Melanoma",[90],"2022-05-17",[9927],"Mucosal Melanoma",[9929,9913],"Nivolumab and\u002For Ipilimumab",{"nctId":9931,"briefTitle":9932,"status":244,"phases":9933,"primaryCompletion":9934,"completion":9934,"start":9935,"enrollment":1412,"conditions":9936,"interventions":9938},"NCT04337970","Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer",[89,90],"2025-05-23","2020-04-06",[783,5422,9937,4876],"Unresectable Renal Cell Carcinoma",[4766,9939],"Axitinib",{"trials":9941,"activeCount":101},[],{"trials":9943,"activeCount":101},[],{"trials":9945,"activeCount":101},[],{"intervention":2467,"totalTrials":1094,"cells":9947},{"EARLY_PHASE1":9948,"PHASE1":9950,"PHASE2":9952,"PHASE3":9968,"PHASE4":9970,"NA":9972},{"trials":9949,"activeCount":101},[],{"trials":9951,"activeCount":101},[],{"trials":9953,"activeCount":97,"soonestReadout":2459},[9954,9958],{"nctId":2456,"briefTitle":2457,"status":113,"phases":9955,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":2462,"conditions":9956,"interventions":9957},[90],[33,2464,2465],[2467,42],{"nctId":9959,"briefTitle":9960,"status":244,"phases":9961,"primaryCompletion":9962,"completion":9962,"start":9963,"enrollment":2446,"conditions":9964,"interventions":9966},"NCT02819843","A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",[90],"2024-02-22","2016-06-21",[2341,2342,9965],"Other Solid Tumors",[9967],"TALIMOGENE LAHERPAREPVEC",{"trials":9969,"activeCount":101},[],{"trials":9971,"activeCount":101},[],{"trials":9973,"activeCount":101},[],{"intervention":594,"totalTrials":1094,"cells":9975},{"EARLY_PHASE1":9976,"PHASE1":9978,"PHASE2":9980,"PHASE3":9990,"PHASE4":9992,"NA":9994},{"trials":9977,"activeCount":101},[],{"trials":9979,"activeCount":101},[],{"trials":9981,"activeCount":97,"soonestReadout":498},[9982,9986],{"nctId":584,"briefTitle":585,"status":244,"phases":9983,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":9984,"interventions":9985},[90],[27,24,592],[288,594,202,346,442],{"nctId":701,"briefTitle":702,"status":113,"phases":9987,"primaryCompletion":498,"completion":498,"start":704,"enrollment":705,"conditions":9988,"interventions":9989},[90],[27,308,416,707],[709,710,418,218,711],{"trials":9991,"activeCount":101},[],{"trials":9993,"activeCount":101},[],{"trials":9995,"activeCount":101},[],{"intervention":9997,"totalTrials":1094,"cells":9998},"Plerixafor",{"EARLY_PHASE1":9999,"PHASE1":10001,"PHASE2":10011,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10000,"activeCount":101},[],{"trials":10002,"activeCount":101},[10003],{"nctId":10004,"briefTitle":10005,"status":244,"phases":10006,"primaryCompletion":10007,"completion":10007,"start":10008,"enrollment":438,"conditions":10009,"interventions":10010},"NCT02193191","Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease",[89],"2025-03-27","2014-09-17",[456],[9997],{"trials":10012,"activeCount":97,"soonestReadout":115},[10013],{"nctId":10014,"briefTitle":10015,"status":113,"phases":10016,"primaryCompletion":115,"completion":115,"start":10017,"enrollment":533,"conditions":10018,"interventions":10021},"NCT02570542","Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)",[90],"2015-10",[1444,10019,10020],"Relapsed Diffuse Large B-cell Lymphoma (DLBCL)","Refractory Diffuse Large B-cell Lymphoma (DLBCL)",[9997,10022],"carmustine, etoposide, cytarabine, melphalan",{"trials":10024,"activeCount":101},[],{"trials":10026,"activeCount":101},[],{"trials":10028,"activeCount":101},[],{"intervention":1108,"totalTrials":1094,"cells":10030},{"EARLY_PHASE1":10031,"PHASE1":10033,"PHASE2":10039,"PHASE3":10045,"PHASE4":10047,"NA":10049},{"trials":10032,"activeCount":101},[],{"trials":10034,"activeCount":101},[10035],{"nctId":2970,"briefTitle":2971,"status":244,"phases":10036,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":356,"conditions":10037,"interventions":10038},[89],[2976],[1108,47,1645],{"trials":10040,"activeCount":97,"soonestReadout":115},[10041],{"nctId":1099,"briefTitle":1100,"status":158,"phases":10042,"primaryCompletion":115,"completion":115,"start":1102,"enrollment":162,"conditions":10043,"interventions":10044},[90],[21,1104,1105],[974,1107,923,224,1108,942],{"trials":10046,"activeCount":101},[],{"trials":10048,"activeCount":101},[],{"trials":10050,"activeCount":101},[],{"intervention":5115,"totalTrials":1094,"cells":10052},{"EARLY_PHASE1":10053,"PHASE1":10055,"PHASE2":10057,"PHASE3":10071,"PHASE4":10073,"NA":10075},{"trials":10054,"activeCount":101},[],{"trials":10056,"activeCount":101},[],{"trials":10058,"activeCount":97,"soonestReadout":498},[10059,10067],{"nctId":10060,"briefTitle":10061,"status":244,"phases":10062,"primaryCompletion":10063,"completion":10063,"start":1565,"enrollment":10064,"conditions":10065,"interventions":10066},"NCT00445965","Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",[90],"2023-02-01",78,[3259,4733,21,4734,2349,215,30,651,33,1687],[5115],{"nctId":5109,"briefTitle":5110,"status":113,"phases":10068,"primaryCompletion":498,"completion":498,"start":1266,"enrollment":5112,"conditions":10069,"interventions":10070},[90],[36],[1616,391,3603,5115,378],{"trials":10072,"activeCount":101},[],{"trials":10074,"activeCount":101},[],{"trials":10076,"activeCount":101},[],{"intervention":10078,"totalTrials":97,"cells":10079},"IO102\u002FIO103",{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10095,"PHASE4":10097,"NA":10099},{"trials":10081,"activeCount":101},[],{"trials":10083,"activeCount":101},[],{"trials":10085,"activeCount":97,"soonestReadout":10090},[10086],{"nctId":10087,"briefTitle":10088,"status":113,"phases":10089,"primaryCompletion":10090,"completion":10090,"start":10091,"enrollment":3017,"conditions":10092,"interventions":10093},"NCT05912244","A Study of IO102\u002FIO103, Nivolumab, and Relatlimab in People With Melanoma",[90],"2027-06-09","2023-06-09",[2341],[10078,10094],"Nivolumab-Relatlimab",{"trials":10096,"activeCount":101},[],{"trials":10098,"activeCount":101},[],{"trials":10100,"activeCount":101},[],{"intervention":10094,"totalTrials":97,"cells":10102},{"EARLY_PHASE1":10103,"PHASE1":10105,"PHASE2":10107,"PHASE3":10113,"PHASE4":10115,"NA":10117},{"trials":10104,"activeCount":101},[],{"trials":10106,"activeCount":101},[],{"trials":10108,"activeCount":97,"soonestReadout":10090},[10109],{"nctId":10087,"briefTitle":10088,"status":113,"phases":10110,"primaryCompletion":10090,"completion":10090,"start":10091,"enrollment":3017,"conditions":10111,"interventions":10112},[90],[2341],[10078,10094],{"trials":10114,"activeCount":101},[],{"trials":10116,"activeCount":101},[],{"trials":10118,"activeCount":101},[],{"intervention":10120,"totalTrials":97,"cells":10121},"Acute Normovolemic Hemodilution\u002FANH",{"EARLY_PHASE1":10122,"PHASE1":10124,"PHASE2":10126,"PHASE3":10143,"PHASE4":10145,"NA":10147},{"trials":10123,"activeCount":101},[],{"trials":10125,"activeCount":101},[],{"trials":10127,"activeCount":97,"soonestReadout":10132},[10128],{"nctId":10129,"briefTitle":10130,"status":158,"phases":10131,"primaryCompletion":10132,"completion":10132,"start":10133,"enrollment":1291,"conditions":10134,"interventions":10142},"NCT06290193","Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery",[90],"2029-02-23","2024-02-23",[30,10135,10136,10137,10138,10139,10140,10141,285,3437],"Fallopian Tube Carcinoma","Ovarian Carcinoma","Peritoneal Carcinoma","Ovarian Cancer Stage IIIC","Fallopian Tube Cancer Stage IIIC","Ovarian Cancer Stage IV","Fallopian Tube Cancer Stage IV",[10120],{"trials":10144,"activeCount":101},[],{"trials":10146,"activeCount":101},[],{"trials":10148,"activeCount":101},[],{"intervention":2683,"totalTrials":97,"cells":10150},{"EARLY_PHASE1":10151,"PHASE1":10153,"PHASE2":10155,"PHASE3":10161,"PHASE4":10163,"NA":10165},{"trials":10152,"activeCount":101},[],{"trials":10154,"activeCount":101},[],{"trials":10156,"activeCount":97,"soonestReadout":304},[10157],{"nctId":2673,"briefTitle":2674,"status":113,"phases":10158,"primaryCompletion":304,"completion":304,"start":2676,"enrollment":573,"conditions":10159,"interventions":10160},[90],[2678,2679],[2681,2682,2683],{"trials":10162,"activeCount":101},[],{"trials":10164,"activeCount":101},[],{"trials":10166,"activeCount":101},[],{"intervention":7019,"totalTrials":97,"cells":10168},{"EARLY_PHASE1":10169,"PHASE1":10171,"PHASE2":10173,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10170,"activeCount":101},[],{"trials":10172,"activeCount":101},[],{"trials":10174,"activeCount":97,"soonestReadout":7015},[10175],{"nctId":7012,"briefTitle":7013,"status":158,"phases":10176,"primaryCompletion":7015,"completion":7015,"start":7016,"enrollment":356,"conditions":10177,"interventions":10178},[90],[18],[7019,711],{"trials":10180,"activeCount":101},[],{"trials":10182,"activeCount":101},[],{"trials":10184,"activeCount":101},[],{"intervention":10186,"totalTrials":97,"cells":10187},"conditioning regimen",{"EARLY_PHASE1":10188,"PHASE1":10190,"PHASE2":10192,"PHASE3":10205,"PHASE4":10207,"NA":10209},{"trials":10189,"activeCount":101},[],{"trials":10191,"activeCount":101},[],{"trials":10193,"activeCount":97,"soonestReadout":304},[10194],{"nctId":10195,"briefTitle":10196,"status":113,"phases":10197,"primaryCompletion":304,"completion":304,"start":10198,"enrollment":4866,"conditions":10199,"interventions":10204},"NCT04761770","Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders",[90],"2021-02-15",[416,10200,10201,10202,10203],"Myeloproliferative Neoplasms","Chronic Myelomonocytic Leukemia","Atypical Chronic Myeloid Leukemia","Myelodysplastic\u002FMyeloproliferative Overlapping Syndrome",[10186],{"trials":10206,"activeCount":101},[],{"trials":10208,"activeCount":101},[],{"trials":10210,"activeCount":101},[],{"intervention":10212,"totalTrials":97,"cells":10213},"Isatuximab",{"EARLY_PHASE1":10214,"PHASE1":10216,"PHASE2":10218,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10215,"activeCount":101},[],{"trials":10217,"activeCount":101},[],{"trials":10219,"activeCount":97,"soonestReadout":10224},[10220],{"nctId":10221,"briefTitle":10222,"status":113,"phases":10223,"primaryCompletion":10224,"completion":10224,"start":10225,"enrollment":283,"conditions":10226,"interventions":10229},"NCT05873205","Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation",[90],"2027-06-29","2023-07-21",[10227,10228],"Blood Cancer","Refractory Immune Cytopenias",[10212],{"trials":10231,"activeCount":101},[],{"trials":10233,"activeCount":101},[],{"trials":10235,"activeCount":101},[],{"intervention":10237,"totalTrials":97,"cells":10238},"Eribulin",{"EARLY_PHASE1":10239,"PHASE1":10241,"PHASE2":10243,"PHASE3":10254,"PHASE4":10256,"NA":10258},{"trials":10240,"activeCount":101},[],{"trials":10242,"activeCount":101},[],{"trials":10244,"activeCount":97,"soonestReadout":194},[10245],{"nctId":10246,"briefTitle":10247,"status":158,"phases":10248,"primaryCompletion":194,"completion":194,"start":10249,"enrollment":34,"conditions":10250,"interventions":10252},"NCT05570253","A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer",[90],"2022-10-03",[15,10251],"Metastatic Triple-Negative Breast Cancer",[10237,10253],"SDX-7320",{"trials":10255,"activeCount":101},[],{"trials":10257,"activeCount":101},[],{"trials":10259,"activeCount":101},[],{"intervention":10253,"totalTrials":97,"cells":10261},{"EARLY_PHASE1":10262,"PHASE1":10264,"PHASE2":10266,"PHASE3":10272,"PHASE4":10274,"NA":10276},{"trials":10263,"activeCount":101},[],{"trials":10265,"activeCount":101},[],{"trials":10267,"activeCount":97,"soonestReadout":194},[10268],{"nctId":10246,"briefTitle":10247,"status":158,"phases":10269,"primaryCompletion":194,"completion":194,"start":10249,"enrollment":34,"conditions":10270,"interventions":10271},[90],[15,10251],[10237,10253],{"trials":10273,"activeCount":101},[],{"trials":10275,"activeCount":101},[],{"trials":10277,"activeCount":101},[],{"intervention":10279,"totalTrials":97,"cells":10280},"Flibanserin Pill",{"EARLY_PHASE1":10281,"PHASE1":10283,"PHASE2":10285,"PHASE3":10296,"PHASE4":10298,"NA":10300},{"trials":10282,"activeCount":101},[],{"trials":10284,"activeCount":101},[],{"trials":10286,"activeCount":97,"soonestReadout":10291},[10287],{"nctId":10288,"briefTitle":10289,"status":113,"phases":10290,"primaryCompletion":10291,"completion":10291,"start":10292,"enrollment":3017,"conditions":10293,"interventions":10295},"NCT03707340","A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors",[90],"2026-10-14","2018-09-14",[15,10294],"Hyposexual Desire Disorder",[10279],{"trials":10297,"activeCount":101},[],{"trials":10299,"activeCount":101},[],{"trials":10301,"activeCount":101},[],{"intervention":1297,"totalTrials":97,"cells":10303},{"EARLY_PHASE1":10304,"PHASE1":10306,"PHASE2":10308,"PHASE3":10314,"PHASE4":10316,"NA":10318},{"trials":10305,"activeCount":101},[],{"trials":10307,"activeCount":101},[],{"trials":10309,"activeCount":97,"soonestReadout":1290},[10310],{"nctId":1287,"briefTitle":1288,"status":158,"phases":10311,"primaryCompletion":1290,"completion":1290,"start":61,"enrollment":1291,"conditions":10312,"interventions":10313},[90],[1293],[1295,1296,1297,465],{"trials":10315,"activeCount":101},[],{"trials":10317,"activeCount":101},[],{"trials":10319,"activeCount":101},[],{"intervention":2375,"totalTrials":97,"cells":10321},{"EARLY_PHASE1":10322,"PHASE1":10324,"PHASE2":10326,"PHASE3":10332,"PHASE4":10334,"NA":10336},{"trials":10323,"activeCount":101},[],{"trials":10325,"activeCount":101},[],{"trials":10327,"activeCount":97,"soonestReadout":2038},[10328],{"nctId":2366,"briefTitle":2367,"status":158,"phases":10329,"primaryCompletion":2038,"completion":2038,"start":2369,"enrollment":356,"conditions":10330,"interventions":10331},[90],[33,2371,2372,2373],[42,2375],{"trials":10333,"activeCount":101},[],{"trials":10335,"activeCount":101},[],{"trials":10337,"activeCount":101},[],{"intervention":10339,"totalTrials":97,"cells":10340},"[18F]- PARPi",{"EARLY_PHASE1":10341,"PHASE1":10343,"PHASE2":10345,"PHASE3":10354,"PHASE4":10356,"NA":10358},{"trials":10342,"activeCount":101},[],{"trials":10344,"activeCount":101},[],{"trials":10346,"activeCount":97,"soonestReadout":324},[10347],{"nctId":10348,"briefTitle":10349,"status":113,"phases":10350,"primaryCompletion":324,"completion":324,"start":10351,"enrollment":283,"conditions":10352,"interventions":10353},"NCT03631017","Imaging With a PET Agent for Detection of Cancers of the Head and Neck",[89,90],"2018-08-10",[1586],[10339],{"trials":10355,"activeCount":101},[],{"trials":10357,"activeCount":101},[],{"trials":10359,"activeCount":101},[],{"intervention":10361,"totalTrials":97,"cells":10362},"IgPro20",{"EARLY_PHASE1":10363,"PHASE1":10365,"PHASE2":10367,"PHASE3":10379,"PHASE4":10381,"NA":10383},{"trials":10364,"activeCount":101},[],{"trials":10366,"activeCount":101},[],{"trials":10368,"activeCount":97,"soonestReadout":10373},[10369],{"nctId":10370,"briefTitle":10371,"status":158,"phases":10372,"primaryCompletion":10373,"completion":10373,"start":10374,"enrollment":3814,"conditions":10375,"interventions":10378},"NCT06976476","Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia",[90],"2029-05-08","2025-05-08",[308,10376,10377],"Hypogammaglobulinemia","Hypogammaglobulinemia, Acquired",[10361],{"trials":10380,"activeCount":101},[],{"trials":10382,"activeCount":101},[],{"trials":10384,"activeCount":101},[],{"intervention":7972,"totalTrials":97,"cells":10386},{"EARLY_PHASE1":10387,"PHASE1":10389,"PHASE2":10391,"PHASE3":10397,"PHASE4":10399,"NA":10401},{"trials":10388,"activeCount":101},[],{"trials":10390,"activeCount":101},[],{"trials":10392,"activeCount":97,"soonestReadout":7966},[10393],{"nctId":7963,"briefTitle":7964,"status":158,"phases":10394,"primaryCompletion":7966,"completion":7966,"start":7967,"enrollment":2334,"conditions":10395,"interventions":10396},[89,90],[3094,7969,7970],[7972,3246],{"trials":10398,"activeCount":101},[],{"trials":10400,"activeCount":101},[],{"trials":10402,"activeCount":101},[],{"intervention":4986,"totalTrials":97,"cells":10404},{"EARLY_PHASE1":10405,"PHASE1":10407,"PHASE2":10409,"PHASE3":10415,"PHASE4":10417,"NA":10419},{"trials":10406,"activeCount":101},[],{"trials":10408,"activeCount":101},[],{"trials":10410,"activeCount":97,"soonestReadout":1208},[10411],{"nctId":4979,"briefTitle":4980,"status":158,"phases":10412,"primaryCompletion":1208,"completion":1208,"start":4982,"enrollment":4983,"conditions":10413,"interventions":10414},[89,90],[1695],[4961,4986,3509],{"trials":10416,"activeCount":101},[],{"trials":10418,"activeCount":101},[],{"trials":10420,"activeCount":101},[],{"intervention":4220,"totalTrials":97,"cells":10422},{"EARLY_PHASE1":10423,"PHASE1":10425,"PHASE2":10427,"PHASE3":10433,"PHASE4":10435,"NA":10437},{"trials":10424,"activeCount":101},[],{"trials":10426,"activeCount":101},[],{"trials":10428,"activeCount":97,"soonestReadout":232},[10429],{"nctId":4214,"briefTitle":4215,"status":113,"phases":10430,"primaryCompletion":232,"completion":232,"start":4217,"enrollment":2462,"conditions":10431,"interventions":10432},[90],[2948],[4220,52,4221],{"trials":10434,"activeCount":101},[],{"trials":10436,"activeCount":101},[],{"trials":10438,"activeCount":101},[],{"intervention":5414,"totalTrials":97,"cells":10440},{"EARLY_PHASE1":10441,"PHASE1":10443,"PHASE2":10445,"PHASE3":10451,"PHASE4":10453,"NA":10455},{"trials":10442,"activeCount":101},[],{"trials":10444,"activeCount":101},[],{"trials":10446,"activeCount":97,"soonestReadout":3072},[10447],{"nctId":5407,"briefTitle":5408,"status":5409,"phases":10448,"primaryCompletion":3072,"completion":3072,"start":232,"enrollment":908,"conditions":10449,"interventions":10450},[90],[5412],[1594,5414],{"trials":10452,"activeCount":101},[],{"trials":10454,"activeCount":101},[],{"trials":10456,"activeCount":101},[],{"intervention":10458,"totalTrials":97,"cells":10459},"Etrumadenant",{"EARLY_PHASE1":10460,"PHASE1":10462,"PHASE2":10464,"PHASE3":10477,"PHASE4":10479,"NA":10481},{"trials":10461,"activeCount":101},[],{"trials":10463,"activeCount":101},[],{"trials":10465,"activeCount":97,"soonestReadout":10470},[10466],{"nctId":10467,"briefTitle":10468,"status":113,"phases":10469,"primaryCompletion":10470,"completion":10470,"start":10471,"enrollment":1447,"conditions":10472,"interventions":10475},"NCT05886634","A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma",[90],"2027-05-23","2023-05-23",[4868,1176,1177,33,10473,6682,10474],"Recurrent Dedifferentiated Liposarcoma","Metastatic Dedifferentiated Liposarcoma",[10458,10476],"Zimberelimab",{"trials":10478,"activeCount":101},[],{"trials":10480,"activeCount":101},[],{"trials":10482,"activeCount":101},[],{"intervention":10476,"totalTrials":97,"cells":10484},{"EARLY_PHASE1":10485,"PHASE1":10487,"PHASE2":10489,"PHASE3":10495,"PHASE4":10497,"NA":10499},{"trials":10486,"activeCount":101},[],{"trials":10488,"activeCount":101},[],{"trials":10490,"activeCount":97,"soonestReadout":10470},[10491],{"nctId":10467,"briefTitle":10468,"status":113,"phases":10492,"primaryCompletion":10470,"completion":10470,"start":10471,"enrollment":1447,"conditions":10493,"interventions":10494},[90],[4868,1176,1177,33,10473,6682,10474],[10458,10476],{"trials":10496,"activeCount":101},[],{"trials":10498,"activeCount":101},[],{"trials":10500,"activeCount":101},[],{"intervention":10502,"totalTrials":97,"cells":10503},"sorafenib with everolimus",{"EARLY_PHASE1":10504,"PHASE1":10506,"PHASE2":10508,"PHASE3":10516,"PHASE4":10518,"NA":10520},{"trials":10505,"activeCount":101},[],{"trials":10507,"activeCount":101},[],{"trials":10509,"activeCount":97,"soonestReadout":258},[10510],{"nctId":10511,"briefTitle":10512,"status":113,"phases":10513,"primaryCompletion":258,"completion":258,"start":316,"enrollment":2462,"conditions":10514,"interventions":10515},"NCT01141309","Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer",[90],[4054],[10502],{"trials":10517,"activeCount":101},[],{"trials":10519,"activeCount":101},[],{"trials":10521,"activeCount":101},[],{"intervention":10523,"totalTrials":97,"cells":10524},"Bumetanide",{"EARLY_PHASE1":10525,"PHASE1":10527,"PHASE2":10529,"PHASE3":10540,"PHASE4":10542,"NA":10544},{"trials":10526,"activeCount":101},[],{"trials":10528,"activeCount":101},[],{"trials":10530,"activeCount":97,"soonestReadout":10535},[10531],{"nctId":10532,"briefTitle":10533,"status":113,"phases":10534,"primaryCompletion":10535,"completion":10535,"start":10536,"enrollment":356,"conditions":10537,"interventions":10539},"NCT03107416","Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells",[89,90],"2027-04-05","2017-04-05",[10538],"Unresectable Hepatocellular Carcinoma",[10523],{"trials":10541,"activeCount":101},[],{"trials":10543,"activeCount":101},[],{"trials":10545,"activeCount":101},[],{"intervention":10547,"totalTrials":97,"cells":10548},"Anti-PD-(L)1 based immunotherapy",{"EARLY_PHASE1":10549,"PHASE1":10551,"PHASE2":10553,"PHASE3":10567,"PHASE4":10569,"NA":10571},{"trials":10550,"activeCount":101},[],{"trials":10552,"activeCount":101},[],{"trials":10554,"activeCount":97,"soonestReadout":10559},[10555],{"nctId":10556,"briefTitle":10557,"status":158,"phases":10558,"primaryCompletion":10559,"completion":10559,"start":10560,"enrollment":10561,"conditions":10562,"interventions":10565},"NCT05657873","A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)",[90],"2026-12-09","2022-12-09",68,[3094,6007,10563,4244,10564],"Non-small Cell Carcinoma","NSCLC Stage IV",[10547,10566],"Platinum based chemotherapy",{"trials":10568,"activeCount":101},[],{"trials":10570,"activeCount":101},[],{"trials":10572,"activeCount":101},[],{"intervention":10566,"totalTrials":97,"cells":10574},{"EARLY_PHASE1":10575,"PHASE1":10577,"PHASE2":10579,"PHASE3":10585,"PHASE4":10587,"NA":10589},{"trials":10576,"activeCount":101},[],{"trials":10578,"activeCount":101},[],{"trials":10580,"activeCount":97,"soonestReadout":10559},[10581],{"nctId":10556,"briefTitle":10557,"status":158,"phases":10582,"primaryCompletion":10559,"completion":10559,"start":10560,"enrollment":10561,"conditions":10583,"interventions":10584},[90],[3094,6007,10563,4244,10564],[10547,10566],{"trials":10586,"activeCount":101},[],{"trials":10588,"activeCount":101},[],{"trials":10590,"activeCount":101},[],{"intervention":10592,"totalTrials":97,"cells":10593},"Emapalumab",{"EARLY_PHASE1":10594,"PHASE1":10596,"PHASE2":10598,"PHASE3":10611,"PHASE4":10613,"NA":10615},{"trials":10595,"activeCount":101},[],{"trials":10597,"activeCount":101},[],{"trials":10599,"activeCount":97,"soonestReadout":10604},[10600],{"nctId":10601,"briefTitle":10602,"status":158,"phases":10603,"primaryCompletion":10604,"completion":10604,"start":10605,"enrollment":1052,"conditions":10606,"interventions":10610},"NCT06430788","A Study of Emapalumab for Pediatric Aplastic Anemia",[90],"2029-05-21","2024-05-21",[10607,10608,10609],"Aplastic Anemia","Cytopenia","Hypocellular Marrow",[10592],{"trials":10612,"activeCount":101},[],{"trials":10614,"activeCount":101},[],{"trials":10616,"activeCount":101},[],{"intervention":10618,"totalTrials":97,"cells":10619},"Vericiguat",{"EARLY_PHASE1":10620,"PHASE1":10622,"PHASE2":10624,"PHASE3":10635,"PHASE4":10637,"NA":10639},{"trials":10621,"activeCount":101},[],{"trials":10623,"activeCount":101},[],{"trials":10625,"activeCount":97,"soonestReadout":10630},[10626],{"nctId":10627,"briefTitle":10628,"status":113,"phases":10629,"primaryCompletion":10630,"completion":10630,"start":10631,"enrollment":899,"conditions":10632,"interventions":10634},"NCT05806138","A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction",[90],"2028-07-17","2023-07-17",[15,10633],"Cardiac Dysfunction",[10618],{"trials":10636,"activeCount":101},[],{"trials":10638,"activeCount":101},[],{"trials":10640,"activeCount":101},[],{"intervention":10642,"totalTrials":97,"cells":10643},"fluorescent cRGDY-PEG-Cy5.5-C dots",{"EARLY_PHASE1":10644,"PHASE1":10646,"PHASE2":10648,"PHASE3":10659,"PHASE4":10661,"NA":10663},{"trials":10645,"activeCount":101},[],{"trials":10647,"activeCount":101},[],{"trials":10649,"activeCount":97,"soonestReadout":531},[10650],{"nctId":10651,"briefTitle":10652,"status":113,"phases":10653,"primaryCompletion":531,"completion":531,"start":10654,"enrollment":10655,"conditions":10656,"interventions":10658},"NCT02106598","Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases",[89,90],"2014-04-03",67,[10657],"Head and Neck Melanoma",[10642],{"trials":10660,"activeCount":101},[],{"trials":10662,"activeCount":101},[],{"trials":10664,"activeCount":101},[],{"intervention":10666,"totalTrials":97,"cells":10667},"ERAS-601",{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10672,"PHASE3":10682,"PHASE4":10684,"NA":10686},{"trials":10669,"activeCount":101},[],{"trials":10671,"activeCount":101},[],{"trials":10673,"activeCount":97,"soonestReadout":531},[10674],{"nctId":10675,"briefTitle":10676,"status":113,"phases":10677,"primaryCompletion":531,"completion":531,"start":10678,"enrollment":283,"conditions":10679,"interventions":10681},"NCT06957327","A Study of ERAS-601 in People With Chordoma",[89,90],"2025-04-25",[10680],"Chordoma",[10666],{"trials":10683,"activeCount":101},[],{"trials":10685,"activeCount":101},[],{"trials":10687,"activeCount":101},[],{"intervention":10689,"totalTrials":97,"cells":10690},"Hu3F8 With GM-CSF",{"EARLY_PHASE1":10691,"PHASE1":10693,"PHASE2":10695,"PHASE3":10703,"PHASE4":10705,"NA":10707},{"trials":10692,"activeCount":101},[],{"trials":10694,"activeCount":101},[],{"trials":10696,"activeCount":97,"soonestReadout":498},[10697],{"nctId":10698,"briefTitle":10699,"status":113,"phases":10700,"primaryCompletion":498,"completion":498,"start":704,"enrollment":260,"conditions":10701,"interventions":10702},"NCT01757626","Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed\u002FRefractory High-Risk Neuroblastoma",[89,90],[215],[10689,10689],{"trials":10704,"activeCount":101},[],{"trials":10706,"activeCount":101},[],{"trials":10708,"activeCount":101},[],{"intervention":10710,"totalTrials":97,"cells":10711},"Dostarlimab",{"EARLY_PHASE1":10712,"PHASE1":10714,"PHASE2":10716,"PHASE3":10725,"PHASE4":10727,"NA":10729},{"trials":10713,"activeCount":101},[],{"trials":10715,"activeCount":101},[],{"trials":10717,"activeCount":97,"soonestReadout":304},[10718],{"nctId":10719,"briefTitle":10720,"status":158,"phases":10721,"primaryCompletion":304,"completion":304,"start":10722,"enrollment":2888,"conditions":10723,"interventions":10724},"NCT04774419","Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery",[90],"2021-04-02",[3359],[10710],{"trials":10726,"activeCount":101},[],{"trials":10728,"activeCount":101},[],{"trials":10730,"activeCount":101},[],{"intervention":3081,"totalTrials":97,"cells":10732},{"EARLY_PHASE1":10733,"PHASE1":10735,"PHASE2":10737,"PHASE3":10743,"PHASE4":10745,"NA":10747},{"trials":10734,"activeCount":101},[],{"trials":10736,"activeCount":101},[],{"trials":10738,"activeCount":97,"soonestReadout":3072},[10739],{"nctId":3069,"briefTitle":3070,"status":158,"phases":10740,"primaryCompletion":3072,"completion":3073,"start":3074,"enrollment":341,"conditions":10741,"interventions":10742},[90],[3076,3077],[579,221,974,3079,3080,3081,1087,222],{"trials":10744,"activeCount":101},[],{"trials":10746,"activeCount":101},[],{"trials":10748,"activeCount":101},[],{"intervention":462,"totalTrials":97,"cells":10750},{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10755,"PHASE3":10761,"PHASE4":10763,"NA":10765},{"trials":10752,"activeCount":101},[],{"trials":10754,"activeCount":101},[],{"trials":10756,"activeCount":97,"soonestReadout":452},[10757],{"nctId":449,"briefTitle":450,"status":158,"phases":10758,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":10759,"interventions":10760},[90],[456,457,458],[331,218,460,461,462,463,464,465],{"trials":10762,"activeCount":101},[],{"trials":10764,"activeCount":101},[],{"trials":10766,"activeCount":101},[],{"intervention":5366,"totalTrials":97,"cells":10768},{"EARLY_PHASE1":10769,"PHASE1":10771,"PHASE2":10773,"PHASE3":10779,"PHASE4":10781,"NA":10783},{"trials":10770,"activeCount":101},[],{"trials":10772,"activeCount":101},[],{"trials":10774,"activeCount":97,"soonestReadout":85},[10775],{"nctId":83,"briefTitle":84,"status":113,"phases":10776,"primaryCompletion":85,"completion":1469,"start":5362,"enrollment":1232,"conditions":10777,"interventions":10778},[90],[2030],[86,5365,577,5366,5367],{"trials":10780,"activeCount":101},[],{"trials":10782,"activeCount":101},[],{"trials":10784,"activeCount":101},[],{"intervention":5830,"totalTrials":97,"cells":10786},{"EARLY_PHASE1":10787,"PHASE1":10789,"PHASE2":10791,"PHASE3":10797,"PHASE4":10799,"NA":10801},{"trials":10788,"activeCount":101},[],{"trials":10790,"activeCount":101},[],{"trials":10792,"activeCount":97,"soonestReadout":2005},[10793],{"nctId":5824,"briefTitle":5825,"status":158,"phases":10794,"primaryCompletion":2005,"completion":2005,"start":5827,"enrollment":370,"conditions":10795,"interventions":10796},[89,90],[18],[5830,5831,5367],{"trials":10798,"activeCount":101},[],{"trials":10800,"activeCount":101},[],{"trials":10802,"activeCount":101},[],{"intervention":5831,"totalTrials":97,"cells":10804},{"EARLY_PHASE1":10805,"PHASE1":10807,"PHASE2":10809,"PHASE3":10815,"PHASE4":10817,"NA":10819},{"trials":10806,"activeCount":101},[],{"trials":10808,"activeCount":101},[],{"trials":10810,"activeCount":97,"soonestReadout":2005},[10811],{"nctId":5824,"briefTitle":5825,"status":158,"phases":10812,"primaryCompletion":2005,"completion":2005,"start":5827,"enrollment":370,"conditions":10813,"interventions":10814},[89,90],[18],[5830,5831,5367],{"trials":10816,"activeCount":101},[],{"trials":10818,"activeCount":101},[],{"trials":10820,"activeCount":101},[],{"intervention":1326,"totalTrials":97,"cells":10822},{"EARLY_PHASE1":10823,"PHASE1":10825,"PHASE2":10827,"PHASE3":10833,"PHASE4":10835,"NA":10837},{"trials":10824,"activeCount":101},[],{"trials":10826,"activeCount":101},[],{"trials":10828,"activeCount":97,"soonestReadout":1320},[10829],{"nctId":1317,"briefTitle":1318,"status":158,"phases":10830,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":718,"conditions":10831,"interventions":10832},[90],[1323,1324],[1326,1327,465],{"trials":10834,"activeCount":101},[],{"trials":10836,"activeCount":101},[],{"trials":10838,"activeCount":101},[],{"intervention":10840,"totalTrials":97,"cells":10841},"Isoquercetin",{"EARLY_PHASE1":10842,"PHASE1":10844,"PHASE2":10846,"PHASE3":10858,"PHASE4":10860,"NA":10862},{"trials":10843,"activeCount":101},[],{"trials":10845,"activeCount":101},[],{"trials":10847,"activeCount":97,"soonestReadout":10852},[10848],{"nctId":10849,"briefTitle":10850,"status":158,"phases":10851,"primaryCompletion":10852,"completion":10852,"start":2725,"enrollment":10853,"conditions":10854,"interventions":10857},"NCT07303894","A Study of Isoquercetin in People With Ovarian Cancer",[90],"2032-01",90,[30,10855,10856],"Epithelial Ovarian Cancer","Serous Ovarian Tumor",[10840],{"trials":10859,"activeCount":101},[],{"trials":10861,"activeCount":101},[],{"trials":10863,"activeCount":101},[],{"intervention":9136,"totalTrials":97,"cells":10865},{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10870,"PHASE3":10876,"PHASE4":10878,"NA":10880},{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[],{"trials":10871,"activeCount":97,"soonestReadout":304},[10872],{"nctId":9127,"briefTitle":9128,"status":113,"phases":10873,"primaryCompletion":304,"completion":304,"start":9130,"enrollment":9131,"conditions":10874,"interventions":10875},[90],[9133,9134],[9118,9136],{"trials":10877,"activeCount":101},[],{"trials":10879,"activeCount":101},[],{"trials":10881,"activeCount":101},[],{"intervention":492,"totalTrials":97,"cells":10883},{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10894,"PHASE4":10896,"NA":10898},{"trials":10885,"activeCount":101},[],{"trials":10887,"activeCount":101},[],{"trials":10889,"activeCount":97,"soonestReadout":484},[10890],{"nctId":481,"briefTitle":482,"status":158,"phases":10891,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":10892,"interventions":10893},[90],[488,489],[491,492,465,218,221,493],{"trials":10895,"activeCount":101},[],{"trials":10897,"activeCount":101},[],{"trials":10899,"activeCount":101},[],{"intervention":493,"totalTrials":97,"cells":10901},{"EARLY_PHASE1":10902,"PHASE1":10904,"PHASE2":10906,"PHASE3":10912,"PHASE4":10914,"NA":10916},{"trials":10903,"activeCount":101},[],{"trials":10905,"activeCount":101},[],{"trials":10907,"activeCount":97,"soonestReadout":484},[10908],{"nctId":481,"briefTitle":482,"status":158,"phases":10909,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":10910,"interventions":10911},[90],[488,489],[491,492,465,218,221,493],{"trials":10913,"activeCount":101},[],{"trials":10915,"activeCount":101},[],{"trials":10917,"activeCount":101},[],{"intervention":3428,"totalTrials":97,"cells":10919},{"EARLY_PHASE1":10920,"PHASE1":10922,"PHASE2":10924,"PHASE3":10930,"PHASE4":10932,"NA":10934},{"trials":10921,"activeCount":101},[],{"trials":10923,"activeCount":101},[],{"trials":10925,"activeCount":97,"soonestReadout":3422},[10926],{"nctId":3419,"briefTitle":3420,"status":158,"phases":10927,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":10928,"interventions":10929},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"trials":10931,"activeCount":101},[],{"trials":10933,"activeCount":101},[],{"trials":10935,"activeCount":101},[],{"intervention":3429,"totalTrials":97,"cells":10937},{"EARLY_PHASE1":10938,"PHASE1":10940,"PHASE2":10942,"PHASE3":10948,"PHASE4":10950,"NA":10952},{"trials":10939,"activeCount":101},[],{"trials":10941,"activeCount":101},[],{"trials":10943,"activeCount":97,"soonestReadout":3422},[10944],{"nctId":3419,"briefTitle":3420,"status":158,"phases":10945,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":341,"conditions":10946,"interventions":10947},[90],[3425,215,3426],[3428,2649,3429,219,220,221,222,223,224,819,818],{"trials":10949,"activeCount":101},[],{"trials":10951,"activeCount":101},[],{"trials":10953,"activeCount":101},[],{"intervention":10955,"totalTrials":97,"cells":10956},"Fluorescein Sodium",{"EARLY_PHASE1":10957,"PHASE1":10959,"PHASE2":10961,"PHASE3":10971,"PHASE4":10973,"NA":10975},{"trials":10958,"activeCount":101},[],{"trials":10960,"activeCount":101},[],{"trials":10962,"activeCount":97,"soonestReadout":990},[10963],{"nctId":10964,"briefTitle":10965,"status":158,"phases":10966,"primaryCompletion":990,"completion":990,"start":10967,"enrollment":1600,"conditions":10968,"interventions":10970},"NCT06873815","A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)",[90],"2025-03-07",[10969],"Extramammary Paget's Disease",[10955],{"trials":10972,"activeCount":101},[],{"trials":10974,"activeCount":101},[],{"trials":10976,"activeCount":101},[],{"intervention":3116,"totalTrials":97,"cells":10978},{"EARLY_PHASE1":10979,"PHASE1":10981,"PHASE2":10983,"PHASE3":10989,"PHASE4":10991,"NA":10993},{"trials":10980,"activeCount":101},[],{"trials":10982,"activeCount":101},[],{"trials":10984,"activeCount":97,"soonestReadout":1130},[10985],{"nctId":3110,"briefTitle":3111,"status":113,"phases":10986,"primaryCompletion":1130,"completion":1130,"start":3113,"enrollment":1114,"conditions":10987,"interventions":10988},[90],[1586],[3116,974],{"trials":10990,"activeCount":101},[],{"trials":10992,"activeCount":101},[],{"trials":10994,"activeCount":101},[],{"intervention":10996,"totalTrials":97,"cells":10997},"Ensartinib",{"EARLY_PHASE1":10998,"PHASE1":11000,"PHASE2":11002,"PHASE3":11011,"PHASE4":11013,"NA":11015},{"trials":10999,"activeCount":101},[],{"trials":11001,"activeCount":101},[],{"trials":11003,"activeCount":97,"soonestReadout":2472},[11004],{"nctId":11005,"briefTitle":11006,"status":113,"phases":11007,"primaryCompletion":2472,"completion":2472,"start":11008,"enrollment":326,"conditions":11009,"interventions":11010},"NCT03420508","Treating Patients With Melanoma and ALK Alterations With Ensartinib",[90],"2018-01-10",[2341],[10996],{"trials":11012,"activeCount":101},[],{"trials":11014,"activeCount":101},[],{"trials":11016,"activeCount":101},[],{"intervention":11018,"totalTrials":97,"cells":11019},"topical ruxolitinib 1.5% cream",{"EARLY_PHASE1":11020,"PHASE1":11022,"PHASE2":11024,"PHASE3":11035,"PHASE4":11037,"NA":11039},{"trials":11021,"activeCount":101},[],{"trials":11023,"activeCount":101},[],{"trials":11025,"activeCount":97,"soonestReadout":11030},[11026],{"nctId":11027,"briefTitle":11028,"status":113,"phases":11029,"primaryCompletion":11030,"completion":11030,"start":11031,"enrollment":454,"conditions":11032,"interventions":11034},"NCT03954236","Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease",[90],"2027-02-06","2019-05-14",[11033],"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease",[11018],{"trials":11036,"activeCount":101},[],{"trials":11038,"activeCount":101},[],{"trials":11040,"activeCount":101},[],{"intervention":11042,"totalTrials":97,"cells":11043},"TSR-042 or Dostarlimab",{"EARLY_PHASE1":11044,"PHASE1":11046,"PHASE2":11048,"PHASE3":11062,"PHASE4":11064,"NA":11066},{"trials":11045,"activeCount":101},[],{"trials":11047,"activeCount":101},[],{"trials":11049,"activeCount":97,"soonestReadout":11054},[11050],{"nctId":11051,"briefTitle":11052,"status":158,"phases":11053,"primaryCompletion":11054,"completion":11054,"start":11055,"enrollment":11056,"conditions":11057,"interventions":11060},"NCT04165772","Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",[90],"2026-11-30","2019-12-11",212,[7483,11058,11059,2351,6266],"Clinical Stage: Stage II (T3-4, N-)","Stage III (Any T, N+)",[11042,11061],"capecitabine or 5-FU",{"trials":11063,"activeCount":101},[],{"trials":11065,"activeCount":101},[],{"trials":11067,"activeCount":101},[],{"intervention":11061,"totalTrials":97,"cells":11069},{"EARLY_PHASE1":11070,"PHASE1":11072,"PHASE2":11074,"PHASE3":11080,"PHASE4":11082,"NA":11084},{"trials":11071,"activeCount":101},[],{"trials":11073,"activeCount":101},[],{"trials":11075,"activeCount":97,"soonestReadout":11054},[11076],{"nctId":11051,"briefTitle":11052,"status":158,"phases":11077,"primaryCompletion":11054,"completion":11054,"start":11055,"enrollment":11056,"conditions":11078,"interventions":11079},[90],[7483,11058,11059,2351,6266],[11042,11061],{"trials":11081,"activeCount":101},[],{"trials":11083,"activeCount":101},[],{"trials":11085,"activeCount":101},[],{"intervention":11087,"totalTrials":97,"cells":11088},"ado-trastuzumab emtansine",{"EARLY_PHASE1":11089,"PHASE1":11091,"PHASE2":11093,"PHASE3":11104,"PHASE4":11106,"NA":11108},{"trials":11090,"activeCount":101},[],{"trials":11092,"activeCount":101},[],{"trials":11094,"activeCount":97,"soonestReadout":304},[11095],{"nctId":11096,"briefTitle":11097,"status":113,"phases":11098,"primaryCompletion":304,"completion":304,"start":1092,"enrollment":11099,"conditions":11100,"interventions":11103},"NCT02675829","Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers",[90],131,[11101,21,971,11102],"Solid Tumor Cancers","Urinary Tract Cancers",[11087],{"trials":11105,"activeCount":101},[],{"trials":11107,"activeCount":101},[],{"trials":11109,"activeCount":101},[],{"intervention":4558,"totalTrials":97,"cells":11111},{"EARLY_PHASE1":11112,"PHASE1":11114,"PHASE2":11116,"PHASE3":11122,"PHASE4":11124,"NA":11126},{"trials":11113,"activeCount":101},[],{"trials":11115,"activeCount":101},[],{"trials":11117,"activeCount":97,"soonestReadout":4552},[11118],{"nctId":4549,"briefTitle":4550,"status":113,"phases":11119,"primaryCompletion":4552,"completion":4552,"start":4553,"enrollment":899,"conditions":11120,"interventions":11121},[90],[4555,4556,308],[4558,1261],{"trials":11123,"activeCount":101},[],{"trials":11125,"activeCount":101},[],{"trials":11127,"activeCount":101},[],{"intervention":11129,"totalTrials":97,"cells":11130},"iobenguane I 131",{"EARLY_PHASE1":11131,"PHASE1":11133,"PHASE2":11135,"PHASE3":11145,"PHASE4":11147,"NA":11149},{"trials":11132,"activeCount":101},[],{"trials":11134,"activeCount":101},[],{"trials":11136,"activeCount":97,"soonestReadout":812},[11137],{"nctId":11138,"briefTitle":11139,"status":158,"phases":11140,"primaryCompletion":812,"completion":812,"start":1151,"enrollment":11141,"conditions":11142,"interventions":11144},"NCT00107289","Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma",[90],200,[215,11143],"Pheochromocytoma",[11129],{"trials":11146,"activeCount":101},[],{"trials":11148,"activeCount":101},[],{"trials":11150,"activeCount":101},[],{"intervention":11152,"totalTrials":97,"cells":11153},"Plinabulin",{"EARLY_PHASE1":11154,"PHASE1":11156,"PHASE2":11158,"PHASE3":11167,"PHASE4":11169,"NA":11171},{"trials":11155,"activeCount":101},[],{"trials":11157,"activeCount":101},[],{"trials":11159,"activeCount":97,"soonestReadout":1130},[11160],{"nctId":11161,"briefTitle":11162,"status":113,"phases":11163,"primaryCompletion":1130,"completion":1130,"start":11164,"enrollment":234,"conditions":11165,"interventions":11166},"NCT05130827","Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)",[90],"2021-12-21",[308],[11152],{"trials":11168,"activeCount":101},[],{"trials":11170,"activeCount":101},[],{"trials":11172,"activeCount":101},[],{"intervention":9929,"totalTrials":97,"cells":11174},{"EARLY_PHASE1":11175,"PHASE1":11177,"PHASE2":11179,"PHASE3":11185,"PHASE4":11187,"NA":11189},{"trials":11176,"activeCount":101},[],{"trials":11178,"activeCount":101},[],{"trials":11180,"activeCount":97,"soonestReadout":812},[11181],{"nctId":9922,"briefTitle":9923,"status":158,"phases":11182,"primaryCompletion":812,"completion":812,"start":9925,"enrollment":306,"conditions":11183,"interventions":11184},[90],[9927],[9929,9913],{"trials":11186,"activeCount":101},[],{"trials":11188,"activeCount":101},[],{"trials":11190,"activeCount":101},[],{"intervention":11192,"totalTrials":97,"cells":11193},"131 I-omburtamab",{"EARLY_PHASE1":11194,"PHASE1":11196,"PHASE2":11198,"PHASE3":11207,"PHASE4":11209,"NA":11211},{"trials":11195,"activeCount":101},[],{"trials":11197,"activeCount":101},[],{"trials":11199,"activeCount":97,"soonestReadout":2082},[11200],{"nctId":11201,"briefTitle":11202,"status":113,"phases":11203,"primaryCompletion":2082,"completion":2082,"start":11204,"enrollment":473,"conditions":11205,"interventions":11206},"NCT04022213","A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum",[90],"2019-07-15",[6529,3437,10137],[11192],{"trials":11208,"activeCount":101},[],{"trials":11210,"activeCount":101},[],{"trials":11212,"activeCount":101},[],{"intervention":11214,"totalTrials":97,"cells":11215},"Neoadjuvant endocrine therapy",{"EARLY_PHASE1":11216,"PHASE1":11218,"PHASE2":11220,"PHASE3":11232,"PHASE4":11234,"NA":11236},{"trials":11217,"activeCount":101},[],{"trials":11219,"activeCount":101},[],{"trials":11221,"activeCount":97,"soonestReadout":11226},[11222],{"nctId":11223,"briefTitle":11224,"status":158,"phases":11225,"primaryCompletion":11226,"completion":11226,"start":11227,"enrollment":11228,"conditions":11229,"interventions":11231},"NCT07483307","A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer",[90],"2030-03-13","2026-03-13",176,[15,4857,4858,11230],"ER+ Breast Cancer",[11214],{"trials":11233,"activeCount":101},[],{"trials":11235,"activeCount":101},[],{"trials":11237,"activeCount":101},[],{"intervention":5263,"totalTrials":97,"cells":11239},{"EARLY_PHASE1":11240,"PHASE1":11242,"PHASE2":11244,"PHASE3":11250,"PHASE4":11252,"NA":11254},{"trials":11241,"activeCount":101},[],{"trials":11243,"activeCount":101},[],{"trials":11245,"activeCount":97,"soonestReadout":5247},[11246],{"nctId":5244,"briefTitle":5245,"status":113,"phases":11247,"primaryCompletion":5247,"completion":5247,"start":1674,"enrollment":306,"conditions":11248,"interventions":11249},[90],[5249,5250,5251,5252,5253,5254,5255,5256,5257,5258,5259,5260,5261],[5263,5264,5265,3246,1595],{"trials":11251,"activeCount":101},[],{"trials":11253,"activeCount":101},[],{"trials":11255,"activeCount":101},[],{"intervention":11257,"totalTrials":97,"cells":11258},"ASTX727",{"EARLY_PHASE1":11259,"PHASE1":11261,"PHASE2":11263,"PHASE3":11273,"PHASE4":11275,"NA":11277},{"trials":11260,"activeCount":101},[],{"trials":11262,"activeCount":101},[],{"trials":11264,"activeCount":97,"soonestReadout":531},[11265],{"nctId":11266,"briefTitle":11267,"status":158,"phases":11268,"primaryCompletion":531,"completion":531,"start":11269,"enrollment":438,"conditions":11270,"interventions":11272},"NCT04872543","A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)",[90],"2021-04-29",[11271],"Malignant Peripheral Nerve Sheath Tumors (MPNST)",[11257],{"trials":11274,"activeCount":101},[],{"trials":11276,"activeCount":101},[],{"trials":11278,"activeCount":101},[],{"intervention":11280,"totalTrials":97,"cells":11281},"Dara-RVd",{"EARLY_PHASE1":11282,"PHASE1":11284,"PHASE2":11286,"PHASE3":11296,"PHASE4":11298,"NA":11300},{"trials":11283,"activeCount":101},[],{"trials":11285,"activeCount":101},[],{"trials":11287,"activeCount":97,"soonestReadout":11292},[11288],{"nctId":11289,"briefTitle":11290,"status":158,"phases":11291,"primaryCompletion":11292,"completion":11292,"start":979,"enrollment":523,"conditions":11293,"interventions":11294},"NCT07099391","A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma",[89,90],"2029-07-24",[308],[11280,11295],"Tec-RVd",{"trials":11297,"activeCount":101},[],{"trials":11299,"activeCount":101},[],{"trials":11301,"activeCount":101},[],{"intervention":11295,"totalTrials":97,"cells":11303},{"EARLY_PHASE1":11304,"PHASE1":11306,"PHASE2":11308,"PHASE3":11314,"PHASE4":11316,"NA":11318},{"trials":11305,"activeCount":101},[],{"trials":11307,"activeCount":101},[],{"trials":11309,"activeCount":97,"soonestReadout":11292},[11310],{"nctId":11289,"briefTitle":11290,"status":158,"phases":11311,"primaryCompletion":11292,"completion":11292,"start":979,"enrollment":523,"conditions":11312,"interventions":11313},[89,90],[308],[11280,11295],{"trials":11315,"activeCount":101},[],{"trials":11317,"activeCount":101},[],{"trials":11319,"activeCount":101},[],{"intervention":539,"totalTrials":97,"cells":11321},{"EARLY_PHASE1":11322,"PHASE1":11324,"PHASE2":11326,"PHASE3":11332,"PHASE4":11334,"NA":11336},{"trials":11323,"activeCount":101},[],{"trials":11325,"activeCount":101},[],{"trials":11327,"activeCount":97,"soonestReadout":531},[11328],{"nctId":528,"briefTitle":529,"status":113,"phases":11329,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":11330,"interventions":11331},[90],[535,536,537],[418,218,539,419,420,331],{"trials":11333,"activeCount":101},[],{"trials":11335,"activeCount":101},[],{"trials":11337,"activeCount":101},[],{"intervention":11339,"totalTrials":97,"cells":11340},"Niraparib",{"EARLY_PHASE1":11341,"PHASE1":11343,"PHASE2":11345,"PHASE3":11355,"PHASE4":11357,"NA":11359},{"trials":11342,"activeCount":101},[],{"trials":11344,"activeCount":101},[],{"trials":11346,"activeCount":97,"soonestReadout":324},[11347],{"nctId":11348,"briefTitle":11349,"status":113,"phases":11350,"primaryCompletion":324,"completion":324,"start":11351,"enrollment":952,"conditions":11352,"interventions":11354},"NCT05515575","A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA",[90],"2022-08-23",[1177,11353],"Sarcoma Uterus",[11339],{"trials":11356,"activeCount":101},[],{"trials":11358,"activeCount":101},[],{"trials":11360,"activeCount":101},[],{"intervention":11362,"totalTrials":97,"cells":11363},"Anakinra",{"EARLY_PHASE1":11364,"PHASE1":11366,"PHASE2":11368,"PHASE3":11380,"PHASE4":11382,"NA":11384},{"trials":11365,"activeCount":101},[],{"trials":11367,"activeCount":101},[],{"trials":11369,"activeCount":97,"soonestReadout":115},[11370],{"nctId":11371,"briefTitle":11372,"status":113,"phases":11373,"primaryCompletion":115,"completion":115,"start":11374,"enrollment":2888,"conditions":11375,"interventions":11379},"NCT04148430","A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy",[90],"2019-10-30",[11376,11377,11378],"B Cell ALL","B-Cell Lymphoma","B-cell Non Hodgkin Lymphoma",[11362],{"trials":11381,"activeCount":101},[],{"trials":11383,"activeCount":101},[],{"trials":11385,"activeCount":101},[],{"intervention":576,"totalTrials":97,"cells":11387},{"EARLY_PHASE1":11388,"PHASE1":11390,"PHASE2":11392,"PHASE3":11398,"PHASE4":11400,"NA":11402},{"trials":11389,"activeCount":101},[],{"trials":11391,"activeCount":101},[],{"trials":11393,"activeCount":97,"soonestReadout":324},[11394],{"nctId":569,"briefTitle":570,"status":113,"phases":11395,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":11396,"interventions":11397},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"trials":11399,"activeCount":101},[],{"trials":11401,"activeCount":101},[],{"trials":11403,"activeCount":101},[],{"intervention":578,"totalTrials":97,"cells":11405},{"EARLY_PHASE1":11406,"PHASE1":11408,"PHASE2":11410,"PHASE3":11416,"PHASE4":11418,"NA":11420},{"trials":11407,"activeCount":101},[],{"trials":11409,"activeCount":101},[],{"trials":11411,"activeCount":97,"soonestReadout":324},[11412],{"nctId":569,"briefTitle":570,"status":113,"phases":11413,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":11414,"interventions":11415},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"trials":11417,"activeCount":101},[],{"trials":11419,"activeCount":101},[],{"trials":11421,"activeCount":101},[],{"intervention":580,"totalTrials":97,"cells":11423},{"EARLY_PHASE1":11424,"PHASE1":11426,"PHASE2":11428,"PHASE3":11434,"PHASE4":11436,"NA":11438},{"trials":11425,"activeCount":101},[],{"trials":11427,"activeCount":101},[],{"trials":11429,"activeCount":97,"soonestReadout":324},[11430],{"nctId":569,"briefTitle":570,"status":113,"phases":11431,"primaryCompletion":324,"completion":324,"start":572,"enrollment":573,"conditions":11432,"interventions":11433},[90],[27],[576,220,577,578,579,580,218,581,582,463],{"trials":11435,"activeCount":101},[],{"trials":11437,"activeCount":101},[],{"trials":11439,"activeCount":101},[],{"intervention":6123,"totalTrials":97,"cells":11441},{"EARLY_PHASE1":11442,"PHASE1":11444,"PHASE2":11446,"PHASE3":11452,"PHASE4":11454,"NA":11456},{"trials":11443,"activeCount":101},[],{"trials":11445,"activeCount":101},[],{"trials":11447,"activeCount":97,"soonestReadout":6113},[11448],{"nctId":6110,"briefTitle":6111,"status":113,"phases":11449,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":2446,"conditions":11450,"interventions":11451},[90],[4054,6116,6117,6118,6119,6120,6121],[3080,6092,6123],{"trials":11453,"activeCount":101},[],{"trials":11455,"activeCount":101},[],{"trials":11457,"activeCount":101},[],{"intervention":1077,"totalTrials":97,"cells":11459},{"EARLY_PHASE1":11460,"PHASE1":11462,"PHASE2":11464,"PHASE3":11470,"PHASE4":11472,"NA":11474},{"trials":11461,"activeCount":101},[],{"trials":11463,"activeCount":101},[],{"trials":11465,"activeCount":97,"soonestReadout":324},[11466],{"nctId":1068,"briefTitle":1069,"status":158,"phases":11467,"primaryCompletion":324,"completion":324,"start":1071,"enrollment":1072,"conditions":11468,"interventions":11469},[90],[604,1074],[798,1022,1076,1077],{"trials":11471,"activeCount":101},[],{"trials":11473,"activeCount":101},[],{"trials":11475,"activeCount":101},[],{"intervention":2779,"totalTrials":97,"cells":11477},{"EARLY_PHASE1":11478,"PHASE1":11480,"PHASE2":11482,"PHASE3":11488,"PHASE4":11490,"NA":11492},{"trials":11479,"activeCount":101},[],{"trials":11481,"activeCount":101},[],{"trials":11483,"activeCount":97,"soonestReadout":990},[11484],{"nctId":2771,"briefTitle":2772,"status":113,"phases":11485,"primaryCompletion":990,"completion":990,"start":2774,"enrollment":601,"conditions":11486,"interventions":11487},[90],[2776,783,2777],[2779,942],{"trials":11489,"activeCount":101},[],{"trials":11491,"activeCount":101},[],{"trials":11493,"activeCount":101},[],{"intervention":7127,"totalTrials":97,"cells":11495},{"EARLY_PHASE1":11496,"PHASE1":11498,"PHASE2":11500,"PHASE3":11506,"PHASE4":11508,"NA":11510},{"trials":11497,"activeCount":101},[],{"trials":11499,"activeCount":101},[],{"trials":11501,"activeCount":97,"soonestReadout":2082},[11502],{"nctId":7121,"briefTitle":7122,"status":113,"phases":11503,"primaryCompletion":2082,"completion":2082,"start":803,"enrollment":6397,"conditions":11504,"interventions":11505},[90],[7125],[7127,4693],{"trials":11507,"activeCount":101},[],{"trials":11509,"activeCount":101},[],{"trials":11511,"activeCount":101},[],{"intervention":2506,"totalTrials":97,"cells":11513},{"EARLY_PHASE1":11514,"PHASE1":11516,"PHASE2":11518,"PHASE3":11524,"PHASE4":11526,"NA":11528},{"trials":11515,"activeCount":101},[],{"trials":11517,"activeCount":101},[],{"trials":11519,"activeCount":97,"soonestReadout":2472},[11520],{"nctId":2499,"briefTitle":2500,"status":158,"phases":11521,"primaryCompletion":2472,"completion":2472,"start":2502,"enrollment":1665,"conditions":11522,"interventions":11523},[90],[2504],[42,2506],{"trials":11525,"activeCount":101},[],{"trials":11527,"activeCount":101},[],{"trials":11529,"activeCount":101},[],{"intervention":11531,"totalTrials":97,"cells":11532},"Tibetree Pain Relieving Plaster",{"EARLY_PHASE1":11533,"PHASE1":11535,"PHASE2":11537,"PHASE3":11548,"PHASE4":11550,"NA":11552},{"trials":11534,"activeCount":101},[],{"trials":11536,"activeCount":101},[],{"trials":11538,"activeCount":97,"soonestReadout":11543},[11539],{"nctId":11540,"briefTitle":11541,"status":113,"phases":11542,"primaryCompletion":11543,"completion":11543,"start":11544,"enrollment":10561,"conditions":11545,"interventions":11547},"NCT04916249","Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors",[90],"2026-05-28","2021-05-28",[1155,11546],"Remission",[11531],{"trials":11549,"activeCount":101},[],{"trials":11551,"activeCount":101},[],{"trials":11553,"activeCount":101},[],{"intervention":11555,"totalTrials":97,"cells":11556},"adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH",{"EARLY_PHASE1":11557,"PHASE1":11559,"PHASE2":11561,"PHASE3":11572,"PHASE4":11574,"NA":11576},{"trials":11558,"activeCount":101},[],{"trials":11560,"activeCount":101},[],{"trials":11562,"activeCount":97,"soonestReadout":232},[11563],{"nctId":11564,"briefTitle":11565,"status":113,"phases":11566,"primaryCompletion":232,"completion":232,"start":11567,"enrollment":11568,"conditions":11569,"interventions":11570},"NCT00911560","Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma",[89,90],"2009-05-27",374,[215],[11555,11571],"oral β-glucan",{"trials":11573,"activeCount":101},[],{"trials":11575,"activeCount":101},[],{"trials":11577,"activeCount":101},[],{"intervention":11571,"totalTrials":97,"cells":11579},{"EARLY_PHASE1":11580,"PHASE1":11582,"PHASE2":11584,"PHASE3":11590,"PHASE4":11592,"NA":11594},{"trials":11581,"activeCount":101},[],{"trials":11583,"activeCount":101},[],{"trials":11585,"activeCount":97,"soonestReadout":232},[11586],{"nctId":11564,"briefTitle":11565,"status":113,"phases":11587,"primaryCompletion":232,"completion":232,"start":11567,"enrollment":11568,"conditions":11588,"interventions":11589},[89,90],[215],[11555,11571],{"trials":11591,"activeCount":101},[],{"trials":11593,"activeCount":101},[],{"trials":11595,"activeCount":101},[],{"intervention":11597,"totalTrials":97,"cells":11598},"89Zr-DFO-SC16.56",{"EARLY_PHASE1":11599,"PHASE1":11601,"PHASE2":11603,"PHASE3":11616,"PHASE4":11618,"NA":11620},{"trials":11600,"activeCount":101},[],{"trials":11602,"activeCount":101},[],{"trials":11604,"activeCount":97,"soonestReadout":11609},[11605],{"nctId":11606,"briefTitle":11607,"status":158,"phases":11608,"primaryCompletion":11609,"completion":11609,"start":11055,"enrollment":4992,"conditions":11610,"interventions":11612},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[89,90],"2026-06-11",[6548,11611],"Small Cell Lung Carcinoma",[11597,11613,11614,11615],"SC16.56, Phase I, Cohort 2","SC16.56, Phase I, Cohort 3","SC16.56, Phase II",{"trials":11617,"activeCount":101},[],{"trials":11619,"activeCount":101},[],{"trials":11621,"activeCount":101},[],{"intervention":11613,"totalTrials":97,"cells":11623},{"EARLY_PHASE1":11624,"PHASE1":11626,"PHASE2":11628,"PHASE3":11634,"PHASE4":11636,"NA":11638},{"trials":11625,"activeCount":101},[],{"trials":11627,"activeCount":101},[],{"trials":11629,"activeCount":97,"soonestReadout":11609},[11630],{"nctId":11606,"briefTitle":11607,"status":158,"phases":11631,"primaryCompletion":11609,"completion":11609,"start":11055,"enrollment":4992,"conditions":11632,"interventions":11633},[89,90],[6548,11611],[11597,11613,11614,11615],{"trials":11635,"activeCount":101},[],{"trials":11637,"activeCount":101},[],{"trials":11639,"activeCount":101},[],{"intervention":11614,"totalTrials":97,"cells":11641},{"EARLY_PHASE1":11642,"PHASE1":11644,"PHASE2":11646,"PHASE3":11652,"PHASE4":11654,"NA":11656},{"trials":11643,"activeCount":101},[],{"trials":11645,"activeCount":101},[],{"trials":11647,"activeCount":97,"soonestReadout":11609},[11648],{"nctId":11606,"briefTitle":11607,"status":158,"phases":11649,"primaryCompletion":11609,"completion":11609,"start":11055,"enrollment":4992,"conditions":11650,"interventions":11651},[89,90],[6548,11611],[11597,11613,11614,11615],{"trials":11653,"activeCount":101},[],{"trials":11655,"activeCount":101},[],{"trials":11657,"activeCount":101},[],{"intervention":11615,"totalTrials":97,"cells":11659},{"EARLY_PHASE1":11660,"PHASE1":11662,"PHASE2":11664,"PHASE3":11670,"PHASE4":11672,"NA":11674},{"trials":11661,"activeCount":101},[],{"trials":11663,"activeCount":101},[],{"trials":11665,"activeCount":97,"soonestReadout":11609},[11666],{"nctId":11606,"briefTitle":11607,"status":158,"phases":11667,"primaryCompletion":11609,"completion":11609,"start":11055,"enrollment":4992,"conditions":11668,"interventions":11669},[89,90],[6548,11611],[11597,11613,11614,11615],{"trials":11671,"activeCount":101},[],{"trials":11673,"activeCount":101},[],{"trials":11675,"activeCount":101},[],{"intervention":67,"totalTrials":97,"cells":11677},{"EARLY_PHASE1":11678,"PHASE1":11680,"PHASE2":11682,"PHASE3":11691,"PHASE4":11693,"NA":11695},{"trials":11679,"activeCount":101},[],{"trials":11681,"activeCount":101},[],{"trials":11683,"activeCount":97,"soonestReadout":66},[11684],{"nctId":64,"briefTitle":65,"status":113,"phases":11685,"primaryCompletion":66,"completion":2472,"start":11686,"enrollment":11687,"conditions":11688,"interventions":11689},[90],"2019-01-14",139,[18],[67,11690],"Rocuronium 1.5mg\u002Fkg\u002Fhr",{"trials":11692,"activeCount":101},[],{"trials":11694,"activeCount":101},[],{"trials":11696,"activeCount":101},[],{"intervention":11690,"totalTrials":97,"cells":11698},{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11703,"PHASE3":11709,"PHASE4":11711,"NA":11713},{"trials":11700,"activeCount":101},[],{"trials":11702,"activeCount":101},[],{"trials":11704,"activeCount":97,"soonestReadout":66},[11705],{"nctId":64,"briefTitle":65,"status":113,"phases":11706,"primaryCompletion":66,"completion":2472,"start":11686,"enrollment":11687,"conditions":11707,"interventions":11708},[90],[18],[67,11690],{"trials":11710,"activeCount":101},[],{"trials":11712,"activeCount":101},[],{"trials":11714,"activeCount":101},[],{"intervention":11716,"totalTrials":97,"cells":11717},"Glipizide",{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11736,"PHASE4":11738,"NA":11740},{"trials":11719,"activeCount":101},[],{"trials":11721,"activeCount":101},[],{"trials":11723,"activeCount":97,"soonestReadout":11728},[11724],{"nctId":11725,"briefTitle":11726,"status":113,"phases":11727,"primaryCompletion":11728,"completion":11728,"start":11729,"enrollment":1462,"conditions":11730,"interventions":11735},"NCT06168812","A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer",[90],"2026-12-05","2023-12-05",[1226,11731,11732,11733,11734,2475],"Pancreatic Carcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer Metastatic","Metastatic Pancreatic Cancer",[11716],{"trials":11737,"activeCount":101},[],{"trials":11739,"activeCount":101},[],{"trials":11741,"activeCount":101},[],{"intervention":11743,"totalTrials":97,"cells":11744},"Tislelizumab",{"EARLY_PHASE1":11745,"PHASE1":11747,"PHASE2":11749,"PHASE3":11759,"PHASE4":11761,"NA":11763},{"trials":11746,"activeCount":101},[],{"trials":11748,"activeCount":101},[],{"trials":11750,"activeCount":97,"soonestReadout":11755},[11751],{"nctId":11752,"briefTitle":11753,"status":158,"phases":11754,"primaryCompletion":11755,"completion":11755,"start":11756,"enrollment":718,"conditions":11757,"interventions":11758},"NCT06529523","Tislelizumab in People With Colorectal Cancer",[90],"2028-07","2024-07-26",[36],[11743],{"trials":11760,"activeCount":101},[],{"trials":11762,"activeCount":101},[],{"trials":11764,"activeCount":101},[],{"intervention":11766,"totalTrials":97,"cells":11767},"2141-V11 Antibody",{"EARLY_PHASE1":11768,"PHASE1":11770,"PHASE2":11772,"PHASE3":11782,"PHASE4":11784,"NA":11786},{"trials":11769,"activeCount":101},[],{"trials":11771,"activeCount":101},[],{"trials":11773,"activeCount":97,"soonestReadout":11778},[11774],{"nctId":11775,"briefTitle":11776,"status":158,"phases":11777,"primaryCompletion":11778,"completion":11778,"start":11779,"enrollment":1665,"conditions":11780,"interventions":11781},"NCT06347705","A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer",[90],"2029-03-28","2024-03-28",[18],[11766],{"trials":11783,"activeCount":101},[],{"trials":11785,"activeCount":101},[],{"trials":11787,"activeCount":101},[],{"intervention":625,"totalTrials":97,"cells":11789},{"EARLY_PHASE1":11790,"PHASE1":11792,"PHASE2":11794,"PHASE3":11800,"PHASE4":11802,"NA":11804},{"trials":11791,"activeCount":101},[],{"trials":11793,"activeCount":101},[],{"trials":11795,"activeCount":97,"soonestReadout":621},[11796],{"nctId":618,"briefTitle":619,"status":158,"phases":11797,"primaryCompletion":621,"completion":621,"start":622,"enrollment":213,"conditions":11798,"interventions":11799},[90],[308],[625,218],{"trials":11801,"activeCount":101},[],{"trials":11803,"activeCount":101},[],{"trials":11805,"activeCount":101},[],{"intervention":11807,"totalTrials":97,"cells":11808},"Systemic Therapy\u002FStandard of Care",{"EARLY_PHASE1":11809,"PHASE1":11811,"PHASE2":11813,"PHASE3":11824,"PHASE4":11826,"NA":11828},{"trials":11810,"activeCount":101},[],{"trials":11812,"activeCount":101},[],{"trials":11814,"activeCount":97,"soonestReadout":2472},[11815],{"nctId":11816,"briefTitle":11817,"status":158,"phases":11818,"primaryCompletion":2472,"completion":2472,"start":11819,"enrollment":11820,"conditions":11821,"interventions":11823},"NCT03808337","Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease",[90],"2019-01-16",145,[2313,3094,2311,11822],"Metastatic Non-Small Cell Lung Carcinoma",[11807],{"trials":11825,"activeCount":101},[],{"trials":11827,"activeCount":101},[],{"trials":11829,"activeCount":101},[],{"intervention":11831,"totalTrials":97,"cells":11832},"Oral Minoxidil",{"EARLY_PHASE1":11833,"PHASE1":11835,"PHASE2":11837,"PHASE3":11848,"PHASE4":11850,"NA":11852},{"trials":11834,"activeCount":101},[],{"trials":11836,"activeCount":101},[],{"trials":11838,"activeCount":97,"soonestReadout":990},[11839],{"nctId":11840,"briefTitle":11841,"status":113,"phases":11842,"primaryCompletion":990,"completion":990,"start":11843,"enrollment":1434,"conditions":11844,"interventions":11847},"NCT05778825","A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors",[90],"2023-03-10",[11845,11846],"Survivors of Childhood Cancer","Alopecia",[11831],{"trials":11849,"activeCount":101},[],{"trials":11851,"activeCount":101},[],{"trials":11853,"activeCount":101},[],{"intervention":3215,"totalTrials":97,"cells":11855},{"EARLY_PHASE1":11856,"PHASE1":11858,"PHASE2":11860,"PHASE3":11866,"PHASE4":11868,"NA":11870},{"trials":11857,"activeCount":101},[],{"trials":11859,"activeCount":101},[],{"trials":11861,"activeCount":97,"soonestReadout":3208},[11862],{"nctId":3205,"briefTitle":3206,"status":113,"phases":11863,"primaryCompletion":3208,"completion":3208,"start":3209,"enrollment":3210,"conditions":11864,"interventions":11865},[90],[3212,3213],[974,224,3215],{"trials":11867,"activeCount":101},[],{"trials":11869,"activeCount":101},[],{"trials":11871,"activeCount":101},[],{"intervention":11873,"totalTrials":97,"cells":11874},"Obecabtagene Autoleucel",{"EARLY_PHASE1":11875,"PHASE1":11877,"PHASE2":11879,"PHASE3":11889,"PHASE4":11891,"NA":11893},{"trials":11876,"activeCount":101},[],{"trials":11878,"activeCount":101},[],{"trials":11880,"activeCount":97,"soonestReadout":11885},[11881],{"nctId":11882,"briefTitle":11883,"status":158,"phases":11884,"primaryCompletion":11885,"completion":11885,"start":11886,"enrollment":718,"conditions":11887,"interventions":11888},"NCT07400029","A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",[90],"2029-02","2026-02-03",[414],[11873],{"trials":11890,"activeCount":101},[],{"trials":11892,"activeCount":101},[],{"trials":11894,"activeCount":101},[],{"intervention":62,"totalTrials":97,"cells":11896},{"EARLY_PHASE1":11897,"PHASE1":11899,"PHASE2":11901,"PHASE3":11907,"PHASE4":11909,"NA":11911},{"trials":11898,"activeCount":101},[],{"trials":11900,"activeCount":101},[],{"trials":11902,"activeCount":97,"soonestReadout":61},[11903],{"nctId":59,"briefTitle":60,"status":113,"phases":11904,"primaryCompletion":61,"completion":2472,"start":2509,"enrollment":356,"conditions":11905,"interventions":11906},[90],[33],[62,42],{"trials":11908,"activeCount":101},[],{"trials":11910,"activeCount":101},[],{"trials":11912,"activeCount":101},[],{"intervention":10022,"totalTrials":97,"cells":11914},{"EARLY_PHASE1":11915,"PHASE1":11917,"PHASE2":11919,"PHASE3":11925,"PHASE4":11927,"NA":11929},{"trials":11916,"activeCount":101},[],{"trials":11918,"activeCount":101},[],{"trials":11920,"activeCount":97,"soonestReadout":115},[11921],{"nctId":10014,"briefTitle":10015,"status":113,"phases":11922,"primaryCompletion":115,"completion":115,"start":10017,"enrollment":533,"conditions":11923,"interventions":11924},[90],[1444,10019,10020],[9997,10022],{"trials":11926,"activeCount":101},[],{"trials":11928,"activeCount":101},[],{"trials":11930,"activeCount":101},[],{"intervention":11932,"totalTrials":97,"cells":11933},"RP-3500",{"EARLY_PHASE1":11934,"PHASE1":11936,"PHASE2":11938,"PHASE3":11947,"PHASE4":11949,"NA":11951},{"trials":11935,"activeCount":101},[],{"trials":11937,"activeCount":101},[],{"trials":11939,"activeCount":97,"soonestReadout":270},[11940],{"nctId":11941,"briefTitle":11942,"status":113,"phases":11943,"primaryCompletion":270,"completion":270,"start":11944,"enrollment":565,"conditions":11945,"interventions":11946},"NCT05566574","A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer",[89,90],"2022-09-30",[2351,2349],[11932],{"trials":11948,"activeCount":101},[],{"trials":11950,"activeCount":101},[],{"trials":11952,"activeCount":101},[],{"intervention":11954,"totalTrials":97,"cells":11955},"Standard of care",{"EARLY_PHASE1":11956,"PHASE1":11958,"PHASE2":11960,"PHASE3":11970,"PHASE4":11972,"NA":11974},{"trials":11957,"activeCount":101},[],{"trials":11959,"activeCount":101},[],{"trials":11961,"activeCount":97,"soonestReadout":2472},[11962],{"nctId":11963,"briefTitle":11964,"status":113,"phases":11965,"primaryCompletion":2472,"completion":2472,"start":11819,"enrollment":11966,"conditions":11967,"interventions":11969},"NCT03808662","Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung",[90],107,[2523,2313,4244,10564,3094,6007,11968],"NSCLC Stage IV Without EGFR\u002FALK Mutation",[11954],{"trials":11971,"activeCount":101},[],{"trials":11973,"activeCount":101},[],{"trials":11975,"activeCount":101},[],{"intervention":11977,"totalTrials":97,"cells":11978},"Venetoclax monotherapy",{"EARLY_PHASE1":11979,"PHASE1":11981,"PHASE2":11983,"PHASE3":11994,"PHASE4":11996,"NA":11998},{"trials":11980,"activeCount":101},[],{"trials":11982,"activeCount":101},[],{"trials":11984,"activeCount":97,"soonestReadout":812},[11985],{"nctId":11986,"briefTitle":11987,"status":113,"phases":11988,"primaryCompletion":812,"completion":812,"start":11989,"enrollment":2690,"conditions":11990,"interventions":11992},"NCT04419519","Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax",[90],"2020-05-13",[3848,11991],"Small Lymphocytic Lymphoma (SLL)",[11977,11993],"Venetoclax with anti CD20 monoclonal antibody",{"trials":11995,"activeCount":101},[],{"trials":11997,"activeCount":101},[],{"trials":11999,"activeCount":101},[],{"intervention":11993,"totalTrials":97,"cells":12001},{"EARLY_PHASE1":12002,"PHASE1":12004,"PHASE2":12006,"PHASE3":12012,"PHASE4":12014,"NA":12016},{"trials":12003,"activeCount":101},[],{"trials":12005,"activeCount":101},[],{"trials":12007,"activeCount":97,"soonestReadout":812},[12008],{"nctId":11986,"briefTitle":11987,"status":113,"phases":12009,"primaryCompletion":812,"completion":812,"start":11989,"enrollment":2690,"conditions":12010,"interventions":12011},[90],[3848,11991],[11977,11993],{"trials":12013,"activeCount":101},[],{"trials":12015,"activeCount":101},[],{"trials":12017,"activeCount":101},[],{"intervention":5846,"totalTrials":97,"cells":12019},{"EARLY_PHASE1":12020,"PHASE1":12022,"PHASE2":12024,"PHASE3":12030,"PHASE4":12032,"NA":12034},{"trials":12021,"activeCount":101},[],{"trials":12023,"activeCount":101},[],{"trials":12025,"activeCount":97,"soonestReadout":194},[12026],{"nctId":5840,"briefTitle":5841,"status":158,"phases":12027,"primaryCompletion":194,"completion":194,"start":5843,"enrollment":1441,"conditions":12028,"interventions":12029},[90],[2311],[5367,5846,5847],{"trials":12031,"activeCount":101},[],{"trials":12033,"activeCount":101},[],{"trials":12035,"activeCount":101},[],{"intervention":5847,"totalTrials":97,"cells":12037},{"EARLY_PHASE1":12038,"PHASE1":12040,"PHASE2":12042,"PHASE3":12048,"PHASE4":12050,"NA":12052},{"trials":12039,"activeCount":101},[],{"trials":12041,"activeCount":101},[],{"trials":12043,"activeCount":97,"soonestReadout":194},[12044],{"nctId":5840,"briefTitle":5841,"status":158,"phases":12045,"primaryCompletion":194,"completion":194,"start":5843,"enrollment":1441,"conditions":12046,"interventions":12047},[90],[2311],[5367,5846,5847],{"trials":12049,"activeCount":101},[],{"trials":12051,"activeCount":101},[],{"trials":12053,"activeCount":101},[],{"intervention":12055,"totalTrials":97,"cells":12056},"ZEN003694",{"EARLY_PHASE1":12057,"PHASE1":12059,"PHASE2":12061,"PHASE3":12071,"PHASE4":12073,"NA":12075},{"trials":12058,"activeCount":101},[],{"trials":12060,"activeCount":101},[],{"trials":12062,"activeCount":97,"soonestReadout":1240},[12063],{"nctId":12064,"briefTitle":12065,"status":158,"phases":12066,"primaryCompletion":1240,"completion":1240,"start":12067,"enrollment":296,"conditions":12068,"interventions":12070},"NCT05607108","A Study of ZEN003694 in People With Squamous Cell Lung Cancer",[90],"2022-11-01",[12069],"Squamous Cell Lung Cancer",[12055],{"trials":12072,"activeCount":101},[],{"trials":12074,"activeCount":101},[],{"trials":12076,"activeCount":101},[],{"intervention":12078,"totalTrials":97,"cells":12079},"CPI-613",{"EARLY_PHASE1":12080,"PHASE1":12082,"PHASE2":12084,"PHASE3":12093,"PHASE4":12095,"NA":12097},{"trials":12081,"activeCount":101},[],{"trials":12083,"activeCount":101},[],{"trials":12085,"activeCount":97,"soonestReadout":498},[12086],{"nctId":12087,"briefTitle":12088,"status":113,"phases":12089,"primaryCompletion":498,"completion":498,"start":12090,"enrollment":454,"conditions":12091,"interventions":12092},"NCT03793140","A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma\u002FLeukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations",[90],"2018-12-31",[24,27],[12078],{"trials":12094,"activeCount":101},[],{"trials":12096,"activeCount":101},[],{"trials":12098,"activeCount":101},[],{"intervention":8488,"totalTrials":97,"cells":12100},{"EARLY_PHASE1":12101,"PHASE1":12103,"PHASE2":12105,"PHASE3":12111,"PHASE4":12113,"NA":12115},{"trials":12102,"activeCount":101},[],{"trials":12104,"activeCount":101},[],{"trials":12106,"activeCount":97,"soonestReadout":8480},[12107],{"nctId":8477,"briefTitle":8478,"status":158,"phases":12108,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":2426,"conditions":12109,"interventions":12110},[89,90],[27,5615,8483,8484,8485,3816,414,8486],[8488,8459],{"trials":12112,"activeCount":101},[],{"trials":12114,"activeCount":101},[],{"trials":12116,"activeCount":101},[],{"intervention":12118,"totalTrials":97,"cells":12119},"Sacituzumab govitecan-hziy",{"EARLY_PHASE1":12120,"PHASE1":12122,"PHASE2":12124,"PHASE3":12136,"PHASE4":12138,"NA":12140},{"trials":12121,"activeCount":101},[],{"trials":12123,"activeCount":101},[],{"trials":12125,"activeCount":97,"soonestReadout":12130},[12126],{"nctId":12127,"briefTitle":12128,"status":158,"phases":12129,"primaryCompletion":12130,"completion":12130,"start":12131,"enrollment":4866,"conditions":12132,"interventions":12135},"NCT06477419","A Study of Sacituzumab Govitecan in People With Mesothelioma",[90],"2029-06-21","2024-06-21",[794,12133,12134],"Mesotheliomas Pleural","Mesothelioma; Pleura",[12118],{"trials":12137,"activeCount":101},[],{"trials":12139,"activeCount":101},[],{"trials":12141,"activeCount":101},[],{"intervention":2819,"totalTrials":97,"cells":12143},{"EARLY_PHASE1":12144,"PHASE1":12146,"PHASE2":12148,"PHASE3":12154,"PHASE4":12156,"NA":12158},{"trials":12145,"activeCount":101},[],{"trials":12147,"activeCount":101},[],{"trials":12149,"activeCount":97,"soonestReadout":1469},[12150],{"nctId":2811,"briefTitle":2812,"status":113,"phases":12151,"primaryCompletion":1469,"completion":1469,"start":2814,"enrollment":2815,"conditions":12152,"interventions":12153},[90],[2817],[2819,942],{"trials":12155,"activeCount":101},[],{"trials":12157,"activeCount":101},[],{"trials":12159,"activeCount":101},[],{"intervention":4898,"totalTrials":97,"cells":12161},{"EARLY_PHASE1":12162,"PHASE1":12164,"PHASE2":12166,"PHASE3":12172,"PHASE4":12174,"NA":12176},{"trials":12163,"activeCount":101},[],{"trials":12165,"activeCount":101},[],{"trials":12167,"activeCount":97,"soonestReadout":4894},[12168],{"nctId":4891,"briefTitle":4892,"status":158,"phases":12169,"primaryCompletion":4894,"completion":4894,"start":4895,"enrollment":31,"conditions":12170,"interventions":12171},[90],[3359],[4107,4898],{"trials":12173,"activeCount":101},[],{"trials":12175,"activeCount":101},[],{"trials":12177,"activeCount":101},[],{"intervention":12179,"totalTrials":97,"cells":12180},"Belumosudil",{"EARLY_PHASE1":12181,"PHASE1":12183,"PHASE2":12185,"PHASE3":12194,"PHASE4":12196,"NA":12198},{"trials":12182,"activeCount":101},[],{"trials":12184,"activeCount":101},[],{"trials":12186,"activeCount":97,"soonestReadout":10604},[12187],{"nctId":12188,"briefTitle":12189,"status":158,"phases":12190,"primaryCompletion":10604,"completion":10604,"start":71,"enrollment":6397,"conditions":12191,"interventions":12193},"NCT07006506","A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant",[90],[1973,12192,910],"Graft Vs Host Disease",[12179],{"trials":12195,"activeCount":101},[],{"trials":12197,"activeCount":101},[],{"trials":12199,"activeCount":101},[],{"intervention":12201,"totalTrials":97,"cells":12202},"pemetrexed and cisplatin or carboplatin",{"EARLY_PHASE1":12203,"PHASE1":12205,"PHASE2":12207,"PHASE3":12216,"PHASE4":12218,"NA":12220},{"trials":12204,"activeCount":101},[],{"trials":12206,"activeCount":101},[],{"trials":12208,"activeCount":97,"soonestReadout":2082},[12209],{"nctId":12210,"briefTitle":12211,"status":113,"phases":12212,"primaryCompletion":2082,"completion":2082,"start":12213,"enrollment":523,"conditions":12214,"interventions":12215},"NCT00715611","Pleurectomy\u002FDecortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma",[90],"2008-10-11",[794],[12201],{"trials":12217,"activeCount":101},[],{"trials":12219,"activeCount":101},[],{"trials":12221,"activeCount":101},[],{"intervention":12223,"totalTrials":97,"cells":12224},"Tisagenlecleucel",{"EARLY_PHASE1":12225,"PHASE1":12227,"PHASE2":12229,"PHASE3":12238,"PHASE4":12240,"NA":12242},{"trials":12226,"activeCount":101},[],{"trials":12228,"activeCount":101},[],{"trials":12230,"activeCount":97,"soonestReadout":1028},[12231],{"nctId":12232,"briefTitle":12233,"status":113,"phases":12234,"primaryCompletion":1028,"completion":1028,"start":12235,"enrollment":356,"conditions":12236,"interventions":12237},"NCT05460533","A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)",[90],"2022-07-12",[849],[12223],{"trials":12239,"activeCount":101},[],{"trials":12241,"activeCount":101},[],{"trials":12243,"activeCount":101},[],{"intervention":12245,"totalTrials":97,"cells":12246},"Tarlatamab",{"EARLY_PHASE1":12247,"PHASE1":12249,"PHASE2":12251,"PHASE3":12261,"PHASE4":12263,"NA":12265},{"trials":12248,"activeCount":101},[],{"trials":12250,"activeCount":101},[],{"trials":12252,"activeCount":97,"soonestReadout":12257},[12253],{"nctId":12254,"briefTitle":12255,"status":158,"phases":12256,"primaryCompletion":12257,"completion":12257,"start":12258,"enrollment":992,"conditions":12259,"interventions":12260},"NCT07111507","A Study of Tarlatamab for People With Prostate Cancer",[90],"2027-08-31","2025-07-31",[2030],[12245],{"trials":12262,"activeCount":101},[],{"trials":12264,"activeCount":101},[],{"trials":12266,"activeCount":101},[],{"intervention":12268,"totalTrials":97,"cells":12269},"Ide-cel",{"EARLY_PHASE1":12270,"PHASE1":12272,"PHASE2":12274,"PHASE3":12283,"PHASE4":12285,"NA":12287},{"trials":12271,"activeCount":101},[],{"trials":12273,"activeCount":101},[],{"trials":12275,"activeCount":97,"soonestReadout":812},[12276],{"nctId":12277,"briefTitle":12278,"status":113,"phases":12279,"primaryCompletion":812,"completion":812,"start":12280,"enrollment":454,"conditions":12281,"interventions":12282},"NCT05393804","A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant",[90],"2022-05-20",[308],[12268],{"trials":12284,"activeCount":101},[],{"trials":12286,"activeCount":101},[],{"trials":12288,"activeCount":101},[],{"intervention":2828,"totalTrials":97,"cells":12290},{"EARLY_PHASE1":12291,"PHASE1":12293,"PHASE2":12295,"PHASE3":12301,"PHASE4":12303,"NA":12305},{"trials":12292,"activeCount":101},[],{"trials":12294,"activeCount":101},[],{"trials":12296,"activeCount":97,"soonestReadout":1469},[12297],{"nctId":2821,"briefTitle":2822,"status":113,"phases":12298,"primaryCompletion":1469,"completion":1469,"start":2824,"enrollment":454,"conditions":12299,"interventions":12300},[90],[2826,2363],[942,2828],{"trials":12302,"activeCount":101},[],{"trials":12304,"activeCount":101},[],{"trials":12306,"activeCount":101},[],{"intervention":674,"totalTrials":97,"cells":12308},{"EARLY_PHASE1":12309,"PHASE1":12311,"PHASE2":12313,"PHASE3":12319,"PHASE4":12321,"NA":12323},{"trials":12310,"activeCount":101},[],{"trials":12312,"activeCount":101},[],{"trials":12314,"activeCount":97,"soonestReadout":667},[12315],{"nctId":664,"briefTitle":665,"status":158,"phases":12316,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":12317,"interventions":12318},[90],[415,414,475,671,604,27,24,672],[674,218,331,421,419,418,460,461,675],{"trials":12320,"activeCount":101},[],{"trials":12322,"activeCount":101},[],{"trials":12324,"activeCount":101},[],{"intervention":5480,"totalTrials":97,"cells":12326},{"EARLY_PHASE1":12327,"PHASE1":12329,"PHASE2":12331,"PHASE3":12337,"PHASE4":12339,"NA":12341},{"trials":12328,"activeCount":101},[],{"trials":12330,"activeCount":101},[],{"trials":12332,"activeCount":97,"soonestReadout":1240},[12333],{"nctId":5474,"briefTitle":5475,"status":158,"phases":12334,"primaryCompletion":1240,"completion":1240,"start":5477,"enrollment":969,"conditions":12335,"interventions":12336},[89,90],[2311],[2412,5480,4889],{"trials":12338,"activeCount":101},[],{"trials":12340,"activeCount":101},[],{"trials":12342,"activeCount":101},[],{"intervention":1531,"totalTrials":97,"cells":12344},{"EARLY_PHASE1":12345,"PHASE1":12347,"PHASE2":12349,"PHASE3":12355,"PHASE4":12357,"NA":12359},{"trials":12346,"activeCount":101},[],{"trials":12348,"activeCount":101},[],{"trials":12350,"activeCount":97,"soonestReadout":1518},[12351],{"nctId":1515,"briefTitle":1516,"status":158,"phases":12352,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":473,"conditions":12353,"interventions":12354},[90],[1521,1522,1523,1524,1525,1526,1527,1528,1529],[421,331,419,1531,461,1532],{"trials":12356,"activeCount":101},[],{"trials":12358,"activeCount":101},[],{"trials":12360,"activeCount":101},[],{"intervention":12362,"totalTrials":97,"cells":12363},"Sucralfate",{"EARLY_PHASE1":12364,"PHASE1":12366,"PHASE2":12368,"PHASE3":12379,"PHASE4":12381,"NA":12383},{"trials":12365,"activeCount":101},[],{"trials":12367,"activeCount":101},[],{"trials":12369,"activeCount":97,"soonestReadout":498},[12370],{"nctId":12371,"briefTitle":12372,"status":113,"phases":12373,"primaryCompletion":498,"completion":498,"start":12374,"enrollment":12375,"conditions":12376,"interventions":12378},"NCT05659576","Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation",[90],"2022-12-13",142,[12377],"Radiation Esophagitis",[12362],{"trials":12380,"activeCount":101},[],{"trials":12382,"activeCount":101},[],{"trials":12384,"activeCount":101},[],{"intervention":12386,"totalTrials":97,"cells":12387},"BIO 300",{"EARLY_PHASE1":12388,"PHASE1":12390,"PHASE2":12392,"PHASE3":12405,"PHASE4":12407,"NA":12409},{"trials":12389,"activeCount":101},[],{"trials":12391,"activeCount":101},[],{"trials":12393,"activeCount":97,"soonestReadout":12398},[12394],{"nctId":12395,"briefTitle":12396,"status":158,"phases":12397,"primaryCompletion":12398,"completion":12398,"start":12399,"enrollment":438,"conditions":12400,"interventions":12404},"NCT07323732","A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease",[90],"2029-01-06","2026-01-06",[4244,12401,4282,3094,4245,4246,12402,12403],"NSCLC, Stage I","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[12386],{"trials":12406,"activeCount":101},[],{"trials":12408,"activeCount":101},[],{"trials":12410,"activeCount":101},[],{"intervention":710,"totalTrials":97,"cells":12412},{"EARLY_PHASE1":12413,"PHASE1":12415,"PHASE2":12417,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12414,"activeCount":101},[],{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":97,"soonestReadout":498},[12419],{"nctId":701,"briefTitle":702,"status":113,"phases":12420,"primaryCompletion":498,"completion":498,"start":704,"enrollment":705,"conditions":12421,"interventions":12422},[90],[27,308,416,707],[709,710,418,218,711],{"trials":12424,"activeCount":101},[],{"trials":12426,"activeCount":101},[],{"trials":12428,"activeCount":101},[],{"intervention":4292,"totalTrials":97,"cells":12430},{"EARLY_PHASE1":12431,"PHASE1":12433,"PHASE2":12435,"PHASE3":12441,"PHASE4":12443,"NA":12445},{"trials":12432,"activeCount":101},[],{"trials":12434,"activeCount":101},[],{"trials":12436,"activeCount":97,"soonestReadout":1130},[12437],{"nctId":4286,"briefTitle":4287,"status":113,"phases":12438,"primaryCompletion":1130,"completion":1130,"start":1829,"enrollment":2407,"conditions":12439,"interventions":12440},[89,90],[4290,2398],[4186,4292,4212],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":101},[],{"trials":12446,"activeCount":101},[],{"intervention":12448,"totalTrials":97,"cells":12449},"HIPEC with Mitomycin-C",{"EARLY_PHASE1":12450,"PHASE1":12452,"PHASE2":12454,"PHASE3":12465,"PHASE4":12467,"NA":12469},{"trials":12451,"activeCount":101},[],{"trials":12453,"activeCount":101},[],{"trials":12455,"activeCount":97,"soonestReadout":1469},[12456],{"nctId":12457,"briefTitle":12458,"status":113,"phases":12459,"primaryCompletion":1469,"completion":1469,"start":7778,"enrollment":12460,"conditions":12461,"interventions":12463},"NCT01815359","ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis",[90],292,[12462,36],"Appendix Cancer",[12448,12464],"EPIC with FUDR and Leucovorin",{"trials":12466,"activeCount":101},[],{"trials":12468,"activeCount":101},[],{"trials":12470,"activeCount":101},[],{"intervention":12464,"totalTrials":97,"cells":12472},{"EARLY_PHASE1":12473,"PHASE1":12475,"PHASE2":12477,"PHASE3":12483,"PHASE4":12485,"NA":12487},{"trials":12474,"activeCount":101},[],{"trials":12476,"activeCount":101},[],{"trials":12478,"activeCount":97,"soonestReadout":1469},[12479],{"nctId":12457,"briefTitle":12458,"status":113,"phases":12480,"primaryCompletion":1469,"completion":1469,"start":7778,"enrollment":12460,"conditions":12481,"interventions":12482},[90],[12462,36],[12448,12464],{"trials":12484,"activeCount":101},[],{"trials":12486,"activeCount":101},[],{"trials":12488,"activeCount":101},[],{"intervention":12490,"totalTrials":97,"cells":12491},"Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs",{"EARLY_PHASE1":12492,"PHASE1":12494,"PHASE2":12496,"PHASE3":12507,"PHASE4":12509,"NA":12511},{"trials":12493,"activeCount":101},[],{"trials":12495,"activeCount":101},[],{"trials":12497,"activeCount":97,"soonestReadout":12502},[12498],{"nctId":12499,"briefTitle":12500,"status":158,"phases":12501,"primaryCompletion":12502,"completion":12502,"start":12503,"enrollment":12504,"conditions":12505,"interventions":12506},"NCT07053085","A Study of Surgery and Radiotherapy in People With Breast Cancer",[90],"2029-09-17","2025-09-17",178,[2311,5161],[12490],{"trials":12508,"activeCount":101},[],{"trials":12510,"activeCount":101},[],{"trials":12512,"activeCount":101},[],{"intervention":12514,"totalTrials":97,"cells":12515},"fam-trastuzumab deruxtecan-nxki",{"EARLY_PHASE1":12516,"PHASE1":12518,"PHASE2":12520,"PHASE3":12531,"PHASE4":12533,"NA":12535},{"trials":12517,"activeCount":101},[],{"trials":12519,"activeCount":101},[],{"trials":12521,"activeCount":97,"soonestReadout":12526},[12522],{"nctId":12523,"briefTitle":12524,"status":158,"phases":12525,"primaryCompletion":12526,"completion":12526,"start":12527,"enrollment":162,"conditions":12528,"interventions":12529},"NCT07459673","HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission",[90],"2030-03-04","2026-03-04",[15,5161,2312],[12514,12530],"pertuzumab, called T-DXd+P",{"trials":12532,"activeCount":101},[],{"trials":12534,"activeCount":101},[],{"trials":12536,"activeCount":101},[],{"intervention":12530,"totalTrials":97,"cells":12538},{"EARLY_PHASE1":12539,"PHASE1":12541,"PHASE2":12543,"PHASE3":12549,"PHASE4":12551,"NA":12553},{"trials":12540,"activeCount":101},[],{"trials":12542,"activeCount":101},[],{"trials":12544,"activeCount":97,"soonestReadout":12526},[12545],{"nctId":12523,"briefTitle":12524,"status":158,"phases":12546,"primaryCompletion":12526,"completion":12526,"start":12527,"enrollment":162,"conditions":12547,"interventions":12548},[90],[15,5161,2312],[12514,12530],{"trials":12550,"activeCount":101},[],{"trials":12552,"activeCount":101},[],{"trials":12554,"activeCount":101},[],{"intervention":12556,"totalTrials":97,"cells":12557},"Erdafitinib",{"EARLY_PHASE1":12558,"PHASE1":12560,"PHASE2":12562,"PHASE3":12573,"PHASE4":12575,"NA":12577},{"trials":12559,"activeCount":101},[],{"trials":12561,"activeCount":101},[],{"trials":12563,"activeCount":97,"soonestReadout":324},[12564],{"nctId":12565,"briefTitle":12566,"status":113,"phases":12567,"primaryCompletion":324,"completion":324,"start":12568,"enrollment":306,"conditions":12569,"interventions":12572},"NCT04917809","A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer",[90],"2022-02-17",[971,12570,12571],"Recurrent Bladder Cancer","FGFR3 Gene Mutation",[12556],{"trials":12574,"activeCount":101},[],{"trials":12576,"activeCount":101},[],{"trials":12578,"activeCount":101},[],{"intervention":6356,"totalTrials":97,"cells":12580},{"EARLY_PHASE1":12581,"PHASE1":12583,"PHASE2":12585,"PHASE3":12591,"PHASE4":12593,"NA":12595},{"trials":12582,"activeCount":101},[],{"trials":12584,"activeCount":101},[],{"trials":12586,"activeCount":97,"soonestReadout":6349},[12587],{"nctId":6346,"briefTitle":6347,"status":113,"phases":12588,"primaryCompletion":6349,"completion":6350,"start":6351,"enrollment":1654,"conditions":12589,"interventions":12590},[90],[18],[6354,6355,577,6356],{"trials":12592,"activeCount":101},[],{"trials":12594,"activeCount":101},[],{"trials":12596,"activeCount":101},[],{"intervention":12598,"totalTrials":97,"cells":12599},"Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide",{"EARLY_PHASE1":12600,"PHASE1":12602,"PHASE2":12604,"PHASE3":12615,"PHASE4":12617,"NA":12619},{"trials":12601,"activeCount":101},[],{"trials":12603,"activeCount":101},[],{"trials":12605,"activeCount":97,"soonestReadout":498},[12606],{"nctId":12607,"briefTitle":12608,"status":113,"phases":12609,"primaryCompletion":498,"completion":498,"start":588,"enrollment":326,"conditions":12610,"interventions":12614},"NCT01025089","Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma",[90],[12611,12612,12613],"Thymoma","Thymic Carcinoma","Clinical Masaoka Stage II to IVA",[12598],{"trials":12616,"activeCount":101},[],{"trials":12618,"activeCount":101},[],{"trials":12620,"activeCount":101},[],{"intervention":12622,"totalTrials":97,"cells":12623},"Iberdomide",{"EARLY_PHASE1":12624,"PHASE1":12626,"PHASE2":12628,"PHASE3":12638,"PHASE4":12640,"NA":12642},{"trials":12625,"activeCount":101},[],{"trials":12627,"activeCount":101},[],{"trials":12629,"activeCount":97,"soonestReadout":12634},[12630],{"nctId":12631,"briefTitle":12632,"status":113,"phases":12633,"primaryCompletion":12634,"completion":12634,"start":12635,"enrollment":1447,"conditions":12636,"interventions":12637},"NCT05354557","Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)",[90],"2027-04-26","2022-04-26",[308],[12622],{"trials":12639,"activeCount":101},[],{"trials":12641,"activeCount":101},[],{"trials":12643,"activeCount":101},[],{"intervention":9834,"totalTrials":97,"cells":12645},{"EARLY_PHASE1":12646,"PHASE1":12648,"PHASE2":12650,"PHASE3":12656,"PHASE4":12658,"NA":12660},{"trials":12647,"activeCount":101},[],{"trials":12649,"activeCount":101},[],{"trials":12651,"activeCount":97,"soonestReadout":2082},[12652],{"nctId":9827,"briefTitle":9828,"status":113,"phases":12653,"primaryCompletion":2082,"completion":2082,"start":9830,"enrollment":1798,"conditions":12654,"interventions":12655},[90],[2790,8193,9832],[9834,9805],{"trials":12657,"activeCount":101},[],{"trials":12659,"activeCount":101},[],{"trials":12661,"activeCount":101},[],{"intervention":8833,"totalTrials":97,"cells":12663},{"EARLY_PHASE1":12664,"PHASE1":12666,"PHASE2":12668,"PHASE3":12674,"PHASE4":12676,"NA":12678},{"trials":12665,"activeCount":101},[],{"trials":12667,"activeCount":101},[],{"trials":12669,"activeCount":97,"soonestReadout":8819},[12670],{"nctId":8816,"briefTitle":8817,"status":158,"phases":12671,"primaryCompletion":8819,"completion":8819,"start":8820,"enrollment":718,"conditions":12672,"interventions":12673},[90],[8822,8823,8824,8825,1755,8826,8827,8828,8829,8830,8831,1758],[8833,1593],{"trials":12675,"activeCount":101},[],{"trials":12677,"activeCount":101},[],{"trials":12679,"activeCount":101},[],{"intervention":8537,"totalTrials":97,"cells":12681},{"EARLY_PHASE1":12682,"PHASE1":12684,"PHASE2":12686,"PHASE3":12692,"PHASE4":12694,"NA":12696},{"trials":12683,"activeCount":101},[],{"trials":12685,"activeCount":101},[],{"trials":12687,"activeCount":97,"soonestReadout":498},[12688],{"nctId":8530,"briefTitle":8531,"status":158,"phases":12689,"primaryCompletion":498,"completion":498,"start":8533,"enrollment":8534,"conditions":12690,"interventions":12691},[90],[1831,24],[8537,3859],{"trials":12693,"activeCount":101},[],{"trials":12695,"activeCount":101},[],{"trials":12697,"activeCount":101},[],{"intervention":12699,"totalTrials":97,"cells":12700},"NALIRIFOX",{"EARLY_PHASE1":12701,"PHASE1":12703,"PHASE2":12705,"PHASE3":12715,"PHASE4":12717,"NA":12719},{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":101},[],{"trials":12706,"activeCount":97,"soonestReadout":232},[12707],{"nctId":12708,"briefTitle":12709,"status":158,"phases":12710,"primaryCompletion":232,"completion":232,"start":12711,"enrollment":162,"conditions":12712,"interventions":12713},"NCT05851924","A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)",[90],"2023-05-12",[11732],[12699,12714],"AD-XRT and Capecitabine",{"trials":12716,"activeCount":101},[],{"trials":12718,"activeCount":101},[],{"trials":12720,"activeCount":101},[],{"intervention":12714,"totalTrials":97,"cells":12722},{"EARLY_PHASE1":12723,"PHASE1":12725,"PHASE2":12727,"PHASE3":12733,"PHASE4":12735,"NA":12737},{"trials":12724,"activeCount":101},[],{"trials":12726,"activeCount":101},[],{"trials":12728,"activeCount":97,"soonestReadout":232},[12729],{"nctId":12708,"briefTitle":12709,"status":158,"phases":12730,"primaryCompletion":232,"completion":232,"start":12711,"enrollment":162,"conditions":12731,"interventions":12732},[90],[11732],[12699,12714],{"trials":12734,"activeCount":101},[],{"trials":12736,"activeCount":101},[],{"trials":12738,"activeCount":101},[],{"intervention":12740,"totalTrials":97,"cells":12741},"Pertzye",{"EARLY_PHASE1":12742,"PHASE1":12744,"PHASE2":12746,"PHASE3":12763,"PHASE4":12765,"NA":12767},{"trials":12743,"activeCount":101},[],{"trials":12745,"activeCount":101},[],{"trials":12747,"activeCount":97,"soonestReadout":11054},[12748],{"nctId":12749,"briefTitle":12750,"status":113,"phases":12751,"primaryCompletion":11054,"completion":11054,"start":12752,"enrollment":234,"conditions":12753,"interventions":12762},"NCT05642962","Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)",[89,90],"2022-11-30",[2475,11734,12754,12755,11731,12756,12757,1226,12758,12759,11733,12760,12761],"Metastatic Pancreatic Adenocarcinoma","Metastatic Pancreatic Carcinoma","Pancreatic Carcinoma Metastatic","Pancreatic Carcinoma Non-resectable","Pancreatic Cancer Non-resectable","Pancreatic Cancer Stage IV","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma",[12740],{"trials":12764,"activeCount":101},[],{"trials":12766,"activeCount":101},[],{"trials":12768,"activeCount":101},[],{"intervention":12770,"totalTrials":97,"cells":12771},"Ga-HBED-iPSMA PET",{"EARLY_PHASE1":12772,"PHASE1":12774,"PHASE2":12776,"PHASE3":12786,"PHASE4":12788,"NA":12790},{"trials":12773,"activeCount":101},[],{"trials":12775,"activeCount":101},[],{"trials":12777,"activeCount":97,"soonestReadout":258},[12778],{"nctId":12779,"briefTitle":12780,"status":113,"phases":12781,"primaryCompletion":258,"completion":258,"start":12782,"enrollment":12783,"conditions":12784,"interventions":12785},"NCT03204123","PSMA PET Imaging of Recurrent Prostate Cancer",[90],"2017-06-26",1171,[4761,18],[12770],{"trials":12787,"activeCount":101},[],{"trials":12789,"activeCount":101},[],{"trials":12791,"activeCount":101},[],{"intervention":12793,"totalTrials":97,"cells":12794},"Talquetamab",{"EARLY_PHASE1":12795,"PHASE1":12797,"PHASE2":12799,"PHASE3":12807,"PHASE4":12809,"NA":12811},{"trials":12796,"activeCount":101},[],{"trials":12798,"activeCount":101},[],{"trials":12800,"activeCount":97,"soonestReadout":194},[12801],{"nctId":12802,"briefTitle":12803,"status":158,"phases":12804,"primaryCompletion":194,"completion":194,"start":2571,"enrollment":234,"conditions":12805,"interventions":12806},"NCT06066346","A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy",[90],[308],[12793],{"trials":12808,"activeCount":101},[],{"trials":12810,"activeCount":101},[],{"trials":12812,"activeCount":101},[],{"intervention":6693,"totalTrials":97,"cells":12814},{"EARLY_PHASE1":12815,"PHASE1":12817,"PHASE2":12819,"PHASE3":12825,"PHASE4":12827,"NA":12829},{"trials":12816,"activeCount":101},[],{"trials":12818,"activeCount":101},[],{"trials":12820,"activeCount":97,"soonestReadout":258},[12821],{"nctId":6686,"briefTitle":6687,"status":113,"phases":12822,"primaryCompletion":258,"completion":258,"start":6689,"enrollment":486,"conditions":12823,"interventions":12824},[90],[6691],[6693,6641],{"trials":12826,"activeCount":101},[],{"trials":12828,"activeCount":101},[],{"trials":12830,"activeCount":101},[],{"intervention":797,"totalTrials":97,"cells":12832},{"EARLY_PHASE1":12833,"PHASE1":12835,"PHASE2":12837,"PHASE3":12843,"PHASE4":12845,"NA":12847},{"trials":12834,"activeCount":101},[],{"trials":12836,"activeCount":101},[],{"trials":12838,"activeCount":97,"soonestReadout":789},[12839],{"nctId":786,"briefTitle":787,"status":113,"phases":12840,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":12841,"interventions":12842},[89,90],[793,794,795,21,15],[797,202,798],{"trials":12844,"activeCount":101},[],{"trials":12846,"activeCount":101},[],{"trials":12848,"activeCount":101},[],{"intervention":2585,"totalTrials":97,"cells":12850},{"EARLY_PHASE1":12851,"PHASE1":12853,"PHASE2":12855,"PHASE3":12861,"PHASE4":12863,"NA":12865},{"trials":12852,"activeCount":101},[],{"trials":12854,"activeCount":101},[],{"trials":12856,"activeCount":97,"soonestReadout":258},[12857],{"nctId":2577,"briefTitle":2578,"status":113,"phases":12858,"primaryCompletion":258,"completion":258,"start":2580,"enrollment":1015,"conditions":12859,"interventions":12860},[90],[24,2582,2583],[2585,42],{"trials":12862,"activeCount":101},[],{"trials":12864,"activeCount":101},[],{"trials":12866,"activeCount":101},[],{"intervention":12868,"totalTrials":97,"cells":12869},"AG-120",{"EARLY_PHASE1":12870,"PHASE1":12872,"PHASE2":12874,"PHASE3":12887,"PHASE4":12889,"NA":12891},{"trials":12871,"activeCount":101},[],{"trials":12873,"activeCount":101},[],{"trials":12875,"activeCount":97,"soonestReadout":990},[12876],{"nctId":12877,"briefTitle":12878,"status":113,"phases":12879,"primaryCompletion":990,"completion":990,"start":12880,"enrollment":332,"conditions":12881,"interventions":12886},"NCT04278781","AG-120 in People With IDH1 Mutant Chondrosarcoma",[90],"2020-03-04",[12882,12883,12884,12885],"Chondrosarcoma","Chondrosarcoma, Grade 2","Chondrosarcoma, Grade 3","IDH1 Gene Mutation",[12868],{"trials":12888,"activeCount":101},[],{"trials":12890,"activeCount":101},[],{"trials":12892,"activeCount":101},[],{"intervention":820,"totalTrials":97,"cells":12894},{"EARLY_PHASE1":12895,"PHASE1":12897,"PHASE2":12899,"PHASE3":12905,"PHASE4":12907,"NA":12909},{"trials":12896,"activeCount":101},[],{"trials":12898,"activeCount":101},[],{"trials":12900,"activeCount":97,"soonestReadout":812},[12901],{"nctId":809,"briefTitle":810,"status":113,"phases":12902,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":12903,"interventions":12904},[90],[816],[218,220,222,223,818,819,225,820,516],{"trials":12906,"activeCount":101},[],{"trials":12908,"activeCount":101},[],{"trials":12910,"activeCount":101},[],{"intervention":1180,"totalTrials":97,"cells":12912},{"EARLY_PHASE1":12913,"PHASE1":12915,"PHASE2":12917,"PHASE3":12923,"PHASE4":12925,"NA":12927},{"trials":12914,"activeCount":101},[],{"trials":12916,"activeCount":101},[],{"trials":12918,"activeCount":97,"soonestReadout":1173},[12919],{"nctId":1170,"briefTitle":1171,"status":158,"phases":12920,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":836,"conditions":12921,"interventions":12922},[89,90],[1176,1177,33,1178],[1180,923,1181],{"trials":12924,"activeCount":101},[],{"trials":12926,"activeCount":101},[],{"trials":12928,"activeCount":101},[],{"intervention":7847,"totalTrials":97,"cells":12930},{"EARLY_PHASE1":12931,"PHASE1":12933,"PHASE2":12935,"PHASE3":12941,"PHASE4":12943,"NA":12945},{"trials":12932,"activeCount":101},[],{"trials":12934,"activeCount":101},[],{"trials":12936,"activeCount":97,"soonestReadout":7843},[12937],{"nctId":7840,"briefTitle":7841,"status":113,"phases":12938,"primaryCompletion":7843,"completion":7843,"start":7844,"enrollment":1871,"conditions":12939,"interventions":12940},[90],[15,2312,2311],[7847,4889,7848],{"trials":12942,"activeCount":101},[],{"trials":12944,"activeCount":101},[],{"trials":12946,"activeCount":101},[],{"intervention":7848,"totalTrials":97,"cells":12948},{"EARLY_PHASE1":12949,"PHASE1":12951,"PHASE2":12953,"PHASE3":12959,"PHASE4":12961,"NA":12963},{"trials":12950,"activeCount":101},[],{"trials":12952,"activeCount":101},[],{"trials":12954,"activeCount":97,"soonestReadout":7843},[12955],{"nctId":7840,"briefTitle":7841,"status":113,"phases":12956,"primaryCompletion":7843,"completion":7843,"start":7844,"enrollment":1871,"conditions":12957,"interventions":12958},[90],[15,2312,2311],[7847,4889,7848],{"trials":12960,"activeCount":101},[],{"trials":12962,"activeCount":101},[],{"trials":12964,"activeCount":101},[],{"intervention":12966,"totalTrials":97,"cells":12967},"Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab",{"EARLY_PHASE1":12968,"PHASE1":12970,"PHASE2":12972,"PHASE3":12984,"PHASE4":12986,"NA":12988},{"trials":12969,"activeCount":101},[],{"trials":12971,"activeCount":101},[],{"trials":12973,"activeCount":97,"soonestReadout":115},[12974],{"nctId":12975,"briefTitle":12976,"status":113,"phases":12977,"primaryCompletion":115,"completion":115,"start":12978,"enrollment":3717,"conditions":12979,"interventions":12983},"NCT03693014","A Study of Several Radiation Doses for Patients With Progression on Immunotherapy\u002FCheckpoint Inhibitors",[90],"2018-10-01",[2349,12980,21,971,12981,12982],"Melanoma Cancer","Renal Cancer","Head\u002FNeck Cancers",[12966],{"trials":12985,"activeCount":101},[],{"trials":12987,"activeCount":101},[],{"trials":12989,"activeCount":101},[],{"intervention":12991,"totalTrials":97,"cells":12992},"Repotrectinib",{"EARLY_PHASE1":12993,"PHASE1":12995,"PHASE2":12997,"PHASE3":13009,"PHASE4":13011,"NA":13013},{"trials":12994,"activeCount":101},[],{"trials":12996,"activeCount":101},[],{"trials":12998,"activeCount":97,"soonestReadout":1851},[12999],{"nctId":13000,"briefTitle":13001,"status":158,"phases":13002,"primaryCompletion":1851,"completion":1851,"start":13003,"enrollment":13004,"conditions":13005,"interventions":13007},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[89,90],"2021-08-09",77,[2348,13006],"Metastatic Solid Tumor",[12991,13008],"Irinotecan and temozolomide",{"trials":13010,"activeCount":101},[],{"trials":13012,"activeCount":101},[],{"trials":13014,"activeCount":101},[],{"intervention":13008,"totalTrials":97,"cells":13016},{"EARLY_PHASE1":13017,"PHASE1":13019,"PHASE2":13021,"PHASE3":13027,"PHASE4":13029,"NA":13031},{"trials":13018,"activeCount":101},[],{"trials":13020,"activeCount":101},[],{"trials":13022,"activeCount":97,"soonestReadout":1851},[13023],{"nctId":13000,"briefTitle":13001,"status":158,"phases":13024,"primaryCompletion":1851,"completion":1851,"start":13003,"enrollment":13004,"conditions":13025,"interventions":13026},[89,90],[2348,13006],[12991,13008],{"trials":13028,"activeCount":101},[],{"trials":13030,"activeCount":101},[],{"trials":13032,"activeCount":101},[],{"intervention":4953,"totalTrials":97,"cells":13034},{"EARLY_PHASE1":13035,"PHASE1":13037,"PHASE2":13039,"PHASE3":13045,"PHASE4":13047,"NA":13049},{"trials":13036,"activeCount":101},[],{"trials":13038,"activeCount":101},[],{"trials":13040,"activeCount":97,"soonestReadout":304},[13041],{"nctId":4947,"briefTitle":4948,"status":113,"phases":13042,"primaryCompletion":304,"completion":304,"start":4217,"enrollment":34,"conditions":13043,"interventions":13044},[90],[606,4951],[4953,1296],{"trials":13046,"activeCount":101},[],{"trials":13048,"activeCount":101},[],{"trials":13050,"activeCount":101},[],{"intervention":288,"totalTrials":1152,"cells":13052},{"EARLY_PHASE1":13053,"PHASE1":13055,"PHASE2":13083,"PHASE3":13260,"PHASE4":13266,"NA":13268},{"trials":13054,"activeCount":101},[],{"trials":13056,"activeCount":101},[13057,13061,13065,13069,13073,13077],{"nctId":3586,"briefTitle":3587,"status":244,"phases":13058,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":13059,"interventions":13060},[89],[27],[288,3593,643,479,750,447],{"nctId":3367,"briefTitle":3368,"status":244,"phases":13062,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":356,"conditions":13063,"interventions":13064},[89],[971,2992],[288,390,345,441,741],{"nctId":278,"briefTitle":279,"status":244,"phases":13066,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":13067,"interventions":13068},[89],[285,30,286],[288,289,202],{"nctId":3877,"briefTitle":3878,"status":244,"phases":13070,"primaryCompletion":3880,"completion":3880,"start":3881,"conditions":13071,"interventions":13072},[89],[27,475,476],[288,346],{"nctId":2987,"briefTitle":2988,"status":244,"phases":13074,"primaryCompletion":695,"completion":695,"start":2990,"enrollment":356,"conditions":13075,"interventions":13076},[89],[971,2992],[288,47,345,441,741],{"nctId":13078,"briefTitle":13079,"status":244,"phases":13080,"primaryCompletion":325,"completion":325,"start":3444,"enrollment":438,"conditions":13081,"interventions":13082},"NCT00450827","Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma",[89],[215],[920,288],{"trials":13084,"activeCount":97,"soonestReadout":194},[13085,13089,13093,13097,13101,13105,13109,13113,13117,13121,13125,13129,13133,13137,13141,13145,13149,13153,13157,13161,13165,13169,13173,13177,13181,13185,13189,13193,13197,13201,13205,13209,13213,13217,13221,13225,13229,13236,13240,13244,13248,13252,13256],{"nctId":336,"briefTitle":337,"status":244,"phases":13086,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":13087,"interventions":13088},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":3041,"briefTitle":3042,"status":244,"phases":13090,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":13091,"interventions":13092},[89,90],[971,2992],[288,47,345,441,442,741],{"nctId":3408,"briefTitle":3409,"status":244,"phases":13094,"primaryCompletion":1014,"completion":1014,"start":3141,"enrollment":3411,"conditions":13095,"interventions":13096},[89,90],[387,30,868],[288,390,346,442,741],{"nctId":365,"briefTitle":366,"status":244,"phases":13098,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":13099,"interventions":13100},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":5516,"briefTitle":5517,"status":244,"phases":13102,"primaryCompletion":3477,"completion":3477,"start":426,"conditions":13103,"interventions":13104},[90],[828],[288,444],{"nctId":381,"briefTitle":382,"status":244,"phases":13106,"primaryCompletion":384,"completion":384,"start":385,"conditions":13107,"interventions":13108},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":393,"briefTitle":394,"status":244,"phases":13110,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":13111,"interventions":13112},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":3048,"briefTitle":3049,"status":244,"phases":13114,"primaryCompletion":695,"completion":695,"start":3051,"enrollment":356,"conditions":13115,"interventions":13116},[90],[971],[288,47,345,362,3054],{"nctId":6392,"briefTitle":6393,"status":244,"phases":13118,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":6397,"conditions":13119,"interventions":13120},[90],[3816,414,5615,475,6399,1154,6400,604,27],[675,461,6402,912],{"nctId":467,"briefTitle":468,"status":244,"phases":13122,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":13123,"interventions":13124},[90],[27,24,475,476],[401,288,202,361,478,479],{"nctId":7253,"briefTitle":7254,"status":244,"phases":13126,"primaryCompletion":426,"completion":426,"start":3930,"conditions":13127,"interventions":13128},[90],[7257,27,3939,7258],[288,7260,361,642],{"nctId":3118,"briefTitle":3119,"status":244,"phases":13130,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":13131,"interventions":13132},[90],[33],[288,47,345,442,391,362,3125],{"nctId":3138,"briefTitle":3139,"status":244,"phases":13134,"primaryCompletion":695,"completion":695,"start":3141,"enrollment":3017,"conditions":13135,"interventions":13136},[89,90],[30,868],[288,47,442,741],{"nctId":518,"briefTitle":519,"status":244,"phases":13138,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":13139,"interventions":13140},[90],[24],[526,288,374,202,345,445,349],{"nctId":3440,"briefTitle":3441,"status":244,"phases":13142,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":213,"conditions":13143,"interventions":13144},[89,90],[3259,387,30,3260,868],[288,390,442,741],{"nctId":3934,"briefTitle":3935,"status":244,"phases":13146,"primaryCompletion":1702,"completion":1702,"start":3937,"enrollment":162,"conditions":13147,"interventions":13148},[90],[27,475,3939],[288,3941,361,346,3942],{"nctId":541,"briefTitle":542,"status":244,"phases":13150,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":13151,"interventions":13152},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":1353,"briefTitle":1354,"status":244,"phases":13154,"primaryCompletion":1356,"completion":1356,"start":1357,"conditions":13155,"interventions":13156},[90],[24],[288,374,390,346,442],{"nctId":7281,"briefTitle":7282,"status":244,"phases":13158,"primaryCompletion":588,"completion":588,"start":3323,"enrollment":992,"conditions":13159,"interventions":13160},[89,90],[27,475,476],[288,361],{"nctId":3474,"briefTitle":3475,"status":244,"phases":13162,"primaryCompletion":3477,"completion":3477,"start":3478,"conditions":13163,"interventions":13164},[90],[24],[288,360,390,346,442],{"nctId":584,"briefTitle":585,"status":244,"phases":13166,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":13167,"interventions":13168},[90],[27,24,592],[288,594,202,346,442],{"nctId":6906,"briefTitle":6907,"status":244,"phases":13170,"primaryCompletion":587,"completion":587,"start":2990,"enrollment":3344,"conditions":13171,"interventions":13172},[90],[3259,867,387,30,651,868,1568,556],[288,479],{"nctId":5566,"briefTitle":5567,"status":244,"phases":13174,"primaryCompletion":5569,"completion":5569,"start":5570,"enrollment":3599,"conditions":13175,"interventions":13176},[89,90],[1973,27,475],[288,3593,444,405,5573,479],{"nctId":3494,"briefTitle":3495,"status":244,"phases":13178,"primaryCompletion":688,"completion":688,"start":3497,"conditions":13179,"interventions":13180},[90],[24],[288,390,549,361,346,442,444],{"nctId":627,"briefTitle":628,"status":244,"phases":13182,"primaryCompletion":630,"completion":630,"start":427,"enrollment":573,"conditions":13183,"interventions":13184},[90],[27],[288,374,202,404],{"nctId":634,"briefTitle":635,"status":244,"phases":13186,"primaryCompletion":637,"completion":637,"start":638,"conditions":13187,"interventions":13188},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":3968,"briefTitle":3969,"status":244,"phases":13190,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":13191,"interventions":13192},[90],[24],[288,549,361,346,444,362],{"nctId":645,"briefTitle":646,"status":244,"phases":13194,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":13195,"interventions":13196},[90],[651],[288,390,47,202,346,347,349],{"nctId":677,"briefTitle":678,"status":113,"phases":13198,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":13199,"interventions":13200},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":685,"briefTitle":686,"status":244,"phases":13202,"primaryCompletion":688,"completion":688,"start":427,"enrollment":162,"conditions":13203,"interventions":13204},[90],[27,24],[288,374,202,375],{"nctId":3519,"briefTitle":3520,"status":244,"phases":13206,"primaryCompletion":3522,"completion":3522,"start":3523,"conditions":13207,"interventions":13208},[90],[867,387,1586,783,2610,24,215,30,651,33,868],[288,390,479,750],{"nctId":1682,"briefTitle":1683,"status":244,"phases":13210,"primaryCompletion":680,"completion":680,"start":1685,"enrollment":705,"conditions":13211,"interventions":13212},[90],[30,33,1687],[288,1023,441],{"nctId":724,"briefTitle":725,"status":244,"phases":13214,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":13215,"interventions":13216},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":733,"briefTitle":734,"status":244,"phases":13218,"primaryCompletion":736,"completion":736,"start":737,"conditions":13219,"interventions":13220},[90],[15],[288,202,740,741],{"nctId":743,"briefTitle":744,"status":244,"phases":13222,"primaryCompletion":746,"completion":746,"start":637,"conditions":13223,"interventions":13224},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":752,"briefTitle":753,"status":244,"phases":13226,"primaryCompletion":727,"completion":755,"start":756,"enrollment":438,"conditions":13227,"interventions":13228},[90],[27,24,475,476],[401,288,202,404,479],{"nctId":13230,"briefTitle":13231,"status":244,"phases":13232,"primaryCompletion":764,"start":3323,"enrollment":1052,"conditions":13233,"interventions":13234},"NCT00016159","Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia",[90],[27],[288,3941,9394,3942,13235],"tretinoin",{"nctId":771,"briefTitle":772,"status":244,"phases":13237,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":13238,"interventions":13239},[90],[27,24],[288,374,202,403,404,405],{"nctId":1393,"briefTitle":1394,"status":244,"phases":13241,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":13242,"interventions":13243},[90],[24],[288,374,360,549,361,346,444],{"nctId":4006,"briefTitle":4007,"status":244,"phases":13245,"primaryCompletion":3323,"completion":3323,"start":4009,"enrollment":341,"conditions":13246,"interventions":13247},[90],[4011,27],[288,346],{"nctId":6490,"briefTitle":6491,"status":244,"phases":13249,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":13250,"interventions":13251},[90],[3259],[288,830,3342,446,479,349],{"nctId":3773,"briefTitle":3774,"status":244,"phases":13253,"primaryCompletion":3776,"start":3777,"conditions":13254,"interventions":13255},[90],[828],[288,643,444,558],{"nctId":832,"briefTitle":833,"status":244,"phases":13257,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":13258,"interventions":13259},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":13261,"activeCount":101},[13262],{"nctId":861,"briefTitle":862,"status":244,"phases":13263,"completion":727,"start":864,"enrollment":865,"conditions":13264,"interventions":13265},[91],[867,387,868],[870,288,390,47,202,346],{"trials":13267,"activeCount":101},[],{"trials":13269,"activeCount":101},[13270],{"nctId":903,"briefTitle":904,"status":244,"phases":13271,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":13272,"interventions":13273},[93],[910],[444,239,479,218,225,461,912,460],{"intervention":345,"totalTrials":2483,"cells":13275},{"EARLY_PHASE1":13276,"PHASE1":13278,"PHASE2":13294,"PHASE3":13367,"PHASE4":13373,"NA":13375},{"trials":13277,"activeCount":101},[],{"trials":13279,"activeCount":101},[13280,13284,13290],{"nctId":3367,"briefTitle":3368,"status":244,"phases":13281,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":356,"conditions":13282,"interventions":13283},[89],[971,2992],[288,390,345,441,741],{"nctId":13285,"briefTitle":13286,"status":244,"phases":13287,"primaryCompletion":7407,"completion":7407,"start":8675,"conditions":13288,"interventions":13289},"NCT00004930","Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases",[89],[21,2349],[345],{"nctId":2987,"briefTitle":2988,"status":244,"phases":13291,"primaryCompletion":695,"completion":695,"start":2990,"enrollment":356,"conditions":13292,"interventions":13293},[89],[971,2992],[288,47,345,441,741],{"trials":13295,"activeCount":97,"soonestReadout":194},[13296,13300,13304,13308,13312,13316,13320,13324,13328,13335,13339,13343,13347,13351,13355,13359,13363],{"nctId":336,"briefTitle":337,"status":244,"phases":13297,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":13298,"interventions":13299},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":3041,"briefTitle":3042,"status":244,"phases":13301,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":13302,"interventions":13303},[89,90],[971,2992],[288,47,345,441,442,741],{"nctId":381,"briefTitle":382,"status":244,"phases":13305,"primaryCompletion":384,"completion":384,"start":385,"conditions":13306,"interventions":13307},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":3048,"briefTitle":3049,"status":244,"phases":13309,"primaryCompletion":695,"completion":695,"start":3051,"enrollment":356,"conditions":13310,"interventions":13311},[90],[971],[288,47,345,362,3054],{"nctId":423,"briefTitle":424,"status":244,"phases":13313,"primaryCompletion":426,"completion":426,"start":427,"conditions":13314,"interventions":13315},[90],[33],[202,430,431,345,349],{"nctId":3660,"briefTitle":3661,"status":244,"phases":13317,"primaryCompletion":1565,"completion":1565,"start":426,"conditions":13318,"interventions":13319},[90],[828],[643,345,558],{"nctId":3118,"briefTitle":3119,"status":244,"phases":13321,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":13322,"interventions":13323},[90],[33],[288,47,345,442,391,362,3125],{"nctId":518,"briefTitle":519,"status":244,"phases":13325,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":13326,"interventions":13327},[90],[24],[526,288,374,202,345,445,349],{"nctId":13329,"briefTitle":13330,"status":244,"phases":13331,"completion":688,"start":13332,"conditions":13333,"interventions":13334},"NCT00052390","Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma",[90],"2002-10",[33],[920,345],{"nctId":677,"briefTitle":678,"status":113,"phases":13336,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":13337,"interventions":13338},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":724,"briefTitle":725,"status":244,"phases":13340,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":13341,"interventions":13342},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":743,"briefTitle":744,"status":244,"phases":13344,"primaryCompletion":746,"completion":746,"start":637,"conditions":13345,"interventions":13346},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":3539,"briefTitle":3540,"status":244,"phases":13348,"primaryCompletion":695,"completion":695,"start":637,"conditions":13349,"interventions":13350},[90],[3359],[390,345,741],{"nctId":1699,"briefTitle":1700,"status":244,"phases":13352,"primaryCompletion":1702,"start":1703,"conditions":13353,"interventions":13354},[90],[18,1705],[1023,345,1707,1708,1709],{"nctId":760,"briefTitle":761,"status":244,"phases":13356,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":13357,"interventions":13358},[90],[15],[768,202,345,769,741],{"nctId":778,"briefTitle":779,"status":244,"phases":13360,"primaryCompletion":564,"completion":564,"start":781,"conditions":13361,"interventions":13362},[90],[783,33],[202,345,346,442,349],{"nctId":832,"briefTitle":833,"status":244,"phases":13364,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":13365,"interventions":13366},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":13368,"activeCount":101},[13369],{"nctId":872,"briefTitle":873,"status":244,"phases":13370,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":13371,"interventions":13372},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":13374,"activeCount":101},[],{"trials":13376,"activeCount":101},[13377],{"nctId":914,"briefTitle":915,"status":916,"phases":13378,"start":727,"enrollment":31,"conditions":13379,"interventions":13380},[93],[15],[920,373,202,345,921],{"intervention":349,"totalTrials":234,"cells":13382},{"EARLY_PHASE1":13383,"PHASE1":13385,"PHASE2":13391,"PHASE3":13449,"PHASE4":13455,"NA":13457},{"trials":13384,"activeCount":101},[],{"trials":13386,"activeCount":101},[13387],{"nctId":8688,"briefTitle":8689,"status":244,"phases":13388,"primaryCompletion":1663,"completion":1663,"start":728,"enrollment":326,"conditions":13389,"interventions":13390},[89],[36],[8693,549,1616,8694,349],{"trials":13392,"activeCount":97,"soonestReadout":194},[13393,13397,13401,13405,13409,13413,13417,13421,13425,13429,13433,13437,13441,13445],{"nctId":336,"briefTitle":337,"status":244,"phases":13394,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":13395,"interventions":13396},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":381,"briefTitle":382,"status":244,"phases":13398,"primaryCompletion":384,"completion":384,"start":385,"conditions":13399,"interventions":13400},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":423,"briefTitle":424,"status":244,"phases":13402,"primaryCompletion":426,"completion":426,"start":427,"conditions":13403,"interventions":13404},[90],[33],[202,430,431,345,349],{"nctId":433,"briefTitle":434,"status":244,"phases":13406,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":13407,"interventions":13408},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":518,"briefTitle":519,"status":244,"phases":13410,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":13411,"interventions":13412},[90],[24],[526,288,374,202,345,445,349],{"nctId":634,"briefTitle":635,"status":244,"phases":13414,"primaryCompletion":637,"completion":637,"start":638,"conditions":13415,"interventions":13416},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":645,"briefTitle":646,"status":244,"phases":13418,"primaryCompletion":648,"completion":648,"start":649,"enrollment":370,"conditions":13419,"interventions":13420},[90],[651],[288,390,47,202,346,347,349],{"nctId":677,"briefTitle":678,"status":113,"phases":13422,"primaryCompletion":194,"completion":194,"start":680,"enrollment":523,"conditions":13423,"interventions":13424},[90],[33],[288,390,202,430,345,346,442,683,349],{"nctId":692,"briefTitle":693,"status":244,"phases":13426,"primaryCompletion":695,"completion":695,"start":696,"conditions":13427,"interventions":13428},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"nctId":724,"briefTitle":725,"status":244,"phases":13430,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":13431,"interventions":13432},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"nctId":743,"briefTitle":744,"status":244,"phases":13434,"primaryCompletion":746,"completion":746,"start":637,"conditions":13435,"interventions":13436},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":778,"briefTitle":779,"status":244,"phases":13438,"primaryCompletion":564,"completion":564,"start":781,"conditions":13439,"interventions":13440},[90],[783,33],[202,345,346,442,349],{"nctId":6490,"briefTitle":6491,"status":244,"phases":13442,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":13443,"interventions":13444},[90],[3259],[288,830,3342,446,479,349],{"nctId":832,"briefTitle":833,"status":244,"phases":13446,"primaryCompletion":835,"completion":835,"start":736,"enrollment":836,"conditions":13447,"interventions":13448},[90],[24],[288,374,390,202,345,346,442,445,349],{"trials":13450,"activeCount":101},[13451],{"nctId":872,"briefTitle":873,"status":244,"phases":13452,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":13453,"interventions":13454},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":13456,"activeCount":101},[],{"trials":13458,"activeCount":101},[13459],{"nctId":3336,"briefTitle":3337,"status":244,"phases":13460,"primaryCompletion":3339,"completion":3339,"start":1610,"enrollment":332,"conditions":13461,"interventions":13462},[93],[3259],[47,3342,349],{"intervention":920,"totalTrials":1871,"cells":13464},{"EARLY_PHASE1":13465,"PHASE1":13467,"PHASE2":13477,"PHASE3":13519,"PHASE4":13521,"NA":13523},{"trials":13466,"activeCount":101},[],{"trials":13468,"activeCount":101},[13469,13473],{"nctId":2919,"briefTitle":2920,"status":244,"phases":13470,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":234,"conditions":13471,"interventions":13472},[89],[30,2633,285],[2926,1157,974,77],{"nctId":13078,"briefTitle":13079,"status":244,"phases":13474,"primaryCompletion":325,"completion":325,"start":3444,"enrollment":438,"conditions":13475,"interventions":13476},[89],[215],[920,288],{"trials":13478,"activeCount":97,"soonestReadout":1130},[13479,13483,13487,13491,13495,13499,13503,13507,13511,13515],{"nctId":5992,"briefTitle":5993,"status":244,"phases":13480,"primaryCompletion":5995,"completion":5995,"start":5996,"enrollment":565,"conditions":13481,"interventions":13482},[89,90],[2948,5998],[6000,1157],{"nctId":5863,"briefTitle":5864,"status":244,"phases":13484,"primaryCompletion":3655,"completion":3655,"start":4750,"enrollment":2888,"conditions":13485,"interventions":13486},[89,90],[15],[1679,1157],{"nctId":1009,"briefTitle":1010,"status":244,"phases":13488,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":13489,"interventions":13490},[90],[33,1017,1018,1019,1020],[1022,1023,920],{"nctId":3145,"briefTitle":3146,"status":244,"phases":13492,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":2439,"conditions":13493,"interventions":13494},[90],[1602],[920,47,683,3152],{"nctId":13329,"briefTitle":13330,"status":244,"phases":13496,"completion":688,"start":13332,"conditions":13497,"interventions":13498},[90],[33],[920,345],{"nctId":3678,"briefTitle":3679,"status":244,"phases":13500,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":2483,"conditions":13501,"interventions":13502},[90],[2610],[920,643,1615,379],{"nctId":2785,"briefTitle":2786,"status":113,"phases":13504,"primaryCompletion":1130,"completion":1130,"start":2788,"enrollment":573,"conditions":13505,"interventions":13506},[90],[2790],[1157,942],{"nctId":3228,"briefTitle":3229,"status":244,"phases":13508,"primaryCompletion":3231,"completion":3231,"start":3032,"enrollment":908,"conditions":13509,"interventions":13510},[90],[1586],[920,47],{"nctId":5280,"briefTitle":5281,"status":244,"phases":13512,"primaryCompletion":774,"completion":774,"start":1423,"enrollment":908,"conditions":13513,"interventions":13514},[90],[21],[1595,1107,1157],{"nctId":1147,"briefTitle":1148,"status":244,"phases":13516,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":13517,"interventions":13518},[90],[1154,938,1155],[1157,224,923],{"trials":13520,"activeCount":101},[],{"trials":13522,"activeCount":101},[],{"trials":13524,"activeCount":101},[13525,13533,13537],{"nctId":13526,"briefTitle":13527,"status":244,"phases":13528,"primaryCompletion":13529,"completion":13529,"start":13530,"enrollment":438,"conditions":13531,"interventions":13532},"NCT00675597","Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer",[93],"2012-02","2008-05",[21],[1157],{"nctId":914,"briefTitle":915,"status":916,"phases":13534,"start":727,"enrollment":31,"conditions":13535,"interventions":13536},[93],[15],[920,373,202,345,921],{"nctId":5127,"briefTitle":5128,"status":244,"phases":13538,"primaryCompletion":5130,"completion":5130,"start":764,"enrollment":1052,"conditions":13539,"interventions":13540},[93],[36],[920,1616,391,3603],{"intervention":2909,"totalTrials":1934,"cells":13542},{"EARLY_PHASE1":13543,"PHASE1":13545,"PHASE2":13562,"PHASE3":13568,"PHASE4":13570,"NA":13572},{"trials":13544,"activeCount":101},[],{"trials":13546,"activeCount":101},[13547,13551,13555],{"nctId":2903,"briefTitle":2904,"status":244,"phases":13548,"primaryCompletion":648,"start":2906,"enrollment":454,"conditions":13549,"interventions":13550},[89],[285,30,286],[2909,47,441],{"nctId":2979,"briefTitle":2980,"status":244,"phases":13552,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":454,"conditions":13553,"interventions":13554},[89],[1602],[2909,47,741],{"nctId":13556,"briefTitle":13557,"status":244,"phases":13558,"primaryCompletion":756,"completion":756,"start":7415,"conditions":13559,"interventions":13560},"NCT00021034","Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[89],[285,30,286],[2909,13561],"taurolidine",{"trials":13563,"activeCount":97,"soonestReadout":232},[13564],{"nctId":4214,"briefTitle":4215,"status":113,"phases":13565,"primaryCompletion":232,"completion":232,"start":4217,"enrollment":2462,"conditions":13566,"interventions":13567},[90],[2948],[4220,52,4221],{"trials":13569,"activeCount":101},[],{"trials":13571,"activeCount":101},[],{"trials":13573,"activeCount":101},[13574],{"nctId":13575,"briefTitle":13576,"status":244,"phases":13577,"primaryCompletion":764,"start":3382,"enrollment":13578,"conditions":13579,"interventions":13580},"NCT00004891","PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery",[93],149,[36],[2909],{"intervention":378,"totalTrials":1114,"cells":13582},{"EARLY_PHASE1":13583,"PHASE1":13585,"PHASE2":13591,"PHASE3":13601,"PHASE4":13603,"NA":13605},{"trials":13584,"activeCount":101},[],{"trials":13586,"activeCount":101},[13587],{"nctId":8950,"briefTitle":8951,"status":244,"phases":13588,"primaryCompletion":5650,"completion":5650,"start":3032,"enrollment":2483,"conditions":13589,"interventions":13590},[89],[27,21,3163,475,286],[8955,8956,360,378],{"trials":13592,"activeCount":97,"soonestReadout":498},[13593,13597],{"nctId":365,"briefTitle":366,"status":244,"phases":13594,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":13595,"interventions":13596},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":5109,"briefTitle":5110,"status":113,"phases":13598,"primaryCompletion":498,"completion":498,"start":1266,"enrollment":5112,"conditions":13599,"interventions":13600},[90],[36],[1616,391,3603,5115,378],{"trials":13602,"activeCount":101},[],{"trials":13604,"activeCount":101},[],{"trials":13606,"activeCount":101},[13607],{"nctId":13608,"briefTitle":13609,"status":244,"phases":13610,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":13611,"interventions":13613},"NCT00550628","Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer",[],[36,13612],"Neoplasm of Uncertain Malignant Potential",[13614,376,2964,378,379,4775],"DNA methylation analysis",{"intervention":13616,"totalTrials":1094,"cells":13617},"Androgen deprivation therapy",{"EARLY_PHASE1":13618,"PHASE1":13620,"PHASE2":13622,"PHASE3":13632,"PHASE4":13634,"NA":13636},{"trials":13619,"activeCount":101},[],{"trials":13621,"activeCount":101},[],{"trials":13623,"activeCount":97,"soonestReadout":13628},[13624],{"nctId":13625,"briefTitle":13626,"status":113,"phases":13627,"primaryCompletion":13628,"completion":13628,"start":13629,"enrollment":370,"conditions":13630,"interventions":13631},"NCT05100472","A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer",[90],"2026-10-19","2021-10-19",[18],[13616],{"trials":13633,"activeCount":101},[],{"trials":13635,"activeCount":101},[],{"trials":13637,"activeCount":101},[13638],{"nctId":7060,"briefTitle":7061,"status":244,"phases":13639,"primaryCompletion":7063,"completion":7063,"start":7064,"enrollment":2462,"conditions":13640,"interventions":13641},[93],[18,7066],[7068,7068,7069],{"intervention":4119,"totalTrials":509,"cells":13643},{"EARLY_PHASE1":13644,"PHASE1":13646,"PHASE2":13666,"PHASE3":13668,"PHASE4":13670,"NA":13672},{"trials":13645,"activeCount":101},[],{"trials":13647,"activeCount":1094,"soonestReadout":1766},[13648,13652,13656],{"nctId":7614,"briefTitle":7615,"status":244,"phases":13649,"primaryCompletion":7617,"completion":7617,"start":7618,"enrollment":7619,"conditions":13650,"interventions":13651},[89],[24,7621],[4611,464,7623],{"nctId":4109,"briefTitle":4110,"status":158,"phases":13653,"primaryCompletion":1766,"completion":1766,"start":4112,"enrollment":2751,"conditions":13654,"interventions":13655},[89],[4114,4115,4116,4117],[722,4119],{"nctId":13657,"briefTitle":13658,"status":158,"phases":13659,"primaryCompletion":13660,"completion":13660,"start":8470,"enrollment":356,"conditions":13661,"interventions":13664},"NCT07001384","A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)",[89],"2031-08-08",[13662,13663],"Anaplastic Lymphoma Kinase","Anaplastic Large Cell Lymphoma",[13665,4119],"Alectinib",{"trials":13667,"activeCount":101},[],{"trials":13669,"activeCount":101},[],{"trials":13671,"activeCount":101},[],{"trials":13673,"activeCount":101},[],{"intervention":13675,"totalTrials":1094,"cells":13676},"Lifileucel",{"EARLY_PHASE1":13677,"PHASE1":13679,"PHASE2":13696,"PHASE3":13698,"PHASE4":13700,"NA":13702},{"trials":13678,"activeCount":101},[],{"trials":13680,"activeCount":1094,"soonestReadout":1130},[13681,13688],{"nctId":13682,"briefTitle":13683,"status":113,"phases":13684,"primaryCompletion":1130,"completion":1130,"start":13685,"enrollment":1434,"conditions":13686,"interventions":13687},"NCT05640193","A Study of LN-144 in People With Metastatic Melanoma to the Brain",[89],"2022-11-25",[2753],[13675],{"nctId":13689,"briefTitle":13690,"status":158,"phases":13691,"primaryCompletion":13692,"completion":13692,"start":12067,"enrollment":356,"conditions":13693,"interventions":13695},"NCT05607095","A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma",[89],"2027-05-01",[2622,2341,13694,2753],"Metastatic Uveal Melanoma",[13675],{"trials":13697,"activeCount":101},[],{"trials":13699,"activeCount":101},[],{"trials":13701,"activeCount":101},[],{"trials":13703,"activeCount":101},[],{"intervention":238,"totalTrials":1094,"cells":13705},{"EARLY_PHASE1":13706,"PHASE1":13708,"PHASE2":13718,"PHASE3":13720,"PHASE4":13722,"NA":13724},{"trials":13707,"activeCount":101},[],{"trials":13709,"activeCount":1094,"soonestReadout":232},[13710,13714],{"nctId":229,"briefTitle":230,"status":113,"phases":13711,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":13712,"interventions":13713},[89],[236],[238,239,202,240],{"nctId":1466,"briefTitle":1467,"status":113,"phases":13715,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":573,"conditions":13716,"interventions":13717},[89],[720],[1473,331,420,238,1474],{"trials":13719,"activeCount":101},[],{"trials":13721,"activeCount":101},[],{"trials":13723,"activeCount":101},[],{"trials":13725,"activeCount":101},[],{"intervention":945,"totalTrials":1094,"cells":13727},{"EARLY_PHASE1":13728,"PHASE1":13730,"PHASE2":13740,"PHASE3":13742,"PHASE4":13744,"NA":13746},{"trials":13729,"activeCount":101},[],{"trials":13731,"activeCount":1094,"soonestReadout":258},[13732,13736],{"nctId":3885,"briefTitle":3886,"status":113,"phases":13733,"primaryCompletion":258,"completion":258,"start":3888,"enrollment":2630,"conditions":13734,"interventions":13735},[89],[21],[3509,945,223],{"nctId":930,"briefTitle":931,"status":158,"phases":13737,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":13738,"interventions":13739},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"trials":13741,"activeCount":101},[],{"trials":13743,"activeCount":101},[],{"trials":13745,"activeCount":101},[],{"trials":13747,"activeCount":101},[],{"intervention":4725,"totalTrials":1094,"cells":13749},{"EARLY_PHASE1":13750,"PHASE1":13752,"PHASE2":13764,"PHASE3":13766,"PHASE4":13768,"NA":13770},{"trials":13751,"activeCount":101},[],{"trials":13753,"activeCount":1094,"soonestReadout":194},[13754,13760],{"nctId":13755,"briefTitle":13756,"status":113,"phases":13757,"primaryCompletion":194,"completion":194,"start":1029,"enrollment":1462,"conditions":13758,"interventions":13759},"NCT05079698","A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer",[89],[18],[4725],{"nctId":4714,"briefTitle":4715,"status":158,"phases":13761,"primaryCompletion":194,"completion":194,"start":4717,"enrollment":306,"conditions":13762,"interventions":13763},[89],[2504,4719,4720,4721,4722,4723],[818,4725],{"trials":13765,"activeCount":101},[],{"trials":13767,"activeCount":101},[],{"trials":13769,"activeCount":101},[],{"trials":13771,"activeCount":101},[],{"intervention":373,"totalTrials":332,"cells":13773},{"EARLY_PHASE1":13774,"PHASE1":13776,"PHASE2":13790,"PHASE3":13804,"PHASE4":13806,"NA":13808},{"trials":13775,"activeCount":101},[],{"trials":13777,"activeCount":1094,"soonestReadout":1469},[13778,13786],{"nctId":13779,"briefTitle":13780,"status":113,"phases":13781,"primaryCompletion":1469,"completion":1469,"start":13782,"enrollment":6397,"conditions":13783,"interventions":13785},"NCT02909036","Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.",[89],"2016-09",[308,13784],"Amyloidosis",[3898],{"nctId":3892,"briefTitle":3893,"status":113,"phases":13787,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":13788,"interventions":13789},[89],[707],[3897,223,581,420,3898,3899],{"trials":13791,"activeCount":101},[13792,13796,13800],{"nctId":365,"briefTitle":366,"status":244,"phases":13793,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":13794,"interventions":13795},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":5271,"briefTitle":5272,"status":244,"phases":13797,"primaryCompletion":5274,"completion":5274,"start":1141,"enrollment":306,"conditions":13798,"interventions":13799},[90],[5276],[1595,984,5278,3898],{"nctId":3255,"briefTitle":3256,"status":244,"phases":13801,"primaryCompletion":259,"completion":259,"start":764,"enrollment":162,"conditions":13802,"interventions":13803},[90],[3259,387,30,3260,868],[373,47,442,741],{"trials":13805,"activeCount":101},[],{"trials":13807,"activeCount":101},[],{"trials":13809,"activeCount":101},[13810],{"nctId":914,"briefTitle":915,"status":916,"phases":13811,"start":727,"enrollment":31,"conditions":13812,"interventions":13813},[93],[15],[920,373,202,345,921],{"intervention":549,"totalTrials":601,"cells":13815},{"EARLY_PHASE1":13816,"PHASE1":13818,"PHASE2":13832,"PHASE3":13858,"PHASE4":13864,"NA":13866},{"trials":13817,"activeCount":101},[],{"trials":13819,"activeCount":97,"soonestReadout":531},[13820,13824,13828],{"nctId":4697,"briefTitle":4698,"status":244,"phases":13821,"primaryCompletion":3477,"completion":588,"start":3251,"conditions":13822,"interventions":13823},[89],[3259],[549,4691],{"nctId":8688,"briefTitle":8689,"status":244,"phases":13825,"primaryCompletion":1663,"completion":1663,"start":728,"enrollment":326,"conditions":13826,"interventions":13827},[89],[36],[8693,549,1616,8694,349],{"nctId":3892,"briefTitle":3893,"status":113,"phases":13829,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":13830,"interventions":13831},[89],[707],[3897,223,581,420,3898,3899],{"trials":13833,"activeCount":101},[13834,13842,13846,13850,13854],{"nctId":13835,"briefTitle":13836,"status":244,"phases":13837,"primaryCompletion":1610,"completion":1610,"start":4424,"enrollment":4298,"conditions":13838,"interventions":13839},"NCT00003346","Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma",[90],[4734],[13840,13841,549],"acetaminophen","acetylcysteine",{"nctId":541,"briefTitle":542,"status":244,"phases":13843,"primaryCompletion":544,"start":545,"enrollment":546,"conditions":13844,"interventions":13845},[90],[24],[288,390,549,202,361,346,442,444],{"nctId":3494,"briefTitle":3495,"status":244,"phases":13847,"primaryCompletion":688,"completion":688,"start":3497,"conditions":13848,"interventions":13849},[90],[24],[288,390,549,361,346,442,444],{"nctId":3968,"briefTitle":3969,"status":244,"phases":13851,"primaryCompletion":369,"start":427,"enrollment":356,"conditions":13852,"interventions":13853},[90],[24],[288,549,361,346,444,362],{"nctId":1393,"briefTitle":1394,"status":244,"phases":13855,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":272,"conditions":13856,"interventions":13857},[90],[24],[288,374,360,549,361,346,444],{"trials":13859,"activeCount":101},[13860],{"nctId":872,"briefTitle":873,"status":244,"phases":13861,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":13862,"interventions":13863},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":13865,"activeCount":101},[],{"trials":13867,"activeCount":101},[],{"intervention":1860,"totalTrials":1094,"cells":13869},{"EARLY_PHASE1":13870,"PHASE1":13872,"PHASE2":13878,"PHASE3":13884,"PHASE4":13886,"NA":13888},{"trials":13871,"activeCount":101},[],{"trials":13873,"activeCount":97,"soonestReadout":1851},[13874],{"nctId":1848,"briefTitle":1849,"status":158,"phases":13875,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":213,"conditions":13876,"interventions":13877},[89],[1257,1854,1855,1856,1244,1857,1258],[1859,1860],{"trials":13879,"activeCount":101},[13880],{"nctId":4620,"briefTitle":4621,"status":2832,"phases":13881,"primaryCompletion":4623,"completion":4623,"start":1852,"enrollment":101,"conditions":13882,"interventions":13883},[90],[24],[1860,1261,4589],{"trials":13885,"activeCount":101},[],{"trials":13887,"activeCount":101},[],{"trials":13889,"activeCount":101},[],{"intervention":2303,"totalTrials":1094,"cells":13891},{"EARLY_PHASE1":13892,"PHASE1":13894,"PHASE2":13900,"PHASE3":13911,"PHASE4":13913,"NA":13915},{"trials":13893,"activeCount":101},[],{"trials":13895,"activeCount":97,"soonestReadout":2082},[13896],{"nctId":2296,"briefTitle":2297,"status":113,"phases":13897,"primaryCompletion":2082,"completion":2082,"start":2299,"enrollment":1232,"conditions":13898,"interventions":13899},[89],[21],[42,2302,2303],{"trials":13901,"activeCount":101},[13902],{"nctId":13903,"briefTitle":13904,"status":505,"phases":13905,"primaryCompletion":13906,"completion":13906,"start":1012,"enrollment":2291,"conditions":13907,"interventions":13910},"NCT02282358","Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",[89,90],"2023-05-26",[24,13908,13909],"Relapsed and Refractory","Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",[2303],{"trials":13912,"activeCount":101},[],{"trials":13914,"activeCount":101},[],{"trials":13916,"activeCount":101},[],{"intervention":13918,"totalTrials":1094,"cells":13919},"Bexarotene",{"EARLY_PHASE1":13920,"PHASE1":13922,"PHASE2":13932,"PHASE3":13941,"PHASE4":13943,"NA":13945},{"trials":13921,"activeCount":101},[],{"trials":13923,"activeCount":97,"soonestReadout":990},[13924],{"nctId":13925,"briefTitle":13926,"status":158,"phases":13927,"primaryCompletion":990,"completion":990,"start":13928,"enrollment":306,"conditions":13929,"interventions":13931},"NCT05296304","A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides",[89],"2022-03-16",[13930],"Cutaneous T-cell Lymphoma",[13918],{"trials":13933,"activeCount":101},[13934],{"nctId":13935,"briefTitle":13936,"status":244,"phases":13937,"primaryCompletion":339,"completion":588,"start":2931,"conditions":13938,"interventions":13939},"NCT00030849","Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma",[90],[24],[359,13940],"bexarotene",{"trials":13942,"activeCount":101},[],{"trials":13944,"activeCount":101},[],{"trials":13946,"activeCount":101},[],{"intervention":3736,"totalTrials":1094,"cells":13948},{"EARLY_PHASE1":13949,"PHASE1":13951,"PHASE2":13962,"PHASE3":13968,"PHASE4":13970,"NA":13972},{"trials":13950,"activeCount":101},[],{"trials":13952,"activeCount":97,"soonestReadout":115},[13953],{"nctId":13954,"briefTitle":13955,"status":113,"phases":13956,"primaryCompletion":115,"completion":115,"start":13957,"enrollment":601,"conditions":13958,"interventions":13959},"NCT05556798","A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment",[89],"2022-10-04",[308],[13960,13961,3736],"Belantamab Mafodotin","Nirogacestat",{"trials":13963,"activeCount":101},[13964],{"nctId":3730,"briefTitle":3731,"status":244,"phases":13965,"primaryCompletion":3733,"completion":3733,"start":704,"enrollment":1412,"conditions":13966,"interventions":13967},[90],[308],[3736,463,3737],{"trials":13969,"activeCount":101},[],{"trials":13971,"activeCount":101},[],{"trials":13973,"activeCount":101},[],{"intervention":299,"totalTrials":1094,"cells":13975},{"EARLY_PHASE1":13976,"PHASE1":13978,"PHASE2":13992,"PHASE3":13994,"PHASE4":13996,"NA":13998},{"trials":13977,"activeCount":101},[],{"trials":13979,"activeCount":97,"soonestReadout":232},[13980,13984],{"nctId":291,"briefTitle":292,"status":244,"phases":13981,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":13982,"interventions":13983},[89],[27],[202,299],{"nctId":13985,"briefTitle":13986,"status":113,"phases":13987,"primaryCompletion":232,"completion":232,"start":813,"enrollment":1412,"conditions":13988,"interventions":13990},"NCT01860937","T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia",[89],[13989],"Relapsed B-Cell Acute Lymphoblastic Leukemia",[13991,299],"cyclophosphamide based chemotherapy regimens",{"trials":13993,"activeCount":101},[],{"trials":13995,"activeCount":101},[],{"trials":13997,"activeCount":101},[],{"trials":13999,"activeCount":101},[],{"intervention":6715,"totalTrials":97,"cells":14001},{"EARLY_PHASE1":14002,"PHASE1":14004,"PHASE2":14010,"PHASE3":14012,"PHASE4":14014,"NA":14016},{"trials":14003,"activeCount":101},[],{"trials":14005,"activeCount":97,"soonestReadout":6711},[14006],{"nctId":6708,"briefTitle":6709,"status":158,"phases":14007,"primaryCompletion":6711,"completion":6711,"start":6712,"enrollment":718,"conditions":14008,"interventions":14009},[89],[3816],[6715,6701],{"trials":14011,"activeCount":101},[],{"trials":14013,"activeCount":101},[],{"trials":14015,"activeCount":101},[],{"trials":14017,"activeCount":101},[],{"intervention":14019,"totalTrials":97,"cells":14020},"anti-EGFR-bispecific antibody armed activated T-cells",{"EARLY_PHASE1":14021,"PHASE1":14023,"PHASE2":14034,"PHASE3":14036,"PHASE4":14038,"NA":14040},{"trials":14022,"activeCount":101},[],{"trials":14024,"activeCount":97,"soonestReadout":531},[14025],{"nctId":14026,"briefTitle":14027,"status":113,"phases":14028,"primaryCompletion":531,"completion":531,"start":14029,"enrollment":2291,"conditions":14030,"interventions":14033},"NCT04137536","A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer",[89],"2019-10-17",[1226,14031,4236,14032],"Advanced Pancreatic Cancer","Pancreatic Neoplasms",[14019],{"trials":14035,"activeCount":101},[],{"trials":14037,"activeCount":101},[],{"trials":14039,"activeCount":101},[],{"trials":14041,"activeCount":101},[],{"intervention":14043,"totalTrials":97,"cells":14044},"AZD1390",{"EARLY_PHASE1":14045,"PHASE1":14047,"PHASE2":14058,"PHASE3":14060,"PHASE4":14062,"NA":14064},{"trials":14046,"activeCount":101},[],{"trials":14048,"activeCount":97,"soonestReadout":14053},[14049],{"nctId":14050,"briefTitle":14051,"status":113,"phases":14052,"primaryCompletion":14053,"completion":14053,"start":14054,"enrollment":969,"conditions":14055,"interventions":14057},"NCT05678010","A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer",[89],"2028-05-17","2023-05-17",[2351,13006,6267,6266,14056,2349],"Metastatic Tumor",[14043],{"trials":14059,"activeCount":101},[],{"trials":14061,"activeCount":101},[],{"trials":14063,"activeCount":101},[],{"trials":14065,"activeCount":101},[],{"intervention":5343,"totalTrials":97,"cells":14067},{"EARLY_PHASE1":14068,"PHASE1":14070,"PHASE2":14076,"PHASE3":14078,"PHASE4":14080,"NA":14082},{"trials":14069,"activeCount":101},[],{"trials":14071,"activeCount":97,"soonestReadout":2472},[14072],{"nctId":5336,"briefTitle":5337,"status":158,"phases":14073,"primaryCompletion":2472,"completion":2472,"start":5339,"enrollment":454,"conditions":14074,"interventions":14075},[89],[5341],[5343,86],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":101},[],{"trials":14081,"activeCount":101},[],{"trials":14083,"activeCount":101},[],{"intervention":240,"totalTrials":97,"cells":14085},{"EARLY_PHASE1":14086,"PHASE1":14088,"PHASE2":14094,"PHASE3":14096,"PHASE4":14098,"NA":14100},{"trials":14087,"activeCount":101},[],{"trials":14089,"activeCount":97,"soonestReadout":232},[14090],{"nctId":229,"briefTitle":230,"status":113,"phases":14091,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":14092,"interventions":14093},[89],[236],[238,239,202,240],{"trials":14095,"activeCount":101},[],{"trials":14097,"activeCount":101},[],{"trials":14099,"activeCount":101},[],{"trials":14101,"activeCount":101},[],{"intervention":14103,"totalTrials":97,"cells":14104},"[18F] 4-L-Fluoroglutamine",{"EARLY_PHASE1":14105,"PHASE1":14107,"PHASE2":14116,"PHASE3":14118,"PHASE4":14120,"NA":14122},{"trials":14106,"activeCount":101},[],{"trials":14108,"activeCount":97,"soonestReadout":1469},[14109],{"nctId":14110,"briefTitle":14111,"status":113,"phases":14112,"primaryCompletion":1469,"completion":1469,"start":4363,"enrollment":10655,"conditions":14113,"interventions":14115},"NCT01697930","A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)",[89],[14114,24],"Solid Malignancy",[14103],{"trials":14117,"activeCount":101},[],{"trials":14119,"activeCount":101},[],{"trials":14121,"activeCount":101},[],{"trials":14123,"activeCount":101},[],{"intervention":264,"totalTrials":97,"cells":14125},{"EARLY_PHASE1":14126,"PHASE1":14128,"PHASE2":14134,"PHASE3":14136,"PHASE4":14138,"NA":14140},{"trials":14127,"activeCount":101},[],{"trials":14129,"activeCount":97,"soonestReadout":258},[14130],{"nctId":255,"briefTitle":256,"status":113,"phases":14131,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":14132,"interventions":14133},[89],[15,262],[218,264,265],{"trials":14135,"activeCount":101},[],{"trials":14137,"activeCount":101},[],{"trials":14139,"activeCount":101},[],{"trials":14141,"activeCount":101},[],{"intervention":265,"totalTrials":97,"cells":14143},{"EARLY_PHASE1":14144,"PHASE1":14146,"PHASE2":14152,"PHASE3":14154,"PHASE4":14156,"NA":14158},{"trials":14145,"activeCount":101},[],{"trials":14147,"activeCount":97,"soonestReadout":258},[14148],{"nctId":255,"briefTitle":256,"status":113,"phases":14149,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":14150,"interventions":14151},[89],[15,262],[218,264,265],{"trials":14153,"activeCount":101},[],{"trials":14155,"activeCount":101},[],{"trials":14157,"activeCount":101},[],{"trials":14159,"activeCount":101},[],{"intervention":14161,"totalTrials":97,"cells":14162},"EGFRt\u002F19-28z\u002F4-1BBL CAR T cells",{"EARLY_PHASE1":14163,"PHASE1":14165,"PHASE2":14173,"PHASE3":14175,"PHASE4":14177,"NA":14179},{"trials":14164,"activeCount":101},[],{"trials":14166,"activeCount":97,"soonestReadout":990},[14167],{"nctId":14168,"briefTitle":14169,"status":113,"phases":14170,"primaryCompletion":990,"completion":990,"start":5145,"enrollment":573,"conditions":14171,"interventions":14172},"NCT03085173","A Trial of \"Armored\" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies",[89],[3848,2582,2583],[14161],{"trials":14174,"activeCount":101},[],{"trials":14176,"activeCount":101},[],{"trials":14178,"activeCount":101},[],{"trials":14180,"activeCount":101},[],{"intervention":14182,"totalTrials":97,"cells":14183},"Infusion of MCARH109 T cells",{"EARLY_PHASE1":14184,"PHASE1":14186,"PHASE2":14195,"PHASE3":14197,"PHASE4":14199,"NA":14201},{"trials":14185,"activeCount":101},[],{"trials":14187,"activeCount":97,"soonestReadout":324},[14188],{"nctId":14189,"briefTitle":14190,"status":113,"phases":14191,"primaryCompletion":324,"completion":324,"start":14192,"enrollment":234,"conditions":14193,"interventions":14194},"NCT04555551","MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma",[89],"2020-09-08",[308],[14182],{"trials":14196,"activeCount":101},[],{"trials":14198,"activeCount":101},[],{"trials":14200,"activeCount":101},[],{"trials":14202,"activeCount":101},[],{"intervention":14204,"totalTrials":97,"cells":14205},"Deferoxamine",{"EARLY_PHASE1":14206,"PHASE1":14208,"PHASE2":14218,"PHASE3":14220,"PHASE4":14222,"NA":14224},{"trials":14207,"activeCount":101},[],{"trials":14209,"activeCount":97,"soonestReadout":498},[14210],{"nctId":14211,"briefTitle":14212,"status":158,"phases":14213,"primaryCompletion":498,"completion":498,"start":14214,"enrollment":1052,"conditions":14215,"interventions":14217},"NCT05184816","A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis",[89],"2021-12-22",[14216],"Leptomeningeal Metastases",[14204],{"trials":14219,"activeCount":101},[],{"trials":14221,"activeCount":101},[],{"trials":14223,"activeCount":101},[],{"trials":14225,"activeCount":101},[],{"intervention":14227,"totalTrials":97,"cells":14228},"Biological\u002FGenetically Modified T cells",{"EARLY_PHASE1":14229,"PHASE1":14231,"PHASE2":14241,"PHASE3":14243,"PHASE4":14245,"NA":14247},{"trials":14230,"activeCount":101},[],{"trials":14232,"activeCount":97,"soonestReadout":1469},[14233],{"nctId":14234,"briefTitle":14235,"status":113,"phases":14236,"primaryCompletion":1469,"completion":1469,"start":875,"enrollment":2446,"conditions":14237,"interventions":14239},"NCT01430390","In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies",[89],[14238,24],"Acute Lymphocytic Leukemia",[14227,14240],"Cyclophosphamide-based chemotherapy",{"trials":14242,"activeCount":101},[],{"trials":14244,"activeCount":101},[],{"trials":14246,"activeCount":101},[],{"trials":14248,"activeCount":101},[],{"intervention":14240,"totalTrials":97,"cells":14250},{"EARLY_PHASE1":14251,"PHASE1":14253,"PHASE2":14259,"PHASE3":14261,"PHASE4":14263,"NA":14265},{"trials":14252,"activeCount":101},[],{"trials":14254,"activeCount":97,"soonestReadout":1469},[14255],{"nctId":14234,"briefTitle":14235,"status":113,"phases":14256,"primaryCompletion":1469,"completion":1469,"start":875,"enrollment":2446,"conditions":14257,"interventions":14258},[89],[14238,24],[14227,14240],{"trials":14260,"activeCount":101},[],{"trials":14262,"activeCount":101},[],{"trials":14264,"activeCount":101},[],{"trials":14266,"activeCount":101},[],{"intervention":14268,"totalTrials":97,"cells":14269},"[68Ga]PSMA",{"EARLY_PHASE1":14270,"PHASE1":14272,"PHASE2":14281,"PHASE3":14283,"PHASE4":14285,"NA":14287},{"trials":14271,"activeCount":101},[],{"trials":14273,"activeCount":97,"soonestReadout":4378},[14274],{"nctId":14275,"briefTitle":14276,"status":158,"phases":14277,"primaryCompletion":4378,"completion":4378,"start":14278,"enrollment":306,"conditions":14279,"interventions":14280},"NCT05562791","A Study of 68Gallium PSMA-PET\u002FCT Scans in People With Bladder Cancer or Skin Cancer",[89],"2022-09-28",[971],[14268],{"trials":14282,"activeCount":101},[],{"trials":14284,"activeCount":101},[],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"intervention":14290,"totalTrials":97,"cells":14291},"Codrituzumab",{"EARLY_PHASE1":14292,"PHASE1":14294,"PHASE2":14305,"PHASE3":14307,"PHASE4":14309,"NA":14311},{"trials":14293,"activeCount":101},[],{"trials":14295,"activeCount":97,"soonestReadout":2005},[14296],{"nctId":14297,"briefTitle":14298,"status":158,"phases":14299,"primaryCompletion":2005,"completion":2005,"start":14300,"enrollment":370,"conditions":14301,"interventions":14304},"NCT04928677","A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment",[89],"2021-06-09",[14302,14303],"Primary Extra-cranial Solid Tumor","Recurrent or Refractory Glypican 3 (GPC3)",[14290],{"trials":14306,"activeCount":101},[],{"trials":14308,"activeCount":101},[],{"trials":14310,"activeCount":101},[],{"trials":14312,"activeCount":101},[],{"intervention":276,"totalTrials":97,"cells":14314},{"EARLY_PHASE1":14315,"PHASE1":14317,"PHASE2":14323,"PHASE3":14325,"PHASE4":14327,"NA":14329},{"trials":14316,"activeCount":101},[],{"trials":14318,"activeCount":97,"soonestReadout":270},[14319],{"nctId":267,"briefTitle":268,"status":113,"phases":14320,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":14321,"interventions":14322},[89],[274],[202,276],{"trials":14324,"activeCount":101},[],{"trials":14326,"activeCount":101},[],{"trials":14328,"activeCount":101},[],{"trials":14330,"activeCount":101},[],{"intervention":14332,"totalTrials":97,"cells":14333},"19-28z\u002FIL-18 CAR T cells",{"EARLY_PHASE1":14334,"PHASE1":14336,"PHASE2":14351,"PHASE3":14353,"PHASE4":14355,"NA":14357},{"trials":14335,"activeCount":101},[],{"trials":14337,"activeCount":97,"soonestReadout":14342},[14338],{"nctId":14339,"briefTitle":14340,"status":158,"phases":14341,"primaryCompletion":14342,"completion":14342,"start":10133,"enrollment":326,"conditions":14343,"interventions":14350},"NCT06287528","A Study of 19-28z\u002FIL-18 in People With Acute Lymphoblastic Leukemia (ALL)",[89],"2028-02-23",[14344,14345,14346,14347,14348,14349],"Philadelphia-Negative ALL","Philadelphia-Positive ALL","Relapsed ALL, Adult","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia (ALL)","Refractory Acute Lymphoid Leukemia in Relapse",[14332],{"trials":14352,"activeCount":101},[],{"trials":14354,"activeCount":101},[],{"trials":14356,"activeCount":101},[],{"trials":14358,"activeCount":101},[],{"intervention":14360,"totalTrials":97,"cells":14361},"177Lu-DTPA-SC16.56",{"EARLY_PHASE1":14362,"PHASE1":14364,"PHASE2":14376,"PHASE3":14378,"PHASE4":14380,"NA":14382},{"trials":14363,"activeCount":101},[],{"trials":14365,"activeCount":97,"soonestReadout":14370},[14366],{"nctId":14367,"briefTitle":14368,"status":5409,"phases":14369,"primaryCompletion":14370,"completion":14370,"start":258,"enrollment":283,"conditions":14371,"interventions":14375},"NCT06941480","A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate",[89],"2030-05",[14372,14373,7400,14374],"Neuroendocrine Tumor of the Lung","Neuroendocrine Carcinoma of Lung","Neuroendocrine Carcinoma of Prostate",[14360],{"trials":14377,"activeCount":101},[],{"trials":14379,"activeCount":101},[],{"trials":14381,"activeCount":101},[],{"trials":14383,"activeCount":101},[],{"intervention":2302,"totalTrials":97,"cells":14385},{"EARLY_PHASE1":14386,"PHASE1":14388,"PHASE2":14394,"PHASE3":14396,"PHASE4":14398,"NA":14400},{"trials":14387,"activeCount":101},[],{"trials":14389,"activeCount":97,"soonestReadout":2082},[14390],{"nctId":2296,"briefTitle":2297,"status":113,"phases":14391,"primaryCompletion":2082,"completion":2082,"start":2299,"enrollment":1232,"conditions":14392,"interventions":14393},[89],[21],[42,2302,2303],{"trials":14395,"activeCount":101},[],{"trials":14397,"activeCount":101},[],{"trials":14399,"activeCount":101},[],{"trials":14401,"activeCount":101},[],{"intervention":14403,"totalTrials":97,"cells":14404},"(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, or (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots",{"EARLY_PHASE1":14405,"PHASE1":14407,"PHASE2":14416,"PHASE3":14418,"PHASE4":14420,"NA":14422},{"trials":14406,"activeCount":101},[],{"trials":14408,"activeCount":97,"soonestReadout":1130},[14409],{"nctId":14410,"briefTitle":14411,"status":158,"phases":14412,"primaryCompletion":1130,"completion":1130,"start":14413,"enrollment":1447,"conditions":14414,"interventions":14415},"NCT04167969","The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer",[89],"2021-02-17",[18],[14403],{"trials":14417,"activeCount":101},[],{"trials":14419,"activeCount":101},[],{"trials":14421,"activeCount":101},[],{"trials":14423,"activeCount":101},[],{"intervention":14425,"totalTrials":97,"cells":14426},"MB-CART19.1 Cellular Therapy",{"EARLY_PHASE1":14427,"PHASE1":14429,"PHASE2":14439,"PHASE3":14441,"PHASE4":14443,"NA":14445},{"trials":14428,"activeCount":101},[],{"trials":14430,"activeCount":97,"soonestReadout":1851},[14431],{"nctId":14432,"briefTitle":14433,"status":158,"phases":14434,"primaryCompletion":1851,"completion":1851,"start":14435,"enrollment":283,"conditions":14436,"interventions":14438},"NCT07137494","A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)",[89],"2025-08-14",[14437,1857],"Primary Central Nervous System (CNS) Lymphoma",[14425],{"trials":14440,"activeCount":101},[],{"trials":14442,"activeCount":101},[],{"trials":14444,"activeCount":101},[],{"trials":14446,"activeCount":101},[],{"intervention":8000,"totalTrials":97,"cells":14448},{"EARLY_PHASE1":14449,"PHASE1":14451,"PHASE2":14457,"PHASE3":14459,"PHASE4":14461,"NA":14463},{"trials":14450,"activeCount":101},[],{"trials":14452,"activeCount":97,"soonestReadout":304},[14453],{"nctId":7994,"briefTitle":7995,"status":158,"phases":14454,"primaryCompletion":304,"completion":304,"start":7997,"enrollment":326,"conditions":14455,"interventions":14456},[89],[535],[8000,3833,1315],{"trials":14458,"activeCount":101},[],{"trials":14460,"activeCount":101},[],{"trials":14462,"activeCount":101},[],{"trials":14464,"activeCount":101},[],{"intervention":14466,"totalTrials":97,"cells":14467},"GDC-0084",{"EARLY_PHASE1":14468,"PHASE1":14470,"PHASE2":14479,"PHASE3":14481,"PHASE4":14483,"NA":14485},{"trials":14469,"activeCount":101},[],{"trials":14471,"activeCount":97,"soonestReadout":498},[14472],{"nctId":14473,"briefTitle":14474,"status":113,"phases":14475,"primaryCompletion":498,"completion":498,"start":14476,"enrollment":899,"conditions":14477,"interventions":14478},"NCT04192981","GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases",[89],"2019-12-06",[6031,8192],[14466],{"trials":14480,"activeCount":101},[],{"trials":14482,"activeCount":101},[],{"trials":14484,"activeCount":101},[],{"trials":14486,"activeCount":101},[],{"intervention":14488,"totalTrials":97,"cells":14489},"Cytokine Induced Memory-Like Natural Killer Cells",{"EARLY_PHASE1":14490,"PHASE1":14492,"PHASE2":14505,"PHASE3":14507,"PHASE4":14509,"NA":14511},{"trials":14491,"activeCount":101},[],{"trials":14493,"activeCount":97,"soonestReadout":1741},[14494],{"nctId":14495,"briefTitle":14496,"status":158,"phases":14497,"primaryCompletion":1741,"completion":1741,"start":14498,"enrollment":326,"conditions":14499,"interventions":14502},"NCT07011004","A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia",[89],"2025-05-30",[14500,14501],"Acute Myeloid Leukemia Refractory","Acute Myeloid Leukemia, in Relapse",[14488,14503,14504],"Atezolizumb","CIML-NK cell therapy",{"trials":14506,"activeCount":101},[],{"trials":14508,"activeCount":101},[],{"trials":14510,"activeCount":101},[],{"trials":14512,"activeCount":101},[],{"intervention":14503,"totalTrials":97,"cells":14514},{"EARLY_PHASE1":14515,"PHASE1":14517,"PHASE2":14523,"PHASE3":14525,"PHASE4":14527,"NA":14529},{"trials":14516,"activeCount":101},[],{"trials":14518,"activeCount":97,"soonestReadout":1741},[14519],{"nctId":14495,"briefTitle":14496,"status":158,"phases":14520,"primaryCompletion":1741,"completion":1741,"start":14498,"enrollment":326,"conditions":14521,"interventions":14522},[89],[14500,14501],[14488,14503,14504],{"trials":14524,"activeCount":101},[],{"trials":14526,"activeCount":101},[],{"trials":14528,"activeCount":101},[],{"trials":14530,"activeCount":101},[],{"intervention":14504,"totalTrials":97,"cells":14532},{"EARLY_PHASE1":14533,"PHASE1":14535,"PHASE2":14541,"PHASE3":14543,"PHASE4":14545,"NA":14547},{"trials":14534,"activeCount":101},[],{"trials":14536,"activeCount":97,"soonestReadout":1741},[14537],{"nctId":14495,"briefTitle":14496,"status":158,"phases":14538,"primaryCompletion":1741,"completion":1741,"start":14498,"enrollment":326,"conditions":14539,"interventions":14540},[89],[14500,14501],[14488,14503,14504],{"trials":14542,"activeCount":101},[],{"trials":14544,"activeCount":101},[],{"trials":14546,"activeCount":101},[],{"trials":14548,"activeCount":101},[],{"intervention":6725,"totalTrials":97,"cells":14550},{"EARLY_PHASE1":14551,"PHASE1":14553,"PHASE2":14559,"PHASE3":14561,"PHASE4":14563,"NA":14565},{"trials":14552,"activeCount":101},[],{"trials":14554,"activeCount":97,"soonestReadout":115},[14555],{"nctId":6717,"briefTitle":6718,"status":113,"phases":14556,"primaryCompletion":115,"completion":115,"start":6720,"enrollment":306,"conditions":14557,"interventions":14558},[89],[605,6722,6723],[6701,6725],{"trials":14560,"activeCount":101},[],{"trials":14562,"activeCount":101},[],{"trials":14564,"activeCount":101},[],{"trials":14566,"activeCount":101},[],{"intervention":14568,"totalTrials":97,"cells":14569},"Romosozumab",{"EARLY_PHASE1":14570,"PHASE1":14572,"PHASE2":14582,"PHASE3":14584,"PHASE4":14586,"NA":14588},{"trials":14571,"activeCount":101},[],{"trials":14573,"activeCount":97,"soonestReadout":990},[14574],{"nctId":14575,"briefTitle":14576,"status":113,"phases":14577,"primaryCompletion":990,"completion":990,"start":14578,"enrollment":1434,"conditions":14579,"interventions":14581},"NCT05775094","A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis",[89],"2023-03-07",[14580,308],"Osteoporosis",[14568],{"trials":14583,"activeCount":101},[],{"trials":14585,"activeCount":101},[],{"trials":14587,"activeCount":101},[],{"trials":14589,"activeCount":101},[],{"intervention":14591,"totalTrials":97,"cells":14592},"Iodine-124",{"EARLY_PHASE1":14593,"PHASE1":14595,"PHASE2":14604,"PHASE3":14606,"PHASE4":14608,"NA":14610},{"trials":14594,"activeCount":101},[],{"trials":14596,"activeCount":97,"soonestReadout":1766},[14597],{"nctId":14598,"briefTitle":14599,"status":158,"phases":14600,"primaryCompletion":1766,"completion":1766,"start":4885,"enrollment":162,"conditions":14601,"interventions":14603},"NCT03647358","Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma",[89],[7752,14602],"Metastatic Thyroid Carcinoma",[14591],{"trials":14605,"activeCount":101},[],{"trials":14607,"activeCount":101},[],{"trials":14609,"activeCount":101},[],{"trials":14611,"activeCount":101},[],{"intervention":14613,"totalTrials":97,"cells":14614},"89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging",{"EARLY_PHASE1":14615,"PHASE1":14617,"PHASE2":14627,"PHASE3":14629,"PHASE4":14631,"NA":14633},{"trials":14616,"activeCount":101},[],{"trials":14618,"activeCount":97,"soonestReadout":990},[14619],{"nctId":14620,"briefTitle":14621,"status":113,"phases":14622,"primaryCompletion":990,"completion":990,"start":14623,"enrollment":234,"conditions":14624,"interventions":14626},"NCT03465618","A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors",[89],"2018-03-07",[8191,14625],"Pituitary Adenoma",[14613],{"trials":14628,"activeCount":101},[],{"trials":14630,"activeCount":101},[],{"trials":14632,"activeCount":101},[],{"trials":14634,"activeCount":101},[],{"intervention":14636,"totalTrials":97,"cells":14637},"Topical herbal plaster",{"EARLY_PHASE1":14638,"PHASE1":14640,"PHASE2":14653,"PHASE3":14655,"PHASE4":14657,"NA":14659},{"trials":14639,"activeCount":101},[],{"trials":14641,"activeCount":97,"soonestReadout":5419},[14642],{"nctId":14643,"briefTitle":14644,"status":158,"phases":14645,"primaryCompletion":5419,"completion":5419,"start":14646,"enrollment":14647,"conditions":14648,"interventions":14652},"NCT07447856","A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain",[89],"2026-02-23",150,[14649,14650,14651],"Cancer Patients","Survivor Patients","Cancer Pain",[14636],{"trials":14654,"activeCount":101},[],{"trials":14656,"activeCount":101},[],{"trials":14658,"activeCount":101},[],{"trials":14660,"activeCount":101},[],{"intervention":14662,"totalTrials":97,"cells":14663},"MCARH125",{"EARLY_PHASE1":14664,"PHASE1":14666,"PHASE2":14678,"PHASE3":14680,"PHASE4":14682,"NA":14684},{"trials":14665,"activeCount":101},[],{"trials":14667,"activeCount":97,"soonestReadout":1583},[14668],{"nctId":14669,"briefTitle":14670,"status":113,"phases":14671,"primaryCompletion":1583,"completion":1583,"start":14672,"enrollment":1871,"conditions":14673,"interventions":14676},"NCT05431608","A Study of MCARH109 and MCARH125 in People With Multiple Myeloma",[89],"2022-06-20",[308,14674,14675],"Refractory Multiple Myeloma","Relapse Multiple Myeloma",[14662,14677],"MCARH109",{"trials":14679,"activeCount":101},[],{"trials":14681,"activeCount":101},[],{"trials":14683,"activeCount":101},[],{"trials":14685,"activeCount":101},[],{"intervention":14677,"totalTrials":97,"cells":14687},{"EARLY_PHASE1":14688,"PHASE1":14690,"PHASE2":14696,"PHASE3":14698,"PHASE4":14700,"NA":14702},{"trials":14689,"activeCount":101},[],{"trials":14691,"activeCount":97,"soonestReadout":1583},[14692],{"nctId":14669,"briefTitle":14670,"status":113,"phases":14693,"primaryCompletion":1583,"completion":1583,"start":14672,"enrollment":1871,"conditions":14694,"interventions":14695},[89],[308,14674,14675],[14662,14677],{"trials":14697,"activeCount":101},[],{"trials":14699,"activeCount":101},[],{"trials":14701,"activeCount":101},[],{"trials":14703,"activeCount":101},[],{"intervention":14705,"totalTrials":97,"cells":14706},"89Zr-ss-pertuzumab PET\u002FCT",{"EARLY_PHASE1":14707,"PHASE1":14709,"PHASE2":14721,"PHASE3":14723,"PHASE4":14725,"NA":14727},{"trials":14708,"activeCount":101},[],{"trials":14710,"activeCount":97,"soonestReadout":11054},[14711],{"nctId":14712,"briefTitle":14713,"status":113,"phases":14714,"primaryCompletion":11054,"completion":11054,"start":14715,"enrollment":162,"conditions":14716,"interventions":14720},"NCT04692831","Testing a New Imaging Agent to Identify Cancer",[89],"2020-11-30",[14717,14718,14719],"HER-2 Positive Malignant Carcinoma of Breast","HER-2 Protein Overexpression","HER2-positive Metastatic Breast Cancer",[14705],{"trials":14722,"activeCount":101},[],{"trials":14724,"activeCount":101},[],{"trials":14726,"activeCount":101},[],{"trials":14728,"activeCount":101},[],{"intervention":14730,"totalTrials":97,"cells":14731},"CD371-specific\u002FYSNVz\u002FI-18 CAR T cells",{"EARLY_PHASE1":14732,"PHASE1":14734,"PHASE2":14746,"PHASE3":14748,"PHASE4":14750,"NA":14752},{"trials":14733,"activeCount":101},[],{"trials":14735,"activeCount":97,"soonestReadout":14740},[14736],{"nctId":14737,"briefTitle":14738,"status":158,"phases":14739,"primaryCompletion":14740,"completion":14740,"start":14741,"enrollment":1871,"conditions":14742,"interventions":14745},"NCT06017258","A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia",[89],"2026-08-22","2023-08-22",[14743,14744,3816,14501,14500],"Refractory Acute Myeloid Leukemia","Relapsed Acute Myeloid Leukemia",[14730],{"trials":14747,"activeCount":101},[],{"trials":14749,"activeCount":101},[],{"trials":14751,"activeCount":101},[],{"trials":14753,"activeCount":101},[],{"intervention":14755,"totalTrials":97,"cells":14756},"TTI-622",{"EARLY_PHASE1":14757,"PHASE1":14759,"PHASE2":14769,"PHASE3":14771,"PHASE4":14773,"NA":14775},{"trials":14758,"activeCount":101},[],{"trials":14760,"activeCount":97,"soonestReadout":115},[14761],{"nctId":14762,"briefTitle":14763,"status":113,"phases":14764,"primaryCompletion":115,"completion":115,"start":14765,"enrollment":2291,"conditions":14766,"interventions":14767},"NCT05139225","A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma",[89],"2021-10-28",[308],[14755,14768],"Daratumumab Hyaluronidase-fihj",{"trials":14770,"activeCount":101},[],{"trials":14772,"activeCount":101},[],{"trials":14774,"activeCount":101},[],{"trials":14776,"activeCount":101},[],{"intervention":14768,"totalTrials":97,"cells":14778},{"EARLY_PHASE1":14779,"PHASE1":14781,"PHASE2":14787,"PHASE3":14789,"PHASE4":14791,"NA":14793},{"trials":14780,"activeCount":101},[],{"trials":14782,"activeCount":97,"soonestReadout":115},[14783],{"nctId":14762,"briefTitle":14763,"status":113,"phases":14784,"primaryCompletion":115,"completion":115,"start":14765,"enrollment":2291,"conditions":14785,"interventions":14786},[89],[308],[14755,14768],{"trials":14788,"activeCount":101},[],{"trials":14790,"activeCount":101},[],{"trials":14792,"activeCount":101},[],{"trials":14794,"activeCount":101},[],{"intervention":14796,"totalTrials":97,"cells":14797},"WST 11-mediated VTP therapy",{"EARLY_PHASE1":14798,"PHASE1":14800,"PHASE2":14811,"PHASE3":14813,"PHASE4":14815,"NA":14817},{"trials":14799,"activeCount":101},[],{"trials":14801,"activeCount":97,"soonestReadout":14806},[14802],{"nctId":14803,"briefTitle":14804,"status":113,"phases":14805,"primaryCompletion":14806,"completion":14806,"start":14807,"enrollment":283,"conditions":14808,"interventions":14810},"NCT03133650","A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing",[89],"2027-02-23","2017-04-26",[2678,14809],"Moderate to Severe Dysphagia",[14796],{"trials":14812,"activeCount":101},[],{"trials":14814,"activeCount":101},[],{"trials":14816,"activeCount":101},[],{"trials":14818,"activeCount":101},[],{"intervention":14820,"totalTrials":97,"cells":14821},"M28z1XXPD1DNR CAR",{"EARLY_PHASE1":14822,"PHASE1":14824,"PHASE2":14840,"PHASE3":14842,"PHASE4":14844,"NA":14846},{"trials":14823,"activeCount":101},[],{"trials":14825,"activeCount":97,"soonestReadout":14830},[14826],{"nctId":14827,"briefTitle":14828,"status":158,"phases":14829,"primaryCompletion":14830,"completion":14830,"start":7063,"enrollment":326,"conditions":14831,"interventions":14839},"NCT06623396","A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer",[89],"2028-09-30",[14832,14833,4290,14834,14835,14836,14837,14838],"Mesothelin Positive","Mesothelin-Expressing Tumors","Esophageal Adenocarcinomas","Esophagogastric Adenocarcinoma","Peritoneal Carcinomatosis","Breast Neoplasms","Diabetes Mellitus",[14820],{"trials":14841,"activeCount":101},[],{"trials":14843,"activeCount":101},[],{"trials":14845,"activeCount":101},[],{"trials":14847,"activeCount":101},[],{"intervention":8473,"totalTrials":97,"cells":14849},{"EARLY_PHASE1":14850,"PHASE1":14852,"PHASE2":14858,"PHASE3":14860,"PHASE4":14862,"NA":14864},{"trials":14851,"activeCount":101},[],{"trials":14853,"activeCount":97,"soonestReadout":8469},[14854],{"nctId":8466,"briefTitle":8467,"status":158,"phases":14855,"primaryCompletion":8469,"completion":8469,"start":8470,"enrollment":326,"conditions":14856,"interventions":14857},[89],[308],[8473,8459],{"trials":14859,"activeCount":101},[],{"trials":14861,"activeCount":101},[],{"trials":14863,"activeCount":101},[],{"trials":14865,"activeCount":101},[],{"intervention":2657,"totalTrials":97,"cells":14867},{"EARLY_PHASE1":14868,"PHASE1":14870,"PHASE2":14876,"PHASE3":14878,"PHASE4":14880,"NA":14882},{"trials":14869,"activeCount":101},[],{"trials":14871,"activeCount":97,"soonestReadout":1130},[14872],{"nctId":2651,"briefTitle":2652,"status":113,"phases":14873,"primaryCompletion":1130,"completion":1130,"start":2654,"enrollment":2483,"conditions":14874,"interventions":14875},[89],[2293],[942,1107,2657],{"trials":14877,"activeCount":101},[],{"trials":14879,"activeCount":101},[],{"trials":14881,"activeCount":101},[],{"trials":14883,"activeCount":101},[],{"intervention":14885,"totalTrials":97,"cells":14886},"anti-CD40 antibody 2141-V11",{"EARLY_PHASE1":14887,"PHASE1":14889,"PHASE2":14899,"PHASE3":14901,"PHASE4":14903,"NA":14905},{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":97,"soonestReadout":1240},[14891],{"nctId":14892,"briefTitle":14893,"status":158,"phases":14894,"primaryCompletion":1240,"completion":1240,"start":14895,"enrollment":34,"conditions":14896,"interventions":14898},"NCT05126472","Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment",[89],"2021-11-08",[14897],"Non-muscle Invasive Bladder Cancer",[14885,14885,14885],{"trials":14900,"activeCount":101},[],{"trials":14902,"activeCount":101},[],{"trials":14904,"activeCount":101},[],{"trials":14906,"activeCount":101},[],{"intervention":940,"totalTrials":97,"cells":14908},{"EARLY_PHASE1":14909,"PHASE1":14911,"PHASE2":14917,"PHASE3":14919,"PHASE4":14921,"NA":14923},{"trials":14910,"activeCount":101},[],{"trials":14912,"activeCount":97,"soonestReadout":933},[14913],{"nctId":930,"briefTitle":931,"status":158,"phases":14914,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":14915,"interventions":14916},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"trials":14918,"activeCount":101},[],{"trials":14920,"activeCount":101},[],{"trials":14922,"activeCount":101},[],{"trials":14924,"activeCount":101},[],{"intervention":943,"totalTrials":97,"cells":14926},{"EARLY_PHASE1":14927,"PHASE1":14929,"PHASE2":14935,"PHASE3":14937,"PHASE4":14939,"NA":14941},{"trials":14928,"activeCount":101},[],{"trials":14930,"activeCount":97,"soonestReadout":933},[14931],{"nctId":930,"briefTitle":931,"status":158,"phases":14932,"primaryCompletion":933,"completion":933,"start":934,"enrollment":162,"conditions":14933,"interventions":14934},[89],[936,937,938],[940,941,942,943,582,944,923,945],{"trials":14936,"activeCount":101},[],{"trials":14938,"activeCount":101},[],{"trials":14940,"activeCount":101},[],{"trials":14942,"activeCount":101},[],{"intervention":14944,"totalTrials":97,"cells":14945},"Gadobutrol",{"EARLY_PHASE1":14946,"PHASE1":14948,"PHASE2":14958,"PHASE3":14960,"PHASE4":14962,"NA":14964},{"trials":14947,"activeCount":101},[],{"trials":14949,"activeCount":97,"soonestReadout":812},[14950],{"nctId":14951,"briefTitle":14952,"status":113,"phases":14953,"primaryCompletion":812,"completion":812,"start":14954,"enrollment":454,"conditions":14955,"interventions":14957},"NCT04893434","Novel Imaging Technique to Assess Gynecologic Cancer",[89],"2021-05-13",[14956],"Gynecologic Cancer",[14944],{"trials":14959,"activeCount":101},[],{"trials":14961,"activeCount":101},[],{"trials":14963,"activeCount":101},[],{"trials":14965,"activeCount":101},[],{"intervention":13960,"totalTrials":97,"cells":14967},{"EARLY_PHASE1":14968,"PHASE1":14970,"PHASE2":14976,"PHASE3":14978,"PHASE4":14980,"NA":14982},{"trials":14969,"activeCount":101},[],{"trials":14971,"activeCount":97,"soonestReadout":115},[14972],{"nctId":13954,"briefTitle":13955,"status":113,"phases":14973,"primaryCompletion":115,"completion":115,"start":13957,"enrollment":601,"conditions":14974,"interventions":14975},[89],[308],[13960,13961,3736],{"trials":14977,"activeCount":101},[],{"trials":14979,"activeCount":101},[],{"trials":14981,"activeCount":101},[],{"trials":14983,"activeCount":101},[],{"intervention":13961,"totalTrials":97,"cells":14985},{"EARLY_PHASE1":14986,"PHASE1":14988,"PHASE2":14994,"PHASE3":14996,"PHASE4":14998,"NA":15000},{"trials":14987,"activeCount":101},[],{"trials":14989,"activeCount":97,"soonestReadout":115},[14990],{"nctId":13954,"briefTitle":13955,"status":113,"phases":14991,"primaryCompletion":115,"completion":115,"start":13957,"enrollment":601,"conditions":14992,"interventions":14993},[89],[308],[13960,13961,3736],{"trials":14995,"activeCount":101},[],{"trials":14997,"activeCount":101},[],{"trials":14999,"activeCount":101},[],{"trials":15001,"activeCount":101},[],{"intervention":4710,"totalTrials":97,"cells":15003},{"EARLY_PHASE1":15004,"PHASE1":15006,"PHASE2":15012,"PHASE3":15014,"PHASE4":15016,"NA":15018},{"trials":15005,"activeCount":101},[],{"trials":15007,"activeCount":97,"soonestReadout":1208},[15008],{"nctId":4703,"briefTitle":4704,"status":158,"phases":15009,"primaryCompletion":1208,"completion":1208,"start":4706,"enrollment":162,"conditions":15010,"interventions":15011},[89],[2790,4708],[4710,4711,4712,818],{"trials":15013,"activeCount":101},[],{"trials":15015,"activeCount":101},[],{"trials":15017,"activeCount":101},[],{"trials":15019,"activeCount":101},[],{"intervention":4711,"totalTrials":97,"cells":15021},{"EARLY_PHASE1":15022,"PHASE1":15024,"PHASE2":15030,"PHASE3":15032,"PHASE4":15034,"NA":15036},{"trials":15023,"activeCount":101},[],{"trials":15025,"activeCount":97,"soonestReadout":1208},[15026],{"nctId":4703,"briefTitle":4704,"status":158,"phases":15027,"primaryCompletion":1208,"completion":1208,"start":4706,"enrollment":162,"conditions":15028,"interventions":15029},[89],[2790,4708],[4710,4711,4712,818],{"trials":15031,"activeCount":101},[],{"trials":15033,"activeCount":101},[],{"trials":15035,"activeCount":101},[],{"trials":15037,"activeCount":101},[],{"intervention":4712,"totalTrials":97,"cells":15039},{"EARLY_PHASE1":15040,"PHASE1":15042,"PHASE2":15048,"PHASE3":15050,"PHASE4":15052,"NA":15054},{"trials":15041,"activeCount":101},[],{"trials":15043,"activeCount":97,"soonestReadout":1208},[15044],{"nctId":4703,"briefTitle":4704,"status":158,"phases":15045,"primaryCompletion":1208,"completion":1208,"start":4706,"enrollment":162,"conditions":15046,"interventions":15047},[89],[2790,4708],[4710,4711,4712,818],{"trials":15049,"activeCount":101},[],{"trials":15051,"activeCount":101},[],{"trials":15053,"activeCount":101},[],{"trials":15055,"activeCount":101},[],{"intervention":15057,"totalTrials":97,"cells":15058},"SER-155",{"EARLY_PHASE1":15059,"PHASE1":15061,"PHASE2":15073,"PHASE3":15075,"PHASE4":15077,"NA":15079},{"trials":15060,"activeCount":101},[],{"trials":15062,"activeCount":97,"soonestReadout":15067},[15063],{"nctId":15064,"briefTitle":15065,"status":158,"phases":15066,"primaryCompletion":15067,"completion":15067,"start":15068,"enrollment":1871,"conditions":15069,"interventions":15072},"NCT06801067","A Study of SER-155 to Treat Diarrhea in People on Immunotherapy",[89],"2027-01-24","2025-01-24",[15070,15071],"Diarrhea","Enterocolitis",[15057],{"trials":15074,"activeCount":101},[],{"trials":15076,"activeCount":101},[],{"trials":15078,"activeCount":101},[],{"trials":15080,"activeCount":101},[],{"intervention":1473,"totalTrials":97,"cells":15082},{"EARLY_PHASE1":15083,"PHASE1":15085,"PHASE2":15091,"PHASE3":15093,"PHASE4":15095,"NA":15097},{"trials":15084,"activeCount":101},[],{"trials":15086,"activeCount":97,"soonestReadout":1469},[15087],{"nctId":1466,"briefTitle":1467,"status":113,"phases":15088,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":573,"conditions":15089,"interventions":15090},[89],[720],[1473,331,420,238,1474],{"trials":15092,"activeCount":101},[],{"trials":15094,"activeCount":101},[],{"trials":15096,"activeCount":101},[],{"trials":15098,"activeCount":101},[],{"intervention":1474,"totalTrials":97,"cells":15100},{"EARLY_PHASE1":15101,"PHASE1":15103,"PHASE2":15109,"PHASE3":15111,"PHASE4":15113,"NA":15115},{"trials":15102,"activeCount":101},[],{"trials":15104,"activeCount":97,"soonestReadout":1469},[15105],{"nctId":1466,"briefTitle":1467,"status":113,"phases":15106,"primaryCompletion":1469,"completion":1469,"start":1470,"enrollment":573,"conditions":15107,"interventions":15108},[89],[720],[1473,331,420,238,1474],{"trials":15110,"activeCount":101},[],{"trials":15112,"activeCount":101},[],{"trials":15114,"activeCount":101},[],{"trials":15116,"activeCount":101},[],{"intervention":4975,"totalTrials":97,"cells":15118},{"EARLY_PHASE1":15119,"PHASE1":15121,"PHASE2":15127,"PHASE3":15129,"PHASE4":15131,"NA":15133},{"trials":15120,"activeCount":101},[],{"trials":15122,"activeCount":97,"soonestReadout":4971},[15123],{"nctId":4968,"briefTitle":4969,"status":158,"phases":15124,"primaryCompletion":4971,"completion":4971,"start":4972,"enrollment":1447,"conditions":15125,"interventions":15126},[89],[1695],[4975,4961],{"trials":15128,"activeCount":101},[],{"trials":15130,"activeCount":101},[],{"trials":15132,"activeCount":101},[],{"trials":15134,"activeCount":101},[],{"intervention":1279,"totalTrials":97,"cells":15136},{"EARLY_PHASE1":15137,"PHASE1":15139,"PHASE2":15145,"PHASE3":15147,"PHASE4":15149,"NA":15151},{"trials":15138,"activeCount":101},[],{"trials":15140,"activeCount":97,"soonestReadout":1130},[15141],{"nctId":1273,"briefTitle":1274,"status":113,"phases":15142,"primaryCompletion":1130,"completion":1130,"start":1276,"enrollment":1232,"conditions":15143,"interventions":15144},[89],[24],[374,1279,444],{"trials":15146,"activeCount":101},[],{"trials":15148,"activeCount":101},[],{"trials":15150,"activeCount":101},[],{"trials":15152,"activeCount":101},[],{"intervention":15154,"totalTrials":97,"cells":15155},"19(T2)28z1xx TRAC T cell",{"EARLY_PHASE1":15156,"PHASE1":15158,"PHASE2":15171,"PHASE3":15173,"PHASE4":15175,"NA":15177},{"trials":15157,"activeCount":101},[],{"trials":15159,"activeCount":97,"soonestReadout":14806},[15160],{"nctId":15161,"briefTitle":15162,"status":113,"phases":15163,"primaryCompletion":14806,"completion":14806,"start":15164,"enrollment":356,"conditions":15165,"interventions":15170},"NCT05757700","Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma",[89],"2023-02-23",[11377,15166,15167,15168,15169],"Large B-cell Lymphoma","DLBCL, Nos Genetic Subtypes","High-grade B Cell Lymphoma","Mediastinal Large B-cell Lymphoma",[15154],{"trials":15172,"activeCount":101},[],{"trials":15174,"activeCount":101},[],{"trials":15176,"activeCount":101},[],{"trials":15178,"activeCount":101},[],{"intervention":5352,"totalTrials":97,"cells":15180},{"EARLY_PHASE1":15181,"PHASE1":15183,"PHASE2":15189,"PHASE3":15191,"PHASE4":15193,"NA":15195},{"trials":15182,"activeCount":101},[],{"trials":15184,"activeCount":97,"soonestReadout":5348},[15185],{"nctId":5345,"briefTitle":5346,"status":113,"phases":15186,"primaryCompletion":5348,"completion":5348,"start":5349,"enrollment":1462,"conditions":15187,"interventions":15188},[89],[1226],[86,5352,5353],{"trials":15190,"activeCount":101},[],{"trials":15192,"activeCount":101},[],{"trials":15194,"activeCount":101},[],{"trials":15196,"activeCount":101},[],{"intervention":5353,"totalTrials":97,"cells":15198},{"EARLY_PHASE1":15199,"PHASE1":15201,"PHASE2":15207,"PHASE3":15209,"PHASE4":15211,"NA":15213},{"trials":15200,"activeCount":101},[],{"trials":15202,"activeCount":97,"soonestReadout":5348},[15203],{"nctId":5345,"briefTitle":5346,"status":113,"phases":15204,"primaryCompletion":5348,"completion":5348,"start":5349,"enrollment":1462,"conditions":15205,"interventions":15206},[89],[1226],[86,5352,5353],{"trials":15208,"activeCount":101},[],{"trials":15210,"activeCount":101},[],{"trials":15212,"activeCount":101},[],{"trials":15214,"activeCount":101},[],{"intervention":15216,"totalTrials":97,"cells":15217},"19(T2)28z1xx CAR T cells",{"EARLY_PHASE1":15218,"PHASE1":15220,"PHASE2":15234,"PHASE3":15236,"PHASE4":15238,"NA":15240},{"trials":15219,"activeCount":101},[],{"trials":15221,"activeCount":97,"soonestReadout":2082},[15222],{"nctId":15223,"briefTitle":15224,"status":113,"phases":15225,"primaryCompletion":2082,"completion":2082,"start":15226,"enrollment":356,"conditions":15227,"interventions":15233},"NCT04464200","19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers",[89],"2020-07-06",[1885,15228,15229,606,15230,1370,1323,15231,15232],"Primary Mediastinal Large B Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma","Indolent Non-Hodgkin Lymphoma","Burkitt's Lymphoma","Primary CNS Lymphoma",[15216],{"trials":15235,"activeCount":101},[],{"trials":15237,"activeCount":101},[],{"trials":15239,"activeCount":101},[],{"trials":15241,"activeCount":101},[],{"intervention":15243,"totalTrials":97,"cells":15244},"MAB HER 2",{"EARLY_PHASE1":15245,"PHASE1":15247,"PHASE2":15255,"PHASE3":15257,"PHASE4":15259,"NA":15261},{"trials":15246,"activeCount":101},[],{"trials":15248,"activeCount":97,"soonestReadout":232},[15249],{"nctId":15250,"briefTitle":15251,"status":113,"phases":15252,"primaryCompletion":232,"completion":232,"start":1151,"enrollment":296,"conditions":15253,"interventions":15254},"NCT00393783","Xenogeneic HER2\u002FNeu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity",[89],[15],[15243],{"trials":15256,"activeCount":101},[],{"trials":15258,"activeCount":101},[],{"trials":15260,"activeCount":101},[],{"trials":15262,"activeCount":101},[],{"intervention":3899,"totalTrials":97,"cells":15264},{"EARLY_PHASE1":15265,"PHASE1":15267,"PHASE2":15273,"PHASE3":15275,"PHASE4":15277,"NA":15279},{"trials":15266,"activeCount":101},[],{"trials":15268,"activeCount":97,"soonestReadout":531},[15269],{"nctId":3892,"briefTitle":3893,"status":113,"phases":15270,"primaryCompletion":531,"completion":531,"start":1141,"enrollment":234,"conditions":15271,"interventions":15272},[89],[707],[3897,223,581,420,3898,3899],{"trials":15274,"activeCount":101},[],{"trials":15276,"activeCount":101},[],{"trials":15278,"activeCount":101},[],{"trials":15280,"activeCount":101},[],{"intervention":310,"totalTrials":97,"cells":15282},{"EARLY_PHASE1":15283,"PHASE1":15285,"PHASE2":15291,"PHASE3":15293,"PHASE4":15295,"NA":15297},{"trials":15284,"activeCount":101},[],{"trials":15286,"activeCount":97,"soonestReadout":304},[15287],{"nctId":301,"briefTitle":302,"status":113,"phases":15288,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":15289,"interventions":15290},[89],[308],[310,218,311],{"trials":15292,"activeCount":101},[],{"trials":15294,"activeCount":101},[],{"trials":15296,"activeCount":101},[],{"trials":15298,"activeCount":101},[],{"intervention":311,"totalTrials":97,"cells":15300},{"EARLY_PHASE1":15301,"PHASE1":15303,"PHASE2":15309,"PHASE3":15311,"PHASE4":15313,"NA":15315},{"trials":15302,"activeCount":101},[],{"trials":15304,"activeCount":97,"soonestReadout":304},[15305],{"nctId":301,"briefTitle":302,"status":113,"phases":15306,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":15307,"interventions":15308},[89],[308],[310,218,311],{"trials":15310,"activeCount":101},[],{"trials":15312,"activeCount":101},[],{"trials":15314,"activeCount":101},[],{"trials":15316,"activeCount":101},[],{"intervention":319,"totalTrials":97,"cells":15318},{"EARLY_PHASE1":15319,"PHASE1":15321,"PHASE2":15327,"PHASE3":15329,"PHASE4":15331,"NA":15333},{"trials":15320,"activeCount":101},[],{"trials":15322,"activeCount":97,"soonestReadout":258},[15323],{"nctId":313,"briefTitle":314,"status":113,"phases":15324,"primaryCompletion":258,"completion":258,"start":316,"enrollment":296,"conditions":15325,"interventions":15326},[89],[18],[319,202],{"trials":15328,"activeCount":101},[],{"trials":15330,"activeCount":101},[],{"trials":15332,"activeCount":101},[],{"trials":15334,"activeCount":101},[],{"intervention":2353,"totalTrials":97,"cells":15336},{"EARLY_PHASE1":15337,"PHASE1":15339,"PHASE2":15345,"PHASE3":15347,"PHASE4":15349,"NA":15351},{"trials":15338,"activeCount":101},[],{"trials":15340,"activeCount":97,"soonestReadout":2332},[15341],{"nctId":2329,"briefTitle":2330,"status":158,"phases":15342,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":15343,"interventions":15344},[89],[2336,2337,2338,2339,2340,2341,2342,2343,2344,2345,1590,1591,2346,1020,2347,2348,2349,2350,2351],[2353,42],{"trials":15346,"activeCount":101},[],{"trials":15348,"activeCount":101},[],{"trials":15350,"activeCount":101},[],{"trials":15352,"activeCount":101},[],{"intervention":15354,"totalTrials":97,"cells":15355},"CRD3874",{"EARLY_PHASE1":15356,"PHASE1":15358,"PHASE2":15368,"PHASE3":15370,"PHASE4":15372,"NA":15374},{"trials":15357,"activeCount":101},[],{"trials":15359,"activeCount":97,"soonestReadout":15364},[15360],{"nctId":15361,"briefTitle":15362,"status":158,"phases":15363,"primaryCompletion":15364,"completion":15364,"start":15365,"enrollment":2690,"conditions":15366,"interventions":15367},"NCT06021626","A Study of CRD3874-SI in People With Solid Tumors",[89],"2029-08","2023-08-25",[33,2342],[15354],{"trials":15369,"activeCount":101},[],{"trials":15371,"activeCount":101},[],{"trials":15373,"activeCount":101},[],{"trials":15375,"activeCount":101},[],{"intervention":15377,"totalTrials":97,"cells":15378},"gene-modified T cells targeted",{"EARLY_PHASE1":15379,"PHASE1":15381,"PHASE2":15390,"PHASE3":15392,"PHASE4":15394,"NA":15396},{"trials":15380,"activeCount":101},[],{"trials":15382,"activeCount":97,"soonestReadout":2472},[15383],{"nctId":15384,"briefTitle":15385,"status":113,"phases":15386,"primaryCompletion":2472,"completion":2472,"start":15387,"enrollment":1906,"conditions":15388,"interventions":15389},"NCT01044069","Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",[89],"2010-01-05",[27,414],[15377],{"trials":15391,"activeCount":101},[],{"trials":15393,"activeCount":101},[],{"trials":15395,"activeCount":101},[],{"trials":15397,"activeCount":101},[],{"intervention":15399,"totalTrials":97,"cells":15400},"Zirconium Zr 89 crefmirlimab berdoxam",{"EARLY_PHASE1":15401,"PHASE1":15403,"PHASE2":15413,"PHASE3":15415,"PHASE4":15417,"NA":15419},{"trials":15402,"activeCount":101},[],{"trials":15404,"activeCount":97,"soonestReadout":15409},[15405],{"nctId":15406,"briefTitle":15407,"status":158,"phases":15408,"primaryCompletion":15409,"completion":15409,"start":15410,"enrollment":1934,"conditions":15411,"interventions":15412},"NCT06863233","A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer",[89],"2028-03-03","2025-03-03",[21,3094,9745],[15399],{"trials":15414,"activeCount":101},[],{"trials":15416,"activeCount":101},[],{"trials":15418,"activeCount":101},[],{"trials":15420,"activeCount":101},[],{"intervention":330,"totalTrials":97,"cells":15422},{"EARLY_PHASE1":15423,"PHASE1":15425,"PHASE2":15431,"PHASE3":15433,"PHASE4":15435,"NA":15437},{"trials":15424,"activeCount":101},[],{"trials":15426,"activeCount":97,"soonestReadout":324},[15427],{"nctId":321,"briefTitle":322,"status":113,"phases":15428,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":15429,"interventions":15430},[89],[328],[218,330,331],{"trials":15432,"activeCount":101},[],{"trials":15434,"activeCount":101},[],{"trials":15436,"activeCount":101},[],{"trials":15438,"activeCount":101},[],{"intervention":13665,"totalTrials":97,"cells":15440},{"EARLY_PHASE1":15441,"PHASE1":15443,"PHASE2":15449,"PHASE3":15451,"PHASE4":15453,"NA":15455},{"trials":15442,"activeCount":101},[],{"trials":15444,"activeCount":97,"soonestReadout":13660},[15445],{"nctId":13657,"briefTitle":13658,"status":158,"phases":15446,"primaryCompletion":13660,"completion":13660,"start":8470,"enrollment":356,"conditions":15447,"interventions":15448},[89],[13662,13663],[13665,4119],{"trials":15450,"activeCount":101},[],{"trials":15452,"activeCount":101},[],{"trials":15454,"activeCount":101},[],{"trials":15456,"activeCount":101},[],{"intervention":15458,"totalTrials":97,"cells":15459},"Hyperpolarized [13C] Pyruvate",{"EARLY_PHASE1":15460,"PHASE1":15462,"PHASE2":15473,"PHASE3":15475,"PHASE4":15477,"NA":15479},{"trials":15461,"activeCount":101},[],{"trials":15463,"activeCount":97,"soonestReadout":1469},[15464],{"nctId":15465,"briefTitle":15466,"status":15467,"phases":15468,"primaryCompletion":1469,"completion":1469,"start":15469,"enrollment":370,"conditions":15470,"interventions":15472},"NCT05041166","A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers","ENROLLING_BY_INVITATION",[89],"2021-09-01",[15471],"Healthy Volunteers",[15458],{"trials":15474,"activeCount":101},[],{"trials":15476,"activeCount":101},[],{"trials":15478,"activeCount":101},[],{"trials":15480,"activeCount":101},[],{"intervention":13991,"totalTrials":97,"cells":15482},{"EARLY_PHASE1":15483,"PHASE1":15485,"PHASE2":15491,"PHASE3":15493,"PHASE4":15495,"NA":15497},{"trials":15484,"activeCount":101},[],{"trials":15486,"activeCount":97,"soonestReadout":232},[15487],{"nctId":13985,"briefTitle":13986,"status":113,"phases":15488,"primaryCompletion":232,"completion":232,"start":813,"enrollment":1412,"conditions":15489,"interventions":15490},[89],[13989],[13991,299],{"trials":15492,"activeCount":101},[],{"trials":15494,"activeCount":101},[],{"trials":15496,"activeCount":101},[],{"trials":15498,"activeCount":101},[],{"intervention":4692,"totalTrials":509,"cells":15500},{"EARLY_PHASE1":15501,"PHASE1":15507,"PHASE2":15513,"PHASE3":15519,"PHASE4":15521,"NA":15523},{"trials":15502,"activeCount":97,"soonestReadout":258},[15503],{"nctId":4684,"briefTitle":4685,"status":113,"phases":15504,"primaryCompletion":258,"completion":258,"start":4687,"enrollment":1798,"conditions":15505,"interventions":15506},[88],[4689],[819,4691,4692,4693],{"trials":15508,"activeCount":101},[15509],{"nctId":242,"briefTitle":243,"status":244,"phases":15510,"primaryCompletion":246,"completion":246,"start":247,"enrollment":28,"conditions":15511,"interventions":15512},[89],[215,249],[202,251,252,253],{"trials":15514,"activeCount":101},[15515],{"nctId":7139,"briefTitle":7140,"status":244,"phases":15516,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":533,"conditions":15517,"interventions":15518},[90],[215],[4692,4693,7146],{"trials":15520,"activeCount":101},[],{"trials":15522,"activeCount":101},[],{"trials":15524,"activeCount":101},[],{"intervention":15526,"totalTrials":1094,"cells":15527},"CAR T-Cell",{"EARLY_PHASE1":15528,"PHASE1":15547,"PHASE2":15557,"PHASE3":15559,"PHASE4":15561,"NA":15563},{"trials":15529,"activeCount":97,"soonestReadout":2472},[15530],{"nctId":15531,"briefTitle":15532,"status":158,"phases":15533,"primaryCompletion":2472,"completion":2472,"start":15534,"enrollment":283,"conditions":15535,"interventions":15544},"NCT04512716","Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",[88],"2021-02-02",[8245,15536,15537,15538,15539,15167,15540,15541,1873,15542,15543],"DLBCL","B ALL","Dlbcl-Ci","DLBCL Unclassifiable","DLBCL Activated B-Cell Type","DLBCL Germinal Center B-Cell Type","HGBL","HGBL, Nos",[15545,15546],"131-I Apamistamab","CAR T-cell",{"trials":15548,"activeCount":101},[15549],{"nctId":15550,"briefTitle":15551,"status":2832,"phases":15552,"primaryCompletion":5995,"completion":5995,"start":15553,"enrollment":101,"conditions":15554,"interventions":15556},"NCT04556266","A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies",[89],"2021-07-01",[27,24,15555],"Lymphoma, B-Cell",[15526],{"trials":15558,"activeCount":101},[],{"trials":15560,"activeCount":101},[],{"trials":15562,"activeCount":101},[],{"trials":15564,"activeCount":101},[],{"intervention":15566,"totalTrials":97,"cells":15567},"Tirzepatide",{"EARLY_PHASE1":15568,"PHASE1":15577,"PHASE2":15579,"PHASE3":15581,"PHASE4":15583,"NA":15585},{"trials":15569,"activeCount":97,"soonestReadout":1310},[15570],{"nctId":15571,"briefTitle":15572,"status":158,"phases":15573,"primaryCompletion":1310,"completion":1310,"start":15574,"enrollment":3344,"conditions":15575,"interventions":15576},"NCT06751589","A Study of a Weight Loss Intervention in People With Endometrial Cancer",[88],"2024-12-19",[3359],[15566],{"trials":15578,"activeCount":101},[],{"trials":15580,"activeCount":101},[],{"trials":15582,"activeCount":101},[],{"trials":15584,"activeCount":101},[],{"trials":15586,"activeCount":101},[],{"intervention":15588,"totalTrials":97,"cells":15589},"177Lu-DOTATATE",{"EARLY_PHASE1":15590,"PHASE1":15600,"PHASE2":15602,"PHASE3":15604,"PHASE4":15606,"NA":15608},{"trials":15591,"activeCount":97,"soonestReadout":4378},[15592],{"nctId":15593,"briefTitle":15594,"status":113,"phases":15595,"primaryCompletion":4378,"completion":4378,"start":6114,"enrollment":1434,"conditions":15596,"interventions":15599},"NCT04544098","Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver",[88],[15597,15598],"Neuroendocrine Tumors","Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors",[15588],{"trials":15601,"activeCount":101},[],{"trials":15603,"activeCount":101},[],{"trials":15605,"activeCount":101},[],{"trials":15607,"activeCount":101},[],{"trials":15609,"activeCount":101},[],{"intervention":15611,"totalTrials":97,"cells":15612},"[68Ga]-Pentixafor",{"EARLY_PHASE1":15613,"PHASE1":15623,"PHASE2":15625,"PHASE3":15627,"PHASE4":15629,"NA":15631},{"trials":15614,"activeCount":97,"soonestReadout":194},[15615],{"nctId":15616,"briefTitle":15617,"status":158,"phases":15618,"primaryCompletion":194,"completion":194,"start":1029,"enrollment":356,"conditions":15619,"interventions":15622},"NCT05093335","In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET",[88],[605,308,8215,15620,15621],"Erdheim-Chester Disease","Rosai-Dorfman Disease",[15611],{"trials":15624,"activeCount":101},[],{"trials":15626,"activeCount":101},[],{"trials":15628,"activeCount":101},[],{"trials":15630,"activeCount":101},[],{"trials":15632,"activeCount":101},[],{"intervention":15634,"totalTrials":97,"cells":15635},"irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator",{"EARLY_PHASE1":15636,"PHASE1":15645,"PHASE2":15647,"PHASE3":15649,"PHASE4":15651,"NA":15653},{"trials":15637,"activeCount":97,"soonestReadout":324},[15638],{"nctId":15639,"briefTitle":15640,"status":113,"phases":15641,"primaryCompletion":324,"completion":324,"start":4635,"enrollment":1871,"conditions":15642,"interventions":15644},"NCT01189643","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",[88],[33,15643],"Desmoplastic Small Round Cell Tumor (DSRCT)",[15634],{"trials":15646,"activeCount":101},[],{"trials":15648,"activeCount":101},[],{"trials":15650,"activeCount":101},[],{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[],{"intervention":2612,"totalTrials":97,"cells":15656},{"EARLY_PHASE1":15657,"PHASE1":15663,"PHASE2":15665,"PHASE3":15667,"PHASE4":15669,"NA":15671},{"trials":15658,"activeCount":97,"soonestReadout":531},[15659],{"nctId":2605,"briefTitle":2606,"status":113,"phases":15660,"primaryCompletion":531,"completion":531,"start":2608,"enrollment":306,"conditions":15661,"interventions":15662},[88],[2610],[2612,942],{"trials":15664,"activeCount":101},[],{"trials":15666,"activeCount":101},[],{"trials":15668,"activeCount":101},[],{"trials":15670,"activeCount":101},[],{"trials":15672,"activeCount":101},[],{"intervention":15674,"totalTrials":97,"cells":15675},"HB-200",{"EARLY_PHASE1":15676,"PHASE1":15686,"PHASE2":15688,"PHASE3":15690,"PHASE4":15692,"NA":15694},{"trials":15677,"activeCount":97,"soonestReadout":531},[15678],{"nctId":15679,"briefTitle":15680,"status":113,"phases":15681,"primaryCompletion":531,"completion":531,"start":15682,"enrollment":2291,"conditions":15683,"interventions":15685},"NCT06373380","A Study of HB-202\u002FHB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)",[88],"2024-04-15",[15684],"HPV16+ Squamous Cell Carcinoma",[15674],{"trials":15687,"activeCount":101},[],{"trials":15689,"activeCount":101},[],{"trials":15691,"activeCount":101},[],{"trials":15693,"activeCount":101},[],{"trials":15695,"activeCount":101},[],{"intervention":15545,"totalTrials":97,"cells":15697},{"EARLY_PHASE1":15698,"PHASE1":15704,"PHASE2":15706,"PHASE3":15708,"PHASE4":15710,"NA":15712},{"trials":15699,"activeCount":97,"soonestReadout":2472},[15700],{"nctId":15531,"briefTitle":15532,"status":158,"phases":15701,"primaryCompletion":2472,"completion":2472,"start":15534,"enrollment":283,"conditions":15702,"interventions":15703},[88],[8245,15536,15537,15538,15539,15167,15540,15541,1873,15542,15543],[15545,15546],{"trials":15705,"activeCount":101},[],{"trials":15707,"activeCount":101},[],{"trials":15709,"activeCount":101},[],{"trials":15711,"activeCount":101},[],{"trials":15713,"activeCount":101},[],{"intervention":15715,"totalTrials":97,"cells":15716},"PET Imaging using 124 IPUH71",{"EARLY_PHASE1":15717,"PHASE1":15728,"PHASE2":15730,"PHASE3":15732,"PHASE4":15734,"NA":15736},{"trials":15718,"activeCount":97,"soonestReadout":498},[15719],{"nctId":15720,"briefTitle":15721,"status":113,"phases":15722,"primaryCompletion":498,"completion":498,"start":15723,"enrollment":203,"conditions":15724,"interventions":15727},"NCT01269593","PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study",[88],"2010-12",[707,15725,15726],"Myeloma","Active Solid Malignancy",[15715],{"trials":15729,"activeCount":101},[],{"trials":15731,"activeCount":101},[],{"trials":15733,"activeCount":101},[],{"trials":15735,"activeCount":101},[],{"trials":15737,"activeCount":101},[],{"intervention":1247,"totalTrials":97,"cells":15739},{"EARLY_PHASE1":15740,"PHASE1":15746,"PHASE2":15748,"PHASE3":15750,"PHASE4":15752,"NA":15754},{"trials":15741,"activeCount":97,"soonestReadout":1240},[15742],{"nctId":1237,"briefTitle":1238,"status":113,"phases":15743,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":15744,"interventions":15745},[88],[1244],[579,465,1246,1247],{"trials":15747,"activeCount":101},[],{"trials":15749,"activeCount":101},[],{"trials":15751,"activeCount":101},[],{"trials":15753,"activeCount":101},[],{"trials":15755,"activeCount":101},[],{"intervention":3054,"totalTrials":1094,"cells":15757},{"EARLY_PHASE1":15758,"PHASE1":15760,"PHASE2":15762,"PHASE3":15768,"PHASE4":15770,"NA":15772},{"trials":15759,"activeCount":101},[],{"trials":15761,"activeCount":101},[],{"trials":15763,"activeCount":101},[15764],{"nctId":3048,"briefTitle":3049,"status":244,"phases":15765,"primaryCompletion":695,"completion":695,"start":3051,"enrollment":356,"conditions":15766,"interventions":15767},[90],[971],[288,47,345,362,3054],{"trials":15769,"activeCount":101},[],{"trials":15771,"activeCount":101},[],{"trials":15773,"activeCount":97,"soonestReadout":232},[15774],{"nctId":7199,"briefTitle":7200,"status":113,"phases":15775,"primaryCompletion":232,"completion":232,"start":813,"enrollment":546,"conditions":15776,"interventions":15777},[93],[604],[1004,7204,7205,1006],{"intervention":1229,"totalTrials":1094,"cells":15779},{"EARLY_PHASE1":15780,"PHASE1":15782,"PHASE2":15793,"PHASE3":15795,"PHASE4":15797,"NA":15799},{"trials":15781,"activeCount":101},[],{"trials":15783,"activeCount":101},[15784],{"nctId":15785,"briefTitle":15786,"status":244,"phases":15787,"primaryCompletion":15788,"completion":15788,"start":15789,"enrollment":283,"conditions":15790,"interventions":15791},"NCT03166085","PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer",[89],"2021-12-14","2017-05-23",[2311],[15792,1229],"PU-H71",{"trials":15794,"activeCount":101},[],{"trials":15796,"activeCount":101},[],{"trials":15798,"activeCount":101},[],{"trials":15800,"activeCount":97,"soonestReadout":115},[15801],{"nctId":1220,"briefTitle":1221,"status":113,"phases":15802,"primaryCompletion":115,"completion":115,"start":1223,"enrollment":1224,"conditions":15803,"interventions":15804},[93],[1226,1227],[923,1229,1230],{"intervention":1230,"totalTrials":1094,"cells":15806},{"EARLY_PHASE1":15807,"PHASE1":15809,"PHASE2":15811,"PHASE3":15813,"PHASE4":15815,"NA":15817},{"trials":15808,"activeCount":101},[],{"trials":15810,"activeCount":101},[],{"trials":15812,"activeCount":101},[],{"trials":15814,"activeCount":101},[],{"trials":15816,"activeCount":101},[],{"trials":15818,"activeCount":97,"soonestReadout":115},[15819,15823],{"nctId":1220,"briefTitle":1221,"status":113,"phases":15820,"primaryCompletion":115,"completion":115,"start":1223,"enrollment":1224,"conditions":15821,"interventions":15822},[93],[1226,1227],[923,1229,1230],{"nctId":8845,"briefTitle":8846,"status":244,"phases":15824,"primaryCompletion":8848,"completion":8848,"start":8849,"enrollment":1094,"conditions":15825,"interventions":15826},[93],[1226],[1230,1593],{"intervention":15828,"totalTrials":97,"cells":15829},"ORAGENE",{"EARLY_PHASE1":15830,"PHASE1":15832,"PHASE2":15834,"PHASE3":15836,"PHASE4":15838,"NA":15840},{"trials":15831,"activeCount":101},[],{"trials":15833,"activeCount":101},[],{"trials":15835,"activeCount":101},[],{"trials":15837,"activeCount":101},[],{"trials":15839,"activeCount":101},[],{"trials":15841,"activeCount":97,"soonestReadout":933},[15842],{"nctId":15843,"briefTitle":15844,"status":158,"phases":15845,"primaryCompletion":933,"completion":933,"start":15846,"enrollment":15847,"conditions":15848,"interventions":15849},"NCT03922893","Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer",[],"2019-04-17",1500,[1155],[15828,15850],"Blood",{"intervention":15850,"totalTrials":97,"cells":15852},{"EARLY_PHASE1":15853,"PHASE1":15855,"PHASE2":15857,"PHASE3":15859,"PHASE4":15861,"NA":15863},{"trials":15854,"activeCount":101},[],{"trials":15856,"activeCount":101},[],{"trials":15858,"activeCount":101},[],{"trials":15860,"activeCount":101},[],{"trials":15862,"activeCount":101},[],{"trials":15864,"activeCount":97,"soonestReadout":933},[15865],{"nctId":15843,"briefTitle":15844,"status":158,"phases":15866,"primaryCompletion":933,"completion":933,"start":15846,"enrollment":15847,"conditions":15867,"interventions":15868},[],[1155],[15828,15850],{"intervention":7204,"totalTrials":97,"cells":15870},{"EARLY_PHASE1":15871,"PHASE1":15873,"PHASE2":15875,"PHASE3":15877,"PHASE4":15879,"NA":15881},{"trials":15872,"activeCount":101},[],{"trials":15874,"activeCount":101},[],{"trials":15876,"activeCount":101},[],{"trials":15878,"activeCount":101},[],{"trials":15880,"activeCount":101},[],{"trials":15882,"activeCount":97,"soonestReadout":232},[15883],{"nctId":7199,"briefTitle":7200,"status":113,"phases":15884,"primaryCompletion":232,"completion":232,"start":813,"enrollment":546,"conditions":15885,"interventions":15886},[93],[604],[1004,7204,7205,1006],{"intervention":15888,"totalTrials":97,"cells":15889},"Propranolol",{"EARLY_PHASE1":15890,"PHASE1":15892,"PHASE2":15894,"PHASE3":15896,"PHASE4":15898,"NA":15900},{"trials":15891,"activeCount":101},[],{"trials":15893,"activeCount":101},[],{"trials":15895,"activeCount":101},[],{"trials":15897,"activeCount":101},[],{"trials":15899,"activeCount":101},[],{"trials":15901,"activeCount":97,"soonestReadout":15906},[15902],{"nctId":15903,"briefTitle":15904,"status":158,"phases":15905,"primaryCompletion":15906,"completion":15906,"start":15907,"enrollment":1052,"conditions":15908,"interventions":15918},"NCT05429970","A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)",[93],"2026-06-17","2022-06-17",[30,10136,15909,15910,15911,15912,15913,15914,10855,285,15915,15916,15917,5821],"Stage II Ovary Cancer","Stage II Ovarian Cancer","Stage III Ovary Cancer","Stage III Ovarian Cancer","Stage IV Ovary Cancer","Stage IV Ovarian Cancer","Stage II Fallopian Tube Cancer","Stage III Fallopian Tube Cancer","Stage IV Fallopian Tube Cancer",[15888,15919],"Etodolac",{"intervention":15919,"totalTrials":97,"cells":15921},{"EARLY_PHASE1":15922,"PHASE1":15924,"PHASE2":15926,"PHASE3":15928,"PHASE4":15930,"NA":15932},{"trials":15923,"activeCount":101},[],{"trials":15925,"activeCount":101},[],{"trials":15927,"activeCount":101},[],{"trials":15929,"activeCount":101},[],{"trials":15931,"activeCount":101},[],{"trials":15933,"activeCount":97,"soonestReadout":15906},[15934],{"nctId":15903,"briefTitle":15904,"status":158,"phases":15935,"primaryCompletion":15906,"completion":15906,"start":15907,"enrollment":1052,"conditions":15936,"interventions":15937},[93],[30,10136,15909,15910,15911,15912,15913,15914,10855,285,15915,15916,15917,5821],[15888,15919],{"intervention":15939,"totalTrials":97,"cells":15940},"molecular profiling of tumors",{"EARLY_PHASE1":15941,"PHASE1":15943,"PHASE2":15945,"PHASE3":15947,"PHASE4":15949,"NA":15951},{"trials":15942,"activeCount":101},[],{"trials":15944,"activeCount":101},[],{"trials":15946,"activeCount":101},[],{"trials":15948,"activeCount":101},[],{"trials":15950,"activeCount":101},[],{"trials":15952,"activeCount":97,"soonestReadout":2472},[15953],{"nctId":15954,"briefTitle":15955,"status":158,"phases":15956,"primaryCompletion":2472,"completion":2472,"start":15957,"enrollment":11141,"conditions":15958,"interventions":15960},"NCT01775072","Genomic Profiling in Cancer Patients",[],"2013-01",[328,15959],"Hematologic Cancers",[15939,15961],"Clinical Germline Analysis",{"intervention":15961,"totalTrials":97,"cells":15963},{"EARLY_PHASE1":15964,"PHASE1":15966,"PHASE2":15968,"PHASE3":15970,"PHASE4":15972,"NA":15974},{"trials":15965,"activeCount":101},[],{"trials":15967,"activeCount":101},[],{"trials":15969,"activeCount":101},[],{"trials":15971,"activeCount":101},[],{"trials":15973,"activeCount":101},[],{"trials":15975,"activeCount":97,"soonestReadout":2472},[15976],{"nctId":15954,"briefTitle":15955,"status":158,"phases":15977,"primaryCompletion":2472,"completion":2472,"start":15957,"enrollment":11141,"conditions":15978,"interventions":15979},[],[328,15959],[15939,15961],{"intervention":15981,"totalTrials":97,"cells":15982},"PET scan with 124I-cRGDY-PEG-dots",{"EARLY_PHASE1":15983,"PHASE1":15985,"PHASE2":15987,"PHASE3":15989,"PHASE4":15991,"NA":15993},{"trials":15984,"activeCount":101},[],{"trials":15986,"activeCount":101},[],{"trials":15988,"activeCount":101},[],{"trials":15990,"activeCount":101},[],{"trials":15992,"activeCount":101},[],{"trials":15994,"activeCount":97,"soonestReadout":498},[15995],{"nctId":15996,"briefTitle":15997,"status":113,"phases":15998,"primaryCompletion":498,"completion":498,"start":15999,"enrollment":1434,"conditions":16000,"interventions":16003},"NCT01266096","PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study",[93],"2011-01",[16001,16002],"Newly Diagnosed or Recurrent Metastatic Melanoma Patients","Malignant Brain Tumors",[15981],{"intervention":16005,"totalTrials":97,"cells":16006},"[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone",{"EARLY_PHASE1":16007,"PHASE1":16009,"PHASE2":16011,"PHASE3":16013,"PHASE4":16015,"NA":16017},{"trials":16008,"activeCount":101},[],{"trials":16010,"activeCount":101},[],{"trials":16012,"activeCount":101},[],{"trials":16014,"activeCount":101},[],{"trials":16016,"activeCount":101},[],{"trials":16018,"activeCount":97,"soonestReadout":304},[16019],{"nctId":16020,"briefTitle":16021,"status":158,"phases":16022,"primaryCompletion":304,"completion":304,"start":1610,"enrollment":16023,"conditions":16024,"interventions":16025},"NCT00588185","[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer",[93],300,[18],[16005],{"intervention":16027,"totalTrials":97,"cells":16028},"KIR genotyping",{"EARLY_PHASE1":16029,"PHASE1":16031,"PHASE2":16033,"PHASE3":16035,"PHASE4":16037,"NA":16039},{"trials":16030,"activeCount":101},[],{"trials":16032,"activeCount":101},[],{"trials":16034,"activeCount":101},[],{"trials":16036,"activeCount":101},[],{"trials":16038,"activeCount":101},[],{"trials":16040,"activeCount":97,"soonestReadout":232},[16041],{"nctId":16042,"briefTitle":16043,"status":113,"phases":16044,"primaryCompletion":232,"completion":232,"start":790,"enrollment":16045,"conditions":16046,"interventions":16047},"NCT02450708","Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes",[93],511,[27],[16027,16048],"HLA genotyping",{"intervention":16048,"totalTrials":97,"cells":16050},{"EARLY_PHASE1":16051,"PHASE1":16053,"PHASE2":16055,"PHASE3":16057,"PHASE4":16059,"NA":16061},{"trials":16052,"activeCount":101},[],{"trials":16054,"activeCount":101},[],{"trials":16056,"activeCount":101},[],{"trials":16058,"activeCount":101},[],{"trials":16060,"activeCount":101},[],{"trials":16062,"activeCount":97,"soonestReadout":232},[16063],{"nctId":16042,"briefTitle":16043,"status":113,"phases":16064,"primaryCompletion":232,"completion":232,"start":790,"enrollment":16045,"conditions":16065,"interventions":16066},[93],[27],[16027,16048],{"intervention":16068,"totalTrials":97,"cells":16069},"Hyperpolarized Pyruvate",{"EARLY_PHASE1":16070,"PHASE1":16072,"PHASE2":16074,"PHASE3":16076,"PHASE4":16078,"NA":16080},{"trials":16071,"activeCount":101},[],{"trials":16073,"activeCount":101},[],{"trials":16075,"activeCount":101},[],{"trials":16077,"activeCount":101},[],{"trials":16079,"activeCount":101},[],{"trials":16081,"activeCount":97,"soonestReadout":2490},[16082],{"nctId":16083,"briefTitle":16084,"status":158,"phases":16085,"primaryCompletion":2490,"completion":2490,"start":1641,"enrollment":16086,"conditions":16087,"interventions":16089},"NCT02421380","Characterization of Hyperpolarized Pyruvate MRI Reproducibility",[93],109,[16088],"Malignant Solid Tumors",[16068],{"intervention":16091,"totalTrials":97,"cells":16092},"Meclofenamate",{"EARLY_PHASE1":16093,"PHASE1":16095,"PHASE2":16097,"PHASE3":16099,"PHASE4":16101,"NA":16103},{"trials":16094,"activeCount":101},[],{"trials":16096,"activeCount":101},[],{"trials":16098,"activeCount":101},[],{"trials":16100,"activeCount":101},[],{"trials":16102,"activeCount":101},[],{"trials":16104,"activeCount":97,"soonestReadout":531},[16105],{"nctId":16106,"briefTitle":16107,"status":113,"phases":16108,"primaryCompletion":531,"completion":531,"start":16109,"enrollment":356,"conditions":16110,"interventions":16113},"NCT02429570","Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary",[93],"2015-04-22",[16111,16112],"Recurrent Brain Metastases","Progressive Brain Metastases",[16091],{"intervention":16115,"totalTrials":97,"cells":16116},"PCR\u002FPCR\u002FLDR Strategy",{"EARLY_PHASE1":16117,"PHASE1":16119,"PHASE2":16121,"PHASE3":16123,"PHASE4":16125,"NA":16127},{"trials":16118,"activeCount":101},[],{"trials":16120,"activeCount":101},[],{"trials":16122,"activeCount":101},[],{"trials":16124,"activeCount":101},[],{"trials":16126,"activeCount":101},[],{"trials":16128,"activeCount":97,"soonestReadout":990},[16129],{"nctId":16130,"briefTitle":16131,"status":113,"phases":16132,"primaryCompletion":990,"completion":990,"start":3121,"enrollment":16133,"conditions":16134,"interventions":16136},"NCT00579514","Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients",[93],21081,[15,971,783,16135,18,21,30],"Colon Cancer",[16115],{"intervention":16138,"totalTrials":97,"cells":16139},"colonic biopsies",{"EARLY_PHASE1":16140,"PHASE1":16142,"PHASE2":16144,"PHASE3":16146,"PHASE4":16148,"NA":16150},{"trials":16141,"activeCount":101},[],{"trials":16143,"activeCount":101},[],{"trials":16145,"activeCount":101},[],{"trials":16147,"activeCount":101},[],{"trials":16149,"activeCount":101},[],{"trials":16151,"activeCount":97,"soonestReadout":304},[16152],{"nctId":16153,"briefTitle":16154,"status":113,"phases":16155,"primaryCompletion":304,"completion":304,"start":891,"enrollment":13004,"conditions":16156,"interventions":16159},"NCT02371135","Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes",[],[16157,16158],"Lynch Syndrome","Hereditary Colonic Polyposis Syndromes",[16138,16160],"questionnaires",{"intervention":16160,"totalTrials":97,"cells":16162},{"EARLY_PHASE1":16163,"PHASE1":16165,"PHASE2":16167,"PHASE3":16169,"PHASE4":16171,"NA":16173},{"trials":16164,"activeCount":101},[],{"trials":16166,"activeCount":101},[],{"trials":16168,"activeCount":101},[],{"trials":16170,"activeCount":101},[],{"trials":16172,"activeCount":101},[],{"trials":16174,"activeCount":97,"soonestReadout":304},[16175],{"nctId":16153,"briefTitle":16154,"status":113,"phases":16176,"primaryCompletion":304,"completion":304,"start":891,"enrollment":13004,"conditions":16177,"interventions":16178},[],[16157,16158],[16138,16160],{"intervention":16180,"totalTrials":97,"cells":16181},"124IcG250",{"EARLY_PHASE1":16182,"PHASE1":16184,"PHASE2":16186,"PHASE3":16188,"PHASE4":16190,"NA":16192},{"trials":16183,"activeCount":101},[],{"trials":16185,"activeCount":101},[],{"trials":16187,"activeCount":101},[],{"trials":16189,"activeCount":101},[],{"trials":16191,"activeCount":101},[],{"trials":16193,"activeCount":97,"soonestReadout":2490},[16194],{"nctId":16195,"briefTitle":16196,"status":113,"phases":16197,"primaryCompletion":2490,"completion":2490,"start":16198,"enrollment":234,"conditions":16199,"interventions":16200},"NCT01582204","Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma",[93],"2012-04",[12981],[16180],{"intervention":16202,"totalTrials":97,"cells":16203},"18F-DCFPyL-iPSMA",{"EARLY_PHASE1":16204,"PHASE1":16206,"PHASE2":16208,"PHASE3":16210,"PHASE4":16212,"NA":16214},{"trials":16205,"activeCount":101},[],{"trials":16207,"activeCount":101},[],{"trials":16209,"activeCount":101},[],{"trials":16211,"activeCount":101},[],{"trials":16213,"activeCount":101},[],{"trials":16215,"activeCount":97,"soonestReadout":2082},[16216],{"nctId":16217,"briefTitle":16218,"status":113,"phases":16219,"primaryCompletion":2082,"completion":2082,"start":4279,"enrollment":1242,"conditions":16220,"interventions":16221},"NCT04030338","Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer",[],[18,4762,4761,4763,2030],[16202,16222],"68Ga-HBED-iPSMA",{"intervention":16222,"totalTrials":97,"cells":16224},{"EARLY_PHASE1":16225,"PHASE1":16227,"PHASE2":16229,"PHASE3":16231,"PHASE4":16233,"NA":16235},{"trials":16226,"activeCount":101},[],{"trials":16228,"activeCount":101},[],{"trials":16230,"activeCount":101},[],{"trials":16232,"activeCount":101},[],{"trials":16234,"activeCount":101},[],{"trials":16236,"activeCount":97,"soonestReadout":2082},[16237],{"nctId":16217,"briefTitle":16218,"status":113,"phases":16238,"primaryCompletion":2082,"completion":2082,"start":4279,"enrollment":1242,"conditions":16239,"interventions":16240},[],[18,4762,4761,4763,2030],[16202,16222],{"intervention":16242,"totalTrials":97,"cells":16243},"124I-Humanized 3F8",{"EARLY_PHASE1":16244,"PHASE1":16246,"PHASE2":16248,"PHASE3":16250,"PHASE4":16252,"NA":16254},{"trials":16245,"activeCount":101},[],{"trials":16247,"activeCount":101},[],{"trials":16249,"activeCount":101},[],{"trials":16251,"activeCount":101},[],{"trials":16253,"activeCount":101},[],{"trials":16255,"activeCount":97,"soonestReadout":1130},[16256],{"nctId":16257,"briefTitle":16258,"status":113,"phases":16259,"primaryCompletion":1130,"completion":1130,"start":1013,"enrollment":2291,"conditions":16260,"interventions":16261},"NCT02307630","PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study",[93],[2341,215,33],[16242],{"intervention":16263,"totalTrials":97,"cells":16264},"ctDNA Testing",{"EARLY_PHASE1":16265,"PHASE1":16267,"PHASE2":16269,"PHASE3":16271,"PHASE4":16273,"NA":16275},{"trials":16266,"activeCount":101},[],{"trials":16268,"activeCount":101},[],{"trials":16270,"activeCount":101},[],{"trials":16272,"activeCount":101},[],{"trials":16274,"activeCount":101},[],{"trials":16276,"activeCount":97,"soonestReadout":1240},[16277],{"nctId":16278,"briefTitle":16279,"status":158,"phases":16280,"primaryCompletion":1240,"completion":1240,"start":16281,"enrollment":356,"conditions":16282,"interventions":16283},"NCT07270666","ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer",[93],"2025-11-25",[3359],[16263],{"intervention":16285,"totalTrials":97,"cells":16286},"cheek (buccal) swab",{"EARLY_PHASE1":16287,"PHASE1":16289,"PHASE2":16291,"PHASE3":16293,"PHASE4":16295,"NA":16297},{"trials":16288,"activeCount":101},[],{"trials":16290,"activeCount":101},[],{"trials":16292,"activeCount":101},[],{"trials":16294,"activeCount":101},[],{"trials":16296,"activeCount":101},[],{"trials":16298,"activeCount":97,"soonestReadout":4378},[16299],{"nctId":16300,"briefTitle":16301,"status":158,"phases":16302,"primaryCompletion":4378,"completion":4378,"start":16303,"enrollment":14647,"conditions":16304,"interventions":16307},"NCT07197723","Study of How People Make Decisions About Prostate Cancer Risk",[],"2025-09-25",[16305,16306],"BRCA1\u002F2","Geneitic Testing",[16285],{"intervention":16309,"totalTrials":97,"cells":16310},"Blood assay",{"EARLY_PHASE1":16311,"PHASE1":16313,"PHASE2":16315,"PHASE3":16317,"PHASE4":16319,"NA":16321},{"trials":16312,"activeCount":101},[],{"trials":16314,"activeCount":101},[],{"trials":16316,"activeCount":101},[],{"trials":16318,"activeCount":101},[],{"trials":16320,"activeCount":101},[],{"trials":16322,"activeCount":97,"soonestReadout":12526},[16323],{"nctId":16324,"briefTitle":16325,"status":158,"phases":16326,"primaryCompletion":12526,"completion":12526,"start":16327,"enrollment":438,"conditions":16328,"interventions":16330},"NCT06305728","Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms",[],"2024-03-04",[16329],"Pancreatic Cyst",[16309],{"intervention":16332,"totalTrials":97,"cells":16333},"Octreotide",{"EARLY_PHASE1":16334,"PHASE1":16336,"PHASE2":16338,"PHASE3":16340,"PHASE4":16342,"NA":16353},{"trials":16335,"activeCount":101},[],{"trials":16337,"activeCount":101},[],{"trials":16339,"activeCount":101},[],{"trials":16341,"activeCount":101},[],{"trials":16343,"activeCount":101},[16344],{"nctId":16345,"briefTitle":16346,"status":244,"phases":16347,"primaryCompletion":16348,"completion":16348,"start":16349,"enrollment":1152,"conditions":16350,"interventions":16351},"NCT03289741","A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide",[92],"2023-04-10","2017-09-19",[15597],[16332,16352],"LAR Lanreotide",{"trials":16354,"activeCount":101},[],{"intervention":16352,"totalTrials":97,"cells":16356},{"EARLY_PHASE1":16357,"PHASE1":16359,"PHASE2":16361,"PHASE3":16363,"PHASE4":16365,"NA":16371},{"trials":16358,"activeCount":101},[],{"trials":16360,"activeCount":101},[],{"trials":16362,"activeCount":101},[],{"trials":16364,"activeCount":101},[],{"trials":16366,"activeCount":101},[16367],{"nctId":16345,"briefTitle":16346,"status":244,"phases":16368,"primaryCompletion":16348,"completion":16348,"start":16349,"enrollment":1152,"conditions":16369,"interventions":16370},[92],[15597],[16332,16352],{"trials":16372,"activeCount":101},[],{"intervention":16374,"totalTrials":97,"cells":16375},"PVB Protocol",{"EARLY_PHASE1":16376,"PHASE1":16378,"PHASE2":16380,"PHASE3":16382,"PHASE4":16384,"NA":16398},{"trials":16377,"activeCount":101},[],{"trials":16379,"activeCount":101},[],{"trials":16381,"activeCount":101},[],{"trials":16383,"activeCount":101},[],{"trials":16385,"activeCount":101},[16386],{"nctId":16387,"briefTitle":16388,"status":244,"phases":16389,"primaryCompletion":16390,"completion":16390,"start":16391,"enrollment":16392,"conditions":16393,"interventions":16395},"NCT04016376","Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction",[92],"2026-02-25","2019-07-05",1507,[15,16394],"Breast Cancer Female",[16374,16396,16397],"PECS-1","Serratus",{"trials":16399,"activeCount":101},[],{"intervention":16396,"totalTrials":97,"cells":16401},{"EARLY_PHASE1":16402,"PHASE1":16404,"PHASE2":16406,"PHASE3":16408,"PHASE4":16410,"NA":16416},{"trials":16403,"activeCount":101},[],{"trials":16405,"activeCount":101},[],{"trials":16407,"activeCount":101},[],{"trials":16409,"activeCount":101},[],{"trials":16411,"activeCount":101},[16412],{"nctId":16387,"briefTitle":16388,"status":244,"phases":16413,"primaryCompletion":16390,"completion":16390,"start":16391,"enrollment":16392,"conditions":16414,"interventions":16415},[92],[15,16394],[16374,16396,16397],{"trials":16417,"activeCount":101},[],{"intervention":16397,"totalTrials":97,"cells":16419},{"EARLY_PHASE1":16420,"PHASE1":16422,"PHASE2":16424,"PHASE3":16426,"PHASE4":16428,"NA":16434},{"trials":16421,"activeCount":101},[],{"trials":16423,"activeCount":101},[],{"trials":16425,"activeCount":101},[],{"trials":16427,"activeCount":101},[],{"trials":16429,"activeCount":101},[16430],{"nctId":16387,"briefTitle":16388,"status":244,"phases":16431,"primaryCompletion":16390,"completion":16390,"start":16391,"enrollment":16392,"conditions":16432,"interventions":16433},[92],[15,16394],[16374,16396,16397],{"trials":16435,"activeCount":101},[],{"intervention":16437,"totalTrials":97,"cells":16438},"micafungin",{"EARLY_PHASE1":16439,"PHASE1":16441,"PHASE2":16443,"PHASE3":16445,"PHASE4":16447,"NA":16459},{"trials":16440,"activeCount":101},[],{"trials":16442,"activeCount":101},[],{"trials":16444,"activeCount":101},[],{"trials":16446,"activeCount":101},[],{"trials":16448,"activeCount":101},[16449],{"nctId":16450,"briefTitle":16451,"status":244,"phases":16452,"primaryCompletion":16453,"completion":16454,"start":16455,"enrollment":791,"conditions":16456,"interventions":16457},"NCT01200355","Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome",[92],"2017-04-20","2018-04-03","2010-09-09",[415,416],[16437,16458],"posaconazole",{"trials":16460,"activeCount":101},[],{"intervention":16458,"totalTrials":97,"cells":16462},{"EARLY_PHASE1":16463,"PHASE1":16465,"PHASE2":16467,"PHASE3":16469,"PHASE4":16471,"NA":16477},{"trials":16464,"activeCount":101},[],{"trials":16466,"activeCount":101},[],{"trials":16468,"activeCount":101},[],{"trials":16470,"activeCount":101},[],{"trials":16472,"activeCount":101},[16473],{"nctId":16450,"briefTitle":16451,"status":244,"phases":16474,"primaryCompletion":16453,"completion":16454,"start":16455,"enrollment":791,"conditions":16475,"interventions":16476},[92],[415,416],[16437,16458],{"trials":16478,"activeCount":101},[],{"intervention":642,"totalTrials":1114,"cells":16480},{"EARLY_PHASE1":16481,"PHASE1":16483,"PHASE2":16485,"PHASE3":16499,"PHASE4":16505,"NA":16507},{"trials":16482,"activeCount":101},[],{"trials":16484,"activeCount":101},[],{"trials":16486,"activeCount":101},[16487,16491,16495],{"nctId":7253,"briefTitle":7254,"status":244,"phases":16488,"primaryCompletion":426,"completion":426,"start":3930,"conditions":16489,"interventions":16490},[90],[7257,27,3939,7258],[288,7260,361,642],{"nctId":634,"briefTitle":635,"status":244,"phases":16492,"primaryCompletion":637,"completion":637,"start":638,"conditions":16493,"interventions":16494},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":692,"briefTitle":693,"status":244,"phases":16496,"primaryCompletion":695,"completion":695,"start":696,"conditions":16497,"interventions":16498},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"trials":16500,"activeCount":101},[16501],{"nctId":872,"briefTitle":873,"status":244,"phases":16502,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":16503,"interventions":16504},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":16506,"activeCount":101},[],{"trials":16508,"activeCount":101},[],{"intervention":363,"totalTrials":509,"cells":16510},{"EARLY_PHASE1":16511,"PHASE1":16513,"PHASE2":16515,"PHASE3":16525,"PHASE4":16531,"NA":16533},{"trials":16512,"activeCount":101},[],{"trials":16514,"activeCount":101},[],{"trials":16516,"activeCount":101},[16517,16521],{"nctId":351,"briefTitle":352,"status":244,"phases":16518,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":16519,"interventions":16520},[90],[27],[359,360,202,361,346,362,363],{"nctId":365,"briefTitle":366,"status":244,"phases":16522,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":16523,"interventions":16524},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"trials":16526,"activeCount":101},[16527],{"nctId":872,"briefTitle":873,"status":244,"phases":16528,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":16529,"interventions":16530},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":16532,"activeCount":101},[],{"trials":16534,"activeCount":101},[],{"intervention":389,"totalTrials":509,"cells":16536},{"EARLY_PHASE1":16537,"PHASE1":16539,"PHASE2":16541,"PHASE3":16551,"PHASE4":16557,"NA":16559},{"trials":16538,"activeCount":101},[],{"trials":16540,"activeCount":101},[],{"trials":16542,"activeCount":101},[16543,16547],{"nctId":381,"briefTitle":382,"status":244,"phases":16544,"primaryCompletion":384,"completion":384,"start":385,"conditions":16545,"interventions":16546},[90],[387,30],[389,288,390,202,345,346,391,362,349],{"nctId":5530,"briefTitle":5531,"status":244,"phases":16548,"primaryCompletion":4772,"start":3930,"enrollment":1052,"conditions":16549,"interventions":16550},[90],[4734,33],[389,5535,444],{"trials":16552,"activeCount":101},[16553],{"nctId":872,"briefTitle":873,"status":244,"phases":16554,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":16555,"interventions":16556},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":16558,"activeCount":101},[],{"trials":16560,"activeCount":101},[],{"intervention":3455,"totalTrials":509,"cells":16562},{"EARLY_PHASE1":16563,"PHASE1":16565,"PHASE2":16567,"PHASE3":16577,"PHASE4":16583,"NA":16585},{"trials":16564,"activeCount":101},[],{"trials":16566,"activeCount":101},[],{"trials":16568,"activeCount":101},[16569,16573],{"nctId":3448,"briefTitle":3449,"status":244,"phases":16570,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":16571,"interventions":16572},[89,90],[18],[390,3454,1707,3455,3456,741],{"nctId":9067,"briefTitle":9068,"status":244,"phases":16574,"primaryCompletion":2914,"completion":2914,"start":1703,"conditions":16575,"interventions":16576},[90],[285,30,286],[9034,3455],{"trials":16578,"activeCount":101},[16579],{"nctId":9075,"briefTitle":9076,"status":244,"phases":16580,"primaryCompletion":9078,"completion":9079,"start":587,"enrollment":509,"conditions":16581,"interventions":16582},[91],[18],[9034,3455],{"trials":16584,"activeCount":101},[],{"trials":16586,"activeCount":101},[],{"intervention":16588,"totalTrials":1094,"cells":16589},"Mitomycin C",{"EARLY_PHASE1":16590,"PHASE1":16592,"PHASE2":16606,"PHASE3":16608,"PHASE4":16619,"NA":16621},{"trials":16591,"activeCount":101},[],{"trials":16593,"activeCount":101},[16594],{"nctId":16595,"briefTitle":16596,"status":244,"phases":16597,"primaryCompletion":16598,"completion":16598,"start":5349,"enrollment":1434,"conditions":16599,"interventions":16603},"NCT04200417","Chemoembolization for Lung Tumors",[89],"2022-04-19",[6318,16600,16601,16602],"Endobronchial Metastases","Pleural Metastases","Mediastinal Metastases",[16588,16604,16605],"Lipiodol","Embospheres",{"trials":16607,"activeCount":101},[],{"trials":16609,"activeCount":101},[16610],{"nctId":16611,"briefTitle":16612,"status":505,"phases":16613,"primaryCompletion":16614,"completion":16614,"start":16615,"enrollment":370,"conditions":16616,"interventions":16617},"NCT00974818","Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients",[91],"2012-03","2009-09",[971],[16588,16618],"Bacillus Calmette-Guerin",{"trials":16620,"activeCount":101},[],{"trials":16622,"activeCount":101},[],{"intervention":16624,"totalTrials":97,"cells":16625},"caspofungin acetate",{"EARLY_PHASE1":16626,"PHASE1":16628,"PHASE2":16630,"PHASE3":16632,"PHASE4":16641,"NA":16643},{"trials":16627,"activeCount":101},[],{"trials":16629,"activeCount":101},[],{"trials":16631,"activeCount":101},[],{"trials":16633,"activeCount":101},[16634],{"nctId":16635,"briefTitle":16636,"status":244,"phases":16637,"primaryCompletion":1702,"start":426,"conditions":16638,"interventions":16639},"NCT00008359","Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment",[91],[1155],[16624,16640],"liposomal amphotericin B",{"trials":16642,"activeCount":101},[],{"trials":16644,"activeCount":101},[],{"intervention":16640,"totalTrials":97,"cells":16646},{"EARLY_PHASE1":16647,"PHASE1":16649,"PHASE2":16651,"PHASE3":16653,"PHASE4":16659,"NA":16661},{"trials":16648,"activeCount":101},[],{"trials":16650,"activeCount":101},[],{"trials":16652,"activeCount":101},[],{"trials":16654,"activeCount":101},[16655],{"nctId":16635,"briefTitle":16636,"status":244,"phases":16656,"primaryCompletion":1702,"start":426,"conditions":16657,"interventions":16658},[91],[1155],[16624,16640],{"trials":16660,"activeCount":101},[],{"trials":16662,"activeCount":101},[],{"intervention":16664,"totalTrials":97,"cells":16665},"Dexmedetomidine",{"EARLY_PHASE1":16666,"PHASE1":16668,"PHASE2":16670,"PHASE3":16672,"PHASE4":16683,"NA":16685},{"trials":16667,"activeCount":101},[],{"trials":16669,"activeCount":101},[],{"trials":16671,"activeCount":101},[],{"trials":16673,"activeCount":101},[16674],{"nctId":16675,"briefTitle":16676,"status":244,"phases":16677,"primaryCompletion":16678,"completion":16678,"start":16679,"enrollment":16680,"conditions":16681,"interventions":16682},"NCT01973452","Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery",[91],"2022-12-22","2013-10",333,[1996],[16664],{"trials":16684,"activeCount":101},[],{"trials":16686,"activeCount":101},[],{"intervention":16688,"totalTrials":97,"cells":16689},"Neostigmine+glycopyrrolate",{"EARLY_PHASE1":16690,"PHASE1":16692,"PHASE2":16694,"PHASE3":16696,"PHASE4":16708,"NA":16710},{"trials":16691,"activeCount":101},[],{"trials":16693,"activeCount":101},[],{"trials":16695,"activeCount":101},[],{"trials":16697,"activeCount":101},[16698],{"nctId":16699,"briefTitle":16700,"status":244,"phases":16701,"primaryCompletion":16702,"completion":16702,"start":16703,"enrollment":1441,"conditions":16704,"interventions":16706},"NCT03116997","Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant",[91],"2022-03-03","2017-04-07",[16705],"Surgery",[16688,16707],"Sugammadex",{"trials":16709,"activeCount":101},[],{"trials":16711,"activeCount":101},[],{"intervention":16707,"totalTrials":97,"cells":16713},{"EARLY_PHASE1":16714,"PHASE1":16716,"PHASE2":16718,"PHASE3":16720,"PHASE4":16726,"NA":16728},{"trials":16715,"activeCount":101},[],{"trials":16717,"activeCount":101},[],{"trials":16719,"activeCount":101},[],{"trials":16721,"activeCount":101},[16722],{"nctId":16699,"briefTitle":16700,"status":244,"phases":16723,"primaryCompletion":16702,"completion":16702,"start":16703,"enrollment":1441,"conditions":16724,"interventions":16725},[91],[16705],[16688,16707],{"trials":16727,"activeCount":101},[],{"trials":16729,"activeCount":101},[],{"intervention":16731,"totalTrials":97,"cells":16732},"Topical Dapsone 5% Gel",{"EARLY_PHASE1":16733,"PHASE1":16735,"PHASE2":16737,"PHASE3":16739,"PHASE4":16751,"NA":16753},{"trials":16734,"activeCount":101},[],{"trials":16736,"activeCount":101},[],{"trials":16738,"activeCount":101},[],{"trials":16740,"activeCount":101},[16741],{"nctId":16742,"briefTitle":16743,"status":244,"phases":16744,"primaryCompletion":16745,"completion":16745,"start":1113,"enrollment":2630,"conditions":16746,"interventions":16749},"NCT01931150","Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT",[91],"2015-09",[16747,16748],"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have","Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma",[16731,16750],"oral antibiotics",{"trials":16752,"activeCount":101},[],{"trials":16754,"activeCount":101},[],{"intervention":16750,"totalTrials":97,"cells":16756},{"EARLY_PHASE1":16757,"PHASE1":16759,"PHASE2":16761,"PHASE3":16763,"PHASE4":16769,"NA":16771},{"trials":16758,"activeCount":101},[],{"trials":16760,"activeCount":101},[],{"trials":16762,"activeCount":101},[],{"trials":16764,"activeCount":101},[16765],{"nctId":16742,"briefTitle":16743,"status":244,"phases":16766,"primaryCompletion":16745,"completion":16745,"start":1113,"enrollment":2630,"conditions":16767,"interventions":16768},[91],[16747,16748],[16731,16750],{"trials":16770,"activeCount":101},[],{"trials":16772,"activeCount":101},[],{"intervention":3326,"totalTrials":97,"cells":16774},{"EARLY_PHASE1":16775,"PHASE1":16777,"PHASE2":16779,"PHASE3":16781,"PHASE4":16787,"NA":16789},{"trials":16776,"activeCount":101},[],{"trials":16778,"activeCount":101},[],{"trials":16780,"activeCount":101},[],{"trials":16782,"activeCount":101},[16783],{"nctId":3320,"briefTitle":3321,"status":244,"phases":16784,"primaryCompletion":3323,"completion":3323,"start":1357,"conditions":16785,"interventions":16786},[91],[3163],[47,3326],{"trials":16788,"activeCount":101},[],{"trials":16790,"activeCount":101},[],{"intervention":16618,"totalTrials":97,"cells":16792},{"EARLY_PHASE1":16793,"PHASE1":16795,"PHASE2":16797,"PHASE3":16799,"PHASE4":16805,"NA":16807},{"trials":16794,"activeCount":101},[],{"trials":16796,"activeCount":101},[],{"trials":16798,"activeCount":101},[],{"trials":16800,"activeCount":101},[16801],{"nctId":16611,"briefTitle":16612,"status":505,"phases":16802,"primaryCompletion":16614,"completion":16614,"start":16615,"enrollment":370,"conditions":16803,"interventions":16804},[91],[971],[16588,16618],{"trials":16806,"activeCount":101},[],{"trials":16808,"activeCount":101},[],{"intervention":16810,"totalTrials":97,"cells":16811},"Empirical Vancomycin",{"EARLY_PHASE1":16812,"PHASE1":16814,"PHASE2":16816,"PHASE3":16818,"PHASE4":16830,"NA":16832},{"trials":16813,"activeCount":101},[],{"trials":16815,"activeCount":101},[],{"trials":16817,"activeCount":101},[],{"trials":16819,"activeCount":101},[16820],{"nctId":16821,"briefTitle":16822,"status":244,"phases":16823,"completion":16824,"start":3880,"enrollment":16825,"conditions":16826,"interventions":16828},"NCT00138112","Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation",[91],"2005-11",126,[16827,720],"Streptococcal Sepsis",[16810,16829],"Prophylactic Vancomycin",{"trials":16831,"activeCount":101},[],{"trials":16833,"activeCount":101},[],{"intervention":16829,"totalTrials":97,"cells":16835},{"EARLY_PHASE1":16836,"PHASE1":16838,"PHASE2":16840,"PHASE3":16842,"PHASE4":16848,"NA":16850},{"trials":16837,"activeCount":101},[],{"trials":16839,"activeCount":101},[],{"trials":16841,"activeCount":101},[],{"trials":16843,"activeCount":101},[16844],{"nctId":16821,"briefTitle":16822,"status":244,"phases":16845,"completion":16824,"start":3880,"enrollment":16825,"conditions":16846,"interventions":16847},[91],[16827,720],[16810,16829],{"trials":16849,"activeCount":101},[],{"trials":16851,"activeCount":101},[],{"intervention":16853,"totalTrials":97,"cells":16854},"indocyanine green",{"EARLY_PHASE1":16855,"PHASE1":16857,"PHASE2":16859,"PHASE3":16861,"PHASE4":16871,"NA":16873},{"trials":16856,"activeCount":101},[],{"trials":16858,"activeCount":101},[],{"trials":16860,"activeCount":101},[],{"trials":16862,"activeCount":101},[16863],{"nctId":16864,"briefTitle":16865,"status":244,"phases":16866,"primaryCompletion":16867,"completion":16867,"start":8848,"enrollment":332,"conditions":16868,"interventions":16870},"NCT02910726","A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers",[90,91],"2022-09-02",[16869],"Pediatric Patients With Solid Tumors",[16853],{"trials":16872,"activeCount":101},[],{"trials":16874,"activeCount":101},[],{"intervention":16876,"totalTrials":97,"cells":16877},"Rifaximin",{"EARLY_PHASE1":16878,"PHASE1":16880,"PHASE2":16882,"PHASE3":16884,"PHASE4":16893,"NA":16895},{"trials":16879,"activeCount":101},[],{"trials":16881,"activeCount":101},[],{"trials":16883,"activeCount":101},[],{"trials":16885,"activeCount":101},[16886],{"nctId":16887,"briefTitle":16888,"status":244,"phases":16889,"primaryCompletion":4646,"completion":4646,"start":16890,"enrollment":3717,"conditions":16891,"interventions":16892},"NCT01345175","Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer",[91],"2011-04-26",[5080],[16876],{"trials":16894,"activeCount":101},[],{"trials":16896,"activeCount":101},[],{"intervention":16898,"totalTrials":97,"cells":16899},"epoetin alfa",{"EARLY_PHASE1":16900,"PHASE1":16902,"PHASE2":16904,"PHASE3":16906,"PHASE4":16916,"NA":16918},{"trials":16901,"activeCount":101},[],{"trials":16903,"activeCount":101},[],{"trials":16905,"activeCount":101},[],{"trials":16907,"activeCount":101},[16908],{"nctId":16909,"briefTitle":16910,"status":244,"phases":16911,"primaryCompletion":16912,"completion":16912,"start":3371,"enrollment":16913,"conditions":16914,"interventions":16915},"NCT00003341","Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy",[91],"2003-09",275,[7257,27,24,828],[16898],{"trials":16917,"activeCount":101},[],{"trials":16919,"activeCount":101},[],{"intervention":16921,"totalTrials":97,"cells":16922},"mannitol",{"EARLY_PHASE1":16923,"PHASE1":16925,"PHASE2":16927,"PHASE3":16929,"PHASE4":16940,"NA":16942},{"trials":16924,"activeCount":101},[],{"trials":16926,"activeCount":101},[],{"trials":16928,"activeCount":101},[],{"trials":16930,"activeCount":101},[16931],{"nctId":16932,"briefTitle":16933,"status":244,"phases":16934,"primaryCompletion":16935,"completion":16935,"start":16936,"enrollment":16937,"conditions":16938,"interventions":16939},"NCT01606787","Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes",[91],"2018-02","2012-05-22",210,[12981],[16921],{"trials":16941,"activeCount":101},[],{"trials":16943,"activeCount":101},[],{"intervention":16945,"totalTrials":97,"cells":16946},"sildenafil citrate and questionaires",{"EARLY_PHASE1":16947,"PHASE1":16949,"PHASE2":16951,"PHASE3":16953,"PHASE4":16963,"NA":16965},{"trials":16948,"activeCount":101},[],{"trials":16950,"activeCount":101},[],{"trials":16952,"activeCount":101},[],{"trials":16954,"activeCount":101},[16955],{"nctId":16956,"briefTitle":16957,"status":244,"phases":16958,"primaryCompletion":774,"completion":774,"start":3274,"enrollment":16959,"conditions":16960,"interventions":16962},"NCT00142506","Study of Sildenafil Citrate During and After Radiotherapy\u002FHormone Therapy for Erectile Function Versus Radiotherapy\u002FHormone Therapy for Prostate Cancer",[91],290,[18,16961],"Erectile Dysfunction",[16945],{"trials":16964,"activeCount":101},[],{"trials":16966,"activeCount":101},[],{"intervention":16968,"totalTrials":97,"cells":16969},"Propofol+ Rocuronium+ Fentanyl 2 mcg\u002Fkg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg\u002Fml",{"EARLY_PHASE1":16970,"PHASE1":16972,"PHASE2":16974,"PHASE3":16976,"PHASE4":16988,"NA":16990},{"trials":16971,"activeCount":101},[],{"trials":16973,"activeCount":101},[],{"trials":16975,"activeCount":101},[],{"trials":16977,"activeCount":101},[16978],{"nctId":16979,"briefTitle":16980,"status":244,"phases":16981,"primaryCompletion":16982,"completion":16982,"start":16983,"enrollment":16984,"conditions":16985,"interventions":16986},"NCT03434678","Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection",[91],"2024-07-10","2018-01-30",133,[1226],[16968,16987],"Propofol+ Rocuronium+ Fentanyl + Inhalational",{"trials":16989,"activeCount":101},[],{"trials":16991,"activeCount":101},[],{"intervention":16987,"totalTrials":97,"cells":16993},{"EARLY_PHASE1":16994,"PHASE1":16996,"PHASE2":16998,"PHASE3":17000,"PHASE4":17006,"NA":17008},{"trials":16995,"activeCount":101},[],{"trials":16997,"activeCount":101},[],{"trials":16999,"activeCount":101},[],{"trials":17001,"activeCount":101},[17002],{"nctId":16979,"briefTitle":16980,"status":244,"phases":17003,"primaryCompletion":16982,"completion":16982,"start":16983,"enrollment":16984,"conditions":17004,"interventions":17005},[91],[1226],[16968,16987],{"trials":17007,"activeCount":101},[],{"trials":17009,"activeCount":101},[],{"intervention":870,"totalTrials":97,"cells":17011},{"EARLY_PHASE1":17012,"PHASE1":17014,"PHASE2":17016,"PHASE3":17018,"PHASE4":17024,"NA":17026},{"trials":17013,"activeCount":101},[],{"trials":17015,"activeCount":101},[],{"trials":17017,"activeCount":101},[],{"trials":17019,"activeCount":101},[17020],{"nctId":861,"briefTitle":862,"status":244,"phases":17021,"completion":727,"start":864,"enrollment":865,"conditions":17022,"interventions":17023},[91],[867,387,868],[870,288,390,47,202,346],{"trials":17025,"activeCount":101},[],{"trials":17027,"activeCount":101},[],{"intervention":17029,"totalTrials":97,"cells":17030},"patient-controlled epidural analgesia",{"EARLY_PHASE1":17031,"PHASE1":17033,"PHASE2":17035,"PHASE3":17037,"PHASE4":17048,"NA":17050},{"trials":17032,"activeCount":101},[],{"trials":17034,"activeCount":101},[],{"trials":17036,"activeCount":101},[],{"trials":17038,"activeCount":101},[17039],{"nctId":17040,"briefTitle":17041,"status":244,"phases":17042,"primaryCompletion":3370,"completion":3370,"start":3044,"enrollment":17043,"conditions":17044,"interventions":17046},"NCT00136682","Patient-Controlled Epidural Analgesia (PCEA) for Patients Who Have Had Major Open Gynecologic Surgery",[91],240,[17045],"Postoperative Pain",[17029,17047],"patient-controlled intravenous analgesia",{"trials":17049,"activeCount":101},[],{"trials":17051,"activeCount":101},[],{"intervention":17047,"totalTrials":97,"cells":17053},{"EARLY_PHASE1":17054,"PHASE1":17056,"PHASE2":17058,"PHASE3":17060,"PHASE4":17066,"NA":17068},{"trials":17055,"activeCount":101},[],{"trials":17057,"activeCount":101},[],{"trials":17059,"activeCount":101},[],{"trials":17061,"activeCount":101},[17062],{"nctId":17040,"briefTitle":17041,"status":244,"phases":17063,"primaryCompletion":3370,"completion":3370,"start":3044,"enrollment":17043,"conditions":17064,"interventions":17065},[91],[17045],[17029,17047],{"trials":17067,"activeCount":101},[],{"trials":17069,"activeCount":101},[],{"intervention":1975,"totalTrials":97,"cells":17071},{"EARLY_PHASE1":17072,"PHASE1":17074,"PHASE2":17076,"PHASE3":17078,"PHASE4":17084,"NA":17086},{"trials":17073,"activeCount":101},[],{"trials":17075,"activeCount":101},[],{"trials":17077,"activeCount":101},[],{"trials":17079,"activeCount":101},[17080],{"nctId":1968,"briefTitle":1969,"status":244,"phases":17081,"completion":1971,"start":1566,"conditions":17082,"interventions":17083},[91],[1973],[1975,478,445],{"trials":17085,"activeCount":101},[],{"trials":17087,"activeCount":101},[],{"intervention":9150,"totalTrials":97,"cells":17089},{"EARLY_PHASE1":17090,"PHASE1":17092,"PHASE2":17094,"PHASE3":17096,"PHASE4":17102,"NA":17104},{"trials":17091,"activeCount":101},[],{"trials":17093,"activeCount":101},[],{"trials":17095,"activeCount":101},[],{"trials":17097,"activeCount":101},[17098],{"nctId":9140,"briefTitle":9141,"status":244,"phases":17099,"primaryCompletion":9143,"completion":9143,"start":9144,"enrollment":9145,"conditions":17100,"interventions":17101},[91],[1226,9147,9148],[9150,9118],{"trials":17103,"activeCount":101},[],{"trials":17105,"activeCount":101},[],{"intervention":880,"totalTrials":97,"cells":17107},{"EARLY_PHASE1":17108,"PHASE1":17110,"PHASE2":17112,"PHASE3":17114,"PHASE4":17120,"NA":17122},{"trials":17109,"activeCount":101},[],{"trials":17111,"activeCount":101},[],{"trials":17113,"activeCount":101},[],{"trials":17115,"activeCount":101},[17116],{"nctId":872,"briefTitle":873,"status":244,"phases":17117,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":17118,"interventions":17119},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":17121,"activeCount":101},[],{"trials":17123,"activeCount":101},[],{"intervention":881,"totalTrials":97,"cells":17125},{"EARLY_PHASE1":17126,"PHASE1":17128,"PHASE2":17130,"PHASE3":17132,"PHASE4":17138,"NA":17140},{"trials":17127,"activeCount":101},[],{"trials":17129,"activeCount":101},[],{"trials":17131,"activeCount":101},[],{"trials":17133,"activeCount":101},[17134],{"nctId":872,"briefTitle":873,"status":244,"phases":17135,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":17136,"interventions":17137},[91],[27,24],[389,360,549,202,361,642,345,346,880,362,363,881,445,349],{"trials":17139,"activeCount":101},[],{"trials":17141,"activeCount":101},[],{"intervention":441,"totalTrials":283,"cells":17143},{"EARLY_PHASE1":17144,"PHASE1":17146,"PHASE2":17173,"PHASE3":17205,"PHASE4":17207,"NA":17209},{"trials":17145,"activeCount":101},[],{"trials":17147,"activeCount":101},[17148,17155,17159,17165,17169],{"nctId":17149,"briefTitle":17150,"status":244,"phases":17151,"start":384,"conditions":17152,"interventions":17153},"NCT00043095","BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors",[89],[1568],[441,17154],"ixabepilone",{"nctId":2903,"briefTitle":2904,"status":244,"phases":17156,"primaryCompletion":648,"start":2906,"enrollment":454,"conditions":17157,"interventions":17158},[89],[285,30,286],[2909,47,441],{"nctId":17160,"briefTitle":17161,"status":244,"phases":17162,"primaryCompletion":1629,"completion":1629,"start":3451,"conditions":17163,"interventions":17164},"NCT00003426","Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer",[89],[1226],[441],{"nctId":3367,"briefTitle":3368,"status":244,"phases":17166,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":356,"conditions":17167,"interventions":17168},[89],[971,2992],[288,390,345,441,741],{"nctId":2987,"briefTitle":2988,"status":244,"phases":17170,"primaryCompletion":695,"completion":695,"start":2990,"enrollment":356,"conditions":17171,"interventions":17172},[89],[971,2992],[288,47,345,441,741],{"trials":17174,"activeCount":101},[17175,17179,17183,17187,17191,17197,17201],{"nctId":3041,"briefTitle":3042,"status":244,"phases":17176,"primaryCompletion":3044,"completion":3044,"start":2990,"enrollment":356,"conditions":17177,"interventions":17178},[89,90],[971,2992],[288,47,345,441,442,741],{"nctId":433,"briefTitle":434,"status":244,"phases":17180,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":17181,"interventions":17182},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":1626,"briefTitle":1627,"status":244,"phases":17184,"primaryCompletion":1629,"completion":1629,"start":1630,"conditions":17185,"interventions":17186},[89,90],[21],[47,1023,441],{"nctId":1638,"briefTitle":1639,"status":244,"phases":17188,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":17189,"interventions":17190},[90],[21],[1645,47,224,1646,1647,1181],{"nctId":17192,"briefTitle":17193,"status":244,"phases":17194,"primaryCompletion":1356,"completion":1356,"start":728,"enrollment":356,"conditions":17195,"interventions":17196},"NCT00003540","Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel",[90],[15],[441],{"nctId":1682,"briefTitle":1683,"status":244,"phases":17198,"primaryCompletion":680,"completion":680,"start":1685,"enrollment":705,"conditions":17199,"interventions":17200},[90],[30,33,1687],[288,1023,441],{"nctId":5095,"briefTitle":5096,"status":244,"phases":17202,"primaryCompletion":4363,"completion":5098,"start":1397,"enrollment":573,"conditions":17203,"interventions":17204},[90],[1226],[441,3603,379,3152],{"trials":17206,"activeCount":101},[],{"trials":17208,"activeCount":101},[],{"trials":17210,"activeCount":101},[],{"intervention":9394,"totalTrials":1434,"cells":17212},{"EARLY_PHASE1":17213,"PHASE1":17215,"PHASE2":17229,"PHASE3":17276,"PHASE4":17278,"NA":17280},{"trials":17214,"activeCount":101},[],{"trials":17216,"activeCount":101},[17217,17223],{"nctId":17218,"briefTitle":17219,"status":244,"phases":17220,"primaryCompletion":3121,"completion":3121,"start":3451,"conditions":17221,"interventions":17222},"NCT00003395","Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer",[89],[27,24,828],[9394],{"nctId":17224,"briefTitle":17225,"status":244,"phases":17226,"primaryCompletion":426,"completion":426,"start":545,"conditions":17227,"interventions":17228},"NCT00003630","Arsenic Trioxide in Treating Patients With Advanced Solid Tumors",[89],[1568,556],[9394],{"trials":17230,"activeCount":101},[17231,17238,17244,17250,17256,17262,17268,17272],{"nctId":17232,"briefTitle":17233,"status":244,"phases":17234,"primaryCompletion":554,"completion":554,"start":17235,"conditions":17236,"interventions":17237},"NCT00005040","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma",[90],"2000-01",[24],[9394],{"nctId":17239,"briefTitle":17240,"status":505,"phases":17241,"primaryCompletion":15999,"completion":15999,"start":1199,"enrollment":97,"conditions":17242,"interventions":17243},"NCT00528450","Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia",[90],[27],[9394,3942,13235],{"nctId":17245,"briefTitle":17246,"status":244,"phases":17247,"completion":587,"start":3881,"conditions":17248,"interventions":17249},"NCT00005999","Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer",[90],[5017],[9394],{"nctId":17251,"briefTitle":17252,"status":244,"phases":17253,"primaryCompletion":630,"completion":630,"start":7415,"enrollment":2483,"conditions":17254,"interventions":17255},"NCT00024258","Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors",[90],[3259,867,387,783,2610,215,30,651,33],[9394],{"nctId":17257,"briefTitle":17258,"status":244,"phases":17259,"completion":1575,"start":1611,"conditions":17260,"interventions":17261},"NCT00005618","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia",[90],[27],[9394],{"nctId":17263,"briefTitle":17264,"status":244,"phases":17265,"primaryCompletion":554,"completion":554,"start":17235,"conditions":17266,"interventions":17267},"NCT00005069","Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer",[90],[783],[9394],{"nctId":13230,"briefTitle":13231,"status":244,"phases":17269,"primaryCompletion":764,"start":3323,"enrollment":1052,"conditions":17270,"interventions":17271},[90],[27],[288,3941,9394,3942,13235],{"nctId":9389,"briefTitle":9390,"status":244,"phases":17273,"primaryCompletion":3274,"completion":3274,"start":3220,"conditions":17274,"interventions":17275},[89,90],[27],[9394,3012],{"trials":17277,"activeCount":101},[],{"trials":17279,"activeCount":101},[],{"trials":17281,"activeCount":101},[],{"intervention":344,"totalTrials":601,"cells":17283},{"EARLY_PHASE1":17284,"PHASE1":17286,"PHASE2":17306,"PHASE3":17336,"PHASE4":17338,"NA":17340},{"trials":17285,"activeCount":101},[],{"trials":17287,"activeCount":101},[17288,17294,17298],{"nctId":17289,"briefTitle":17290,"status":244,"phases":17291,"primaryCompletion":1971,"start":3402,"conditions":17292,"interventions":17293},"NCT00037011","Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma",[89],[215],[1271,344],{"nctId":8944,"briefTitle":8945,"status":244,"phases":17295,"primaryCompletion":1141,"completion":1141,"start":4750,"enrollment":992,"conditions":17296,"interventions":17297},[89],[215],[344,360],{"nctId":17299,"briefTitle":17300,"status":244,"phases":17301,"primaryCompletion":17302,"completion":17302,"start":17303,"enrollment":341,"conditions":17304,"interventions":17305},"NCT00492167","Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma",[89],"2022-03-04","2005-09-09",[215],[1271,344],{"trials":17307,"activeCount":101},[17308,17312,17320,17324,17328,17332],{"nctId":336,"briefTitle":337,"status":244,"phases":17309,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":17310,"interventions":17311},[90],[215],[288,344,47,202,345,346,347,348,349],{"nctId":17313,"briefTitle":17314,"status":244,"phases":17315,"primaryCompletion":17316,"completion":17316,"start":17317,"conditions":17318,"interventions":17319},"NCT00002458","Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission",[90],"2001-09","1987-11",[215],[344],{"nctId":3927,"briefTitle":3928,"status":244,"phases":17321,"primaryCompletion":339,"start":3930,"conditions":17322,"interventions":17323},[90],[215],[344,346,749],{"nctId":8983,"briefTitle":8984,"status":244,"phases":17325,"primaryCompletion":3522,"completion":3522,"start":8986,"enrollment":718,"conditions":17326,"interventions":17327},[90],[215],[344,360],{"nctId":8996,"briefTitle":8997,"status":244,"phases":17329,"primaryCompletion":736,"start":4662,"enrollment":1743,"conditions":17330,"interventions":17331},[90],[215],[1271,344,360,749],{"nctId":743,"briefTitle":744,"status":244,"phases":17333,"primaryCompletion":746,"completion":746,"start":637,"conditions":17334,"interventions":17335},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"trials":17337,"activeCount":101},[],{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[],{"intervention":2963,"totalTrials":952,"cells":17343},{"EARLY_PHASE1":17344,"PHASE1":17346,"PHASE2":17356,"PHASE3":17400,"PHASE4":17402,"NA":17404},{"trials":17345,"activeCount":101},[],{"trials":17347,"activeCount":101},[17348,17352],{"nctId":9763,"briefTitle":9764,"status":244,"phases":17349,"primaryCompletion":9766,"completion":9766,"start":774,"enrollment":601,"conditions":17350,"interventions":17351},[89],[18],[9756,9769],{"nctId":2958,"briefTitle":2959,"status":244,"phases":17353,"primaryCompletion":875,"completion":875,"start":736,"enrollment":356,"conditions":17354,"interventions":17355},[89],[1568],[47,2963,2964],{"trials":17357,"activeCount":101},[17358,17366,17370,17376,17380,17388],{"nctId":17359,"briefTitle":17360,"status":244,"phases":17361,"primaryCompletion":9818,"completion":9818,"start":17362,"enrollment":6397,"conditions":17363,"interventions":17365},"NCT00805129","Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium",[90],"2008-12-05",[971,17364],"Metastatic Transitional Cell Carcinoma",[9769],{"nctId":9238,"briefTitle":9239,"status":244,"phases":17367,"primaryCompletion":9241,"completion":9241,"start":1267,"enrollment":1743,"conditions":17368,"interventions":17369},[89,90],[21],[2963,1578],{"nctId":17371,"briefTitle":17372,"status":244,"phases":17373,"primaryCompletion":3548,"completion":3548,"start":588,"enrollment":2630,"conditions":17374,"interventions":17375},"NCT01024946","Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin\u002FNF2 Loss as a Biomarker to Predict Sensitivity",[90],[2293],[2963],{"nctId":9245,"briefTitle":9246,"status":244,"phases":17377,"primaryCompletion":1652,"completion":1652,"start":1575,"enrollment":398,"conditions":17378,"interventions":17379},[89,90],[3259,18],[2963,1578],{"nctId":17381,"briefTitle":17382,"status":244,"phases":17383,"primaryCompletion":17384,"completion":17384,"start":305,"enrollment":899,"conditions":17385,"interventions":17386},"NCT03070301","A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",[90],"2024-01-31",[15597],[17387,2963],"LEE011",{"nctId":17389,"briefTitle":17390,"status":244,"phases":17391,"primaryCompletion":17392,"completion":17392,"start":17393,"enrollment":1232,"conditions":17394,"interventions":17397},"NCT01642186","Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)",[90],"2021-07-16","2012-07-12",[17395,17396],"Fibrolamellar Carcinoma","Fibrolamellar Liver Cancer",[2963,17398,17399],"letrozole plus leuprolide","combination of everolimus, letrozole and leuprolide",{"trials":17401,"activeCount":101},[],{"trials":17403,"activeCount":101},[],{"trials":17405,"activeCount":101},[],{"intervention":17154,"totalTrials":332,"cells":17407},{"EARLY_PHASE1":17408,"PHASE1":17410,"PHASE2":17416,"PHASE3":17448,"PHASE4":17450,"NA":17452},{"trials":17409,"activeCount":101},[],{"trials":17411,"activeCount":101},[17412],{"nctId":17149,"briefTitle":17150,"status":244,"phases":17413,"start":384,"conditions":17414,"interventions":17415},[89],[1568],[441,17154],{"trials":17417,"activeCount":101},[17418,17424,17430,17436,17442],{"nctId":17419,"briefTitle":17420,"status":244,"phases":17421,"completion":3370,"start":13332,"enrollment":1052,"conditions":17422,"interventions":17423},"NCT00052572","Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders",[90],[27,24],[17154],{"nctId":17425,"briefTitle":17426,"status":244,"phases":17427,"primaryCompletion":695,"completion":695,"start":7408,"conditions":17428,"interventions":17429},"NCT00020904","BMS-247550 in Treating Women With Metastatic Breast Cancer",[90],[15],[17154],{"nctId":17431,"briefTitle":17432,"status":244,"phases":17433,"completion":727,"start":554,"conditions":17434,"interventions":17435},"NCT00025194","Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer",[89,90],[18],[1707,17154],{"nctId":17437,"briefTitle":17438,"status":244,"phases":17439,"primaryCompletion":6493,"completion":6493,"start":7408,"conditions":17440,"interventions":17441},"NCT00017056","BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy",[90],[1602,1613],[17154],{"nctId":17443,"briefTitle":17444,"status":244,"phases":17445,"completion":4772,"start":737,"enrollment":1462,"conditions":17446,"interventions":17447},"NCT00070096","Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors",[90],[3259,387,30,868],[17154],{"trials":17449,"activeCount":101},[],{"trials":17451,"activeCount":101},[],{"trials":17453,"activeCount":101},[],{"intervention":1570,"totalTrials":1934,"cells":17455},{"EARLY_PHASE1":17456,"PHASE1":17458,"PHASE2":17472,"PHASE3":17482,"PHASE4":17484,"NA":17486},{"trials":17457,"activeCount":101},[],{"trials":17459,"activeCount":101},[17460,17464,17468],{"nctId":1562,"briefTitle":1563,"status":244,"phases":17461,"primaryCompletion":1565,"completion":588,"start":1566,"conditions":17462,"interventions":17463},[89],[1568],[1570,1023],{"nctId":7335,"briefTitle":7336,"status":244,"phases":17465,"primaryCompletion":3220,"start":1703,"conditions":17466,"interventions":17467},[89],[1568],[1570,683],{"nctId":2999,"briefTitle":3000,"status":244,"phases":17469,"primaryCompletion":2931,"completion":2931,"start":3002,"enrollment":3003,"conditions":17470,"interventions":17471},[89],[1568],[1570,47,741],{"trials":17473,"activeCount":101},[17474,17478],{"nctId":5221,"briefTitle":5222,"status":244,"phases":17475,"completion":804,"start":5224,"conditions":17476,"interventions":17477},[90],[1602],[1570,741],{"nctId":7389,"briefTitle":7390,"status":244,"phases":17479,"completion":727,"start":354,"conditions":17480,"interventions":17481},[90],[2610],[1570,683],{"trials":17483,"activeCount":101},[],{"trials":17485,"activeCount":101},[],{"trials":17487,"activeCount":101},[],{"intervention":17489,"totalTrials":1934,"cells":17490},"sunitinib malate",{"EARLY_PHASE1":17491,"PHASE1":17493,"PHASE2":17495,"PHASE3":17531,"PHASE4":17533,"NA":17535},{"trials":17492,"activeCount":101},[],{"trials":17494,"activeCount":101},[],{"trials":17496,"activeCount":101},[17497,17505,17511,17518,17525],{"nctId":17498,"briefTitle":17499,"status":244,"phases":17500,"primaryCompletion":3281,"completion":3281,"start":3590,"enrollment":4992,"conditions":17501,"interventions":17504},"NCT00474994","Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",[90],[17502,17503,3359,30,33,1687],"Adult Malignant Fibrous Histiocytoma of Bone","Desmoid Tumor",[17489],{"nctId":17506,"briefTitle":17507,"status":244,"phases":17508,"primaryCompletion":3281,"completion":3281,"start":764,"enrollment":454,"conditions":17509,"interventions":17510},"NCT00459875","Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer",[90],[783],[17489],{"nctId":17512,"briefTitle":17513,"status":244,"phases":17514,"primaryCompletion":13529,"completion":13529,"start":17515,"enrollment":10064,"conditions":17516,"interventions":17517},"NCT00397488","Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",[90],"2006-09",[971,2992,3202],[17489],{"nctId":17519,"briefTitle":17520,"status":244,"phases":17521,"primaryCompletion":17522,"completion":17522,"start":764,"enrollment":1434,"conditions":17523,"interventions":17524},"NCT00453310","Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment",[90],"2008-11",[387,30,3260,868],[17489],{"nctId":17526,"briefTitle":17527,"status":244,"phases":17528,"primaryCompletion":1266,"completion":1266,"start":764,"enrollment":952,"conditions":17529,"interventions":17530},"NCT00462982","Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",[90],[783,4734,2349],[17489],{"trials":17532,"activeCount":101},[],{"trials":17534,"activeCount":101},[],{"trials":17536,"activeCount":101},[],{"intervention":750,"totalTrials":1114,"cells":17538},{"EARLY_PHASE1":17539,"PHASE1":17541,"PHASE2":17551,"PHASE3":17561,"PHASE4":17563,"NA":17565},{"trials":17540,"activeCount":101},[],{"trials":17542,"activeCount":101},[17543,17547],{"nctId":3586,"briefTitle":3587,"status":244,"phases":17544,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":17545,"interventions":17546},[89],[27],[288,3593,643,479,750,447],{"nctId":4421,"briefTitle":4422,"status":244,"phases":17548,"primaryCompletion":825,"completion":825,"start":4424,"conditions":17549,"interventions":17550},[89],[1568],[442,750],{"trials":17552,"activeCount":101},[17553,17557],{"nctId":3519,"briefTitle":3520,"status":244,"phases":17554,"primaryCompletion":3522,"completion":3522,"start":3523,"conditions":17555,"interventions":17556},[90],[867,387,1586,783,2610,24,215,30,651,33,868],[288,390,479,750],{"nctId":743,"briefTitle":744,"status":244,"phases":17558,"primaryCompletion":746,"completion":746,"start":637,"conditions":17559,"interventions":17560},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"trials":17562,"activeCount":101},[],{"trials":17564,"activeCount":101},[],{"trials":17566,"activeCount":101},[],{"intervention":447,"totalTrials":1114,"cells":17568},{"EARLY_PHASE1":17569,"PHASE1":17571,"PHASE2":17577,"PHASE3":17591,"PHASE4":17593,"NA":17595},{"trials":17570,"activeCount":101},[],{"trials":17572,"activeCount":101},[17573],{"nctId":3586,"briefTitle":3587,"status":244,"phases":17574,"primaryCompletion":3589,"completion":3589,"start":3590,"enrollment":1412,"conditions":17575,"interventions":17576},[89],[27],[288,3593,643,479,750,447],{"trials":17578,"activeCount":101},[17579,17583,17587],{"nctId":433,"briefTitle":434,"status":244,"phases":17580,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":17581,"interventions":17582},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":1638,"briefTitle":1639,"status":244,"phases":17584,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":486,"conditions":17585,"interventions":17586},[90],[21],[1645,47,224,1646,1647,1181],{"nctId":4816,"briefTitle":4817,"status":244,"phases":17588,"primaryCompletion":4819,"completion":4819,"start":554,"enrollment":565,"conditions":17589,"interventions":17590},[89,90],[2349],[4691,447],{"trials":17592,"activeCount":101},[],{"trials":17594,"activeCount":101},[],{"trials":17596,"activeCount":101},[],{"intervention":359,"totalTrials":1114,"cells":17598},{"EARLY_PHASE1":17599,"PHASE1":17601,"PHASE2":17610,"PHASE3":17624,"PHASE4":17626,"NA":17628},{"trials":17600,"activeCount":101},[],{"trials":17602,"activeCount":101},[17603],{"nctId":17604,"briefTitle":17605,"status":244,"phases":17606,"primaryCompletion":3880,"completion":3880,"start":1566,"conditions":17607,"interventions":17608},"NCT00045370","Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",[89],[783],[359,17609],"temsirolimus",{"trials":17611,"activeCount":101},[17612,17616,17620],{"nctId":351,"briefTitle":352,"status":244,"phases":17613,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":17614,"interventions":17615},[90],[27],[359,360,202,361,346,362,363],{"nctId":13935,"briefTitle":13936,"status":244,"phases":17617,"primaryCompletion":339,"completion":588,"start":2931,"conditions":17618,"interventions":17619},[90],[24],[359,13940],{"nctId":9383,"briefTitle":9384,"status":244,"phases":17621,"primaryCompletion":680,"completion":680,"start":1566,"conditions":17622,"interventions":17623},[90],[27],[359,3012],{"trials":17625,"activeCount":101},[],{"trials":17627,"activeCount":101},[],{"trials":17629,"activeCount":101},[],{"intervention":1271,"totalTrials":1114,"cells":17631},{"EARLY_PHASE1":17632,"PHASE1":17634,"PHASE2":17648,"PHASE3":17654,"PHASE4":17656,"NA":17658},{"trials":17633,"activeCount":101},[],{"trials":17635,"activeCount":101},[17636,17640,17644],{"nctId":17289,"briefTitle":17290,"status":244,"phases":17637,"primaryCompletion":1971,"start":3402,"conditions":17638,"interventions":17639},[89],[215],[1271,344],{"nctId":1263,"briefTitle":1264,"status":505,"phases":17641,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":509,"conditions":17642,"interventions":17643},[89],[27,24,1269],[1271,374],{"nctId":17299,"briefTitle":17300,"status":244,"phases":17645,"primaryCompletion":17302,"completion":17302,"start":17303,"enrollment":341,"conditions":17646,"interventions":17647},[89],[215],[1271,344],{"trials":17649,"activeCount":101},[17650],{"nctId":8996,"briefTitle":8997,"status":244,"phases":17651,"primaryCompletion":736,"start":4662,"enrollment":1743,"conditions":17652,"interventions":17653},[90],[215],[1271,344,360,749],{"trials":17655,"activeCount":101},[],{"trials":17657,"activeCount":101},[],{"trials":17659,"activeCount":101},[],{"intervention":3658,"totalTrials":1114,"cells":17661},{"EARLY_PHASE1":17662,"PHASE1":17664,"PHASE2":17673,"PHASE3":17690,"PHASE4":17692,"NA":17694},{"trials":17663,"activeCount":101},[],{"trials":17665,"activeCount":101},[17666],{"nctId":17667,"briefTitle":17668,"status":244,"phases":17669,"primaryCompletion":1566,"completion":1566,"start":3323,"conditions":17670,"interventions":17671},"NCT00016172","ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma",[89],[24,1687,1568],[3658,17672],"picoplatin",{"trials":17674,"activeCount":101},[17675,17679,17683],{"nctId":7460,"briefTitle":7461,"status":244,"phases":17676,"primaryCompletion":737,"completion":737,"start":3930,"conditions":17677,"interventions":17678},[89,90],[15],[768,3658],{"nctId":3652,"briefTitle":3653,"status":244,"phases":17680,"primaryCompletion":3655,"completion":3655,"start":736,"enrollment":341,"conditions":17681,"interventions":17682},[90],[828],[662,643,3658,558],{"nctId":17684,"briefTitle":17685,"status":244,"phases":17686,"primaryCompletion":4130,"completion":4130,"start":16824,"enrollment":1883,"conditions":17687,"interventions":17688},"NCT00255801","Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma",[90],[24],[17689,3658],"Targretin®",{"trials":17691,"activeCount":101},[],{"trials":17693,"activeCount":101},[],{"trials":17695,"activeCount":101},[],{"intervention":1899,"totalTrials":1114,"cells":17697},{"EARLY_PHASE1":17698,"PHASE1":17700,"PHASE2":17706,"PHASE3":17720,"PHASE4":17722,"NA":17724},{"trials":17699,"activeCount":101},[],{"trials":17701,"activeCount":101},[17702],{"nctId":7758,"briefTitle":7759,"status":244,"phases":17703,"primaryCompletion":7761,"completion":7761,"start":7762,"enrollment":952,"conditions":17704,"interventions":17705},[89],[7752,4054,6116,7764,7765,7766],[1295,1899],{"trials":17707,"activeCount":101},[17708,17712,17716],{"nctId":7032,"briefTitle":7033,"status":2832,"phases":17709,"primaryCompletion":2472,"completion":2472,"start":7035,"enrollment":101,"conditions":17710,"interventions":17711},[89,90],[18],[1899,711],{"nctId":1891,"briefTitle":1892,"status":244,"phases":17713,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":952,"conditions":17714,"interventions":17715},[89,90],[1897],[1899,1260],{"nctId":1915,"briefTitle":1916,"status":244,"phases":17717,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":326,"conditions":17718,"interventions":17719},[89,90],[1921],[1260,1899],{"trials":17721,"activeCount":101},[],{"trials":17723,"activeCount":101},[],{"trials":17725,"activeCount":101},[],{"intervention":3942,"totalTrials":1114,"cells":17727},{"EARLY_PHASE1":17728,"PHASE1":17730,"PHASE2":17732,"PHASE3":17750,"PHASE4":17752,"NA":17754},{"trials":17729,"activeCount":101},[],{"trials":17731,"activeCount":101},[],{"trials":17733,"activeCount":101},[17734,17738,17742,17746],{"nctId":17239,"briefTitle":17240,"status":505,"phases":17735,"primaryCompletion":15999,"completion":15999,"start":1199,"enrollment":97,"conditions":17736,"interventions":17737},[90],[27],[9394,3942,13235],{"nctId":3934,"briefTitle":3935,"status":244,"phases":17739,"primaryCompletion":1702,"completion":1702,"start":3937,"enrollment":162,"conditions":17740,"interventions":17741},[90],[27,475,3939],[288,3941,361,346,3942],{"nctId":7274,"briefTitle":7275,"status":244,"phases":17743,"primaryCompletion":1610,"completion":1610,"start":7277,"enrollment":718,"conditions":17744,"interventions":17745},[90],[27],[3941,361,3942],{"nctId":13230,"briefTitle":13231,"status":244,"phases":17747,"primaryCompletion":764,"start":3323,"enrollment":1052,"conditions":17748,"interventions":17749},[90],[27],[288,3941,9394,3942,13235],{"trials":17751,"activeCount":101},[],{"trials":17753,"activeCount":101},[],{"trials":17755,"activeCount":101},[],{"intervention":17757,"totalTrials":1114,"cells":17758},"Romiplostim",{"EARLY_PHASE1":17759,"PHASE1":17761,"PHASE2":17763,"PHASE3":17801,"PHASE4":17803,"NA":17805},{"trials":17760,"activeCount":101},[],{"trials":17762,"activeCount":101},[],{"trials":17764,"activeCount":101},[17765,17773,17782,17792],{"nctId":17766,"briefTitle":17767,"status":244,"phases":17768,"primaryCompletion":934,"completion":934,"start":17769,"enrollment":2630,"conditions":17770,"interventions":17772},"NCT04673266","Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma",[90],"2020-12-14",[17771,7258],"Lymphoma Patients",[17757],{"nctId":17774,"briefTitle":17775,"status":244,"phases":17776,"primaryCompletion":17777,"completion":17777,"start":17778,"enrollment":2888,"conditions":17779,"interventions":17781},"NCT04478123","Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer",[90],"2023-06-08","2020-07-14",[308,604,605,17780],"HDT-AHCT",[17757],{"nctId":17783,"briefTitle":17784,"status":244,"phases":17785,"primaryCompletion":17786,"completion":17786,"start":17787,"enrollment":162,"conditions":17788,"interventions":17790},"NCT02052882","Study of Romiplostim for Chemotherapy Induced Thrombocytopenia",[90],"2023-11-13","2014-01-30",[17789],"Isolated Chemotherapy-induced Thrombocytopenia",[17791],"romiplostim",{"nctId":17793,"briefTitle":17794,"status":505,"phases":17795,"primaryCompletion":17796,"completion":17796,"start":17797,"enrollment":1094,"conditions":17798,"interventions":17800},"NCT04671901","A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors",[90],"2023-03-29","2020-12-10",[2351,17799,6267],"Solid Tumor, Childhood",[17757],{"trials":17802,"activeCount":101},[],{"trials":17804,"activeCount":101},[],{"trials":17806,"activeCount":101},[],{"intervention":749,"totalTrials":1114,"cells":17808},{"EARLY_PHASE1":17809,"PHASE1":17811,"PHASE2":17813,"PHASE3":17831,"PHASE4":17833,"NA":17835},{"trials":17810,"activeCount":101},[],{"trials":17812,"activeCount":101},[],{"trials":17814,"activeCount":101},[17815,17819,17823,17827],{"nctId":3927,"briefTitle":3928,"status":244,"phases":17816,"primaryCompletion":339,"start":3930,"conditions":17817,"interventions":17818},[90],[215],[344,346,749],{"nctId":8996,"briefTitle":8997,"status":244,"phases":17820,"primaryCompletion":736,"start":4662,"enrollment":1743,"conditions":17821,"interventions":17822},[90],[215],[1271,344,360,749],{"nctId":743,"briefTitle":744,"status":244,"phases":17824,"primaryCompletion":746,"completion":746,"start":637,"conditions":17825,"interventions":17826},[90],[215],[288,344,360,390,47,202,345,346,749,479,750,349],{"nctId":7139,"briefTitle":7140,"status":244,"phases":17828,"primaryCompletion":7142,"completion":7142,"start":7143,"enrollment":533,"conditions":17829,"interventions":17830},[90],[215],[4692,4693,7146],{"trials":17832,"activeCount":101},[],{"trials":17834,"activeCount":101},[],{"trials":17836,"activeCount":101},[],{"intervention":4611,"totalTrials":1114,"cells":17838},{"EARLY_PHASE1":17839,"PHASE1":17841,"PHASE2":17847,"PHASE3":17864,"PHASE4":17866,"NA":17868},{"trials":17840,"activeCount":101},[],{"trials":17842,"activeCount":101},[17843],{"nctId":7614,"briefTitle":7615,"status":244,"phases":17844,"primaryCompletion":7617,"completion":7617,"start":7618,"enrollment":7619,"conditions":17845,"interventions":17846},[89],[24,7621],[4611,464,7623],{"trials":17848,"activeCount":101},[17849,17853,17857],{"nctId":4603,"briefTitle":4604,"status":244,"phases":17850,"primaryCompletion":4606,"completion":4606,"start":4607,"enrollment":1600,"conditions":17851,"interventions":17852},[89,90],[4114,4609],[3676,4611,1261],{"nctId":4613,"briefTitle":4614,"status":244,"phases":17854,"primaryCompletion":4616,"completion":4616,"start":704,"enrollment":565,"conditions":17855,"interventions":17856},[89,90],[308,707],[4611,1261],{"nctId":17858,"briefTitle":17859,"status":244,"phases":17860,"primaryCompletion":1994,"start":3777,"conditions":17861,"interventions":17862},"NCT00042822","FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma",[90],[27,24,475,476],[17863],"romidepsin",{"trials":17865,"activeCount":101},[],{"trials":17867,"activeCount":101},[],{"trials":17869,"activeCount":101},[],{"intervention":3941,"totalTrials":1114,"cells":17871},{"EARLY_PHASE1":17872,"PHASE1":17874,"PHASE2":17883,"PHASE3":17897,"PHASE4":17899,"NA":17901},{"trials":17873,"activeCount":101},[],{"trials":17875,"activeCount":101},[17876],{"nctId":17877,"briefTitle":17878,"status":244,"phases":17879,"primaryCompletion":648,"completion":648,"start":17880,"enrollment":454,"conditions":17881,"interventions":17882},"NCT00002890","Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia",[89],"1996-10",[27,475],[3941],{"trials":17884,"activeCount":101},[17885,17889,17893],{"nctId":3934,"briefTitle":3935,"status":244,"phases":17886,"primaryCompletion":1702,"completion":1702,"start":3937,"enrollment":162,"conditions":17887,"interventions":17888},[90],[27,475,3939],[288,3941,361,346,3942],{"nctId":7274,"briefTitle":7275,"status":244,"phases":17890,"primaryCompletion":1610,"completion":1610,"start":7277,"enrollment":718,"conditions":17891,"interventions":17892},[90],[27],[3941,361,3942],{"nctId":13230,"briefTitle":13231,"status":244,"phases":17894,"primaryCompletion":764,"start":3323,"enrollment":1052,"conditions":17895,"interventions":17896},[90],[27],[288,3941,9394,3942,13235],{"trials":17898,"activeCount":101},[],{"trials":17900,"activeCount":101},[],{"trials":17902,"activeCount":101},[],{"intervention":13235,"totalTrials":509,"cells":17904},{"EARLY_PHASE1":17905,"PHASE1":17907,"PHASE2":17909,"PHASE3":17928,"PHASE4":17930,"NA":17932},{"trials":17906,"activeCount":101},[],{"trials":17908,"activeCount":101},[],{"trials":17910,"activeCount":101},[17911,17920,17924],{"nctId":17912,"briefTitle":17913,"status":244,"phases":17914,"primaryCompletion":17915,"completion":17915,"start":727,"enrollment":969,"conditions":17916,"interventions":17917},"NCT00382200","Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes",[89,90],"2023-01-05",[475],[17918,13235,13614,17919,1351],"decitabine","cytogenetic analysis",{"nctId":17239,"briefTitle":17240,"status":505,"phases":17921,"primaryCompletion":15999,"completion":15999,"start":1199,"enrollment":97,"conditions":17922,"interventions":17923},[90],[27],[9394,3942,13235],{"nctId":13230,"briefTitle":13231,"status":244,"phases":17925,"primaryCompletion":764,"start":3323,"enrollment":1052,"conditions":17926,"interventions":17927},[90],[27],[288,3941,9394,3942,13235],{"trials":17929,"activeCount":101},[],{"trials":17931,"activeCount":101},[],{"trials":17933,"activeCount":101},[],{"intervention":375,"totalTrials":509,"cells":17935},{"EARLY_PHASE1":17936,"PHASE1":17938,"PHASE2":17940,"PHASE3":17954,"PHASE4":17956,"NA":17958},{"trials":17937,"activeCount":101},[],{"trials":17939,"activeCount":101},[],{"trials":17941,"activeCount":101},[17942,17946,17950],{"nctId":365,"briefTitle":366,"status":244,"phases":17943,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":17944,"interventions":17945},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":560,"briefTitle":561,"status":244,"phases":17947,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":17948,"interventions":17949},[90],[27,24],[374,202,375],{"nctId":685,"briefTitle":686,"status":244,"phases":17951,"primaryCompletion":688,"completion":688,"start":427,"enrollment":162,"conditions":17952,"interventions":17953},[90],[27,24],[288,374,202,375],{"trials":17955,"activeCount":101},[],{"trials":17957,"activeCount":101},[],{"trials":17959,"activeCount":101},[],{"intervention":1887,"totalTrials":509,"cells":17961},{"EARLY_PHASE1":17962,"PHASE1":17964,"PHASE2":17970,"PHASE3":17988,"PHASE4":17990,"NA":17992},{"trials":17963,"activeCount":101},[],{"trials":17965,"activeCount":101},[17966],{"nctId":1878,"briefTitle":1879,"status":244,"phases":17967,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1883,"conditions":17968,"interventions":17969},[89],[24,1874,1831,1885],[1887,1260],{"trials":17971,"activeCount":101},[17972,17979],{"nctId":17973,"briefTitle":17974,"status":244,"phases":17975,"primaryCompletion":6114,"completion":6114,"start":16614,"enrollment":2446,"conditions":17976,"interventions":17978},"NCT01551030","Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium",[90],[17977],"Metastatic Transitional Cell Carcinoma of the Urothelium",[1887],{"nctId":17980,"briefTitle":17981,"status":244,"phases":17982,"primaryCompletion":17983,"completion":17983,"start":17984,"enrollment":1114,"conditions":17985,"interventions":17987},"NCT02301364","Buparlisib (BKM120) In Patients With Recurrent\u002FRefractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent\u002FRefractory Secondary Central Nervous System Lymphoma (SCNSL)",[90],"2016-10-11","2014-11-20",[24,1854,17986],"Recurrent\u002FRefractory Secondary Central Nervous System Lymphoma",[1887],{"trials":17989,"activeCount":101},[],{"trials":17991,"activeCount":101},[],{"trials":17993,"activeCount":101},[],{"intervention":17995,"totalTrials":509,"cells":17996},"MKC-1",{"EARLY_PHASE1":17997,"PHASE1":17999,"PHASE2":18013,"PHASE3":18021,"PHASE4":18023,"NA":18025},{"trials":17998,"activeCount":101},[],{"trials":18000,"activeCount":101},[18001,18007],{"nctId":18002,"briefTitle":18003,"status":244,"phases":18004,"primaryCompletion":2931,"completion":2931,"start":2982,"conditions":18005,"interventions":18006},"NCT00014365","Ro 31-7453 in Treating Patients With Metastatic Solid Tumors",[89],[1568],[17995],{"nctId":18008,"briefTitle":18009,"status":244,"phases":18010,"primaryCompletion":756,"completion":756,"start":2954,"enrollment":718,"conditions":18011,"interventions":18012},"NCT00003755","Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor",[89],[1568],[17995],{"trials":18014,"activeCount":101},[18015],{"nctId":18016,"briefTitle":18017,"status":244,"phases":18018,"primaryCompletion":384,"completion":384,"start":5206,"conditions":18019,"interventions":18020},"NCT00016250","Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer",[90],[36],[17995],{"trials":18022,"activeCount":101},[],{"trials":18024,"activeCount":101},[],{"trials":18026,"activeCount":101},[],{"intervention":18028,"totalTrials":509,"cells":18029},"panitumumab",{"EARLY_PHASE1":18030,"PHASE1":18032,"PHASE2":18034,"PHASE3":18053,"PHASE4":18055,"NA":18057},{"trials":18031,"activeCount":101},[],{"trials":18033,"activeCount":101},[],{"trials":18035,"activeCount":101},[18036,18045,18049],{"nctId":18037,"briefTitle":18038,"status":244,"phases":18039,"primaryCompletion":18040,"completion":18040,"start":18041,"enrollment":31,"conditions":18042,"interventions":18043},"NCT01312857","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",[90],"2024-07-15","2011-03-07",[2441],[18028,18044],"Randomization to No Panitumumab",{"nctId":3690,"briefTitle":3691,"status":2832,"phases":18046,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":101,"conditions":18047,"interventions":18048},[90],[3696],[1045,819,3698,3699,960,582],{"nctId":1110,"briefTitle":1111,"status":505,"phases":18050,"primaryCompletion":803,"start":1113,"enrollment":1114,"conditions":18051,"interventions":18052},[90],[971],[923,224,1117],{"trials":18054,"activeCount":101},[],{"trials":18056,"activeCount":101},[],{"trials":18058,"activeCount":101},[],{"intervention":1338,"totalTrials":509,"cells":18060},{"EARLY_PHASE1":18061,"PHASE1":18063,"PHASE2":18065,"PHASE3":18083,"PHASE4":18085,"NA":18087},{"trials":18062,"activeCount":101},[],{"trials":18064,"activeCount":101},[],{"trials":18066,"activeCount":101},[18067,18071,18075],{"nctId":1333,"briefTitle":1334,"status":244,"phases":18068,"completion":354,"start":695,"conditions":18069,"interventions":18070},[90],[24],[1338,374],{"nctId":8990,"briefTitle":8991,"status":2832,"phases":18072,"primaryCompletion":1994,"completion":1994,"start":1575,"enrollment":101,"conditions":18073,"interventions":18074},[90],[4734],[1338,360],{"nctId":18076,"briefTitle":18077,"status":244,"phases":18078,"primaryCompletion":7408,"completion":7408,"start":5696,"enrollment":438,"conditions":18079,"interventions":18080},"NCT00002637","Biological Therapy in Treating Patients With Prostate Cancer",[89,90],[18],[1338,18081,18082],"gene-modified tumor cell vaccine therapy","recombinant interferon gamma",{"trials":18084,"activeCount":101},[],{"trials":18086,"activeCount":101},[],{"trials":18088,"activeCount":101},[],{"intervention":3125,"totalTrials":509,"cells":18090},{"EARLY_PHASE1":18091,"PHASE1":18093,"PHASE2":18099,"PHASE3":18109,"PHASE4":18111,"NA":18113},{"trials":18092,"activeCount":101},[],{"trials":18094,"activeCount":101},[18095],{"nctId":5635,"briefTitle":5636,"status":244,"phases":18096,"primaryCompletion":3590,"start":3522,"enrollment":326,"conditions":18097,"interventions":18098},[89],[33],[391,362,3125],{"trials":18100,"activeCount":101},[18101,18105],{"nctId":3118,"briefTitle":3119,"status":244,"phases":18102,"primaryCompletion":3121,"completion":3121,"start":3122,"conditions":18103,"interventions":18104},[90],[33],[288,47,345,442,391,362,3125],{"nctId":8625,"briefTitle":8626,"status":244,"phases":18106,"primaryCompletion":7945,"completion":7945,"start":8628,"enrollment":438,"conditions":18107,"interventions":18108},[90],[27,24,33],[391,3125],{"trials":18110,"activeCount":101},[],{"trials":18112,"activeCount":101},[],{"trials":18114,"activeCount":101},[],{"intervention":1707,"totalTrials":509,"cells":18116},{"EARLY_PHASE1":18117,"PHASE1":18119,"PHASE2":18121,"PHASE3":18135,"PHASE4":18137,"NA":18139},{"trials":18118,"activeCount":101},[],{"trials":18120,"activeCount":101},[],{"trials":18122,"activeCount":101},[18123,18127,18131],{"nctId":3448,"briefTitle":3449,"status":244,"phases":18124,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":18125,"interventions":18126},[89,90],[18],[390,3454,1707,3455,3456,741],{"nctId":17431,"briefTitle":17432,"status":244,"phases":18128,"completion":727,"start":554,"conditions":18129,"interventions":18130},[89,90],[18],[1707,17154],{"nctId":1699,"briefTitle":1700,"status":244,"phases":18132,"primaryCompletion":1702,"start":1703,"conditions":18133,"interventions":18134},[90],[18,1705],[1023,345,1707,1708,1709],{"trials":18136,"activeCount":101},[],{"trials":18138,"activeCount":101},[],{"trials":18140,"activeCount":101},[],{"intervention":4754,"totalTrials":509,"cells":18142},{"EARLY_PHASE1":18143,"PHASE1":18145,"PHASE2":18147,"PHASE3":18165,"PHASE4":18167,"NA":18169},{"trials":18144,"activeCount":101},[],{"trials":18146,"activeCount":101},[],{"trials":18148,"activeCount":101},[18149,18153,18159],{"nctId":4747,"briefTitle":4748,"status":244,"phases":18150,"primaryCompletion":4750,"completion":4750,"start":4751,"conditions":18151,"interventions":18152},[90],[4733,4734],[4754,4691],{"nctId":18154,"briefTitle":18155,"status":244,"phases":18156,"primaryCompletion":2914,"completion":2914,"start":9009,"enrollment":1242,"conditions":18157,"interventions":18158},"NCT00003542","Interferon Alfa in Treating Patients With Advanced Kidney Cancer",[89,90],[783],[4754],{"nctId":18160,"briefTitle":18161,"status":244,"phases":18162,"primaryCompletion":7415,"completion":7415,"start":3251,"conditions":18163,"interventions":18164},"NCT00006039","Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma",[90],[24,1687],[4754],{"trials":18166,"activeCount":101},[],{"trials":18168,"activeCount":101},[],{"trials":18170,"activeCount":101},[],{"intervention":4766,"totalTrials":509,"cells":18172},{"EARLY_PHASE1":18173,"PHASE1":18175,"PHASE2":18177,"PHASE3":18191,"PHASE4":18193,"NA":18195},{"trials":18174,"activeCount":101},[],{"trials":18176,"activeCount":101},[],{"trials":18178,"activeCount":101},[18179,18183,18187],{"nctId":4756,"briefTitle":4757,"status":244,"phases":18180,"primaryCompletion":2545,"completion":2545,"start":4759,"enrollment":1447,"conditions":18181,"interventions":18182},[89,90],[18,4761,4762,4763,4764],[4766,818],{"nctId":9931,"briefTitle":9932,"status":244,"phases":18184,"primaryCompletion":9934,"completion":9934,"start":9935,"enrollment":1412,"conditions":18185,"interventions":18186},[89,90],[783,5422,9937,4876],[4766,9939],{"nctId":9339,"briefTitle":9340,"status":244,"phases":18188,"primaryCompletion":9342,"completion":9342,"start":9343,"enrollment":326,"conditions":18189,"interventions":18190},[90],[4876,2715,2716],[4766,6591],{"trials":18192,"activeCount":101},[],{"trials":18194,"activeCount":101},[],{"trials":18196,"activeCount":101},[],{"intervention":2935,"totalTrials":509,"cells":18198},{"EARLY_PHASE1":18199,"PHASE1":18201,"PHASE2":18207,"PHASE3":18220,"PHASE4":18222,"NA":18224},{"trials":18200,"activeCount":101},[],{"trials":18202,"activeCount":101},[18203],{"nctId":2928,"briefTitle":2929,"status":244,"phases":18204,"primaryCompletion":2931,"completion":2931,"start":2932,"conditions":18205,"interventions":18206},[89],[1568],[2935,47,741],{"trials":18208,"activeCount":101},[18209,18216],{"nctId":18210,"briefTitle":18211,"status":244,"phases":18212,"primaryCompletion":4751,"completion":4751,"start":18213,"conditions":18214,"interventions":18215},"NCT00003443","Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",[90],"1998-07",[1586],[2935],{"nctId":5294,"briefTitle":5295,"status":244,"phases":18217,"completion":3044,"start":1611,"conditions":18218,"interventions":18219},[90],[1602,1613],[2935,741],{"trials":18221,"activeCount":101},[],{"trials":18223,"activeCount":101},[],{"trials":18225,"activeCount":101},[],{"intervention":18227,"totalTrials":509,"cells":18228},"Gemcitabine and Cisplatin",{"EARLY_PHASE1":18229,"PHASE1":18231,"PHASE2":18241,"PHASE3":18257,"PHASE4":18259,"NA":18261},{"trials":18230,"activeCount":101},[],{"trials":18232,"activeCount":101},[18233],{"nctId":18234,"briefTitle":18235,"status":244,"phases":18236,"primaryCompletion":18237,"completion":18237,"start":18238,"enrollment":97,"conditions":18239,"interventions":18240},"NCT05182112","Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver",[89],"2024-11-04","2021-12-20",[1226],[18227],{"trials":18242,"activeCount":101},[18243,18249],{"nctId":18244,"briefTitle":18245,"status":244,"phases":18246,"primaryCompletion":3434,"completion":3434,"start":16198,"enrollment":1152,"conditions":18247,"interventions":18248},"NCT01589094","Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer",[90],[971],[18227],{"nctId":18250,"briefTitle":18251,"status":244,"phases":18252,"primaryCompletion":18253,"completion":18253,"start":18254,"enrollment":1665,"conditions":18255,"interventions":18256},"NCT01261728","Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma",[90],"2025-08-06","2010-12-14",[938],[18227],{"trials":18258,"activeCount":101},[],{"trials":18260,"activeCount":101},[],{"trials":18262,"activeCount":101},[],{"intervention":18264,"totalTrials":1094,"cells":18265},"vitespen",{"EARLY_PHASE1":18266,"PHASE1":18268,"PHASE2":18277,"PHASE3":18285,"PHASE4":18287,"NA":18289},{"trials":18267,"activeCount":101},[],{"trials":18269,"activeCount":101},[18270],{"nctId":18271,"briefTitle":18272,"status":244,"phases":18273,"primaryCompletion":2940,"completion":2940,"start":18274,"enrollment":1447,"conditions":18275,"interventions":18276},"NCT00003025","Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer",[89],"1997-03",[1226],[18264],{"trials":18278,"activeCount":101},[18279],{"nctId":18280,"briefTitle":18281,"status":244,"phases":18282,"primaryCompletion":756,"completion":756,"start":1357,"conditions":18283,"interventions":18284},"NCT00005628","Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma",[90],[33],[18264],{"trials":18286,"activeCount":101},[],{"trials":18288,"activeCount":101},[],{"trials":18290,"activeCount":101},[],{"intervention":6320,"totalTrials":1094,"cells":18292},{"EARLY_PHASE1":18293,"PHASE1":18295,"PHASE2":18297,"PHASE3":18311,"PHASE4":18313,"NA":18315},{"trials":18294,"activeCount":101},[],{"trials":18296,"activeCount":101},[],{"trials":18298,"activeCount":101},[18299,18303],{"nctId":6312,"briefTitle":6313,"status":244,"phases":18300,"primaryCompletion":6315,"completion":6315,"start":6316,"enrollment":2439,"conditions":18301,"interventions":18302},[90],[21,6318],[6320,577],{"nctId":18304,"briefTitle":18305,"status":244,"phases":18306,"primaryCompletion":18307,"completion":18307,"start":18308,"enrollment":2439,"conditions":18309,"interventions":18310},"NCT02234596","Nintedanib in Patients With Advanced Esophagogastric Cancer",[90],"2020-04-22","2014-09-04",[14835],[6320],{"trials":18312,"activeCount":101},[],{"trials":18314,"activeCount":101},[],{"trials":18316,"activeCount":101},[],{"intervention":17918,"totalTrials":1094,"cells":18318},{"EARLY_PHASE1":18319,"PHASE1":18321,"PHASE2":18323,"PHASE3":18335,"PHASE4":18337,"NA":18339},{"trials":18320,"activeCount":101},[],{"trials":18322,"activeCount":101},[],{"trials":18324,"activeCount":101},[18325,18329],{"nctId":17912,"briefTitle":17913,"status":244,"phases":18326,"primaryCompletion":17915,"completion":17915,"start":727,"enrollment":969,"conditions":18327,"interventions":18328},[89,90],[475],[17918,13235,13614,17919,1351],{"nctId":18330,"briefTitle":18331,"status":244,"phases":18332,"primaryCompletion":16912,"completion":588,"start":3451,"enrollment":31,"conditions":18333,"interventions":18334},"NCT00003361","Decitabine in Treating Patients With Myelodysplastic Syndrome",[90],[27,475],[17918],{"trials":18336,"activeCount":101},[],{"trials":18338,"activeCount":101},[],{"trials":18340,"activeCount":101},[],{"intervention":1351,"totalTrials":1094,"cells":18342},{"EARLY_PHASE1":18343,"PHASE1":18345,"PHASE2":18347,"PHASE3":18357,"PHASE4":18359,"NA":18361},{"trials":18344,"activeCount":101},[],{"trials":18346,"activeCount":101},[],{"trials":18348,"activeCount":101},[18349,18353],{"nctId":17912,"briefTitle":17913,"status":244,"phases":18350,"primaryCompletion":17915,"completion":17915,"start":727,"enrollment":969,"conditions":18351,"interventions":18352},[89,90],[475],[17918,13235,13614,17919,1351],{"nctId":1344,"briefTitle":1345,"status":505,"phases":18354,"primaryCompletion":1083,"completion":1083,"start":1347,"enrollment":509,"conditions":18355,"interventions":18356},[90],[828],[374,1350,1351],{"trials":18358,"activeCount":101},[],{"trials":18360,"activeCount":101},[],{"trials":18362,"activeCount":101},[],{"intervention":5654,"totalTrials":1094,"cells":18364},{"EARLY_PHASE1":18365,"PHASE1":18367,"PHASE2":18369,"PHASE3":18379,"PHASE4":18381,"NA":18383},{"trials":18366,"activeCount":101},[],{"trials":18368,"activeCount":101},[],{"trials":18370,"activeCount":101},[18371,18375],{"nctId":5647,"briefTitle":5648,"status":244,"phases":18372,"primaryCompletion":3220,"completion":5650,"start":4009,"enrollment":326,"conditions":18373,"interventions":18374},[90],[1426],[579,5653,5654],{"nctId":5692,"briefTitle":5693,"status":244,"phases":18376,"primaryCompletion":5695,"completion":5650,"start":5696,"enrollment":1934,"conditions":18377,"interventions":18378},[90],[5698],[579,5654,5700],{"trials":18380,"activeCount":101},[],{"trials":18382,"activeCount":101},[],{"trials":18384,"activeCount":101},[],{"intervention":2901,"totalTrials":1094,"cells":18386},{"EARLY_PHASE1":18387,"PHASE1":18389,"PHASE2":18395,"PHASE3":18403,"PHASE4":18405,"NA":18407},{"trials":18388,"activeCount":101},[],{"trials":18390,"activeCount":101},[18391],{"nctId":2895,"briefTitle":2896,"status":244,"phases":18392,"primaryCompletion":2898,"completion":588,"start":737,"conditions":18393,"interventions":18394},[89],[1602,1613,1568],[47,2901],{"trials":18396,"activeCount":101},[18397],{"nctId":18398,"briefTitle":18399,"status":244,"phases":18400,"primaryCompletion":3149,"completion":588,"start":3477,"conditions":18401,"interventions":18402},"NCT00070031","Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy",[90],[15],[2901],{"trials":18404,"activeCount":101},[],{"trials":18406,"activeCount":101},[],{"trials":18408,"activeCount":101},[],{"intervention":6402,"totalTrials":1094,"cells":18410},{"EARLY_PHASE1":18411,"PHASE1":18413,"PHASE2":18415,"PHASE3":18429,"PHASE4":18431,"NA":18433},{"trials":18412,"activeCount":101},[],{"trials":18414,"activeCount":101},[],{"trials":18416,"activeCount":101},[18417,18421],{"nctId":6392,"briefTitle":6393,"status":244,"phases":18418,"primaryCompletion":6395,"completion":6395,"start":6396,"enrollment":6397,"conditions":18419,"interventions":18420},[90],[3816,414,5615,475,6399,1154,6400,604,27],[675,461,6402,912],{"nctId":18422,"briefTitle":18423,"status":505,"phases":18424,"primaryCompletion":18425,"completion":18425,"start":1797,"enrollment":601,"conditions":18426,"interventions":18428},"NCT04377659","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection",[90],"2022-10-28",[18427],"COVID-19",[6402],{"trials":18430,"activeCount":101},[],{"trials":18432,"activeCount":101},[],{"trials":18434,"activeCount":101},[],{"intervention":18436,"totalTrials":1094,"cells":18437},"perifosine",{"EARLY_PHASE1":18438,"PHASE1":18440,"PHASE2":18449,"PHASE3":18461,"PHASE4":18463,"NA":18465},{"trials":18439,"activeCount":101},[],{"trials":18441,"activeCount":101},[18442],{"nctId":18443,"briefTitle":18444,"status":244,"phases":18445,"primaryCompletion":18446,"completion":18446,"start":471,"enrollment":3599,"conditions":18447,"interventions":18448},"NCT00776867","Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors",[89],"2017-07",[328],[18436],{"trials":18450,"activeCount":101},[18451],{"nctId":18452,"briefTitle":18453,"status":244,"phases":18454,"primaryCompletion":18455,"completion":18455,"start":1151,"enrollment":992,"conditions":18456,"interventions":18459},"NCT00590954","Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent\u002FProgressive Malignant Gliomas",[90],"2019-11-11",[18457,18458,8191,1155],"Malignant Gliomas","CNS",[18460],"Perifosine",{"trials":18462,"activeCount":101},[],{"trials":18464,"activeCount":101},[],{"trials":18466,"activeCount":101},[],{"intervention":18468,"totalTrials":1094,"cells":18469},"irofulven",{"EARLY_PHASE1":18470,"PHASE1":18472,"PHASE2":18474,"PHASE3":18488,"PHASE4":18490,"NA":18492},{"trials":18471,"activeCount":101},[],{"trials":18473,"activeCount":101},[],{"trials":18475,"activeCount":101},[18476,18482],{"nctId":18477,"briefTitle":18478,"status":244,"phases":18479,"completion":3044,"start":728,"conditions":18480,"interventions":18481},"NCT00003390","6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer",[90],[783],[18468],{"nctId":18483,"briefTitle":18484,"status":244,"phases":18485,"primaryCompletion":4751,"completion":4751,"start":17235,"conditions":18486,"interventions":18487},"NCT00005070","Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer",[90],[5017],[18468],{"trials":18489,"activeCount":101},[],{"trials":18491,"activeCount":101},[],{"trials":18493,"activeCount":101},[],{"intervention":18495,"totalTrials":1094,"cells":18496},"canfosfamide hydrochloride",{"EARLY_PHASE1":18497,"PHASE1":18499,"PHASE2":18501,"PHASE3":18515,"PHASE4":18517,"NA":18519},{"trials":18498,"activeCount":101},[],{"trials":18500,"activeCount":101},[],{"trials":18502,"activeCount":101},[18503,18509],{"nctId":18504,"briefTitle":18505,"status":244,"phases":18506,"primaryCompletion":1663,"completion":588,"start":6493,"conditions":18507,"interventions":18508},"NCT00036920","TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer",[90],[21],[18495],{"nctId":18510,"briefTitle":18511,"status":244,"phases":18512,"primaryCompletion":2914,"completion":588,"start":4751,"conditions":18513,"interventions":18514},"NCT00022347","TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[90],[285,30,286],[18495],{"trials":18516,"activeCount":101},[],{"trials":18518,"activeCount":101},[],{"trials":18520,"activeCount":101},[],{"intervention":18522,"totalTrials":1094,"cells":18523},"epothilone D",{"EARLY_PHASE1":18524,"PHASE1":18526,"PHASE2":18528,"PHASE3":18542,"PHASE4":18544,"NA":18546},{"trials":18525,"activeCount":101},[],{"trials":18527,"activeCount":101},[],{"trials":18529,"activeCount":101},[18530,18536],{"nctId":18531,"briefTitle":18532,"status":244,"phases":18533,"primaryCompletion":339,"start":680,"conditions":18534,"interventions":18535},"NCT00077259","Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer",[90],[36],[18522],{"nctId":18537,"briefTitle":18538,"status":244,"phases":18539,"primaryCompletion":1433,"completion":1433,"start":3220,"conditions":18540,"interventions":18541},"NCT00081107","Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy",[90],[21],[18522],{"trials":18543,"activeCount":101},[],{"trials":18545,"activeCount":101},[],{"trials":18547,"activeCount":101},[],{"intervention":446,"totalTrials":1094,"cells":18549},{"EARLY_PHASE1":18550,"PHASE1":18552,"PHASE2":18554,"PHASE3":18564,"PHASE4":18566,"NA":18568},{"trials":18551,"activeCount":101},[],{"trials":18553,"activeCount":101},[],{"trials":18555,"activeCount":101},[18556,18560],{"nctId":433,"briefTitle":434,"status":244,"phases":18557,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":18558,"interventions":18559},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":6490,"briefTitle":6491,"status":244,"phases":18561,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":18562,"interventions":18563},[90],[3259],[288,830,3342,446,479,349],{"trials":18565,"activeCount":101},[],{"trials":18567,"activeCount":101},[],{"trials":18569,"activeCount":101},[],{"intervention":18571,"totalTrials":1094,"cells":18572},"Benralizumab",{"EARLY_PHASE1":18573,"PHASE1":18575,"PHASE2":18577,"PHASE3":18595,"PHASE4":18597,"NA":18599},{"trials":18574,"activeCount":101},[],{"trials":18576,"activeCount":101},[],{"trials":18578,"activeCount":101},[18579,18587],{"nctId":18580,"briefTitle":18581,"status":244,"phases":18582,"primaryCompletion":18583,"completion":5007,"start":18584,"enrollment":1152,"conditions":18585,"interventions":18586},"NCT04552288","Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies",[90],"2024-07-19","2020-09-16",[2351,6267,6266,910],[18571],{"nctId":18588,"briefTitle":18589,"status":505,"phases":18590,"primaryCompletion":18591,"completion":18591,"start":4226,"enrollment":97,"conditions":18592,"interventions":18593},"NCT05966584","A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer",[90],"2024-08-02",[15],[18571,18594],"fulvestrant or AIs) and PI3K inhibition",{"trials":18596,"activeCount":101},[],{"trials":18598,"activeCount":101},[],{"trials":18600,"activeCount":101},[],{"intervention":18602,"totalTrials":1094,"cells":18603},"MK-2206",{"EARLY_PHASE1":18604,"PHASE1":18606,"PHASE2":18608,"PHASE3":18625,"PHASE4":18627,"NA":18629},{"trials":18605,"activeCount":101},[],{"trials":18607,"activeCount":101},[],{"trials":18609,"activeCount":101},[18610,18618],{"nctId":18611,"briefTitle":18612,"status":244,"phases":18613,"primaryCompletion":5130,"completion":5130,"start":9241,"enrollment":2630,"conditions":18614,"interventions":18617},"NCT01169649","Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)",[90],[18615,18616],"PANCREAS","Neuroendocrine",[18602],{"nctId":18619,"briefTitle":18620,"status":505,"phases":18621,"primaryCompletion":18622,"completion":18622,"start":4635,"enrollment":97,"conditions":18623,"interventions":18624},"NCT01186705","Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer",[90],"2011-08",[16135,5080],[18602],{"trials":18626,"activeCount":101},[],{"trials":18628,"activeCount":101},[],{"trials":18630,"activeCount":101},[],{"intervention":9054,"totalTrials":1094,"cells":18632},{"EARLY_PHASE1":18633,"PHASE1":18635,"PHASE2":18637,"PHASE3":18647,"PHASE4":18649,"NA":18651},{"trials":18634,"activeCount":101},[],{"trials":18636,"activeCount":101},[],{"trials":18638,"activeCount":101},[18639,18643],{"nctId":9047,"briefTitle":9048,"status":244,"phases":18640,"primaryCompletion":4807,"completion":4807,"start":554,"enrollment":3344,"conditions":18641,"interventions":18642},[90],[9051,1155,9052],[9054,9055,6667,9056,9057],{"nctId":1649,"briefTitle":1650,"status":244,"phases":18644,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":1654,"conditions":18645,"interventions":18646},[90],[18],[1657,1658,1181],{"trials":18648,"activeCount":101},[],{"trials":18650,"activeCount":101},[],{"trials":18652,"activeCount":101},[],{"intervention":9055,"totalTrials":1094,"cells":18654},{"EARLY_PHASE1":18655,"PHASE1":18657,"PHASE2":18659,"PHASE3":18669,"PHASE4":18671,"NA":18673},{"trials":18656,"activeCount":101},[],{"trials":18658,"activeCount":101},[],{"trials":18660,"activeCount":101},[18661,18665],{"nctId":9047,"briefTitle":9048,"status":244,"phases":18662,"primaryCompletion":4807,"completion":4807,"start":554,"enrollment":3344,"conditions":18663,"interventions":18664},[90],[9051,1155,9052],[9054,9055,6667,9056,9057],{"nctId":1699,"briefTitle":1700,"status":244,"phases":18666,"primaryCompletion":1702,"start":1703,"conditions":18667,"interventions":18668},[90],[18,1705],[1023,345,1707,1708,1709],{"trials":18670,"activeCount":101},[],{"trials":18672,"activeCount":101},[],{"trials":18674,"activeCount":101},[],{"intervention":985,"totalTrials":1094,"cells":18676},{"EARLY_PHASE1":18677,"PHASE1":18679,"PHASE2":18685,"PHASE3":18691,"PHASE4":18693,"NA":18695},{"trials":18678,"activeCount":101},[],{"trials":18680,"activeCount":101},[18681],{"nctId":5156,"briefTitle":5157,"status":244,"phases":18682,"primaryCompletion":5159,"completion":5159,"start":774,"enrollment":601,"conditions":18683,"interventions":18684},[89],[5161,5162,5163,5164,5165,5166,4855],[5168,741,768,5169],{"trials":18686,"activeCount":101},[18687],{"nctId":976,"briefTitle":977,"status":244,"phases":18688,"primaryCompletion":979,"completion":979,"start":980,"enrollment":341,"conditions":18689,"interventions":18690},[90],[982],[923,984,985],{"trials":18692,"activeCount":101},[],{"trials":18694,"activeCount":101},[],{"trials":18696,"activeCount":101},[],{"intervention":18698,"totalTrials":1094,"cells":18699},"keyhole limpet hemocyanin",{"EARLY_PHASE1":18700,"PHASE1":18702,"PHASE2":18712,"PHASE3":18721,"PHASE4":18723,"NA":18725},{"trials":18701,"activeCount":101},[],{"trials":18703,"activeCount":101},[18704],{"nctId":18705,"briefTitle":18706,"status":244,"phases":18707,"primaryCompletion":4807,"completion":4807,"start":728,"enrollment":899,"conditions":18708,"interventions":18709},"NCT00003819","Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer",[89],[18],[9012,18710,18711,18698],"TF(c)-KLH conjugate vaccine","Thomsen-Friedenreich antigen",{"trials":18713,"activeCount":101},[18714],{"nctId":18715,"briefTitle":18716,"status":244,"phases":18717,"primaryCompletion":3402,"completion":3402,"start":545,"conditions":18718,"interventions":18719},"NCT00004249","Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy",[90],[21],[9012,18698,18720],"polysialic acid",{"trials":18722,"activeCount":101},[],{"trials":18724,"activeCount":101},[],{"trials":18726,"activeCount":101},[],{"intervention":8678,"totalTrials":1094,"cells":18728},{"EARLY_PHASE1":18729,"PHASE1":18731,"PHASE2":18737,"PHASE3":18743,"PHASE4":18745,"NA":18747},{"trials":18730,"activeCount":101},[],{"trials":18732,"activeCount":101},[18733],{"nctId":8672,"briefTitle":8673,"status":244,"phases":18734,"primaryCompletion":1622,"completion":1622,"start":8675,"conditions":18735,"interventions":18736},[89],[1568],[8678,1616],{"trials":18738,"activeCount":101},[18739],{"nctId":8706,"briefTitle":8707,"status":244,"phases":18740,"completion":339,"start":2940,"conditions":18741,"interventions":18742},[90],[1226],[8678,1616],{"trials":18744,"activeCount":101},[],{"trials":18746,"activeCount":101},[],{"trials":18748,"activeCount":101},[],{"intervention":3152,"totalTrials":1094,"cells":18750},{"EARLY_PHASE1":18751,"PHASE1":18753,"PHASE2":18755,"PHASE3":18765,"PHASE4":18767,"NA":18769},{"trials":18752,"activeCount":101},[],{"trials":18754,"activeCount":101},[],{"trials":18756,"activeCount":101},[18757,18761],{"nctId":3145,"briefTitle":3146,"status":244,"phases":18758,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":2439,"conditions":18759,"interventions":18760},[90],[1602],[920,47,683,3152],{"nctId":5095,"briefTitle":5096,"status":244,"phases":18762,"primaryCompletion":4363,"completion":5098,"start":1397,"enrollment":573,"conditions":18763,"interventions":18764},[90],[1226],[441,3603,379,3152],{"trials":18766,"activeCount":101},[],{"trials":18768,"activeCount":101},[],{"trials":18770,"activeCount":101},[],{"intervention":9014,"totalTrials":1094,"cells":18772},{"EARLY_PHASE1":18773,"PHASE1":18775,"PHASE2":18786,"PHASE3":18792,"PHASE4":18794,"NA":18796},{"trials":18774,"activeCount":101},[],{"trials":18776,"activeCount":101},[18777],{"nctId":18778,"briefTitle":18779,"status":244,"phases":18780,"primaryCompletion":384,"completion":384,"start":1685,"conditions":18781,"interventions":18782},"NCT00005633","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",[89],[4734],[18783,18784,18785,9014],"OVA BiP peptide","gp209-2M antigen","recombinant 70-kD heat-shock protein",{"trials":18787,"activeCount":101},[18788],{"nctId":9006,"briefTitle":9007,"status":244,"phases":18789,"primaryCompletion":7408,"completion":7408,"start":9009,"conditions":18790,"interventions":18791},[90],[4734],[9012,9013,8956,360,9014],{"trials":18793,"activeCount":101},[],{"trials":18795,"activeCount":101},[],{"trials":18797,"activeCount":101},[],{"intervention":8956,"totalTrials":1094,"cells":18799},{"EARLY_PHASE1":18800,"PHASE1":18802,"PHASE2":18808,"PHASE3":18814,"PHASE4":18816,"NA":18818},{"trials":18801,"activeCount":101},[],{"trials":18803,"activeCount":101},[18804],{"nctId":8950,"briefTitle":8951,"status":244,"phases":18805,"primaryCompletion":5650,"completion":5650,"start":3032,"enrollment":2483,"conditions":18806,"interventions":18807},[89],[27,21,3163,475,286],[8955,8956,360,378],{"trials":18809,"activeCount":101},[18810],{"nctId":9006,"briefTitle":9007,"status":244,"phases":18811,"primaryCompletion":7408,"completion":7408,"start":9009,"conditions":18812,"interventions":18813},[90],[4734],[9012,9013,8956,360,9014],{"trials":18815,"activeCount":101},[],{"trials":18817,"activeCount":101},[],{"trials":18819,"activeCount":101},[],{"intervention":6656,"totalTrials":1094,"cells":18821},{"EARLY_PHASE1":18822,"PHASE1":18824,"PHASE2":18830,"PHASE3":18844,"PHASE4":18846,"NA":18848},{"trials":18823,"activeCount":101},[],{"trials":18825,"activeCount":101},[18826],{"nctId":6648,"briefTitle":6649,"status":2832,"phases":18827,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":101,"conditions":18828,"interventions":18829},[89],[2311,6654],[6280,6641,6656],{"trials":18831,"activeCount":101},[18832],{"nctId":18833,"briefTitle":18834,"status":244,"phases":18835,"primaryCompletion":18836,"completion":18836,"start":18837,"enrollment":2439,"conditions":18838,"interventions":18842},"NCT03909152","A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone",[90],"2024-09-03","2019-05-02",[18839,18840,18841],"Granulosa Cell Ovarian Cancer","Low Grade Serous Ovarian\u002F Primary Peritoneal Cancer","Endometrioid Endometrial Cancer",[6656,18843],"Onapristone ER + Anastrozole",{"trials":18845,"activeCount":101},[],{"trials":18847,"activeCount":101},[],{"trials":18849,"activeCount":101},[],{"intervention":4589,"totalTrials":1094,"cells":18851},{"EARLY_PHASE1":18852,"PHASE1":18854,"PHASE2":18856,"PHASE3":18866,"PHASE4":18868,"NA":18870},{"trials":18853,"activeCount":101},[],{"trials":18855,"activeCount":101},[],{"trials":18857,"activeCount":101},[18858,18862],{"nctId":4583,"briefTitle":4584,"status":505,"phases":18859,"primaryCompletion":4586,"completion":4586,"start":2553,"enrollment":1114,"conditions":18860,"interventions":18861},[90],[1874,4536],[4589,1261],{"nctId":4620,"briefTitle":4621,"status":2832,"phases":18863,"primaryCompletion":4623,"completion":4623,"start":1852,"enrollment":101,"conditions":18864,"interventions":18865},[90],[24],[1860,1261,4589],{"trials":18867,"activeCount":101},[],{"trials":18869,"activeCount":101},[],{"trials":18871,"activeCount":101},[],{"intervention":18873,"totalTrials":1094,"cells":18874},"trabectedin",{"EARLY_PHASE1":18875,"PHASE1":18877,"PHASE2":18879,"PHASE3":18893,"PHASE4":18895,"NA":18897},{"trials":18876,"activeCount":101},[],{"trials":18878,"activeCount":101},[],{"trials":18880,"activeCount":101},[18881,18887],{"nctId":18882,"briefTitle":18883,"status":244,"phases":18884,"primaryCompletion":16912,"completion":16912,"start":3251,"conditions":18885,"interventions":18886},"NCT00005625","Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma",[90],[33],[18873],{"nctId":18888,"briefTitle":18889,"status":244,"phases":18890,"primaryCompletion":695,"completion":588,"start":7408,"conditions":18891,"interventions":18892},"NCT00017030","Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma",[90],[33],[18873],{"trials":18894,"activeCount":101},[],{"trials":18896,"activeCount":101},[],{"trials":18898,"activeCount":101},[],{"intervention":641,"totalTrials":1094,"cells":18900},{"EARLY_PHASE1":18901,"PHASE1":18903,"PHASE2":18905,"PHASE3":18915,"PHASE4":18917,"NA":18919},{"trials":18902,"activeCount":101},[],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[18907,18911],{"nctId":634,"briefTitle":635,"status":244,"phases":18908,"primaryCompletion":637,"completion":637,"start":638,"conditions":18909,"interventions":18910},[90],[24],[288,641,202,361,642,643,346,391,347,362,349],{"nctId":692,"briefTitle":693,"status":244,"phases":18912,"primaryCompletion":695,"completion":695,"start":696,"conditions":18913,"interventions":18914},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"trials":18916,"activeCount":101},[],{"trials":18918,"activeCount":101},[],{"trials":18920,"activeCount":101},[],{"intervention":18922,"totalTrials":1094,"cells":18923},"Hydroxychloroquine",{"EARLY_PHASE1":18924,"PHASE1":18926,"PHASE2":18928,"PHASE3":18948,"PHASE4":18950,"NA":18952},{"trials":18925,"activeCount":101},[],{"trials":18927,"activeCount":101},[],{"trials":18929,"activeCount":101},[18930,18941],{"nctId":18931,"briefTitle":18932,"status":2832,"phases":18933,"primaryCompletion":18934,"completion":18934,"start":18935,"enrollment":101,"conditions":18936,"interventions":18940},"NCT04379492","A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19",[90],"2020-09-25","2020-05-05",[18427,18937,18938,18939],"COVID19","Sars-CoV2","SARS-Cov-2",[18922],{"nctId":18942,"briefTitle":18943,"status":505,"phases":18944,"primaryCompletion":2521,"completion":2521,"start":18945,"enrollment":1114,"conditions":18946,"interventions":18947},"NCT04381988","A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy",[90],"2020-05-07",[18427,1155],[18922],{"trials":18949,"activeCount":101},[],{"trials":18951,"activeCount":101},[],{"trials":18953,"activeCount":101},[],{"intervention":18955,"totalTrials":1094,"cells":18956},"tanespimycin",{"EARLY_PHASE1":18957,"PHASE1":18959,"PHASE2":18967,"PHASE3":18975,"PHASE4":18977,"NA":18979},{"trials":18958,"activeCount":101},[],{"trials":18960,"activeCount":101},[18961],{"nctId":18962,"briefTitle":18963,"status":244,"phases":18964,"primaryCompletion":1994,"completion":1994,"start":8675,"conditions":18965,"interventions":18966},"NCT00004065","Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer",[89],[971,15,36,1613,1586,783,27,21,4734,30,18,1568],[18955],{"trials":18968,"activeCount":101},[18969],{"nctId":18970,"briefTitle":18971,"status":244,"phases":18972,"completion":16824,"start":3044,"conditions":18973,"interventions":18974},"NCT00093405","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer",[90],[783],[18955],{"trials":18976,"activeCount":101},[],{"trials":18978,"activeCount":101},[],{"trials":18980,"activeCount":101},[],{"intervention":18982,"totalTrials":1094,"cells":18983},"STA-9090",{"EARLY_PHASE1":18984,"PHASE1":18986,"PHASE2":18988,"PHASE3":19003,"PHASE4":19005,"NA":19007},{"trials":18985,"activeCount":101},[],{"trials":18987,"activeCount":101},[],{"trials":18989,"activeCount":101},[18990,18996],{"nctId":18991,"briefTitle":18992,"status":244,"phases":18993,"primaryCompletion":3548,"completion":3548,"start":544,"enrollment":306,"conditions":18994,"interventions":18995},"NCT01111838","Clinical and Translational Study of STA-9090",[90],[16135,5080],[18982],{"nctId":18997,"briefTitle":18998,"status":244,"phases":18999,"primaryCompletion":19000,"completion":19000,"start":15999,"enrollment":2483,"conditions":19001,"interventions":19002},"NCT01273896","Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer",[90],"2013-09",[15],[18982],{"trials":19004,"activeCount":101},[],{"trials":19006,"activeCount":101},[],{"trials":19008,"activeCount":101},[],{"intervention":19010,"totalTrials":1094,"cells":19011},"pralatrexate",{"EARLY_PHASE1":19012,"PHASE1":19014,"PHASE2":19023,"PHASE3":19031,"PHASE4":19033,"NA":19035},{"trials":19013,"activeCount":101},[],{"trials":19015,"activeCount":101},[19016],{"nctId":19017,"briefTitle":19018,"status":244,"phases":19019,"completion":856,"start":4751,"conditions":19020,"interventions":19021},"NCT00024245","10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors",[89],[1568],[19010,19022],"probenecid",{"trials":19024,"activeCount":101},[19025],{"nctId":19026,"briefTitle":19027,"status":244,"phases":19028,"primaryCompletion":384,"completion":384,"start":8675,"conditions":19029,"interventions":19030},"NCT00004238","10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[90],[21],[19010],{"trials":19032,"activeCount":101},[],{"trials":19034,"activeCount":101},[],{"trials":19036,"activeCount":101},[],{"intervention":9655,"totalTrials":97,"cells":19038},{"EARLY_PHASE1":19039,"PHASE1":19041,"PHASE2":19043,"PHASE3":19049,"PHASE4":19051,"NA":19053},{"trials":19040,"activeCount":101},[],{"trials":19042,"activeCount":101},[],{"trials":19044,"activeCount":101},[19045],{"nctId":9649,"briefTitle":9650,"status":244,"phases":19046,"primaryCompletion":2725,"completion":2725,"start":9652,"enrollment":2407,"conditions":19047,"interventions":19048},[90],[18],[9655,5365,9656],{"trials":19050,"activeCount":101},[],{"trials":19052,"activeCount":101},[],{"trials":19054,"activeCount":101},[],{"intervention":9656,"totalTrials":97,"cells":19056},{"EARLY_PHASE1":19057,"PHASE1":19059,"PHASE2":19061,"PHASE3":19067,"PHASE4":19069,"NA":19071},{"trials":19058,"activeCount":101},[],{"trials":19060,"activeCount":101},[],{"trials":19062,"activeCount":101},[19063],{"nctId":9649,"briefTitle":9650,"status":244,"phases":19064,"primaryCompletion":2725,"completion":2725,"start":9652,"enrollment":2407,"conditions":19065,"interventions":19066},[90],[18],[9655,5365,9656],{"trials":19068,"activeCount":101},[],{"trials":19070,"activeCount":101},[],{"trials":19072,"activeCount":101},[],{"intervention":19074,"totalTrials":97,"cells":19075},"Sho-saiko-to",{"EARLY_PHASE1":19076,"PHASE1":19078,"PHASE2":19080,"PHASE3":19090,"PHASE4":19092,"NA":19094},{"trials":19077,"activeCount":101},[],{"trials":19079,"activeCount":101},[],{"trials":19081,"activeCount":101},[19082],{"nctId":19083,"briefTitle":19084,"status":244,"phases":19085,"primaryCompletion":19086,"completion":19086,"start":13332,"enrollment":486,"conditions":19087,"interventions":19089},"NCT00590564","SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study",[90],"2011-02",[19088],"Hepatitis C",[19074],{"trials":19091,"activeCount":101},[],{"trials":19093,"activeCount":101},[],{"trials":19095,"activeCount":101},[],{"intervention":348,"totalTrials":97,"cells":19097},{"EARLY_PHASE1":19098,"PHASE1":19100,"PHASE2":19102,"PHASE3":19108,"PHASE4":19110,"NA":19112},{"trials":19099,"activeCount":101},[],{"trials":19101,"activeCount":101},[],{"trials":19103,"activeCount":101},[19104],{"nctId":336,"briefTitle":337,"status":244,"phases":19105,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":19106,"interventions":19107},[90],[215],[288,344,47,202,345,346,347,348,349],{"trials":19109,"activeCount":101},[],{"trials":19111,"activeCount":101},[],{"trials":19113,"activeCount":101},[],{"intervention":19115,"totalTrials":97,"cells":19116},"Ofatumumab",{"EARLY_PHASE1":19117,"PHASE1":19119,"PHASE2":19121,"PHASE3":19130,"PHASE4":19132,"NA":19134},{"trials":19118,"activeCount":101},[],{"trials":19120,"activeCount":101},[],{"trials":19122,"activeCount":101},[19123],{"nctId":19124,"briefTitle":19125,"status":244,"phases":19126,"primaryCompletion":19127,"completion":19127,"start":875,"enrollment":356,"conditions":19128,"interventions":19129},"NCT01437709","Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant",[90],"2023-09-12",[1874],[19115],{"trials":19131,"activeCount":101},[],{"trials":19133,"activeCount":101},[],{"trials":19135,"activeCount":101},[],{"intervention":19137,"totalTrials":97,"cells":19138},"liposomal paclitaxel",{"EARLY_PHASE1":19139,"PHASE1":19141,"PHASE2":19143,"PHASE3":19151,"PHASE4":19153,"NA":19155},{"trials":19140,"activeCount":101},[],{"trials":19142,"activeCount":101},[],{"trials":19144,"activeCount":101},[19145],{"nctId":19146,"briefTitle":19147,"status":244,"phases":19148,"primaryCompletion":898,"completion":898,"start":5206,"conditions":19149,"interventions":19150},"NCT00016900","PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus",[90],[1602],[19137],{"trials":19152,"activeCount":101},[],{"trials":19154,"activeCount":101},[],{"trials":19156,"activeCount":101},[],{"intervention":19158,"totalTrials":97,"cells":19159},"Pemetrexed plus Gemcitabine",{"EARLY_PHASE1":19160,"PHASE1":19162,"PHASE2":19164,"PHASE3":19172,"PHASE4":19174,"NA":19176},{"trials":19161,"activeCount":101},[],{"trials":19163,"activeCount":101},[],{"trials":19165,"activeCount":101},[19166],{"nctId":19167,"briefTitle":19168,"status":244,"phases":19169,"primaryCompletion":9241,"completion":9241,"start":17515,"enrollment":213,"conditions":19170,"interventions":19171},"NCT00589667","A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic\u002FRecurrent Head and Neck Cancer (HNSCC)",[90],[1586],[19158],{"trials":19173,"activeCount":101},[],{"trials":19175,"activeCount":101},[],{"trials":19177,"activeCount":101},[],{"intervention":17919,"totalTrials":97,"cells":19179},{"EARLY_PHASE1":19180,"PHASE1":19182,"PHASE2":19184,"PHASE3":19190,"PHASE4":19192,"NA":19194},{"trials":19181,"activeCount":101},[],{"trials":19183,"activeCount":101},[],{"trials":19185,"activeCount":101},[19186],{"nctId":17912,"briefTitle":17913,"status":244,"phases":19187,"primaryCompletion":17915,"completion":17915,"start":727,"enrollment":969,"conditions":19188,"interventions":19189},[89,90],[475],[17918,13235,13614,17919,1351],{"trials":19191,"activeCount":101},[],{"trials":19193,"activeCount":101},[],{"trials":19195,"activeCount":101},[],{"intervention":19197,"totalTrials":97,"cells":19198},"Pre-surgical Treatment with Bevacizumab plus Chemotherapy",{"EARLY_PHASE1":19199,"PHASE1":19201,"PHASE2":19203,"PHASE3":19213,"PHASE4":19215,"NA":19217},{"trials":19200,"activeCount":101},[],{"trials":19202,"activeCount":101},[],{"trials":19204,"activeCount":101},[19205],{"nctId":19206,"briefTitle":19207,"status":244,"phases":19208,"primaryCompletion":7788,"completion":7788,"start":4661,"enrollment":669,"conditions":19209,"interventions":19211},"NCT00130780","Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC",[90],[19210],"Carcinoma, Non-Small-Cell Lung",[19197,19212],"Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab",{"trials":19214,"activeCount":101},[],{"trials":19216,"activeCount":101},[],{"trials":19218,"activeCount":101},[],{"intervention":19212,"totalTrials":97,"cells":19220},{"EARLY_PHASE1":19221,"PHASE1":19223,"PHASE2":19225,"PHASE3":19231,"PHASE4":19233,"NA":19235},{"trials":19222,"activeCount":101},[],{"trials":19224,"activeCount":101},[],{"trials":19226,"activeCount":101},[19227],{"nctId":19206,"briefTitle":19207,"status":244,"phases":19228,"primaryCompletion":7788,"completion":7788,"start":4661,"enrollment":669,"conditions":19229,"interventions":19230},[90],[19210],[19197,19212],{"trials":19232,"activeCount":101},[],{"trials":19234,"activeCount":101},[],{"trials":19236,"activeCount":101},[],{"intervention":19238,"totalTrials":97,"cells":19239},"Letermovir Pill",{"EARLY_PHASE1":19240,"PHASE1":19242,"PHASE2":19244,"PHASE3":19257,"PHASE4":19259,"NA":19261},{"trials":19241,"activeCount":101},[],{"trials":19243,"activeCount":101},[],{"trials":19245,"activeCount":101},[19246],{"nctId":19247,"briefTitle":19248,"status":244,"phases":19249,"primaryCompletion":19250,"completion":19251,"start":4279,"enrollment":1654,"conditions":19252,"interventions":19256},"NCT04017962","A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection",[90],"2024-08-07","2025-07-29",[19253,19254,19255],"CMV","CMV Infection","Hematopoietic Cell Transplant",[19238],{"trials":19258,"activeCount":101},[],{"trials":19260,"activeCount":101},[],{"trials":19262,"activeCount":101},[],{"intervention":7030,"totalTrials":97,"cells":19264},{"EARLY_PHASE1":19265,"PHASE1":19267,"PHASE2":19269,"PHASE3":19275,"PHASE4":19277,"NA":19279},{"trials":19266,"activeCount":101},[],{"trials":19268,"activeCount":101},[],{"trials":19270,"activeCount":101},[19271],{"nctId":7021,"briefTitle":7022,"status":244,"phases":19272,"primaryCompletion":7024,"completion":7024,"start":7025,"enrollment":7026,"conditions":19273,"interventions":19274},[90],[18],[7029,7030,711],{"trials":19276,"activeCount":101},[],{"trials":19278,"activeCount":101},[],{"trials":19280,"activeCount":101},[],{"intervention":19282,"totalTrials":97,"cells":19283},"Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination",{"EARLY_PHASE1":19284,"PHASE1":19286,"PHASE2":19288,"PHASE3":19299,"PHASE4":19301,"NA":19303},{"trials":19285,"activeCount":101},[],{"trials":19287,"activeCount":101},[],{"trials":19289,"activeCount":101},[19290],{"nctId":19291,"briefTitle":19292,"status":505,"phases":19293,"primaryCompletion":19294,"completion":19294,"start":18622,"enrollment":1934,"conditions":19295,"interventions":19298},"NCT01418001","Gemcitabine and Docetaxel in Combination With Pazopanib (Gem\u002FDoce\u002FPzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)",[89,90],"2015-11",[33,1017,19296,1018,19297],"Malignant Peripheral Nerve Sheath Tumor","Histiocytoma\u002FUndifferentiated Pleomorphic Sarcoma",[19282],{"trials":19300,"activeCount":101},[],{"trials":19302,"activeCount":101},[],{"trials":19304,"activeCount":101},[],{"intervention":19306,"totalTrials":97,"cells":19307},"AC [Adriamycin",{"EARLY_PHASE1":19308,"PHASE1":19310,"PHASE2":19312,"PHASE3":19320,"PHASE4":19322,"NA":19324},{"trials":19309,"activeCount":101},[],{"trials":19311,"activeCount":101},[],{"trials":19313,"activeCount":101},[19314],{"nctId":19315,"briefTitle":19316,"status":244,"phases":19317,"primaryCompletion":755,"completion":755,"start":1433,"enrollment":2751,"conditions":19318,"interventions":19319},"NCT00591851","Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2\u002F NEU-Amplified Breast Cancer: Feasibility",[90],[15],[19306],{"trials":19321,"activeCount":101},[],{"trials":19323,"activeCount":101},[],{"trials":19325,"activeCount":101},[],{"intervention":377,"totalTrials":97,"cells":19327},{"EARLY_PHASE1":19328,"PHASE1":19330,"PHASE2":19332,"PHASE3":19338,"PHASE4":19340,"NA":19342},{"trials":19329,"activeCount":101},[],{"trials":19331,"activeCount":101},[],{"trials":19333,"activeCount":101},[19334],{"nctId":365,"briefTitle":366,"status":244,"phases":19335,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":19336,"interventions":19337},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"trials":19339,"activeCount":101},[],{"trials":19341,"activeCount":101},[],{"trials":19343,"activeCount":101},[],{"intervention":13840,"totalTrials":97,"cells":19345},{"EARLY_PHASE1":19346,"PHASE1":19348,"PHASE2":19350,"PHASE3":19356,"PHASE4":19358,"NA":19360},{"trials":19347,"activeCount":101},[],{"trials":19349,"activeCount":101},[],{"trials":19351,"activeCount":101},[19352],{"nctId":13835,"briefTitle":13836,"status":244,"phases":19353,"primaryCompletion":1610,"completion":1610,"start":4424,"enrollment":4298,"conditions":19354,"interventions":19355},[90],[4734],[13840,13841,549],{"trials":19357,"activeCount":101},[],{"trials":19359,"activeCount":101},[],{"trials":19361,"activeCount":101},[],{"intervention":13841,"totalTrials":97,"cells":19363},{"EARLY_PHASE1":19364,"PHASE1":19366,"PHASE2":19368,"PHASE3":19374,"PHASE4":19376,"NA":19378},{"trials":19365,"activeCount":101},[],{"trials":19367,"activeCount":101},[],{"trials":19369,"activeCount":101},[19370],{"nctId":13835,"briefTitle":13836,"status":244,"phases":19371,"primaryCompletion":1610,"completion":1610,"start":4424,"enrollment":4298,"conditions":19372,"interventions":19373},[90],[4734],[13840,13841,549],{"trials":19375,"activeCount":101},[],{"trials":19377,"activeCount":101},[],{"trials":19379,"activeCount":101},[],{"intervention":19381,"totalTrials":97,"cells":19382},"Paclitaxel,Cisplatin, Bevacizumab",{"EARLY_PHASE1":19383,"PHASE1":19385,"PHASE2":19387,"PHASE3":19396,"PHASE4":19398,"NA":19400},{"trials":19384,"activeCount":101},[],{"trials":19386,"activeCount":101},[],{"trials":19388,"activeCount":101},[19389],{"nctId":19390,"briefTitle":19391,"status":244,"phases":19392,"primaryCompletion":1013,"completion":1013,"start":3444,"enrollment":486,"conditions":19393,"interventions":19395},"NCT00588237","Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",[90],[30,19394,285],"Primary PERITONEUM",[19381],{"trials":19397,"activeCount":101},[],{"trials":19399,"activeCount":101},[],{"trials":19401,"activeCount":101},[],{"intervention":19403,"totalTrials":97,"cells":19404},"Tetrathiomolybdate",{"EARLY_PHASE1":19405,"PHASE1":19407,"PHASE2":19409,"PHASE3":19418,"PHASE4":19420,"NA":19422},{"trials":19406,"activeCount":101},[],{"trials":19408,"activeCount":101},[],{"trials":19410,"activeCount":101},[19411],{"nctId":19412,"briefTitle":19413,"status":505,"phases":19414,"primaryCompletion":19415,"completion":19415,"start":3220,"enrollment":1447,"conditions":19416,"interventions":19417},"NCT00195091","Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer",[90],"2023-03-02",[15],[19403],{"trials":19419,"activeCount":101},[],{"trials":19421,"activeCount":101},[],{"trials":19423,"activeCount":101},[],{"intervention":19425,"totalTrials":97,"cells":19426},"becatecarin",{"EARLY_PHASE1":19427,"PHASE1":19429,"PHASE2":19431,"PHASE3":19440,"PHASE4":19442,"NA":19444},{"trials":19428,"activeCount":101},[],{"trials":19430,"activeCount":101},[],{"trials":19432,"activeCount":101},[19433],{"nctId":19434,"briefTitle":19435,"status":244,"phases":19436,"primaryCompletion":17515,"completion":17515,"start":19437,"enrollment":356,"conditions":19438,"interventions":19439},"NCT00003737","Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma",[90],"1999-01",[215],[19425],{"trials":19441,"activeCount":101},[],{"trials":19443,"activeCount":101},[],{"trials":19445,"activeCount":101},[],{"intervention":19447,"totalTrials":97,"cells":19448},"Vorinostat and Etoposide",{"EARLY_PHASE1":19449,"PHASE1":19451,"PHASE2":19453,"PHASE3":19464,"PHASE4":19466,"NA":19468},{"trials":19450,"activeCount":101},[],{"trials":19452,"activeCount":101},[],{"trials":19454,"activeCount":101},[19455],{"nctId":19456,"briefTitle":19457,"status":244,"phases":19458,"primaryCompletion":19459,"completion":19459,"start":19460,"enrollment":1600,"conditions":19461,"interventions":19463},"NCT01294670","Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients \u003C 21 Years at Diagnosis With Refractory Solid Tumors",[89,90],"2020-12-08","2011-02-09",[328,19462],"Relapsed\u002FRefractory Sarcomas",[19447],{"trials":19465,"activeCount":101},[],{"trials":19467,"activeCount":101},[],{"trials":19469,"activeCount":101},[],{"intervention":19471,"totalTrials":97,"cells":19472},"pevonedistat",{"EARLY_PHASE1":19473,"PHASE1":19475,"PHASE2":19477,"PHASE3":19488,"PHASE4":19490,"NA":19492},{"trials":19474,"activeCount":101},[],{"trials":19476,"activeCount":101},[],{"trials":19478,"activeCount":101},[19479],{"nctId":19480,"briefTitle":19481,"status":505,"phases":19482,"primaryCompletion":19483,"completion":19483,"start":19484,"enrollment":601,"conditions":19485,"interventions":19486},"NCT03319537","Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma",[89,90],"2023-06-05","2017-10-05",[794],[19471,19487],"Pemetrexed and cisplatin",{"trials":19489,"activeCount":101},[],{"trials":19491,"activeCount":101},[],{"trials":19493,"activeCount":101},[],{"intervention":19487,"totalTrials":97,"cells":19495},{"EARLY_PHASE1":19496,"PHASE1":19498,"PHASE2":19500,"PHASE3":19506,"PHASE4":19508,"NA":19510},{"trials":19497,"activeCount":101},[],{"trials":19499,"activeCount":101},[],{"trials":19501,"activeCount":101},[19502],{"nctId":19480,"briefTitle":19481,"status":505,"phases":19503,"primaryCompletion":19483,"completion":19483,"start":19484,"enrollment":601,"conditions":19504,"interventions":19505},[89,90],[794],[19471,19487],{"trials":19507,"activeCount":101},[],{"trials":19509,"activeCount":101},[],{"trials":19511,"activeCount":101},[],{"intervention":402,"totalTrials":97,"cells":19513},{"EARLY_PHASE1":19514,"PHASE1":19516,"PHASE2":19518,"PHASE3":19524,"PHASE4":19526,"NA":19528},{"trials":19515,"activeCount":101},[],{"trials":19517,"activeCount":101},[],{"trials":19519,"activeCount":101},[19520],{"nctId":393,"briefTitle":394,"status":244,"phases":19521,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":19522,"interventions":19523},[90],[27,24],[401,288,402,374,202,403,404,405],{"trials":19525,"activeCount":101},[],{"trials":19527,"activeCount":101},[],{"trials":19529,"activeCount":101},[],{"intervention":19531,"totalTrials":97,"cells":19532},"Mocetinostat Plus Brentuximab Vedotin",{"EARLY_PHASE1":19533,"PHASE1":19535,"PHASE2":19537,"PHASE3":19545,"PHASE4":19547,"NA":19549},{"trials":19534,"activeCount":101},[],{"trials":19536,"activeCount":101},[],{"trials":19538,"activeCount":101},[19539],{"nctId":19540,"briefTitle":19541,"status":244,"phases":19542,"primaryCompletion":14413,"completion":14413,"start":16109,"enrollment":2291,"conditions":19543,"interventions":19544},"NCT02429375","Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma",[89,90],[604],[19531],{"trials":19546,"activeCount":101},[],{"trials":19548,"activeCount":101},[],{"trials":19550,"activeCount":101},[],{"intervention":19552,"totalTrials":97,"cells":19553},"pertuzumab in combination with trastuzumab and paclitaxel",{"EARLY_PHASE1":19554,"PHASE1":19556,"PHASE2":19558,"PHASE3":19568,"PHASE4":19570,"NA":19572},{"trials":19555,"activeCount":101},[],{"trials":19557,"activeCount":101},[],{"trials":19559,"activeCount":101},[19560],{"nctId":19561,"briefTitle":19562,"status":244,"phases":19563,"primaryCompletion":19564,"completion":19564,"start":19565,"enrollment":2751,"conditions":19566,"interventions":19567},"NCT01276041","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",[90],"2019-08-07","2011-01-05",[15],[19552],{"trials":19569,"activeCount":101},[],{"trials":19571,"activeCount":101},[],{"trials":19573,"activeCount":101},[],{"intervention":19575,"totalTrials":97,"cells":19576},"Avatrombopag",{"EARLY_PHASE1":19577,"PHASE1":19579,"PHASE2":19581,"PHASE3":19591,"PHASE4":19593,"NA":19595},{"trials":19578,"activeCount":101},[],{"trials":19580,"activeCount":101},[],{"trials":19582,"activeCount":101},[19583],{"nctId":19584,"briefTitle":19585,"status":2832,"phases":19586,"primaryCompletion":3846,"completion":3846,"start":19587,"enrollment":101,"conditions":19588,"interventions":19590},"NCT04437953","Avatrombopag for Thrombocytopenia in People With Cancer",[90],"2020-05-27",[7258,1155,19589],"Liver Diseases",[19575],{"trials":19592,"activeCount":101},[],{"trials":19594,"activeCount":101},[],{"trials":19596,"activeCount":101},[],{"intervention":19598,"totalTrials":97,"cells":19599},"d-Methadone",{"EARLY_PHASE1":19600,"PHASE1":19602,"PHASE2":19604,"PHASE3":19615,"PHASE4":19617,"NA":19619},{"trials":19601,"activeCount":101},[],{"trials":19603,"activeCount":101},[],{"trials":19605,"activeCount":101},[19606],{"nctId":19607,"briefTitle":19608,"status":244,"phases":19609,"primaryCompletion":5695,"completion":5695,"start":9078,"enrollment":1434,"conditions":19610,"interventions":19613},"NCT00588640","Study of D-Methadone in Patients With Chronic Pain",[89,90],[1996,971,15,9565,16135,1602,1226,18,2763,1586,19611,19612],"Eye Cancer","Otorhinolaryngologic Neoplasms",[19598,19614],"D-methadone",{"trials":19616,"activeCount":101},[],{"trials":19618,"activeCount":101},[],{"trials":19620,"activeCount":101},[],{"intervention":19622,"totalTrials":97,"cells":19623},"89Zr- DFO-MSTP2109A",{"EARLY_PHASE1":19624,"PHASE1":19626,"PHASE2":19628,"PHASE3":19637,"PHASE4":19639,"NA":19641},{"trials":19625,"activeCount":101},[],{"trials":19627,"activeCount":101},[],{"trials":19629,"activeCount":101},[19630],{"nctId":19631,"briefTitle":19632,"status":244,"phases":19633,"primaryCompletion":6545,"completion":6545,"start":15957,"enrollment":2446,"conditions":19634,"interventions":19635},"NCT01774071","Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer",[89,90],[18],[19622,19636],"89Zr DFO-MSTP2109A",{"trials":19638,"activeCount":101},[],{"trials":19640,"activeCount":101},[],{"trials":19642,"activeCount":101},[],{"intervention":19636,"totalTrials":97,"cells":19644},{"EARLY_PHASE1":19645,"PHASE1":19647,"PHASE2":19649,"PHASE3":19655,"PHASE4":19657,"NA":19659},{"trials":19646,"activeCount":101},[],{"trials":19648,"activeCount":101},[],{"trials":19650,"activeCount":101},[19651],{"nctId":19631,"briefTitle":19632,"status":244,"phases":19652,"primaryCompletion":6545,"completion":6545,"start":15957,"enrollment":2446,"conditions":19653,"interventions":19654},[89,90],[18],[19622,19636],{"trials":19656,"activeCount":101},[],{"trials":19658,"activeCount":101},[],{"trials":19660,"activeCount":101},[],{"intervention":431,"totalTrials":97,"cells":19662},{"EARLY_PHASE1":19663,"PHASE1":19665,"PHASE2":19667,"PHASE3":19673,"PHASE4":19675,"NA":19677},{"trials":19664,"activeCount":101},[],{"trials":19666,"activeCount":101},[],{"trials":19668,"activeCount":101},[19669],{"nctId":423,"briefTitle":424,"status":244,"phases":19670,"primaryCompletion":426,"completion":426,"start":427,"conditions":19671,"interventions":19672},[90],[33],[202,430,431,345,349],{"trials":19674,"activeCount":101},[],{"trials":19676,"activeCount":101},[],{"trials":19678,"activeCount":101},[],{"intervention":9825,"totalTrials":97,"cells":19680},{"EARLY_PHASE1":19681,"PHASE1":19683,"PHASE2":19685,"PHASE3":19691,"PHASE4":19693,"NA":19695},{"trials":19682,"activeCount":101},[],{"trials":19684,"activeCount":101},[],{"trials":19686,"activeCount":101},[19687],{"nctId":9814,"briefTitle":9815,"status":244,"phases":19688,"primaryCompletion":9817,"completion":9817,"start":9818,"enrollment":326,"conditions":19689,"interventions":19690},[90],[15,9820,9821,9822,9823,2312],[9805,9825],{"trials":19692,"activeCount":101},[],{"trials":19694,"activeCount":101},[],{"trials":19696,"activeCount":101},[],{"intervention":19698,"totalTrials":97,"cells":19699},"busulfan, melphalan and fludarabine",{"EARLY_PHASE1":19700,"PHASE1":19702,"PHASE2":19704,"PHASE3":19714,"PHASE4":19716,"NA":19718},{"trials":19701,"activeCount":101},[],{"trials":19703,"activeCount":101},[],{"trials":19705,"activeCount":101},[19706],{"nctId":19707,"briefTitle":19708,"status":244,"phases":19709,"primaryCompletion":19710,"completion":19710,"start":19711,"enrollment":4983,"conditions":19712,"interventions":19713},"NCT01131169","Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions",[90],"2020-05-15","2010-05",[308],[19698,19698],{"trials":19715,"activeCount":101},[],{"trials":19717,"activeCount":101},[],{"trials":19719,"activeCount":101},[],{"intervention":2693,"totalTrials":97,"cells":19721},{"EARLY_PHASE1":19722,"PHASE1":19724,"PHASE2":19726,"PHASE3":19732,"PHASE4":19734,"NA":19736},{"trials":19723,"activeCount":101},[],{"trials":19725,"activeCount":101},[],{"trials":19727,"activeCount":101},[19728],{"nctId":2685,"briefTitle":2686,"status":244,"phases":19729,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":2690,"conditions":19730,"interventions":19731},[90],[971,2341],[942,2693],{"trials":19733,"activeCount":101},[],{"trials":19735,"activeCount":101},[],{"trials":19737,"activeCount":101},[],{"intervention":19739,"totalTrials":97,"cells":19740},"etaracizumab",{"EARLY_PHASE1":19741,"PHASE1":19743,"PHASE2":19745,"PHASE3":19753,"PHASE4":19755,"NA":19757},{"trials":19742,"activeCount":101},[],{"trials":19744,"activeCount":101},[],{"trials":19746,"activeCount":101},[19747],{"nctId":19748,"briefTitle":19749,"status":244,"phases":19750,"primaryCompletion":1693,"completion":1693,"start":898,"conditions":19751,"interventions":19752},"NCT00027729","Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer",[89,90],[36],[19739],{"trials":19754,"activeCount":101},[],{"trials":19756,"activeCount":101},[],{"trials":19758,"activeCount":101},[],{"intervention":19760,"totalTrials":97,"cells":19761},"Cyclophosphamide, Topotecan, and Bevacizumab",{"EARLY_PHASE1":19762,"PHASE1":19764,"PHASE2":19766,"PHASE3":19775,"PHASE4":19777,"NA":19779},{"trials":19763,"activeCount":101},[],{"trials":19765,"activeCount":101},[],{"trials":19767,"activeCount":101},[19768],{"nctId":19769,"briefTitle":19770,"status":244,"phases":19771,"primaryCompletion":19772,"completion":19772,"start":1150,"enrollment":601,"conditions":19773,"interventions":19774},"NCT01492673","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed\u002FRefractory Ewing's Sarcoma and Neuroblastoma",[90],"2018-10-31",[215,33],[19760],{"trials":19776,"activeCount":101},[],{"trials":19778,"activeCount":101},[],{"trials":19780,"activeCount":101},[],{"intervention":443,"totalTrials":97,"cells":19782},{"EARLY_PHASE1":19783,"PHASE1":19785,"PHASE2":19787,"PHASE3":19793,"PHASE4":19795,"NA":19797},{"trials":19784,"activeCount":101},[],{"trials":19786,"activeCount":101},[],{"trials":19788,"activeCount":101},[19789],{"nctId":433,"briefTitle":434,"status":244,"phases":19790,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":19791,"interventions":19792},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"trials":19794,"activeCount":101},[],{"trials":19796,"activeCount":101},[],{"trials":19798,"activeCount":101},[],{"intervention":19800,"totalTrials":97,"cells":19801},"Afatinib and Paclitaxel",{"EARLY_PHASE1":19802,"PHASE1":19804,"PHASE2":19806,"PHASE3":19815,"PHASE4":19817,"NA":19819},{"trials":19803,"activeCount":101},[],{"trials":19805,"activeCount":101},[],{"trials":19807,"activeCount":101},[19808],{"nctId":19809,"briefTitle":19810,"status":244,"phases":19811,"primaryCompletion":19812,"completion":19812,"start":16614,"enrollment":486,"conditions":19813,"interventions":19814},"NCT01522768","Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer",[90],"2023-02-20",[1602,1613],[19800],{"trials":19816,"activeCount":101},[],{"trials":19818,"activeCount":101},[],{"trials":19820,"activeCount":101},[],{"intervention":19822,"totalTrials":97,"cells":19823},"E7820",{"EARLY_PHASE1":19824,"PHASE1":19826,"PHASE2":19828,"PHASE3":19838,"PHASE4":19840,"NA":19842},{"trials":19825,"activeCount":101},[],{"trials":19827,"activeCount":101},[],{"trials":19829,"activeCount":101},[19830],{"nctId":19831,"briefTitle":19832,"status":244,"phases":19833,"primaryCompletion":19834,"completion":19834,"start":19835,"enrollment":283,"conditions":19836,"interventions":19837},"NCT05024994","A Study of E7820 in People With Bone Marrow (Myeloid) Cancers",[90],"2025-06-19","2021-08-13",[3816,475,10201],[19822],{"trials":19839,"activeCount":101},[],{"trials":19841,"activeCount":101},[],{"trials":19843,"activeCount":101},[],{"intervention":5065,"totalTrials":97,"cells":19845},{"EARLY_PHASE1":19846,"PHASE1":19848,"PHASE2":19850,"PHASE3":19856,"PHASE4":19858,"NA":19860},{"trials":19847,"activeCount":101},[],{"trials":19849,"activeCount":101},[],{"trials":19851,"activeCount":101},[19852],{"nctId":5060,"briefTitle":5061,"status":244,"phases":19853,"completion":3044,"start":1663,"conditions":19854,"interventions":19855},[89,90],[36],[5065,1616,391,3603],{"trials":19857,"activeCount":101},[],{"trials":19859,"activeCount":101},[],{"trials":19861,"activeCount":101},[],{"intervention":17689,"totalTrials":97,"cells":19863},{"EARLY_PHASE1":19864,"PHASE1":19866,"PHASE2":19868,"PHASE3":19874,"PHASE4":19876,"NA":19878},{"trials":19865,"activeCount":101},[],{"trials":19867,"activeCount":101},[],{"trials":19869,"activeCount":101},[19870],{"nctId":17684,"briefTitle":17685,"status":244,"phases":19871,"primaryCompletion":4130,"completion":4130,"start":16824,"enrollment":1883,"conditions":19872,"interventions":19873},[90],[24],[17689,3658],{"trials":19875,"activeCount":101},[],{"trials":19877,"activeCount":101},[],{"trials":19879,"activeCount":101},[],{"intervention":18044,"totalTrials":97,"cells":19881},{"EARLY_PHASE1":19882,"PHASE1":19884,"PHASE2":19886,"PHASE3":19892,"PHASE4":19894,"NA":19896},{"trials":19883,"activeCount":101},[],{"trials":19885,"activeCount":101},[],{"trials":19887,"activeCount":101},[19888],{"nctId":18037,"briefTitle":18038,"status":244,"phases":19889,"primaryCompletion":18040,"completion":18040,"start":18041,"enrollment":31,"conditions":19890,"interventions":19891},[90],[2441],[18028,18044],{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"trials":19897,"activeCount":101},[],{"intervention":19899,"totalTrials":97,"cells":19900},"capecitabine, lapatinib",{"EARLY_PHASE1":19901,"PHASE1":19903,"PHASE2":19905,"PHASE3":19913,"PHASE4":19915,"NA":19917},{"trials":19902,"activeCount":101},[],{"trials":19904,"activeCount":101},[],{"trials":19906,"activeCount":101},[19907],{"nctId":19908,"briefTitle":19909,"status":244,"phases":19910,"primaryCompletion":3231,"completion":3231,"start":5695,"enrollment":454,"conditions":19911,"interventions":19912},"NCT00721630","Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed\u002FAmplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer",[90],[15],[19899],{"trials":19914,"activeCount":101},[],{"trials":19916,"activeCount":101},[],{"trials":19918,"activeCount":101},[],{"intervention":19920,"totalTrials":97,"cells":19921},"Haploidentical donor CD34+ cells",{"EARLY_PHASE1":19922,"PHASE1":19924,"PHASE2":19926,"PHASE3":19937,"PHASE4":19939,"NA":19941},{"trials":19923,"activeCount":101},[],{"trials":19925,"activeCount":101},[],{"trials":19927,"activeCount":101},[19928],{"nctId":19929,"briefTitle":19930,"status":244,"phases":19931,"primaryCompletion":19932,"completion":19932,"start":19933,"enrollment":19934,"conditions":19935,"interventions":19936},"NCT01682226","Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies",[90],"2021-01-08","2012-09-05",84,[27,416,24],[19920],{"trials":19938,"activeCount":101},[],{"trials":19940,"activeCount":101},[],{"trials":19942,"activeCount":101},[],{"intervention":9056,"totalTrials":97,"cells":19944},{"EARLY_PHASE1":19945,"PHASE1":19947,"PHASE2":19949,"PHASE3":19955,"PHASE4":19957,"NA":19959},{"trials":19946,"activeCount":101},[],{"trials":19948,"activeCount":101},[],{"trials":19950,"activeCount":101},[19951],{"nctId":9047,"briefTitle":9048,"status":244,"phases":19952,"primaryCompletion":4807,"completion":4807,"start":554,"enrollment":3344,"conditions":19953,"interventions":19954},[90],[9051,1155,9052],[9054,9055,6667,9056,9057],{"trials":19956,"activeCount":101},[],{"trials":19958,"activeCount":101},[],{"trials":19960,"activeCount":101},[],{"intervention":9057,"totalTrials":97,"cells":19962},{"EARLY_PHASE1":19963,"PHASE1":19965,"PHASE2":19967,"PHASE3":19973,"PHASE4":19975,"NA":19977},{"trials":19964,"activeCount":101},[],{"trials":19966,"activeCount":101},[],{"trials":19968,"activeCount":101},[19969],{"nctId":9047,"briefTitle":9048,"status":244,"phases":19970,"primaryCompletion":4807,"completion":4807,"start":554,"enrollment":3344,"conditions":19971,"interventions":19972},[90],[9051,1155,9052],[9054,9055,6667,9056,9057],{"trials":19974,"activeCount":101},[],{"trials":19976,"activeCount":101},[],{"trials":19978,"activeCount":101},[],{"intervention":19980,"totalTrials":97,"cells":19981},"Etoposide, carboplatin, ifosfamide",{"EARLY_PHASE1":19982,"PHASE1":19984,"PHASE2":19986,"PHASE3":19998,"PHASE4":20000,"NA":20002},{"trials":19983,"activeCount":101},[],{"trials":19985,"activeCount":101},[],{"trials":19987,"activeCount":101},[19988],{"nctId":19989,"briefTitle":19990,"status":244,"phases":19991,"primaryCompletion":19992,"completion":19992,"start":19993,"enrollment":22,"conditions":19994,"interventions":19995},"NCT00712582","Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma",[90],"2021-03-12","2008-07-01",[707],[19980,19996,19997],"Rituximab, Ifosfamide, Etoposide, Carboplatin","Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine",{"trials":19999,"activeCount":101},[],{"trials":20001,"activeCount":101},[],{"trials":20003,"activeCount":101},[],{"intervention":19996,"totalTrials":97,"cells":20005},{"EARLY_PHASE1":20006,"PHASE1":20008,"PHASE2":20010,"PHASE3":20016,"PHASE4":20018,"NA":20020},{"trials":20007,"activeCount":101},[],{"trials":20009,"activeCount":101},[],{"trials":20011,"activeCount":101},[20012],{"nctId":19989,"briefTitle":19990,"status":244,"phases":20013,"primaryCompletion":19992,"completion":19992,"start":19993,"enrollment":22,"conditions":20014,"interventions":20015},[90],[707],[19980,19996,19997],{"trials":20017,"activeCount":101},[],{"trials":20019,"activeCount":101},[],{"trials":20021,"activeCount":101},[],{"intervention":19997,"totalTrials":97,"cells":20023},{"EARLY_PHASE1":20024,"PHASE1":20026,"PHASE2":20028,"PHASE3":20034,"PHASE4":20036,"NA":20038},{"trials":20025,"activeCount":101},[],{"trials":20027,"activeCount":101},[],{"trials":20029,"activeCount":101},[20030],{"nctId":19989,"briefTitle":19990,"status":244,"phases":20031,"primaryCompletion":19992,"completion":19992,"start":19993,"enrollment":22,"conditions":20032,"interventions":20033},[90],[707],[19980,19996,19997],{"trials":20035,"activeCount":101},[],{"trials":20037,"activeCount":101},[],{"trials":20039,"activeCount":101},[],{"intervention":20041,"totalTrials":97,"cells":20042},"CMVpp65 Specific T-cells",{"EARLY_PHASE1":20043,"PHASE1":20045,"PHASE2":20047,"PHASE3":20058,"PHASE4":20060,"NA":20062},{"trials":20044,"activeCount":101},[],{"trials":20046,"activeCount":101},[],{"trials":20048,"activeCount":101},[20049],{"nctId":20050,"briefTitle":20051,"status":244,"phases":20052,"primaryCompletion":20053,"completion":20053,"start":20054,"enrollment":13004,"conditions":20055,"interventions":20057},"NCT02136797","Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation",[90],"2024-02-08","2014-05-08",[19254,20056],"Persistent CMV Viremia",[20041],{"trials":20059,"activeCount":101},[],{"trials":20061,"activeCount":101},[],{"trials":20063,"activeCount":101},[],{"intervention":7260,"totalTrials":97,"cells":20065},{"EARLY_PHASE1":20066,"PHASE1":20068,"PHASE2":20070,"PHASE3":20076,"PHASE4":20078,"NA":20080},{"trials":20067,"activeCount":101},[],{"trials":20069,"activeCount":101},[],{"trials":20071,"activeCount":101},[20072],{"nctId":7253,"briefTitle":7254,"status":244,"phases":20073,"primaryCompletion":426,"completion":426,"start":3930,"conditions":20074,"interventions":20075},[90],[7257,27,3939,7258],[288,7260,361,642],{"trials":20077,"activeCount":101},[],{"trials":20079,"activeCount":101},[],{"trials":20081,"activeCount":101},[],{"intervention":20083,"totalTrials":97,"cells":20084},"MEDI4736",{"EARLY_PHASE1":20085,"PHASE1":20087,"PHASE2":20089,"PHASE3":20100,"PHASE4":20102,"NA":20104},{"trials":20086,"activeCount":101},[],{"trials":20088,"activeCount":101},[],{"trials":20090,"activeCount":101},[20091],{"nctId":20092,"briefTitle":20093,"status":244,"phases":20094,"primaryCompletion":20095,"completion":20095,"start":20096,"enrollment":1447,"conditions":20097,"interventions":20099},"NCT02227667","Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer",[90],"2020-06-29","2014-12-02",[20098],"Advanced Colorectal Cancer",[20083],{"trials":20101,"activeCount":101},[],{"trials":20103,"activeCount":101},[],{"trials":20105,"activeCount":101},[],{"intervention":1998,"totalTrials":97,"cells":20107},{"EARLY_PHASE1":20108,"PHASE1":20110,"PHASE2":20112,"PHASE3":20118,"PHASE4":20120,"NA":20122},{"trials":20109,"activeCount":101},[],{"trials":20111,"activeCount":101},[],{"trials":20113,"activeCount":101},[20114],{"nctId":1990,"briefTitle":1991,"status":244,"phases":20115,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":370,"conditions":20116,"interventions":20117},[90],[1996],[1981,1998],{"trials":20119,"activeCount":101},[],{"trials":20121,"activeCount":101},[],{"trials":20123,"activeCount":101},[],{"intervention":20125,"totalTrials":97,"cells":20126},"MLN0128",{"EARLY_PHASE1":20127,"PHASE1":20129,"PHASE2":20131,"PHASE3":20141,"PHASE4":20143,"NA":20145},{"trials":20128,"activeCount":101},[],{"trials":20130,"activeCount":101},[],{"trials":20132,"activeCount":101},[20133],{"nctId":20134,"briefTitle":20135,"status":244,"phases":20136,"primaryCompletion":20137,"completion":20137,"start":1186,"enrollment":601,"conditions":20138,"interventions":20140},"NCT02091531","Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients",[90],"2018-10",[20139],"Metastatic Castration-Resistant Prostate Cancer",[20125],{"trials":20142,"activeCount":101},[],{"trials":20144,"activeCount":101},[],{"trials":20146,"activeCount":101},[],{"intervention":20148,"totalTrials":97,"cells":20149},"Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant",{"EARLY_PHASE1":20150,"PHASE1":20152,"PHASE2":20154,"PHASE3":20163,"PHASE4":20165,"NA":20167},{"trials":20151,"activeCount":101},[],{"trials":20153,"activeCount":101},[],{"trials":20155,"activeCount":101},[20156],{"nctId":20157,"briefTitle":20158,"status":244,"phases":20159,"primaryCompletion":8749,"completion":8749,"start":680,"enrollment":306,"conditions":20160,"interventions":20162},"NCT00588094","Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL",[90],[24,20161],"B-cell Non-Hodgkin's Lymphoma",[20148],{"trials":20164,"activeCount":101},[],{"trials":20166,"activeCount":101},[],{"trials":20168,"activeCount":101},[],{"intervention":20170,"totalTrials":97,"cells":20171},"Cisplatin, Vinblastine, Temozolomide",{"EARLY_PHASE1":20172,"PHASE1":20174,"PHASE2":20176,"PHASE3":20184,"PHASE4":20186,"NA":20188},{"trials":20173,"activeCount":101},[],{"trials":20175,"activeCount":101},[],{"trials":20177,"activeCount":101},[20178],{"nctId":20179,"briefTitle":20180,"status":244,"phases":20181,"primaryCompletion":16679,"completion":16679,"start":1014,"enrollment":2291,"conditions":20182,"interventions":20183},"NCT00885534","Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma",[90],[2341,4809],[20170],{"trials":20185,"activeCount":101},[],{"trials":20187,"activeCount":101},[],{"trials":20189,"activeCount":101},[],{"intervention":20191,"totalTrials":97,"cells":20192},"Radium dichloride",{"EARLY_PHASE1":20193,"PHASE1":20195,"PHASE2":20197,"PHASE3":20207,"PHASE4":20209,"NA":20211},{"trials":20194,"activeCount":101},[],{"trials":20196,"activeCount":101},[],{"trials":20198,"activeCount":101},[20199],{"nctId":20200,"briefTitle":20201,"status":244,"phases":20202,"primaryCompletion":20203,"completion":20203,"start":20204,"enrollment":283,"conditions":20205,"interventions":20206},"NCT05133440","A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones",[90],"2026-04-27","2021-11-12",[18],[20191],{"trials":20208,"activeCount":101},[],{"trials":20210,"activeCount":101},[],{"trials":20212,"activeCount":101},[],{"intervention":20214,"totalTrials":97,"cells":20215},"Maitake",{"EARLY_PHASE1":20216,"PHASE1":20218,"PHASE2":20220,"PHASE3":20228,"PHASE4":20230,"NA":20232},{"trials":20217,"activeCount":101},[],{"trials":20219,"activeCount":101},[],{"trials":20221,"activeCount":101},[20222],{"nctId":20223,"briefTitle":20224,"status":244,"phases":20225,"primaryCompletion":9109,"completion":9109,"start":544,"enrollment":341,"conditions":20226,"interventions":20227},"NCT01099917","Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?",[90],[416],[20214],{"trials":20229,"activeCount":101},[],{"trials":20231,"activeCount":101},[],{"trials":20233,"activeCount":101},[],{"intervention":5535,"totalTrials":97,"cells":20235},{"EARLY_PHASE1":20236,"PHASE1":20238,"PHASE2":20240,"PHASE3":20246,"PHASE4":20248,"NA":20250},{"trials":20237,"activeCount":101},[],{"trials":20239,"activeCount":101},[],{"trials":20241,"activeCount":101},[20242],{"nctId":5530,"briefTitle":5531,"status":244,"phases":20243,"primaryCompletion":4772,"start":3930,"enrollment":1052,"conditions":20244,"interventions":20245},[90],[4734,33],[389,5535,444],{"trials":20247,"activeCount":101},[],{"trials":20249,"activeCount":101},[],{"trials":20251,"activeCount":101},[],{"intervention":20253,"totalTrials":97,"cells":20254},"Ritalin",{"EARLY_PHASE1":20255,"PHASE1":20257,"PHASE2":20259,"PHASE3":20268,"PHASE4":20270,"NA":20272},{"trials":20256,"activeCount":101},[],{"trials":20258,"activeCount":101},[],{"trials":20260,"activeCount":101},[20261],{"nctId":20262,"briefTitle":20263,"status":244,"phases":20264,"completion":3444,"start":13332,"enrollment":1200,"conditions":20265,"interventions":20267},"NCT00138138","Psychostimulants for Fatigue in Prostate Cancer",[90],[20266,18],"Fatigue",[20253],{"trials":20269,"activeCount":101},[],{"trials":20271,"activeCount":101},[],{"trials":20273,"activeCount":101},[],{"intervention":20275,"totalTrials":97,"cells":20276},"Isavuconazole",{"EARLY_PHASE1":20277,"PHASE1":20279,"PHASE2":20281,"PHASE3":20291,"PHASE4":20293,"NA":20295},{"trials":20278,"activeCount":101},[],{"trials":20280,"activeCount":101},[],{"trials":20282,"activeCount":101},[20283],{"nctId":20284,"briefTitle":20285,"status":244,"phases":20286,"primaryCompletion":20287,"completion":14895,"start":4780,"enrollment":20288,"conditions":20289,"interventions":20290},"NCT03149055","Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)",[90],"2019-08-20",99,[910,1154],[20275],{"trials":20292,"activeCount":101},[],{"trials":20294,"activeCount":101},[],{"trials":20296,"activeCount":101},[],{"intervention":6532,"totalTrials":97,"cells":20298},{"EARLY_PHASE1":20299,"PHASE1":20301,"PHASE2":20303,"PHASE3":20309,"PHASE4":20311,"NA":20313},{"trials":20300,"activeCount":101},[],{"trials":20302,"activeCount":101},[],{"trials":20304,"activeCount":101},[20305],{"nctId":6523,"briefTitle":6524,"status":244,"phases":20306,"primaryCompletion":6526,"completion":6526,"start":6527,"enrollment":899,"conditions":20307,"interventions":20308},[89,90],[6529,6530],[6532,819],{"trials":20310,"activeCount":101},[],{"trials":20312,"activeCount":101},[],{"trials":20314,"activeCount":101},[],{"intervention":18594,"totalTrials":97,"cells":20316},{"EARLY_PHASE1":20317,"PHASE1":20319,"PHASE2":20321,"PHASE3":20327,"PHASE4":20329,"NA":20331},{"trials":20318,"activeCount":101},[],{"trials":20320,"activeCount":101},[],{"trials":20322,"activeCount":101},[20323],{"nctId":18588,"briefTitle":18589,"status":505,"phases":20324,"primaryCompletion":18591,"completion":18591,"start":4226,"enrollment":97,"conditions":20325,"interventions":20326},[90],[15],[18571,18594],{"trials":20328,"activeCount":101},[],{"trials":20330,"activeCount":101},[],{"trials":20332,"activeCount":101},[],{"intervention":4568,"totalTrials":97,"cells":20334},{"EARLY_PHASE1":20335,"PHASE1":20337,"PHASE2":20339,"PHASE3":20345,"PHASE4":20347,"NA":20349},{"trials":20336,"activeCount":101},[],{"trials":20338,"activeCount":101},[],{"trials":20340,"activeCount":101},[20341],{"nctId":4560,"briefTitle":4561,"status":244,"phases":20342,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":565,"conditions":20343,"interventions":20344},[90],[1874,4566],[1261,4568,4569],{"trials":20346,"activeCount":101},[],{"trials":20348,"activeCount":101},[],{"trials":20350,"activeCount":101},[],{"intervention":4569,"totalTrials":97,"cells":20352},{"EARLY_PHASE1":20353,"PHASE1":20355,"PHASE2":20357,"PHASE3":20363,"PHASE4":20365,"NA":20367},{"trials":20354,"activeCount":101},[],{"trials":20356,"activeCount":101},[],{"trials":20358,"activeCount":101},[20359],{"nctId":4560,"briefTitle":4561,"status":244,"phases":20360,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":565,"conditions":20361,"interventions":20362},[90],[1874,4566],[1261,4568,4569],{"trials":20364,"activeCount":101},[],{"trials":20366,"activeCount":101},[],{"trials":20368,"activeCount":101},[],{"intervention":20370,"totalTrials":97,"cells":20371},"iratumumab",{"EARLY_PHASE1":20372,"PHASE1":20374,"PHASE2":20376,"PHASE3":20385,"PHASE4":20387,"NA":20389},{"trials":20373,"activeCount":101},[],{"trials":20375,"activeCount":101},[],{"trials":20377,"activeCount":101},[20378],{"nctId":20379,"briefTitle":20380,"status":244,"phases":20381,"primaryCompletion":1397,"completion":20382,"start":695,"conditions":20383,"interventions":20384},"NCT00059995","MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma",[89,90],"2009-11",[24],[20370],{"trials":20386,"activeCount":101},[],{"trials":20388,"activeCount":101},[],{"trials":20390,"activeCount":101},[],{"intervention":526,"totalTrials":97,"cells":20392},{"EARLY_PHASE1":20393,"PHASE1":20395,"PHASE2":20397,"PHASE3":20403,"PHASE4":20405,"NA":20407},{"trials":20394,"activeCount":101},[],{"trials":20396,"activeCount":101},[],{"trials":20398,"activeCount":101},[20399],{"nctId":518,"briefTitle":519,"status":244,"phases":20400,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":20401,"interventions":20402},[90],[24],[526,288,374,202,345,445,349],{"trials":20404,"activeCount":101},[],{"trials":20406,"activeCount":101},[],{"trials":20408,"activeCount":101},[],{"intervention":20410,"totalTrials":97,"cells":20411},"Fludarabine, Cyclophosphamide",{"EARLY_PHASE1":20412,"PHASE1":20414,"PHASE2":20416,"PHASE3":20425,"PHASE4":20427,"NA":20429},{"trials":20413,"activeCount":101},[],{"trials":20415,"activeCount":101},[],{"trials":20417,"activeCount":101},[20418],{"nctId":20419,"briefTitle":20420,"status":244,"phases":20421,"primaryCompletion":16745,"completion":16745,"start":20422,"enrollment":1232,"conditions":20423,"interventions":20424},"NCT00597519","A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy",[90],"2006-03",[1155,27,416,707],[20410],{"trials":20426,"activeCount":101},[],{"trials":20428,"activeCount":101},[],{"trials":20430,"activeCount":101},[],{"intervention":20432,"totalTrials":97,"cells":20433},"Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.",{"EARLY_PHASE1":20434,"PHASE1":20436,"PHASE2":20438,"PHASE3":20447,"PHASE4":20449,"NA":20451},{"trials":20435,"activeCount":101},[],{"trials":20437,"activeCount":101},[],{"trials":20439,"activeCount":101},[20440],{"nctId":20441,"briefTitle":20442,"status":244,"phases":20443,"primaryCompletion":4172,"completion":4172,"start":20444,"enrollment":341,"conditions":20445,"interventions":20446},"NCT00987480","Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine",[90],"2009-09-25",[10607,27,416],[20432],{"trials":20448,"activeCount":101},[],{"trials":20450,"activeCount":101},[],{"trials":20452,"activeCount":101},[],{"intervention":3454,"totalTrials":97,"cells":20454},{"EARLY_PHASE1":20455,"PHASE1":20457,"PHASE2":20459,"PHASE3":20465,"PHASE4":20467,"NA":20469},{"trials":20456,"activeCount":101},[],{"trials":20458,"activeCount":101},[],{"trials":20460,"activeCount":101},[20461],{"nctId":3448,"briefTitle":3449,"status":244,"phases":20462,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":20463,"interventions":20464},[89,90],[18],[390,3454,1707,3455,3456,741],{"trials":20466,"activeCount":101},[],{"trials":20468,"activeCount":101},[],{"trials":20470,"activeCount":101},[],{"intervention":3456,"totalTrials":97,"cells":20472},{"EARLY_PHASE1":20473,"PHASE1":20475,"PHASE2":20477,"PHASE3":20483,"PHASE4":20485,"NA":20487},{"trials":20474,"activeCount":101},[],{"trials":20476,"activeCount":101},[],{"trials":20478,"activeCount":101},[20479],{"nctId":3448,"briefTitle":3449,"status":244,"phases":20480,"primaryCompletion":856,"completion":856,"start":3451,"enrollment":326,"conditions":20481,"interventions":20482},[89,90],[18],[390,3454,1707,3455,3456,741],{"trials":20484,"activeCount":101},[],{"trials":20486,"activeCount":101},[],{"trials":20488,"activeCount":101},[],{"intervention":20490,"totalTrials":97,"cells":20491},"erlotinib with cetuximab",{"EARLY_PHASE1":20492,"PHASE1":20494,"PHASE2":20496,"PHASE3":20504,"PHASE4":20506,"NA":20508},{"trials":20493,"activeCount":101},[],{"trials":20495,"activeCount":101},[],{"trials":20497,"activeCount":101},[20498],{"nctId":20499,"briefTitle":20500,"status":244,"phases":20501,"primaryCompletion":4634,"completion":4634,"start":5695,"enrollment":899,"conditions":20502,"interventions":20503},"NCT00716456","Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed \"Acquired Resistance\" to Erlotinib",[89,90],[6130],[20490],{"trials":20505,"activeCount":101},[],{"trials":20507,"activeCount":101},[],{"trials":20509,"activeCount":101},[],{"intervention":20511,"totalTrials":97,"cells":20512},"LY3023414",{"EARLY_PHASE1":20513,"PHASE1":20515,"PHASE2":20517,"PHASE3":20527,"PHASE4":20529,"NA":20531},{"trials":20514,"activeCount":101},[],{"trials":20516,"activeCount":101},[],{"trials":20518,"activeCount":101},[20519],{"nctId":20520,"briefTitle":20521,"status":244,"phases":20522,"primaryCompletion":20523,"completion":20523,"start":16745,"enrollment":1232,"conditions":20524,"interventions":20526},"NCT02549989","Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer",[90],"2022-03-23",[3359,20525],"Recurrent Endometrial Cancer",[20511],{"trials":20528,"activeCount":101},[],{"trials":20530,"activeCount":101},[],{"trials":20532,"activeCount":101},[],{"intervention":20534,"totalTrials":97,"cells":20535},"Bevacizumab, Irinotecan and Temozolomide",{"EARLY_PHASE1":20536,"PHASE1":20538,"PHASE2":20540,"PHASE3":20550,"PHASE4":20552,"NA":20554},{"trials":20537,"activeCount":101},[],{"trials":20539,"activeCount":101},[],{"trials":20541,"activeCount":101},[20542],{"nctId":20543,"briefTitle":20544,"status":244,"phases":20545,"primaryCompletion":20546,"completion":20546,"start":20547,"enrollment":2439,"conditions":20548,"interventions":20549},"NCT01114555","Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma",[90],"2018-11-02","2010-04-29",[215],[20534],{"trials":20551,"activeCount":101},[],{"trials":20553,"activeCount":101},[],{"trials":20555,"activeCount":101},[],{"intervention":20557,"totalTrials":97,"cells":20558},"Tretinoin and Arsenic Trioxide",{"EARLY_PHASE1":20559,"PHASE1":20561,"PHASE2":20563,"PHASE3":20573,"PHASE4":20575,"NA":20577},{"trials":20560,"activeCount":101},[],{"trials":20562,"activeCount":101},[],{"trials":20564,"activeCount":101},[20565],{"nctId":20566,"briefTitle":20567,"status":244,"phases":20568,"primaryCompletion":20569,"completion":20569,"start":763,"enrollment":234,"conditions":20570,"interventions":20572},"NCT01404949","Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy",[90],"2021-02-01",[20571],"Acute Promyelocytic Leukemia",[20557],{"trials":20574,"activeCount":101},[],{"trials":20576,"activeCount":101},[],{"trials":20578,"activeCount":101},[],{"intervention":20580,"totalTrials":97,"cells":20581},"Binimetinib",{"EARLY_PHASE1":20582,"PHASE1":20584,"PHASE2":20586,"PHASE3":20598,"PHASE4":20600,"NA":20602},{"trials":20583,"activeCount":101},[],{"trials":20585,"activeCount":101},[],{"trials":20587,"activeCount":101},[20588],{"nctId":20589,"briefTitle":20590,"status":244,"phases":20591,"primaryCompletion":20592,"completion":20592,"start":20593,"enrollment":234,"conditions":20594,"interventions":20596},"NCT03843775","A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers",[89,90],"2023-09-02","2019-02-14",[20595],"Advanced BRAF Mutant Cancers",[20580,20597],"Encorafenib",{"trials":20599,"activeCount":101},[],{"trials":20601,"activeCount":101},[],{"trials":20603,"activeCount":101},[],{"intervention":20597,"totalTrials":97,"cells":20605},{"EARLY_PHASE1":20606,"PHASE1":20608,"PHASE2":20610,"PHASE3":20616,"PHASE4":20618,"NA":20620},{"trials":20607,"activeCount":101},[],{"trials":20609,"activeCount":101},[],{"trials":20611,"activeCount":101},[20612],{"nctId":20589,"briefTitle":20590,"status":244,"phases":20613,"primaryCompletion":20592,"completion":20592,"start":20593,"enrollment":234,"conditions":20614,"interventions":20615},[89,90],[20595],[20580,20597],{"trials":20617,"activeCount":101},[],{"trials":20619,"activeCount":101},[],{"trials":20621,"activeCount":101},[],{"intervention":20623,"totalTrials":97,"cells":20624},"rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim",{"EARLY_PHASE1":20625,"PHASE1":20627,"PHASE2":20629,"PHASE3":20637,"PHASE4":20639,"NA":20641},{"trials":20626,"activeCount":101},[],{"trials":20628,"activeCount":101},[],{"trials":20630,"activeCount":101},[20631],{"nctId":20632,"briefTitle":20633,"status":244,"phases":20634,"primaryCompletion":5098,"completion":5098,"start":4819,"enrollment":356,"conditions":20635,"interventions":20636},"NCT00667615","Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],[1426,24],[20623],{"trials":20638,"activeCount":101},[],{"trials":20640,"activeCount":101},[],{"trials":20642,"activeCount":101},[],{"intervention":20644,"totalTrials":97,"cells":20645},"Ipilimumab, Melphalan and Dactinomycin",{"EARLY_PHASE1":20646,"PHASE1":20648,"PHASE2":20650,"PHASE3":20659,"PHASE4":20661,"NA":20663},{"trials":20647,"activeCount":101},[],{"trials":20649,"activeCount":101},[],{"trials":20651,"activeCount":101},[20652],{"nctId":20653,"briefTitle":20654,"status":244,"phases":20655,"primaryCompletion":20656,"completion":20656,"start":19086,"enrollment":213,"conditions":20657,"interventions":20658},"NCT01323517","Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity",[90],"2017-08-14",[2341],[20644],{"trials":20660,"activeCount":101},[],{"trials":20662,"activeCount":101},[],{"trials":20664,"activeCount":101},[],{"intervention":20666,"totalTrials":97,"cells":20667},"Sorafenib and Dacarbazine",{"EARLY_PHASE1":20668,"PHASE1":20670,"PHASE2":20672,"PHASE3":20681,"PHASE4":20683,"NA":20685},{"trials":20669,"activeCount":101},[],{"trials":20671,"activeCount":101},[],{"trials":20673,"activeCount":101},[20674],{"nctId":20675,"briefTitle":20676,"status":244,"phases":20677,"primaryCompletion":3589,"completion":3589,"start":1083,"enrollment":1883,"conditions":20678,"interventions":20680},"NCT00837148","Sorafenib and Dacarbazine in Soft Tissue Sarcoma",[90],[33,20679,1017,19296],"Synovial Sarcoma",[20666],{"trials":20682,"activeCount":101},[],{"trials":20684,"activeCount":101},[],{"trials":20686,"activeCount":101},[],{"intervention":20688,"totalTrials":97,"cells":20689},"Dasatinib and Paclitaxel",{"EARLY_PHASE1":20690,"PHASE1":20692,"PHASE2":20694,"PHASE3":20703,"PHASE4":20705,"NA":20707},{"trials":20691,"activeCount":101},[],{"trials":20693,"activeCount":101},[],{"trials":20695,"activeCount":101},[20696],{"nctId":20697,"briefTitle":20698,"status":244,"phases":20699,"primaryCompletion":3434,"completion":3434,"start":20700,"enrollment":34,"conditions":20701,"interventions":20702},"NCT00820170","Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194",[89,90],"2009-01",[15],[20688],{"trials":20704,"activeCount":101},[],{"trials":20706,"activeCount":101},[],{"trials":20708,"activeCount":101},[],{"intervention":1057,"totalTrials":97,"cells":20710},{"EARLY_PHASE1":20711,"PHASE1":20713,"PHASE2":20715,"PHASE3":20721,"PHASE4":20723,"NA":20725},{"trials":20712,"activeCount":101},[],{"trials":20714,"activeCount":101},[],{"trials":20716,"activeCount":101},[20717],{"nctId":1047,"briefTitle":1048,"status":244,"phases":20718,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":1052,"conditions":20719,"interventions":20720},[90],[36,1054],[1045,923,944,819,1056,1057],{"trials":20722,"activeCount":101},[],{"trials":20724,"activeCount":101},[],{"trials":20726,"activeCount":101},[],{"intervention":1066,"totalTrials":97,"cells":20728},{"EARLY_PHASE1":20729,"PHASE1":20731,"PHASE2":20733,"PHASE3":20739,"PHASE4":20741,"NA":20743},{"trials":20730,"activeCount":101},[],{"trials":20732,"activeCount":101},[],{"trials":20734,"activeCount":101},[20735],{"nctId":1059,"briefTitle":1060,"status":244,"phases":20736,"primaryCompletion":1062,"completion":1062,"start":325,"enrollment":718,"conditions":20737,"interventions":20738},[90],[21,1064],[1066,1022],{"trials":20740,"activeCount":101},[],{"trials":20742,"activeCount":101},[],{"trials":20744,"activeCount":101},[],{"intervention":6599,"totalTrials":97,"cells":20746},{"EARLY_PHASE1":20747,"PHASE1":20749,"PHASE2":20751,"PHASE3":20757,"PHASE4":20759,"NA":20761},{"trials":20748,"activeCount":101},[],{"trials":20750,"activeCount":101},[],{"trials":20752,"activeCount":101},[20753],{"nctId":6593,"briefTitle":6594,"status":244,"phases":20754,"completion":737,"start":825,"conditions":20755,"interventions":20756},[90],[27,21,24,828,475,18],[6598,6599],{"trials":20758,"activeCount":101},[],{"trials":20760,"activeCount":101},[],{"trials":20762,"activeCount":101},[],{"intervention":20764,"totalTrials":97,"cells":20765},"CMV-pp65 CTLs",{"EARLY_PHASE1":20766,"PHASE1":20768,"PHASE2":20770,"PHASE3":20780,"PHASE4":20782,"NA":20784},{"trials":20767,"activeCount":101},[],{"trials":20769,"activeCount":101},[],{"trials":20771,"activeCount":101},[20772],{"nctId":20773,"briefTitle":20774,"status":244,"phases":20775,"primaryCompletion":11055,"completion":11055,"start":20776,"enrollment":1242,"conditions":20777,"interventions":20779},"NCT01646645","Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation",[90],"2012-07-13",[20778],"Cytomegalovirus",[20764],{"trials":20781,"activeCount":101},[],{"trials":20783,"activeCount":101},[],{"trials":20785,"activeCount":101},[],{"intervention":5560,"totalTrials":97,"cells":20787},{"EARLY_PHASE1":20788,"PHASE1":20790,"PHASE2":20792,"PHASE3":20798,"PHASE4":20800,"NA":20802},{"trials":20789,"activeCount":101},[],{"trials":20791,"activeCount":101},[],{"trials":20793,"activeCount":101},[20794],{"nctId":5554,"briefTitle":5555,"status":244,"phases":20795,"primaryCompletion":5557,"completion":5557,"start":4750,"enrollment":1434,"conditions":20796,"interventions":20797},[90],[33],[5560,830,444,479],{"trials":20799,"activeCount":101},[],{"trials":20801,"activeCount":101},[],{"trials":20803,"activeCount":101},[],{"intervention":17387,"totalTrials":97,"cells":20805},{"EARLY_PHASE1":20806,"PHASE1":20808,"PHASE2":20810,"PHASE3":20816,"PHASE4":20818,"NA":20820},{"trials":20807,"activeCount":101},[],{"trials":20809,"activeCount":101},[],{"trials":20811,"activeCount":101},[20812],{"nctId":17381,"briefTitle":17382,"status":244,"phases":20813,"primaryCompletion":17384,"completion":17384,"start":305,"enrollment":899,"conditions":20814,"interventions":20815},[90],[15597],[17387,2963],{"trials":20817,"activeCount":101},[],{"trials":20819,"activeCount":101},[],{"trials":20821,"activeCount":101},[],{"intervention":4266,"totalTrials":97,"cells":20823},{"EARLY_PHASE1":20824,"PHASE1":20826,"PHASE2":20828,"PHASE3":20834,"PHASE4":20836,"NA":20838},{"trials":20825,"activeCount":101},[],{"trials":20827,"activeCount":101},[],{"trials":20829,"activeCount":101},[20830],{"nctId":4260,"briefTitle":4261,"status":244,"phases":20831,"primaryCompletion":1584,"completion":1584,"start":4263,"enrollment":1462,"conditions":20832,"interventions":20833},[90],[30],[4266,52],{"trials":20835,"activeCount":101},[],{"trials":20837,"activeCount":101},[],{"trials":20839,"activeCount":101},[],{"intervention":1658,"totalTrials":97,"cells":20841},{"EARLY_PHASE1":20842,"PHASE1":20844,"PHASE2":20846,"PHASE3":20852,"PHASE4":20854,"NA":20856},{"trials":20843,"activeCount":101},[],{"trials":20845,"activeCount":101},[],{"trials":20847,"activeCount":101},[20848],{"nctId":1649,"briefTitle":1650,"status":244,"phases":20849,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":1654,"conditions":20850,"interventions":20851},[90],[18],[1657,1658,1181],{"trials":20853,"activeCount":101},[],{"trials":20855,"activeCount":101},[],{"trials":20857,"activeCount":101},[],{"intervention":20859,"totalTrials":97,"cells":20860},"Colesevelam Pill",{"EARLY_PHASE1":20861,"PHASE1":20863,"PHASE2":20865,"PHASE3":20875,"PHASE4":20877,"NA":20879},{"trials":20862,"activeCount":101},[],{"trials":20864,"activeCount":101},[],{"trials":20866,"activeCount":101},[20867],{"nctId":20868,"briefTitle":20869,"status":244,"phases":20870,"primaryCompletion":20871,"completion":20871,"start":20872,"enrollment":438,"conditions":20873,"interventions":20874},"NCT03767257","A Study of Colesevelam for Lenalidomide-Associated Diarrhea",[90],"2024-11-27","2018-12-03",[308,15070],[20859],{"trials":20876,"activeCount":101},[],{"trials":20878,"activeCount":101},[],{"trials":20880,"activeCount":101},[],{"intervention":20882,"totalTrials":97,"cells":20883},"Temsirolimus + Weekly Paclitaxel + Carboplatin",{"EARLY_PHASE1":20884,"PHASE1":20886,"PHASE2":20888,"PHASE3":20896,"PHASE4":20898,"NA":20900},{"trials":20885,"activeCount":101},[],{"trials":20887,"activeCount":101},[],{"trials":20889,"activeCount":101},[20890],{"nctId":20891,"briefTitle":20892,"status":244,"phases":20893,"primaryCompletion":5159,"completion":5159,"start":20382,"enrollment":1798,"conditions":20894,"interventions":20895},"NCT01016769","Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)",[89,90],[8813,1586],[20882],{"trials":20897,"activeCount":101},[],{"trials":20899,"activeCount":101},[],{"trials":20901,"activeCount":101},[],{"intervention":20903,"totalTrials":97,"cells":20904},"cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant",{"EARLY_PHASE1":20905,"PHASE1":20907,"PHASE2":20909,"PHASE3":20922,"PHASE4":20924,"NA":20926},{"trials":20906,"activeCount":101},[],{"trials":20908,"activeCount":101},[],{"trials":20910,"activeCount":101},[20911],{"nctId":20912,"briefTitle":20913,"status":244,"phases":20914,"primaryCompletion":4634,"completion":4634,"start":898,"enrollment":20915,"conditions":20916,"interventions":20921},"NCT00587054","Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders",[90],129,[20917,27,20918,20919,416,20920],"Allogeneic Stem Cell Transplant","Non-Hodgkins","Lymphoblastic Lymphoma","Paroxysmal Nocturnal Hemoglobinuria (PNH)",[20903],{"trials":20923,"activeCount":101},[],{"trials":20925,"activeCount":101},[],{"trials":20927,"activeCount":101},[],{"intervention":20929,"totalTrials":97,"cells":20930},"OSI-774: erlotinib, TarcevaTM",{"EARLY_PHASE1":20931,"PHASE1":20933,"PHASE2":20935,"PHASE3":20944,"PHASE4":20946,"NA":20948},{"trials":20932,"activeCount":101},[],{"trials":20934,"activeCount":101},[],{"trials":20936,"activeCount":101},[20937],{"nctId":20938,"briefTitle":20939,"status":244,"phases":20940,"primaryCompletion":3443,"completion":3443,"start":1629,"enrollment":2690,"conditions":20941,"interventions":20943},"NCT00590902","Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer",[90],[20942],"Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer",[20929],{"trials":20945,"activeCount":101},[],{"trials":20947,"activeCount":101},[],{"trials":20949,"activeCount":101},[],{"intervention":20951,"totalTrials":97,"cells":20952},"3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic",{"EARLY_PHASE1":20953,"PHASE1":20955,"PHASE2":20957,"PHASE3":20967,"PHASE4":20969,"NA":20971},{"trials":20954,"activeCount":101},[],{"trials":20956,"activeCount":101},[],{"trials":20958,"activeCount":101},[20959],{"nctId":20960,"briefTitle":20961,"status":244,"phases":20962,"primaryCompletion":20963,"completion":20963,"start":20964,"enrollment":473,"conditions":20965,"interventions":20966},"NCT01183897","3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow",[90],"2018-09-25","2010-08-12",[215],[20951],{"trials":20968,"activeCount":101},[],{"trials":20970,"activeCount":101},[],{"trials":20972,"activeCount":101},[],{"intervention":20974,"totalTrials":97,"cells":20975},"Sorafenib, administered orally",{"EARLY_PHASE1":20976,"PHASE1":20978,"PHASE2":20980,"PHASE3":20988,"PHASE4":20990,"NA":20992},{"trials":20977,"activeCount":101},[],{"trials":20979,"activeCount":101},[],{"trials":20981,"activeCount":101},[20982],{"nctId":20983,"briefTitle":20984,"status":244,"phases":20985,"primaryCompletion":3434,"completion":3434,"start":5650,"enrollment":1052,"conditions":20986,"interventions":20987},"NCT00917462","Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer",[90],[1602,2400],[20974],{"trials":20989,"activeCount":101},[],{"trials":20991,"activeCount":101},[],{"trials":20993,"activeCount":101},[],{"intervention":20995,"totalTrials":97,"cells":20996},"anti-GD2 murine IgG3 monoclonal antibody 3F8",{"EARLY_PHASE1":20997,"PHASE1":20999,"PHASE2":21001,"PHASE3":21010,"PHASE4":21012,"NA":21014},{"trials":20998,"activeCount":101},[],{"trials":21000,"activeCount":101},[],{"trials":21002,"activeCount":101},[21003],{"nctId":21004,"briefTitle":21005,"status":244,"phases":21006,"primaryCompletion":21007,"completion":21007,"start":1653,"enrollment":1768,"conditions":21008,"interventions":21009},"NCT00072358","Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma",[90],"2021-01-15",[215],[20995,20995],{"trials":21011,"activeCount":101},[],{"trials":21013,"activeCount":101},[],{"trials":21015,"activeCount":101},[],{"intervention":18843,"totalTrials":97,"cells":21017},{"EARLY_PHASE1":21018,"PHASE1":21020,"PHASE2":21022,"PHASE3":21028,"PHASE4":21030,"NA":21032},{"trials":21019,"activeCount":101},[],{"trials":21021,"activeCount":101},[],{"trials":21023,"activeCount":101},[21024],{"nctId":18833,"briefTitle":18834,"status":244,"phases":21025,"primaryCompletion":18836,"completion":18836,"start":18837,"enrollment":2439,"conditions":21026,"interventions":21027},[90],[18839,18840,18841],[6656,18843],{"trials":21029,"activeCount":101},[],{"trials":21031,"activeCount":101},[],{"trials":21033,"activeCount":101},[],{"intervention":21035,"totalTrials":97,"cells":21036},"low dose 5'-azacitidine",{"EARLY_PHASE1":21037,"PHASE1":21039,"PHASE2":21041,"PHASE3":21049,"PHASE4":21051,"NA":21053},{"trials":21038,"activeCount":101},[],{"trials":21040,"activeCount":101},[],{"trials":21042,"activeCount":101},[21043],{"nctId":21044,"briefTitle":21045,"status":244,"phases":21046,"primaryCompletion":2571,"completion":2571,"start":4771,"enrollment":992,"conditions":21047,"interventions":21048},"NCT01995578","Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse",[90],[537,513],[21035],{"trials":21050,"activeCount":101},[],{"trials":21052,"activeCount":101},[],{"trials":21054,"activeCount":101},[],{"intervention":1911,"totalTrials":97,"cells":21056},{"EARLY_PHASE1":21057,"PHASE1":21059,"PHASE2":21061,"PHASE3":21067,"PHASE4":21069,"NA":21071},{"trials":21058,"activeCount":101},[],{"trials":21060,"activeCount":101},[],{"trials":21062,"activeCount":101},[21063],{"nctId":1901,"briefTitle":1902,"status":244,"phases":21064,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":21065,"interventions":21066},[89,90],[1908,1909],[1260,1911,1912,1913],{"trials":21068,"activeCount":101},[],{"trials":21070,"activeCount":101},[],{"trials":21072,"activeCount":101},[],{"intervention":1912,"totalTrials":97,"cells":21074},{"EARLY_PHASE1":21075,"PHASE1":21077,"PHASE2":21079,"PHASE3":21085,"PHASE4":21087,"NA":21089},{"trials":21076,"activeCount":101},[],{"trials":21078,"activeCount":101},[],{"trials":21080,"activeCount":101},[21081],{"nctId":1901,"briefTitle":1902,"status":244,"phases":21082,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":21083,"interventions":21084},[89,90],[1908,1909],[1260,1911,1912,1913],{"trials":21086,"activeCount":101},[],{"trials":21088,"activeCount":101},[],{"trials":21090,"activeCount":101},[],{"intervention":1913,"totalTrials":97,"cells":21092},{"EARLY_PHASE1":21093,"PHASE1":21095,"PHASE2":21097,"PHASE3":21103,"PHASE4":21105,"NA":21107},{"trials":21094,"activeCount":101},[],{"trials":21096,"activeCount":101},[],{"trials":21098,"activeCount":101},[21099],{"nctId":1901,"briefTitle":1902,"status":244,"phases":21100,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":21101,"interventions":21102},[89,90],[1908,1909],[1260,1911,1912,1913],{"trials":21104,"activeCount":101},[],{"trials":21106,"activeCount":101},[],{"trials":21108,"activeCount":101},[],{"intervention":7658,"totalTrials":97,"cells":21110},{"EARLY_PHASE1":21111,"PHASE1":21113,"PHASE2":21115,"PHASE3":21121,"PHASE4":21123,"NA":21125},{"trials":21112,"activeCount":101},[],{"trials":21114,"activeCount":101},[],{"trials":21116,"activeCount":101},[21117],{"nctId":7651,"briefTitle":7652,"status":244,"phases":21118,"primaryCompletion":7654,"completion":7654,"start":7655,"enrollment":234,"conditions":21119,"interventions":21120},[90],[1695],[464,7658],{"trials":21122,"activeCount":101},[],{"trials":21124,"activeCount":101},[],{"trials":21126,"activeCount":101},[],{"intervention":21128,"totalTrials":97,"cells":21129},"3F8 monoclonal antibody and 13-cis-Retinoic Acid",{"EARLY_PHASE1":21130,"PHASE1":21132,"PHASE2":21134,"PHASE3":21142,"PHASE4":21144,"NA":21146},{"trials":21131,"activeCount":101},[],{"trials":21133,"activeCount":101},[],{"trials":21135,"activeCount":101},[21136],{"nctId":21137,"briefTitle":21138,"status":244,"phases":21139,"primaryCompletion":19772,"completion":19772,"start":4635,"enrollment":1114,"conditions":21140,"interventions":21141},"NCT01183416","High-Dose 3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation",[90],[215],[21128],{"trials":21143,"activeCount":101},[],{"trials":21145,"activeCount":101},[],{"trials":21147,"activeCount":101},[],{"intervention":21149,"totalTrials":97,"cells":21150},"bendamustine hcl",{"EARLY_PHASE1":21151,"PHASE1":21153,"PHASE2":21155,"PHASE3":21163,"PHASE4":21165,"NA":21167},{"trials":21152,"activeCount":101},[],{"trials":21154,"activeCount":101},[],{"trials":21156,"activeCount":101},[21157],{"nctId":21158,"briefTitle":21159,"status":244,"phases":21160,"primaryCompletion":5794,"completion":5794,"start":755,"enrollment":3344,"conditions":21161,"interventions":21162},"NCT00705250","Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma",[90],[1426,24],[21149],{"trials":21164,"activeCount":101},[],{"trials":21166,"activeCount":101},[],{"trials":21168,"activeCount":101},[],{"intervention":1668,"totalTrials":97,"cells":21170},{"EARLY_PHASE1":21171,"PHASE1":21173,"PHASE2":21175,"PHASE3":21181,"PHASE4":21183,"NA":21185},{"trials":21172,"activeCount":101},[],{"trials":21174,"activeCount":101},[],{"trials":21176,"activeCount":101},[21177],{"nctId":1660,"briefTitle":1661,"status":244,"phases":21178,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1665,"conditions":21179,"interventions":21180},[89,90],[971,15,36,1602,1586,783,21,30,18,1568],[1668,1023],{"trials":21182,"activeCount":101},[],{"trials":21184,"activeCount":101},[],{"trials":21186,"activeCount":101},[],{"intervention":21188,"totalTrials":97,"cells":21189},"gemcitabine and cisplatin plus sorafenib",{"EARLY_PHASE1":21190,"PHASE1":21192,"PHASE2":21194,"PHASE3":21203,"PHASE4":21205,"NA":21207},{"trials":21191,"activeCount":101},[],{"trials":21193,"activeCount":101},[],{"trials":21195,"activeCount":101},[21196],{"nctId":21197,"briefTitle":21198,"status":505,"phases":21199,"primaryCompletion":7779,"completion":7779,"start":5695,"enrollment":1094,"conditions":21200,"interventions":21202},"NCT00714948","Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma",[90],[971,21201],"URINARY BLADDER",[21188],{"trials":21204,"activeCount":101},[],{"trials":21206,"activeCount":101},[],{"trials":21208,"activeCount":101},[],{"intervention":18720,"totalTrials":97,"cells":21210},{"EARLY_PHASE1":21211,"PHASE1":21213,"PHASE2":21215,"PHASE3":21221,"PHASE4":21223,"NA":21225},{"trials":21212,"activeCount":101},[],{"trials":21214,"activeCount":101},[],{"trials":21216,"activeCount":101},[21217],{"nctId":18715,"briefTitle":18716,"status":244,"phases":21218,"primaryCompletion":3402,"completion":3402,"start":545,"conditions":21219,"interventions":21220},[90],[21],[9012,18698,18720],{"trials":21222,"activeCount":101},[],{"trials":21224,"activeCount":101},[],{"trials":21226,"activeCount":101},[],{"intervention":21228,"totalTrials":97,"cells":21229},"porfimer sodium",{"EARLY_PHASE1":21230,"PHASE1":21232,"PHASE2":21234,"PHASE3":21244,"PHASE4":21246,"NA":21248},{"trials":21231,"activeCount":101},[],{"trials":21233,"activeCount":101},[],{"trials":21235,"activeCount":101},[21236],{"nctId":21237,"briefTitle":21238,"status":244,"phases":21239,"primaryCompletion":21240,"completion":21240,"start":21241,"enrollment":1114,"conditions":21242,"interventions":21243},"NCT00003923","Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas",[90],"2002-02","1999-03",[1189,1190,2610,1226],[21228],{"trials":21245,"activeCount":101},[],{"trials":21247,"activeCount":101},[],{"trials":21249,"activeCount":101},[],{"intervention":21251,"totalTrials":97,"cells":21252},"3F8 and 13-cis-retinoic acid",{"EARLY_PHASE1":21253,"PHASE1":21255,"PHASE2":21257,"PHASE3":21266,"PHASE4":21268,"NA":21270},{"trials":21254,"activeCount":101},[],{"trials":21256,"activeCount":101},[],{"trials":21258,"activeCount":101},[21259],{"nctId":21260,"briefTitle":21261,"status":244,"phases":21262,"primaryCompletion":21263,"completion":21263,"start":20964,"enrollment":573,"conditions":21264,"interventions":21265},"NCT01183429","3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma",[90],"2018-09-13",[215],[21251],{"trials":21267,"activeCount":101},[],{"trials":21269,"activeCount":101},[],{"trials":21271,"activeCount":101},[],{"intervention":1097,"totalTrials":97,"cells":21273},{"EARLY_PHASE1":21274,"PHASE1":21276,"PHASE2":21278,"PHASE3":21284,"PHASE4":21286,"NA":21288},{"trials":21275,"activeCount":101},[],{"trials":21277,"activeCount":101},[],{"trials":21279,"activeCount":101},[21280],{"nctId":1089,"briefTitle":1090,"status":505,"phases":21281,"primaryCompletion":1092,"completion":1092,"start":1093,"enrollment":1094,"conditions":21282,"interventions":21283},[90],[971],[923,1097],{"trials":21285,"activeCount":101},[],{"trials":21287,"activeCount":101},[],{"trials":21289,"activeCount":101},[],{"intervention":21291,"totalTrials":97,"cells":21292},"sorafenib tosylate",{"EARLY_PHASE1":21293,"PHASE1":21295,"PHASE2":21297,"PHASE3":21305,"PHASE4":21307,"NA":21309},{"trials":21294,"activeCount":101},[],{"trials":21296,"activeCount":101},[],{"trials":21298,"activeCount":101},[21299],{"nctId":21300,"briefTitle":21301,"status":505,"phases":21302,"primaryCompletion":1424,"completion":1424,"start":3370,"enrollment":332,"conditions":21303,"interventions":21304},"NCT00522301","Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission",[90],[285,30,286],[21291],{"trials":21306,"activeCount":101},[],{"trials":21308,"activeCount":101},[],{"trials":21310,"activeCount":101},[],{"intervention":21312,"totalTrials":97,"cells":21313},"Everolimus and Intravesical Gemcitabine",{"EARLY_PHASE1":21314,"PHASE1":21316,"PHASE2":21318,"PHASE3":21327,"PHASE4":21329,"NA":21331},{"trials":21315,"activeCount":101},[],{"trials":21317,"activeCount":101},[],{"trials":21319,"activeCount":101},[21320],{"nctId":21321,"briefTitle":21322,"status":244,"phases":21323,"primaryCompletion":21324,"completion":21324,"start":15723,"enrollment":4866,"conditions":21325,"interventions":21326},"NCT01259063","RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder",[89,90],"2017-06",[971],[21312],{"trials":21328,"activeCount":101},[],{"trials":21330,"activeCount":101},[],{"trials":21332,"activeCount":101},[],{"intervention":21334,"totalTrials":97,"cells":21335},"Pralatrexate With Vitamin B12 and Folic Acid",{"EARLY_PHASE1":21336,"PHASE1":21338,"PHASE2":21340,"PHASE3":21348,"PHASE4":21350,"NA":21352},{"trials":21337,"activeCount":101},[],{"trials":21339,"activeCount":101},[],{"trials":21341,"activeCount":101},[21342],{"nctId":21343,"briefTitle":21344,"status":244,"phases":21345,"primaryCompletion":774,"completion":774,"start":4635,"enrollment":296,"conditions":21346,"interventions":21347},"NCT01183065","Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)",[90],[1586],[21334],{"trials":21349,"activeCount":101},[],{"trials":21351,"activeCount":101},[],{"trials":21353,"activeCount":101},[],{"intervention":21355,"totalTrials":97,"cells":21356},"temozolomide followed by high dose busulfan and thiotepa",{"EARLY_PHASE1":21357,"PHASE1":21359,"PHASE2":21361,"PHASE3":21370,"PHASE4":21372,"NA":21374},{"trials":21358,"activeCount":101},[],{"trials":21360,"activeCount":101},[],{"trials":21362,"activeCount":101},[21363],{"nctId":21364,"briefTitle":21365,"status":244,"phases":21366,"primaryCompletion":4350,"completion":4350,"start":1622,"enrollment":162,"conditions":21367,"interventions":21369},"NCT00588523","Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma",[90],[9565,21368],"CNS BRAIN",[21355],{"trials":21371,"activeCount":101},[],{"trials":21373,"activeCount":101},[],{"trials":21375,"activeCount":101},[],{"intervention":18081,"totalTrials":97,"cells":21377},{"EARLY_PHASE1":21378,"PHASE1":21380,"PHASE2":21382,"PHASE3":21388,"PHASE4":21390,"NA":21392},{"trials":21379,"activeCount":101},[],{"trials":21381,"activeCount":101},[],{"trials":21383,"activeCount":101},[21384],{"nctId":18076,"briefTitle":18077,"status":244,"phases":21385,"primaryCompletion":7408,"completion":7408,"start":5696,"enrollment":438,"conditions":21386,"interventions":21387},[89,90],[18],[1338,18081,18082],{"trials":21389,"activeCount":101},[],{"trials":21391,"activeCount":101},[],{"trials":21393,"activeCount":101},[],{"intervention":18082,"totalTrials":97,"cells":21395},{"EARLY_PHASE1":21396,"PHASE1":21398,"PHASE2":21400,"PHASE3":21406,"PHASE4":21408,"NA":21410},{"trials":21397,"activeCount":101},[],{"trials":21399,"activeCount":101},[],{"trials":21401,"activeCount":101},[21402],{"nctId":18076,"briefTitle":18077,"status":244,"phases":21403,"primaryCompletion":7408,"completion":7408,"start":5696,"enrollment":438,"conditions":21404,"interventions":21405},[89,90],[18],[1338,18081,18082],{"trials":21407,"activeCount":101},[],{"trials":21409,"activeCount":101},[],{"trials":21411,"activeCount":101},[],{"intervention":21413,"totalTrials":97,"cells":21414},"Trametinib 0.5 mg",{"EARLY_PHASE1":21415,"PHASE1":21417,"PHASE2":21419,"PHASE3":21435,"PHASE4":21437,"NA":21439},{"trials":21416,"activeCount":101},[],{"trials":21418,"activeCount":101},[],{"trials":21420,"activeCount":101},[21421],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21424,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21427,"interventions":21429},"NCT03704688","Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer",[89,90],"2022-02-04","2018-10-09",[3094,21428],"KRAS Gene Mutation",[21413,21430,21431,21432,21433,21434],"Trametinib 1 MG","Trametinib 1.5 MG","Trametinib 2 mg","Ponatinib 15 MG","Ponatinib 30 MG",{"trials":21436,"activeCount":101},[],{"trials":21438,"activeCount":101},[],{"trials":21440,"activeCount":101},[],{"intervention":21430,"totalTrials":97,"cells":21442},{"EARLY_PHASE1":21443,"PHASE1":21445,"PHASE2":21447,"PHASE3":21453,"PHASE4":21455,"NA":21457},{"trials":21444,"activeCount":101},[],{"trials":21446,"activeCount":101},[],{"trials":21448,"activeCount":101},[21449],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21450,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21451,"interventions":21452},[89,90],[3094,21428],[21413,21430,21431,21432,21433,21434],{"trials":21454,"activeCount":101},[],{"trials":21456,"activeCount":101},[],{"trials":21458,"activeCount":101},[],{"intervention":21431,"totalTrials":97,"cells":21460},{"EARLY_PHASE1":21461,"PHASE1":21463,"PHASE2":21465,"PHASE3":21471,"PHASE4":21473,"NA":21475},{"trials":21462,"activeCount":101},[],{"trials":21464,"activeCount":101},[],{"trials":21466,"activeCount":101},[21467],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21468,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21469,"interventions":21470},[89,90],[3094,21428],[21413,21430,21431,21432,21433,21434],{"trials":21472,"activeCount":101},[],{"trials":21474,"activeCount":101},[],{"trials":21476,"activeCount":101},[],{"intervention":21432,"totalTrials":97,"cells":21478},{"EARLY_PHASE1":21479,"PHASE1":21481,"PHASE2":21483,"PHASE3":21489,"PHASE4":21491,"NA":21493},{"trials":21480,"activeCount":101},[],{"trials":21482,"activeCount":101},[],{"trials":21484,"activeCount":101},[21485],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21486,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21487,"interventions":21488},[89,90],[3094,21428],[21413,21430,21431,21432,21433,21434],{"trials":21490,"activeCount":101},[],{"trials":21492,"activeCount":101},[],{"trials":21494,"activeCount":101},[],{"intervention":21433,"totalTrials":97,"cells":21496},{"EARLY_PHASE1":21497,"PHASE1":21499,"PHASE2":21501,"PHASE3":21507,"PHASE4":21509,"NA":21511},{"trials":21498,"activeCount":101},[],{"trials":21500,"activeCount":101},[],{"trials":21502,"activeCount":101},[21503],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21504,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21505,"interventions":21506},[89,90],[3094,21428],[21413,21430,21431,21432,21433,21434],{"trials":21508,"activeCount":101},[],{"trials":21510,"activeCount":101},[],{"trials":21512,"activeCount":101},[],{"intervention":21434,"totalTrials":97,"cells":21514},{"EARLY_PHASE1":21515,"PHASE1":21517,"PHASE2":21519,"PHASE3":21525,"PHASE4":21527,"NA":21529},{"trials":21516,"activeCount":101},[],{"trials":21518,"activeCount":101},[],{"trials":21520,"activeCount":101},[21521],{"nctId":21422,"briefTitle":21423,"status":244,"phases":21522,"primaryCompletion":21425,"completion":21425,"start":21426,"enrollment":283,"conditions":21523,"interventions":21524},[89,90],[3094,21428],[21413,21430,21431,21432,21433,21434],{"trials":21526,"activeCount":101},[],{"trials":21528,"activeCount":101},[],{"trials":21530,"activeCount":101},[],{"intervention":21532,"totalTrials":97,"cells":21533},"XmAb23104",{"EARLY_PHASE1":21534,"PHASE1":21536,"PHASE2":21538,"PHASE3":21546,"PHASE4":21548,"NA":21550},{"trials":21535,"activeCount":101},[],{"trials":21537,"activeCount":101},[],{"trials":21539,"activeCount":101},[21540],{"nctId":21541,"briefTitle":21542,"status":505,"phases":21543,"primaryCompletion":18583,"completion":18583,"start":2629,"enrollment":332,"conditions":21544,"interventions":21545},"NCT05879185","A Study of XmAb23104 in People With Sarcoma",[90],[33],[21532],{"trials":21547,"activeCount":101},[],{"trials":21549,"activeCount":101},[],{"trials":21551,"activeCount":101},[],{"intervention":21553,"totalTrials":97,"cells":21554},"motexafin gadolinium",{"EARLY_PHASE1":21555,"PHASE1":21557,"PHASE2":21559,"PHASE3":21567,"PHASE4":21569,"NA":21571},{"trials":21556,"activeCount":101},[],{"trials":21558,"activeCount":101},[],{"trials":21560,"activeCount":101},[21561],{"nctId":21562,"briefTitle":21563,"status":244,"phases":21564,"primaryCompletion":856,"completion":856,"start":3101,"conditions":21565,"interventions":21566},"NCT00022256","Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90],[3259],[21553],{"trials":21568,"activeCount":101},[],{"trials":21570,"activeCount":101},[],{"trials":21572,"activeCount":101},[],{"intervention":21574,"totalTrials":97,"cells":21575},"Systemic Therapy",{"EARLY_PHASE1":21576,"PHASE1":21578,"PHASE2":21580,"PHASE3":21590,"PHASE4":21592,"NA":21594},{"trials":21577,"activeCount":101},[],{"trials":21579,"activeCount":101},[],{"trials":21581,"activeCount":101},[21582],{"nctId":21583,"briefTitle":21584,"status":244,"phases":21585,"primaryCompletion":6712,"completion":6712,"start":21586,"enrollment":10064,"conditions":21587,"interventions":21589},"NCT03523351","Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain",[89,90],"2018-05-01",[21588],"Metastatic Solid Tumors of Metastatic Disease",[21574],{"trials":21591,"activeCount":101},[],{"trials":21593,"activeCount":101},[],{"trials":21595,"activeCount":101},[],{"intervention":21597,"totalTrials":97,"cells":21598},"Carvedilol",{"EARLY_PHASE1":21599,"PHASE1":21601,"PHASE2":21603,"PHASE3":21612,"PHASE4":21614,"NA":21616},{"trials":21600,"activeCount":101},[],{"trials":21602,"activeCount":101},[],{"trials":21604,"activeCount":101},[21605],{"nctId":21606,"briefTitle":21607,"status":244,"phases":21608,"primaryCompletion":9062,"completion":9062,"start":21609,"enrollment":705,"conditions":21610,"interventions":21611},"NCT02177175","Carvedilol for the Prevention of Anthracycline\u002FAnti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification",[90],"2014-06-24",[15],[21597],{"trials":21613,"activeCount":101},[],{"trials":21615,"activeCount":101},[],{"trials":21617,"activeCount":101},[],{"intervention":21619,"totalTrials":97,"cells":21620},"Temsirolimus and Sorafenib",{"EARLY_PHASE1":21621,"PHASE1":21623,"PHASE2":21625,"PHASE3":21635,"PHASE4":21637,"NA":21639},{"trials":21622,"activeCount":101},[],{"trials":21624,"activeCount":101},[],{"trials":21626,"activeCount":101},[21627],{"nctId":21628,"briefTitle":21629,"status":244,"phases":21630,"primaryCompletion":21631,"completion":21631,"start":21632,"enrollment":1883,"conditions":21633,"interventions":21634},"NCT01025453","Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer",[90],"2018-01-16","2009-12-01",[4054],[21619],{"trials":21636,"activeCount":101},[],{"trials":21638,"activeCount":101},[],{"trials":21640,"activeCount":101},[],{"intervention":21642,"totalTrials":97,"cells":21643},"durvalumab and tremelimumab",{"EARLY_PHASE1":21644,"PHASE1":21646,"PHASE2":21648,"PHASE3":21662,"PHASE4":21664,"NA":21666},{"trials":21645,"activeCount":101},[],{"trials":21647,"activeCount":101},[],{"trials":21649,"activeCount":101},[21650],{"nctId":21651,"briefTitle":21652,"status":244,"phases":21653,"primaryCompletion":21654,"completion":21654,"start":21655,"enrollment":1871,"conditions":21656,"interventions":21661},"NCT03430895","Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract",[90],"2021-02-10","2018-01-31",[21657,21658,21659,21660,972],"Non-Transitional Cell Carcinoma of the Urothelial Tract","Small Cell of the Bladder","Adenocarcinoma of the Bladder","Squamous Cell Carcinoma of the Bladder",[21642],{"trials":21663,"activeCount":101},[],{"trials":21665,"activeCount":101},[],{"trials":21667,"activeCount":101},[],{"intervention":21669,"totalTrials":97,"cells":21670},"amonafide dihydrochloride",{"EARLY_PHASE1":21671,"PHASE1":21673,"PHASE2":21675,"PHASE3":21683,"PHASE4":21685,"NA":21687},{"trials":21672,"activeCount":101},[],{"trials":21674,"activeCount":101},[],{"trials":21676,"activeCount":101},[21677],{"nctId":21678,"briefTitle":21679,"status":244,"phases":21680,"completion":339,"start":737,"conditions":21681,"interventions":21682},"NCT00074100","Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy",[90],[15],[21669],{"trials":21684,"activeCount":101},[],{"trials":21686,"activeCount":101},[],{"trials":21688,"activeCount":101},[],{"intervention":21690,"totalTrials":97,"cells":21691},"EBV-specific T-cells",{"EARLY_PHASE1":21692,"PHASE1":21694,"PHASE2":21696,"PHASE3":21708,"PHASE4":21710,"NA":21712},{"trials":21693,"activeCount":101},[],{"trials":21695,"activeCount":101},[],{"trials":21697,"activeCount":101},[21698],{"nctId":21699,"briefTitle":21700,"status":2832,"phases":21701,"primaryCompletion":21702,"completion":21702,"start":21703,"enrollment":101,"conditions":21704,"interventions":21707},"NCT03988582","Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies",[90],"2020-06-08","2019-06-11",[21705,21706],"EBV Lymphomas","EBV-associated Malignancies",[21690],{"trials":21709,"activeCount":101},[],{"trials":21711,"activeCount":101},[],{"trials":21713,"activeCount":101},[],{"intervention":21715,"totalTrials":97,"cells":21716},"arzoxifene hydrochloride",{"EARLY_PHASE1":21717,"PHASE1":21719,"PHASE2":21721,"PHASE3":21729,"PHASE4":21731,"NA":21733},{"trials":21718,"activeCount":101},[],{"trials":21720,"activeCount":101},[],{"trials":21722,"activeCount":101},[21723],{"nctId":21724,"briefTitle":21725,"status":244,"phases":21726,"primaryCompletion":898,"completion":898,"start":9009,"enrollment":7619,"conditions":21727,"interventions":21728},"NCT00003428","Hormone Therapy in Treating Women With Breast Cancer",[90],[15],[21715],{"trials":21730,"activeCount":101},[],{"trials":21732,"activeCount":101},[],{"trials":21734,"activeCount":101},[],{"intervention":21736,"totalTrials":97,"cells":21737},"Palbociclib 200mg",{"EARLY_PHASE1":21738,"PHASE1":21740,"PHASE2":21742,"PHASE3":21753,"PHASE4":21755,"NA":21757},{"trials":21739,"activeCount":101},[],{"trials":21741,"activeCount":101},[],{"trials":21743,"activeCount":101},[21744],{"nctId":21745,"briefTitle":21746,"status":244,"phases":21747,"primaryCompletion":21748,"completion":21748,"start":21749,"enrollment":10853,"conditions":21750,"interventions":21751},"NCT01209598","PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma",[90],"2016-10-25","2010-09-23",[33,6676],[21736,21752],"Palbociclib 125mg",{"trials":21754,"activeCount":101},[],{"trials":21756,"activeCount":101},[],{"trials":21758,"activeCount":101},[],{"intervention":21752,"totalTrials":97,"cells":21760},{"EARLY_PHASE1":21761,"PHASE1":21763,"PHASE2":21765,"PHASE3":21771,"PHASE4":21773,"NA":21775},{"trials":21762,"activeCount":101},[],{"trials":21764,"activeCount":101},[],{"trials":21766,"activeCount":101},[21767],{"nctId":21745,"briefTitle":21746,"status":244,"phases":21768,"primaryCompletion":21748,"completion":21748,"start":21749,"enrollment":10853,"conditions":21769,"interventions":21770},[90],[33,6676],[21736,21752],{"trials":21772,"activeCount":101},[],{"trials":21774,"activeCount":101},[],{"trials":21776,"activeCount":101},[],{"intervention":21778,"totalTrials":97,"cells":21779},"embolization therapy",{"EARLY_PHASE1":21780,"PHASE1":21782,"PHASE2":21784,"PHASE3":21792,"PHASE4":21794,"NA":21796},{"trials":21781,"activeCount":101},[],{"trials":21783,"activeCount":101},[],{"trials":21785,"activeCount":101},[21786],{"nctId":21787,"briefTitle":21788,"status":244,"phases":21789,"primaryCompletion":470,"completion":470,"start":756,"conditions":21790,"interventions":21791},"NCT00028626","Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer",[90],[36,2349],[21778],{"trials":21793,"activeCount":101},[],{"trials":21795,"activeCount":101},[],{"trials":21797,"activeCount":101},[],{"intervention":21799,"totalTrials":97,"cells":21800},"paclitaxel poliglumex",{"EARLY_PHASE1":21801,"PHASE1":21803,"PHASE2":21805,"PHASE3":21813,"PHASE4":21815,"NA":21817},{"trials":21802,"activeCount":101},[],{"trials":21804,"activeCount":101},[],{"trials":21806,"activeCount":101},[21807],{"nctId":21808,"briefTitle":21809,"status":244,"phases":21810,"primaryCompletion":1610,"completion":588,"start":7408,"conditions":21811,"interventions":21812},"NCT00017017","CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer",[89,90],[285,30,286],[21799],{"trials":21814,"activeCount":101},[],{"trials":21816,"activeCount":101},[],{"trials":21818,"activeCount":101},[],{"intervention":3737,"totalTrials":97,"cells":21820},{"EARLY_PHASE1":21821,"PHASE1":21823,"PHASE2":21825,"PHASE3":21831,"PHASE4":21833,"NA":21835},{"trials":21822,"activeCount":101},[],{"trials":21824,"activeCount":101},[],{"trials":21826,"activeCount":101},[21827],{"nctId":3730,"briefTitle":3731,"status":244,"phases":21828,"primaryCompletion":3733,"completion":3733,"start":704,"enrollment":1412,"conditions":21829,"interventions":21830},[90],[308],[3736,463,3737],{"trials":21832,"activeCount":101},[],{"trials":21834,"activeCount":101},[],{"trials":21836,"activeCount":101},[],{"intervention":21838,"totalTrials":97,"cells":21839},"BEZ235",{"EARLY_PHASE1":21840,"PHASE1":21842,"PHASE2":21844,"PHASE3":21852,"PHASE4":21854,"NA":21856},{"trials":21841,"activeCount":101},[],{"trials":21843,"activeCount":101},[],{"trials":21845,"activeCount":101},[21846],{"nctId":21847,"briefTitle":21848,"status":505,"phases":21849,"primaryCompletion":774,"completion":774,"start":1642,"enrollment":1434,"conditions":21850,"interventions":21851},"NCT01453595","BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)",[89,90],[12981],[21838],{"trials":21853,"activeCount":101},[],{"trials":21855,"activeCount":101},[],{"trials":21857,"activeCount":101},[],{"intervention":21859,"totalTrials":97,"cells":21860},"Jet injection of ALA",{"EARLY_PHASE1":21861,"PHASE1":21863,"PHASE2":21865,"PHASE3":21877,"PHASE4":21879,"NA":21881},{"trials":21862,"activeCount":101},[],{"trials":21864,"activeCount":101},[],{"trials":21866,"activeCount":101},[21867],{"nctId":21868,"briefTitle":21869,"status":244,"phases":21870,"primaryCompletion":5015,"completion":5015,"start":21871,"enrollment":1447,"conditions":21872,"interventions":21876},"NCT04552990","Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma",[90],"2020-09-09",[2339,2340,2338,21873,21874,21875],"Basal Cell Cancer","Superficial Basal Cell Carcinoma","Nodular Basal Cell Carcinoma",[21859],{"trials":21878,"activeCount":101},[],{"trials":21880,"activeCount":101},[],{"trials":21882,"activeCount":101},[],{"intervention":21884,"totalTrials":97,"cells":21885},"inactivated influenza vaccine and the 23- valent pneumococcal vaccine",{"EARLY_PHASE1":21886,"PHASE1":21888,"PHASE2":21890,"PHASE3":21899,"PHASE4":21901,"NA":21903},{"trials":21887,"activeCount":101},[],{"trials":21889,"activeCount":101},[],{"trials":21891,"activeCount":101},[21892],{"nctId":21893,"briefTitle":21894,"status":244,"phases":21895,"primaryCompletion":8810,"completion":8810,"start":1266,"enrollment":16825,"conditions":21896,"interventions":21897},"NCT00741039","Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older",[90],[15,21,18],[21884,21898],"inactivated influenza vaccine and the PPV23 vaccine",{"trials":21900,"activeCount":101},[],{"trials":21902,"activeCount":101},[],{"trials":21904,"activeCount":101},[],{"intervention":21898,"totalTrials":97,"cells":21906},{"EARLY_PHASE1":21907,"PHASE1":21909,"PHASE2":21911,"PHASE3":21917,"PHASE4":21919,"NA":21921},{"trials":21908,"activeCount":101},[],{"trials":21910,"activeCount":101},[],{"trials":21912,"activeCount":101},[21913],{"nctId":21893,"briefTitle":21894,"status":244,"phases":21914,"primaryCompletion":8810,"completion":8810,"start":1266,"enrollment":16825,"conditions":21915,"interventions":21916},[90],[15,21,18],[21884,21898],{"trials":21918,"activeCount":101},[],{"trials":21920,"activeCount":101},[],{"trials":21922,"activeCount":101},[],{"intervention":21924,"totalTrials":97,"cells":21925},"vitamin D repletion with Cholecalciferol",{"EARLY_PHASE1":21926,"PHASE1":21928,"PHASE2":21930,"PHASE3":21939,"PHASE4":21941,"NA":21943},{"trials":21927,"activeCount":101},[],{"trials":21929,"activeCount":101},[],{"trials":21931,"activeCount":101},[21932],{"nctId":21933,"briefTitle":21934,"status":244,"phases":21935,"primaryCompletion":1012,"completion":1012,"start":21936,"enrollment":341,"conditions":21937,"interventions":21938},"NCT01074216","Vitamin D Levels in Stage IV Colorectal Cancer Patients",[90],"2010-02",[36],[21924],{"trials":21940,"activeCount":101},[],{"trials":21942,"activeCount":101},[],{"trials":21944,"activeCount":101},[],{"intervention":9748,"totalTrials":97,"cells":21946},{"EARLY_PHASE1":21947,"PHASE1":21949,"PHASE2":21951,"PHASE3":21957,"PHASE4":21959,"NA":21961},{"trials":21948,"activeCount":101},[],{"trials":21950,"activeCount":101},[],{"trials":21952,"activeCount":101},[21953],{"nctId":9740,"briefTitle":9741,"status":244,"phases":21954,"primaryCompletion":5977,"completion":5977,"start":9743,"enrollment":3017,"conditions":21955,"interventions":21956},[90],[9745,9746],[9724,9748],{"trials":21958,"activeCount":101},[],{"trials":21960,"activeCount":101},[],{"trials":21962,"activeCount":101},[],{"intervention":21964,"totalTrials":97,"cells":21965},"Docetaxel, Leucovorin, Fluorouracil, Cisplatin",{"EARLY_PHASE1":21966,"PHASE1":21968,"PHASE2":21970,"PHASE3":21982,"PHASE4":21984,"NA":21986},{"trials":21967,"activeCount":101},[],{"trials":21969,"activeCount":101},[],{"trials":21971,"activeCount":101},[21972],{"nctId":21973,"briefTitle":21974,"status":244,"phases":21975,"primaryCompletion":21976,"completion":21976,"start":21977,"enrollment":590,"conditions":21978,"interventions":21979},"NCT00515411","Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",[90],"2018-10-26","2006-10-23",[2398,1613],[21964,21980,21981],"Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen","Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab",{"trials":21983,"activeCount":101},[],{"trials":21985,"activeCount":101},[],{"trials":21987,"activeCount":101},[],{"intervention":21980,"totalTrials":97,"cells":21989},{"EARLY_PHASE1":21990,"PHASE1":21992,"PHASE2":21994,"PHASE3":22000,"PHASE4":22002,"NA":22004},{"trials":21991,"activeCount":101},[],{"trials":21993,"activeCount":101},[],{"trials":21995,"activeCount":101},[21996],{"nctId":21973,"briefTitle":21974,"status":244,"phases":21997,"primaryCompletion":21976,"completion":21976,"start":21977,"enrollment":590,"conditions":21998,"interventions":21999},[90],[2398,1613],[21964,21980,21981],{"trials":22001,"activeCount":101},[],{"trials":22003,"activeCount":101},[],{"trials":22005,"activeCount":101},[],{"intervention":21981,"totalTrials":97,"cells":22007},{"EARLY_PHASE1":22008,"PHASE1":22010,"PHASE2":22012,"PHASE3":22018,"PHASE4":22020,"NA":22022},{"trials":22009,"activeCount":101},[],{"trials":22011,"activeCount":101},[],{"trials":22013,"activeCount":101},[22014],{"nctId":21973,"briefTitle":21974,"status":244,"phases":22015,"primaryCompletion":21976,"completion":21976,"start":21977,"enrollment":590,"conditions":22016,"interventions":22017},[90],[2398,1613],[21964,21980,21981],{"trials":22019,"activeCount":101},[],{"trials":22021,"activeCount":101},[],{"trials":22023,"activeCount":101},[],{"intervention":22025,"totalTrials":97,"cells":22026},"lenalidomide and dexamethasone",{"EARLY_PHASE1":22027,"PHASE1":22029,"PHASE2":22031,"PHASE3":22040,"PHASE4":22042,"NA":22044},{"trials":22028,"activeCount":101},[],{"trials":22030,"activeCount":101},[],{"trials":22032,"activeCount":101},[22033],{"nctId":22034,"briefTitle":22035,"status":244,"phases":22036,"primaryCompletion":1993,"completion":1993,"start":22037,"enrollment":10655,"conditions":22038,"interventions":22039},"NCT00807599","Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L",[90],"2008-12-10",[308],[22025],{"trials":22041,"activeCount":101},[],{"trials":22043,"activeCount":101},[],{"trials":22045,"activeCount":101},[],{"intervention":5278,"totalTrials":97,"cells":22047},{"EARLY_PHASE1":22048,"PHASE1":22050,"PHASE2":22052,"PHASE3":22058,"PHASE4":22060,"NA":22062},{"trials":22049,"activeCount":101},[],{"trials":22051,"activeCount":101},[],{"trials":22053,"activeCount":101},[22054],{"nctId":5271,"briefTitle":5272,"status":244,"phases":22055,"primaryCompletion":5274,"completion":5274,"start":1141,"enrollment":306,"conditions":22056,"interventions":22057},[90],[5276],[1595,984,5278,3898],{"trials":22059,"activeCount":101},[],{"trials":22061,"activeCount":101},[],{"trials":22063,"activeCount":101},[],{"intervention":22065,"totalTrials":97,"cells":22066},"Bevacizumab HAI plus systemic chemotherapy",{"EARLY_PHASE1":22067,"PHASE1":22069,"PHASE2":22071,"PHASE3":22083,"PHASE4":22085,"NA":22087},{"trials":22068,"activeCount":101},[],{"trials":22070,"activeCount":101},[],{"trials":22072,"activeCount":101},[22073],{"nctId":22074,"briefTitle":22075,"status":244,"phases":22076,"primaryCompletion":22077,"completion":22077,"start":22078,"enrollment":3003,"conditions":22079,"interventions":22081},"NCT00200200","Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With\u002FWithout Bevacizumab for Hepatic Metastases From Colorectal Cancer",[90],"2025-03-13","2004-11-19",[22080,16135,5080],"Hepatic Metastases",[22065,22082],"HAI plus systemic chemotherapy",{"trials":22084,"activeCount":101},[],{"trials":22086,"activeCount":101},[],{"trials":22088,"activeCount":101},[],{"intervention":22082,"totalTrials":97,"cells":22090},{"EARLY_PHASE1":22091,"PHASE1":22093,"PHASE2":22095,"PHASE3":22101,"PHASE4":22103,"NA":22105},{"trials":22092,"activeCount":101},[],{"trials":22094,"activeCount":101},[],{"trials":22096,"activeCount":101},[22097],{"nctId":22074,"briefTitle":22075,"status":244,"phases":22098,"primaryCompletion":22077,"completion":22077,"start":22078,"enrollment":3003,"conditions":22099,"interventions":22100},[90],[22080,16135,5080],[22065,22082],{"trials":22102,"activeCount":101},[],{"trials":22104,"activeCount":101},[],{"trials":22106,"activeCount":101},[],{"intervention":22108,"totalTrials":97,"cells":22109},"ZW25",{"EARLY_PHASE1":22110,"PHASE1":22112,"PHASE2":22114,"PHASE3":22124,"PHASE4":22126,"NA":22128},{"trials":22111,"activeCount":101},[],{"trials":22113,"activeCount":101},[],{"trials":22115,"activeCount":101},[22116],{"nctId":22117,"briefTitle":22118,"status":244,"phases":22119,"primaryCompletion":22120,"completion":22120,"start":22121,"enrollment":1447,"conditions":22122,"interventions":22123},"NCT04513665","ZW25 in Women With Endometrial Cancers",[90],"2024-03-08","2020-08-12",[3359,2765],[22108],{"trials":22125,"activeCount":101},[],{"trials":22127,"activeCount":101},[],{"trials":22129,"activeCount":101},[],{"intervention":2837,"totalTrials":97,"cells":22131},{"EARLY_PHASE1":22132,"PHASE1":22134,"PHASE2":22136,"PHASE3":22142,"PHASE4":22144,"NA":22146},{"trials":22133,"activeCount":101},[],{"trials":22135,"activeCount":101},[],{"trials":22137,"activeCount":101},[22138],{"nctId":2830,"briefTitle":2831,"status":2832,"phases":22139,"primaryCompletion":2834,"completion":2834,"start":1895,"enrollment":101,"conditions":22140,"interventions":22141},[90],[36],[2837,942],{"trials":22143,"activeCount":101},[],{"trials":22145,"activeCount":101},[],{"trials":22147,"activeCount":101},[],{"intervention":22149,"totalTrials":97,"cells":22150},"BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF",{"EARLY_PHASE1":22151,"PHASE1":22153,"PHASE2":22155,"PHASE3":22164,"PHASE4":22166,"NA":22168},{"trials":22152,"activeCount":101},[],{"trials":22154,"activeCount":101},[],{"trials":22156,"activeCount":101},[22157],{"nctId":22158,"briefTitle":22159,"status":244,"phases":22160,"primaryCompletion":4819,"completion":1014,"start":4751,"enrollment":22,"conditions":22161,"interventions":22163},"NCT00582933","Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor",[90],[27,416,707,22162],"Allogeneic Marrow Transplant",[22149,22149,22149],{"trials":22165,"activeCount":101},[],{"trials":22167,"activeCount":101},[],{"trials":22169,"activeCount":101},[],{"intervention":22171,"totalTrials":97,"cells":22172},"PEG-interferon alfa-2b",{"EARLY_PHASE1":22173,"PHASE1":22175,"PHASE2":22177,"PHASE3":22185,"PHASE4":22187,"NA":22189},{"trials":22174,"activeCount":101},[],{"trials":22176,"activeCount":101},[],{"trials":22178,"activeCount":101},[22179],{"nctId":22180,"briefTitle":22181,"status":244,"phases":22182,"primaryCompletion":1621,"completion":1621,"start":1566,"conditions":22183,"interventions":22184},"NCT00045279","PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer",[90],[783],[22171],{"trials":22186,"activeCount":101},[],{"trials":22188,"activeCount":101},[],{"trials":22190,"activeCount":101},[],{"intervention":699,"totalTrials":97,"cells":22192},{"EARLY_PHASE1":22193,"PHASE1":22195,"PHASE2":22197,"PHASE3":22203,"PHASE4":22205,"NA":22207},{"trials":22194,"activeCount":101},[],{"trials":22196,"activeCount":101},[],{"trials":22198,"activeCount":101},[22199],{"nctId":692,"briefTitle":693,"status":244,"phases":22200,"primaryCompletion":695,"completion":695,"start":696,"conditions":22201,"interventions":22202},[90],[27,24],[641,202,361,642,643,346,391,362,478,699,479,349],{"trials":22204,"activeCount":101},[],{"trials":22206,"activeCount":101},[],{"trials":22208,"activeCount":101},[],{"intervention":22210,"totalTrials":97,"cells":22211},"Immunization Schedule patients \u003C7 years.",{"EARLY_PHASE1":22212,"PHASE1":22214,"PHASE2":22216,"PHASE3":22231,"PHASE4":22233,"NA":22235},{"trials":22213,"activeCount":101},[],{"trials":22215,"activeCount":101},[],{"trials":22217,"activeCount":101},[22218],{"nctId":22219,"briefTitle":22220,"status":244,"phases":22221,"primaryCompletion":22222,"completion":22222,"start":22223,"enrollment":22224,"conditions":22225,"interventions":22228},"NCT00505063","Prospective Trial of Vaccine Responses in Childhood Cancer Survivors",[90],"2025-06-11","2007-07-10",76,[22226,22227],"Childhood Cancer","Multiple Diseases",[22210,22229,22230],"Immunization Schedule patients > or = to 7 years and \u003C11 years of age","Immunization Schedule patients > or = to 11 years of age",{"trials":22232,"activeCount":101},[],{"trials":22234,"activeCount":101},[],{"trials":22236,"activeCount":101},[],{"intervention":22229,"totalTrials":97,"cells":22238},{"EARLY_PHASE1":22239,"PHASE1":22241,"PHASE2":22243,"PHASE3":22249,"PHASE4":22251,"NA":22253},{"trials":22240,"activeCount":101},[],{"trials":22242,"activeCount":101},[],{"trials":22244,"activeCount":101},[22245],{"nctId":22219,"briefTitle":22220,"status":244,"phases":22246,"primaryCompletion":22222,"completion":22222,"start":22223,"enrollment":22224,"conditions":22247,"interventions":22248},[90],[22226,22227],[22210,22229,22230],{"trials":22250,"activeCount":101},[],{"trials":22252,"activeCount":101},[],{"trials":22254,"activeCount":101},[],{"intervention":22230,"totalTrials":97,"cells":22256},{"EARLY_PHASE1":22257,"PHASE1":22259,"PHASE2":22261,"PHASE3":22267,"PHASE4":22269,"NA":22271},{"trials":22258,"activeCount":101},[],{"trials":22260,"activeCount":101},[],{"trials":22262,"activeCount":101},[22263],{"nctId":22219,"briefTitle":22220,"status":244,"phases":22264,"primaryCompletion":22222,"completion":22222,"start":22223,"enrollment":22224,"conditions":22265,"interventions":22266},[90],[22226,22227],[22210,22229,22230],{"trials":22268,"activeCount":101},[],{"trials":22270,"activeCount":101},[],{"trials":22272,"activeCount":101},[],{"intervention":22274,"totalTrials":97,"cells":22275},"LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU",{"EARLY_PHASE1":22276,"PHASE1":22278,"PHASE2":22280,"PHASE3":22288,"PHASE4":22290,"NA":22292},{"trials":22277,"activeCount":101},[],{"trials":22279,"activeCount":101},[],{"trials":22281,"activeCount":101},[22282],{"nctId":22283,"briefTitle":22284,"status":244,"phases":22285,"primaryCompletion":1423,"completion":1423,"start":781,"enrollment":234,"conditions":22286,"interventions":22287},"NCT00610883","LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma",[90],[707],[22274],{"trials":22289,"activeCount":101},[],{"trials":22291,"activeCount":101},[],{"trials":22293,"activeCount":101},[],{"intervention":22295,"totalTrials":97,"cells":22296},"Carboplatin Hyperthermic Intraperitoneal Chemotherapy",{"EARLY_PHASE1":22297,"PHASE1":22299,"PHASE2":22301,"PHASE3":22312,"PHASE4":22314,"NA":22316},{"trials":22298,"activeCount":101},[],{"trials":22300,"activeCount":101},[],{"trials":22302,"activeCount":101},[22303],{"nctId":22304,"briefTitle":22305,"status":244,"phases":22306,"primaryCompletion":9311,"completion":9311,"start":22307,"enrollment":20288,"conditions":22308,"interventions":22310},"NCT01767675","Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2013-01-08",[30,22309,3437],"Fallopian Tubes Cancer",[22295,22311,22311],"platinum-based systemic chemotherapy postoperatively",{"trials":22313,"activeCount":101},[],{"trials":22315,"activeCount":101},[],{"trials":22317,"activeCount":101},[],{"intervention":22311,"totalTrials":97,"cells":22319},{"EARLY_PHASE1":22320,"PHASE1":22322,"PHASE2":22324,"PHASE3":22330,"PHASE4":22332,"NA":22334},{"trials":22321,"activeCount":101},[],{"trials":22323,"activeCount":101},[],{"trials":22325,"activeCount":101},[22326],{"nctId":22304,"briefTitle":22305,"status":244,"phases":22327,"primaryCompletion":9311,"completion":9311,"start":22307,"enrollment":20288,"conditions":22328,"interventions":22329},[90],[30,22309,3437],[22295,22311,22311],{"trials":22331,"activeCount":101},[],{"trials":22333,"activeCount":101},[],{"trials":22335,"activeCount":101},[],{"intervention":22337,"totalTrials":97,"cells":22338},"epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan",{"EARLY_PHASE1":22339,"PHASE1":22341,"PHASE2":22343,"PHASE3":22351,"PHASE4":22353,"NA":22355},{"trials":22340,"activeCount":101},[],{"trials":22342,"activeCount":101},[],{"trials":22344,"activeCount":101},[22345],{"nctId":22346,"briefTitle":22347,"status":244,"phases":22348,"primaryCompletion":891,"completion":891,"start":1266,"enrollment":2483,"conditions":22349,"interventions":22350},"NCT00737438","Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma",[90],[1602,1613],[22337],{"trials":22352,"activeCount":101},[],{"trials":22354,"activeCount":101},[],{"trials":22356,"activeCount":101},[],{"intervention":731,"totalTrials":97,"cells":22358},{"EARLY_PHASE1":22359,"PHASE1":22361,"PHASE2":22363,"PHASE3":22369,"PHASE4":22371,"NA":22373},{"trials":22360,"activeCount":101},[],{"trials":22362,"activeCount":101},[],{"trials":22364,"activeCount":101},[22365],{"nctId":724,"briefTitle":725,"status":244,"phases":22366,"primaryCompletion":727,"completion":727,"start":728,"enrollment":454,"conditions":22367,"interventions":22368},[89,90],[24],[288,731,390,202,345,346,442,445,349],{"trials":22370,"activeCount":101},[],{"trials":22372,"activeCount":101},[],{"trials":22374,"activeCount":101},[],{"intervention":5594,"totalTrials":97,"cells":22376},{"EARLY_PHASE1":22377,"PHASE1":22379,"PHASE2":22381,"PHASE3":22387,"PHASE4":22389,"NA":22391},{"trials":22378,"activeCount":101},[],{"trials":22380,"activeCount":101},[],{"trials":22382,"activeCount":101},[22383],{"nctId":5589,"briefTitle":5590,"status":244,"phases":22384,"primaryCompletion":1014,"completion":1014,"start":554,"enrollment":1152,"conditions":22385,"interventions":22386},[90],[27,24,828,475,476],[5594,403,404,444],{"trials":22388,"activeCount":101},[],{"trials":22390,"activeCount":101},[],{"trials":22392,"activeCount":101},[],{"intervention":22394,"totalTrials":97,"cells":22395},"AG-013736",{"EARLY_PHASE1":22396,"PHASE1":22398,"PHASE2":22400,"PHASE3":22409,"PHASE4":22411,"NA":22413},{"trials":22397,"activeCount":101},[],{"trials":22399,"activeCount":101},[],{"trials":22401,"activeCount":101},[22402],{"nctId":22403,"briefTitle":22404,"status":244,"phases":22405,"primaryCompletion":22406,"completion":22406,"start":16614,"enrollment":4866,"conditions":22407,"interventions":22408},"NCT01558661","Axitinib (AG-013736) in Patients With Progressive, Recurrent\u002FMetastatic Adenoid Cystic Carcinoma",[90],"2016-08",[2409],[22394],{"trials":22410,"activeCount":101},[],{"trials":22412,"activeCount":101},[],{"trials":22414,"activeCount":101},[],{"intervention":9013,"totalTrials":97,"cells":22416},{"EARLY_PHASE1":22417,"PHASE1":22419,"PHASE2":22421,"PHASE3":22427,"PHASE4":22429,"NA":22431},{"trials":22418,"activeCount":101},[],{"trials":22420,"activeCount":101},[],{"trials":22422,"activeCount":101},[22423],{"nctId":9006,"briefTitle":9007,"status":244,"phases":22424,"primaryCompletion":7408,"completion":7408,"start":9009,"conditions":22425,"interventions":22426},[90],[4734],[9012,9013,8956,360,9014],{"trials":22428,"activeCount":101},[],{"trials":22430,"activeCount":101},[],{"trials":22432,"activeCount":101},[],{"intervention":22434,"totalTrials":97,"cells":22435},"89Zr-DFO-huJ591",{"EARLY_PHASE1":22436,"PHASE1":22438,"PHASE2":22440,"PHASE3":22450,"PHASE4":22452,"NA":22454},{"trials":22437,"activeCount":101},[],{"trials":22439,"activeCount":101},[],{"trials":22441,"activeCount":101},[22442],{"nctId":22443,"briefTitle":22444,"status":244,"phases":22445,"primaryCompletion":22446,"completion":22446,"start":22447,"enrollment":13004,"conditions":22448,"interventions":22449},"NCT01543659","Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer",[89,90],"2026-02-10","2012-02-21",[18],[22434],{"trials":22451,"activeCount":101},[],{"trials":22453,"activeCount":101},[],{"trials":22455,"activeCount":101},[],{"intervention":22457,"totalTrials":97,"cells":22458},"Abiraterone acetate 1000 mg po daily",{"EARLY_PHASE1":22459,"PHASE1":22461,"PHASE2":22463,"PHASE3":22475,"PHASE4":22477,"NA":22479},{"trials":22460,"activeCount":101},[],{"trials":22462,"activeCount":101},[],{"trials":22464,"activeCount":101},[22465],{"nctId":22466,"briefTitle":22467,"status":244,"phases":22468,"primaryCompletion":22469,"completion":22469,"start":22470,"enrollment":2690,"conditions":22471,"interventions":22472},"NCT02218606","Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer",[90],"2023-10-13","2014-08",[18],[22457,22473,22474],"Cabazitaxel 25 mg\u002Fm2 IV","prednisone 5 mg po BID",{"trials":22476,"activeCount":101},[],{"trials":22478,"activeCount":101},[],{"trials":22480,"activeCount":101},[],{"intervention":22473,"totalTrials":97,"cells":22482},{"EARLY_PHASE1":22483,"PHASE1":22485,"PHASE2":22487,"PHASE3":22493,"PHASE4":22495,"NA":22497},{"trials":22484,"activeCount":101},[],{"trials":22486,"activeCount":101},[],{"trials":22488,"activeCount":101},[22489],{"nctId":22466,"briefTitle":22467,"status":244,"phases":22490,"primaryCompletion":22469,"completion":22469,"start":22470,"enrollment":2690,"conditions":22491,"interventions":22492},[90],[18],[22457,22473,22474],{"trials":22494,"activeCount":101},[],{"trials":22496,"activeCount":101},[],{"trials":22498,"activeCount":101},[],{"intervention":22474,"totalTrials":97,"cells":22500},{"EARLY_PHASE1":22501,"PHASE1":22503,"PHASE2":22505,"PHASE3":22511,"PHASE4":22513,"NA":22515},{"trials":22502,"activeCount":101},[],{"trials":22504,"activeCount":101},[],{"trials":22506,"activeCount":101},[22507],{"nctId":22466,"briefTitle":22467,"status":244,"phases":22508,"primaryCompletion":22469,"completion":22469,"start":22470,"enrollment":2690,"conditions":22509,"interventions":22510},[90],[18],[22457,22473,22474],{"trials":22512,"activeCount":101},[],{"trials":22514,"activeCount":101},[],{"trials":22516,"activeCount":101},[],{"intervention":740,"totalTrials":97,"cells":22518},{"EARLY_PHASE1":22519,"PHASE1":22521,"PHASE2":22523,"PHASE3":22529,"PHASE4":22531,"NA":22533},{"trials":22520,"activeCount":101},[],{"trials":22522,"activeCount":101},[],{"trials":22524,"activeCount":101},[22525],{"nctId":733,"briefTitle":734,"status":244,"phases":22526,"primaryCompletion":736,"completion":736,"start":737,"conditions":22527,"interventions":22528},[90],[15],[288,202,740,741],{"trials":22530,"activeCount":101},[],{"trials":22532,"activeCount":101},[],{"trials":22534,"activeCount":101},[],{"intervention":22536,"totalTrials":97,"cells":22537},"RAD001 (Everolimus) and Pasireotide (SOM230) LAR",{"EARLY_PHASE1":22538,"PHASE1":22540,"PHASE2":22542,"PHASE3":22550,"PHASE4":22552,"NA":22554},{"trials":22539,"activeCount":101},[],{"trials":22541,"activeCount":101},[],{"trials":22543,"activeCount":101},[22544],{"nctId":22545,"briefTitle":22546,"status":244,"phases":22547,"primaryCompletion":259,"completion":259,"start":3281,"enrollment":272,"conditions":22548,"interventions":22549},"NCT01252251","RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma",[90],[2622],[22536],{"trials":22551,"activeCount":101},[],{"trials":22553,"activeCount":101},[],{"trials":22555,"activeCount":101},[],{"intervention":22557,"totalTrials":97,"cells":22558},"L-alanosine",{"EARLY_PHASE1":22559,"PHASE1":22561,"PHASE2":22563,"PHASE3":22571,"PHASE4":22573,"NA":22575},{"trials":22560,"activeCount":101},[],{"trials":22562,"activeCount":101},[],{"trials":22564,"activeCount":101},[22565],{"nctId":22566,"briefTitle":22567,"status":244,"phases":22568,"primaryCompletion":2898,"completion":588,"start":1702,"conditions":22569,"interventions":22570},"NCT00062283","Alanosine in Treating Patients With Cancer",[90],[21,3163,1226,33],[22557],{"trials":22572,"activeCount":101},[],{"trials":22574,"activeCount":101},[],{"trials":22576,"activeCount":101},[],{"intervention":22578,"totalTrials":97,"cells":22579},"MK-0646",{"EARLY_PHASE1":22580,"PHASE1":22582,"PHASE2":22584,"PHASE3":22594,"PHASE4":22596,"NA":22598},{"trials":22581,"activeCount":101},[],{"trials":22583,"activeCount":101},[],{"trials":22585,"activeCount":101},[22586],{"nctId":22587,"briefTitle":22588,"status":244,"phases":22589,"primaryCompletion":835,"completion":835,"start":22590,"enrollment":438,"conditions":22591,"interventions":22593},"NCT00610129","Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)",[90],"2008-01",[15597,22592],"Metastatic Neuroendocrine Tumors",[22578],{"trials":22595,"activeCount":101},[],{"trials":22597,"activeCount":101},[],{"trials":22599,"activeCount":101},[],{"intervention":1697,"totalTrials":97,"cells":22601},{"EARLY_PHASE1":22602,"PHASE1":22604,"PHASE2":22606,"PHASE3":22612,"PHASE4":22614,"NA":22616},{"trials":22603,"activeCount":101},[],{"trials":22605,"activeCount":101},[],{"trials":22607,"activeCount":101},[22608],{"nctId":1690,"briefTitle":1691,"status":244,"phases":22609,"completion":746,"start":1693,"enrollment":306,"conditions":22610,"interventions":22611},[90],[1695],[1181,1697],{"trials":22613,"activeCount":101},[],{"trials":22615,"activeCount":101},[],{"trials":22617,"activeCount":101},[],{"intervention":22619,"totalTrials":97,"cells":22620},"89Zr-daratumumab",{"EARLY_PHASE1":22621,"PHASE1":22623,"PHASE2":22625,"PHASE3":22635,"PHASE4":22637,"NA":22639},{"trials":22622,"activeCount":101},[],{"trials":22624,"activeCount":101},[],{"trials":22626,"activeCount":101},[22627],{"nctId":22628,"briefTitle":22629,"status":244,"phases":22630,"primaryCompletion":22631,"completion":22631,"start":22632,"enrollment":2630,"conditions":22633,"interventions":22634},"NCT03665155","First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody",[89,90],"2020-04-20","2018-09-05",[308],[22619],{"trials":22636,"activeCount":101},[],{"trials":22638,"activeCount":101},[],{"trials":22640,"activeCount":101},[],{"intervention":22642,"totalTrials":97,"cells":22643},"iodinated contrast dye",{"EARLY_PHASE1":22644,"PHASE1":22646,"PHASE2":22648,"PHASE3":22658,"PHASE4":22660,"NA":22662},{"trials":22645,"activeCount":101},[],{"trials":22647,"activeCount":101},[],{"trials":22649,"activeCount":101},[22650],{"nctId":22651,"briefTitle":22652,"status":244,"phases":22653,"primaryCompletion":22654,"start":22655,"conditions":22656,"interventions":22657},"NCT00004152","PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma",[90],"2002-12","1999-02",[4734],[22642],{"trials":22659,"activeCount":101},[],{"trials":22661,"activeCount":101},[],{"trials":22663,"activeCount":101},[],{"intervention":17398,"totalTrials":97,"cells":22665},{"EARLY_PHASE1":22666,"PHASE1":22668,"PHASE2":22670,"PHASE3":22676,"PHASE4":22678,"NA":22680},{"trials":22667,"activeCount":101},[],{"trials":22669,"activeCount":101},[],{"trials":22671,"activeCount":101},[22672],{"nctId":17389,"briefTitle":17390,"status":244,"phases":22673,"primaryCompletion":17392,"completion":17392,"start":17393,"enrollment":1232,"conditions":22674,"interventions":22675},[90],[17395,17396],[2963,17398,17399],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[],{"trials":22681,"activeCount":101},[],{"intervention":17399,"totalTrials":97,"cells":22683},{"EARLY_PHASE1":22684,"PHASE1":22686,"PHASE2":22688,"PHASE3":22694,"PHASE4":22696,"NA":22698},{"trials":22685,"activeCount":101},[],{"trials":22687,"activeCount":101},[],{"trials":22689,"activeCount":101},[22690],{"nctId":17389,"briefTitle":17390,"status":244,"phases":22691,"primaryCompletion":17392,"completion":17392,"start":17393,"enrollment":1232,"conditions":22692,"interventions":22693},[90],[17395,17396],[2963,17398,17399],{"trials":22695,"activeCount":101},[],{"trials":22697,"activeCount":101},[],{"trials":22699,"activeCount":101},[],{"intervention":22701,"totalTrials":97,"cells":22702},"semaxanib",{"EARLY_PHASE1":22703,"PHASE1":22705,"PHASE2":22707,"PHASE3":22716,"PHASE4":22718,"NA":22720},{"trials":22704,"activeCount":101},[],{"trials":22706,"activeCount":101},[],{"trials":22708,"activeCount":101},[22709],{"nctId":22710,"briefTitle":22711,"status":244,"phases":22712,"primaryCompletion":695,"start":5206,"conditions":22713,"interventions":22715},"NCT00006361","SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck",[90],[7399,1586,22714],"Non-melanomatous Skin Cancer",[22701],{"trials":22717,"activeCount":101},[],{"trials":22719,"activeCount":101},[],{"trials":22721,"activeCount":101},[],{"intervention":22723,"totalTrials":97,"cells":22724},"Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin",{"EARLY_PHASE1":22725,"PHASE1":22727,"PHASE2":22729,"PHASE3":22739,"PHASE4":22741,"NA":22743},{"trials":22726,"activeCount":101},[],{"trials":22728,"activeCount":101},[],{"trials":22730,"activeCount":101},[22731],{"nctId":22732,"briefTitle":22733,"status":244,"phases":22734,"primaryCompletion":22735,"completion":22735,"start":3032,"enrollment":1798,"conditions":22736,"interventions":22738},"NCT00390416","Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma",[90],"2012-01",[22737,2395],"Stomach Neoplasms",[22723],{"trials":22740,"activeCount":101},[],{"trials":22742,"activeCount":101},[],{"trials":22744,"activeCount":101},[],{"intervention":1709,"totalTrials":97,"cells":22746},{"EARLY_PHASE1":22747,"PHASE1":22749,"PHASE2":22751,"PHASE3":22757,"PHASE4":22759,"NA":22761},{"trials":22748,"activeCount":101},[],{"trials":22750,"activeCount":101},[],{"trials":22752,"activeCount":101},[22753],{"nctId":1699,"briefTitle":1700,"status":244,"phases":22754,"primaryCompletion":1702,"start":1703,"conditions":22755,"interventions":22756},[90],[18,1705],[1023,345,1707,1708,1709],{"trials":22758,"activeCount":101},[],{"trials":22760,"activeCount":101},[],{"trials":22762,"activeCount":101},[],{"intervention":1168,"totalTrials":97,"cells":22764},{"EARLY_PHASE1":22765,"PHASE1":22767,"PHASE2":22769,"PHASE3":22775,"PHASE4":22777,"NA":22779},{"trials":22766,"activeCount":101},[],{"trials":22768,"activeCount":101},[],{"trials":22770,"activeCount":101},[22771],{"nctId":1159,"briefTitle":1160,"status":244,"phases":22772,"primaryCompletion":1162,"completion":1162,"start":1163,"enrollment":272,"conditions":22773,"interventions":22774},[90],[1165,1166],[1168,923],{"trials":22776,"activeCount":101},[],{"trials":22778,"activeCount":101},[],{"trials":22780,"activeCount":101},[],{"intervention":22782,"totalTrials":97,"cells":22783},"Cobimetinib",{"EARLY_PHASE1":22784,"PHASE1":22786,"PHASE2":22788,"PHASE3":22798,"PHASE4":22800,"NA":22802},{"trials":22785,"activeCount":101},[],{"trials":22787,"activeCount":101},[],{"trials":22789,"activeCount":101},[22790],{"nctId":22791,"briefTitle":22792,"status":244,"phases":22793,"primaryCompletion":22794,"completion":22794,"start":563,"enrollment":1052,"conditions":22795,"interventions":22797},"NCT02649972","Single-agent Cobimetinib for Adults With Histiocytic Disorders",[90],"2022-12-16",[22796],"Histiocytic Disorders",[22782],{"trials":22799,"activeCount":101},[],{"trials":22801,"activeCount":101},[],{"trials":22803,"activeCount":101},[],{"intervention":22805,"totalTrials":97,"cells":22806},"oral erlotinib and pulsed doses of oral AT-101",{"EARLY_PHASE1":22807,"PHASE1":22809,"PHASE2":22811,"PHASE3":22819,"PHASE4":22821,"NA":22823},{"trials":22808,"activeCount":101},[],{"trials":22810,"activeCount":101},[],{"trials":22812,"activeCount":101},[22813],{"nctId":22814,"briefTitle":22815,"status":505,"phases":22816,"primaryCompletion":19711,"completion":19711,"start":16615,"enrollment":332,"conditions":22817,"interventions":22818},"NCT00988169","Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations",[90],[21],[22805],{"trials":22820,"activeCount":101},[],{"trials":22822,"activeCount":101},[],{"trials":22824,"activeCount":101},[],{"intervention":769,"totalTrials":97,"cells":22826},{"EARLY_PHASE1":22827,"PHASE1":22829,"PHASE2":22831,"PHASE3":22837,"PHASE4":22839,"NA":22841},{"trials":22828,"activeCount":101},[],{"trials":22830,"activeCount":101},[],{"trials":22832,"activeCount":101},[22833],{"nctId":760,"briefTitle":761,"status":244,"phases":22834,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":22835,"interventions":22836},[90],[15],[768,202,345,769,741],{"trials":22838,"activeCount":101},[],{"trials":22840,"activeCount":101},[],{"trials":22842,"activeCount":101},[],{"intervention":22844,"totalTrials":97,"cells":22845},"everolimus and bevacizumab",{"EARLY_PHASE1":22846,"PHASE1":22848,"PHASE2":22850,"PHASE3":22859,"PHASE4":22861,"NA":22863},{"trials":22847,"activeCount":101},[],{"trials":22849,"activeCount":101},[],{"trials":22851,"activeCount":101},[22852],{"nctId":22853,"briefTitle":22854,"status":244,"phases":22855,"primaryCompletion":22856,"completion":22856,"start":763,"enrollment":1665,"conditions":22857,"interventions":22858},"NCT01399918","Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)",[90],"2020-12-28",[5422],[22844],{"trials":22860,"activeCount":101},[],{"trials":22862,"activeCount":101},[],{"trials":22864,"activeCount":101},[],{"intervention":6550,"totalTrials":97,"cells":22866},{"EARLY_PHASE1":22867,"PHASE1":22869,"PHASE2":22871,"PHASE3":22877,"PHASE4":22879,"NA":22881},{"trials":22868,"activeCount":101},[],{"trials":22870,"activeCount":101},[],{"trials":22872,"activeCount":101},[22873],{"nctId":6542,"briefTitle":6543,"status":505,"phases":22874,"primaryCompletion":6545,"completion":6545,"start":6546,"enrollment":2483,"conditions":22875,"interventions":22876},[89,90],[6548],[6550,6551],{"trials":22878,"activeCount":101},[],{"trials":22880,"activeCount":101},[],{"trials":22882,"activeCount":101},[],{"intervention":2855,"totalTrials":97,"cells":22884},{"EARLY_PHASE1":22885,"PHASE1":22887,"PHASE2":22889,"PHASE3":22895,"PHASE4":22897,"NA":22899},{"trials":22886,"activeCount":101},[],{"trials":22888,"activeCount":101},[],{"trials":22890,"activeCount":101},[22891],{"nctId":2847,"briefTitle":2848,"status":244,"phases":22892,"primaryCompletion":2850,"completion":2850,"start":2851,"enrollment":1462,"conditions":22893,"interventions":22894},[90],[2853],[2682,2855],{"trials":22896,"activeCount":101},[],{"trials":22898,"activeCount":101},[],{"trials":22900,"activeCount":101},[],{"intervention":22902,"totalTrials":97,"cells":22903},"AUY922",{"EARLY_PHASE1":22904,"PHASE1":22906,"PHASE2":22908,"PHASE3":22916,"PHASE4":22918,"NA":22920},{"trials":22905,"activeCount":101},[],{"trials":22907,"activeCount":101},[],{"trials":22909,"activeCount":101},[22910],{"nctId":22911,"briefTitle":22912,"status":505,"phases":22913,"primaryCompletion":790,"completion":790,"start":8810,"enrollment":2291,"conditions":22914,"interventions":22915},"NCT01668173","HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV\u002FET",[90],[10200],[22902],{"trials":22917,"activeCount":101},[],{"trials":22919,"activeCount":101},[],{"trials":22921,"activeCount":101},[],{"intervention":7838,"totalTrials":97,"cells":22923},{"EARLY_PHASE1":22924,"PHASE1":22926,"PHASE2":22928,"PHASE3":22934,"PHASE4":22936,"NA":22938},{"trials":22925,"activeCount":101},[],{"trials":22927,"activeCount":101},[],{"trials":22929,"activeCount":101},[22930],{"nctId":7832,"briefTitle":7833,"status":244,"phases":22931,"primaryCompletion":4112,"completion":4112,"start":7835,"enrollment":1434,"conditions":22932,"interventions":22933},[89,90],[15],[4889,7838],{"trials":22935,"activeCount":101},[],{"trials":22937,"activeCount":101},[],{"trials":22939,"activeCount":101},[],{"intervention":22941,"totalTrials":97,"cells":22942},"INS316",{"EARLY_PHASE1":22943,"PHASE1":22945,"PHASE2":22947,"PHASE3":22955,"PHASE4":22957,"NA":22959},{"trials":22944,"activeCount":101},[],{"trials":22946,"activeCount":101},[],{"trials":22948,"activeCount":101},[22949],{"nctId":22950,"briefTitle":22951,"status":244,"phases":22952,"completion":1267,"start":426,"conditions":22953,"interventions":22954},"NCT00008255","INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer",[90],[21],[22941],{"trials":22956,"activeCount":101},[],{"trials":22958,"activeCount":101},[],{"trials":22960,"activeCount":101},[],{"intervention":22962,"totalTrials":97,"cells":22963},"bcr-abl peptide vaccine",{"EARLY_PHASE1":22964,"PHASE1":22966,"PHASE2":22968,"PHASE3":22976,"PHASE4":22978,"NA":22980},{"trials":22965,"activeCount":101},[],{"trials":22967,"activeCount":101},[],{"trials":22969,"activeCount":101},[22970],{"nctId":22971,"briefTitle":22972,"status":244,"phases":22973,"primaryCompletion":4661,"completion":4661,"start":21241,"enrollment":454,"conditions":22974,"interventions":22975},"NCT00004052","Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia",[90],[27],[9012,22962],{"trials":22977,"activeCount":101},[],{"trials":22979,"activeCount":101},[],{"trials":22981,"activeCount":101},[],{"intervention":807,"totalTrials":97,"cells":22983},{"EARLY_PHASE1":22984,"PHASE1":22986,"PHASE2":22988,"PHASE3":22994,"PHASE4":22996,"NA":22998},{"trials":22985,"activeCount":101},[],{"trials":22987,"activeCount":101},[],{"trials":22989,"activeCount":101},[22990],{"nctId":800,"briefTitle":801,"status":244,"phases":22991,"primaryCompletion":803,"completion":803,"start":804,"enrollment":283,"conditions":22992,"interventions":22993},[90],[27,475],[807,202,239],{"trials":22995,"activeCount":101},[],{"trials":22997,"activeCount":101},[],{"trials":22999,"activeCount":101},[],{"intervention":23001,"totalTrials":97,"cells":23002},"COPP\u002FABV",{"EARLY_PHASE1":23003,"PHASE1":23005,"PHASE2":23007,"PHASE3":23017,"PHASE4":23019,"NA":23021},{"trials":23004,"activeCount":101},[],{"trials":23006,"activeCount":101},[],{"trials":23008,"activeCount":101},[23009],{"nctId":23010,"briefTitle":23011,"status":244,"phases":23012,"primaryCompletion":22655,"completion":22590,"start":876,"enrollment":899,"conditions":23013,"interventions":23015},"NCT00592111","A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)",[90],[23014,1426],"Pediatric",[23001,23001,23016],"intensive chemo with concurrent growth factor",{"trials":23018,"activeCount":101},[],{"trials":23020,"activeCount":101},[],{"trials":23022,"activeCount":101},[],{"intervention":23016,"totalTrials":97,"cells":23024},{"EARLY_PHASE1":23025,"PHASE1":23027,"PHASE2":23029,"PHASE3":23035,"PHASE4":23037,"NA":23039},{"trials":23026,"activeCount":101},[],{"trials":23028,"activeCount":101},[],{"trials":23030,"activeCount":101},[23031],{"nctId":23010,"briefTitle":23011,"status":244,"phases":23032,"primaryCompletion":22655,"completion":22590,"start":876,"enrollment":899,"conditions":23033,"interventions":23034},[90],[23014,1426],[23001,23001,23016],{"trials":23036,"activeCount":101},[],{"trials":23038,"activeCount":101},[],{"trials":23040,"activeCount":101},[],{"intervention":23042,"totalTrials":97,"cells":23043},"LGX818",{"EARLY_PHASE1":23044,"PHASE1":23046,"PHASE2":23048,"PHASE3":23057,"PHASE4":23059,"NA":23061},{"trials":23045,"activeCount":101},[],{"trials":23047,"activeCount":101},[],{"trials":23049,"activeCount":101},[23050],{"nctId":23051,"briefTitle":23052,"status":244,"phases":23053,"primaryCompletion":23054,"completion":23054,"start":1396,"enrollment":2291,"conditions":23055,"interventions":23056},"NCT01894672","BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",[90],"2016-03-17",[2341],[23042],{"trials":23058,"activeCount":101},[],{"trials":23060,"activeCount":101},[],{"trials":23062,"activeCount":101},[],{"intervention":23064,"totalTrials":97,"cells":23065},"monoclonal antibody huJ591",{"EARLY_PHASE1":23066,"PHASE1":23068,"PHASE2":23070,"PHASE3":23078,"PHASE4":23080,"NA":23082},{"trials":23067,"activeCount":101},[],{"trials":23069,"activeCount":101},[],{"trials":23071,"activeCount":101},[23072],{"nctId":23073,"briefTitle":23074,"status":244,"phases":23075,"primaryCompletion":7407,"completion":7407,"start":898,"conditions":23076,"interventions":23077},"NCT00024232","Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer",[90],[18],[23064],{"trials":23079,"activeCount":101},[],{"trials":23081,"activeCount":101},[],{"trials":23083,"activeCount":101},[],{"intervention":23085,"totalTrials":97,"cells":23086},"89Zr-DFO-daratumumab",{"EARLY_PHASE1":23087,"PHASE1":23089,"PHASE2":23091,"PHASE3":23100,"PHASE4":23102,"NA":23104},{"trials":23088,"activeCount":101},[],{"trials":23090,"activeCount":101},[],{"trials":23092,"activeCount":101},[23093],{"nctId":23094,"briefTitle":23095,"status":2832,"phases":23096,"primaryCompletion":23097,"completion":23097,"start":2144,"enrollment":101,"conditions":23098,"interventions":23099},"NCT04467281","A Study of PET\u002FCT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma",[90],"2021-02-26",[308],[23085],{"trials":23101,"activeCount":101},[],{"trials":23103,"activeCount":101},[],{"trials":23105,"activeCount":101},[],{"intervention":3316,"totalTrials":97,"cells":23107},{"EARLY_PHASE1":23108,"PHASE1":23110,"PHASE2":23112,"PHASE3":23118,"PHASE4":23120,"NA":23122},{"trials":23109,"activeCount":101},[],{"trials":23111,"activeCount":101},[],{"trials":23113,"activeCount":101},[23114],{"nctId":3306,"briefTitle":3307,"status":244,"phases":23115,"primaryCompletion":3309,"completion":3309,"start":3310,"enrollment":509,"conditions":23116,"interventions":23117},[90],[3312,3313,3314],[974,3316],{"trials":23119,"activeCount":101},[],{"trials":23121,"activeCount":101},[],{"trials":23123,"activeCount":101},[],{"intervention":23125,"totalTrials":97,"cells":23126},"fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft",{"EARLY_PHASE1":23127,"PHASE1":23129,"PHASE2":23131,"PHASE3":23143,"PHASE4":23145,"NA":23147},{"trials":23128,"activeCount":101},[],{"trials":23130,"activeCount":101},[],{"trials":23132,"activeCount":101},[23133],{"nctId":23134,"briefTitle":23135,"status":244,"phases":23136,"primaryCompletion":23137,"completion":23137,"start":23138,"enrollment":1291,"conditions":23139,"interventions":23142},"NCT00739141","Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.",[90],"2021-10-15","2008-08-12",[27,416,5617,23140,23141],"Chronic Myelogenous Leukemia","Hodgkins Lymphoma",[23125],{"trials":23144,"activeCount":101},[],{"trials":23146,"activeCount":101},[],{"trials":23148,"activeCount":101},[],{"intervention":23150,"totalTrials":97,"cells":23151},"Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant",{"EARLY_PHASE1":23152,"PHASE1":23154,"PHASE2":23156,"PHASE3":23167,"PHASE4":23169,"NA":23171},{"trials":23153,"activeCount":101},[],{"trials":23155,"activeCount":101},[],{"trials":23157,"activeCount":101},[23158],{"nctId":23159,"briefTitle":23160,"status":244,"phases":23161,"primaryCompletion":23162,"completion":23162,"start":23163,"enrollment":2407,"conditions":23164,"interventions":23166},"NCT00629798","Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)",[90],"2020-10-20","2008-02-12",[3816,23165],"Advanced Myelodysplastic Syndromes",[23150],{"trials":23168,"activeCount":101},[],{"trials":23170,"activeCount":101},[],{"trials":23172,"activeCount":101},[],{"intervention":23174,"totalTrials":97,"cells":23175},"3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid",{"EARLY_PHASE1":23176,"PHASE1":23178,"PHASE2":23180,"PHASE3":23188,"PHASE4":23190,"NA":23192},{"trials":23177,"activeCount":101},[],{"trials":23179,"activeCount":101},[],{"trials":23181,"activeCount":101},[23182],{"nctId":23183,"briefTitle":23184,"status":505,"phases":23185,"primaryCompletion":2445,"completion":2445,"start":4635,"enrollment":6397,"conditions":23186,"interventions":23187},"NCT01183884","3F8\u002FGM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma",[90],[215],[23174],{"trials":23189,"activeCount":101},[],{"trials":23191,"activeCount":101},[],{"trials":23193,"activeCount":101},[],{"intervention":7454,"totalTrials":509,"cells":23195},{"EARLY_PHASE1":23196,"PHASE1":23198,"PHASE2":23212,"PHASE3":23214,"PHASE4":23216,"NA":23218},{"trials":23197,"activeCount":101},[],{"trials":23199,"activeCount":101},[23200,23204,23208],{"nctId":8763,"briefTitle":8764,"status":244,"phases":23201,"primaryCompletion":8766,"completion":8766,"start":8767,"enrollment":1447,"conditions":23202,"interventions":23203},[89],[6040],[1593,7454],{"nctId":9588,"briefTitle":9589,"status":244,"phases":23205,"primaryCompletion":5816,"completion":5816,"start":813,"enrollment":2426,"conditions":23206,"interventions":23207},[89],[9592],[7454,6280,9594],{"nctId":7447,"briefTitle":7448,"status":244,"phases":23209,"primaryCompletion":7450,"completion":7450,"start":7451,"enrollment":1412,"conditions":23210,"interventions":23211},[89],[15],[7454,7455,7456],{"trials":23213,"activeCount":101},[],{"trials":23215,"activeCount":101},[],{"trials":23217,"activeCount":101},[],{"trials":23219,"activeCount":101},[],{"intervention":23221,"totalTrials":509,"cells":23222},"MUC1-KLH vaccine\u002FQS21",{"EARLY_PHASE1":23223,"PHASE1":23225,"PHASE2":23246,"PHASE3":23248,"PHASE4":23250,"NA":23252},{"trials":23224,"activeCount":101},[],{"trials":23226,"activeCount":101},[23227,23233,23239],{"nctId":23228,"briefTitle":23229,"status":244,"phases":23230,"primaryCompletion":4807,"completion":4807,"start":1685,"enrollment":1600,"conditions":23231,"interventions":23232},"NCT00005632","Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer",[89],[18],[23221],{"nctId":23234,"briefTitle":23235,"status":244,"phases":23236,"primaryCompletion":755,"start":589,"enrollment":341,"conditions":23237,"interventions":23238},"NCT00004156","Vaccine Therapy in Treating Patients With Breast Cancer",[89],[15],[23221],{"nctId":23240,"briefTitle":23241,"status":244,"phases":23242,"primaryCompletion":21240,"completion":21240,"start":1611,"conditions":23243,"interventions":23244},"NCT00006041","Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer",[89],[285,30,286],[23245,23221,9012],"MUC1-KLH conjugate vaccine",{"trials":23247,"activeCount":101},[],{"trials":23249,"activeCount":101},[],{"trials":23251,"activeCount":101},[],{"trials":23253,"activeCount":101},[],{"intervention":5209,"totalTrials":1094,"cells":23255},{"EARLY_PHASE1":23256,"PHASE1":23258,"PHASE2":23270,"PHASE3":23272,"PHASE4":23274,"NA":23276},{"trials":23257,"activeCount":101},[],{"trials":23259,"activeCount":101},[23260,23266],{"nctId":23261,"briefTitle":23262,"status":244,"phases":23263,"primaryCompletion":3881,"completion":3881,"start":3451,"enrollment":718,"conditions":23264,"interventions":23265},"NCT00003430","L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors",[89],[1586,1568],[5209],{"nctId":5203,"briefTitle":5204,"status":244,"phases":23267,"primaryCompletion":5206,"completion":5206,"start":3122,"enrollment":718,"conditions":23268,"interventions":23269},[89],[24,1568],[5209,741],{"trials":23271,"activeCount":101},[],{"trials":23273,"activeCount":101},[],{"trials":23275,"activeCount":101},[],{"trials":23277,"activeCount":101},[],{"intervention":23279,"totalTrials":1094,"cells":23280},"mouse gp100 plasmid DNA vaccine",{"EARLY_PHASE1":23281,"PHASE1":23283,"PHASE2":23298,"PHASE3":23300,"PHASE4":23302,"NA":23304},{"trials":23282,"activeCount":101},[],{"trials":23284,"activeCount":101},[23285,23292],{"nctId":23286,"briefTitle":23287,"status":244,"phases":23288,"primaryCompletion":875,"completion":875,"start":339,"enrollment":2446,"conditions":23289,"interventions":23290},"NCT00104845","Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",[89],[4734],[23291,23279],"human gp100 plasmid DNA vaccine",{"nctId":23293,"briefTitle":23287,"status":244,"phases":23294,"primaryCompletion":23295,"completion":23295,"start":3032,"enrollment":1052,"conditions":23296,"interventions":23297},"NCT00398073",[89],"2011-03",[4733,4734],[23279],{"trials":23299,"activeCount":101},[],{"trials":23301,"activeCount":101},[],{"trials":23303,"activeCount":101},[],{"trials":23305,"activeCount":101},[],{"intervention":8942,"totalTrials":1094,"cells":23307},{"EARLY_PHASE1":23308,"PHASE1":23310,"PHASE2":23320,"PHASE3":23322,"PHASE4":23324,"NA":23326},{"trials":23309,"activeCount":101},[],{"trials":23311,"activeCount":101},[23312,23316],{"nctId":8937,"briefTitle":8938,"status":244,"phases":23313,"primaryCompletion":3777,"completion":3777,"start":8675,"conditions":23314,"interventions":23315},[89],[21],[8942,360],{"nctId":8958,"briefTitle":8959,"status":244,"phases":23317,"primaryCompletion":8961,"start":1685,"enrollment":97,"conditions":23318,"interventions":23319},[89],[27,475],[8942,360],{"trials":23321,"activeCount":101},[],{"trials":23323,"activeCount":101},[],{"trials":23325,"activeCount":101},[],{"trials":23327,"activeCount":101},[],{"intervention":3602,"totalTrials":1094,"cells":23329},{"EARLY_PHASE1":23330,"PHASE1":23332,"PHASE2":23342,"PHASE3":23344,"PHASE4":23346,"NA":23348},{"trials":23331,"activeCount":101},[],{"trials":23333,"activeCount":101},[23334,23338],{"nctId":3595,"briefTitle":3596,"status":244,"phases":23335,"primaryCompletion":3598,"completion":3598,"start":695,"enrollment":3599,"conditions":23336,"interventions":23337},[89],[36,2349],[3602,643,1615,1616,391,3603],{"nctId":3605,"briefTitle":3606,"status":244,"phases":23339,"primaryCompletion":1151,"start":426,"conditions":23340,"interventions":23341},[89],[36,2349],[3602,643,1615,1616,391,3603],{"trials":23343,"activeCount":101},[],{"trials":23345,"activeCount":101},[],{"trials":23347,"activeCount":101},[],{"trials":23349,"activeCount":101},[],{"intervention":5970,"totalTrials":1094,"cells":23351},{"EARLY_PHASE1":23352,"PHASE1":23358,"PHASE2":23364,"PHASE3":23366,"PHASE4":23368,"NA":23370},{"trials":23353,"activeCount":101},[23354],{"nctId":5961,"briefTitle":5962,"status":244,"phases":23355,"primaryCompletion":5964,"completion":5964,"start":5965,"enrollment":234,"conditions":23356,"interventions":23357},[88],[5967,21,5968],[5970,3509],{"trials":23359,"activeCount":101},[23360],{"nctId":5974,"briefTitle":5975,"status":244,"phases":23361,"primaryCompletion":5977,"completion":5977,"start":5978,"enrollment":2483,"conditions":23362,"interventions":23363},[89],[3507],[5970,3509],{"trials":23365,"activeCount":101},[],{"trials":23367,"activeCount":101},[],{"trials":23369,"activeCount":101},[],{"trials":23371,"activeCount":101},[],{"intervention":15792,"totalTrials":1094,"cells":23373},{"EARLY_PHASE1":23374,"PHASE1":23376,"PHASE2":23390,"PHASE3":23392,"PHASE4":23394,"NA":23396},{"trials":23375,"activeCount":101},[],{"trials":23377,"activeCount":101},[23378,23382],{"nctId":15785,"briefTitle":15786,"status":244,"phases":23379,"primaryCompletion":15788,"completion":15788,"start":15789,"enrollment":283,"conditions":23380,"interventions":23381},[89],[2311],[15792,1229],{"nctId":23383,"briefTitle":23384,"status":244,"phases":23385,"primaryCompletion":4646,"completion":4646,"start":23386,"enrollment":1015,"conditions":23387,"interventions":23389},"NCT01393509","The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies",[89],"2011-07-06",[13006,24,23388],"Myeloproliferative Neoplasms (MPN)",[15792],{"trials":23391,"activeCount":101},[],{"trials":23393,"activeCount":101},[],{"trials":23395,"activeCount":101},[],{"trials":23397,"activeCount":101},[],{"intervention":13561,"totalTrials":1094,"cells":23399},{"EARLY_PHASE1":23400,"PHASE1":23402,"PHASE2":23414,"PHASE3":23416,"PHASE4":23418,"NA":23420},{"trials":23401,"activeCount":101},[],{"trials":23403,"activeCount":101},[23404,23410],{"nctId":23405,"briefTitle":23406,"status":244,"phases":23407,"primaryCompletion":2931,"completion":2931,"start":4751,"conditions":23408,"interventions":23409},"NCT00022360","Taurolidine in Treating Patients With Recurrent or Progressive Glioma",[89],[3259],[13561],{"nctId":13556,"briefTitle":13557,"status":244,"phases":23411,"primaryCompletion":756,"completion":756,"start":7415,"conditions":23412,"interventions":23413},[89],[285,30,286],[2909,13561],{"trials":23415,"activeCount":101},[],{"trials":23417,"activeCount":101},[],{"trials":23419,"activeCount":101},[],{"trials":23421,"activeCount":101},[],{"intervention":23423,"totalTrials":1094,"cells":23424},"vorinostat",{"EARLY_PHASE1":23425,"PHASE1":23427,"PHASE2":23441,"PHASE3":23443,"PHASE4":23445,"NA":23447},{"trials":23426,"activeCount":101},[],{"trials":23428,"activeCount":101},[23429,23435],{"nctId":23430,"briefTitle":23431,"status":244,"phases":23432,"primaryCompletion":13332,"completion":13332,"start":17235,"conditions":23433,"interventions":23434},"NCT00005634","Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy",[89],[27,24,828,18,1687,1568],[23423],{"nctId":23436,"briefTitle":23437,"status":244,"phases":23438,"primaryCompletion":2898,"completion":5695,"start":554,"conditions":23439,"interventions":23440},"NCT00045006","Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer",[89],[1155],[23423],{"trials":23442,"activeCount":101},[],{"trials":23444,"activeCount":101},[],{"trials":23446,"activeCount":101},[],{"trials":23448,"activeCount":101},[],{"intervention":23450,"totalTrials":1094,"cells":23451},"MUC-2-Globo H-KLH conjugate vaccine",{"EARLY_PHASE1":23452,"PHASE1":23454,"PHASE2":23468,"PHASE3":23470,"PHASE4":23472,"NA":23474},{"trials":23453,"activeCount":101},[],{"trials":23455,"activeCount":101},[23456,23461],{"nctId":23457,"briefTitle":23229,"status":244,"phases":23458,"primaryCompletion":4807,"completion":4807,"start":1629,"enrollment":601,"conditions":23459,"interventions":23460},"NCT00036933",[89],[18],[23450,9012],{"nctId":23462,"briefTitle":23463,"status":244,"phases":23464,"primaryCompletion":4807,"completion":4807,"start":5224,"enrollment":2439,"conditions":23465,"interventions":23466},"NCT00016146","Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer",[89],[18],[23467,23450],"GPI-0100",{"trials":23469,"activeCount":101},[],{"trials":23471,"activeCount":101},[],{"trials":23473,"activeCount":101},[],{"trials":23475,"activeCount":101},[],{"intervention":23477,"totalTrials":97,"cells":23478},"cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8",{"EARLY_PHASE1":23479,"PHASE1":23481,"PHASE2":23491,"PHASE3":23493,"PHASE4":23495,"NA":23497},{"trials":23480,"activeCount":101},[],{"trials":23482,"activeCount":101},[23483],{"nctId":23484,"briefTitle":23485,"status":244,"phases":23486,"primaryCompletion":294,"completion":294,"start":23487,"enrollment":669,"conditions":23488,"interventions":23490},"NCT00877110","Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma",[89],"2009-04-02",[215,23489],"Bone Marrow, Sympathetic Nervous System",[23477],{"trials":23492,"activeCount":101},[],{"trials":23494,"activeCount":101},[],{"trials":23496,"activeCount":101},[],{"trials":23498,"activeCount":101},[],{"intervention":23291,"totalTrials":97,"cells":23500},{"EARLY_PHASE1":23501,"PHASE1":23503,"PHASE2":23509,"PHASE3":23511,"PHASE4":23513,"NA":23515},{"trials":23502,"activeCount":101},[],{"trials":23504,"activeCount":101},[23505],{"nctId":23286,"briefTitle":23287,"status":244,"phases":23506,"primaryCompletion":875,"completion":875,"start":339,"enrollment":2446,"conditions":23507,"interventions":23508},[89],[4734],[23291,23279],{"trials":23510,"activeCount":101},[],{"trials":23512,"activeCount":101},[],{"trials":23514,"activeCount":101},[],{"trials":23516,"activeCount":101},[],{"intervention":23518,"totalTrials":97,"cells":23519},"perifosine + temsirolimus",{"EARLY_PHASE1":23520,"PHASE1":23522,"PHASE2":23532,"PHASE3":23534,"PHASE4":23536,"NA":23538},{"trials":23521,"activeCount":101},[],{"trials":23523,"activeCount":101},[23524],{"nctId":23525,"briefTitle":23526,"status":244,"phases":23527,"primaryCompletion":23528,"completion":23528,"start":835,"enrollment":1412,"conditions":23529,"interventions":23531},"NCT01049841","Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors",[89],"2017-03",[23530],"Pediatric Solid Tumors",[23518],{"trials":23533,"activeCount":101},[],{"trials":23535,"activeCount":101},[],{"trials":23537,"activeCount":101},[],{"trials":23539,"activeCount":101},[],{"intervention":8662,"totalTrials":97,"cells":23541},{"EARLY_PHASE1":23542,"PHASE1":23544,"PHASE2":23550,"PHASE3":23552,"PHASE4":23554,"NA":23556},{"trials":23543,"activeCount":101},[],{"trials":23545,"activeCount":101},[23546],{"nctId":8656,"briefTitle":8657,"status":244,"phases":23547,"primaryCompletion":3402,"completion":3402,"start":8659,"conditions":23548,"interventions":23549},[89],[36],[1616,8662],{"trials":23551,"activeCount":101},[],{"trials":23553,"activeCount":101},[],{"trials":23555,"activeCount":101},[],{"trials":23557,"activeCount":101},[],{"intervention":251,"totalTrials":97,"cells":23559},{"EARLY_PHASE1":23560,"PHASE1":23562,"PHASE2":23568,"PHASE3":23570,"PHASE4":23572,"NA":23574},{"trials":23561,"activeCount":101},[],{"trials":23563,"activeCount":101},[23564],{"nctId":242,"briefTitle":243,"status":244,"phases":23565,"primaryCompletion":246,"completion":246,"start":247,"enrollment":28,"conditions":23566,"interventions":23567},[89],[215,249],[202,251,252,253],{"trials":23569,"activeCount":101},[],{"trials":23571,"activeCount":101},[],{"trials":23573,"activeCount":101},[],{"trials":23575,"activeCount":101},[],{"intervention":253,"totalTrials":97,"cells":23577},{"EARLY_PHASE1":23578,"PHASE1":23580,"PHASE2":23586,"PHASE3":23588,"PHASE4":23590,"NA":23592},{"trials":23579,"activeCount":101},[],{"trials":23581,"activeCount":101},[23582],{"nctId":242,"briefTitle":243,"status":244,"phases":23583,"primaryCompletion":246,"completion":246,"start":247,"enrollment":28,"conditions":23584,"interventions":23585},[89],[215,249],[202,251,252,253],{"trials":23587,"activeCount":101},[],{"trials":23589,"activeCount":101},[],{"trials":23591,"activeCount":101},[],{"trials":23593,"activeCount":101},[],{"intervention":5788,"totalTrials":97,"cells":23595},{"EARLY_PHASE1":23596,"PHASE1":23598,"PHASE2":23604,"PHASE3":23606,"PHASE4":23608,"NA":23610},{"trials":23597,"activeCount":101},[],{"trials":23599,"activeCount":101},[23600],{"nctId":5780,"briefTitle":5781,"status":244,"phases":23601,"primaryCompletion":5783,"completion":5783,"start":5784,"enrollment":283,"conditions":23602,"interventions":23603},[89],[15,18,5786],[5788,5367,4889],{"trials":23605,"activeCount":101},[],{"trials":23607,"activeCount":101},[],{"trials":23609,"activeCount":101},[],{"trials":23611,"activeCount":101},[],{"intervention":17609,"totalTrials":97,"cells":23613},{"EARLY_PHASE1":23614,"PHASE1":23616,"PHASE2":23622,"PHASE3":23624,"PHASE4":23626,"NA":23628},{"trials":23615,"activeCount":101},[],{"trials":23617,"activeCount":101},[23618],{"nctId":17604,"briefTitle":17605,"status":244,"phases":23619,"primaryCompletion":3880,"completion":3880,"start":1566,"conditions":23620,"interventions":23621},[89],[783],[359,17609],{"trials":23623,"activeCount":101},[],{"trials":23625,"activeCount":101},[],{"trials":23627,"activeCount":101},[],{"trials":23629,"activeCount":101},[],{"intervention":23631,"totalTrials":97,"cells":23632},"plasmid DNA vaccine therapy",{"EARLY_PHASE1":23633,"PHASE1":23635,"PHASE2":23643,"PHASE3":23645,"PHASE4":23647,"NA":23649},{"trials":23634,"activeCount":101},[],{"trials":23636,"activeCount":101},[23637],{"nctId":23638,"briefTitle":23639,"status":244,"phases":23640,"primaryCompletion":19294,"completion":19294,"start":1397,"enrollment":952,"conditions":23641,"interventions":23642},"NCT00561756","Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",[89],[24],[23631],{"trials":23644,"activeCount":101},[],{"trials":23646,"activeCount":101},[],{"trials":23648,"activeCount":101},[],{"trials":23650,"activeCount":101},[],{"intervention":23652,"totalTrials":97,"cells":23653},"Floxuridine, Oxaliplatin, CPT-11",{"EARLY_PHASE1":23654,"PHASE1":23656,"PHASE2":23664,"PHASE3":23666,"PHASE4":23668,"NA":23670},{"trials":23655,"activeCount":101},[],{"trials":23657,"activeCount":101},[23658],{"nctId":23659,"briefTitle":23660,"status":244,"phases":23661,"primaryCompletion":9766,"completion":9766,"start":426,"enrollment":2426,"conditions":23662,"interventions":23663},"NCT00695201","Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer",[89],[16135,5080],[23652,23652],{"trials":23665,"activeCount":101},[],{"trials":23667,"activeCount":101},[],{"trials":23669,"activeCount":101},[],{"trials":23671,"activeCount":101},[],{"intervention":23673,"totalTrials":97,"cells":23674},"Chinese Herb Huanglian",{"EARLY_PHASE1":23675,"PHASE1":23677,"PHASE2":23685,"PHASE3":23687,"PHASE4":23689,"NA":23691},{"trials":23676,"activeCount":101},[],{"trials":23678,"activeCount":101},[23679],{"nctId":23680,"briefTitle":23681,"status":244,"phases":23682,"primaryCompletion":3776,"completion":3776,"start":2982,"enrollment":2439,"conditions":23683,"interventions":23684},"NCT00014378","Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors",[89],[1568],[23673],{"trials":23686,"activeCount":101},[],{"trials":23688,"activeCount":101},[],{"trials":23690,"activeCount":101},[],{"trials":23692,"activeCount":101},[],{"intervention":9531,"totalTrials":97,"cells":23694},{"EARLY_PHASE1":23695,"PHASE1":23697,"PHASE2":23703,"PHASE3":23705,"PHASE4":23707,"NA":23709},{"trials":23696,"activeCount":101},[],{"trials":23698,"activeCount":101},[23699],{"nctId":9525,"briefTitle":9526,"status":244,"phases":23700,"primaryCompletion":4255,"completion":4255,"start":9528,"enrollment":509,"conditions":23701,"interventions":23702},[89],[9380],[1145,9531],{"trials":23704,"activeCount":101},[],{"trials":23706,"activeCount":101},[],{"trials":23708,"activeCount":101},[],{"trials":23710,"activeCount":101},[],{"intervention":23712,"totalTrials":97,"cells":23713},"PV701",{"EARLY_PHASE1":23714,"PHASE1":23716,"PHASE2":23724,"PHASE3":23726,"PHASE4":23728,"NA":23730},{"trials":23715,"activeCount":101},[],{"trials":23717,"activeCount":101},[23718],{"nctId":23719,"briefTitle":23720,"status":244,"phases":23721,"start":695,"conditions":23722,"interventions":23723},"NCT00055705","PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer",[89],[1155],[23712],{"trials":23725,"activeCount":101},[],{"trials":23727,"activeCount":101},[],{"trials":23729,"activeCount":101},[],{"trials":23731,"activeCount":101},[],{"intervention":23733,"totalTrials":97,"cells":23734},"sodium salicylate",{"EARLY_PHASE1":23735,"PHASE1":23737,"PHASE2":23745,"PHASE3":23747,"PHASE4":23749,"NA":23751},{"trials":23736,"activeCount":101},[],{"trials":23738,"activeCount":101},[23739],{"nctId":23740,"briefTitle":23741,"status":244,"phases":23742,"primaryCompletion":339,"start":3930,"conditions":23743,"interventions":23744},"NCT00004245","Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia",[89],[27,475,476],[23733],{"trials":23746,"activeCount":101},[],{"trials":23748,"activeCount":101},[],{"trials":23750,"activeCount":101},[],{"trials":23752,"activeCount":101},[],{"intervention":8557,"totalTrials":97,"cells":23754},{"EARLY_PHASE1":23755,"PHASE1":23757,"PHASE2":23763,"PHASE3":23765,"PHASE4":23767,"NA":23769},{"trials":23756,"activeCount":101},[],{"trials":23758,"activeCount":101},[23759],{"nctId":8551,"briefTitle":8552,"status":244,"phases":23760,"primaryCompletion":648,"completion":588,"start":8554,"enrollment":438,"conditions":23761,"interventions":23762},[89],[24,1568],[1616,391,8557],{"trials":23764,"activeCount":101},[],{"trials":23766,"activeCount":101},[],{"trials":23768,"activeCount":101},[],{"trials":23770,"activeCount":101},[],{"intervention":23772,"totalTrials":97,"cells":23773},"injection of mouse TYRP2 DNA",{"EARLY_PHASE1":23774,"PHASE1":23776,"PHASE2":23784,"PHASE3":23786,"PHASE4":23788,"NA":23790},{"trials":23775,"activeCount":101},[],{"trials":23777,"activeCount":101},[23778],{"nctId":23779,"briefTitle":23780,"status":244,"phases":23781,"primaryCompletion":23295,"completion":23295,"start":727,"enrollment":283,"conditions":23782,"interventions":23783},"NCT00680589","Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response",[89],[2341],[23772],{"trials":23785,"activeCount":101},[],{"trials":23787,"activeCount":101},[],{"trials":23789,"activeCount":101},[],{"trials":23791,"activeCount":101},[],{"intervention":23793,"totalTrials":97,"cells":23794},"ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195",{"EARLY_PHASE1":23795,"PHASE1":23797,"PHASE2":23805,"PHASE3":23807,"PHASE4":23809,"NA":23811},{"trials":23796,"activeCount":101},[],{"trials":23798,"activeCount":101},[23799],{"nctId":23800,"briefTitle":23801,"status":244,"phases":23802,"primaryCompletion":891,"completion":891,"start":369,"enrollment":1412,"conditions":23803,"interventions":23804},"NCT00672165","Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies",[89],[27,416],[23793],{"trials":23806,"activeCount":101},[],{"trials":23808,"activeCount":101},[],{"trials":23810,"activeCount":101},[],{"trials":23812,"activeCount":101},[],{"intervention":23814,"totalTrials":97,"cells":23815},"BKM120 days 1 - 21 plus paclitaxel + carboplatin",{"EARLY_PHASE1":23816,"PHASE1":23818,"PHASE2":23831,"PHASE3":23833,"PHASE4":23835,"NA":23837},{"trials":23817,"activeCount":101},[],{"trials":23819,"activeCount":101},[23820],{"nctId":23821,"briefTitle":23822,"status":244,"phases":23823,"primaryCompletion":23824,"completion":23824,"start":23825,"enrollment":341,"conditions":23826,"interventions":23827},"NCT01297452","BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors",[89],"2017-03-29","2011-02-15",[328],[23814,23828,23829,23830],"BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin","BKM120","BKM120, Paclitaxel + Carboplatin",{"trials":23832,"activeCount":101},[],{"trials":23834,"activeCount":101},[],{"trials":23836,"activeCount":101},[],{"trials":23838,"activeCount":101},[],{"intervention":23828,"totalTrials":97,"cells":23840},{"EARLY_PHASE1":23841,"PHASE1":23843,"PHASE2":23849,"PHASE3":23851,"PHASE4":23853,"NA":23855},{"trials":23842,"activeCount":101},[],{"trials":23844,"activeCount":101},[23845],{"nctId":23821,"briefTitle":23822,"status":244,"phases":23846,"primaryCompletion":23824,"completion":23824,"start":23825,"enrollment":341,"conditions":23847,"interventions":23848},[89],[328],[23814,23828,23829,23830],{"trials":23850,"activeCount":101},[],{"trials":23852,"activeCount":101},[],{"trials":23854,"activeCount":101},[],{"trials":23856,"activeCount":101},[],{"intervention":23829,"totalTrials":97,"cells":23858},{"EARLY_PHASE1":23859,"PHASE1":23861,"PHASE2":23867,"PHASE3":23869,"PHASE4":23871,"NA":23873},{"trials":23860,"activeCount":101},[],{"trials":23862,"activeCount":101},[23863],{"nctId":23821,"briefTitle":23822,"status":244,"phases":23864,"primaryCompletion":23824,"completion":23824,"start":23825,"enrollment":341,"conditions":23865,"interventions":23866},[89],[328],[23814,23828,23829,23830],{"trials":23868,"activeCount":101},[],{"trials":23870,"activeCount":101},[],{"trials":23872,"activeCount":101},[],{"trials":23874,"activeCount":101},[],{"intervention":23830,"totalTrials":97,"cells":23876},{"EARLY_PHASE1":23877,"PHASE1":23879,"PHASE2":23885,"PHASE3":23887,"PHASE4":23889,"NA":23891},{"trials":23878,"activeCount":101},[],{"trials":23880,"activeCount":101},[23881],{"nctId":23821,"briefTitle":23822,"status":244,"phases":23882,"primaryCompletion":23824,"completion":23824,"start":23825,"enrollment":341,"conditions":23883,"interventions":23884},[89],[328],[23814,23828,23829,23830],{"trials":23886,"activeCount":101},[],{"trials":23888,"activeCount":101},[],{"trials":23890,"activeCount":101},[],{"trials":23892,"activeCount":101},[],{"intervention":23894,"totalTrials":97,"cells":23895},"Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21",{"EARLY_PHASE1":23896,"PHASE1":23898,"PHASE2":23907,"PHASE3":23909,"PHASE4":23911,"NA":23913},{"trials":23897,"activeCount":101},[],{"trials":23899,"activeCount":101},[23900],{"nctId":23901,"briefTitle":23902,"status":244,"phases":23903,"primaryCompletion":23528,"completion":23528,"start":3281,"enrollment":213,"conditions":23904,"interventions":23906},"NCT01248273","Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission",[89],[23905,30,3437],"Fallopian Tubes",[23894],{"trials":23908,"activeCount":101},[],{"trials":23910,"activeCount":101},[],{"trials":23912,"activeCount":101},[],{"trials":23914,"activeCount":101},[],{"intervention":23916,"totalTrials":97,"cells":23917},"Illuminare-1",{"EARLY_PHASE1":23918,"PHASE1":23920,"PHASE2":23930,"PHASE3":23932,"PHASE4":23934,"NA":23936},{"trials":23919,"activeCount":101},[],{"trials":23921,"activeCount":101},[23922],{"nctId":23923,"briefTitle":23924,"status":244,"phases":23925,"primaryCompletion":23926,"completion":23926,"start":23927,"enrollment":2462,"conditions":23928,"interventions":23929},"NCT04983862","Fluorescent Imaging of Nerves With Illuminare-1 During Surgery",[89],"2025-09-09","2021-10-04",[4761],[23916],{"trials":23931,"activeCount":101},[],{"trials":23933,"activeCount":101},[],{"trials":23935,"activeCount":101},[],{"trials":23937,"activeCount":101},[],{"intervention":23939,"totalTrials":97,"cells":23940},"GM2-KLH vaccine",{"EARLY_PHASE1":23941,"PHASE1":23943,"PHASE2":23951,"PHASE3":23953,"PHASE4":23955,"NA":23957},{"trials":23942,"activeCount":101},[],{"trials":23944,"activeCount":101},[23945],{"nctId":23946,"briefTitle":23947,"status":244,"phases":23948,"primaryCompletion":3402,"completion":3402,"start":2906,"enrollment":601,"conditions":23949,"interventions":23950},"NCT00003357","Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease",[89],[15],[23939,9012],{"trials":23952,"activeCount":101},[],{"trials":23954,"activeCount":101},[],{"trials":23956,"activeCount":101},[],{"trials":23958,"activeCount":101},[],{"intervention":23960,"totalTrials":97,"cells":23961},"RAD001 + docetaxel + cisplatin",{"EARLY_PHASE1":23962,"PHASE1":23964,"PHASE2":23974,"PHASE3":23976,"PHASE4":23978,"NA":23980},{"trials":23963,"activeCount":101},[],{"trials":23965,"activeCount":101},[23966],{"nctId":23967,"briefTitle":23968,"status":244,"phases":23969,"primaryCompletion":1113,"completion":1113,"start":23970,"enrollment":326,"conditions":23971,"interventions":23973},"NCT00935961","RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer",[89],"2009-07",[23972],"HEAD & NECK Cancer",[23960],{"trials":23975,"activeCount":101},[],{"trials":23977,"activeCount":101},[],{"trials":23979,"activeCount":101},[],{"trials":23981,"activeCount":101},[],{"intervention":23983,"totalTrials":97,"cells":23984},"Langerhans-type dendritic cells",{"EARLY_PHASE1":23985,"PHASE1":23987,"PHASE2":23997,"PHASE3":23999,"PHASE4":24001,"NA":24003},{"trials":23986,"activeCount":101},[],{"trials":23988,"activeCount":101},[23989],{"nctId":23990,"briefTitle":23991,"status":244,"phases":23992,"primaryCompletion":23993,"completion":23993,"start":23994,"enrollment":601,"conditions":23995,"interventions":23996},"NCT01456104","Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma",[89],"2023-01-12","2011-10-17",[2341],[23983],{"trials":23998,"activeCount":101},[],{"trials":24000,"activeCount":101},[],{"trials":24002,"activeCount":101},[],{"trials":24004,"activeCount":101},[],{"intervention":8777,"totalTrials":97,"cells":24006},{"EARLY_PHASE1":24007,"PHASE1":24009,"PHASE2":24015,"PHASE3":24017,"PHASE4":24019,"NA":24021},{"trials":24008,"activeCount":101},[],{"trials":24010,"activeCount":101},[24011],{"nctId":8771,"briefTitle":8772,"status":244,"phases":24012,"primaryCompletion":8774,"completion":8774,"start":5888,"enrollment":454,"conditions":24013,"interventions":24014},[89],[1590,2336,1586,3562],[8777,8777,8777,1593,8777,8777],{"trials":24016,"activeCount":101},[],{"trials":24018,"activeCount":101},[],{"trials":24020,"activeCount":101},[],{"trials":24022,"activeCount":101},[],{"intervention":24024,"totalTrials":97,"cells":24025},"pyroxamide",{"EARLY_PHASE1":24026,"PHASE1":24028,"PHASE2":24038,"PHASE3":24040,"PHASE4":24042,"NA":24044},{"trials":24027,"activeCount":101},[],{"trials":24029,"activeCount":101},[24030],{"nctId":24031,"briefTitle":24032,"status":244,"phases":24033,"primaryCompletion":1622,"completion":1622,"start":1566,"conditions":24034,"interventions":24037},"NCT00042900","Pyroxamide in Treating Patients With Advanced Cancer",[89],[24035,27,24,828,475,24036,1687,1568],"Chronic Myeloproliferative Disorders","Precancerous Condition",[24024],{"trials":24039,"activeCount":101},[],{"trials":24041,"activeCount":101},[],{"trials":24043,"activeCount":101},[],{"trials":24045,"activeCount":101},[],{"intervention":24047,"totalTrials":97,"cells":24048},"Afatinib, Ribavirin, and weekly carboplatin\u002Fpaclitaxel",{"EARLY_PHASE1":24049,"PHASE1":24051,"PHASE2":24059,"PHASE3":24061,"PHASE4":24063,"NA":24065},{"trials":24050,"activeCount":101},[],{"trials":24052,"activeCount":101},[24053],{"nctId":24054,"briefTitle":24055,"status":244,"phases":24056,"primaryCompletion":3209,"completion":3209,"start":1082,"enrollment":1434,"conditions":24057,"interventions":24058},"NCT01721525","Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin\u002FPaclitaxel for Stage IVA\u002FIVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)",[89],[1586,8813],[24047],{"trials":24060,"activeCount":101},[],{"trials":24062,"activeCount":101},[],{"trials":24064,"activeCount":101},[],{"trials":24066,"activeCount":101},[],{"intervention":18710,"totalTrials":97,"cells":24068},{"EARLY_PHASE1":24069,"PHASE1":24071,"PHASE2":24077,"PHASE3":24079,"PHASE4":24081,"NA":24083},{"trials":24070,"activeCount":101},[],{"trials":24072,"activeCount":101},[24073],{"nctId":18705,"briefTitle":18706,"status":244,"phases":24074,"primaryCompletion":4807,"completion":4807,"start":728,"enrollment":899,"conditions":24075,"interventions":24076},[89],[18],[9012,18710,18711,18698],{"trials":24078,"activeCount":101},[],{"trials":24080,"activeCount":101},[],{"trials":24082,"activeCount":101},[],{"trials":24084,"activeCount":101},[],{"intervention":18711,"totalTrials":97,"cells":24086},{"EARLY_PHASE1":24087,"PHASE1":24089,"PHASE2":24095,"PHASE3":24097,"PHASE4":24099,"NA":24101},{"trials":24088,"activeCount":101},[],{"trials":24090,"activeCount":101},[24091],{"nctId":18705,"briefTitle":18706,"status":244,"phases":24092,"primaryCompletion":4807,"completion":4807,"start":728,"enrollment":899,"conditions":24093,"interventions":24094},[89],[18],[9012,18710,18711,18698],{"trials":24096,"activeCount":101},[],{"trials":24098,"activeCount":101},[],{"trials":24100,"activeCount":101},[],{"trials":24102,"activeCount":101},[],{"intervention":24104,"totalTrials":97,"cells":24105},"lumiliximab",{"EARLY_PHASE1":24106,"PHASE1":24108,"PHASE2":24116,"PHASE3":24118,"PHASE4":24120,"NA":24122},{"trials":24107,"activeCount":101},[],{"trials":24109,"activeCount":101},[24110],{"nctId":24111,"briefTitle":24112,"status":244,"phases":24113,"primaryCompletion":9078,"start":13332,"conditions":24114,"interventions":24115},"NCT00058396","Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[89],[27,24],[24104],{"trials":24117,"activeCount":101},[],{"trials":24119,"activeCount":101},[],{"trials":24121,"activeCount":101},[],{"trials":24123,"activeCount":101},[],{"intervention":24125,"totalTrials":97,"cells":24126},"concurrent capecitabine or 5-FU",{"EARLY_PHASE1":24127,"PHASE1":24129,"PHASE2":24140,"PHASE3":24142,"PHASE4":24144,"NA":24146},{"trials":24128,"activeCount":101},[],{"trials":24130,"activeCount":101},[24131],{"nctId":24132,"briefTitle":24133,"status":244,"phases":24134,"primaryCompletion":24135,"completion":24135,"start":24136,"enrollment":1871,"conditions":24137,"interventions":24139},"NCT02199236","Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management",[89],"2024-10-29","2014-07",[24138],"Rectal or Anal Cancer",[24125],{"trials":24141,"activeCount":101},[],{"trials":24143,"activeCount":101},[],{"trials":24145,"activeCount":101},[],{"trials":24147,"activeCount":101},[],{"intervention":2624,"totalTrials":97,"cells":24149},{"EARLY_PHASE1":24150,"PHASE1":24152,"PHASE2":24158,"PHASE3":24160,"PHASE4":24162,"NA":24164},{"trials":24151,"activeCount":101},[],{"trials":24153,"activeCount":101},[24154],{"nctId":2616,"briefTitle":2617,"status":244,"phases":24155,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":601,"conditions":24156,"interventions":24157},[89],[2622],[2624,942,941],{"trials":24159,"activeCount":101},[],{"trials":24161,"activeCount":101},[],{"trials":24163,"activeCount":101},[],{"trials":24165,"activeCount":101},[],{"intervention":24167,"totalTrials":97,"cells":24168},"Iso-Fludelone",{"EARLY_PHASE1":24169,"PHASE1":24171,"PHASE2":24181,"PHASE3":24183,"PHASE4":24185,"NA":24187},{"trials":24170,"activeCount":101},[],{"trials":24172,"activeCount":101},[24173],{"nctId":24174,"briefTitle":24175,"status":244,"phases":24176,"primaryCompletion":24177,"completion":24177,"start":24178,"enrollment":1462,"conditions":24179,"interventions":24180},"NCT01379287","Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors",[89],"2023-01-31","2011-06-20",[328],[24167],{"trials":24182,"activeCount":101},[],{"trials":24184,"activeCount":101},[],{"trials":24186,"activeCount":101},[],{"trials":24188,"activeCount":101},[],{"intervention":24190,"totalTrials":97,"cells":24191},"vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant",{"EARLY_PHASE1":24192,"PHASE1":24194,"PHASE2":24203,"PHASE3":24205,"PHASE4":24207,"NA":24209},{"trials":24193,"activeCount":101},[],{"trials":24195,"activeCount":101},[24196],{"nctId":24197,"briefTitle":24198,"status":244,"phases":24199,"primaryCompletion":803,"completion":803,"start":4634,"enrollment":899,"conditions":24200,"interventions":24201},"NCT01349647","Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid",[89],[21],[24190,24202],"Biological\u002FVaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant",{"trials":24204,"activeCount":101},[],{"trials":24206,"activeCount":101},[],{"trials":24208,"activeCount":101},[],{"trials":24210,"activeCount":101},[],{"intervention":24202,"totalTrials":97,"cells":24212},{"EARLY_PHASE1":24213,"PHASE1":24215,"PHASE2":24221,"PHASE3":24223,"PHASE4":24225,"NA":24227},{"trials":24214,"activeCount":101},[],{"trials":24216,"activeCount":101},[24217],{"nctId":24197,"briefTitle":24198,"status":244,"phases":24218,"primaryCompletion":803,"completion":803,"start":4634,"enrollment":899,"conditions":24219,"interventions":24220},[89],[21],[24190,24202],{"trials":24222,"activeCount":101},[],{"trials":24224,"activeCount":101},[],{"trials":24226,"activeCount":101},[],{"trials":24228,"activeCount":101},[],{"intervention":8569,"totalTrials":97,"cells":24230},{"EARLY_PHASE1":24231,"PHASE1":24233,"PHASE2":24239,"PHASE3":24241,"PHASE4":24243,"NA":24245},{"trials":24232,"activeCount":101},[],{"trials":24234,"activeCount":101},[24235],{"nctId":8563,"briefTitle":8564,"status":244,"phases":24236,"primaryCompletion":3220,"completion":588,"start":8566,"enrollment":356,"conditions":24237,"interventions":24238},[89],[36],[391,8569],{"trials":24240,"activeCount":101},[],{"trials":24242,"activeCount":101},[],{"trials":24244,"activeCount":101},[],{"trials":24246,"activeCount":101},[],{"intervention":24248,"totalTrials":97,"cells":24249},"dendritic cell vaccine",{"EARLY_PHASE1":24250,"PHASE1":24252,"PHASE2":24260,"PHASE3":24262,"PHASE4":24264,"NA":24266},{"trials":24251,"activeCount":101},[],{"trials":24253,"activeCount":101},[24254],{"nctId":24255,"briefTitle":24256,"status":244,"phases":24257,"primaryCompletion":3655,"completion":3655,"start":17316,"enrollment":3017,"conditions":24258,"interventions":24259},"NCT00700167","Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy",[89],[2341],[24248],{"trials":24261,"activeCount":101},[],{"trials":24263,"activeCount":101},[],{"trials":24265,"activeCount":101},[],{"trials":24267,"activeCount":101},[],{"intervention":24269,"totalTrials":97,"cells":24270},"LY293111",{"EARLY_PHASE1":24271,"PHASE1":24273,"PHASE2":24281,"PHASE3":24283,"PHASE4":24285,"NA":24287},{"trials":24272,"activeCount":101},[],{"trials":24274,"activeCount":101},[24275],{"nctId":24276,"briefTitle":24277,"status":244,"phases":24278,"primaryCompletion":1610,"completion":1610,"start":637,"conditions":24279,"interventions":24280},"NCT00006375","LY293111 in Treating Patients With Advanced Solid Tumors",[89],[1568],[24269],{"trials":24282,"activeCount":101},[],{"trials":24284,"activeCount":101},[],{"trials":24286,"activeCount":101},[],{"trials":24288,"activeCount":101},[],{"intervention":24290,"totalTrials":97,"cells":24291},"GL-ONC1",{"EARLY_PHASE1":24292,"PHASE1":24294,"PHASE2":24303,"PHASE3":24305,"PHASE4":24307,"NA":24309},{"trials":24293,"activeCount":101},[],{"trials":24295,"activeCount":101},[24296],{"nctId":24297,"briefTitle":24298,"status":244,"phases":24299,"primaryCompletion":24300,"completion":24300,"start":15957,"enrollment":326,"conditions":24301,"interventions":24302},"NCT01766739","Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma",[89],"2024-10-24",[21],[24290],{"trials":24304,"activeCount":101},[],{"trials":24306,"activeCount":101},[],{"trials":24308,"activeCount":101},[],{"trials":24310,"activeCount":101},[],{"intervention":24312,"totalTrials":97,"cells":24313},"MVT-2163",{"EARLY_PHASE1":24314,"PHASE1":24316,"PHASE2":24327,"PHASE3":24329,"PHASE4":24331,"NA":24333},{"trials":24315,"activeCount":101},[],{"trials":24317,"activeCount":101},[24318],{"nctId":24319,"briefTitle":24320,"status":244,"phases":24321,"primaryCompletion":24322,"completion":24322,"start":8901,"enrollment":1114,"conditions":24323,"interventions":24325},"NCT04883775","Study of a New Technique for Imaging Pancreatic Cancer",[89],"2025-01-27",[1226,24324],"Tumors That Express CA19-9",[24312,24326],"MVT-5873",{"trials":24328,"activeCount":101},[],{"trials":24330,"activeCount":101},[],{"trials":24332,"activeCount":101},[],{"trials":24334,"activeCount":101},[],{"intervention":24326,"totalTrials":97,"cells":24336},{"EARLY_PHASE1":24337,"PHASE1":24339,"PHASE2":24345,"PHASE3":24347,"PHASE4":24349,"NA":24351},{"trials":24338,"activeCount":101},[],{"trials":24340,"activeCount":101},[24341],{"nctId":24319,"briefTitle":24320,"status":244,"phases":24342,"primaryCompletion":24322,"completion":24322,"start":8901,"enrollment":1114,"conditions":24343,"interventions":24344},[89],[1226,24324],[24312,24326],{"trials":24346,"activeCount":101},[],{"trials":24348,"activeCount":101},[],{"trials":24350,"activeCount":101},[],{"trials":24352,"activeCount":101},[],{"intervention":24354,"totalTrials":97,"cells":24355},"abagovomab",{"EARLY_PHASE1":24356,"PHASE1":24358,"PHASE2":24366,"PHASE3":24368,"PHASE4":24370,"NA":24372},{"trials":24357,"activeCount":101},[],{"trials":24359,"activeCount":101},[24360],{"nctId":24361,"briefTitle":24362,"status":244,"phases":24363,"primaryCompletion":1575,"completion":1575,"start":22654,"conditions":24364,"interventions":24365},"NCT00058435","Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer",[89],[285,30,286],[24354],{"trials":24367,"activeCount":101},[],{"trials":24369,"activeCount":101},[],{"trials":24371,"activeCount":101},[],{"trials":24373,"activeCount":101},[],{"intervention":24375,"totalTrials":97,"cells":24376},"monoclonal antibody muJ591",{"EARLY_PHASE1":24377,"PHASE1":24379,"PHASE2":24386,"PHASE3":24388,"PHASE4":24390,"NA":24392},{"trials":24378,"activeCount":101},[],{"trials":24380,"activeCount":101},[24381],{"nctId":24382,"briefTitle":23074,"status":244,"phases":24383,"primaryCompletion":1629,"completion":1629,"start":1703,"conditions":24384,"interventions":24385},"NCT00006380",[89],[18],[24375],{"trials":24387,"activeCount":101},[],{"trials":24389,"activeCount":101},[],{"trials":24391,"activeCount":101},[],{"trials":24393,"activeCount":101},[],{"intervention":18783,"totalTrials":97,"cells":24395},{"EARLY_PHASE1":24396,"PHASE1":24398,"PHASE2":24404,"PHASE3":24406,"PHASE4":24408,"NA":24410},{"trials":24397,"activeCount":101},[],{"trials":24399,"activeCount":101},[24400],{"nctId":18778,"briefTitle":18779,"status":244,"phases":24401,"primaryCompletion":384,"completion":384,"start":1685,"conditions":24402,"interventions":24403},[89],[4734],[18783,18784,18785,9014],{"trials":24405,"activeCount":101},[],{"trials":24407,"activeCount":101},[],{"trials":24409,"activeCount":101},[],{"trials":24411,"activeCount":101},[],{"intervention":18784,"totalTrials":97,"cells":24413},{"EARLY_PHASE1":24414,"PHASE1":24416,"PHASE2":24422,"PHASE3":24424,"PHASE4":24426,"NA":24428},{"trials":24415,"activeCount":101},[],{"trials":24417,"activeCount":101},[24418],{"nctId":18778,"briefTitle":18779,"status":244,"phases":24419,"primaryCompletion":384,"completion":384,"start":1685,"conditions":24420,"interventions":24421},[89],[4734],[18783,18784,18785,9014],{"trials":24423,"activeCount":101},[],{"trials":24425,"activeCount":101},[],{"trials":24427,"activeCount":101},[],{"trials":24429,"activeCount":101},[],{"intervention":18785,"totalTrials":97,"cells":24431},{"EARLY_PHASE1":24432,"PHASE1":24434,"PHASE2":24440,"PHASE3":24442,"PHASE4":24444,"NA":24446},{"trials":24433,"activeCount":101},[],{"trials":24435,"activeCount":101},[24436],{"nctId":18778,"briefTitle":18779,"status":244,"phases":24437,"primaryCompletion":384,"completion":384,"start":1685,"conditions":24438,"interventions":24439},[89],[4734],[18783,18784,18785,9014],{"trials":24441,"activeCount":101},[],{"trials":24443,"activeCount":101},[],{"trials":24445,"activeCount":101},[],{"trials":24447,"activeCount":101},[],{"intervention":24449,"totalTrials":97,"cells":24450},"hu5B1-TCO",{"EARLY_PHASE1":24451,"PHASE1":24453,"PHASE2":24464,"PHASE3":24466,"PHASE4":24468,"NA":24470},{"trials":24452,"activeCount":101},[],{"trials":24454,"activeCount":101},[24455],{"nctId":24456,"briefTitle":24457,"status":2832,"phases":24458,"primaryCompletion":22446,"completion":22446,"start":24459,"enrollment":101,"conditions":24460,"interventions":24462},"NCT05737615","PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9",[89],"2023-02-10",[1226,11732,2475,24461,11734],"Primary Pancreatic Ductal Adenocarcinoma",[24449,24463],"64Cu-Tz-SarAr",{"trials":24465,"activeCount":101},[],{"trials":24467,"activeCount":101},[],{"trials":24469,"activeCount":101},[],{"trials":24471,"activeCount":101},[],{"intervention":24463,"totalTrials":97,"cells":24473},{"EARLY_PHASE1":24474,"PHASE1":24476,"PHASE2":24482,"PHASE3":24484,"PHASE4":24486,"NA":24488},{"trials":24475,"activeCount":101},[],{"trials":24477,"activeCount":101},[24478],{"nctId":24456,"briefTitle":24457,"status":2832,"phases":24479,"primaryCompletion":22446,"completion":22446,"start":24459,"enrollment":101,"conditions":24480,"interventions":24481},[89],[1226,11732,2475,24461,11734],[24449,24463],{"trials":24483,"activeCount":101},[],{"trials":24485,"activeCount":101},[],{"trials":24487,"activeCount":101},[],{"trials":24489,"activeCount":101},[],{"intervention":8955,"totalTrials":97,"cells":24491},{"EARLY_PHASE1":24492,"PHASE1":24494,"PHASE2":24500,"PHASE3":24502,"PHASE4":24504,"NA":24506},{"trials":24493,"activeCount":101},[],{"trials":24495,"activeCount":101},[24496],{"nctId":8950,"briefTitle":8951,"status":244,"phases":24497,"primaryCompletion":5650,"completion":5650,"start":3032,"enrollment":2483,"conditions":24498,"interventions":24499},[89],[27,21,3163,475,286],[8955,8956,360,378],{"trials":24501,"activeCount":101},[],{"trials":24503,"activeCount":101},[],{"trials":24505,"activeCount":101},[],{"trials":24507,"activeCount":101},[],{"intervention":24509,"totalTrials":97,"cells":24510},"RXDX-105",{"EARLY_PHASE1":24511,"PHASE1":24513,"PHASE2":24523,"PHASE3":24525,"PHASE4":24527,"NA":24529},{"trials":24512,"activeCount":101},[],{"trials":24514,"activeCount":101},[24515],{"nctId":24516,"briefTitle":24517,"status":244,"phases":24518,"primaryCompletion":271,"completion":271,"start":24519,"enrollment":509,"conditions":24520,"interventions":24522},"NCT03784378","Continued Access to RXDX-105",[89],"2018-12-14",[3094,30,24521,6106],"RET Gene Mutation",[24509],{"trials":24524,"activeCount":101},[],{"trials":24526,"activeCount":101},[],{"trials":24528,"activeCount":101},[],{"trials":24530,"activeCount":101},[],{"intervention":24532,"totalTrials":97,"cells":24533},"RAD001, Sunitinib",{"EARLY_PHASE1":24534,"PHASE1":24536,"PHASE2":24544,"PHASE3":24546,"PHASE4":24548,"NA":24550},{"trials":24535,"activeCount":101},[],{"trials":24537,"activeCount":101},[24538],{"nctId":24539,"briefTitle":24540,"status":244,"phases":24541,"primaryCompletion":21936,"completion":21936,"start":3032,"enrollment":306,"conditions":24542,"interventions":24543},"NCT00422344","A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma",[89],[5422,783],[24532],{"trials":24545,"activeCount":101},[],{"trials":24547,"activeCount":101},[],{"trials":24549,"activeCount":101},[],{"trials":24551,"activeCount":101},[],{"intervention":2636,"totalTrials":97,"cells":24553},{"EARLY_PHASE1":24554,"PHASE1":24556,"PHASE2":24562,"PHASE3":24564,"PHASE4":24566,"NA":24568},{"trials":24555,"activeCount":101},[],{"trials":24557,"activeCount":101},[24558],{"nctId":2626,"briefTitle":2627,"status":244,"phases":24559,"primaryCompletion":2629,"completion":2629,"start":1809,"enrollment":2630,"conditions":24560,"interventions":24561},[89],[30,2632,2633,2634],[2636,942,2637],{"trials":24563,"activeCount":101},[],{"trials":24565,"activeCount":101},[],{"trials":24567,"activeCount":101},[],{"trials":24569,"activeCount":101},[],{"intervention":2637,"totalTrials":97,"cells":24571},{"EARLY_PHASE1":24572,"PHASE1":24574,"PHASE2":24580,"PHASE3":24582,"PHASE4":24584,"NA":24586},{"trials":24573,"activeCount":101},[],{"trials":24575,"activeCount":101},[24576],{"nctId":2626,"briefTitle":2627,"status":244,"phases":24577,"primaryCompletion":2629,"completion":2629,"start":1809,"enrollment":2630,"conditions":24578,"interventions":24579},[89],[30,2632,2633,2634],[2636,942,2637],{"trials":24581,"activeCount":101},[],{"trials":24583,"activeCount":101},[],{"trials":24585,"activeCount":101},[],{"trials":24587,"activeCount":101},[],{"intervention":24589,"totalTrials":97,"cells":24590},"cisplatin or carboplatin-based",{"EARLY_PHASE1":24591,"PHASE1":24593,"PHASE2":24603,"PHASE3":24605,"PHASE4":24607,"NA":24609},{"trials":24592,"activeCount":101},[],{"trials":24594,"activeCount":101},[24595],{"nctId":24596,"briefTitle":24597,"status":244,"phases":24598,"primaryCompletion":24599,"completion":24599,"start":24600,"enrollment":573,"conditions":24601,"interventions":24602},"NCT01899989","Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer",[89],"2024-10-02","2013-07-05",[2948],[24589],{"trials":24604,"activeCount":101},[],{"trials":24606,"activeCount":101},[],{"trials":24608,"activeCount":101},[],{"trials":24610,"activeCount":101},[],{"intervention":5168,"totalTrials":97,"cells":24612},{"EARLY_PHASE1":24613,"PHASE1":24615,"PHASE2":24621,"PHASE3":24623,"PHASE4":24625,"NA":24627},{"trials":24614,"activeCount":101},[],{"trials":24616,"activeCount":101},[24617],{"nctId":5156,"briefTitle":5157,"status":244,"phases":24618,"primaryCompletion":5159,"completion":5159,"start":774,"enrollment":601,"conditions":24619,"interventions":24620},[89],[5161,5162,5163,5164,5165,5166,4855],[5168,741,768,5169],{"trials":24622,"activeCount":101},[],{"trials":24624,"activeCount":101},[],{"trials":24626,"activeCount":101},[],{"trials":24628,"activeCount":101},[],{"intervention":24630,"totalTrials":97,"cells":24631},"PCK3145",{"EARLY_PHASE1":24632,"PHASE1":24634,"PHASE2":24642,"PHASE3":24644,"PHASE4":24646,"NA":24648},{"trials":24633,"activeCount":101},[],{"trials":24635,"activeCount":101},[24636],{"nctId":24637,"briefTitle":24638,"status":244,"phases":24639,"primaryCompletion":4807,"completion":4807,"start":1994,"enrollment":3344,"conditions":24640,"interventions":24641},"NCT00695851","Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.",[89],[18],[24630,24630],{"trials":24643,"activeCount":101},[],{"trials":24645,"activeCount":101},[],{"trials":24647,"activeCount":101},[],{"trials":24649,"activeCount":101},[],{"intervention":9316,"totalTrials":97,"cells":24651},{"EARLY_PHASE1":24652,"PHASE1":24654,"PHASE2":24660,"PHASE3":24662,"PHASE4":24664,"NA":24666},{"trials":24653,"activeCount":101},[],{"trials":24655,"activeCount":101},[24656],{"nctId":9308,"briefTitle":9309,"status":244,"phases":24657,"primaryCompletion":9311,"completion":9311,"start":9312,"enrollment":992,"conditions":24658,"interventions":24659},[89],[33,2428,9314,1017,2372,2371,4868],[9316,6591],{"trials":24661,"activeCount":101},[],{"trials":24663,"activeCount":101},[],{"trials":24665,"activeCount":101},[],{"trials":24667,"activeCount":101},[],{"intervention":2926,"totalTrials":97,"cells":24669},{"EARLY_PHASE1":24670,"PHASE1":24672,"PHASE2":24678,"PHASE3":24680,"PHASE4":24682,"NA":24684},{"trials":24671,"activeCount":101},[],{"trials":24673,"activeCount":101},[24674],{"nctId":2919,"briefTitle":2920,"status":244,"phases":24675,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":234,"conditions":24676,"interventions":24677},[89],[30,2633,285],[2926,1157,974,77],{"trials":24679,"activeCount":101},[],{"trials":24681,"activeCount":101},[],{"trials":24683,"activeCount":101},[],{"trials":24685,"activeCount":101},[],{"intervention":24687,"totalTrials":97,"cells":24688},"cintredekin besudotox",{"EARLY_PHASE1":24689,"PHASE1":24691,"PHASE2":24699,"PHASE3":24701,"PHASE4":24703,"NA":24705},{"trials":24690,"activeCount":101},[],{"trials":24692,"activeCount":101},[24693],{"nctId":24694,"briefTitle":24695,"status":244,"phases":24696,"primaryCompletion":1971,"completion":588,"start":3402,"conditions":24697,"interventions":24698},"NCT00036972","Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma",[89],[3259],[24687],{"trials":24700,"activeCount":101},[],{"trials":24702,"activeCount":101},[],{"trials":24704,"activeCount":101},[],{"trials":24706,"activeCount":101},[],{"intervention":9594,"totalTrials":97,"cells":24708},{"EARLY_PHASE1":24709,"PHASE1":24711,"PHASE2":24717,"PHASE3":24719,"PHASE4":24721,"NA":24723},{"trials":24710,"activeCount":101},[],{"trials":24712,"activeCount":101},[24713],{"nctId":9588,"briefTitle":9589,"status":244,"phases":24714,"primaryCompletion":5816,"completion":5816,"start":813,"enrollment":2426,"conditions":24715,"interventions":24716},[89],[9592],[7454,6280,9594],{"trials":24718,"activeCount":101},[],{"trials":24720,"activeCount":101},[],{"trials":24722,"activeCount":101},[],{"trials":24724,"activeCount":101},[],{"intervention":24726,"totalTrials":97,"cells":24727},"WST11 mediated vascular targeted phototherapy",{"EARLY_PHASE1":24728,"PHASE1":24730,"PHASE2":24740,"PHASE3":24742,"PHASE4":24744,"NA":24746},{"trials":24729,"activeCount":101},[],{"trials":24731,"activeCount":101},[24732],{"nctId":24733,"briefTitle":24734,"status":244,"phases":24735,"primaryCompletion":24736,"completion":24736,"start":1071,"enrollment":356,"conditions":24737,"interventions":24739},"NCT03617003","Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)",[89],"2025-07-15",[24738],"Upper Tract Urothelial Carcinoma",[24726],{"trials":24741,"activeCount":101},[],{"trials":24743,"activeCount":101},[],{"trials":24745,"activeCount":101},[],{"trials":24747,"activeCount":101},[],{"intervention":24749,"totalTrials":97,"cells":24750},"3F8 Monoclonal Antibody Combined with Interleukin-2",{"EARLY_PHASE1":24751,"PHASE1":24753,"PHASE2":24763,"PHASE3":24765,"PHASE4":24767,"NA":24769},{"trials":24752,"activeCount":101},[],{"trials":24754,"activeCount":101},[24755],{"nctId":24756,"briefTitle":24757,"status":244,"phases":24758,"primaryCompletion":24759,"completion":24759,"start":24760,"enrollment":272,"conditions":24761,"interventions":24762},"NCT01662804","Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors",[89],"2021-05-25","2012-08-06",[215],[24749],{"trials":24764,"activeCount":101},[],{"trials":24766,"activeCount":101},[],{"trials":24768,"activeCount":101},[],{"trials":24770,"activeCount":101},[],{"intervention":6093,"totalTrials":97,"cells":24772},{"EARLY_PHASE1":24773,"PHASE1":24775,"PHASE2":24781,"PHASE3":24783,"PHASE4":24785,"NA":24787},{"trials":24774,"activeCount":101},[],{"trials":24776,"activeCount":101},[24777],{"nctId":6086,"briefTitle":6087,"status":244,"phases":24778,"primaryCompletion":6089,"completion":6089,"start":4297,"enrollment":326,"conditions":24779,"interventions":24780},[89],[2341],[6092,3080,6093],{"trials":24782,"activeCount":101},[],{"trials":24784,"activeCount":101},[],{"trials":24786,"activeCount":101},[],{"trials":24788,"activeCount":101},[],{"intervention":24790,"totalTrials":97,"cells":24791},"bevacizumab with chemotherapy, Pleur-XTM catheter placement",{"EARLY_PHASE1":24792,"PHASE1":24794,"PHASE2":24802,"PHASE3":24804,"PHASE4":24806,"NA":24808},{"trials":24793,"activeCount":101},[],{"trials":24795,"activeCount":101},[24796],{"nctId":24797,"briefTitle":24798,"status":244,"phases":24799,"primaryCompletion":4819,"completion":4819,"start":16824,"enrollment":1871,"conditions":24800,"interventions":24801},"NCT00250978","Ph I:Bevacizumab + Chemotherapy in Pts w\u002FMalig Pleural Effusion Due to Adv NSCLC",[89],[19210],[24790],{"trials":24803,"activeCount":101},[],{"trials":24805,"activeCount":101},[],{"trials":24807,"activeCount":101},[],{"trials":24809,"activeCount":101},[],{"intervention":8693,"totalTrials":97,"cells":24811},{"EARLY_PHASE1":24812,"PHASE1":24814,"PHASE2":24820,"PHASE3":24822,"PHASE4":24824,"NA":24826},{"trials":24813,"activeCount":101},[],{"trials":24815,"activeCount":101},[24816],{"nctId":8688,"briefTitle":8689,"status":244,"phases":24817,"primaryCompletion":1663,"completion":1663,"start":728,"enrollment":326,"conditions":24818,"interventions":24819},[89],[36],[8693,549,1616,8694,349],{"trials":24821,"activeCount":101},[],{"trials":24823,"activeCount":101},[],{"trials":24825,"activeCount":101},[],{"trials":24827,"activeCount":101},[],{"intervention":8694,"totalTrials":97,"cells":24829},{"EARLY_PHASE1":24830,"PHASE1":24832,"PHASE2":24838,"PHASE3":24840,"PHASE4":24842,"NA":24844},{"trials":24831,"activeCount":101},[],{"trials":24833,"activeCount":101},[24834],{"nctId":8688,"briefTitle":8689,"status":244,"phases":24835,"primaryCompletion":1663,"completion":1663,"start":728,"enrollment":326,"conditions":24836,"interventions":24837},[89],[36],[8693,549,1616,8694,349],{"trials":24839,"activeCount":101},[],{"trials":24841,"activeCount":101},[],{"trials":24843,"activeCount":101},[],{"trials":24845,"activeCount":101},[],{"intervention":24847,"totalTrials":97,"cells":24848},"monoclonal antibody F19",{"EARLY_PHASE1":24849,"PHASE1":24851,"PHASE2":24860,"PHASE3":24862,"PHASE4":24864,"NA":24866},{"trials":24850,"activeCount":101},[],{"trials":24852,"activeCount":101},[24853],{"nctId":24854,"briefTitle":24855,"status":244,"phases":24856,"primaryCompletion":554,"completion":588,"start":24857,"enrollment":454,"conditions":24858,"interventions":24859},"NCT00004042","Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer",[89],"1998-11",[36],[24847],{"trials":24861,"activeCount":101},[],{"trials":24863,"activeCount":101},[],{"trials":24865,"activeCount":101},[],{"trials":24867,"activeCount":101},[],{"intervention":24869,"totalTrials":97,"cells":24870},"NV1020",{"EARLY_PHASE1":24871,"PHASE1":24873,"PHASE2":24881,"PHASE3":24883,"PHASE4":24885,"NA":24887},{"trials":24872,"activeCount":101},[],{"trials":24874,"activeCount":101},[24875],{"nctId":24876,"briefTitle":24877,"status":244,"phases":24878,"primaryCompletion":1356,"completion":588,"start":2982,"conditions":24879,"interventions":24880},"NCT00012155","Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver",[89],[36,2349],[24869],{"trials":24882,"activeCount":101},[],{"trials":24884,"activeCount":101},[],{"trials":24886,"activeCount":101},[],{"trials":24888,"activeCount":101},[],{"intervention":24890,"totalTrials":97,"cells":24891},"BCG vaccine",{"EARLY_PHASE1":24892,"PHASE1":24894,"PHASE2":24903,"PHASE3":24905,"PHASE4":24907,"NA":24909},{"trials":24893,"activeCount":101},[],{"trials":24895,"activeCount":101},[24896],{"nctId":24897,"briefTitle":24898,"status":244,"phases":24899,"primaryCompletion":1971,"start":18274,"enrollment":454,"conditions":24900,"interventions":24901},"NCT00003023","Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer",[89],[215,33],[24890,24902],"monoclonal antibody A1G4 anti-idiotype vaccine",{"trials":24904,"activeCount":101},[],{"trials":24906,"activeCount":101},[],{"trials":24908,"activeCount":101},[],{"trials":24910,"activeCount":101},[],{"intervention":24902,"totalTrials":97,"cells":24912},{"EARLY_PHASE1":24913,"PHASE1":24915,"PHASE2":24921,"PHASE3":24923,"PHASE4":24925,"NA":24927},{"trials":24914,"activeCount":101},[],{"trials":24916,"activeCount":101},[24917],{"nctId":24897,"briefTitle":24898,"status":244,"phases":24918,"primaryCompletion":1971,"start":18274,"enrollment":454,"conditions":24919,"interventions":24920},[89],[215,33],[24890,24902],{"trials":24922,"activeCount":101},[],{"trials":24924,"activeCount":101},[],{"trials":24926,"activeCount":101},[],{"trials":24928,"activeCount":101},[],{"intervention":2950,"totalTrials":97,"cells":24930},{"EARLY_PHASE1":24931,"PHASE1":24933,"PHASE2":24939,"PHASE3":24941,"PHASE4":24943,"NA":24945},{"trials":24932,"activeCount":101},[],{"trials":24934,"activeCount":101},[24935],{"nctId":2944,"briefTitle":2945,"status":2832,"phases":24936,"primaryCompletion":1641,"completion":1641,"start":1141,"enrollment":101,"conditions":24937,"interventions":24938},[89],[2948],[2950,974,224,1107],{"trials":24940,"activeCount":101},[],{"trials":24942,"activeCount":101},[],{"trials":24944,"activeCount":101},[],{"trials":24946,"activeCount":101},[],{"intervention":24948,"totalTrials":97,"cells":24949},"gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus",{"EARLY_PHASE1":24950,"PHASE1":24952,"PHASE2":24963,"PHASE3":24965,"PHASE4":24967,"NA":24969},{"trials":24951,"activeCount":101},[],{"trials":24953,"activeCount":101},[24954],{"nctId":24955,"briefTitle":24956,"status":244,"phases":24957,"primaryCompletion":24958,"completion":24958,"start":4635,"enrollment":283,"conditions":24959,"interventions":24962},"NCT01182168","Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies",[89],"2016-03",[971,24960,24961],"Renal Pelvis Cancer","Ureter Cancer",[24948],{"trials":24964,"activeCount":101},[],{"trials":24966,"activeCount":101},[],{"trials":24968,"activeCount":101},[],{"trials":24970,"activeCount":101},[],{"intervention":24972,"totalTrials":97,"cells":24973},"Thyrotropin Releasing Hormone",{"EARLY_PHASE1":24974,"PHASE1":24976,"PHASE2":24987,"PHASE3":24989,"PHASE4":24991,"NA":24993},{"trials":24975,"activeCount":101},[],{"trials":24977,"activeCount":101},[24978],{"nctId":24979,"briefTitle":24980,"status":2832,"phases":24981,"primaryCompletion":24982,"completion":24982,"start":24983,"enrollment":101,"conditions":24984,"interventions":24985},"NCT04868045","Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer",[89],"2023-02-15","2021-04-27",[4054],[24972,24986],"levothyroxine",{"trials":24988,"activeCount":101},[],{"trials":24990,"activeCount":101},[],{"trials":24992,"activeCount":101},[],{"trials":24994,"activeCount":101},[],{"intervention":24986,"totalTrials":97,"cells":24996},{"EARLY_PHASE1":24997,"PHASE1":24999,"PHASE2":25005,"PHASE3":25007,"PHASE4":25009,"NA":25011},{"trials":24998,"activeCount":101},[],{"trials":25000,"activeCount":101},[25001],{"nctId":24979,"briefTitle":24980,"status":2832,"phases":25002,"primaryCompletion":24982,"completion":24982,"start":24983,"enrollment":101,"conditions":25003,"interventions":25004},[89],[4054],[24972,24986],{"trials":25006,"activeCount":101},[],{"trials":25008,"activeCount":101},[],{"trials":25010,"activeCount":101},[],{"trials":25012,"activeCount":101},[],{"intervention":1876,"totalTrials":97,"cells":25014},{"EARLY_PHASE1":25015,"PHASE1":25017,"PHASE2":25023,"PHASE3":25025,"PHASE4":25027,"NA":25029},{"trials":25016,"activeCount":101},[],{"trials":25018,"activeCount":101},[25019],{"nctId":1866,"briefTitle":1867,"status":244,"phases":25020,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":25021,"interventions":25022},[89],[1873,1874],[1876,1260],{"trials":25024,"activeCount":101},[],{"trials":25026,"activeCount":101},[],{"trials":25028,"activeCount":101},[],{"trials":25030,"activeCount":101},[],{"intervention":23467,"totalTrials":97,"cells":25032},{"EARLY_PHASE1":25033,"PHASE1":25035,"PHASE2":25041,"PHASE3":25043,"PHASE4":25045,"NA":25047},{"trials":25034,"activeCount":101},[],{"trials":25036,"activeCount":101},[25037],{"nctId":23462,"briefTitle":23463,"status":244,"phases":25038,"primaryCompletion":4807,"completion":4807,"start":5224,"enrollment":2439,"conditions":25039,"interventions":25040},[89],[18],[23467,23450],{"trials":25042,"activeCount":101},[],{"trials":25044,"activeCount":101},[],{"trials":25046,"activeCount":101},[],{"trials":25048,"activeCount":101},[],{"intervention":25050,"totalTrials":97,"cells":25051},"rsPSMA protein plus Alhydrogel® vaccine",{"EARLY_PHASE1":25052,"PHASE1":25054,"PHASE2":25062,"PHASE3":25064,"PHASE4":25066,"NA":25068},{"trials":25053,"activeCount":101},[],{"trials":25055,"activeCount":101},[25056],{"nctId":25057,"briefTitle":25058,"status":244,"phases":25059,"primaryCompletion":22590,"completion":22590,"start":695,"enrollment":272,"conditions":25060,"interventions":25061},"NCT00705835","Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel",[89],[18],[25050],{"trials":25063,"activeCount":101},[],{"trials":25065,"activeCount":101},[],{"trials":25067,"activeCount":101},[],{"trials":25069,"activeCount":101},[],{"intervention":25071,"totalTrials":97,"cells":25072},"Ultrasound with intravenous microbubble contrast",{"EARLY_PHASE1":25073,"PHASE1":25075,"PHASE2":25083,"PHASE3":25085,"PHASE4":25087,"NA":25089},{"trials":25074,"activeCount":101},[],{"trials":25076,"activeCount":101},[25077],{"nctId":25078,"briefTitle":25079,"status":244,"phases":25080,"primaryCompletion":7779,"completion":7779,"start":1424,"enrollment":486,"conditions":25081,"interventions":25082},"NCT00671411","Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast",[89],[12981,783],[25071],{"trials":25084,"activeCount":101},[],{"trials":25086,"activeCount":101},[],{"trials":25088,"activeCount":101},[],{"trials":25090,"activeCount":101},[],{"intervention":25092,"totalTrials":97,"cells":25093},"zoledronic acid",{"EARLY_PHASE1":25094,"PHASE1":25096,"PHASE2":25104,"PHASE3":25106,"PHASE4":25108,"NA":25110},{"trials":25095,"activeCount":101},[],{"trials":25097,"activeCount":101},[25098],{"nctId":25099,"briefTitle":25100,"status":244,"phases":25101,"primaryCompletion":9078,"completion":9078,"start":2915,"conditions":25102,"interventions":25103},"NCT00004928","Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer",[89],[18],[25092],{"trials":25105,"activeCount":101},[],{"trials":25107,"activeCount":101},[],{"trials":25109,"activeCount":101},[],{"trials":25111,"activeCount":101},[],{"intervention":25113,"totalTrials":97,"cells":25114},"[18F] DIHYDRO-TESTOSTERONE",{"EARLY_PHASE1":25115,"PHASE1":25117,"PHASE2":25126,"PHASE3":25128,"PHASE4":25130,"NA":25132},{"trials":25116,"activeCount":101},[],{"trials":25118,"activeCount":101},[25119],{"nctId":25120,"briefTitle":25121,"status":244,"phases":25122,"primaryCompletion":3434,"completion":3434,"start":1013,"enrollment":509,"conditions":25123,"interventions":25125},"NCT02297386","[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer",[89],[18,25124],"Localized Prostate Cancer",[25113],{"trials":25127,"activeCount":101},[],{"trials":25129,"activeCount":101},[],{"trials":25131,"activeCount":101},[],{"trials":25133,"activeCount":101},[],{"intervention":25135,"totalTrials":97,"cells":25136},"Olaparib Pill 50 mg",{"EARLY_PHASE1":25137,"PHASE1":25139,"PHASE2":25155,"PHASE3":25157,"PHASE4":25159,"NA":25161},{"trials":25138,"activeCount":101},[],{"trials":25140,"activeCount":101},[25141],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25144,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25147,"interventions":25149},"NCT03532880","A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer",[89],"2025-02-04","2018-07-12",[25148,11611],"Small-cell Lung Cancer",[25135,25150,25151,25152,25153,25154],"Olaparib Pill 100 mg","Olaparib Pill 150 mg","Olaparib Pill 200 mg","Olaparib Pill 250 mg","Olaparib Pill 300 mg",{"trials":25156,"activeCount":101},[],{"trials":25158,"activeCount":101},[],{"trials":25160,"activeCount":101},[],{"trials":25162,"activeCount":101},[],{"intervention":25150,"totalTrials":97,"cells":25164},{"EARLY_PHASE1":25165,"PHASE1":25167,"PHASE2":25173,"PHASE3":25175,"PHASE4":25177,"NA":25179},{"trials":25166,"activeCount":101},[],{"trials":25168,"activeCount":101},[25169],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25170,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25171,"interventions":25172},[89],[25148,11611],[25135,25150,25151,25152,25153,25154],{"trials":25174,"activeCount":101},[],{"trials":25176,"activeCount":101},[],{"trials":25178,"activeCount":101},[],{"trials":25180,"activeCount":101},[],{"intervention":25151,"totalTrials":97,"cells":25182},{"EARLY_PHASE1":25183,"PHASE1":25185,"PHASE2":25191,"PHASE3":25193,"PHASE4":25195,"NA":25197},{"trials":25184,"activeCount":101},[],{"trials":25186,"activeCount":101},[25187],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25188,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25189,"interventions":25190},[89],[25148,11611],[25135,25150,25151,25152,25153,25154],{"trials":25192,"activeCount":101},[],{"trials":25194,"activeCount":101},[],{"trials":25196,"activeCount":101},[],{"trials":25198,"activeCount":101},[],{"intervention":25152,"totalTrials":97,"cells":25200},{"EARLY_PHASE1":25201,"PHASE1":25203,"PHASE2":25209,"PHASE3":25211,"PHASE4":25213,"NA":25215},{"trials":25202,"activeCount":101},[],{"trials":25204,"activeCount":101},[25205],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25206,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25207,"interventions":25208},[89],[25148,11611],[25135,25150,25151,25152,25153,25154],{"trials":25210,"activeCount":101},[],{"trials":25212,"activeCount":101},[],{"trials":25214,"activeCount":101},[],{"trials":25216,"activeCount":101},[],{"intervention":25153,"totalTrials":97,"cells":25218},{"EARLY_PHASE1":25219,"PHASE1":25221,"PHASE2":25227,"PHASE3":25229,"PHASE4":25231,"NA":25233},{"trials":25220,"activeCount":101},[],{"trials":25222,"activeCount":101},[25223],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25224,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25225,"interventions":25226},[89],[25148,11611],[25135,25150,25151,25152,25153,25154],{"trials":25228,"activeCount":101},[],{"trials":25230,"activeCount":101},[],{"trials":25232,"activeCount":101},[],{"trials":25234,"activeCount":101},[],{"intervention":25154,"totalTrials":97,"cells":25236},{"EARLY_PHASE1":25237,"PHASE1":25239,"PHASE2":25245,"PHASE3":25247,"PHASE4":25249,"NA":25251},{"trials":25238,"activeCount":101},[],{"trials":25240,"activeCount":101},[25241],{"nctId":25142,"briefTitle":25143,"status":244,"phases":25242,"primaryCompletion":25145,"completion":25145,"start":25146,"enrollment":213,"conditions":25243,"interventions":25244},[89],[25148,11611],[25135,25150,25151,25152,25153,25154],{"trials":25246,"activeCount":101},[],{"trials":25248,"activeCount":101},[],{"trials":25250,"activeCount":101},[],{"trials":25252,"activeCount":101},[],{"intervention":5797,"totalTrials":97,"cells":25254},{"EARLY_PHASE1":25255,"PHASE1":25257,"PHASE2":25263,"PHASE3":25265,"PHASE4":25267,"NA":25269},{"trials":25256,"activeCount":101},[],{"trials":25258,"activeCount":101},[25259],{"nctId":5790,"briefTitle":5791,"status":244,"phases":25260,"primaryCompletion":5793,"completion":5793,"start":5794,"enrollment":1232,"conditions":25261,"interventions":25262},[89],[4081],[5367,5797],{"trials":25264,"activeCount":101},[],{"trials":25266,"activeCount":101},[],{"trials":25268,"activeCount":101},[],{"trials":25270,"activeCount":101},[],{"intervention":2648,"totalTrials":97,"cells":25272},{"EARLY_PHASE1":25273,"PHASE1":25275,"PHASE2":25281,"PHASE3":25283,"PHASE4":25285,"NA":25287},{"trials":25274,"activeCount":101},[],{"trials":25276,"activeCount":101},[25277],{"nctId":2639,"briefTitle":2640,"status":244,"phases":25278,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":1434,"conditions":25279,"interventions":25280},[89],[794,2645,2646],[2648,942,2649],{"trials":25282,"activeCount":101},[],{"trials":25284,"activeCount":101},[],{"trials":25286,"activeCount":101},[],{"trials":25288,"activeCount":101},[],{"intervention":25290,"totalTrials":97,"cells":25291},"CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells",{"EARLY_PHASE1":25292,"PHASE1":25294,"PHASE2":25303,"PHASE3":25305,"PHASE4":25307,"NA":25309},{"trials":25293,"activeCount":101},[],{"trials":25295,"activeCount":101},[25296],{"nctId":25297,"briefTitle":25298,"status":244,"phases":25299,"primaryCompletion":14672,"completion":14672,"start":25300,"enrollment":1232,"conditions":25301,"interventions":25302},"NCT01995708","CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",[89],"2014-01-31",[308],[25290],{"trials":25304,"activeCount":101},[],{"trials":25306,"activeCount":101},[],{"trials":25308,"activeCount":101},[],{"trials":25310,"activeCount":101},[],{"intervention":25312,"totalTrials":97,"cells":25313},"Bevacizumab and Sunitinib",{"EARLY_PHASE1":25314,"PHASE1":25316,"PHASE2":25324,"PHASE3":25326,"PHASE4":25328,"NA":25330},{"trials":25315,"activeCount":101},[],{"trials":25317,"activeCount":101},[25318],{"nctId":25319,"briefTitle":25320,"status":244,"phases":25321,"primaryCompletion":13530,"completion":13530,"start":20422,"enrollment":1232,"conditions":25322,"interventions":25323},"NCT00421512","A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients",[89],[4876,783],[25312],{"trials":25325,"activeCount":101},[],{"trials":25327,"activeCount":101},[],{"trials":25329,"activeCount":101},[],{"trials":25331,"activeCount":101},[],{"intervention":7455,"totalTrials":97,"cells":25333},{"EARLY_PHASE1":25334,"PHASE1":25336,"PHASE2":25342,"PHASE3":25344,"PHASE4":25346,"NA":25348},{"trials":25335,"activeCount":101},[],{"trials":25337,"activeCount":101},[25338],{"nctId":7447,"briefTitle":7448,"status":244,"phases":25339,"primaryCompletion":7450,"completion":7450,"start":7451,"enrollment":1412,"conditions":25340,"interventions":25341},[89],[15],[7454,7455,7456],{"trials":25343,"activeCount":101},[],{"trials":25345,"activeCount":101},[],{"trials":25347,"activeCount":101},[],{"trials":25349,"activeCount":101},[],{"intervention":25351,"totalTrials":97,"cells":25352},"Humanized 3F8 Monoclonal Antibody",{"EARLY_PHASE1":25353,"PHASE1":25355,"PHASE2":25365,"PHASE3":25367,"PHASE4":25369,"NA":25371},{"trials":25354,"activeCount":101},[],{"trials":25356,"activeCount":101},[25357],{"nctId":25358,"briefTitle":25359,"status":244,"phases":25360,"primaryCompletion":25361,"completion":25361,"start":25362,"enrollment":10561,"conditions":25363,"interventions":25364},"NCT01419834","Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors",[89],"2023-08-02","2011-08-15",[215],[25351],{"trials":25366,"activeCount":101},[],{"trials":25368,"activeCount":101},[],{"trials":25370,"activeCount":101},[],{"trials":25372,"activeCount":101},[],{"intervention":25374,"totalTrials":97,"cells":25375},"batabulin sodium",{"EARLY_PHASE1":25376,"PHASE1":25378,"PHASE2":25386,"PHASE3":25388,"PHASE4":25390,"NA":25392},{"trials":25377,"activeCount":101},[],{"trials":25379,"activeCount":101},[25380],{"nctId":25381,"briefTitle":25382,"status":244,"phases":25383,"primaryCompletion":648,"completion":648,"start":3451,"enrollment":454,"conditions":25384,"interventions":25385},"NCT00003359","T138067 Sodium in Treating Patients With Advanced Refractory Cancer",[89],[1568],[25374],{"trials":25387,"activeCount":101},[],{"trials":25389,"activeCount":101},[],{"trials":25391,"activeCount":101},[],{"trials":25393,"activeCount":101},[],{"intervention":25395,"totalTrials":97,"cells":25396},"RAD001 (everolimus) + Cisplatin",{"EARLY_PHASE1":25397,"PHASE1":25399,"PHASE2":25407,"PHASE3":25409,"PHASE4":25411,"NA":25413},{"trials":25398,"activeCount":101},[],{"trials":25400,"activeCount":101},[25401],{"nctId":25402,"briefTitle":25403,"status":244,"phases":25404,"primaryCompletion":1396,"completion":1396,"start":4807,"enrollment":296,"conditions":25405,"interventions":25406},"NCT00858663","Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer",[89],[1586],[25395],{"trials":25408,"activeCount":101},[],{"trials":25410,"activeCount":101},[],{"trials":25412,"activeCount":101},[],{"trials":25414,"activeCount":101},[],{"intervention":25416,"totalTrials":97,"cells":25417},"human tyrosinase",{"EARLY_PHASE1":25418,"PHASE1":25420,"PHASE2":25430,"PHASE3":25432,"PHASE4":25434,"NA":25436},{"trials":25419,"activeCount":101},[],{"trials":25421,"activeCount":101},[25422],{"nctId":25423,"briefTitle":25424,"status":244,"phases":25425,"primaryCompletion":875,"completion":875,"start":384,"enrollment":326,"conditions":25426,"interventions":25428},"NCT00698100","Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",[89],[2341,25427],"Skin",[25416,25429],"mouse tyrosinase",{"trials":25431,"activeCount":101},[],{"trials":25433,"activeCount":101},[],{"trials":25435,"activeCount":101},[],{"trials":25437,"activeCount":101},[],{"intervention":25429,"totalTrials":97,"cells":25439},{"EARLY_PHASE1":25440,"PHASE1":25442,"PHASE2":25448,"PHASE3":25450,"PHASE4":25452,"NA":25454},{"trials":25441,"activeCount":101},[],{"trials":25443,"activeCount":101},[25444],{"nctId":25423,"briefTitle":25424,"status":244,"phases":25445,"primaryCompletion":875,"completion":875,"start":384,"enrollment":326,"conditions":25446,"interventions":25447},[89],[2341,25427],[25416,25429],{"trials":25449,"activeCount":101},[],{"trials":25451,"activeCount":101},[],{"trials":25453,"activeCount":101},[],{"trials":25455,"activeCount":101},[],{"intervention":25457,"totalTrials":97,"cells":25458},"Lapatinib in Tandem With Capecitabine",{"EARLY_PHASE1":25459,"PHASE1":25461,"PHASE2":25471,"PHASE3":25473,"PHASE4":25475,"NA":25477},{"trials":25460,"activeCount":101},[],{"trials":25462,"activeCount":101},[25463],{"nctId":25464,"briefTitle":25465,"status":244,"phases":25466,"primaryCompletion":2869,"completion":2869,"start":25467,"enrollment":2630,"conditions":25468,"interventions":25470},"NCT02650752","Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed\u002FAmplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases",[89],"2016-01-06",[2311,25469],"Central Nervous System (CNS) Metastases",[25457],{"trials":25472,"activeCount":101},[],{"trials":25474,"activeCount":101},[],{"trials":25476,"activeCount":101},[],{"trials":25478,"activeCount":101},[],{"intervention":25480,"totalTrials":97,"cells":25481},"131I-MIP-1095",{"EARLY_PHASE1":25482,"PHASE1":25484,"PHASE2":25495,"PHASE3":25497,"PHASE4":25499,"NA":25501},{"trials":25483,"activeCount":101},[],{"trials":25485,"activeCount":101},[25486],{"nctId":25487,"briefTitle":25488,"status":244,"phases":25489,"primaryCompletion":25490,"completion":25490,"start":25491,"enrollment":1434,"conditions":25492,"interventions":25494},"NCT03030885","Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[89],"2019-04-02","2017-01-19",[18,25493],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[25480],{"trials":25496,"activeCount":101},[],{"trials":25498,"activeCount":101},[],{"trials":25500,"activeCount":101},[],{"trials":25502,"activeCount":101},[],{"intervention":17672,"totalTrials":97,"cells":25504},{"EARLY_PHASE1":25505,"PHASE1":25507,"PHASE2":25513,"PHASE3":25515,"PHASE4":25517,"NA":25519},{"trials":25506,"activeCount":101},[],{"trials":25508,"activeCount":101},[25509],{"nctId":17667,"briefTitle":17668,"status":244,"phases":25510,"primaryCompletion":1566,"completion":1566,"start":3323,"conditions":25511,"interventions":25512},[89],[24,1687,1568],[3658,17672],{"trials":25514,"activeCount":101},[],{"trials":25516,"activeCount":101},[],{"trials":25518,"activeCount":101},[],{"trials":25520,"activeCount":101},[],{"intervention":25522,"totalTrials":97,"cells":25523},"therapeutic testosterone",{"EARLY_PHASE1":25524,"PHASE1":25526,"PHASE2":25534,"PHASE3":25536,"PHASE4":25538,"NA":25540},{"trials":25525,"activeCount":101},[],{"trials":25527,"activeCount":101},[25528],{"nctId":25529,"briefTitle":25530,"status":244,"phases":25531,"primaryCompletion":3274,"start":1611,"conditions":25532,"interventions":25533},"NCT00006044","Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy",[89],[18],[25522],{"trials":25535,"activeCount":101},[],{"trials":25537,"activeCount":101},[],{"trials":25539,"activeCount":101},[],{"trials":25541,"activeCount":101},[],{"intervention":25543,"totalTrials":97,"cells":25544},"Pemetrexed\u002FCisplatin",{"EARLY_PHASE1":25545,"PHASE1":25547,"PHASE2":25556,"PHASE3":25558,"PHASE4":25560,"NA":25562},{"trials":25546,"activeCount":101},[],{"trials":25548,"activeCount":101},[25549],{"nctId":25550,"briefTitle":25551,"status":2832,"phases":25552,"primaryCompletion":25553,"start":5794,"enrollment":101,"conditions":25554,"interventions":25555},"NCT02639767","Concurrent Pemetrexed\u002FCisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma",[89],"2016-12",[2293],[25543],{"trials":25557,"activeCount":101},[],{"trials":25559,"activeCount":101},[],{"trials":25561,"activeCount":101},[],{"trials":25563,"activeCount":101},[],{"intervention":25565,"totalTrials":97,"cells":25566},"Erwinia Chrysanthemi asparaginase",{"EARLY_PHASE1":25567,"PHASE1":25569,"PHASE2":25579,"PHASE3":25581,"PHASE4":25583,"NA":25585},{"trials":25568,"activeCount":101},[],{"trials":25570,"activeCount":101},[25571],{"nctId":25572,"briefTitle":25573,"status":2832,"phases":25574,"primaryCompletion":21324,"completion":21324,"start":563,"enrollment":101,"conditions":25575,"interventions":25578},"NCT02647190","Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older",[89],[6735,25576,25577],"Newly Diagnosed Philadelphia Chromosome Negative","Aged 60 Years or Older",[25565],{"trials":25580,"activeCount":101},[],{"trials":25582,"activeCount":101},[],{"trials":25584,"activeCount":101},[],{"trials":25586,"activeCount":101},[],{"intervention":25588,"totalTrials":97,"cells":25589},"CMV-Peptide-Specific T cells",{"EARLY_PHASE1":25590,"PHASE1":25592,"PHASE2":25601,"PHASE3":25603,"PHASE4":25605,"NA":25607},{"trials":25591,"activeCount":101},[],{"trials":25593,"activeCount":101},[25594],{"nctId":25595,"briefTitle":25596,"status":244,"phases":25597,"primaryCompletion":1186,"completion":1186,"start":804,"enrollment":356,"conditions":25598,"interventions":25600},"NCT00674648","Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants",[89],[25599],"Cytomegalovirus Infections",[25588],{"trials":25602,"activeCount":101},[],{"trials":25604,"activeCount":101},[],{"trials":25606,"activeCount":101},[],{"trials":25608,"activeCount":101},[],{"intervention":25610,"totalTrials":97,"cells":25611},"ethanol",{"EARLY_PHASE1":25612,"PHASE1":25614,"PHASE2":25622,"PHASE3":25624,"PHASE4":25626,"NA":25628},{"trials":25613,"activeCount":101},[],{"trials":25615,"activeCount":101},[25616],{"nctId":25617,"briefTitle":25618,"status":244,"phases":25619,"primaryCompletion":21936,"completion":21936,"start":3590,"enrollment":283,"conditions":25620,"interventions":25621},"NCT00471679","Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma",[89],[215],[25610],{"trials":25623,"activeCount":101},[],{"trials":25625,"activeCount":101},[],{"trials":25627,"activeCount":101},[],{"trials":25629,"activeCount":101},[],{"intervention":25631,"totalTrials":97,"cells":25632},"MUC-2-KLH",{"EARLY_PHASE1":25633,"PHASE1":25635,"PHASE2":25643,"PHASE3":25645,"PHASE4":25647,"NA":25649},{"trials":25634,"activeCount":101},[],{"trials":25636,"activeCount":101},[25637],{"nctId":25638,"briefTitle":25639,"status":244,"phases":25640,"primaryCompletion":4807,"completion":4807,"start":4424,"enrollment":1871,"conditions":25641,"interventions":25642},"NCT00698711","Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21",[89],[18],[25631],{"trials":25644,"activeCount":101},[],{"trials":25646,"activeCount":101},[],{"trials":25648,"activeCount":101},[],{"trials":25650,"activeCount":101},[],{"intervention":2669,"totalTrials":97,"cells":25652},{"EARLY_PHASE1":25653,"PHASE1":25655,"PHASE2":25661,"PHASE3":25663,"PHASE4":25665,"NA":25667},{"trials":25654,"activeCount":101},[],{"trials":25656,"activeCount":101},[25657],{"nctId":2663,"briefTitle":2664,"status":244,"phases":25658,"primaryCompletion":2545,"completion":2545,"start":2299,"enrollment":1600,"conditions":25659,"interventions":25660},[89],[2667,2632,2633],[2669,942,941],{"trials":25662,"activeCount":101},[],{"trials":25664,"activeCount":101},[],{"trials":25666,"activeCount":101},[],{"trials":25668,"activeCount":101},[],{"intervention":25670,"totalTrials":97,"cells":25671},"Thiopental Sodium",{"EARLY_PHASE1":25672,"PHASE1":25674,"PHASE2":25687,"PHASE3":25689,"PHASE4":25691,"NA":25693},{"trials":25673,"activeCount":101},[],{"trials":25675,"activeCount":101},[25676],{"nctId":25677,"briefTitle":25678,"status":244,"phases":25679,"primaryCompletion":1266,"completion":1266,"start":339,"enrollment":659,"conditions":25680,"interventions":25683},"NCT00142493","Effect of Affective Content on Drug Induced Amnesia of Episodic Memory",[89],[25681,25682],"Memory Losses","Amnesia-Memory Loss",[25684,25670,25685,25686],"Propofol","Dexmedetomidine Hydrochloride","Midazolam Hydrochloride",{"trials":25688,"activeCount":101},[],{"trials":25690,"activeCount":101},[],{"trials":25692,"activeCount":101},[],{"trials":25694,"activeCount":101},[],{"intervention":25685,"totalTrials":97,"cells":25696},{"EARLY_PHASE1":25697,"PHASE1":25699,"PHASE2":25705,"PHASE3":25707,"PHASE4":25709,"NA":25711},{"trials":25698,"activeCount":101},[],{"trials":25700,"activeCount":101},[25701],{"nctId":25677,"briefTitle":25678,"status":244,"phases":25702,"primaryCompletion":1266,"completion":1266,"start":339,"enrollment":659,"conditions":25703,"interventions":25704},[89],[25681,25682],[25684,25670,25685,25686],{"trials":25706,"activeCount":101},[],{"trials":25708,"activeCount":101},[],{"trials":25710,"activeCount":101},[],{"trials":25712,"activeCount":101},[],{"intervention":25686,"totalTrials":97,"cells":25714},{"EARLY_PHASE1":25715,"PHASE1":25717,"PHASE2":25723,"PHASE3":25725,"PHASE4":25727,"NA":25729},{"trials":25716,"activeCount":101},[],{"trials":25718,"activeCount":101},[25719],{"nctId":25677,"briefTitle":25678,"status":244,"phases":25720,"primaryCompletion":1266,"completion":1266,"start":339,"enrollment":659,"conditions":25721,"interventions":25722},[89],[25681,25682],[25684,25670,25685,25686],{"trials":25724,"activeCount":101},[],{"trials":25726,"activeCount":101},[],{"trials":25728,"activeCount":101},[],{"trials":25730,"activeCount":101},[],{"intervention":25732,"totalTrials":97,"cells":25733},"Dasatinib, Mitoxantrone, Cytarabine",{"EARLY_PHASE1":25734,"PHASE1":25736,"PHASE2":25744,"PHASE3":25746,"PHASE4":25748,"NA":25750},{"trials":25735,"activeCount":101},[],{"trials":25737,"activeCount":101},[25738],{"nctId":25739,"briefTitle":25740,"status":244,"phases":25741,"primaryCompletion":774,"completion":774,"start":23970,"enrollment":2291,"conditions":25742,"interventions":25743},"NCT00940524","Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",[89],[27,414],[25732],{"trials":25745,"activeCount":101},[],{"trials":25747,"activeCount":101},[],{"trials":25749,"activeCount":101},[],{"trials":25751,"activeCount":101},[],{"intervention":16604,"totalTrials":97,"cells":25753},{"EARLY_PHASE1":25754,"PHASE1":25756,"PHASE2":25762,"PHASE3":25764,"PHASE4":25766,"NA":25768},{"trials":25755,"activeCount":101},[],{"trials":25757,"activeCount":101},[25758],{"nctId":16595,"briefTitle":16596,"status":244,"phases":25759,"primaryCompletion":16598,"completion":16598,"start":5349,"enrollment":1434,"conditions":25760,"interventions":25761},[89],[6318,16600,16601,16602],[16588,16604,16605],{"trials":25763,"activeCount":101},[],{"trials":25765,"activeCount":101},[],{"trials":25767,"activeCount":101},[],{"trials":25769,"activeCount":101},[],{"intervention":16605,"totalTrials":97,"cells":25771},{"EARLY_PHASE1":25772,"PHASE1":25774,"PHASE2":25780,"PHASE3":25782,"PHASE4":25784,"NA":25786},{"trials":25773,"activeCount":101},[],{"trials":25775,"activeCount":101},[25776],{"nctId":16595,"briefTitle":16596,"status":244,"phases":25777,"primaryCompletion":16598,"completion":16598,"start":5349,"enrollment":1434,"conditions":25778,"interventions":25779},[89],[6318,16600,16601,16602],[16588,16604,16605],{"trials":25781,"activeCount":101},[],{"trials":25783,"activeCount":101},[],{"trials":25785,"activeCount":101},[],{"trials":25787,"activeCount":101},[],{"intervention":25789,"totalTrials":97,"cells":25790},"Zr-DFO-pertuzumab PET\u002FCT",{"EARLY_PHASE1":25791,"PHASE1":25793,"PHASE2":25805,"PHASE3":25807,"PHASE4":25809,"NA":25811},{"trials":25792,"activeCount":101},[],{"trials":25794,"activeCount":101},[25795],{"nctId":25796,"briefTitle":25797,"status":244,"phases":25798,"primaryCompletion":25799,"completion":25799,"start":25800,"enrollment":332,"conditions":25801,"interventions":25804},"NCT03109977","Imaging With a New Agent That Finds a Cancer Protein Called HER2",[89],"2018-04-12","2017-03-31",[25802,25803],"HER2-positive Carcinoma","HER2-positive Primary Malignancy",[25789],{"trials":25806,"activeCount":101},[],{"trials":25808,"activeCount":101},[],{"trials":25810,"activeCount":101},[],{"trials":25812,"activeCount":101},[],{"intervention":25814,"totalTrials":97,"cells":25815},"RO5126766",{"EARLY_PHASE1":25816,"PHASE1":25818,"PHASE2":25828,"PHASE3":25830,"PHASE4":25832,"NA":25834},{"trials":25817,"activeCount":101},[],{"trials":25819,"activeCount":101},[25820],{"nctId":25821,"briefTitle":25822,"status":244,"phases":25823,"primaryCompletion":25824,"completion":25824,"start":19772,"enrollment":1871,"conditions":25825,"interventions":25827},"NCT03681483","RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer",[89],"2024-07-08",[25826],"Advanced Non-small Cell Lung Cancer",[25814],{"trials":25829,"activeCount":101},[],{"trials":25831,"activeCount":101},[],{"trials":25833,"activeCount":101},[],{"trials":25835,"activeCount":101},[],{"intervention":25837,"totalTrials":97,"cells":25838},"anastrozole",{"EARLY_PHASE1":25839,"PHASE1":25841,"PHASE2":25849,"PHASE3":25851,"PHASE4":25853,"NA":25855},{"trials":25840,"activeCount":101},[],{"trials":25842,"activeCount":101},[25843],{"nctId":25844,"briefTitle":25845,"status":244,"phases":25846,"primaryCompletion":20382,"completion":20382,"start":1575,"enrollment":341,"conditions":25847,"interventions":25848},"NCT00588003","Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer",[89],[15],[25837],{"trials":25850,"activeCount":101},[],{"trials":25852,"activeCount":101},[],{"trials":25854,"activeCount":101},[],{"trials":25856,"activeCount":101},[],{"intervention":25858,"totalTrials":97,"cells":25859},"MUC-2-KLH vaccine",{"EARLY_PHASE1":25860,"PHASE1":25862,"PHASE2":25869,"PHASE3":25871,"PHASE4":25873,"NA":25875},{"trials":25861,"activeCount":101},[],{"trials":25863,"activeCount":101},[25864],{"nctId":25865,"briefTitle":18706,"status":244,"phases":25866,"primaryCompletion":755,"completion":755,"start":3382,"enrollment":1871,"conditions":25867,"interventions":25868},"NCT00004929",[89],[18],[25858,9012],{"trials":25870,"activeCount":101},[],{"trials":25872,"activeCount":101},[],{"trials":25874,"activeCount":101},[],{"trials":25876,"activeCount":101},[],{"intervention":25878,"totalTrials":97,"cells":25879},"polyglutamate camptothecin",{"EARLY_PHASE1":25880,"PHASE1":25882,"PHASE2":25890,"PHASE3":25892,"PHASE4":25894,"NA":25896},{"trials":25881,"activeCount":101},[],{"trials":25883,"activeCount":101},[25884],{"nctId":25885,"briefTitle":25886,"status":244,"phases":25887,"completion":564,"start":695,"conditions":25888,"interventions":25889},"NCT00059917","Polyglutamate Camptothecin in Treating Patients With Advanced Cancer",[89],[1568],[25878],{"trials":25891,"activeCount":101},[],{"trials":25893,"activeCount":101},[],{"trials":25895,"activeCount":101},[],{"trials":25897,"activeCount":101},[],{"intervention":3020,"totalTrials":97,"cells":25899},{"EARLY_PHASE1":25900,"PHASE1":25902,"PHASE2":25908,"PHASE3":25910,"PHASE4":25912,"NA":25914},{"trials":25901,"activeCount":101},[],{"trials":25903,"activeCount":101},[25904],{"nctId":3014,"briefTitle":3015,"status":244,"phases":25905,"primaryCompletion":1083,"completion":1083,"start":1575,"enrollment":3017,"conditions":25906,"interventions":25907},[89],[1568],[47,3020],{"trials":25909,"activeCount":101},[],{"trials":25911,"activeCount":101},[],{"trials":25913,"activeCount":101},[],{"trials":25915,"activeCount":101},[],{"intervention":25917,"totalTrials":97,"cells":25918},"combination panitumumab and vemurafenib",{"EARLY_PHASE1":25919,"PHASE1":25921,"PHASE2":25929,"PHASE3":25931,"PHASE4":25933,"NA":25935},{"trials":25920,"activeCount":101},[],{"trials":25922,"activeCount":101},[25923],{"nctId":25924,"briefTitle":25925,"status":244,"phases":25926,"primaryCompletion":3753,"completion":3753,"start":15957,"enrollment":1447,"conditions":25927,"interventions":25928},"NCT01791309","Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer",[89],[2441],[25917],{"trials":25930,"activeCount":101},[],{"trials":25932,"activeCount":101},[],{"trials":25934,"activeCount":101},[],{"trials":25936,"activeCount":101},[],{"intervention":25938,"totalTrials":97,"cells":25939},"PF-06688992",{"EARLY_PHASE1":25940,"PHASE1":25942,"PHASE2":25952,"PHASE3":25954,"PHASE4":25956,"NA":25958},{"trials":25941,"activeCount":101},[],{"trials":25943,"activeCount":101},[25944],{"nctId":25945,"briefTitle":25946,"status":244,"phases":25947,"primaryCompletion":25948,"completion":25948,"start":25949,"enrollment":2291,"conditions":25950,"interventions":25951},"NCT03159117","Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma",[89],"2020-01-10","2017-05-16",[2341],[25938],{"trials":25953,"activeCount":101},[],{"trials":25955,"activeCount":101},[],{"trials":25957,"activeCount":101},[],{"trials":25959,"activeCount":101},[],{"intervention":25961,"totalTrials":97,"cells":25962},"human prostate-specific membrane antigen plasmid DNA vaccine",{"EARLY_PHASE1":25963,"PHASE1":25965,"PHASE2":25975,"PHASE3":25977,"PHASE4":25979,"NA":25981},{"trials":25964,"activeCount":101},[],{"trials":25966,"activeCount":101},[25967],{"nctId":25968,"briefTitle":25969,"status":244,"phases":25970,"primaryCompletion":25971,"completion":25971,"start":3880,"enrollment":1871,"conditions":25972,"interventions":25973},"NCT00096629","Vaccine Therapy in Treating Patients With Kidney Cancer",[89],"2018-04",[783],[25961,25974],"mouse prostate-specific membrane antigen plasmid DNA vaccine",{"trials":25976,"activeCount":101},[],{"trials":25978,"activeCount":101},[],{"trials":25980,"activeCount":101},[],{"trials":25982,"activeCount":101},[],{"intervention":25974,"totalTrials":97,"cells":25984},{"EARLY_PHASE1":25985,"PHASE1":25987,"PHASE2":25993,"PHASE3":25995,"PHASE4":25997,"NA":25999},{"trials":25986,"activeCount":101},[],{"trials":25988,"activeCount":101},[25989],{"nctId":25968,"briefTitle":25969,"status":244,"phases":25990,"primaryCompletion":25971,"completion":25971,"start":3880,"enrollment":1871,"conditions":25991,"interventions":25992},[89],[783],[25961,25974],{"trials":25994,"activeCount":101},[],{"trials":25996,"activeCount":101},[],{"trials":25998,"activeCount":101},[],{"trials":26000,"activeCount":101},[],{"intervention":5805,"totalTrials":97,"cells":26002},{"EARLY_PHASE1":26003,"PHASE1":26005,"PHASE2":26011,"PHASE3":26013,"PHASE4":26015,"NA":26017},{"trials":26004,"activeCount":101},[],{"trials":26006,"activeCount":101},[26007],{"nctId":5799,"briefTitle":5800,"status":244,"phases":26008,"primaryCompletion":3309,"completion":3309,"start":3231,"enrollment":718,"conditions":26009,"interventions":26010},[89],[18,5803],[5367,5805],{"trials":26012,"activeCount":101},[],{"trials":26014,"activeCount":101},[],{"trials":26016,"activeCount":101},[],{"trials":26018,"activeCount":101},[],{"intervention":26020,"totalTrials":97,"cells":26021},"Ganetespib (STA-9090) and crizotinib",{"EARLY_PHASE1":26022,"PHASE1":26024,"PHASE2":26034,"PHASE3":26036,"PHASE4":26038,"NA":26040},{"trials":26023,"activeCount":101},[],{"trials":26025,"activeCount":101},[26026],{"nctId":26027,"briefTitle":26028,"status":244,"phases":26029,"primaryCompletion":22856,"completion":22856,"start":26030,"enrollment":296,"conditions":26031,"interventions":26033},"NCT01579994","Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers",[89],"2012-04-16",[26032],"Advanced Lung Cancer",[26020],{"trials":26035,"activeCount":101},[],{"trials":26037,"activeCount":101},[],{"trials":26039,"activeCount":101},[],{"trials":26041,"activeCount":101},[],{"intervention":26043,"totalTrials":97,"cells":26044},"WT1-sensitized T cells",{"EARLY_PHASE1":26045,"PHASE1":26047,"PHASE2":26056,"PHASE3":26058,"PHASE4":26060,"NA":26062},{"trials":26046,"activeCount":101},[],{"trials":26048,"activeCount":101},[26049],{"nctId":26050,"briefTitle":26051,"status":244,"phases":26052,"primaryCompletion":23097,"completion":23097,"start":26053,"enrollment":2483,"conditions":26054,"interventions":26055},"NCT00620633","Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation",[89],"2008-02-08",[27,416],[26043],{"trials":26057,"activeCount":101},[],{"trials":26059,"activeCount":101},[],{"trials":26061,"activeCount":101},[],{"trials":26063,"activeCount":101},[],{"intervention":26065,"totalTrials":97,"cells":26066},"LDE225, Etoposide and Cisplatin",{"EARLY_PHASE1":26067,"PHASE1":26069,"PHASE2":26078,"PHASE3":26080,"PHASE4":26082,"NA":26084},{"trials":26068,"activeCount":101},[],{"trials":26070,"activeCount":101},[26071],{"nctId":26072,"briefTitle":26073,"status":244,"phases":26074,"primaryCompletion":26075,"completion":26075,"start":16198,"enrollment":2446,"conditions":26076,"interventions":26077},"NCT01579929","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[89],"2017-08-11",[21],[26065],{"trials":26079,"activeCount":101},[],{"trials":26081,"activeCount":101},[],{"trials":26083,"activeCount":101},[],{"trials":26085,"activeCount":101},[],{"intervention":19022,"totalTrials":97,"cells":26087},{"EARLY_PHASE1":26088,"PHASE1":26090,"PHASE2":26096,"PHASE3":26098,"PHASE4":26100,"NA":26102},{"trials":26089,"activeCount":101},[],{"trials":26091,"activeCount":101},[26092],{"nctId":19017,"briefTitle":19018,"status":244,"phases":26093,"completion":856,"start":4751,"conditions":26094,"interventions":26095},[89],[1568],[19010,19022],{"trials":26097,"activeCount":101},[],{"trials":26099,"activeCount":101},[],{"trials":26101,"activeCount":101},[],{"trials":26103,"activeCount":101},[],{"intervention":26105,"totalTrials":97,"cells":26106},"BMS-214662",{"EARLY_PHASE1":26107,"PHASE1":26109,"PHASE2":26117,"PHASE3":26119,"PHASE4":26121,"NA":26123},{"trials":26108,"activeCount":101},[],{"trials":26110,"activeCount":101},[26111],{"nctId":26112,"briefTitle":26113,"status":244,"phases":26114,"primaryCompletion":3101,"start":8675,"conditions":26115,"interventions":26116},"NCT00004877","BMS-214662 in Treating Patients With Advanced Solid Tumors",[89],[1568],[26105],{"trials":26118,"activeCount":101},[],{"trials":26120,"activeCount":101},[],{"trials":26122,"activeCount":101},[],{"trials":26124,"activeCount":101},[],{"intervention":23245,"totalTrials":97,"cells":26126},{"EARLY_PHASE1":26127,"PHASE1":26129,"PHASE2":26135,"PHASE3":26137,"PHASE4":26139,"NA":26141},{"trials":26128,"activeCount":101},[],{"trials":26130,"activeCount":101},[26131],{"nctId":23240,"briefTitle":23241,"status":244,"phases":26132,"primaryCompletion":21240,"completion":21240,"start":1611,"conditions":26133,"interventions":26134},[89],[285,30,286],[23245,23221,9012],{"trials":26136,"activeCount":101},[],{"trials":26138,"activeCount":101},[],{"trials":26140,"activeCount":101},[],{"trials":26142,"activeCount":101},[],{"intervention":26144,"totalTrials":97,"cells":26145},"Fluorestradiol",{"EARLY_PHASE1":26146,"PHASE1":26156,"PHASE2":26158,"PHASE3":26160,"PHASE4":26162,"NA":26164},{"trials":26147,"activeCount":101},[26148],{"nctId":26149,"briefTitle":26150,"status":244,"phases":26151,"primaryCompletion":26152,"completion":26152,"start":26153,"enrollment":969,"conditions":26154,"interventions":26155},"NCT01916122","Fluorestradiol (FES) PET\u002FCT for Imaging Estrogen Receptor Status",[88],"2024-04-03","2013-08-01",[15],[26144],{"trials":26157,"activeCount":101},[],{"trials":26159,"activeCount":101},[],{"trials":26161,"activeCount":101},[],{"trials":26163,"activeCount":101},[],{"trials":26165,"activeCount":101},[],{"intervention":26167,"totalTrials":97,"cells":26168},"GM-CSF DNA, NSC 683472 gp100: 209-217",{"EARLY_PHASE1":26169,"PHASE1":26178,"PHASE2":26180,"PHASE3":26182,"PHASE4":26184,"NA":26186},{"trials":26170,"activeCount":101},[26171],{"nctId":26172,"briefTitle":26173,"status":244,"phases":26174,"primaryCompletion":26175,"completion":26175,"start":3220,"enrollment":306,"conditions":26176,"interventions":26177},"NCT00580060","Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",[88],"2011-06",[2341],[26167],{"trials":26179,"activeCount":101},[],{"trials":26181,"activeCount":101},[],{"trials":26183,"activeCount":101},[],{"trials":26185,"activeCount":101},[],{"trials":26187,"activeCount":101},[],{"intervention":26189,"totalTrials":97,"cells":26190},"Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid",{"EARLY_PHASE1":26191,"PHASE1":26200,"PHASE2":26202,"PHASE3":26204,"PHASE4":26206,"NA":26208},{"trials":26192,"activeCount":101},[26193],{"nctId":26194,"briefTitle":26195,"status":244,"phases":26196,"primaryCompletion":26197,"completion":26197,"start":813,"enrollment":356,"conditions":26198,"interventions":26199},"NCT01864083","FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients",[88],"2017-08-29",[15],[26189],{"trials":26201,"activeCount":101},[],{"trials":26203,"activeCount":101},[],{"trials":26205,"activeCount":101},[],{"trials":26207,"activeCount":101},[],{"trials":26209,"activeCount":101},[],{"intervention":26211,"totalTrials":97,"cells":26212},"BR-I",{"EARLY_PHASE1":26213,"PHASE1":26224,"PHASE2":26226,"PHASE3":26228,"PHASE4":26230,"NA":26232},{"trials":26214,"activeCount":101},[26215],{"nctId":26216,"briefTitle":26217,"status":244,"phases":26218,"primaryCompletion":26219,"completion":26219,"start":26220,"enrollment":1434,"conditions":26221,"interventions":26222},"NCT03295240","The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",[88],"2024-01-22","2017-09-20",[1874,24],[26211,26223],"VEN",{"trials":26225,"activeCount":101},[],{"trials":26227,"activeCount":101},[],{"trials":26229,"activeCount":101},[],{"trials":26231,"activeCount":101},[],{"trials":26233,"activeCount":101},[],{"intervention":26223,"totalTrials":97,"cells":26235},{"EARLY_PHASE1":26236,"PHASE1":26242,"PHASE2":26244,"PHASE3":26246,"PHASE4":26248,"NA":26250},{"trials":26237,"activeCount":101},[26238],{"nctId":26216,"briefTitle":26217,"status":244,"phases":26239,"primaryCompletion":26219,"completion":26219,"start":26220,"enrollment":1434,"conditions":26240,"interventions":26241},[88],[1874,24],[26211,26223],{"trials":26243,"activeCount":101},[],{"trials":26245,"activeCount":101},[],{"trials":26247,"activeCount":101},[],{"trials":26249,"activeCount":101},[],{"trials":26251,"activeCount":101},[],{"intervention":26253,"totalTrials":97,"cells":26254},"[18F]PARPi",{"EARLY_PHASE1":26255,"PHASE1":26264,"PHASE2":26266,"PHASE3":26268,"PHASE4":26270,"NA":26272},{"trials":26256,"activeCount":101},[26257],{"nctId":26258,"briefTitle":26259,"status":244,"phases":26260,"primaryCompletion":1918,"completion":1918,"start":26261,"enrollment":1934,"conditions":26262,"interventions":26263},"NCT04173104","PET and MRI Imaging of Brain Tumors Using [18F]PARPi",[88],"2019-11-01",[4905,8191],[26253],{"trials":26265,"activeCount":101},[],{"trials":26267,"activeCount":101},[],{"trials":26269,"activeCount":101},[],{"trials":26271,"activeCount":101},[],{"trials":26273,"activeCount":101},[],{"intervention":7754,"totalTrials":97,"cells":26275},{"EARLY_PHASE1":26276,"PHASE1":26282,"PHASE2":26284,"PHASE3":26286,"PHASE4":26288,"NA":26290},{"trials":26277,"activeCount":101},[26278],{"nctId":7747,"briefTitle":7748,"status":244,"phases":26279,"primaryCompletion":2187,"completion":2187,"start":7750,"enrollment":283,"conditions":26280,"interventions":26281},[88],[7752],[1295,7754],{"trials":26283,"activeCount":101},[],{"trials":26285,"activeCount":101},[],{"trials":26287,"activeCount":101},[],{"trials":26289,"activeCount":101},[],{"trials":26291,"activeCount":101},[],{"intervention":26293,"totalTrials":97,"cells":26294},"89Zr-DFO-REGN3767",{"EARLY_PHASE1":26295,"PHASE1":26305,"PHASE2":26307,"PHASE3":26309,"PHASE4":26311,"NA":26313},{"trials":26296,"activeCount":101},[26297],{"nctId":26298,"briefTitle":26299,"status":244,"phases":26300,"primaryCompletion":26301,"completion":26301,"start":26302,"enrollment":2291,"conditions":26303,"interventions":26304},"NCT04566978","89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)",[88],"2025-03-21","2020-09-11",[15166,15536],[26293],{"trials":26306,"activeCount":101},[],{"trials":26308,"activeCount":101},[],{"trials":26310,"activeCount":101},[],{"trials":26312,"activeCount":101},[],{"trials":26314,"activeCount":101},[],{"intervention":26316,"totalTrials":97,"cells":26317},"18F-FDHT",{"EARLY_PHASE1":26318,"PHASE1":26330,"PHASE2":26332,"PHASE3":26334,"PHASE4":26336,"NA":26338},{"trials":26319,"activeCount":101},[26320],{"nctId":26321,"briefTitle":26322,"status":2832,"phases":26323,"primaryCompletion":2688,"completion":2688,"start":26324,"enrollment":101,"conditions":26325,"interventions":26329},"NCT06145399","A Study of 1 8F-FDHT PET\u002FMRIScans in Women With Breast Cancer",[88],"2023-10-24",[15,26326,2311,26327,26328],"Breast Carcinoma","Metastatic Breast Carcinoma","Female Breast Cancer",[26316],{"trials":26331,"activeCount":101},[],{"trials":26333,"activeCount":101},[],{"trials":26335,"activeCount":101},[],{"trials":26337,"activeCount":101},[],{"trials":26339,"activeCount":101},[],{"intervention":26341,"totalTrials":97,"cells":26342},"Method 1: Indocyanine green dye",{"EARLY_PHASE1":26343,"PHASE1":26356,"PHASE2":26358,"PHASE3":26360,"PHASE4":26362,"NA":26364},{"trials":26344,"activeCount":101},[26345],{"nctId":26346,"briefTitle":26347,"status":244,"phases":26348,"primaryCompletion":26349,"completion":26349,"start":26350,"enrollment":1798,"conditions":26351,"interventions":26353},"NCT04051502","ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study",[88],"2025-12-08","2019-08-05",[30,26352],"Adnexal Mass",[26341,26354,26355,26355],"Method 2: Indocyanine green dye","Method 3: Indocyanine green dye",{"trials":26357,"activeCount":101},[],{"trials":26359,"activeCount":101},[],{"trials":26361,"activeCount":101},[],{"trials":26363,"activeCount":101},[],{"trials":26365,"activeCount":101},[],{"intervention":26354,"totalTrials":97,"cells":26367},{"EARLY_PHASE1":26368,"PHASE1":26374,"PHASE2":26376,"PHASE3":26378,"PHASE4":26380,"NA":26382},{"trials":26369,"activeCount":101},[26370],{"nctId":26346,"briefTitle":26347,"status":244,"phases":26371,"primaryCompletion":26349,"completion":26349,"start":26350,"enrollment":1798,"conditions":26372,"interventions":26373},[88],[30,26352],[26341,26354,26355,26355],{"trials":26375,"activeCount":101},[],{"trials":26377,"activeCount":101},[],{"trials":26379,"activeCount":101},[],{"trials":26381,"activeCount":101},[],{"trials":26383,"activeCount":101},[],{"intervention":26355,"totalTrials":97,"cells":26385},{"EARLY_PHASE1":26386,"PHASE1":26392,"PHASE2":26394,"PHASE3":26396,"PHASE4":26398,"NA":26400},{"trials":26387,"activeCount":101},[26388],{"nctId":26346,"briefTitle":26347,"status":244,"phases":26389,"primaryCompletion":26349,"completion":26349,"start":26350,"enrollment":1798,"conditions":26390,"interventions":26391},[88],[30,26352],[26341,26354,26355,26355],{"trials":26393,"activeCount":101},[],{"trials":26395,"activeCount":101},[],{"trials":26397,"activeCount":101},[],{"trials":26399,"activeCount":101},[],{"trials":26401,"activeCount":101},[],{"intervention":9012,"totalTrials":2630,"cells":26403},{"EARLY_PHASE1":26404,"PHASE1":26406,"PHASE2":26428,"PHASE3":26448,"PHASE4":26450,"NA":26452},{"trials":26405,"activeCount":101},[],{"trials":26407,"activeCount":101},[26408,26412,26416,26420,26424],{"nctId":23946,"briefTitle":23947,"status":244,"phases":26409,"primaryCompletion":3402,"completion":3402,"start":2906,"enrollment":601,"conditions":26410,"interventions":26411},[89],[15],[23939,9012],{"nctId":18705,"briefTitle":18706,"status":244,"phases":26413,"primaryCompletion":4807,"completion":4807,"start":728,"enrollment":899,"conditions":26414,"interventions":26415},[89],[18],[9012,18710,18711,18698],{"nctId":23457,"briefTitle":23229,"status":244,"phases":26417,"primaryCompletion":4807,"completion":4807,"start":1629,"enrollment":601,"conditions":26418,"interventions":26419},[89],[18],[23450,9012],{"nctId":25865,"briefTitle":18706,"status":244,"phases":26421,"primaryCompletion":755,"completion":755,"start":3382,"enrollment":1871,"conditions":26422,"interventions":26423},[89],[18],[25858,9012],{"nctId":23240,"briefTitle":23241,"status":244,"phases":26425,"primaryCompletion":21240,"completion":21240,"start":1611,"conditions":26426,"interventions":26427},[89],[285,30,286],[23245,23221,9012],{"trials":26429,"activeCount":101},[26430,26436,26440,26444],{"nctId":26431,"briefTitle":26432,"status":244,"phases":26433,"primaryCompletion":587,"completion":4807,"start":3323,"enrollment":356,"conditions":26434,"interventions":26435},"NCT00579423","Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer",[90],[9051,1155],[9012],{"nctId":18715,"briefTitle":18716,"status":244,"phases":26437,"primaryCompletion":3402,"completion":3402,"start":545,"conditions":26438,"interventions":26439},[90],[21],[9012,18698,18720],{"nctId":9006,"briefTitle":9007,"status":244,"phases":26441,"primaryCompletion":7408,"completion":7408,"start":9009,"conditions":26442,"interventions":26443},[90],[4734],[9012,9013,8956,360,9014],{"nctId":22971,"briefTitle":22972,"status":244,"phases":26445,"primaryCompletion":4661,"completion":4661,"start":21241,"enrollment":454,"conditions":26446,"interventions":26447},[90],[27],[9012,22962],{"trials":26449,"activeCount":101},[],{"trials":26451,"activeCount":101},[],{"trials":26453,"activeCount":101},[26454,26461],{"nctId":26455,"briefTitle":26456,"status":244,"phases":26457,"primaryCompletion":1083,"completion":1083,"start":7415,"enrollment":272,"conditions":26458,"interventions":26459},"NCT00030823","Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence",[93],[15],[26460,9012],"Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine",{"nctId":26462,"briefTitle":26463,"status":244,"phases":26464,"primaryCompletion":26465,"completion":26465,"start":26466,"enrollment":2291,"conditions":26467,"interventions":26468},"NCT00470574","Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer",[93],"2020-01-24","2007-03-20",[15],[9012,26469],"sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine",{"intervention":401,"totalTrials":952,"cells":26471},{"EARLY_PHASE1":26472,"PHASE1":26474,"PHASE2":26480,"PHASE3":26502,"PHASE4":26508,"NA":26510},{"trials":26473,"activeCount":101},[],{"trials":26475,"activeCount":101},[26476],{"nctId":1458,"briefTitle":1459,"status":244,"phases":26477,"primaryCompletion":1461,"completion":1461,"start":704,"enrollment":1462,"conditions":26478,"interventions":26479},[89],[308],[830,444,239,401],{"trials":26481,"activeCount":101},[26482,26486,26490,26494,26498],{"nctId":1482,"briefTitle":1483,"status":505,"phases":26483,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":97,"conditions":26484,"interventions":26485},[90],[1488],[420,418,421,331,515],{"nctId":393,"briefTitle":394,"status":244,"phases":26487,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":26488,"interventions":26489},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":467,"briefTitle":468,"status":244,"phases":26491,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":26492,"interventions":26493},[90],[27,24,475,476],[401,288,202,361,478,479],{"nctId":503,"briefTitle":504,"status":505,"phases":26495,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":26496,"interventions":26497},[90],[511,512,513],[419,331,218,515,516],{"nctId":752,"briefTitle":753,"status":244,"phases":26499,"primaryCompletion":727,"completion":755,"start":756,"enrollment":438,"conditions":26500,"interventions":26501},[90],[27,24,475,476],[401,288,202,404,479],{"trials":26503,"activeCount":101},[26504],{"nctId":853,"briefTitle":854,"status":244,"phases":26505,"primaryCompletion":856,"completion":856,"start":857,"conditions":26506,"interventions":26507},[91],[27],[401,202,361,478,479],{"trials":26509,"activeCount":101},[],{"trials":26511,"activeCount":101},[26512],{"nctId":5610,"briefTitle":5611,"status":505,"phases":26513,"primaryCompletion":3209,"completion":3209,"start":5613,"enrollment":509,"conditions":26514,"interventions":26515},[93],[5615,5616,416,5617],[479,404,444,401,5619],{"intervention":404,"totalTrials":2291,"cells":26517},{"EARLY_PHASE1":26518,"PHASE1":26520,"PHASE2":26522,"PHASE3":26548,"PHASE4":26550,"NA":26552},{"trials":26519,"activeCount":101},[],{"trials":26521,"activeCount":101},[],{"trials":26523,"activeCount":101},[26524,26528,26532,26536,26540,26544],{"nctId":393,"briefTitle":394,"status":244,"phases":26525,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":26526,"interventions":26527},[90],[27,24],[401,288,402,374,202,403,404,405],{"nctId":433,"briefTitle":434,"status":244,"phases":26529,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":26530,"interventions":26531},[90],[24],[202,403,404,441,442,443,444,362,405,445,446,349,447],{"nctId":627,"briefTitle":628,"status":244,"phases":26533,"primaryCompletion":630,"completion":630,"start":427,"enrollment":573,"conditions":26534,"interventions":26535},[90],[27],[288,374,202,404],{"nctId":5589,"briefTitle":5590,"status":244,"phases":26537,"primaryCompletion":1014,"completion":1014,"start":554,"enrollment":1152,"conditions":26538,"interventions":26539},[90],[27,24,828,475,476],[5594,403,404,444],{"nctId":752,"briefTitle":753,"status":244,"phases":26541,"primaryCompletion":727,"completion":755,"start":756,"enrollment":438,"conditions":26542,"interventions":26543},[90],[27,24,475,476],[401,288,202,404,479],{"nctId":771,"briefTitle":772,"status":244,"phases":26545,"primaryCompletion":774,"completion":774,"start":727,"enrollment":234,"conditions":26546,"interventions":26547},[90],[27,24],[288,374,202,403,404,405],{"trials":26549,"activeCount":101},[],{"trials":26551,"activeCount":101},[],{"trials":26553,"activeCount":101},[26554],{"nctId":5610,"briefTitle":5611,"status":505,"phases":26555,"primaryCompletion":3209,"completion":3209,"start":5613,"enrollment":509,"conditions":26556,"interventions":26557},[93],[5615,5616,416,5617],[479,404,444,401,5619],{"intervention":4134,"totalTrials":332,"cells":26559},{"EARLY_PHASE1":26560,"PHASE1":26562,"PHASE2":26573,"PHASE3":26593,"PHASE4":26595,"NA":26597},{"trials":26561,"activeCount":101},[],{"trials":26563,"activeCount":101},[26564],{"nctId":26565,"briefTitle":26566,"status":244,"phases":26567,"primaryCompletion":26568,"completion":26568,"start":26569,"enrollment":4992,"conditions":26570,"interventions":26572},"NCT01967095","Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer",[89],"2018-11-08","2013-10-15",[26571],"EGFR-Mutant Lung Cancer",[3096],{"trials":26574,"activeCount":101},[26575,26579,26583,26589],{"nctId":4127,"briefTitle":4128,"status":244,"phases":26576,"primaryCompletion":4130,"completion":4130,"start":4131,"enrollment":2483,"conditions":26577,"interventions":26578},[89,90],[21],[722,4134],{"nctId":3090,"briefTitle":3091,"status":244,"phases":26580,"primaryCompletion":1150,"completion":1150,"start":1347,"enrollment":601,"conditions":26581,"interventions":26582},[90],[3094,21],[3096,1107,974],{"nctId":26584,"briefTitle":26585,"status":505,"phases":26586,"primaryCompletion":22735,"completion":22735,"start":4635,"enrollment":1094,"conditions":26587,"interventions":26588},"NCT01189435","Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib",[90],[21],[3096],{"nctId":6125,"briefTitle":6126,"status":244,"phases":26590,"primaryCompletion":2473,"completion":2473,"start":6128,"enrollment":454,"conditions":26591,"interventions":26592},[89,90],[6130,21,5968,6131,6132,6133],[3080,4134],{"trials":26594,"activeCount":101},[],{"trials":26596,"activeCount":101},[],{"trials":26598,"activeCount":101},[26599],{"nctId":26600,"briefTitle":26601,"status":244,"phases":26602,"primaryCompletion":26603,"completion":26603,"start":26604,"enrollment":1114,"conditions":26605,"interventions":26607},"NCT02450591","Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations",[93],"2017-12-11","2015-05-14",[26606],"Oligometastatic Lung Adenocarcinoma",[4134],{"intervention":379,"totalTrials":1934,"cells":26609},{"EARLY_PHASE1":26610,"PHASE1":26612,"PHASE2":26614,"PHASE3":26632,"PHASE4":26634,"NA":26636},{"trials":26611,"activeCount":101},[],{"trials":26613,"activeCount":101},[],{"trials":26615,"activeCount":101},[26616,26620,26624,26628],{"nctId":365,"briefTitle":366,"status":244,"phases":26617,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":26618,"interventions":26619},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"nctId":3678,"briefTitle":3679,"status":244,"phases":26621,"primaryCompletion":3681,"completion":3681,"start":3682,"enrollment":2483,"conditions":26622,"interventions":26623},[90],[2610],[920,643,1615,379],{"nctId":4768,"briefTitle":4769,"status":244,"phases":26625,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":1015,"conditions":26626,"interventions":26627},[90],[3259],[4691,379,4775],{"nctId":5095,"briefTitle":5096,"status":244,"phases":26629,"primaryCompletion":4363,"completion":5098,"start":1397,"enrollment":573,"conditions":26630,"interventions":26631},[90],[1226],[441,3603,379,3152],{"trials":26633,"activeCount":101},[],{"trials":26635,"activeCount":101},[],{"trials":26637,"activeCount":101},[26638],{"nctId":13608,"briefTitle":13609,"status":244,"phases":26639,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":26640,"interventions":26641},[],[36,13612],[13614,376,2964,378,379,4775],{"intervention":3342,"totalTrials":509,"cells":26643},{"EARLY_PHASE1":26644,"PHASE1":26646,"PHASE2":26648,"PHASE3":26658,"PHASE4":26660,"NA":26662},{"trials":26645,"activeCount":101},[],{"trials":26647,"activeCount":101},[],{"trials":26649,"activeCount":101},[26650,26654],{"nctId":4729,"briefTitle":4730,"status":244,"phases":26651,"primaryCompletion":3044,"start":1653,"conditions":26652,"interventions":26653},[90],[4733,4734],[3342,4691,558],{"nctId":6490,"briefTitle":6491,"status":244,"phases":26655,"primaryCompletion":6493,"completion":6493,"start":1664,"enrollment":162,"conditions":26656,"interventions":26657},[90],[3259],[288,830,3342,446,479,349],{"trials":26659,"activeCount":101},[],{"trials":26661,"activeCount":101},[],{"trials":26663,"activeCount":101},[26664],{"nctId":3336,"briefTitle":3337,"status":244,"phases":26665,"primaryCompletion":3339,"completion":3339,"start":1610,"enrollment":332,"conditions":26666,"interventions":26667},[93],[3259],[47,3342,349],{"intervention":25684,"totalTrials":509,"cells":26669},{"EARLY_PHASE1":26670,"PHASE1":26672,"PHASE2":26678,"PHASE3":26680,"PHASE4":26682,"NA":26684},{"trials":26671,"activeCount":101},[],{"trials":26673,"activeCount":101},[26674],{"nctId":25677,"briefTitle":25678,"status":244,"phases":26675,"primaryCompletion":1266,"completion":1266,"start":339,"enrollment":659,"conditions":26676,"interventions":26677},[89],[25681,25682],[25684,25670,25685,25686],{"trials":26679,"activeCount":101},[],{"trials":26681,"activeCount":101},[],{"trials":26683,"activeCount":101},[],{"trials":26685,"activeCount":101},[26686,26695],{"nctId":26687,"briefTitle":26688,"status":244,"phases":26689,"primaryCompletion":26690,"completion":26690,"start":3777,"enrollment":1654,"conditions":26691,"interventions":26693},"NCT00576615","Propofol's Hypnotic and Memory Effects",[],"2016-05",[26692],"Healthy",[26694],"propofol",{"nctId":26696,"briefTitle":26697,"status":244,"phases":26698,"primaryCompletion":26699,"completion":26699,"start":13529,"enrollment":3717,"conditions":26700,"interventions":26703},"NCT02278003","A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients",[93],"2017-05-10",[26701,26702],"Pediatric Pateints","Amnesic Properties of Propofol",[25684],{"intervention":7519,"totalTrials":509,"cells":26705},{"EARLY_PHASE1":26706,"PHASE1":26708,"PHASE2":26710,"PHASE3":26722,"PHASE4":26724,"NA":26726},{"trials":26707,"activeCount":101},[],{"trials":26709,"activeCount":101},[],{"trials":26711,"activeCount":101},[26712,26716],{"nctId":7514,"briefTitle":7515,"status":244,"phases":26713,"completion":7407,"start":637,"conditions":26714,"interventions":26715},[90],[15],[768,7519],{"nctId":26717,"briefTitle":26718,"status":244,"phases":26719,"primaryCompletion":1565,"start":2982,"conditions":26720,"interventions":26721},"NCT00014404","Celecoxib in Treating Patients With Precancerous Lesions of the Mouth",[90],[1586],[7519],{"trials":26723,"activeCount":101},[],{"trials":26725,"activeCount":101},[],{"trials":26727,"activeCount":101},[26728],{"nctId":26729,"briefTitle":26730,"status":244,"phases":26731,"primaryCompletion":3032,"completion":26732,"start":3220,"enrollment":283,"conditions":26733,"interventions":26735},"NCT00596219","Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma",[93],"2010-10",[26734],"SQUAMOUS CELL CARCINOMA",[7519],{"intervention":13614,"totalTrials":1094,"cells":26737},{"EARLY_PHASE1":26738,"PHASE1":26740,"PHASE2":26742,"PHASE3":26748,"PHASE4":26750,"NA":26752},{"trials":26739,"activeCount":101},[],{"trials":26741,"activeCount":101},[],{"trials":26743,"activeCount":101},[26744],{"nctId":17912,"briefTitle":17913,"status":244,"phases":26745,"primaryCompletion":17915,"completion":17915,"start":727,"enrollment":969,"conditions":26746,"interventions":26747},[89,90],[475],[17918,13235,13614,17919,1351],{"trials":26749,"activeCount":101},[],{"trials":26751,"activeCount":101},[],{"trials":26753,"activeCount":101},[26754],{"nctId":13608,"briefTitle":13609,"status":244,"phases":26755,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":26756,"interventions":26757},[],[36,13612],[13614,376,2964,378,379,4775],{"intervention":376,"totalTrials":1094,"cells":26759},{"EARLY_PHASE1":26760,"PHASE1":26762,"PHASE2":26764,"PHASE3":26770,"PHASE4":26772,"NA":26774},{"trials":26761,"activeCount":101},[],{"trials":26763,"activeCount":101},[],{"trials":26765,"activeCount":101},[26766],{"nctId":365,"briefTitle":366,"status":244,"phases":26767,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":26768,"interventions":26769},[89,90],[27,24],[288,373,374,360,202,363,375,376,377,378,379],{"trials":26771,"activeCount":101},[],{"trials":26773,"activeCount":101},[],{"trials":26775,"activeCount":101},[26776],{"nctId":13608,"briefTitle":13609,"status":244,"phases":26777,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":26778,"interventions":26779},[],[36,13612],[13614,376,2964,378,379,4775],{"intervention":26781,"totalTrials":1094,"cells":26782},"ribavirin",{"EARLY_PHASE1":26783,"PHASE1":26785,"PHASE2":26787,"PHASE3":26789,"PHASE4":26791,"NA":26793},{"trials":26784,"activeCount":101},[],{"trials":26786,"activeCount":101},[],{"trials":26788,"activeCount":101},[],{"trials":26790,"activeCount":101},[],{"trials":26792,"activeCount":101},[],{"trials":26794,"activeCount":101},[26795,26803],{"nctId":26796,"briefTitle":26797,"status":244,"phases":26798,"primaryCompletion":26799,"completion":26799,"start":26800,"enrollment":601,"conditions":26801,"interventions":26802},"NCT01268579","Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and\u002For Base of Tongue Squamous Cell Carcinoma",[93],"2022-10-31","2010-12-28",[23972],[26781],{"nctId":26804,"briefTitle":26805,"status":244,"phases":26806,"primaryCompletion":26807,"completion":26807,"start":20096,"enrollment":283,"conditions":26808,"interventions":26811},"NCT02308241","Ribavirin for Patients With Recurrent\u002FMetastatic (R\u002FM) Human Papillomavirus (HPV)-Related Malignancies",[93],"2022-03-25",[26809,26810],"Human Papillomavirus (HPV)-Related Malignancies","Recurrent\u002FMetastatic (R\u002FM) Human Papillomavirus (HPV)-Related Malignancies",[26812],"Ribavirin",{"intervention":921,"totalTrials":1094,"cells":26814},{"EARLY_PHASE1":26815,"PHASE1":26817,"PHASE2":26819,"PHASE3":26827,"PHASE4":26829,"NA":26831},{"trials":26816,"activeCount":101},[],{"trials":26818,"activeCount":101},[],{"trials":26820,"activeCount":101},[26821],{"nctId":26822,"briefTitle":26823,"status":244,"phases":26824,"primaryCompletion":471,"start":16912,"enrollment":2407,"conditions":26825,"interventions":26826},"NCT00077246","ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer",[89,90],[21],[921],{"trials":26828,"activeCount":101},[],{"trials":26830,"activeCount":101},[],{"trials":26832,"activeCount":101},[26833],{"nctId":914,"briefTitle":915,"status":916,"phases":26834,"start":727,"enrollment":31,"conditions":26835,"interventions":26836},[93],[15],[920,373,202,345,921],{"intervention":4775,"totalTrials":1094,"cells":26838},{"EARLY_PHASE1":26839,"PHASE1":26841,"PHASE2":26843,"PHASE3":26849,"PHASE4":26851,"NA":26853},{"trials":26840,"activeCount":101},[],{"trials":26842,"activeCount":101},[],{"trials":26844,"activeCount":101},[26845],{"nctId":4768,"briefTitle":4769,"status":244,"phases":26846,"primaryCompletion":4771,"completion":4771,"start":4772,"enrollment":1015,"conditions":26847,"interventions":26848},[90],[3259],[4691,379,4775],{"trials":26850,"activeCount":101},[],{"trials":26852,"activeCount":101},[],{"trials":26854,"activeCount":101},[26855],{"nctId":13608,"briefTitle":13609,"status":244,"phases":26856,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":26857,"interventions":26858},[],[36,13612],[13614,376,2964,378,379,4775],{"intervention":2964,"totalTrials":1094,"cells":26860},{"EARLY_PHASE1":26861,"PHASE1":26863,"PHASE2":26869,"PHASE3":26871,"PHASE4":26873,"NA":26875},{"trials":26862,"activeCount":101},[],{"trials":26864,"activeCount":101},[26865],{"nctId":2958,"briefTitle":2959,"status":244,"phases":26866,"primaryCompletion":875,"completion":875,"start":736,"enrollment":356,"conditions":26867,"interventions":26868},[89],[1568],[47,2963,2964],{"trials":26870,"activeCount":101},[],{"trials":26872,"activeCount":101},[],{"trials":26874,"activeCount":101},[],{"trials":26876,"activeCount":101},[26877],{"nctId":13608,"briefTitle":13609,"status":244,"phases":26878,"primaryCompletion":875,"completion":875,"start":1199,"enrollment":952,"conditions":26879,"interventions":26880},[],[36,13612],[13614,376,2964,378,379,4775],{"intervention":9373,"totalTrials":1094,"cells":26882},{"EARLY_PHASE1":26883,"PHASE1":26885,"PHASE2":26887,"PHASE3":26893,"PHASE4":26895,"NA":26897},{"trials":26884,"activeCount":101},[],{"trials":26886,"activeCount":101},[],{"trials":26888,"activeCount":101},[26889],{"nctId":9365,"briefTitle":9366,"status":244,"phases":26890,"primaryCompletion":9368,"completion":9368,"start":9369,"enrollment":1447,"conditions":26891,"interventions":26892},[89,90],[9371],[9373,9374],{"trials":26894,"activeCount":101},[],{"trials":26896,"activeCount":101},[],{"trials":26898,"activeCount":101},[26899],{"nctId":26900,"briefTitle":26901,"status":244,"phases":26902,"primaryCompletion":26903,"completion":26903,"start":25467,"enrollment":1114,"conditions":26904,"interventions":26906},"NCT02657486","BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder",[93],"2026-02-04",[971,26905],"Non-Muscle-Invasive Urothelial Carcinoma",[9373],{"intervention":26908,"totalTrials":97,"cells":26909},"Family History Questionnaire",{"EARLY_PHASE1":26910,"PHASE1":26912,"PHASE2":26914,"PHASE3":26916,"PHASE4":26918,"NA":26920},{"trials":26911,"activeCount":101},[],{"trials":26913,"activeCount":101},[],{"trials":26915,"activeCount":101},[],{"trials":26917,"activeCount":101},[],{"trials":26919,"activeCount":101},[],{"trials":26921,"activeCount":101},[26922],{"nctId":26923,"briefTitle":26924,"status":244,"phases":26925,"primaryCompletion":26926,"completion":26926,"start":8810,"enrollment":26927,"conditions":26928,"interventions":26930},"NCT01667952","Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness",[],"2025-03-06",1068,[26929],"Pediatric or Young Adult Cancer Survivors",[26908,26931],"Salvia sample",{"intervention":26931,"totalTrials":97,"cells":26933},{"EARLY_PHASE1":26934,"PHASE1":26936,"PHASE2":26938,"PHASE3":26940,"PHASE4":26942,"NA":26944},{"trials":26935,"activeCount":101},[],{"trials":26937,"activeCount":101},[],{"trials":26939,"activeCount":101},[],{"trials":26941,"activeCount":101},[],{"trials":26943,"activeCount":101},[],{"trials":26945,"activeCount":101},[26946],{"nctId":26923,"briefTitle":26924,"status":244,"phases":26947,"primaryCompletion":26926,"completion":26926,"start":8810,"enrollment":26927,"conditions":26948,"interventions":26949},[],[26929],[26908,26931],{"intervention":26951,"totalTrials":97,"cells":26952},"Enoxaparin",{"EARLY_PHASE1":26953,"PHASE1":26955,"PHASE2":26957,"PHASE3":26959,"PHASE4":26961,"NA":26963},{"trials":26954,"activeCount":101},[],{"trials":26956,"activeCount":101},[],{"trials":26958,"activeCount":101},[],{"trials":26960,"activeCount":101},[],{"trials":26962,"activeCount":101},[],{"trials":26964,"activeCount":101},[26965],{"nctId":26966,"briefTitle":26967,"status":244,"phases":26968,"primaryCompletion":26969,"completion":26969,"start":7025,"enrollment":306,"conditions":26970,"interventions":26972},"NCT01763606","Enoxaparin Versus Aspirin in Patients With Cancer and Stroke",[93],"2019-04-03",[26971],"Cancer Patients First-ever Acute Ischemic Stroke",[26951,26973],"Aspirin",{"intervention":26973,"totalTrials":97,"cells":26975},{"EARLY_PHASE1":26976,"PHASE1":26978,"PHASE2":26980,"PHASE3":26982,"PHASE4":26984,"NA":26986},{"trials":26977,"activeCount":101},[],{"trials":26979,"activeCount":101},[],{"trials":26981,"activeCount":101},[],{"trials":26983,"activeCount":101},[],{"trials":26985,"activeCount":101},[],{"trials":26987,"activeCount":101},[26988],{"nctId":26966,"briefTitle":26967,"status":244,"phases":26989,"primaryCompletion":26969,"completion":26969,"start":7025,"enrollment":306,"conditions":26990,"interventions":26991},[93],[26971],[26951,26973],{"intervention":4317,"totalTrials":97,"cells":26993},{"EARLY_PHASE1":26994,"PHASE1":26996,"PHASE2":26998,"PHASE3":27000,"PHASE4":27002,"NA":27004},{"trials":26995,"activeCount":101},[],{"trials":26997,"activeCount":101},[],{"trials":26999,"activeCount":101},[],{"trials":27001,"activeCount":101},[],{"trials":27003,"activeCount":101},[],{"trials":27005,"activeCount":101},[27006],{"nctId":4310,"briefTitle":4311,"status":244,"phases":27007,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1232,"conditions":27008,"interventions":27009},[93],[2311],[4212,4317,52],{"intervention":27011,"totalTrials":97,"cells":27012},"BRCA testing and questionnaire assessments",{"EARLY_PHASE1":27013,"PHASE1":27015,"PHASE2":27017,"PHASE3":27019,"PHASE4":27021,"NA":27023},{"trials":27014,"activeCount":101},[],{"trials":27016,"activeCount":101},[],{"trials":27018,"activeCount":101},[],{"trials":27020,"activeCount":101},[],{"trials":27022,"activeCount":101},[],{"trials":27024,"activeCount":101},[27025],{"nctId":27026,"briefTitle":27027,"status":244,"phases":27028,"primaryCompletion":27029,"completion":27029,"start":27030,"enrollment":3411,"conditions":27031,"interventions":27032},"NCT01386411","Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer",[],"2017-11-03","2011-06-28",[15],[27011],{"intervention":27034,"totalTrials":97,"cells":27035},"AZD6244",{"EARLY_PHASE1":27036,"PHASE1":27038,"PHASE2":27040,"PHASE3":27042,"PHASE4":27044,"NA":27046},{"trials":27037,"activeCount":101},[],{"trials":27039,"activeCount":101},[],{"trials":27041,"activeCount":101},[],{"trials":27043,"activeCount":101},[],{"trials":27045,"activeCount":101},[],{"trials":27047,"activeCount":101},[27048],{"nctId":27049,"briefTitle":27050,"status":244,"phases":27051,"primaryCompletion":1141,"completion":1141,"start":16615,"enrollment":454,"conditions":27052,"interventions":27053},"NCT00970359","Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244",[93],[4054],[27034],{"intervention":27055,"totalTrials":97,"cells":27056},"Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine",{"EARLY_PHASE1":27057,"PHASE1":27059,"PHASE2":27061,"PHASE3":27063,"PHASE4":27065,"NA":27067},{"trials":27058,"activeCount":101},[],{"trials":27060,"activeCount":101},[],{"trials":27062,"activeCount":101},[],{"trials":27064,"activeCount":101},[],{"trials":27066,"activeCount":101},[],{"trials":27068,"activeCount":101},[27069],{"nctId":27070,"briefTitle":27071,"status":244,"phases":27072,"primaryCompletion":4669,"completion":4669,"start":27073,"enrollment":2426,"conditions":27074,"interventions":27075},"NCT00594815","Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma",[93],"2002-08-28",[24],[27055],{"intervention":5619,"totalTrials":97,"cells":27077},{"EARLY_PHASE1":27078,"PHASE1":27080,"PHASE2":27082,"PHASE3":27084,"PHASE4":27086,"NA":27088},{"trials":27079,"activeCount":101},[],{"trials":27081,"activeCount":101},[],{"trials":27083,"activeCount":101},[],{"trials":27085,"activeCount":101},[],{"trials":27087,"activeCount":101},[],{"trials":27089,"activeCount":101},[27090],{"nctId":5610,"briefTitle":5611,"status":505,"phases":27091,"primaryCompletion":3209,"completion":3209,"start":5613,"enrollment":509,"conditions":27092,"interventions":27093},[93],[5615,5616,416,5617],[479,404,444,401,5619],{"intervention":27095,"totalTrials":97,"cells":27096},"Atorvastatin",{"EARLY_PHASE1":27097,"PHASE1":27099,"PHASE2":27101,"PHASE3":27103,"PHASE4":27105,"NA":27107},{"trials":27098,"activeCount":101},[],{"trials":27100,"activeCount":101},[],{"trials":27102,"activeCount":101},[],{"trials":27104,"activeCount":101},[],{"trials":27106,"activeCount":101},[],{"trials":27108,"activeCount":101},[27109],{"nctId":27110,"briefTitle":27111,"status":244,"phases":27112,"primaryCompletion":368,"completion":368,"start":727,"enrollment":27113,"conditions":27114,"interventions":27115},"NCT00375518","Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery",[93],162,[1812],[27095],{"intervention":27117,"totalTrials":97,"cells":27118},"obtain tissue specimens",{"EARLY_PHASE1":27119,"PHASE1":27121,"PHASE2":27123,"PHASE3":27125,"PHASE4":27127,"NA":27129},{"trials":27120,"activeCount":101},[],{"trials":27122,"activeCount":101},[],{"trials":27124,"activeCount":101},[],{"trials":27126,"activeCount":101},[],{"trials":27128,"activeCount":101},[],{"trials":27130,"activeCount":101},[27131],{"nctId":27132,"briefTitle":27133,"status":244,"phases":27134,"primaryCompletion":27135,"completion":27135,"start":27136,"enrollment":356,"conditions":27137,"interventions":27138},"NCT01300429","Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus",[],"2021-01-05","2011-02-08",[21],[27117],{"intervention":27140,"totalTrials":97,"cells":27141},"ropivacaine",{"EARLY_PHASE1":27142,"PHASE1":27144,"PHASE2":27146,"PHASE3":27148,"PHASE4":27150,"NA":27152},{"trials":27143,"activeCount":101},[],{"trials":27145,"activeCount":101},[],{"trials":27147,"activeCount":101},[],{"trials":27149,"activeCount":101},[],{"trials":27151,"activeCount":101},[],{"trials":27153,"activeCount":101},[27154],{"nctId":27155,"briefTitle":27156,"status":244,"phases":27157,"primaryCompletion":27158,"completion":27158,"start":1223,"enrollment":2334,"conditions":27159,"interventions":27160},"NCT02924324","Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients",[93],"2019-11",[215],[27140],{"intervention":27162,"totalTrials":97,"cells":27163},"Bortezomib\u002FDexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib\u002FDexamethasone",{"EARLY_PHASE1":27164,"PHASE1":27166,"PHASE2":27168,"PHASE3":27170,"PHASE4":27172,"NA":27174},{"trials":27165,"activeCount":101},[],{"trials":27167,"activeCount":101},[],{"trials":27169,"activeCount":101},[],{"trials":27171,"activeCount":101},[],{"trials":27173,"activeCount":101},[],{"trials":27175,"activeCount":101},[27176],{"nctId":27177,"briefTitle":27178,"status":244,"phases":27179,"primaryCompletion":27180,"completion":27180,"start":27181,"enrollment":306,"conditions":27182,"interventions":27186},"NCT01383759","Bortezomib\u002FDexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib\u002FDexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis",[93],"2019-04-30","2011-06-24",[27183,27184,27185,13784],"Light Chain Deposition Disease (LCDD or MIDD)","Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)","Monoclonal Immunoglobulin Deposition Disease (MIDD)",[27162],{"intervention":27188,"totalTrials":97,"cells":27189},"Docetaxel plus Gemcitabine",{"EARLY_PHASE1":27190,"PHASE1":27192,"PHASE2":27194,"PHASE3":27196,"PHASE4":27198,"NA":27200},{"trials":27191,"activeCount":101},[],{"trials":27193,"activeCount":101},[],{"trials":27195,"activeCount":101},[],{"trials":27197,"activeCount":101},[],{"trials":27199,"activeCount":101},[],{"trials":27201,"activeCount":101},[27202],{"nctId":27203,"briefTitle":27204,"status":244,"phases":27205,"primaryCompletion":27206,"completion":22735,"start":756,"enrollment":438,"conditions":27207,"interventions":27209},"NCT00614835","Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus",[93],"2006-02",[27208,2763],"Uterine Leiomyosarcoma",[27188],{"intervention":27211,"totalTrials":97,"cells":27212},"MC1R genotyping",{"EARLY_PHASE1":27213,"PHASE1":27215,"PHASE2":27217,"PHASE3":27219,"PHASE4":27221,"NA":27223},{"trials":27214,"activeCount":101},[],{"trials":27216,"activeCount":101},[],{"trials":27218,"activeCount":101},[],{"trials":27220,"activeCount":101},[],{"trials":27222,"activeCount":101},[],{"trials":27224,"activeCount":101},[27225],{"nctId":27226,"briefTitle":27227,"status":244,"phases":27228,"primaryCompletion":27229,"completion":27229,"start":22406,"enrollment":4992,"conditions":27230,"interventions":27232},"NCT02941900","Interest and Impact of Skin Cancer Genetic Testing",[],"2023-01-18",[27231],"Non-melanoma Skin Cancer (NMSC)",[27211],{"intervention":27234,"totalTrials":97,"cells":27235},"epirubicin, cyclophosphamide, Paclitaxel,",{"EARLY_PHASE1":27236,"PHASE1":27238,"PHASE2":27240,"PHASE3":27242,"PHASE4":27244,"NA":27246},{"trials":27237,"activeCount":101},[],{"trials":27239,"activeCount":101},[],{"trials":27241,"activeCount":101},[],{"trials":27243,"activeCount":101},[],{"trials":27245,"activeCount":101},[],{"trials":27247,"activeCount":101},[27248],{"nctId":27249,"briefTitle":27250,"status":244,"phases":27251,"primaryCompletion":369,"completion":755,"start":1693,"enrollment":3599,"conditions":27252,"interventions":27254},"NCT00617370","Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility",[93],[15,27253],"Adenocarcinoma of the Breast",[27234],{"intervention":27256,"totalTrials":97,"cells":27257},"Blood draw",{"EARLY_PHASE1":27258,"PHASE1":27260,"PHASE2":27262,"PHASE3":27264,"PHASE4":27266,"NA":27268},{"trials":27259,"activeCount":101},[],{"trials":27261,"activeCount":101},[],{"trials":27263,"activeCount":101},[],{"trials":27265,"activeCount":101},[],{"trials":27267,"activeCount":101},[],{"trials":27269,"activeCount":101},[27270],{"nctId":27271,"briefTitle":27272,"status":505,"phases":27273,"primaryCompletion":4634,"completion":4634,"start":5650,"enrollment":283,"conditions":27274,"interventions":27275},"NCT00918008","A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer",[],[971],[27256],{"intervention":27277,"totalTrials":97,"cells":27278},"cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim",{"EARLY_PHASE1":27279,"PHASE1":27281,"PHASE2":27283,"PHASE3":27285,"PHASE4":27287,"NA":27289},{"trials":27280,"activeCount":101},[],{"trials":27282,"activeCount":101},[],{"trials":27284,"activeCount":101},[],{"trials":27286,"activeCount":101},[],{"trials":27288,"activeCount":101},[],{"trials":27290,"activeCount":101},[27291],{"nctId":27292,"briefTitle":27293,"status":244,"phases":27294,"primaryCompletion":316,"completion":316,"start":22590,"enrollment":3599,"conditions":27295,"interventions":27296},"NCT00615901","Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer",[93],[15],[27277],{"intervention":27298,"totalTrials":97,"cells":27299},"FOLFOX and bevacizumab",{"EARLY_PHASE1":27300,"PHASE1":27302,"PHASE2":27304,"PHASE3":27306,"PHASE4":27308,"NA":27310},{"trials":27301,"activeCount":101},[],{"trials":27303,"activeCount":101},[],{"trials":27305,"activeCount":101},[],{"trials":27307,"activeCount":101},[],{"trials":27309,"activeCount":101},[],{"trials":27311,"activeCount":101},[27312],{"nctId":27313,"briefTitle":27314,"status":505,"phases":27315,"primaryCompletion":15999,"completion":15999,"start":1083,"enrollment":1094,"conditions":27316,"interventions":27317},"NCT00826800","Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer",[93],[16135],[27298],{"intervention":27319,"totalTrials":97,"cells":27320},"18F-BMS-986229",{"EARLY_PHASE1":27321,"PHASE1":27323,"PHASE2":27325,"PHASE3":27327,"PHASE4":27329,"NA":27331},{"trials":27322,"activeCount":101},[],{"trials":27324,"activeCount":101},[],{"trials":27326,"activeCount":101},[],{"trials":27328,"activeCount":101},[],{"trials":27330,"activeCount":101},[],{"trials":27332,"activeCount":101},[27333],{"nctId":27334,"briefTitle":27335,"status":244,"phases":27336,"primaryCompletion":599,"completion":599,"start":2654,"enrollment":1434,"conditions":27337,"interventions":27340},"NCT04161781","A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer",[],[2678,27338,1602,1613,1676,2398,27339],"Esophagus Cancer","Gastroesophageal Junction Squamous Cell Carcinoma",[27319,27341],"IV 18F-BMS-986229",{"intervention":27341,"totalTrials":97,"cells":27343},{"EARLY_PHASE1":27344,"PHASE1":27346,"PHASE2":27348,"PHASE3":27350,"PHASE4":27352,"NA":27354},{"trials":27345,"activeCount":101},[],{"trials":27347,"activeCount":101},[],{"trials":27349,"activeCount":101},[],{"trials":27351,"activeCount":101},[],{"trials":27353,"activeCount":101},[],{"trials":27355,"activeCount":101},[27356],{"nctId":27334,"briefTitle":27335,"status":244,"phases":27357,"primaryCompletion":599,"completion":599,"start":2654,"enrollment":1434,"conditions":27358,"interventions":27359},[],[2678,27338,1602,1613,1676,2398,27339],[27319,27341],{"intervention":27361,"totalTrials":97,"cells":27362},"Naxitamab\u002FGM-CSF",{"EARLY_PHASE1":27363,"PHASE1":27365,"PHASE2":27367,"PHASE3":27369,"PHASE4":27371,"NA":27373},{"trials":27364,"activeCount":101},[],{"trials":27366,"activeCount":101},[],{"trials":27368,"activeCount":101},[],{"trials":27370,"activeCount":101},[],{"trials":27372,"activeCount":101},[],{"trials":27374,"activeCount":101},[27375],{"nctId":27376,"briefTitle":27377,"status":27378,"phases":27379,"conditions":27380,"interventions":27382},"NCT04501757","Naxitamab and GM-CSF in People With Neuroblastoma","NO_LONGER_AVAILABLE",[],[27381],"High-Risk Neuroblastoma",[27361],{"intervention":27384,"totalTrials":97,"cells":27385},"QBX258",{"EARLY_PHASE1":27386,"PHASE1":27388,"PHASE2":27390,"PHASE3":27392,"PHASE4":27394,"NA":27396},{"trials":27387,"activeCount":101},[],{"trials":27389,"activeCount":101},[],{"trials":27391,"activeCount":101},[],{"trials":27393,"activeCount":101},[],{"trials":27395,"activeCount":101},[],{"trials":27397,"activeCount":101},[27398],{"nctId":27399,"briefTitle":27400,"status":244,"phases":27401,"primaryCompletion":27402,"completion":27402,"start":803,"enrollment":601,"conditions":27403,"interventions":27405},"NCT02494206","Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)",[93],"2018-05",[15,27404],"Upper Extremity Lymphedema",[27384],{"intervention":26460,"totalTrials":97,"cells":27407},{"EARLY_PHASE1":27408,"PHASE1":27410,"PHASE2":27412,"PHASE3":27414,"PHASE4":27416,"NA":27418},{"trials":27409,"activeCount":101},[],{"trials":27411,"activeCount":101},[],{"trials":27413,"activeCount":101},[],{"trials":27415,"activeCount":101},[],{"trials":27417,"activeCount":101},[],{"trials":27419,"activeCount":101},[27420],{"nctId":26455,"briefTitle":26456,"status":244,"phases":27421,"primaryCompletion":1083,"completion":1083,"start":7415,"enrollment":272,"conditions":27422,"interventions":27423},[93],[15],[26460,9012],{"intervention":27425,"totalTrials":97,"cells":27426},"FACBC, Methionine",{"EARLY_PHASE1":27427,"PHASE1":27429,"PHASE2":27431,"PHASE3":27433,"PHASE4":27435,"NA":27437},{"trials":27428,"activeCount":101},[],{"trials":27430,"activeCount":101},[],{"trials":27432,"activeCount":101},[],{"trials":27434,"activeCount":101},[],{"trials":27436,"activeCount":101},[],{"trials":27438,"activeCount":101},[27439],{"nctId":27440,"briefTitle":27441,"status":244,"phases":27442,"primaryCompletion":27443,"completion":27443,"start":27444,"enrollment":356,"conditions":27445,"interventions":27446},"NCT00597246","Imaging Brain Tumors With FACBC and Methionine",[93],"2019-11-27","2003-05-13",[8191,9565],[27425],{"intervention":27448,"totalTrials":97,"cells":27449},"imiquimod",{"EARLY_PHASE1":27450,"PHASE1":27452,"PHASE2":27454,"PHASE3":27456,"PHASE4":27458,"NA":27460},{"trials":27451,"activeCount":101},[],{"trials":27453,"activeCount":101},[],{"trials":27455,"activeCount":101},[],{"trials":27457,"activeCount":101},[],{"trials":27459,"activeCount":101},[],{"trials":27461,"activeCount":101},[27462],{"nctId":27463,"briefTitle":27464,"status":244,"phases":27465,"primaryCompletion":27466,"completion":27466,"start":3590,"enrollment":952,"conditions":27467,"interventions":27469},"NCT00504023","Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva",[93],"2018-01",[27468],"Vulvar Cancer",[27448],{"intervention":27471,"totalTrials":97,"cells":27472},"131I-8H9",{"EARLY_PHASE1":27473,"PHASE1":27475,"PHASE2":27477,"PHASE3":27479,"PHASE4":27481,"NA":27483},{"trials":27474,"activeCount":101},[],{"trials":27476,"activeCount":101},[],{"trials":27478,"activeCount":101},[],{"trials":27480,"activeCount":101},[],{"trials":27482,"activeCount":101},[],{"trials":27484,"activeCount":101},[27485],{"nctId":27486,"briefTitle":27487,"status":505,"phases":27488,"primaryCompletion":630,"completion":630,"start":2931,"enrollment":283,"conditions":27489,"interventions":27490},"NCT00582608","Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9",[93],[9565,215,33],[27471,27491],"8H9",{"intervention":27491,"totalTrials":97,"cells":27493},{"EARLY_PHASE1":27494,"PHASE1":27496,"PHASE2":27498,"PHASE3":27500,"PHASE4":27502,"NA":27504},{"trials":27495,"activeCount":101},[],{"trials":27497,"activeCount":101},[],{"trials":27499,"activeCount":101},[],{"trials":27501,"activeCount":101},[],{"trials":27503,"activeCount":101},[],{"trials":27505,"activeCount":101},[27506],{"nctId":27486,"briefTitle":27487,"status":505,"phases":27507,"primaryCompletion":630,"completion":630,"start":2931,"enrollment":283,"conditions":27508,"interventions":27509},[93],[9565,215,33],[27471,27491],{"intervention":27511,"totalTrials":97,"cells":27512},"methylphenidate via transdermal patch compared to placebo",{"EARLY_PHASE1":27513,"PHASE1":27515,"PHASE2":27517,"PHASE3":27519,"PHASE4":27521,"NA":27523},{"trials":27514,"activeCount":101},[],{"trials":27516,"activeCount":101},[],{"trials":27518,"activeCount":101},[],{"trials":27520,"activeCount":101},[],{"trials":27522,"activeCount":101},[],{"trials":27524,"activeCount":101},[27525],{"nctId":27526,"briefTitle":27527,"status":2832,"phases":27528,"primaryCompletion":27529,"completion":27529,"start":19711,"enrollment":101,"conditions":27530,"interventions":27531},"NCT01124500","Transdermal Methylphenidate for Cancer-Related Fatigue",[93],"2012-05",[1586],[27511],{"intervention":27533,"totalTrials":97,"cells":27534},"varenicline",{"EARLY_PHASE1":27535,"PHASE1":27537,"PHASE2":27539,"PHASE3":27541,"PHASE4":27543,"NA":27545},{"trials":27536,"activeCount":101},[],{"trials":27538,"activeCount":101},[],{"trials":27540,"activeCount":101},[],{"trials":27542,"activeCount":101},[],{"trials":27544,"activeCount":101},[],{"trials":27546,"activeCount":101},[27547],{"nctId":27548,"briefTitle":27549,"status":505,"phases":27550,"primaryCompletion":1012,"completion":1012,"start":13529,"enrollment":2291,"conditions":27551,"interventions":27553},"NCT01532232","Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)",[],[15,27552],"Tobacco Dependence",[27533],{"intervention":27555,"totalTrials":97,"cells":27556},"bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821",{"EARLY_PHASE1":27557,"PHASE1":27559,"PHASE2":27561,"PHASE3":27563,"PHASE4":27565,"NA":27567},{"trials":27558,"activeCount":101},[],{"trials":27560,"activeCount":101},[],{"trials":27562,"activeCount":101},[],{"trials":27564,"activeCount":101},[],{"trials":27566,"activeCount":101},[],{"trials":27568,"activeCount":101},[27569],{"nctId":27570,"briefTitle":27571,"status":244,"phases":27572,"primaryCompletion":890,"completion":890,"start":26732,"enrollment":2483,"conditions":27573,"interventions":27574},"NCT01223235","Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab",[93],[22309,30,3437],[27555],{"intervention":27576,"totalTrials":97,"cells":27577},"AVASTIN",{"EARLY_PHASE1":27578,"PHASE1":27580,"PHASE2":27582,"PHASE3":27584,"PHASE4":27586,"NA":27588},{"trials":27579,"activeCount":101},[],{"trials":27581,"activeCount":101},[],{"trials":27583,"activeCount":101},[],{"trials":27585,"activeCount":101},[],{"trials":27587,"activeCount":101},[],{"trials":27589,"activeCount":101},[27590],{"nctId":27591,"briefTitle":27592,"status":244,"phases":27593,"primaryCompletion":755,"completion":755,"start":3590,"enrollment":97,"conditions":27594,"interventions":27595},"NCT00596362","Treatment With Intravitreal Avastin for Large Uveal Melanomas",[93],[2622],[27576],{"intervention":27597,"totalTrials":97,"cells":27598},"Sildenafil and questionnaire",{"EARLY_PHASE1":27599,"PHASE1":27601,"PHASE2":27603,"PHASE3":27605,"PHASE4":27607,"NA":27609},{"trials":27600,"activeCount":101},[],{"trials":27602,"activeCount":101},[],{"trials":27604,"activeCount":101},[],{"trials":27606,"activeCount":101},[],{"trials":27608,"activeCount":101},[],{"trials":27610,"activeCount":101},[27611],{"nctId":27612,"briefTitle":27613,"status":505,"phases":27614,"primaryCompletion":27615,"completion":27615,"start":27616,"enrollment":22224,"conditions":27617,"interventions":27620},"NCT00955929","Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy",[93],"2020-12-09","2009-08-06",[27618,16961,27619],"Penile Cancer","Radical Prostatectomy",[27597,27621],"Trimix combination (Papavarine 30mg\u002FmL Phentholamine 1mg\u002FmL Prostaglandin E1 10 mcg\u002FmmL) and questionnaires",{"intervention":27621,"totalTrials":97,"cells":27623},{"EARLY_PHASE1":27624,"PHASE1":27626,"PHASE2":27628,"PHASE3":27630,"PHASE4":27632,"NA":27634},{"trials":27625,"activeCount":101},[],{"trials":27627,"activeCount":101},[],{"trials":27629,"activeCount":101},[],{"trials":27631,"activeCount":101},[],{"trials":27633,"activeCount":101},[],{"trials":27635,"activeCount":101},[27636],{"nctId":27612,"briefTitle":27613,"status":505,"phases":27637,"primaryCompletion":27615,"completion":27615,"start":27616,"enrollment":22224,"conditions":27638,"interventions":27639},[93],[27618,16961,27619],[27597,27621],{"intervention":27641,"totalTrials":97,"cells":27642},"Raloxifene followed by combination therapy",{"EARLY_PHASE1":27643,"PHASE1":27645,"PHASE2":27647,"PHASE3":27649,"PHASE4":27651,"NA":27653},{"trials":27644,"activeCount":101},[],{"trials":27646,"activeCount":101},[],{"trials":27648,"activeCount":101},[],{"trials":27650,"activeCount":101},[],{"trials":27652,"activeCount":101},[],{"trials":27654,"activeCount":101},[27655],{"nctId":27656,"briefTitle":27657,"status":244,"phases":27658,"primaryCompletion":1653,"completion":1266,"start":8675,"enrollment":2630,"conditions":27659,"interventions":27660},"NCT00200174","Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease",[93],[15],[27641,27661],"Exemestane followed by combination therapy",{"intervention":27661,"totalTrials":97,"cells":27663},{"EARLY_PHASE1":27664,"PHASE1":27666,"PHASE2":27668,"PHASE3":27670,"PHASE4":27672,"NA":27674},{"trials":27665,"activeCount":101},[],{"trials":27667,"activeCount":101},[],{"trials":27669,"activeCount":101},[],{"trials":27671,"activeCount":101},[],{"trials":27673,"activeCount":101},[],{"trials":27675,"activeCount":101},[27676],{"nctId":27656,"briefTitle":27657,"status":244,"phases":27677,"primaryCompletion":1653,"completion":1266,"start":8675,"enrollment":2630,"conditions":27678,"interventions":27679},[93],[15],[27641,27661],{"intervention":27681,"totalTrials":97,"cells":27682},"11C-choline",{"EARLY_PHASE1":27683,"PHASE1":27685,"PHASE2":27687,"PHASE3":27689,"PHASE4":27691,"NA":27693},{"trials":27684,"activeCount":101},[],{"trials":27686,"activeCount":101},[],{"trials":27688,"activeCount":101},[],{"trials":27690,"activeCount":101},[],{"trials":27692,"activeCount":101},[],{"trials":27694,"activeCount":101},[27695],{"nctId":27696,"briefTitle":27697,"status":27378,"phases":27698,"conditions":27699,"interventions":27701},"NCT02531672","Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography",[],[18,27700],"Recurrent Prostate Cancer",[27681],{"intervention":27703,"totalTrials":97,"cells":27704},"Induction Chemotherapy",{"EARLY_PHASE1":27705,"PHASE1":27707,"PHASE2":27709,"PHASE3":27711,"PHASE4":27713,"NA":27715},{"trials":27706,"activeCount":101},[],{"trials":27708,"activeCount":101},[],{"trials":27710,"activeCount":101},[],{"trials":27712,"activeCount":101},[],{"trials":27714,"activeCount":101},[],{"trials":27716,"activeCount":101},[27717],{"nctId":27718,"briefTitle":27719,"status":505,"phases":27720,"primaryCompletion":890,"completion":890,"start":27721,"enrollment":1114,"conditions":27722,"interventions":27723},"NCT02519712","Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors",[93],"2015-07-28",[535],[27703],{"intervention":27725,"totalTrials":97,"cells":27726},"specimen samples",{"EARLY_PHASE1":27727,"PHASE1":27729,"PHASE2":27731,"PHASE3":27733,"PHASE4":27735,"NA":27737},{"trials":27728,"activeCount":101},[],{"trials":27730,"activeCount":101},[],{"trials":27732,"activeCount":101},[],{"trials":27734,"activeCount":101},[],{"trials":27736,"activeCount":101},[],{"trials":27738,"activeCount":101},[27739],{"nctId":27740,"briefTitle":27741,"status":244,"phases":27742,"primaryCompletion":1396,"completion":1396,"start":1575,"enrollment":27743,"conditions":27744,"interventions":27747},"NCT00582387","Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer",[],116,[971,27745,27746],"Urinary Cancer","Nonmuscle Invasive Bladder Cancer",[27725],{"intervention":27749,"totalTrials":97,"cells":27750},"GCSF, Central venous line placement, Stem cell Collection",{"EARLY_PHASE1":27751,"PHASE1":27753,"PHASE2":27755,"PHASE3":27757,"PHASE4":27759,"NA":27761},{"trials":27752,"activeCount":101},[],{"trials":27754,"activeCount":101},[],{"trials":27756,"activeCount":101},[],{"trials":27758,"activeCount":101},[],{"trials":27760,"activeCount":101},[],{"trials":27762,"activeCount":101},[27763],{"nctId":27764,"briefTitle":27765,"status":244,"phases":27766,"primaryCompletion":19086,"completion":19086,"start":4819,"enrollment":1934,"conditions":27767,"interventions":27770},"NCT00658385","Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major",[93],[27768,27769],"Beta Thalassemia Major","Congenital Anemias",[27749],{"intervention":27772,"totalTrials":97,"cells":27773},"131I-omburtamab",{"EARLY_PHASE1":27774,"PHASE1":27776,"PHASE2":27778,"PHASE3":27780,"PHASE4":27782,"NA":27784},{"trials":27775,"activeCount":101},[],{"trials":27777,"activeCount":101},[],{"trials":27779,"activeCount":101},[],{"trials":27781,"activeCount":101},[],{"trials":27783,"activeCount":101},[],{"trials":27785,"activeCount":101},[27786],{"nctId":27787,"briefTitle":27788,"status":27378,"phases":27789,"conditions":27790,"interventions":27792},"NCT05064306","131I-omburtamab for the Treatment of Central Nervous System\u002FLeptomeningeal Neoplasms in Children and Young Adults",[],[27791],"Central Nervous System\u002FLeptomeningeal Neoplasms",[27772],{"intervention":27794,"totalTrials":97,"cells":27795},"anthracycline and taxane based chemotherapy",{"EARLY_PHASE1":27796,"PHASE1":27798,"PHASE2":27800,"PHASE3":27802,"PHASE4":27804,"NA":27806},{"trials":27797,"activeCount":101},[],{"trials":27799,"activeCount":101},[],{"trials":27801,"activeCount":101},[],{"trials":27803,"activeCount":101},[],{"trials":27805,"activeCount":101},[],{"trials":27807,"activeCount":101},[27808],{"nctId":27809,"briefTitle":27810,"status":244,"phases":27811,"primaryCompletion":4586,"completion":4586,"start":27812,"enrollment":2630,"conditions":27813,"interventions":27814},"NCT02521363","Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer",[93],"2015-07-24",[15],[27794],{"intervention":27816,"totalTrials":97,"cells":27817},"valganciclovir",{"EARLY_PHASE1":27818,"PHASE1":27820,"PHASE2":27822,"PHASE3":27824,"PHASE4":27826,"NA":27828},{"trials":27819,"activeCount":101},[],{"trials":27821,"activeCount":101},[],{"trials":27823,"activeCount":101},[],{"trials":27825,"activeCount":101},[],{"trials":27827,"activeCount":101},[],{"trials":27829,"activeCount":101},[27830],{"nctId":27831,"briefTitle":27832,"status":244,"phases":27833,"primaryCompletion":1652,"completion":1652,"start":2914,"enrollment":332,"conditions":27834,"interventions":27835},"NCT00096538","Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma",[93],[33],[27816],{"intervention":27837,"totalTrials":97,"cells":27838},"sulindac",{"EARLY_PHASE1":27839,"PHASE1":27841,"PHASE2":27843,"PHASE3":27845,"PHASE4":27847,"NA":27849},{"trials":27840,"activeCount":101},[],{"trials":27842,"activeCount":101},[],{"trials":27844,"activeCount":101},[],{"trials":27846,"activeCount":101},[],{"trials":27848,"activeCount":101},[],{"trials":27850,"activeCount":101},[27851],{"nctId":27852,"briefTitle":27853,"status":244,"phases":27854,"primaryCompletion":27855,"completion":27855,"start":27856,"enrollment":203,"conditions":27857,"interventions":27860},"NCT00299195","A Randomized Study of Sulindac in Oral Premalignant Lesions",[93],"2020-01-06","2006-02-23",[27858,27859],"Leukoplakia, Oral","Benign Neoplasms",[27837],{"intervention":27862,"totalTrials":97,"cells":27863},"68Ga-DOTATOC PET\u002FCT Scan",{"EARLY_PHASE1":27864,"PHASE1":27866,"PHASE2":27868,"PHASE3":27870,"PHASE4":27872,"NA":27874},{"trials":27865,"activeCount":101},[],{"trials":27867,"activeCount":101},[],{"trials":27869,"activeCount":101},[],{"trials":27871,"activeCount":101},[],{"trials":27873,"activeCount":101},[],{"trials":27875,"activeCount":101},[27876],{"nctId":27877,"briefTitle":27878,"status":27378,"phases":27879,"conditions":27880,"interventions":27881},"NCT02358018","68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial",[],[15597],[27862],{"intervention":27883,"totalTrials":97,"cells":27884},"L-MTP-PE",{"EARLY_PHASE1":27885,"PHASE1":27887,"PHASE2":27889,"PHASE3":27891,"PHASE4":27893,"NA":27895},{"trials":27886,"activeCount":101},[],{"trials":27888,"activeCount":101},[],{"trials":27890,"activeCount":101},[],{"trials":27892,"activeCount":101},[],{"trials":27894,"activeCount":101},[],{"trials":27896,"activeCount":101},[27897],{"nctId":27898,"briefTitle":27899,"status":27900,"phases":27901,"conditions":27902,"interventions":27903},"NCT04571229","Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma","AVAILABLE",[],[3076],[27883],{"intervention":27905,"totalTrials":97,"cells":27906},"18F-FMISO",{"EARLY_PHASE1":27907,"PHASE1":27909,"PHASE2":27911,"PHASE3":27913,"PHASE4":27915,"NA":27917},{"trials":27908,"activeCount":101},[],{"trials":27910,"activeCount":101},[],{"trials":27912,"activeCount":101},[],{"trials":27914,"activeCount":101},[],{"trials":27916,"activeCount":101},[],{"trials":27918,"activeCount":101},[27919],{"nctId":27920,"briefTitle":27921,"status":244,"phases":27922,"primaryCompletion":25824,"completion":25824,"start":27923,"enrollment":438,"conditions":27924,"interventions":27926},"NCT02016872","Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET\u002FCT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients",[93],"2013-12-16",[27925],"Non-Small-Cell-Lung Cancer (NSCLC)",[27905],{"intervention":27928,"totalTrials":97,"cells":27929},"BIAXIN",{"EARLY_PHASE1":27930,"PHASE1":27932,"PHASE2":27934,"PHASE3":27936,"PHASE4":27938,"NA":27940},{"trials":27931,"activeCount":101},[],{"trials":27933,"activeCount":101},[],{"trials":27935,"activeCount":101},[],{"trials":27937,"activeCount":101},[],{"trials":27939,"activeCount":101},[],{"trials":27941,"activeCount":101},[27942],{"nctId":27943,"briefTitle":27944,"status":244,"phases":27945,"primaryCompletion":9109,"completion":9109,"start":3590,"enrollment":3344,"conditions":27946,"interventions":27947},"NCT00461084","Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma",[],[24],[27928,27948],"Biaxin",{"intervention":27950,"totalTrials":97,"cells":27951},"89Zr-J591",{"EARLY_PHASE1":27952,"PHASE1":27954,"PHASE2":27956,"PHASE3":27958,"PHASE4":27960,"NA":27962},{"trials":27953,"activeCount":101},[],{"trials":27955,"activeCount":101},[],{"trials":27957,"activeCount":101},[],{"trials":27959,"activeCount":101},[],{"trials":27961,"activeCount":101},[],{"trials":27963,"activeCount":101},[27964],{"nctId":27965,"briefTitle":27966,"status":244,"phases":27967,"primaryCompletion":3434,"completion":3434,"start":1641,"enrollment":1094,"conditions":27968,"interventions":27969},"NCT02410577","89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme",[93],[2790],[27950],{"intervention":27971,"totalTrials":97,"cells":27972},"KLH conjugates with GD2L and GD3L",{"EARLY_PHASE1":27973,"PHASE1":27975,"PHASE2":27977,"PHASE3":27979,"PHASE4":27981,"NA":27983},{"trials":27974,"activeCount":101},[],{"trials":27976,"activeCount":101},[],{"trials":27978,"activeCount":101},[],{"trials":27980,"activeCount":101},[],{"trials":27982,"activeCount":101},[],{"trials":27984,"activeCount":101},[27985],{"nctId":27986,"briefTitle":27987,"status":244,"phases":27988,"primaryCompletion":1082,"completion":1082,"start":3776,"enrollment":2439,"conditions":27989,"interventions":27990},"NCT00597272","Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma",[93],[2341],[27971],{"intervention":27992,"totalTrials":97,"cells":27993},"Iodine-124 labeled humanized A33",{"EARLY_PHASE1":27994,"PHASE1":27996,"PHASE2":27998,"PHASE3":28000,"PHASE4":28002,"NA":28004},{"trials":27995,"activeCount":101},[],{"trials":27997,"activeCount":101},[],{"trials":27999,"activeCount":101},[],{"trials":28001,"activeCount":101},[],{"trials":28003,"activeCount":101},[],{"trials":28005,"activeCount":101},[28006],{"nctId":28007,"briefTitle":28008,"status":244,"phases":28009,"primaryCompletion":8820,"completion":8820,"start":7407,"enrollment":356,"conditions":28010,"interventions":28014},"NCT00199862","Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer",[93],[28011,36,28012,28013],"Colorectal Neoplasms","Colorectal Tumor","COlorectal Carcinoma",[27992],{"intervention":28016,"totalTrials":97,"cells":28017},"18F-FLT PET Scan",{"EARLY_PHASE1":28018,"PHASE1":28020,"PHASE2":28022,"PHASE3":28024,"PHASE4":28026,"NA":28028},{"trials":28019,"activeCount":101},[],{"trials":28021,"activeCount":101},[],{"trials":28023,"activeCount":101},[],{"trials":28025,"activeCount":101},[],{"trials":28027,"activeCount":101},[],{"trials":28029,"activeCount":101},[28030],{"nctId":28031,"briefTitle":28032,"status":244,"phases":28033,"primaryCompletion":28034,"completion":28034,"start":28035,"enrollment":2630,"conditions":28036,"interventions":28037},"NCT00979810","Image-Guided Stereotactic Biopsy of High Grade Gliomas",[93],"2020-02-24","2009-09-16",[8191,2504],[28016],{"intervention":28039,"totalTrials":97,"cells":28040},"the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,",{"EARLY_PHASE1":28041,"PHASE1":28043,"PHASE2":28045,"PHASE3":28047,"PHASE4":28049,"NA":28051},{"trials":28042,"activeCount":101},[],{"trials":28044,"activeCount":101},[],{"trials":28046,"activeCount":101},[],{"trials":28048,"activeCount":101},[],{"trials":28050,"activeCount":101},[],{"trials":28052,"activeCount":101},[28053],{"nctId":28054,"briefTitle":28055,"status":244,"phases":28056,"primaryCompletion":16679,"completion":16679,"start":1994,"enrollment":234,"conditions":28057,"interventions":28058},"NCT00620139","Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma",[],[1590],[28039],{"intervention":7159,"totalTrials":97,"cells":28060},{"EARLY_PHASE1":28061,"PHASE1":28063,"PHASE2":28065,"PHASE3":28067,"PHASE4":28069,"NA":28071},{"trials":28062,"activeCount":101},[],{"trials":28064,"activeCount":101},[],{"trials":28066,"activeCount":101},[],{"trials":28068,"activeCount":101},[],{"trials":28070,"activeCount":101},[],{"trials":28072,"activeCount":101},[28073],{"nctId":7154,"briefTitle":7155,"status":244,"phases":28074,"primaryCompletion":4227,"completion":4227,"start":1186,"enrollment":3717,"conditions":28075,"interventions":28076},[93],[215],[7159,4693,7160],{"intervention":7160,"totalTrials":97,"cells":28078},{"EARLY_PHASE1":28079,"PHASE1":28081,"PHASE2":28083,"PHASE3":28085,"PHASE4":28087,"NA":28089},{"trials":28080,"activeCount":101},[],{"trials":28082,"activeCount":101},[],{"trials":28084,"activeCount":101},[],{"trials":28086,"activeCount":101},[],{"trials":28088,"activeCount":101},[],{"trials":28090,"activeCount":101},[28091],{"nctId":7154,"briefTitle":7155,"status":244,"phases":28092,"primaryCompletion":4227,"completion":4227,"start":1186,"enrollment":3717,"conditions":28093,"interventions":28094},[93],[215],[7159,4693,7160],{"intervention":28096,"totalTrials":97,"cells":28097},"Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist",{"EARLY_PHASE1":28098,"PHASE1":28100,"PHASE2":28102,"PHASE3":28104,"PHASE4":28106,"NA":28108},{"trials":28099,"activeCount":101},[],{"trials":28101,"activeCount":101},[],{"trials":28103,"activeCount":101},[],{"trials":28105,"activeCount":101},[],{"trials":28107,"activeCount":101},[],{"trials":28109,"activeCount":101},[28110],{"nctId":28111,"briefTitle":28112,"status":244,"phases":28113,"primaryCompletion":28114,"completion":28114,"start":28115,"enrollment":473,"conditions":28116,"interventions":28118},"NCT00984399","Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen",[93],"2024-05-13","2009-09-22",[28117,15],"Atrophic Vaginitis",[28096],{"intervention":26469,"totalTrials":97,"cells":28120},{"EARLY_PHASE1":28121,"PHASE1":28123,"PHASE2":28125,"PHASE3":28127,"PHASE4":28129,"NA":28131},{"trials":28122,"activeCount":101},[],{"trials":28124,"activeCount":101},[],{"trials":28126,"activeCount":101},[],{"trials":28128,"activeCount":101},[],{"trials":28130,"activeCount":101},[],{"trials":28132,"activeCount":101},[28133],{"nctId":26462,"briefTitle":26463,"status":244,"phases":28134,"primaryCompletion":26465,"completion":26465,"start":26466,"enrollment":2291,"conditions":28135,"interventions":28136},[93],[15],[9012,26469]]